# Patent

## Title
Artificial nucleic acid molecules for improved protein or peptide expression

## Abstract

The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3′UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.

## Background
This application is a national phase application under 35 U.S.C. §371 of International Application No. PCT/EP2013/000937, filed Mar. 27, 2013, which claims priority to International Application No. PCT/EP2012/001336, filed Mar. 27, 2012, and International Application No. PCT/EP2012/002447, filed Jun. 8, 2012. The entire text of each of the above referenced disclosures is specifically incorporated herein by reference.
The invention relates to artificial nucleic acid molecules comprising a 5′UTR element derived from the 5′UTR of a TOP gene, an open reading frame, and optionally a histone stem-loop, a 3′UTR element, a poly(A) sequence and/or a polyadenylation signal. The invention relates further to a vector comprising a 5′UTR element derived from the 5′UTR of a TOP gene, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector, and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition, preferably for use in the field of gene therapy and/or genetic vaccination.
Gene therapy and genetic vaccination belong to the most promising and quickly developing methods of modern medicine. They may provide highly specific and individual options for therapy of a large variety of diseases. Particularly, inherited genetic diseases but also autoimmune diseases, cancerous or tumour-related diseases as well as inflammatory diseases may be the subject of such treatment approaches. Also, it is envisaged to prevent (early) onset of such diseases by these approaches.
The main conceptual rational behind gene therapy is appropriate modulation of impaired gene expression associated with pathological conditions of specific diseases. Pathologically altered gene expression may result in lack or overproduction of essential gene products, for example, signalling factors such as hormones, housekeeping factors, metabolic enzymes, structural proteins or the like. Altered gene expression may not only be due to misregulation of transcription and/or translation, but also due to mutations within the ORF coding for a particular protein. Pathological mutations may be caused by e.g. chromosomal aberration, or by more specific mutations, such as point or frame-shift-mutations, all of them resulting in limited functionality and, potentially, total loss of function of the gene product. However, misregulation of transcription or translation may also occur, if mutations affect genes encoding proteins which are involved in the transcriptional or translational machinery of the cell. Such mutations may lead to pathological up- or down-regulation of genes which are—as such—functional. Genes encoding gene products which exert such regulating functions, may be, e.g., transcription factors, signal receptors, messenger proteins or the like. However, loss of function of such genes encoding regulatory proteins may, under certain circumstances, be reversed by artificial introduction of other factors acting further downstream of the impaired gene product. Such gene defects may also be compensated by gene therapy via substitution of the affected gene itself.
Genetic vaccination allows to evoke a desired immune response to selected antigens, such as characteristic components of bacterial surfaces, viral particles, tumour antigens or the like. Generally, vaccination is one of the pivotal achievements of modern medicine. However, effective vaccines are currently available only for a smaller number of diseases. Accordingly, infections that are not preventable by vaccination still affect millions of people every year.
Commonly, vaccines may be subdivided into “first”, “second” and “third” generation vaccines. “First generation” vaccines are, typically, whole-organism vaccines. They are based on either live and attenuated or killed pathogens, e.g. viruses, bacteria or the like. The major drawback of live and attenuated vaccines is the risk for a reversion to life-threatening variants. Thus, although attenuated, such pathogens may still intrinsically bear unpredictable risks. Killed pathogens may not be as effective as desired for generating a specific immune response. In order to minimize these risks, “second generation” vaccines were developed. These are, typically, subunit vaccines, consisting of defined antigens or recombinant protein components which are derived from pathogens.
Genetic vaccines, i.e. vaccines for genetic vaccination, are usually understood as “third generation” vaccines. They are typically composed of genetically engineered nucleic acid molecules which allow expression of peptide or protein (antigen) fragments characteristic for a pathogen or a tumor antigen in vivo. Genetic vaccines are expressed upon administration to a patient and uptake by competent cells. Expression of the administered nucleic acids results in production of the encoded proteins. In the event these proteins are recognized as foreign by the patient's immune system, an immune response is triggered.
As can be seen from the above, both methods, gene therapy and genetic vaccination, are essentially based on the administration of nucleic acid molecules to a patient and subsequent transcription and/or translation of the encoded genetic information. Alternatively, genetic vaccination or gene therapy may also comprise methods which include isolation of specific body cells from a patient to be treated, subsequent in vitro transfection of such cells, and re-administration of the treated cells to the patient.
DNA as well as RNA may be used as nucleic acid molecules for administration in the context of gene therapy or genetic vaccination. DNA is known to be relatively stable and easy to handle. However, the use of DNA bears the risk of undesired insertion of the administered DNA-fragments into the patient's genome potentially resulting in loss of function of the impaired genes. As a further risk, the undesired generation of anti-DNA antibodies has emerged. Another drawback is the limited expression level of the encoded peptide or protein that is achievable upon DNA administration and its transcription/translation. Among other reasons, the expression level of the administered DNA will be dependent on the presence of specific transcription factors which regulate DNA transcription. In the absence of such factors, DNA transcription will not yield satisfying amounts of RNA. As a result, the level of translated peptide or protein obtained is limited.
By using RNA instead of DNA for gene therapy or genetic vaccination, the risk of undesired genomic integration and generation of anti-DNA antibodies is minimized or avoided. However, RNA is considered to be a rather unstable molecular species which may readily be degraded by ubiquitous RNAses.
In vivo, RNA-degradation contributes to the regulation of the RNA half-life time. That effect was considered and proven to fine tune the regulation of eukaryotic gene expression (Friedel et al., Conserved principles of mammalian transcriptional regulation revealed by RNA half-life, Nucleic Acid Research, 2009, 1-12). Accordingly, each naturally occurring mRNA has its individual half-life depending on the gene from which the mRNA is derived. It contributes to the regulation of the expression level of this gene. Unstable RNAs are important to realize transient gene expression at distinct points in time. However, long-lived RNAs may be associated with accumulation of distinct proteins or continuous expression of genes. In vivo, the half life of mRNAs may also be dependent on environmental factors, such as hormonal treatment, as has been shown, e.g., for insulin-like growth factor I, actin, and albumin mRNA (Johnson et al, Newly synthesized RNA: Simultaneous measurement in intact cells of transcription rates and RNA stability of insulin-like growth factor I, actin, and albumin in growth hormone-stimulated hepatocytes, Proc. Natl. Acad. Sci., Vol. 88, pp. 5287-5291, 1991).
For gene therapy and genetic vaccination, usually stable RNA is desired. This is, on the one hand, due to the fact that the product encoded by the RNA-sequence shall accumulate in vivo. On the other hand, the RNA has to maintain its structural and functional integrity when prepared for a suitable dosage form, in the course of its storage, and when administered. Thus, considerable attention was dedicated to provide stable RNA molecules for gene therapy or genetic vaccination in order to prevent them from being subject to early degradation or decay.
It has been reported that the G/C-content of nucleic acid molecules may influence their stability. Thus, nucleic acids comprising an increased amount of guanine (G) and/or cytosine (C) residues may be functionally more stable than nucleic acids containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides. In this context, WO02/098443 provides a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region. Such a sequence modification takes advantage of the degeneracy of the genetic code. Accordingly, codons which contain a less favourable combination of nucleotides (less favourable in terms of RNA stability) may be substituted by alternative codons without altering the encoded amino acid sequence. This method of RNA stabilization is limited by the provisions of the specific nucleotide sequence of each single RNA molecule which is not allowed to leave the space of the desired amino acid sequence. Also, that approach is restricted to coding regions of the RNA.
As an alternative option for mRNA stabilisation, it has been found that naturally occurring eukaryotic mRNA molecules contain characteristic stabilising elements. For example, they may comprise so-called untranslated regions (UTR) at their 5′-end (5′UTR) and/or at their 3′-end (3′UTR) as well as other structural features, such as a 5′-cap structure or a 3′-poly(A) tail. Both, 5′UTR and 3′UTR are typically transcribed from the genomic DNA and are, thus, an element of the premature mRNA. Characteristic structural features of mature mRNA, such as the 5′-cap and the 3′-poly(A) tail (also called poly(A) tail or poly(A) sequence) are usually added to the transcribed (premature) mRNA during mRNA processing.
A 3′-poly(A) tail is typically a monotonous sequence stretch of adenine nucleotides added to the 3′-end of the transcribed mRNA. It may comprise up to about 400 adenine nucleotides. It was found that the length of such a 3′-poly(A) tail is a potentially critical element for the stability of the individual mRNA.
Nearly all eukaryotic mRNAs end with such a poly(A) sequence that is added to their 3′ end by the ubiquitous cleavage/polyadenylation machinery. The presence of a poly(A) sequence at the 3′ end is one of the most recognizable features of eukaryotic mRNAs. After cleavage, most pre-mRNAs, with the exception of replication-dependent histone transcripts, acquire a polyadenylated tail. In this context, 3′ end processing is a nuclear co-transcriptional process that promotes transport of mRNAs from the nucleus to the cytoplasm and affects the stability and the translation of mRNAs. Formation of this 3′ end occurs in a two step reaction directed by the cleavage/polyadenylation machinery and depends on the presence of two sequence elements in mRNA precursors (pre-mRNAs); a highly conserved hexanucleotide AAUAAA (polyadenylation signal) and a downstream G/U-rich sequence. In a first step, pre-mRNAs are cleaved between these two elements. In a second step tightly coupled to the first step the newly formed 3′ end is extended by addition of a poly(A) sequence consisting of 200-250 adenylates which affects subsequently all aspects of mRNA metabolism, including mRNA export, stability and translation (Dominski, Z. and W. F. Marzluff (2007), Gene 396(2): 373-90).
The only known exception to this rule are the replication-dependent histone mRNAs which terminate with a histone stem-loop instead of a poly(A) sequence. Exemplary histone stem-loop sequences are described in Lopez et al. (Dávila López, M., & Samuelsson, T. (2008), RNA (New York, N.Y.), 14(1), 1-10. doi:10.1261/rna.782308).
The stem-loops in histone pre-mRNAs are typically followed by a purine-rich sequence known as the histone downstream element (HDE). These pre-mRNAs are processed in the nucleus by a single endonucleolytic cleavage approximately 5 nucleotides downstream of the stem-loop, catalyzed by the U7 snRNP through base pairing of the U7 snRNA with the HDE.
Due to the requirement to package newly synthesized DNA into chromatin, histone synthesis is regulated in concert with the cell cycle. Increased synthesis of histone proteins during S phase is achieved by transcriptional activation of histone genes as well as posttranscriptional regulation of histone mRNA levels. It could be shown that the histone stem-loop is essential for all posttranscriptional steps of histone expression regulation. It is necessary for efficient processing, export of the mRNA into the cytoplasm, loading onto polyribosomes, and regulation of mRNA stability.
In the above context, a 32 kDa protein was identified, which is associated with the histone stem-loop at the 3′-end of the histone messages in both the nucleus and the cytoplasm. The expression level of this stem-loop binding protein (SLBP) is cell-cycle regulated and is highest during S-phase when histone mRNA levels are increased. SLBP is necessary for efficient 3′-end processing of histone pre-mRNA by the U7 snRNP. After completion of processing, SLBP remains associated with the stem-loop at the end of mature histone mRNAs and stimulates their translation into histone proteins in the cytoplasm. (Dominski, Z. and W. F. Marzluff (2007), Gene 396(2): 373-90). Interestingly, the RNA binding domain of SLBP is conserved throughout metazoa and protozoa (Dávila López, M., & Samuelsson, T. (2008), RNA (New York, N.Y.), 14(1), 1-10. doi:10.1261/rna.782308) and it could be shown that its binding to the histone stem-loop sequence is dependent on the stem-loop structure and that the minimum binding site contains at least 3 nucleotides 5′ and 2 nucleotides 3′ of the stem-loop (Pandey, N. B., et al. (1994), Molecular and Cellular Biology, 14(3), 1709-1720 and Williams, A. S., & Marzluff, W. F., (1995), Nucleic Acids Research, 23(4), 654-662).
Even though histone genes are generally classified as either “replication-dependent”, giving rise to mRNA ending in a histone stem-loop, or “replacement-type”, giving rise to mRNA bearing a poly(A)-tail instead, naturally occurring mRNAs containing both a histone stem-loop and poly(A) or oligo(A) 3′ thereof have been identified in some very rare cases. Sanchez et al. examined the effect of naturally occurring oligo(A) tails appended 3′ of the histone stem-loop of histone mRNA during Xenopus oogenesis using Luciferase as a reporter protein and found that the oligo(A) tail is an active part of the translation repression mechanism that silences histone mRNA during oogenesis and its removal is part of the mechanism that activates translation of histone mRNAs (Sanchez, R. and W. F. Marzluff (2004), Mol Cell Biol 24(6): 2513-25).
Furthermore, the requirements for regulation of replication dependent histones at the level of pre-mRNA processing and mRNA stability have been investigated using artificial constructs coding for the marker protein alpha globin, taking advantage of the fact that the globin gene contains introns as opposed to the intron-less histone genes. For this purpose constructs were generated in which the alpha globin coding sequence was followed by a histone stem-loop signal (histone stem-loop followed by the histone downstream element) and a polyadenylation signal (Whitelaw, E., et al. (1986). Nucleic Acids Research, 14(17), 7059-7070; Pandey, N. B., & Marzluff, W. F. (1987). Molecular and Cellular Biology, 7(12), 4557-4559; Pandey, N. B., et al. (1990). Nucleic Acids Research, 18(11), 3161-3170).
Also, it was shown that the 3′UTR of α-globin mRNA may be an important factor for the well-known stability of α-globin mRNA (Rodgers et al., Regulated α-globin mRNA decay is a cytoplasmic event proceeding through 3′-to-5′ exosome-dependent decapping, RNA, 8, pp. 1526-1537, 2002). The 3′UTR of α-globin mRNA is obviously involved in the formation of a specific ribonucleoprotein-complex, the α-complex, whose presence correlates with mRNA stability in vitro (Wang et al., An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro, Molecular and Cellular biology, Vol 19, No. 7, July 1999, p. 4552-4560).
Irrespective of factors influencing mRNA stability, effective translation of the administered nucleic acid molecules by the target cells or tissue is crucial for any approach using nucleic acid molecules for gene therapy or genetic vaccination. Along with the regulation of stability, also translation of the majority of mRNAs is regulated by structural features like UTRs, 5′-cap and 3′-poly(A) tail. In this context, it has been reported that the length of the poly(A) tail may play an important role for translational efficiency as well. Stabilizing 3′-elements, however, may also have an attenuating effect on translation.
Further regulative elements, which may have an influence on expression levels, may be found in the 5′UTR. For example, it has been reported that synthesis of particular proteins, e.g. proteins belonging to the translational apparatus, may be regulated not only at the transcriptional but also at the translational level. For example, translation of proteins encoded by so called ‘TOP-genes’ may be down-regulated by translational repression. Therein, the term ‘TOP-gene’ relates to a gene corresponding to an mRNA that is characterized by the presence of a TOP sequence at the 5′end and in most cases by a growth-associated translation regulation (Iadevaia et al., All translation elongation factors and the e, f, and h subunits of translation initiation factor 3 are encoded by 5′-terminal oligopyrimidine (TOP) mRNAs; RNA, 2008, 14:1730-1736). In this context, a TOP sequence—also called the ‘5’-terminal oligopyrimidine tract′—typically consists of a C residue at the cap site, followed by an uninterrupted sequence of up to 13 or even more pyrimidines (Avni et al., Vertebrate mRNAs with a 5′-terminal pyrimidine tract are Candidates for translational repression in quiescent cells: characterization of the translational cis-regulatory element, Molecular and Cellular Biology, 1994, p. 3822-3833). These TOP sequences are reported to be present in many mRNAs encoding components of the translational machinery and to be responsible for selective repression of the translation of these TOP containing mRNAs due to growth arrest (Meyuhas, et al., Translational Control of Ribosomal Protein mRNAs in Eukaryotes, Translational Control. Cold Spring Harbor Monograph Archive. Cold Spring Harbor Laboratory Press, 1996, p. 363-388).
It is the object of the invention to provide nucleic acid molecules which may be suitable for application in gene therapy and/or genetic vaccination. Particularly, it is the object of the invention to provide artificial nucleic acid molecules, such as an mRNA species, which provide for increased protein production from said artificial nucleic acid molecules, preferably which exhibit increased translational efficiency. Another object of the present invention is to provide nucleic acid molecules coding for such a superior mRNA species which may be amenable for use in gene therapy and/or genetic vaccination. It is a further object of the present invention to provide a pharmaceutical composition for use in gene therapy and/or genetic vaccination. In summary, it is the object of the present invention to provide improved nucleic acid species which overcome the above discussed disadvantages of the prior art by a cost-effective and straight-forward approach.
The object underlying the present invention is solved by the claimed subject-matter.
For the sake of clarity and readability the following definitions are provided. Any technical feature mentioned for these definitions may be read on each and every embodiment of the invention. Additional definitions and explanations may be specifically provided in the context of these embodiments.
Adaptive immune response: The adaptive immune response is typically understood to be an antigen-specific response of the immune system. Antigen specificity allows for the generation of responses that are tailored to specific pathogens or pathogen-infected cells. The ability to mount these tailored responses is usually maintained in the body by “memory cells”. Should a pathogen infect the body more than once, these specific memory cells are used to quickly eliminate it. In this context, the first step of an adaptive immune response is the activation of naïve antigen-specific T cells or different immune cells able to induce an antigen-specific immune response by antigen-presenting cells. This occurs in the lymphoid tissues and organs through which naïve T cells are constantly passing. The three cell types that may serve as antigen-presenting cells are dendritic cells, macrophages, and B cells. Each of these cells has a distinct function in eliciting immune responses. Dendritic cells may take up antigens by phagocytosis and macropinocytosis and may become stimulated by contact with e.g. a foreign antigen to migrate to the local lymphoid tissue, where they differentiate into mature dendritic cells. Macrophages ingest particulate antigens such as bacteria and are induced by infectious agents or other appropriate stimuli to express MHC molecules. The unique ability of B cells to bind and internalize soluble protein antigens via their receptors may also be important to induce T cells. MHC-molecules are, typically, responsible for presentation of an antigen to T-cells. Therein, presenting the antigen on MHC molecules leads to activation of T cells which induces their proliferation and differentiation into armed effector T cells. The most important function of effector T cells is the killing of infected cells by CD8+ cytotoxic T cells and the activation of macrophages by Th1 cells which together make up cell-mediated immunity, and the activation of B cells by both Th2 and Th1 cells to produce different classes of antibody, thus driving the humoral immune response. T cells recognize an antigen by their T cell receptors which do not recognize and bind the antigen directly, but instead recognize short peptide fragments e.g. of pathogen-derived protein antigens, e.g. so-called epitopes, which are bound to MHC molecules on the surfaces of other cells.

Adaptive immune system: The adaptive immune system is essentially dedicated to eliminate or prevent pathogenic growth. It typically regulates the adaptive immune response by providing the vertebrate immune system with the ability to recognize and remember specific pathogens (to generate immunity), and to mount stronger attacks each time the pathogen is encountered. The system is highly adaptable because of somatic hypermutation (a process of accelerated somatic mutations), and V(D)J recombination (an irreversible genetic recombination of antigen receptor gene segments). This mechanism allows a small number of genes to generate a vast number of different antigen receptors, which are then uniquely expressed on each individual lymphocyte. Because the gene rearrangement leads to an irreversible change in the DNA of each cell, all of the progeny (offspring) of such a cell will then inherit genes encoding the same receptor specificity, including the Memory B cells and Memory T cells that are the keys to long-lived specific immunity.

Adjuvant/adjuvant component: An adjuvant or an adjuvant component in the broadest sense is typically a pharmacological and/or immunological agent that may modify, e.g. enhance, the effect of other agents, such as a drug or vaccine. It is to be interpreted in a broad sense and refers to a broad spectrum of substances. Typically, these substances are able to increase the immunogenicity of antigens. For example, adjuvants may be recognized by the innate immune systems and, e.g., may elicit an innate immune response. “Adjuvants” typically do not elicit an adaptive immune response. Insofar, “adjuvants” do not qualify as antigens. Their mode of action is distinct from the effects triggered by antigens resulting in an adaptive immune response.

Antigen: In the context of the present invention “antigen” refers typically to a substance which may be recognized by the immune system, preferably by the adaptive immune system, and is capable of triggering an antigen-specific immune response, e.g. by formation of antibodies and/or antigen-specific T cells as part of an adaptive immune response. Typically, an antigen may be or may comprise a peptide or protein which may be presented by the MHC to T-cells.

Artificial nucleic acid molecule: An artificial nucleic acid molecule may typically be understood to be a nucleic acid molecule, e.g. a DNA or an RNA, that does not occur naturally. In other words, an artificial nucleic acid molecule may be understood as a non-natural nucleic acid molecule. Such nucleic acid molecule may be non-natural due to its individual sequence (which does not occur naturally) and/or due to other modifications, e.g. structural modifications of nucleotides which do not occur naturally. An artificial nucleic acid molecule may be a DNA molecule, an RNA molecule or a hybrid-molecule comprising DNA and RNA portions. Typically, artificial nucleic acid molecules may be designed and/or generated by genetic engineering methods to correspond to a desired artificial sequence of nucleotides (heterologous sequence). In this context an artificial sequence is usually a sequence that may not occur naturally, i.e. it differs from the wild type sequence by at least one nucleotide. The term ‘wild type’ may be understood as a sequence occurring in nature. Further, the term ‘artificial nucleic acid molecule’ is not restricted to mean ‘one single molecule’ but is, typically, understood to comprise an ensemble of identical molecules. Accordingly, it may relate to a plurality of identical molecules contained in an aliquot.

Bicistronic RNA, multicistronic RNA: A bicistronic or multicistronic RNA is typically an RNA, preferably an mRNA, that typically may have two (bicistronic) or more (multicistronic) open reading frames (ORF). An open reading frame in this context is a sequence of codons that is translatable into a peptide or protein.

Carrier/polymeric carrier: A carrier in the context of the invention may typically be a compound that facilitates transport and/or complexation of another compound (cargo). A polymeric carrier is typically a carrier that is formed of a polymer. A carrier may be associated to its cargo by covalent or non-covalent interaction. A carrier may transport nucleic acids, e.g. RNA or DNA, to the target cells. The carrier may—for some embodiments—be a cationic component.

Cationic component: The term “cationic component” typically refers to a charged molecule, which is positively charged (cation) at a pH value typically from 1 to 9, preferably at a pH value of or below 9 (e.g. from 5 to 9), of or below 8 (e.g. from 5 to 8), of or below 7 (e.g. from 5 to 7), most preferably at a physiological pH, e.g. from 7.3 to 7.4. Accordingly, a cationic component may be any positively charged compound or polymer, preferably a cationic peptide or protein which is positively charged under physiological conditions, particularly under physiological conditions in vivo. A ‘cationic peptide or protein’ may contain at least one positively charged amino acid, or more than one positively charged amino acid, e.g. selected from Arg, His, Lys or Orn. Accordingly, ‘polycationic’ components are also within the scope exhibiting more than one positive charge under the conditions given.

5′-cap: A 5′-cap is an entity, typically a modified nucleotide entity, which generally ‘caps’ the 5′-end of a mature mRNA. A 5′-cap may typically be formed by a modified nucleotide, particularly by a derivative of a guanine nucleotide. Preferably, the 5′-cap is linked to the 5′-terminus via a 5′-5′-triphosphate linkage. A 5′-cap may be methylated, e.g. m7GpppN, wherein N is the terminal 5′ nucleotide of the nucleic acid carrying the 5′-cap, typically the 5′-end of an RNA. Further examples of 5′cap structures include glyceryl, inverted deoxy abasic residue (moiety), 4′,5′ methylene nucleotide, 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide, carbocyclic nucleotide, 1,5-anhydrohexitol nucleotide, L-nucleotides, alpha-nucleotide, modified base nucleotide, threo-pentofuranosyl nucleotide, acyclic 3′,4′-seco nucleotide, acyclic 3,4-dihydroxybutyl nucleotide, acyclic 3,5 dihydroxypentyl nucleotide, 3′-3′-inverted nucleotide moiety, 3′-3′-inverted abasic moiety, 3′-2′-inverted nucleotide moiety, 3′-2′-inverted abasic moiety, 1,4-butanediol phosphate, 3′-phosphoramidate, hexylphosphate, aminohexyl phosphate, 3′-phosphate, 3′phosphorothioate, phosphorodithioate, or bridging or non-bridging methylphosphonate moiety.

Cellular immunity/cellular immune response: Cellular immunity relates typically to the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. In more general terms, cellular immunity is not based on antibodies, but on the activation of cells of the immune system. Typically, a cellular immune response may be characterized e.g. by activating antigen-specific cytotoxic T-lymphocytes that are able to induce apoptosis in cells, e.g. specific immune cells like dendritic cells or other cells, displaying epitopes of foreign antigens on their surface. Such cells may be virus-infected or infected with intracellular bacteria, or cancer cells displaying tumor antigens. Further characteristics may be activation of macrophages and natural killer cells, enabling them to destroy pathogens and stimulation of cells to secrete a variety of cytokines that influence the function of other cells involved in adaptive immune responses and innate immune responses.

DNA: DNA is the usual abbreviation for deoxy-ribonucleic-acid. It is a nucleic acid molecule, i.e. a polymer consisting of nucleotides. These nucleotides are usually deoxy-adenosine-monophosphate, deoxy-thymidine-monophosphate, deoxy-guanosine-monophosphate and deoxy-cytidine-monophosphate monomers which are—by themselves—composed of a sugar moiety (deoxyribose), a base moiety and a phosphate moiety, and polymerise by a characteristic backbone structure. The backbone structure is, typically, formed by phosphodiester bonds between the sugar moiety of the nucleotide, i.e. deoxyribose, of a first and a phosphate moiety of a second, adjacent monomer. The specific order of the monomers, i.e. the order of the bases linked to the sugar/phosphate-backbone, is called the DNA-sequence. DNA may be single stranded or double stranded. In the double stranded form, the nucleotides of the first strand typically hybridize with the nucleotides of the second strand, e.g. by A/T-base-pairing and G/C-base-pairing.

Epitope: Epitopes (also called ‘antigen determinant’) can be distinguished in T cell epitopes and B cell epitopes. T cell epitopes or parts of the proteins in the context of the present invention may comprise fragments preferably having a length of about 6 to about 20 or even more amino acids, e.g. fragments as processed and presented by MHC class I molecules, preferably having a length of about 8 to about 10 amino acids, e.g. 8, 9, or 10, (or even 11, or 12 amino acids), or fragments as processed and presented by MHC class II molecules, preferably having a length of about 13 or more amino acids, e.g. 13, 14, 15, 16, 17, 18, 19, 20 or even more amino acids, wherein these fragments may be selected from any part of the amino acid sequence. These fragments are typically recognized by T cells in form of a complex consisting of the peptide fragment and an MHC molecule, i.e. the fragments are typically not recognized in their native form. B cell epitopes are typically fragments located on the outer surface of (native) protein or peptide antigens as defined herein, preferably having 5 to 15 amino acids, more preferably having 5 to 12 amino acids, even more preferably having 6 to 9 amino acids, which may be recognized by antibodies, i.e. in their native form.

Such epitopes of proteins or peptides may furthermore be selected from any of the herein mentioned variants of such proteins or peptides. In this context antigenic determinants can be conformational or discontinuous epitopes which are composed of segments of the proteins or peptides as defined herein that are discontinuous in the amino acid sequence of the proteins or peptides as defined herein but are brought together in the three-dimensional structure or continuous or linear epitopes which are composed of a single polypeptide chain.
Fragment of a sequence: A fragment of a sequence may typically be a shorter portion of a full-length sequence of e.g. a nucleic acid molecule or an amino acid sequence. Accordingly, a fragment, typically, consists of a sequence that is identical to the corresponding stretch within the full-length sequence. A preferred fragment of a sequence in the context of the present invention, consists of a continuous stretch of entities, such as nucleotides or amino acids corresponding to a continuous stretch of entities in the molecule the fragment is derived from, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, and most preferably at least 80% of the total (i.e. full-length) molecule from which the fragment is derived.

G/C modified: A G/C-modified nucleic acid may typically be a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, based on a modified wild-type sequence comprising a preferably increased number of guanosine and/or cytosine nucleotides as compared to the wild-type sequence. Such an increased number may be generated by substitution of codons containing adenosine or thymidine nucleotides by codons containing guanosine or cytosine nucleotides. If the enriched G/C content occurs in a coding region of DNA or RNA, it makes use of the degeneracy of the genetic code. Accordingly, the codon substitutions preferably do not alter the encoded amino acid residues, but exclusively increase the G/C content of the nucleic acid molecule.

Gene therapy: Gene therapy may typically be understood to mean a treatment of a patient's body or isolated elements of a patient's body, for example isolated tissues/cells, by nucleic acids encoding a peptide or protein. It typically may comprise at least one of the steps of a) administration of a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, directly to the patient—by whatever administration route—or in vitro to isolated cells/tissues of the patient, which results in transfection of the patient's cells either in vivo/ex vivo or in vitro; b) transcription and/or translation of the introduced nucleic acid molecule; and optionally c) re-administration of isolated, transfected cells to the patient, if the nucleic acid has not been administered directly to the patient.

Genetic vaccination: Genetic vaccination may typically be understood to be vaccination by administration of a nucleic acid molecule encoding an antigen or an immunogen or fragments thereof. The nucleic acid molecule may be administered to a subject's body or to isolated cells of a subject. Upon transfection of certain cells of the body or upon transfection of the isolated cells, the antigen or immunogen may be expressed by those cells and subsequently presented to the immune system, eliciting an adaptive, i.e. antigen-specific immune response. Accordingly, genetic vaccination typically comprises at least one of the steps of a) administration of a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, to a subject, preferably a patient, or to isolated cells of a subject, preferably a patient, which usually results in transfection of the subject's cells either in vivo or in vitro; b) transcription and/or translation of the introduced nucleic acid molecule; and optionally c) re-administration of isolated, transfected cells to the subject, preferably the patient, if the nucleic acid has not been administered directly to the patient.

Heterologous sequence: Two sequences are typically understood to be ‘heterologous’ if they are not derivable from the same gene. I.e., although heterologous sequences may be derivable from the same organism, they naturally (in nature) do not occur in the same nucleic acid molecule, such as in the same mRNA.

Humoral immunity/humoral immune response: Humoral immunity refers typically to antibody production and optionally to accessory processes accompanying antibody production. A humoral immune response may be typically characterized, e.g., by Th2 activation and cytokine production, germinal center formation and isotype switching, affinity maturation and memory cell generation. Humoral immunity also typically may refer to the effector functions of antibodies, which include pathogen and toxin neutralization, classical complement activation, and opsonin promotion of phagocytosis and pathogen elimination.

Immunogen: In the context of the present invention an immunogen may be typically understood to be a compound that is able to stimulate an immune response. Preferably, an immunogen is a peptide, polypeptide, or protein. In a particularly preferred embodiment, an immunogen in the sense of the present invention is the product of translation of a provided nucleic acid molecule, preferably an artificial nucleic acid molecule as defined herein. Typically, an immunogen elicits at least an adaptive immune response.

Immunostimulatory composition: In the context of the invention, an immunostimulatory composition may be typically understood to be a composition containing at least one component which is able to induce an immune response or from which a component which is able to induce an immune response is derivable. Such immune response may be preferably an innate immune response or a combination of an adaptive and an innate immune response. Preferably, an immunostimulatory composition in the context of the invention contains at least one artificial nucleic acid molecule, more preferably an RNA, for example an mRNA molecule. The immunostimulatory component, such as the mRNA may be complexed with a suitable carrier. Thus, the immunostimulatory composition may comprise an mRNA/carrier-complex. Furthermore, the immunostimulatory composition may comprise an adjuvant and/or a suitable vehicle for the immunostimulatory component, such as the mRNA.

Immune response: An immune response may typically be a specific reaction of the adaptive immune system to a particular antigen (so called specific or adaptive immune response) or an unspecific reaction of the innate immune system (so called unspecific or innate immune response), or a combination thereof.

Immune system: The immune system may protect organisms from infection. If a pathogen succeeds in passing a physical barrier of an organism and enters this organism, the innate immune system provides an immediate, but non-specific response. If pathogens evade this innate response, vertebrates possess a second layer of protection, the adaptive immune system. Here, the immune system adapts its response during an infection to improve its recognition of the pathogen. This improved response is then retained after the pathogen has been eliminated, in the form of an immunological memory, and allows the adaptive immune system to mount faster and stronger attacks each time this pathogen is encountered. According to this, the immune system comprises the innate and the adaptive immune system. Each of these two parts typically contains so called humoral and cellular components.

Immunostimulatory RNA: An immunostimulatory RNA (isRNA) in the context of the invention may typically be an RNA that is able to induce an innate immune response. It usually does not have an open reading frame and thus does not provide a peptide-antigen or immunogen but elicits an immune response e.g. by binding to a specific kind of Toll-like-receptor (TLR) or other suitable receptors. However, of course also mRNAs having an open reading frame and coding for a peptide/protein may induce an innate immune response and, thus, may be immunostimulatory RNAs.

Innate immune system: The innate immune system, also known as non-specific (or unspecific) immune system, typically comprises the cells and mechanisms that defend the host from infection by other organisms in a non-specific manner. This means that the cells of the innate system may recognize and respond to pathogens in a generic way, but unlike the adaptive immune system, it does not confer long-lasting or protective immunity to the host. The innate immune system may be, e.g., activated by ligands of Toll-like receptors (TLRs) or other auxiliary substances such as lipopolysaccharides, TNF-alpha, CD40 ligand, or cytokines, monokines, lymphokines, interleukins or chemokines, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IFN-alpha, IFN-beta, IFN-gamma, GM-CSF, G-CSF, M-CSF, LT-beta, TNF-alpha, growth factors, and hGH, a ligand of human Toll-like receptor TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, a ligand of murine Toll-like receptor TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12 or TLR13, a ligand of a NOD-like receptor, a ligand of a RIG-I like receptor, an immunostimulatory nucleic acid, an immunostimulatory RNA (isRNA), a CpG-DNA, an antibacterial agent, or an anti-viral agent. The pharmaceutical composition according to the present invention may comprise one or more such substances. Typically, a response of the innate immune system includes recruiting immune cells to sites of infection, through the production of chemical factors, including specialized chemical mediators, called cytokines; activation of the complement cascade; identification and removal of foreign substances present in organs, tissues, the blood and lymph, by specialized white blood cells; activation of the adaptive immune system; and/or acting as a physical and chemical barrier to infectious agents.

Cloning site: A cloning site is typically understood to be a segment of a nucleic acid molecule, which is suitable for insertion of a nucleic acid sequence, e.g., a nucleic acid sequence comprising an open reading frame. Insertion may be performed by any molecular biological method known to the one skilled in the art, e.g. by restriction and ligation. A cloning site typically comprises one or more restriction enzyme recognition sites (restriction sites). These one or more restrictions sites may be recognized by restriction enzymes which cleave the DNA at these sites. A cloning site which comprises more than one restriction site may also be termed a multiple cloning site (MCS) or a polylinker.

Nucleic acid molecule: A nucleic acid molecule is a molecule comprising, preferably consisting of nucleic acid components. The term nucleic acid molecule preferably refers to DNA or RNA molecules. It is preferably used synonymous with the term “polynucleotide”. Preferably, a nucleic acid molecule is a polymer comprising or consisting of nucleotide monomers which are covalently linked to each other by phosphodiester-bonds of a sugar/phosphate-backbone. The term “nucleic acid molecule” also encompasses modified nucleic acid molecules, such as base-modified, sugar-modified or backbone-modified etc. DNA or RNA molecules.

Open reading frame: An open reading frame (ORF) in the context of the invention may typically be a sequence of several nucleotide triplets which may be translated into a peptide or protein. An open reading frame preferably contains a start codon, i.e. a combination of three subsequent nucleotides coding usually for the amino acid methionine (ATG or AUG), at its 5′-end and a subsequent region which usually exhibits a length which is a multiple of 3 nucleotides. An ORF is preferably terminated by a stop-codon (e.g., TAA, TAG, TGA). Typically, this is the only stop-codon of the open reading frame. Thus, an open reading frame in the context of the present invention is preferably a nucleotide sequence, consisting of a number of nucleotides that may be divided by three, which starts with a start codon (e.g. ATG or AUG) and which preferably terminates with a stop codon (e.g., TAA, TGA, or TAG or UAA, UAG, UGA, respectively). The open reading frame may be isolated or it may be incorporated in a longer nucleic acid sequence, for example in a vector or an mRNA. An open reading frame may also be termed ‘protein coding region’.

Peptide: A peptide or polypeptide is typically a polymer of amino acid monomers, linked by peptide bonds. It typically contains less than 50 monomer units. Nevertheless, the term peptide is not a disclaimer for molecules having more than 50 monomer units. Long peptides are also called polypeptides, typically having between 50 and 600 monomeric units.

Pharmaceutically effective amount: A pharmaceutically effective amount in the context of the invention is typically understood to be an amount that is sufficient to induce a pharmaceutical effect, such as an immune response, altering a pathological level of an expressed peptide or protein, or substituting a lacking gene product, e.g., in case of a pathological situation.

Protein A protein typically comprises one or more peptides or polypeptides. A protein is typically folded into 3-dimensional form, which may be required for to protein to exert its biological function.

Poly(A) sequence: A poly(A) sequence, also called poly(A) tail or 3′-poly(A) tail, is typically understood to be a sequence of adenine nucleotides, e.g., of up to about 400 adenine nucleotides, e.g. from about 20 to about 400, preferably from about 50 to about 400, more preferably from about 50 to about 300, even more preferably from about 50 to about 250, most preferably from about 60 to about 250 adenine nucleotides. A poly(A) sequence is typically located at the 3′end of an mRNA. In the context of the present invention, a poly(A) sequence may be located within an mRNA or any other nucleic acid molecule, such as, e.g., in a vector, for example, in a vector serving as template for the generation of an RNA, preferably an mRNA, e.g., by transcription of the vector.

Polyadenylation: Polyadenylation is typically understood to be the addition of a poly(A) sequence to a nucleic acid molecule, such as an RNA molecule, e.g. to a premature mRNA. Polyadenylation may be induced by a so called polyadenylation signal. This signal is preferably located within a stretch of nucleotides at the 3′-end of a nucleic acid molecule, such as an RNA molecule, to be polyadenylated. A polyadenylation signal typically comprises a hexamer consisting of adenine and uracil/thymine nucleotides, preferably the hexamer sequence AAUAAA. Other sequences, preferably hexamer sequences, are also conceivable. Polyadenylation typically occurs during processing of a pre-mRNA (also called premature-mRNA). Typically, RNA maturation (from pre-mRNA to mature mRNA) comprises the step of polyadenylation.

Restriction site: A restriction site, also termed ‘restriction enzyme recognition site’, is a nucleotide sequence recognized by a restriction enzyme. A restriction site is typically a short, preferably palindromic nucleotide sequence, e.g. a sequence comprising 4 to 8 nucleotides. A restriction site is preferably specifically recognized by a restriction enzyme. The restriction enzyme typically cleaves a nucleotide sequence comprising a restriction site at this site. In a double-stranded nucleotide sequence, such as a double-stranded DNA sequence, the restriction enzyme typically cuts both strands of the nucleotide sequence.

RNA, mRNA: RNA is the usual abbreviation for ribonucleic-acid. It is a nucleic acid molecule, i.e. a polymer consisting of nucleotides. These nucleotides are usually adenosine-monophosphate, uridine-monophosphate, guanosine-monophosphate and cytidine-monophosphate monomers which are connected to each other along a so-called backbone. The backbone is formed by phosphodiester bonds between the sugar, i.e. ribose, of a first and a phosphate moiety of a second, adjacent monomer. The specific succession of the monomers is called the RNA-sequence. Usually RNA may be obtainable by transcription of a DNA-sequence, e.g., inside a cell. In eukaryotic cells, transcription is typically performed inside the nucleus or the mitochondria. In vivo, transcription of DNA usually results in the so-called premature RNA which has to be processed into so-called messenger-RNA, usually abbreviated as mRNA. Processing of the premature RNA, e.g. in eukaryotic organisms, comprises a variety of different posttranscriptional-modifications such as splicing, 5′-capping, polyadenylation, export from the nucleus or the mitochondria and the like. The sum of these processes is also called maturation of RNA. The mature messenger RNA usually provides the nucleotide sequence that may be translated into an amino acid sequence of a particular peptide or protein. Typically, a mature mRNA comprises a 5′-cap, a 5′UTR, an open reading frame, a 3′UTR and a poly(A) sequence. Aside from messenger RNA, several non-coding types of RNA exist which may be involved in regulation of transcription and/or translation.

Sequence of a nucleic acid molecule: The sequence of a nucleic acid molecule is typically understood to be the particular and individual order, i.e. the succession of its nucleotides. The sequence of a protein or peptide is typically understood to be the order, i.e. the succession of its amino acids.

Sequence identity: Two or more sequences are identical if they exhibit the same length and order of nucleotides or amino acids. The percentage of identity typically describes the extent to which two sequences are identical, i.e. it typically describes the percentage of nucleotides that correspond in their sequence position with identical nucleotides of a reference-sequence. For determination of the degree of identity, the sequences to be compared are considered to exhibit the same length, i.e. the length of the longest sequence of the sequences to be compared. This means that a first sequence consisting of 8 nucleotides is 80% identical to a second sequence consisting of 10 nucleotides comprising the first sequence. In other words, in the context of the present invention, identity of sequences preferably relates to the percentage of nucleotides of a sequence which have the same position in two or more sequences having the same length. Gaps are usually regarded as non-identical positions, irrespective of their actual position in an alignment.

Stabilized nucleic acid molecule: A stabilized nucleic acid molecule is a nucleic acid molecule, preferably a DNA or RNA molecule that is modified such, that it is more stable to disintegration or degradation, e.g., by environmental factors or enzymatic digest, such as by an exo- or endonuclease degradation, than the nucleic acid molecule without the modification. Preferably, a stabilized nucleic acid molecule in the context of the present invention is stabilized in a cell, such as a prokaryotic or eukaryotic cell, preferably in a mammalian cell, such as a human cell. The stabilization effect may also be exerted outside of cells, e.g. in a buffer solution etc., for example, in a manufacturing process for a pharmaceutical composition comprising the stabilized nucleic acid molecule.

Transfection: The term ‘transfection’ refers to the introduction of nucleic acid molecules, such as DNA or RNA (e.g. mRNA) molecules, into cells, preferably into eukaryotic cells. In the context of the present invention, the term ‘transfection’ encompasses any method known to the skilled person for introducing nucleic acid molecules into cells, preferably into eukaryotic cells, such as into mammalian cells. Such methods encompass, for example, electroporation, lipofection, e.g. based on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or transfection based on cationic polymers, such as DEAE-dextran or polyethylenimine etc. Preferably, the introduction is non-viral.

Vaccine: A vaccine is typically understood to be a prophylactic or therapeutic material providing at least one antigen, preferably an immunogen. The antigen or immunogen may be derived from any material that is suitable for vaccination. For example, the antigen or immunogen may be derived from a pathogen, such as from bacteria or virus particles etc., or from a tumor or cancerous tissue. The antigen or immunogen stimulates the body's adaptive immune system to provide an adaptive immune response.

Vector: The term ‘vector’ refers to a nucleic acid molecule, preferably to an artificial nucleic acid molecule. A vector in the context of the present invention is suitable for incorporating or harboring a desired nucleic acid sequence, such as a nucleic acid sequence comprising an open reading frame. Such vectors may be storage vectors, expression vectors, cloning vectors, transfer vectors etc. A storage vector is a vector which allows the convenient storage of a nucleic acid molecule, for example, of an mRNA molecule. Thus, the vector may comprise a sequence corresponding, e.g., to a desired mRNA sequence or a part thereof, such as a sequence corresponding to the open reading frame and the 3′UTR of an mRNA. An expression vector may be used for production of expression products such as RNA, e.g. mRNA, or peptides, polypeptides or proteins. For example, an expression vector may comprise sequences needed for transcription of a sequence stretch of the vector, such as a promoter sequence, e.g. an RNA promoter sequence. A cloning vector is typically a vector that contains a cloning site, which may be used to incorporate nucleic acid sequences into the vector. A cloning vector may be, e.g., a plasmid vector or a bacteriophage vector. A transfer vector may be a vector which is suitable for transferring nucleic acid molecules into cells or organisms, for example, viral vectors. A vector in the context of the present invention may be, e.g., an RNA vector or a DNA vector. Preferably, a vector is a DNA molecule. Preferably, a vector in the sense of the present application comprises a cloning site, a selection marker, such as an antibiotic resistance factor, and a sequence suitable for multiplication of the vector, such as an origin of replication. Preferably, a vector in the context of the present application is a plasmid vector.

Vehicle: A vehicle is typically understood to be a material that is suitable for storing, transporting, and/or administering a compound, such as a pharmaceutically active compound. For example, it may be a physiologically acceptable liquid which is suitable for storing, transporting, and/or administering a pharmaceutically active compound.

3′-untranslated region (3′UTR): A 3′UTR is typically the part of an mRNA which is located between the protein coding region (i.e. the open reading frame) and the poly(A) sequence of the mRNA. A 3′UTR of the mRNA is not translated into an amino acid sequence. The 3′UTR sequence is generally encoded by the gene which is transcribed into the respective mRNA during the gene expression process. The genomic sequence is first transcribed into pre-mature mRNA, which comprises optional introns. The pre-mature mRNA is then further processed into mature mRNA in a maturation process. This maturation process comprises the steps of 5′capping, splicing the pre-mature mRNA to excise optional introns and modifications of the 3′-end, such as polyadenylation of the 3′-end of the pre-mature mRNA and optional endo- or exonuclease cleavages etc. In the context of the present invention, a 3′UTR corresponds to the sequence of a mature mRNA which is located 3′ to the stop codon of the protein coding region, preferably immediately 3′ to the stop codon of the protein coding region, and which extends to the 5′-side of the poly(A) sequence, preferably to the nucleotide immediately 5′ to the poly(A) sequence. The term “corresponds to” means that the 3′UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 3′UTR sequence, or a DNA sequence which corresponds to such RNA sequence. In the context of the present invention, the term “a 3′UTR of a gene”, such as “a 3′UTR of an albumin gene”, is the sequence which corresponds to the 3′UTR of the mature mRNA derived from this gene, i.e. the mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term “3′UTR of a gene” encompasses the DNA sequence and the RNA sequence of the 3′UTR.

5′-untranslated region (5′UTR): A 5′UTR is typically understood to be a particular section of messenger RNA (mRNA). It is located 5′ of the open reading frame of the mRNA. Typically, the 5′UTR starts with the transcriptional start site and ends one nucleotide before the start codon of the open reading frame. The 5′UTR may comprise elements for controlling gene expression, also called regulatory elements. Such regulatory elements may be, for example, ribosomal binding sites or a 5′-Terminal Oligopyrimidine Tract. The 5′UTR may be posttranscriptionally modified, for example by addition of a 5′-cap. In the context of the present invention, a 5′UTR corresponds to the sequence of a mature mRNA which is located between the 5′cap and the start codon. Preferably, the 5′UTR corresponds to the sequence which extends from a nucleotide located 3′ to the 5′-cap, preferably from the nucleotide located immediately 3′ to the 5′cap, to a nucleotide located 5′ to the start codon of the protein coding region, preferably to the nucleotide located immediately 5′ to the start codon of the protein coding region. The nucleotide located immediately 3′ to the 5′cap of a mature mRNA typically corresponds to the transcriptional start site. The term “corresponds to” means that the 5′UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 5′UTR sequence, or a DNA sequence which corresponds to such RNA sequence. In the context of the present invention, the term “a 5′UTR of a gene”, such as “a 5′UTR of a TOP gene”, is the sequence which corresponds to the 5′UTR of the mature mRNA derived from this gene, i.e. the mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term “5′UTR of a gene” encompasses the DNA sequence and the RNA sequence of the 5′UTR.

5′Terminal Oligopyrimidine Tract (TOP): The 5′terminal oligopyrimidine tract (TOP) is typically a stretch of pyrimidine nucleotides located at the 5′ terminal region of a nucleic acid molecule, such as the 5′ terminal region of certain mRNA molecules or the 5′ terminal region of a functional entity, e.g. the transcribed region, of certain genes. The sequence starts with a cytidine, which usually corresponds to the transcriptional start site, and is followed by a stretch of usually about 3 to 30 pyrimidine nucleotides. For example, the TOP may comprise 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or even more nucleotides. The pyrimidine stretch and thus the 5′ TOP ends one nucleotide 5′ to the first purine nucleotide located downstream of the TOP. Messenger RNA that contains a 5′terminal oligopyrimidine tract is often referred to as 5′ TOP mRNA. Accordingly, genes that provide such messenger RNAs are referred to as TOP genes. TOP sequences have, for example, been found in genes and mRNAs encoding peptide elongation factors and ribosomal proteins.

TOP motif: In the context of the present invention, a TOP motif is a nucleic acid sequence which corresponds to a 5′TOP as defined above. Thus, a TOP motif in the context of the present invention is preferably a stretch of pyrimidine nucleotides having a length of 3-30 nucleotides. Preferably, the TOP-motif consists of at least 3 pyrimidine nucleotides, preferably at least 4 pyrimidine nucleotides, preferably at least 5 pyrimidine nucleotides, more preferably at least 6 nucleotides, more preferably at least 7 nucleotides, most preferably at least 8 pyrimidine nucleotides, wherein the stretch of pyrimidine nucleotides preferably starts at its 5′end with a cytosine nucleotide. In TOP genes and TOP mRNAs, the TOP-motif preferably starts at its 5′end with the transcriptional start site and ends one nucleotide 5′ to the first purin residue in said gene or mRNA. A TOP motif in the sense of the present invention is preferably located at the 5′end of a sequence which represents a 5′UTR or at the 5′end of a sequence which codes for a 5′UTR. Thus, preferably, a stretch of 3 or more pyrimidine nucleotides is called “TOP motif” in the sense of the present invention if this stretch is located at the 5′end of a respective sequence, such as the artificial nucleic acid molecule according to the present invention, the 5′UTR element of the artificial nucleic acid molecule according to the present invention, or the nucleic acid sequence which is derived from the 5′UTR of a TOP gene as described herein. In other words, a stretch of 3 or more pyrimidine nucleotides which is not located at the 5′-end of a 5′UTR or a 5′UTR element but anywhere within a 5′UTR or a 5′UTR element is preferably not referred to as “TOP motif”.

TOP gene: TOP genes are typically characterised by the presence of a 5′ terminal oligopyrimidine tract. Furthermore, most TOP genes are characterized by a growth-associated translational regulation. However, also TOP genes with a tissue specific translational regulation are known. As defined above, the 5′UTR of a TOP gene corresponds to the sequence of a 5′UTR of a mature mRNA derived from a TOP gene, which preferably extends from the nucleotide located 3′ to the 5′cap to the nucleotide located 5′ to the start codon. A 5′UTR of a TOP gene typically does not comprise any start codons, preferably no upstream AUGs (uAUGs) or upstream open reading frames (uORFs). Therein, upstream AUGs and upstream open reading frames are typically understood to be AUGs and open reading frames that occur 5′ of the start codon (AUG) of the open reading frame that should be translated. The 5′UTRs of TOP genes are generally rather short. The lengths of 5′UTRs of TOP genes may vary between 20 nucleotides up to 500 nucleotides, and are typically less than about 200 nucleotides, preferably less than about 150 nucleotides, more preferably less than about 100 nucleotides. Exemplary 5′UTRs of TOP genes in the sense of the present invention are the nucleic acid sequences extending from the nucleotide at position 5 to the nucleotide located immediately 5′ to the start codon (e.g. the ATG) in the sequences according to SEQ ID NOs. 1-1363, 1435, 1461 and 1462.

In a first aspect, the present invention relates to an artificial nucleic acid molecule comprising:

    a. at least one 5′-untranslated region element (5′UTR element) which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene; and
    b. at least one open reading frame (ORF).


Preferably, the artificial nucleic acid molecule further comprises:

    c. at least one histone stem-loop.


Such an artificial nucleic acid molecule may be DNA or RNA. In case the artificial nucleic acid molecule is DNA it may be used for providing RNA, preferably an mRNA with a corresponding sequence as is described further below. The inventive artificial nucleic acid molecule is particularly useful in gene therapy and genetic vaccination because it may provide increased and/or prolonged protein production of the protein encoded by the open reading frame.
In this context, the term ‘5′UTR element’ preferably refers to a nucleic acid sequence which represents a 5′UTR of an artificial nucleic acid sequence, such as an artificial mRNA, or which codes for a 5′UTR of an artificial nucleic acid molecule. Thus, preferably, a 5′UTR element may be the 5′UTR of an mRNA, preferably of an artificial mRNA, or it may be the transcription template for a 5′UTR of an mRNA. Thus, a 5′UTR element preferably is a nucleic acid sequence which corresponds to the 5′UTR of an mRNA, preferably to the 5′UTR of an artificial mRNA, such as an mRNA obtained by transcription of a genetically engineered vector construct. Preferably, a 5′UTR element in the sense of the present invention functions as a 5′UTR or codes for a nucleotide sequence that fulfils the function of a 5′UTR. The term ‘5′UTR element’ furthermore refers to a fragment or part of a 5′UTR of an artificial nucleic acid sequence, such as an artificial mRNA, or which codes for a part or fragment of a 5′UTR of an artificial nucleic acid molecule. This means that the 5′UTR element in the sense of the present invention may be comprised in the 5′UTR of an artificial nucleic acid sequence, such as an artificial mRNA, or which codes for a 5′UTR of an artificial nucleic acid molecule.
According to the invention, the 5′UTR element comprises or consists of a nucleic acid sequence that is derived from the 5′UTR of a TOP gene or from a variant of the 5′UTR of a TOP gene.
The term ‘a nucleic acid sequence which is derived from the 5′UTR of a TOP gene’ preferably refers to a nucleic acid sequence which is based on the 5′UTR sequence of a TOP gene or on a fragment thereof. This term includes sequences corresponding to the entire 5′UTR sequence, i.e. the full length 5′UTR sequence of a TOP gene, and sequences corresponding to a fragment of the 5′UTR sequence of a TOP gene. Preferably, a fragment of a 5′UTR of a TOP gene consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length 5′UTR of a TOP gene, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full-length 5′UTR of a TOP gene. Such a fragment, in the sense of the present invention, is preferably a functional fragment as described herein. A particularly preferred fragment of a 5′UTR of a TOP gene is a 5′UTR of a TOP gene lacking the 5′TOP motif. The term ‘5′UTR of a TOP gene’ preferably refers to the 5′UTR of a naturally occurring TOP gene.
The terms ‘variant of the 5′UTR of a TOP gene’ and ‘variant thereof’ in the context of a 5′UTR of a TOP gene refers to a variant of the 5′UTR of a naturally occurring TOP gene, preferably to a variant of the 5′UTR of a vertebrate TOP gene, preferably to a variant of the 3′UTR of a mammalian TOP gene, more preferably to a variant of the 3′UTR of a human TOP gene. Such variant may be a modified 5′UTR of a TOP gene. For example, a variant 5′UTR may exhibit one or more nucleotide deletions, insertions, additions and/or substitutions compared to the naturally occurring 5′UTR from which the variant is derived. Preferably, a variant of a 5′UTR of a TOP gene is at least 40%, preferably at least 50%, more preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% identical to the naturally occurring 5′UTR the variant is derived from. Preferably, the variant is a functional variant as described herein.
The term “a nucleic acid sequence that is derived from a variant of the 5′UTR of a TOP gene” preferably refers to a nucleic acid sequence which is based on a variant of a 5′UTR sequence of a TOP gene or on a fragment thereof. This term includes sequences corresponding to the entire variant 5′UTR sequence, i.e. the full length variant 5′UTR sequence of a TOP gene, and sequences corresponding to a fragment of the variant 5′UTR sequence of a TOP gene. Preferably, a fragment of a variant of the 5′UTR of a TOP gene consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length variant 5′UTR of a TOP gene, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full-length variant 5′UTR of a TOP gene. Such a fragment of a variant, in the sense of the present invention, is preferably a functional fragment as described herein.
Thus, the 5′UTR element of the artificial nucleic acid molecule may comprise or consist of a fragment of the 5′UTR of a TOP gene or of a fragment of a variant of the 5′UTR of a TOP gene or may comprise or consist of the entire 5′UTR of a TOP gene or may comprise or consist of a variant of the 5′UTR of a TOP gene.
The 5′UTR element is preferably suitable for increasing protein production from the artificial nucleic acid molecule.
Preferably, the at least one 5′UTR element is functionally linked to the ORF. This means preferably that the 5′UTR element is associated with the ORF such that it may exert a function, such as a protein production increasing function for the protein encoded by the ORF or a stabilizing function on the artificial nucleic acid molecule. Preferably, the 5′UTR element and the ORF are associated in 5′→3′ direction. Thus, preferably, the artificial nucleic acid molecule comprises the structure 5′-5′UTR element-(optional)linker-ORF-3′, wherein the linker may be present or absent. For example, the linker may be one or more nucleotides, such as a stretch of 1-50 or 1-20 nucleotides, e.g., comprising or consisting of one or more restriction enzyme recognition sites (restriction sites).
Preferably, the 5′UTR element and the at least one open reading frame are heterologous. The term ‘heterologous’ in this context means that the open reading frame and the 5′UTR element are not occurring naturally (in nature) in this combination. Preferably, the 5′UTR element is derived from a different gene than the open reading frame. For example, the ORF may be derived from a different gene than the 5′UTR element, e.g. encoding a different protein or the same protein but of a different species etc. For example, the ORF does not encode the protein which is encoded by the gene from which the 5′UTR element is derived.
In a preferred embodiment, the 5′UTR element, preferably the artificial nucleic acid molecule, does not comprise a complete TOP-motif or 5′TOP sequence. Thus, preferably, the 5′UTR element, preferably the artificial nucleic acid molecule, does not comprise the complete TOP-motif of the TOP gene from which the nucleic acid sequence of the 5′UTR element is derived. For example, the 5′UTR element or the artificial nucleic acid molecule according to the present invention may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine residues of the TOP-motif or 5′TOP, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine residues of the TOP-motif located at the 3′side of the TOP-motif or 5′TOP. For example, the 5′UTR element may comprise or consist of a nucleic acid sequence which starts at its 5′end with a pyrimidine residue that corresponds to residue 2, 3, 4, 5, 6, 7, 8, 9, 10 etc. of the TOP-motif or 5′TOP of the TOP gene from which the nucleic acid sequence of the 5′UTR element is derived.
It is particularly preferred that the 5′UTR element, preferably the artificial nucleic acid molecule according to the present invention, does not comprise a TOP-motif or 5′TOP. For example, the nucleic acid sequence of the 5′UTR element which is derived from a 5′UTR of a TOP gene starts at its 5′-end with a nucleotide located at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 downstream of the 5′terminal oligopyrimidine tract (TOP) of the 5′UTR of a TOP gene. Position 1 downstream of the 5′terminal oligopyrimidine tract (TOP) is the first purine based nucleotide 3′ of the TOP-motif or the 5′TOP. Accordingly, position 1 downstream of the 5′terminal oligopyrimidine tract is the first nucleotide following the 3′-end of the 5′terminal oligopyrimidine tract in 5′-3′-direction. Likewise, position 2 downstream of the 5′TOP is the second nucleotide following the end of the 5′terminal oligopyrimidine tract, position 3 the third nucleotide and so on.
Therefore, the 5′UTR element preferably starts 5, 10, 15, 20, 25, 30, 40 or 50 nucleotides downstream of the transcriptional start site of the 5′UTR of a TOP gene.
In some embodiments, the nucleic acid sequence of the 5′UTR element which is derived from a 5′UTR of a TOP gene terminates at its 3′-end with a nucleotide located at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 upstream of the start codon (e.g. A(U/T)G) of the gene or mRNA it is derived from. Thus, the 5′UTR element does not comprise any part of the protein coding region. Thus, preferably, the only protein coding part of the inventive artificial nucleic acid molecule is provided by the open reading frame. However, the open reading frame is preferably derived—as said above—from a gene that is different to the gene the 5′UTR element is derived from.
It is particularly preferred that the 5′UTR element does not comprise a start codon, such as the nucleotide sequence A(U/T)G. Thus, preferably, the artificial nucleic acid molecule will not comprise any upstream AUGs (or upstream ATGs in case it is a DNA molecule). In other words, in some embodiments, it may be preferred that the AUG or ATG, respectively, of the open reading frame is the only start codon of the artificial nucleic acid molecule.
Additionally, it is preferred that the 5′UTR element does not comprise an open reading frame. Thus, preferably, the artificial nucleic acid molecule will not comprise any upstream open reading frames.
The nucleic acid sequence which is derived from the 5′UTR of a TOP gene is derived from a eukaryotic TOP gene, preferably a plant or animal TOP gene, more preferably a chordate TOP gene, even more preferably a vertebrate TOP gene, most preferably a mammalian TOP gene, such as a human or mouse TOP gene.
Preferably, the artificial nucleic acid molecule according to the present invention comprises a 5′UTR element which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene, wherein the TOP gene is a plant or animal TOP gene, more preferably a chordate TOP gene, even more preferably a vertebrate TOP gene, most preferably a mammalian TOP gene, such as a human or mouse TOP gene and which optionally does not comprise the nucleotide sequence A(U/T)G and optionally does not comprise an open reading frame; at least one open reading frame (ORF); and optionally at least one histone-stem loop; wherein optionally the 5′UTR element does not comprise a TOP motif and wherein optionally the 5′UTR element starts at its 5′-end with a nucleotide located at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 downstream of the 5′terminal oligopyrimidine tract (TOP) of the 5′UTR of a TOP gene and wherein further optionally the 5′UTR element which is derived from a 5′UTR of a TOP gene terminates at its 3′-end with a nucleotide located at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 upstream of the start codon (A(U/T)G) of the gene or mRNA it is derived from.
For example, the 5′UTR element comprises or consists of a nucleic acid sequence which is derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from the homologs of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from a variant thereof, or a corresponding RNA sequence. The term “homologs of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462,” refers to sequences of other species than Homo sapiens (human) or Mus musculus (mouse), which are homologous to the sequences according to SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462. For example, SEQ ID NO. 1 relates to a sequence comprising the 5′UTR of Homo sapiens alpha 2 macroglobulin (A2M). A homolog of SEQ ID NO. 1 in the context of the present invention is any such sequence derived from an alpha 2 macroglobulin (A2M) gene or mRNA of another species than Homo sapiens (human), such as any vertebrate, preferably any mammalian alpha 2 macroglobulin (A2M) gene other than the human alpha 2 macroglobulin (A2M) gene, such as a mouse, rat, rabbit, monkey etc. alpha 2 macroglobulin (A2M) gene.
In a preferred embodiment, the 5′UTR element comprises or consists of a nucleic acid sequence which is derived from a nucleic acid sequence extending from nucleotide position 5 (i.e. the nucleotide that is located at position 5 in the sequence) to the nucleotide position immediately 5′ to the start codon (located at the 3′ end of the sequences), e.g. the nucleotide position immediately 5′ to the ATG sequence, of a nucleic acid sequence selected from SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from the homologs of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from a variant thereof, or a corresponding RNA sequence. It is particularly preferred that the 5′ UTR element is derived from a nucleic acid sequence extending from the nucleotide position immediately 3′ to the 5′-TOP to the nucleotide position immediately 5′ to the start codon (located at the 3′ end of the sequences), e.g. the nucleotide position immediately 5′ to the ATG sequence, of a nucleic acid sequence selected from SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from the homologs of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from a variant thereof, or a corresponding RNA sequence.
In a preferred embodiment, the 5′UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence extending from nucleotide position 5 to the nucleotide position immediately 5′ to the start codon (located at the 3′ end of the sequences), e.g. the nucleotide position immediately 5′ to the ATG sequence of a nucleic acid sequence, selected from SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, or a corresponding RNA sequence, or wherein the at least one 5′UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence extending from nucleotide position 5 to the nucleotide position immediately 5′ to the start codon (located at the 3′ end of the sequences), e.g. the nucleotide position immediately 5′ to the ATG sequence of a nucleic acid sequence, selected from SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, or a corresponding RNA sequence, wherein, preferably, the fragment is as described above, i.e. being a continuous stretch of nucleotides representing at least 20% etc. of the full-length 5′UTR the fragment is derived from.
Preferably, the 5′UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence extending from the nucleotide position immediately 3′ to the 5′TOP to the nucleotide position immediately 5′ to the start codon (located at the 3′ end of the sequences), e.g. the nucleotide position immediately 5′ to the ATG sequence, of a nucleic acid sequence selected from SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, or a corresponding RNA sequence, or wherein the at least one 5′UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence extending from the nucleotide position immediately 3′ to the 5′TOP to the nucleotide position immediately 5′ to the start codon (located at the 3′ end of the sequences), e.g. the nucleotide position immediately 5′ to the ATG sequence, of a nucleic acid sequence selected from SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, or a corresponding RNA sequence, wherein, preferably, the fragment is as described above, i.e. being a continuous stretch of nucleotides representing at least 20% etc. of the full-length 5′UTR the fragment is derived from.
Preferably, the above defined fragments and variants (e.g. exhibiting at least 40% identity) of the sequences according to SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, are functional fragments and variants as described herein.
Furthermore, the artificial nucleic acid molecule according to the present invention may comprise more than one 5′UTR elements as described above. For example, the artificial nucleic acid molecule according to the present invention may comprise one, two, three, four or more 5′UTR elements, wherein the individual 5′UTR elements may be the same or they may be different. For example, the artificial nucleic acid molecule according to the present invention may comprise two essentially identical 5′UTR elements as described above, e.g. two 5′UTR elements comprising or consisting of a nucleic acid sequence which is derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from the homologs of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from a variant thereof, or a corresponding RNA sequence or from functional variants thereof, functional fragments thereof, or functional variant fragments thereof as described above.
In a particularly preferred embodiment, the 5′UTR element comprises or consists of a nucleic acid sequence which is derived from a 5′UTR of a TOP gene encoding a ribosomal protein or from a variant of a 5′UTR of a TOP gene encoding a ribosomal protein. Particularly preferred 5′UTR elements comprise or consist of a nucleic acid sequence which are derived from a 5′ UTR of a TOP gene coding for a ribosomal protein selected from RPSA, RPS2, RPS3, RPS3A, RPS4, RPS5, RPS6, RPS7, RPS8, RPS9, RPS10, RPS11, RPS12, RPS13, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS18, RPS19, RPS20, RPS21, RPS23, RPS24, RPS25, RPS26, RPS27, RPS27A, RPS28, RPS29, RPS30, RPL3, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL8, RPL9, RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL14, RPL15, RPL17, RPL18, RPL18A, RPL19, RPL21, RPL22, RPL23, RPL23A, RPL24, RPL26, RPL27, RPL27A, RPL28, RPL29, RPL30, RPL31, RPL32, RPL34, RPL35, RPL35A, RPL36, RPL36A, RPL37, RPL37A, RPL38, RPL39, RPL40, RPL41, RPLP0, RPLP1, RPLP2, RPLP3, UBA52. Particularly preferred are nucleic acid sequences which are derived from a 5′ UTR of TOP genes vertebrate coding for ribosomal proteins, such as mammalian ribosomal proteins e.g. human or mouse ribosomal proteins.
For example, the 5′UTR element comprises or consists of a nucleic acid sequence which is derived from a 5′UTR of a nucleic acid sequence according to any of SEQ ID NOs: 170, 232, 244, 259, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, or 1360; a corresponding RNA sequence, a homolog thereof, or a variant thereof as described herein, preferably lacking the 5′TOP motif. As described above, the sequence extending from position 5 to the nucleotide immediately 5′ to the ATG (which is located at the 3′end of the sequences) corresponds to the 5′UTR of said sequences.
Preferably, the 5′UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the 5′UTR of a nucleic acid sequence according to any of SEQ ID NOs: 170, 232, 244, 259, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, or 1360; or a corresponding RNA sequence, preferably lacking the 5′TOP motif, or wherein the at least one 5′UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the 5′UTR of a nucleic acid sequence according to SEQ ID NOs: 170, 232, 244, 259, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, or 1360; or a corresponding RNA sequence, wherein, preferably, the fragment is as described above, i.e. being a continuous stretch of nucleotides representing at least 20% etc. of the full-length 5′UTR, preferably lacking the 5′TOP motif. Preferably, the fragment exhibits a length of at least about 20 nucleotides or more, preferably of at least about 30 nucleotides or more, more preferably of at least about 40 nucleotides or more. Preferably, the fragment is a functional fragment as described herein.
Preferably, the 5′UTR element comprises or consists of a nucleic acid sequence which is derived from a 5′UTR of a TOP gene encoding a ribosomal Large protein (RPL) or from a variant of a 5′UTR of a TOP gene encoding a ribosomal Large protein (RPL). For example, the 5′UTR element comprises or consists of a nucleic acid sequence which is derived from a 5′UTR of a nucleic acid sequence according to any of SEQ ID NOs: 67, 259, 1284-1318, 1344, 1346, 1348-1354, 1357, 1461 and 1462, a corresponding RNA sequence, a homolog thereof, or a variant thereof as described herein, preferably lacking the 5′TOP motif.
Preferably, the 5′UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the 5′UTR of a nucleic acid sequence according to any of SEQ ID NOs. 67, 259, 1284-1318, 1344, 1346, 1348-1354, 1357, and 1358 or a corresponding RNA sequence, preferably lacking the 5′TOP motif, or wherein the at least one 5′UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the 5′UTR of a nucleic acid sequence according to SEQ ID NOs: 67, 259, 1284-1318, 1344, 1346, 1348-1354, 1357, 1461 and 1462 or a corresponding RNA sequence, wherein, preferably, the fragment is as described above, i.e. being a continuous stretch of nucleotides representing at least 20% etc. of the full-length 5′UTR, preferably lacking the 5′TOP motif. Preferably, the fragment exhibits a length of at least about 20 nucleotides or more, preferably of at least about 30 nucleotides or more, more preferably of at least about 40 nucleotides or more. Preferably, the fragment is a functional fragment as described herein.
In a particularly preferred embodiment, the 5′UTR element comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a ribosomal protein Large 32 gene (RPL32), a ribosomal protein Large 35 gene (RPL35), a ribosomal protein Large 21 gene (RPL21), an ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) gene, an hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD1784), an androgen-induced 1 gene (AIG1), cytochrome c oxidase subunit VIc gene (COX6C), or a N-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variant thereof, preferably from a vertebrate ribosomal protein Large 32 gene (RPL32), a vertebrate ribosomal protein Large 35 gene (RPL35), a vertebrate ribosomal protein Large 21 gene (RPL21), a vertebrate ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) gene, a vertebrate hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD1784), a vertebrate androgen-induced 1 gene (AIG1), a vertebrate cytochrome c oxidase subunit VIc gene (COX6C), or a vertebrate N-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variant thereof, more preferably from a mammalian ribosomal protein Large 32 gene (RPL32), a ribosomal protein Large 35 gene (RPL35), a ribosomal protein Large 21 gene (RPL21), a mammalian ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) gene, a mammalian hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD17B4), a mammalian androgen-induced 1 gene (AIG1), a mammalian cytochrome c oxidase subunit VIc gene (COX6C), or a mammalian N-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variant thereof, most preferably from a human ribosomal protein Large 32 gene (RPL32), a human ribosomal protein Large 35 gene (RPL35), a human ribosomal protein Large 21 gene (RPL21), a human ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) gene, a human hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD17B4), a human androgen-induced 1 gene (AIG1), a human cytochrome c oxidase subunit VIc gene (COX6C), or a human N-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variant thereof, wherein preferably the 5′UTR element does not comprise the 5′TOP of said gene.
Accordingly, in a particularly preferred embodiment, the 5′UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the nucleic acid sequence according to SEQ ID No. 1368, or SEQ ID NOs 1452-1460 or a corresponding RNA sequence, or wherein the at least one 5′UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the nucleic acid sequence according to SEQ ID No. 1368, or SEQ ID NOs 1452-1460 wherein, preferably, the fragment is as described above, i.e. being a continuous stretch of nucleotides representing at least 20% etc. of the full-length 5′UTR. Preferably, the fragment exhibits a length of at least about 20 nucleotides or more, preferably of at least about 30 nucleotides or more, more preferably of at least about 40 nucleotides or more. Preferably, the fragment is a functional fragment as described herein.
Preferably, the at least one 5′UTR element exhibits a length of at least about 20 nucleotides or more, preferably of at least about 30 nucleotides or more, more preferably of at least about 40 nucleotides or more. However, it may be preferred if the 5′UTR element of the artificial nucleic acid molecule is rather short. Accordingly, it may have a length of less than about 200, preferably less than 150, more preferably less than 100 nucleotides. For example, the 5′UTR may have a length of less than about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200 nucleotides Preferably, the 5′UTR element may have a length of about 20-25, 26-30, 31-35, 36-40, 41-45, 46-50, 51-55, 56-60, 61-65, 66-70, 71-80, 81-85, 86-90, 91-95, 96-100, 101-105, 106-110, 111-115, 116-120, 121-125, 126-130, 131-135, 136-140, 141-145, 146-150, 151-155, 156-160, 161-165, 166-170, 171-175, 176-180, 181-185, 186-190, 191-195, 196-200 or more nucleotides. For example, the 5′UTR element may have a length of about 20, 26, 31, 36, 41, 46, 51, 56, 61, 66, 71, 81, 86, 91, 96, 101, 106, 111, 116, 121, 126, 131, 136, 141, 146, 151, 156, 161, 166, 171, 176, 181, 186, 191 or 196 nucleotides. Preferably, the 5′UTR element may have a length from about 20, 30, 40 or more to less than about 200 nucleotides, more preferably from about 20, 30, 40 or more to less than about 150 nucleotides, most preferably from about 20, 30, 40 or more to less than about 100 nucleotides.
Preferred 5′UTR elements are derived from a 5′ UTR of a TOP gene selected from RPSA, RPS2, RPS3, RPS3A, RPS4, RPS5, RPS6, RPS7, RPS8, RPS9, RPS10, RPS11, RPS12, RPS13, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS18, RPS19, RPS20, RPS21, RPS23, RPS24, RPS25, RPS26, RPS27, RPS27A, RPS28, RPS29, RPS30, RPL3, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL8, RPL9, RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL14, RPL15, RPL17, RPL18, RPL18A, RPL19, RPL21, RPL22, RPL23, RPL23A, RPL24, RPL26, RPL27, RPL27A, RPL28, RPL29, RPL30, RPL31, RPL32, RPL34, RPL35, RPL35A, RPL36, RPL36A, RPL37, RPL37A, RPL38, RPL39, RPL40, RPL41, RPLP0, RPLP1, RPLP2, RPLP3, RPLP0, RPLP1, RPLP2, EEF1A1, EEF1B2, EEF1D, EEF1G, EEF2, EIF3E, EIF3F, EIF3H, EIF2S3, EIF3C, EIF3K, EIF3EIP, EIF4A2, PABPC1, HNRNPA1, TPT1, TUBB1, UBA52, NPM1, ATP5G2, GNB2L1, NME2, UQCRB or from a variant thereof.
In some embodiments, the artificial nucleic acid molecule comprises a 5′UTR element which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a vertebrate TOP gene, such as a mammalian, e.g. a human TOP gene, selected from RPSA, RPS2, RPS3, RPS3A, RPS4, RPS5, RPS6, RPS7, RPS8, RPS9, RPS10, RPS11, RPS12, RPS13, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS18, RPS19, RPS20, RPS21, RPS23, RPS24, RPS25, RPS26, RPS27, RPS27A, RPS28, RPS29, RPS30, RPL3, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL8, RPL9, RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL14, RPL15, RPL17, RPL18, RPL18A, RPL19, RPL21, RPL22, RPL23, RPL23A, RPL24, RPL26, RPL27, RPL27A, RPL28, RPL29, RPL30, RPL31, RPL32, RPL34, RPL35, RPL35A, RPL36, RPL36A, RPL37, RPL37A, RPL38, RPL39, RPL40, RPL41, RPLP0, RPLP1, RPLP2, RPLP3, RPLP0, RPLP1, RPLP2, EEF1A1, EEF1B2, EEF1D, EEF1G, EEF2, EIF3E, EIF3F, EIF3H, EIF2S3, EIF3C, EIF3K, EIF3EIP, EIF4A2, PABPC1, HNRNPA1, TPT1, TUBB1, UBA52, NPM1, ATP5G2, GNB2L1, NME2, UQCRB or from a variant thereof, wherein preferably the 5′UTR element does not comprise a TOP motif or the 5′TOP of said genes, and wherein optionally the 5′UTR element starts at its 5′-end with a nucleotide located at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 downstream of the 5′terminal oligopyrimidine tract (TOP) and wherein further optionally the 5′UTR element which is derived from a 5′UTR of a TOP gene terminates at its 3′-end with a nucleotide located at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 upstream of the start codon (A(U/T)G) of the gene it is derived from.
In a particularly preferred embodiment, the artificial nucleic acid molecule further comprises a histone stem-loop.
Accordingly, it is particularly preferred that the artificial nucleic acid molecule according to the present invention comprises:

    a. at least one 5′-untranslated region element (5′UTR element) which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene as described above;
    b. at least one open reading frame (ORE); and
    c. at least one histone stem-loop.


The combination of a 5′UTR element as described above with a histone stem-loop may have a particularly advantageous effect in providing prolonged and possibly also enhanced translation of an RNA molecule.
In the context of the present invention, such a histone stem-loop is typically derived from a histone gene and comprises an intramolecular base pairing of two neighbored entirely or partially reverse complementary sequences, thereby forming a stem-loop. A stem-loop can occur in single-stranded DNA or, more commonly, in RNA. The structure is also known as a hairpin or hairpin loop and usually consists of a stem and a (terminal) loop within a consecutive sequence, wherein the stem is formed by two neighbored entirely or partially reverse complementary sequences separated by a short sequence as sort of spacer, which builds the loop of the stem-loop structure. The two neighbored entirely or partially reverse complementary sequences may be defined as e.g. stem-loop elements stem1 and stem2.
The stem loop is formed when these two neighbored entirely or partially reverse complementary sequences, e.g. stem-loop elements stem1 and stem2, form base-pairs with each other, leading to a double stranded nucleic acid sequence comprising an unpaired loop at its terminal ending formed by the short sequence located between stem-loop elements stem1 and stem2 on the consecutive sequence. The unpaired loop thereby typically represents a region of the nucleic acid which is not capable of base pairing with either of these stem-loop elements. The resulting lollipop-shaped structure is a key building block of many RNA secondary structures. The formation of a stem-loop structure is thus dependent on the stability of the resulting stem and loop regions, wherein the first prerequisite is typically the presence of a sequence that can fold back on itself to form a paired double strand. The stability of paired stem-loop elements is determined by the length, the number of mismatches or bulges it contains (a small number of mismatches is typically tolerable, especially in a long double strand), and the base composition of the paired region. In the context of the present invention, optimal loop length is 3-10 bases, more preferably 3 to 8, 3 to 7, 3 to 6 or even more preferably 4 to 5 bases, and most preferably 4 bases.
Preferably, the at least one histone stem-loop is functionally associated to the ORF. This means that the at least one histone stem-loop is preferably positioned within the artificial nucleic acid molecule such that it is able to exert its function, for example, its function of increasing protein production from the ORF or stabilizing the artificial nucleic acid molecule.
Preferably, the histone stem-loop is located 3′ to the ORF. For example, the histone stem-loop may be connected to the 3′-end of the ORF directly or via a linker, for example via a stretch of nucleotides, such as 2, 4, 6, 8, 10 etc. nucleotides, e.g. comprising one or more restriction sites, or the histone stem-loop may be located within or between or downstream of other structures located 3′ to the ORF, such as within a 3′UTR element, or between a poly(A) sequence and a poly(C) sequence, or down-stream of a poly(A) and/or a poly(C) sequence, or the histone stem-loop may be located at the 3′-end of the artificial nucleic acid molecule. The term “located at the 3′-end” also includes embodiments, wherein the histone stem-loop is followed in 3′-direction by few nucleotides which remain, e.g., after a restriction enzyme cleavage.
Preferably, the 5′UTR element and the histone stem-loop are chosen and positioned such that they exert at least an additive, preferably a synergistic function on protein production from the ORF of the artificial nucleic acid molecule. Preferably, protein production from the ORF is increased at least in an additive, preferably in a synergistic way by the 5′UTR element and the histone stem-loop. Thus, the protein amount of the protein encoded by the ORF, such as a reporter protein, e.g. luciferase, at a certain time point after initiation of expression of the ORF, e.g. after transfection of a test cell line, is at least the same, preferably higher than what would be expected if the protein production increasing effects of the 5′UTR element and the histone stem-loop were purely additive. The additive, preferably synergistic effect may, for example, be determined by the following assay. Four artificial nucleic acid molecules, e.g. mRNAs, comprising an ORF encoding, e.g. a reporter protein such as luciferase, are generated, i.e. (i) lacking a 5′UTR element and a histone stem-loop (E0), (ii) containing a 5′UTR element derived from a 5′UTR of a TOP gene or of a variant thereof (E1), (iii) containing a histone stem-loop (E2), and (iv) containing both the 5′UTR element and the histone stem-loop (E1E2). Expression of the ORF contained in the artificial nucleic acid molecules is initiated, for example, by transfecting a test cell line, such as a mammalian cell line, e.g. HELA cells, or primary cells, e.g. HDF cells. Samples are taken at specific time points after initiation of expression, for example, after 6 hours, 24 hours, 48 hours, and/or 72 hours and the amount of protein produced by expression of the ORF contained in the artificial nucleic acid molecules is measured, for example, by an ELISA assay or a luciferase test, depending on the type of protein encoded by the ORF. The predicted amount of protein at a certain time point after initiation of expression obtained by construct E1E2 if the effects of the 3′UTR element and the 5′UTR element were purely additive (PPA) may be calculated as follows:

PPAX=(E1x−E0x)+(E2x−E0x)+E0x,

E0 is the amount of protein obtained for the construct E0 (lacking a 5′UTR and a histone stem-loop), E1 is the amount of protein obtained for the construct E1, E2 is the protein amount obtained for the construct E2, and x is the time point after initiation of expression. The effect on increasing protein production is additive if E1E2x=PPAX, and synergistic in the sense of the present invention if E1E2x>PPAX, wherein E1E2x is the amount of protein obtained from construct E1E2 at time point x. Preferably, E1E2 is at least 1.0, more preferably at least 1.1, more preferably at least 1.3, more preferably at least 1.5, even more preferably at least 1.75 times PPA at a given time point post initiation of expression, such as 24 hours, 48 hours or 72 hours post initiation of expression.

Thus, in a preferred embodiment, the present invention provides an artificial nucleic acid molecule comprising (a.) at least one 5′UTR element which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene as described above; (b.) at least one open reading frame (ORF); and (c.) at least one histone stem-loop as described herein, wherein the histone stem-loop and the 5′UTR element act at least additively, preferably synergistically to increase protein production from the ORF, preferably wherein E1E2≧PPA, preferably E1E2 is at least PPA, more preferably E1E2 is at least 1.1 times PPA, more preferably E1E2 is at least 1.3 times PPA, even more preferably wherein E1E2 is at least 1.5 times PPA at a given time point post initiation of expression of the ORF, for example 24 hours, preferably 48 hours post initiation of expression, wherein E1E2 and PPA are as described above.
Furthermore, it is preferred that the at least one histone stem-loop and the at least one 5′UTR element have an at least additive, preferably a synergistic effect on total protein production from the artificial nucleic acid molecule in a certain time span, such as within 24 hours, 48 hours, or 72 hours post initiation of expression. The additive, preferably the synergistic effect may be determined as described above, with the difference that the area under the curve (AUC) for the amount of protein over time predicted for E1E2 if the effects are additive is compared to the actual AUC measured for E1E2.
In a preferred embodiment of the present invention, the inventive artificial nucleic acid molecule comprises or codes for (a.) at least one 5′UTR element as described above, (b.) at least one open reading frame; and (c.) at least one histone stem-loop, preferably according to at least one of the following formulae (I) or (II):
formula (I) (stem-loop sequence without stem bordering elements):




formula (II) (stem-loop sequence with stem bordering elements):





wherein:

stem1 or stem2 bordering element N1-6 is a consecutive sequence of 1 to 6, preferably of 2 to 6, more preferably of 2 to 5, even more preferably of 3 to 5, most preferably of 4 to 5 or 5 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C, or a nucleotide analogue thereof;

stem1 [N0-2GN3-5] is reverse complementary or partially reverse complementary with element stem2, and is a consecutive sequence of between 5 to 7 nucleotides;

wherein N0-2 is a consecutive sequence of 0 to 2, preferably of 0 to 1, more preferably of 1 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C or a nucleotide analogue thereof;

wherein N3-5 is a consecutive sequence of 3 to 5, preferably of 4 to 5, more preferably of 4 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C or a nucleotide analogue thereof, and

wherein G is guanosine or an analogue thereof, and may be optionally replaced by a cytidine or an analogue thereof, provided that its complementary nucleotide cytidine in stem2 is replaced by guanosine;

loop sequence [N0-4(U/T)N0-4] is located between elements stem1 and stem2, and is a consecutive sequence of 3 to 5 nucleotides, more preferably of 4 nucleotides;

wherein each N0-4 is independent from another a consecutive sequence of 0 to 4, preferably of 1 to 3, more preferably of 1 to 2 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C or a nucleotide analogue thereof; and

wherein U/T represents uridine, or optionally thymidine;

stem2 [N3-5CN0-2] is reverse complementary or partially reverse complementary with element stem1, and is a consecutive sequence of between 5 to 7 nucleotides;

wherein N3-5 is a consecutive sequence of 3 to 5, preferably of 4 to 5, more preferably of 4 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C or a nucleotide analogue thereof;

wherein N0-2 is a consecutive sequence of 0 to 2, preferably of 0 to 1, more preferably of 1 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G or C or a nucleotide analogue thereof; and

wherein C is cytidine or an analogue thereof, and may be optionally replaced by a guanosine or an analogue thereof provided that its complementary nucleotide guanosine in stem1 is replaced by cytidine;

wherein stem1 and stem2 are capable of base pairing with each other forming a reverse complementary sequence, wherein base pairing may occur between stem1 and stem2, e.g. by Watson-Crick base pairing of nucleotides A and U/T or G and C or by non-Watson-Crick base pairing e.g. wobble base pairing, reverse Watson-Crick base pairing, Hoogsteen base pairing, reverse Hoogsteen base pairing or are capable of base pairing with each other forming a partially reverse complementary sequence, wherein an incomplete base pairing may occur between stem1 and stem2, on the basis that one ore more bases in one stem do not have a complementary base in the reverse complementary sequence of the other stem.

In the above context, a wobble base pairing is typically a non-Watson-Crick base pairing between two nucleotides. The four main wobble base pairs in the present context, which may be used, are guanosine-uridine, inosine-uridine, inosine-adenosine, inosine-cytidine (G-U/T, I-U/T, I-A and I-C) and adenosine-cytidine (A-C).
Accordingly, in the context of the present invention, a wobble base is a base, which forms a wobble base pair with a further base as described above. Therefore, non-Watson-Crick base pairing, e.g. wobble base pairing, may occur in the stem of the histone stem-loop structure according to the present invention.
In the above context, a partially reverse complementary sequence comprises maximally two, preferably only one mismatch in the stem-structure of the stem-loop sequence formed by base pairing of stem1 and stem2. In other words, stem1 and stem2 are preferably capable of (full) base pairing with each other throughout the entire sequence of stem1 and stem2 (100% of possible correct Watson-Crick or non-Watson-Crick base pairings), thereby forming a reverse complementary sequence, wherein each base has its correct Watson-Crick or non-Watson-Crick base pendant as a complementary binding partner. Alternatively, stem1 and stem2 are preferably capable of partial base pairing with each other throughout the entire sequence of stem1 and stem2, wherein at least about 70%, 75%, 80%, 85%, 90%, or 95% of the 100% possible correct Watson-Crick or non-Watson-Crick base pairings are occupied with the correct Watson-Crick or non-Watson-Crick base pairings and at most about 30%, 25%, 20%, 15%, 10%, or 5% of the remaining bases are unpaired.
According to a preferred embodiment of the invention, the at least one histone stem-loop sequence (with stem bordering elements) of the inventive nucleic acid sequence as defined herein comprises a length of about 15 to about 45 nucleotides, preferably a length of about 15 to about 40 nucleotides, preferably a length of about 15 to about 35 nucleotides, preferably a length of about 15 to about 30 nucleotides and even more preferably a length of about 20 to about 30 and most preferably a length of about 24 to about 28 nucleotides.
Furthermore, the at least one histone stem-loop sequence (without stem bordering elements) of the inventive artificial nucleic acid molecule as defined herein may comprise a length of about 10 to about 30 nucleotides, preferably a length of about 10 to about 20 nucleotides, preferably a length of about 12 to about 20 nucleotides, preferably a length of about 14 to about 20 nucleotides and even more preferably a length of about 16 to about 17 and most preferably a length of about 16 nucleotides.
Preferably, the inventive artificial nucleic acid molecule may comprise or code for (a.) at least one 5′UTR element as described above; at least one open reading frame; and (c.) at least one histone stem-loop sequence according to at least one of the following specific formulae (Ia) or (IIa):
formula (Ia) (stem-loon sequence without stem bordering elements):




formula (IIa) (stem-loop sequence with stem bordering elements):





wherein N, C, G, T and U are as defined above.

Preferably, the inventive artificial nucleic acid molecule may comprise or code for (a.) at least one 5′UTR element as described above; at least one open reading frame; and (c.) at least one histone stem-loop sequence according to at least one of the following specific formulae (Ib) or (IIb):
formula (Ib) (stem-loop sequence without stem bordering elements):




formula (IIb) (stem-loop sequence with stem bordering elements):





wherein N, C, G, T and U are as defined above.

Preferably, the inventive artificial nucleic acid molecule may comprise or code for (a.) at least one 5′UTR element as described above; at least one open reading frame; and (c.) at least one histone stem-loop sequence according to at least one of the following specific formulae (Ic) to (Ih) or (IIc) to (IIh), shown alternatively in its stem-loop structure and as a linear sequence representing histone stem-loop sequences as generated according to Example 1:
formula (Ic): (metazoan and protozoan histone stem-loop consensus sequence without stem bordering elements):









     N U



    N   N



     N-N



     N-N



     N-N



     N-N



     G-C



     N-N (stem-loop structure)



 







(SEQ ID NO: 1391)









NGNNNNNNUNNNNNCN



(linear sequence)






formula (IIc): (metazoan and protozoan histone stem-loop consensus sequence with stem bordering elements):










       N U



      N   N



       N-N



       N-N



       N-N



       N-N



       G-C



N*N*NNNN-NNNN*N*N* (stem-loop structure)



 







(SEQ ID NO: 1392)









N*N*NNNNGNNNNNNUNNNNNCNNNN*N*N*



(linear sequence)






formula (Id): (without stem bordering elements)










     N U



    N   N



     N-N



     N-N



     N-N



     N-N



     C-G



     N-N (stem-loop structure)



 







(SEQ ID NO: 1393)









NCNNNNNNUNNNNNGN



(linear sequence)






formula (IId): (with stem bordering elements)










       N U



      N   N



       N-N



       N-N



       N-N



       N-N



       C-G



N*N*NNNN-NNNN*N*N* (stem-loop structure)



 







(SEQ ID NO: 1394)









N*N*NNNNCNNNNNNUNNNNNGNNNN*N*N*



(linear sequence)






formula (Ie): (protozoan histone stem-loop consensus sequence without stem bordering elements)










     N U



    N   N



     N-N



     N-N



     N-N



     N-N



     G-C



     D-H (stem-loop structure)



 







(SEQ ID NO: 1395)









DGNNNNNNUNNNNNCH



(linear sequence)






formula (IIe): (protozoan histone stem-loop consensus sequence with stem bordering elements)










       N U



      N   N



       N-N



       N-N



       N-N



       N-N



       G-C



N*N*NNND-HNNN*N*N* (stem-loop structure)



 







(SEQ ID NO: 1396)









N*N*NNNDGNNNNNNUNNNNNCHNNN*N*N*



(linear sequence)






formula (If): (metazoan histone stem-loop consensus sequence without stem bordering elements)










     N U



    N   N



     Y-V



     Y-N



     B-D



     N-N



     G-C



     N-N (stem-loop structure)



 







(SEQ ID NO: 1397)









NGNBYYNNUNVNDNCN



(linear sequence)






formula (IIf): (metazoan histone stem-loop consensus sequence with stem bordering elements)










       N U



      N   N



       Y-V



       Y-N



       B-D



       N-N



       G-C



N*N*NNNN-NNNN*N*N* (stem-loop structure)



 







(SEQ ID NO: 1398)









N*N*NNNNGNBYYNNUNVNDNCNNNN*N*N*



(linear sequence)






formula (Ig): (vertebrate histone stem-loop consensus sequence without stem bordering elements)










     N U



    D   H



     Y-A



     Y-B



     Y-R



     H-D



     G-C



     N-N (stem-loop structure)



 







(SEQ ID NO: 1399)









NGHYYYDNUHABRDCN



(linear sequence)






formula (IIg): (vertebrate histone stem-loop consensus sequence with stem bordering elements)










       N U



      D   H



       Y-A



       Y-B



       Y-R



       H-D



       G-C



N*N*HNNN-NNNN*N*H* (stem-loop structure)



 







(SEQ ID NO: 1400)









N*N*HNNNGHYYYDNUHABRDCNNNN*N*H*



(linear sequence)






formula (Ih): (human histone stem-loop consensus sequence (Homo sapiens) without stem bordering elements)










     Y U



    D   H



     U-A



     C-S



     Y-R



     H-R



     G-C



     D-C (stem-loop structure)



 







(SEQ ID NO: 1401)









DGHYCUDYUHASRRCC



(linear sequence)






formula (IIh): (human histone stem-loop consensus sequence (Homo sapiens) with stem bordering elements)










       Y U



      D   H



       U-A



       C-S



       Y-R



       H-R



       G-C



N*H*AAHD-CVHB*N*H* (stem loop structure)



 







(SEQ ID NO: 1402)









N*H*AAHDGHYCUDYUHASRRCCVHB*N*H*



(linear sequence)






wherein in each of above formulae (Ic) to (Ih) or (Ic) to (Ih):

N, C, G, A, T and U are as defined above;

each U may be replaced by T;

each (highly) conserved G or C in the stem elements 1 and 2 may be replaced by its complementary nucleotide base C or G, provided that its complementary nucleotide in the corresponding stem is replaced by its complementary nucleotide in parallel; and/or

G, A, T, U, C, R, Y, M, K, S, W, H, B, V, D, and N are nucleotide bases as defined in the following Table:
















abbreviation 
Nucleotide bases
remark









G
G
Guanine



A
A
Adenine



T
T
Thymine



U
U
Uracile



C
C
Cytosine



R
G or A
Purine



Y
T/U or C
Pyrimidine



M
A or C
Amino



K
G or T/U
Keto



S
G or C
Strong (3H bonds)



W
A or T/U
Weak (2H bonds)



H
A or C or T/U
Not G



B
G or T/U or C
Not A



V
G or C or A
Not T/U



D
G or A or T/U
Not C



N
G or C or T/U or A 
Any base



*
Present or not
Base may be present or not










In this context, it is particularly preferred that the histone stem-loop sequence according to at least one of the formulae (I) or (Ia) to (Ih) or (II) or (IIa) to (IIh) of the present invention is selected from a naturally occurring histone stem-loop sequence, more particularly preferred from protozoan or metazoan histone stem-loop sequences, and even more particularly preferred from vertebrate and mostly preferred from mammalian histone stem-loop sequences especially from human histone stem-loop sequences.
Further preferably, the histone stem-loop sequence according to at least one of the specific formulae (I) or (Ia) to (Ih) or (II) or (IIa) to (IIh) of the present invention is a histone stem-loop sequence comprising at each nucleotide position the most frequently occurring nucleotide, or either the most frequently or the second-most frequently occurring nucleotide of naturally occurring histone stem-loop sequences in metazoa and protozoa (FIG. 1), protozoa (FIG. 2), metazoa (FIG. 3), vertebrates (FIG. 4) and humans (FIG. 5) as shown in FIGS. 1-5. In this context, it is particularly preferred that at least 80%, preferably at least 85%, or most preferably at least 90% of all nucleotides correspond to the most frequently occurring nucleotide of naturally occurring histone stem-loop sequences.
Further preferably, the histone stem-loop sequence according to at least one of the specific formulae (I) or (Ia) to (Ih) of the present invention may be selected from following histone stem-loop sequences or corresponding RNA sequences (without stem-bordering elements) representing histone stem-loop sequences as generated according to Example 1:









(SEQ ID NO: 1403 according to formula (Ic))



VGYYYYHHTHRVVRCB



 



(SEQ ID NO: 1404 according to formula (Ic))



SGYYYTTYTMARRRCS



 



(SEQ ID NO: 1405 according to formula (Ic))



SGYYCTTTTMAGRRCS



 



(SEQ ID NO: 1406 according to formula (Ie))



DGNNNBNNTHVNNNCH



 



(SEQ ID NO: 1407 according to formula (Ie))



RGNNNYHBTHRDNNCY



 



(SEQ ID NO: 1408 according to formula (Ie))



RGNDBYHYTHRDHNCY



 



(SEQ ID NO: 1409 according to formula (If)



VGYYYTYHTHRVRRCB



 



(SEQ ID NO: 1410 according to formula (If))



SGYYCTTYTMAGRRCS



 



(SEQ ID NO: 1411 according to formula (If))



SGYYCTTTTMAGRRCS



 



(SEQ ID NO: 1412 according to formula (Ig))



GGYYCTTYTHAGRRCC



 



(SEQ ID NO: 1413 according to formula (Ig))



GGCYCTTYTMAGRGCC



 



(SEQ ID NO: 1414 according to formula (Ig))



GGCTCTTTTMAGRGCC



 



(SEQ ID NO: 1415 according to formula (Ih))



DGHYCTDYTHASRRCC



 



(SEQ ID NO: 1416 according to formula (Ih))



GGCYCTTTTHAGRGCC



 



(SEQ ID NO: 1417 according to formula (Ih))



GGCYCTTTTMAGRGCC






Furthermore, in this context, following histone stem-loop sequences (with stem bordering elements) as generated according to Example 1 according to one of specific formulae (II) or (IIa) to (IIh) and the corresponding RNA sequences are particularly preferred:









(SEQ ID NO: 1418 according to formula (IIc))



H*H*HHVVGYYYYHHTHRVVRCBVHH*N*N*



 



(SEQ ID NO: 1419 according to formula (IIc))



M*H*MHMSGYYYTTYTMARRRCSMCH*H*H*



 



(SEQ ID NO: 1420 according to formula (IIc))



M*M*MMMSGYYCTTTTMAGRRCSACH*M*H*



 



(SEQ ID NO: 1421 according to formula (IIe))



N*N*NNNDGNNNBNNTHVNNNCHNHN*N*N*



 



(SEQ ID NO: 1422 according to formula (IIe))



N*N*HHNRGNNNYHBTHRDNNCYDHH*N*N*



 



(SEQ ID NO: 1423 according to formula (IIe))



N*H*HHVRGNDBYHYTHRDHNCYRHH*H*H*



 



(SEQ ID NO: 1424 according to formula (IIf))



H*H*MHMVGYYYTYHTHRVRRCBVMH*H*N*



 



(SEQ ID NO: 1425 according to formula (IIf))



M*M*MMMSGYYCTTYTMAGRRCSMCH*H*H*



 



(SEQ ID NO: 1426 according to formula (IIf))



M*M*MMMSGYYCTTTTMAGRRCSACH*M*H*



 



(SEQ ID NO: 1427 according to formula (IIg))



H*h*MAMGGYYCTTYTHAGRRCCVHN*N*M*



 



(SEQ ID NO: 1428 according to formula (IIg))



H*H*AAMGGCYCTTYTMAGRGCCVCH*H*M*



 



(SEQ ID NO: 1429 according to formula (IIg))



M*M*AAMGGCTCTTTTMAGRGCCMCY*M*M*



 



(SEQ ID NO: 1430 according to formula (IIh))



N*H*AAHDGHYCTDYTHASRRCCVHB*N*H*



 



(SEQ ID NO: 1431 according to formula (IIh))



H*H*AAMGGCYCTTTTHAGRGCCVMY*N*M*



 



(SEQ ID NO: 1432 according to formula (IIh))



H*M*AAAGGCYCTTTTMAGRGCCRMY*H*M*






A particular preferred histone stem-loop sequence is the sequence according to SEQ ID NO: 1433 (CAAAGGCTCTTTTCAGAGCCACCA) or the corresponding RNA sequence.
Thus, in a particularly preferred embodiment, the artificial nucleic acid molecule according to the present invention comprises (a.) at least one 5′UTR element as described above; (b.) at least one open reading frame; and (c.) at least one histone-stem loop which comprises or consists of a sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence, wherein preferably positions 6, 13 and 20 of the sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence are conserved, i.e. are identical to the nucleotides at positions 6, 13 and 20 of SEQ ID NO. 1433.
According to a further preferred embodiment, the inventive artificial nucleic acid molecule comprises or codes for at least one histone stem-loop sequence showing at least about 80%, preferably at least about 85%, more preferably at least about 90%, or even more preferably at least about 95% sequence identity with the not to 100% conserved nucleotides in the histone stem-loop sequences according to at least one of specific formulae (I) or (Ia) to (Ih) or (II) or (IIa) to (IIh) or with a naturally occurring histone stem-loop sequence.
Furthermore, the artificial nucleic acid molecule according to the present invention may comprise more than one histone stem-loop as described herein. For example, the artificial nucleic acid molecule according to the present invention may comprise one, two, three, four or more histone stem-loops, wherein the individual histone stem-loops may be the same or they may be different. For example, the artificial nucleic acid molecule according to the present invention may comprise two histone stem-loops, wherein each histone stem-loop sequence may be selected from the group consisting of SEQ ID NOs. 1391-1433.
In a particularly preferred embodiment, the present invention provides an artificial nucleic acid molecule comprising:
a. at least one 5′-untranslated region element (5′UTR element) which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene as described above;
b. at least one open reading frame (ORE); and
c. at least one histone stem-loop, wherein preferably the sequence of the histone stem-loop is selected from the group consisting of sequences according to formulae (I) or (Ia) to (Ih) or (II) or (IIa) to (IIh), such as a sequence selected from the group consisting of SEQ ID NOs: 1391-1433, preferably from the group consisting of SEQ ID NOs. 1403-1433.
Thus, for example, the artificial nucleic acid molecule according to the present invention may comprise at least one 5′UTR element which is derived from the 5′UTR of a sequence selected from the group consisting of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, from a homolog thereof, from a variant thereof, or from a corresponding RNA sequence, such as a 5′UTR element which comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence extending from nucleotide position 5 to the nucleotide position immediately 5′ to the start codon (located at the 3′ end of the sequences), e.g. the nucleotide position immediately 5′ to the ATG sequence, of a nucleic acid sequence selected from SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, or a corresponding RNA sequence, or at least one 5′UTR element which comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence extending from nucleotide position 5 to the nucleotide position immediately 5′ to the start codon (located at the 3′ end of the sequences), e.g. the nucleotide position immediately 5′ to the ATG sequence, of a nucleic acid sequence selected from SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461 or SEQ ID NO. 1462, or a corresponding RNA sequence, preferably lacking the 5/TOP motif, wherein, preferably, the fragment is as described above, i.e. being a continuous stretch of nucleotides representing at least 20% etc. of the full-length 5′UTR the fragment is derived from, (b.) at least one open reading frame, and (c.) at least one histone stem-loop sequence selected from the group consisting of SEQ ID NOs: 1391-1433, preferably from the group consisting of SEQ ID NOs: 1403-1433, preferably wherein the at least one histone histone-stem loop comprises or consists of a sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence, wherein preferably positions 6, 13 and 20 of the sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence are conserved, i.e. are identical to the nucleotides at positions 6, 13 and 20 of SEQ ID NO. 1433.
Furthermore, for example, the artificial nucleic acid molecule according to the present invention may comprise at least one 5′UTR element which comprises or consists of a nucleic acid sequence which is derived from a 5′UTR of a TOP gene encoding a ribosomal protein or from a variant of a 5′UTR of a TOP gene encoding a ribosomal protein, e.g. which comprises or consists of a nucleic acid sequence which is derived from a 5′UTR of a nucleic acid sequence according to any of SEQ ID NOs: 170, 232, 244, 259, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, or 1360; a corresponding RNA sequence, a homolog thereof, or a variant thereof as described herein, and at least one histone stem-loop sequence selected from the group consisting of SEQ ID NOs: 1391-1433, preferably from the group consisting of SEQ ID NOs: 1403-1433, preferably wherein the at least one histone-stem loop comprises or consists of a sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence, wherein preferably positions 6, 13 and 20 of the sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence are conserved, i.e. are identical to the nucleotides at positions 6, 13 and 20 of SEQ ID NO. 1433.
In a further embodiment, the artificial nucleic acid molecule according to the present invention may comprise at least one 5′UTR element which comprises or consists of a nucleic acid sequence which is derived from a 5′UTR of a TOP gene encoding a ribosomal Large protein or from a variant of a 5′UTR of a TOP gene encoding a ribosomal Large protein, e.g. which comprises or consists of a nucleic acid sequence which is derived from a 5′UTR of a nucleic acid sequence according to any of SEQ ID NOs: 67, 259, 1284-1318, 1344, 1346, 1348-1354, 1357, 1461 and 1462, a corresponding RNA sequence, a homolog thereof, or a variant thereof as described herein, and at least one histone stem-loop sequence selected from the group consisting of SEQ ID NOs: 1391-1433, preferably from the group consisting of SEQ ID NOs: 1403-1433, preferably wherein the at least one histone histone-stem loop comprises or consists of a sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence, wherein preferably positions 6, 13 and 20 of the sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence are conserved, i.e. are identical to the nucleotides at positions 6, 13 and 20 of SEQ ID NO. 1433.
As preferred example, the artificial nucleic acid molecule according to the present invention may comprise a 5′UTR element which comprises or consists of a nucleic acid sequence which has an identity of at least about 90%, preferably of at least about 95%, even more preferably of at least about 99% to the nucleic acid sequence according to SEQ ID NO: 1368 or SEQ ID NOs: 1452-1460 and a histone stem-loop sequence selected from the group consisting of SEQ ID NOs: 1403-1433, e.g. according to SEQ ID NO: 1433, or wherein the histone histone-stem loop comprises or consists of a sequence having a sequence identity of about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence, wherein positions 6, 13 and 20 of the sequence having a sequence identity of at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence are conserved, i.e. are identical to the nucleotides at positions 6, 13 and 20 of SEQ ID NO. 1433.
In some embodiments, the histone stem-loop sequence according to component (c.) is not derived from a mouse histone gene, e.g. from mouse histone gene H2A614. In one embodiment, the artificial nucleic acid molecule of the invention neither contains a mouse histone stem-loop sequence nor contains mouse histone gene H2A614. Furthermore, in one embodiment, the inventive artificial nucleic acid molecule does not contain a stem-loop processing signal, more specifically, a mouse histone processing signal and, most specifically, does not contain mouse histone stem-loop processing signal H2kA614. Also, in one embodiment, the inventive nucleic acid molecule may contain at least one mammalian histone gene. However, in one embodiment, the at least one mammalian histone gene is not Seq. ID No. 7 of WO 01/12824.
Preferably, the inventive artificial nucleic acid molecule comprises no histone downstream element (HDE).
The term “histone downstream element (HDE)” refers to a purine-rich polynucleotide stretch of about 15 to 20 nucleotides 3′ of naturally occurring stem-loops, which represents the binding site for the U7 snRNA involved in processing of histone pre-mRNA into mature histone mRNA. For example in sea urchins the HDE is CAAGAAAGA (Dominski, Z. and W. F. Marzluff (2007), Gene 396(2): 373-90).
Preferably, the artificial nucleic acid molecule according to the present invention further comprises a poly(A) sequence or a poly(A) signal.
Therefore, it is particularly preferred that the inventive artificial nucleic acid molecule comprises or codes for (a.) at least one 5′UTR element as described above, (b.) at least one open reading frame, preferably encoding a peptide or protein; (c.) at least one histone stem-loops described herein, and (d.) a poly(A) sequence or a polyadenylation signal.
A polyadenylation signal is defined herein as a signal which conveys polyadenylation to a (transcribed) mRNA by specific protein factors (e.g. cleavage and polyadenylation specificity factor (CPSF), cleavage stimulation factor (CstF), cleavage factors I and II (CF I and CF II), poly(A) polymerase (PAP)).
Preferably, the polyadenylation signal comprises the consensus sequence NN(U/T)ANA, with N=A or U, preferably AA(U/T)AAA or A(U/T)(U/T)AAA. Such consensus sequence may be recognised by most animal and bacterial cell-systems, for example by the polyadenylation-factors, such as cleavage/polyadenylation specificity factor (CPSF) cooperating with CstF, PAP, PAB2, CFI and/or CFII. The polyadenylation signal is preferably located within the artificial nucleic acid molecule such that the above described machinery is able to effect polyadenylation of the artificial nucleic acid molecule. For example, the polyadenylation signal may be located less than about 50 nucleotides, more preferably less than about 30 nucleotides, most preferably less than about 25 nucleotides, for example 21 nucleotides, upstream of the 3′-end of the artificial nucleic acid molecule.
Additionally or alternatively to the polyadenylation signal, in some embodiments, the artificial nucleic acid molecule according to the present invention may further comprise a poly(A) sequence. The length of the poly(A) sequence may vary. For example, the poly(A) sequence may have a length of about 20 adenine nucleotides up to about 400 adenine nucleotides, such as about 20 adenine nucleotides up to about 300 adenine nucleotides, preferably about 40 to about 200 adenine nucleotides, more preferably about 50 to about 100 adenine nucleotides, such as about 60, 70, 80, 90 or 100 adenine nucleotides. The term about refers to a deviation of ±10%.
The poly(A) sequence is preferably located 3′ to the ORF. For example, the poly(A) sequence may be connected to the 3′-end of the ORF directly or via a linker, for example via a stretch of nucleotides, such as 2, 4, 6, 8, 10, 20 etc. nucleotides, such as via a linker of 1-50, preferably 1-20 nucleotides, e.g. comprising one or more restriction sites, or the poly(A) sequence may be located within or between or downstream of other structures located 3′ to the ORF, such as between a 3′UTR element and a poly(C) sequence, or downstream of a 3′UTR element and/or a poly(C) sequence, or the poly(A) sequence may be located at the 3′-end of the artificial nucleic acid molecule. The term “located at the 3′-end” also includes embodiments, wherein the poly(A) sequence is followed in 3′-direction by few nucleotides which remain, e.g. after a restriction enzyme cleavage.
It is particularly preferred that the inventive artificial nucleic acid molecule comprises in 5′- to 3′-direction or codes in 5′- to 3′-direction for

    (a.) at least one 5′UTR element derived from a TOP gene as described herein;
    (b.) at least one open reading frame, preferably encoding a peptide or protein;
    (c.) at least one histone stem-loop, optionally without a histone downstream element 3′ to the histone stem-loop, as described herein; and
    (d.) a poly(A) sequence and/or a polyadenylation signal.


In another particularly preferred embodiment, the inventive nucleic acid molecule according to the present invention comprises in 5′- to 3′-direction or codes in 5′- to 3′-direction for:

    (a.) at least one 5′UTR element derived from a TOP gene as described above;
    (b.) at least one open reading frame, preferably encoding a peptide or protein;
    (d.) a poly(A) sequence; and
    (c.) at least one histone stem-loop as described herein.


Thus, the poly(A) sequence and the histone stem-loop of an artificial nucleic acid molecule according to the present invention may be positioned in any desired order from 5′ to 3′. Particularly, the poly(A) sequence may be located 5′ as well as 3′ of the histone stem-loop.
Accordingly, in one embodiment, the artificial nucleic acid molecule according to the present invention comprises

    (a.) at least one 5′-untranslated region element (5′UTR element) which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene;
    (b.) at least one open reading frame (ORF);
    (c.) a histone stem-loop; and
    (d.) a poly(A) sequence and/or a polyadenylation signal, wherein the poly(A) sequence is located 5′ or 3′ of the histone stem-loop.


In a further preferred embodiment, the artificial nucleic acid molecule according to the present invention further comprises a poly(C) sequence. A poly(C) sequence in the context of the present invention preferably consists of about 10 to about 200 cytidine nucleotides, more preferably of about 10 to about 100 cytidine nucleotides, more preferably of about 10 to about 50 cytidine nucleotides, even more preferably of about 20 to about 40 cytidine nucleotides, such as about 20, about 25, about 30, about 35, about 40, preferably about 30 cytidine nucleotides. The poly(C) sequence is preferably located 3′ to the ORF of the artificial nucleic acid molecule. For example, the poly(C) sequence may be connected to the 3′-end of the ORF directly or via a linker of a stretch of nucleotides, such as 2, 4, 6, 8, 10, 20 etc. nucleotides, such as via a linker of 1-50, preferably of 1-20 nucleotides, e.g. comprising one or more restriction sites, or the poly(C) sequence may be located within, between or downstream of any other structures located 3′ to the ORF. For example, the poly(C) sequence may be part of a 3′UTR element or may be located between a poly(A) sequence and a histone stem-loop, or the poly(C) sequence may be located at the 3′-end of the artificial nucleic acid molecule. The term “located at the 3′-end” also includes embodiments, wherein the poly(C) sequence is followed in 3′-direction by a few nucleotides which remain, e.g., after a restriction enzyme cleavage. In a particularly preferred embodiment, the poly(C) sequence is located between a poly(A) sequence and a histone stem-loop.
In a particularly preferred embodiment, the poly(C) sequence is located 5′ to the histone stem-loop.
Thus, in a particularly preferred embodiment, the artificial nucleic acid molecule according to the present application comprises the structure 5′-[ORF]-[optional linker]-[3′UTR element]-[optional linker]-[poly(A) sequence]-[optional linker]-[poly(C) sequence]-[optional linker]-[histone stem-loop]-3′, wherein the optional linkers may be independently of each other present or absent and may be a stretch of 1-50 nucleotides, e.g. comprising one or more restriction sites.
In a further embodiment, the artificial nucleic acid molecule according to the present invention further comprises a 3′UTR element. Thus, in some embodiments, the artificial nucleic acid molecule according to the present invention may comprise at least one 5′UTR element as described above, at least one open reading frame, at least one histone stem-loop as described herein and at least one 3′UTR element as described herein. Furthermore, in some embodiments, the artificial nucleic acid molecule according to the present invention may comprise at least one 5′UTR element as described above, at least one open reading frame, at least one histone stem-loop as described herein, at least one 3′UTR element as described herein, and a poly(A) sequence and/or a polyadenylation signal as described herein. In some embodiments, the histone stem-loop may be part of the 3′UTR element.
The term ‘3′UTR element’ refers to a nucleic acid sequence which comprises or consists of a nucleic acid sequence that is derived from a 3′UTR or from a variant of a 3′UTR. A 3′UTR element in the sense of the present invention may represent the 3′UTR of an mRNA, e.g., in the event that the artificial nucleic acid molecule is an mRNA, or it may represent a sequence in a nucleic acid construct, such as a vector construct, that when transcribed represents the 3′UTR of the transcription product, such as the mRNA. Thus, in the sense of the present invention, preferably, a 3′UTR element may be the 3′UTR of an mRNA, preferably of an artificial mRNA, or it may be the transcription template for a 3′UTR of an mRNA. Thus, a 3′UTR element preferably is a nucleic acid sequence which corresponds to the 3′UTR of an mRNA, preferably to the 3′UTR of an artificial mRNA, such as an mRNA obtained by transcription of a genetically engineered vector construct. Preferably, the 3′UTR element fulfils the function of a 3′UTR or encodes a sequence which fulfils the function of a 3′UTR. The term ‘3UTR element’ furthermore refers to a fragment or part of a 3′UTR of an artificial nucleic acid sequence, such as an artificial mRNA, or which codes for a part or fragment of a 3′UTR of an artificial nucleic acid molecule. This means that the 3′UTR element in the sense of the present invention may be comprised in the 3′UTR of an artificial nucleic acid sequence, such as an artificial mRNA, or which codes for a 3′UTR of an artificial nucleic acid molecule.
In the context of the present invention, the 3′UTR element may be derived from any 3′UTR of a gene or from a variant thereof, such as from a 3′UTR which is naturally associated with the ORF of the artificial nucleic acid molecule according to the present invention or any other 3′UTR of a naturally occurring gene or of a variant thereof.
Preferably, the 3′UTR element is functionally linked to the ORF. This means preferably that the 3′UTR element is associated with the ORF such that it may exert a function, such as a stabilizing function on the expression of the ORF or a stabilizing function on the artificial nucleic acid molecule. Preferably, the ORF and the 3′UTR element are associated in 5′→3′ direction. Thus, preferably, the artificial nucleic acid molecule comprises the structure 5′-ORF-(optional)linker-3′UTR element-3′, wherein the linker may be present or absent. For example, the linker may be one or more nucleotides, such as a stretch of 1-50 or 1-20 nucleotides, e.g., comprising or consisting of one or more restriction enzyme recognition sites (restriction sites).
Preferably, the at least one 5′UTR element and the at least one 3′UTR element are functionally linked to the ORF. This means preferably that the 5′UTR element and the 3′UTR element are associated with the ORF such that they may exert a function, preferably in an additive, more preferably in a synergistic manner, such as a stabilizing function on the expression of the ORF, a protein production increasing function for the protein encoded by the ORF, or a stabilizing function on the artificial nucleic acid molecule. Preferably, the 5′UTR element, the ORF, and the 3′UTR element are associated in 5′→3′ direction. Thus, preferably, the artificial nucleic acid molecule comprises the structure 5′-5′UTR element-(optional)linker-ORF-(optional)linker-3′UTR element-3′, wherein the linker may be present or absent. For example, the linker may be one or more nucleotides, such as a stretch of 1-50 or 1-20 nucleotides, e.g., comprising or consisting of one or more restriction enzyme recognition sites (restriction sites).
In a particularly preferred embodiment, the 5′UTR element and the 3′UTR element are heterologous, e.g. preferably the 5′UTR and the 3′UTR are derived from different genes of the same or of different species. Preferably, the 3′UTR is not derived from the TOP gene the 5′UTR is derived from.
In a preferred embodiment, the 3′UTR element is chosen such that it exerts at least an additive, preferably a synergistic function with the 5′UTR element on the protein production from the ORF of the artificial nucleic acid molecule. Preferably, the protein production is increased in at least an additive, preferably a synergistic way by the 3′UTR element and the 5′UTR element. Thus, the protein amount of the protein encoded by the ORF, such as a reporter protein, e.g. luciferase, at a certain time point after initiation of expression of the ORF, e.g. after transfection of a test cell or cell line, is preferably at least the same, preferably higher than what would be expected if the protein production increasing effects of the 3′UTR element and the 5′UTR element were purely additive. The additive, preferably the synergistic effect may, for example, be determined by the following assay. Four artificial nucleic acid molecules, e.g. mRNAs, comprising an ORF encoding, e.g. a reporter protein such as luciferase, are generated, i.e. (i) lacking UTR elements (E0), (ii) containing a 5′UTR element derived from a 5′UTR of a TOP gene or of a variant thereof (E1), (iii) containing a test 3′UTR element (E2), and (iv) containing both the 5′UTR element and the test 3′UTR element (E1E2). Expression of the ORF contained in the artificial nucleic acid molecules is initiated, for example, by transfecting a test cell line, such as a mammalian cell line, e.g. HELA cells, or primary cells, e.g. HDF cells. Samples are taken at specific time points after initiation of expression, for example, after 6 hours, 24 hours, 48 hours, and 72 hours and the amount of protein produced by expression of the ORF contained in the artificial nucleic acid molecules is measured, for example, by an ELISA assay or a luciferase test, depending on the type of protein encoded by the ORF. The predicted amount of protein at a certain time point after initiation of expression obtained by construct E1E2 if the effects of the 3′UTR element and the 5′UTR element were purely additive (PPA) may be calculated as follows:

PPAx=(E1x−E0x)+(E2x−E0x)+E0x,

E0 is the amount of protein obtained for the construct E0 (lacking UTRs), E1 is the amount of protein obtained for the construct E1, E2 is the protein amount obtained for the construct E2, and x is the time point after initiation of expression. The effect on increasing protein production is additive if E1E2x=PPAx and synergistic in the sense of the present invention if E1E2x>PPAx, wherein E1E2x is the amount of protein obtained from construct E1E2 at time point x. Preferably, E1E2 is at least 1.0, preferably at least 1.1, more preferably at least 1.3, more preferably at least 1.5, even more preferably at least 1.75 times PPA at a given time point post initiation of expression, such as 24 hours, 48 hours or 72 hours post initiation of expression.
Thus, in a preferred embodiment, the present invention provides an artificial nucleic acid molecule comprising (a.) at least one 5′UTR element which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene; (b.) at least one open reading frame (ORF); (c.) at least one histone stem-loop, and at least one 3′UTR element, wherein preferably the 3′UTR element and the 5′UTR element act at least additively, preferably synergistically to increase protein production from the ORF, preferably wherein E1E2≧PPA, preferably E1E2 is at least 1.0 times PPA, preferably E1E2 is at least 1.1 times PPA, more preferably E1E2 is at least 1.3 times PPA, even more preferably wherein E1E2 is at least 1.5 times PPA at a given time point post initiation of expression of the ORF, for example 24 hours, preferably 48 hours post initiation of expression, wherein E1E2 and PPA are as described above.
Furthermore, it is preferred that the 3′UTR element and the 5′UTR element have at least an additive, preferably a synergistic effect on the total protein production from the artificial nucleic acid molecule in a certain time span, such as within 24 hours, 48 hours, or 72 hours post initiation of expression. The additive or the synergistic effect may be determined as described above, with the difference that the area under the curve (AUC) for the amount of protein over time predicted for E1E2 if the effects were purely additive is compared to the actual AUC measured for E1E2.
In a preferred embodiment, the 3′UTR element comprises or consists of a nucleic acid sequence which is derived from the 3′UTR of a stable mRNA or from a variant of the 3′UTR of a stable mRNA. Thus, in a preferred embodiment, the 3′UTR element comprises or consists of a sequence which is derived from a gene providing a stable mRNA or from a variant of a 3′UTR of a gene providing a stable mRNA. The term “stable mRNA”, preferably refers to mRNAs which exhibit a longer half-life in mammalian cells than the average half-life of mRNA molecules in mammalian cells. Preferably, a stable mRNA in the sense of the present application refers to an mRNA which exhibits a half-life of more than 5 hours, preferably more than 8 hours, in a mammalian cell, such as in a mammalian cell line, e.g. in HELA cells, or in primary cells, e.g. in HDF cells, preferably determined by using a transcription inhibitor such as actinomycin D.
For example, the half-life of an mRNA in mammalian cells, such as HELA or HDF cells, may be determined by culturing the cells in presence of a transcription inhibitor, e.g. actinomycin D, 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), or α-amanitin, harvesting the cells at different time points after inhibition of transcription, and determining the amount of the mRNA present in the cell samples by methods well known to the person skilled in the art, e.g. by quantitative RT-PCR. The half-life of a particular mRNA may be calculated based on the amounts of the particular mRNA measured at the different time points post inhibition of transcription. Alternatively, pulse-chase methods, e.g. using radioactively labelled nucleotides, or constructs comprising inducible promoters may be used for determining the half-life of an mRNA in mammalian cells.
It is particularly preferred that the enhanced stability of a stable mRNA in the sense of the present invention is affected by its 3′UTR. Thus, preferably, the 3′UTR element comprises or consists of a nucleic acid sequence which is derived from the 3′UTR of a stable mRNA which exhibits a half-life of more than 5 hours, preferably more than 8 hours, in a mammalian cell, such as in a mammalian cell line, e.g. in HELA cells, or in mammalian primary cells, such as HDF cells, preferably determined by using a transcription inhibitor such as actinomycin D, wherein the enhanced stability of said stable mRNA is effected by its 3′UTR. The ability of a 3′UTR for enhancing stability may be tested as described herein, e.g. by using a reporter open reading frame such as a luciferase encoding open reading frame. Alternatively, an artificial construct encoding the test stable mRNA may be generated, wherein the 3′UTR of the stable mRNA is replaced with a reference 3′UTR, such as a 3′UTR of a short lived mRNA, e.g. a Myc 3′UTR. The stability of the wild type stable mRNA and the 3′UTR modified mRNA may be determined as described above. In the event the 3′UTR modified mRNA exhibits a shorter half-life than the wild type stable mRNA, it may be concluded that a stability enhancing effect is exerted by the 3′UTR of the stable mRNA.
In a particularly preferred embodiment, the 3′UTR element comprises or consists of a nucleic acid sequence which is derived from a 3′UTR of a gene selected from the group consisting of an albumin gene, an α-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, and a collagen alpha gene, such as a collagen alpha 1(I) gene, or from a variant of a 3′UTR of a gene selected from the group consisting of an albumin gene, an α-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, and a collagen alpha gene, such as a collagen alpha 1(I) gene. In a particularly preferred embodiment, the 3′UTR element comprises or consists of a nucleic acid sequence which is derived from a 3′UTR of an albumin gene, preferably a vertebrate albumin gene, more preferably a mammalian albumin gene, most preferably a human albumin gene. In another particularly preferred embodiment, the 3′UTR element comprises or consists of a nucleic acid sequence which is derived from a 3′UTR of an α-globin gene, preferably a vertebrate α-globin gene, more preferably a mammalian α-globin gene, most preferably a human α-globin gene. For example, the 3′UTR element may comprise or consist of the center, α-complex-binding portion of the 3′UTR of an α-globin gene, such as of a human α-globin gene.
Preferably, the at least one 3′UTR element comprises or consists of a nucleic acid sequence which is derived from the 3′UTR of a vertebrate albumin gene, a vertebrate α-globin gene, a vertebrate β-globin gene, a vertebrate tyrosine hydroxylase gene, a vertebrate lipoxygenase gene, and a vertebrate collagen alpha gene, such as a vertebrate collagen alpha 1(I) gene, or from a variant thereof, preferably from the 3′UTR of a mammalian albumin gene, a mammalian α-globin gene, a mammalian β-globin gene, a mammalian tyrosine hydroxylase gene, a mammalian lipoxygenase gene, and a mammalian collagen alpha gene, such as a mammalian collagen alpha 1(I) gene, or from a variant thereof, more preferably from the 3′UTR of a human albumin gene, a human α-globin gene, a human β-globin gene, a human tyrosine hydroxylase gene, a human lipoxygenase gene, and a human collagen alpha gene, such as a human collagen alpha 1(I) gene, or from a variant thereof, even more preferably from the 3′UTR of the human albumin gene according to GenBank Accession number NM_000477.5 or from a variant thereof. In a preferred embodiment, the 3′UTR element is not derived from the 3′UTR of a Xenopus albumin gene. Preferably, the 3′UTR element does not comprise a poly(A) limiting element B (PLEB) of a 3′UTR from a Xenopus albumin gene. Preferably, the 3′UTR element does not consist of a PLEB of a 3′UTR from a Xenopus albumin gene.
In one embodiment, the 3′UTR element and the at least one open reading frame are heterologous, e.g. preferably the 3′UTR element and the ORF are derived from different genes of the same or of different species. Preferably, the ORF does not encode an α-globin protein if the 3′UTR element is derived from an α-globin gene. Preferably, the ORF does not encode a β-globin protein if the 3′UTR element is derived from a β-globin gene. Preferably, the ORF does not encode an albumin protein if the 3′UTR element is derived from an albumin gene. Preferably, the ORF does not encode a tyrosine hydroxylase protein if the 3′UTR element is derived from a tyrosine hydroxylase gene. Preferably, the ORF does not encode a lipoxygenase protein if the 3′UTR element is derived from a lipoxygenase gene. Preferably, the ORF does not encode a collagen alpha protein if the 3′UTR element is derived from a collagene alpha gene.
In one embodiment, the artificial nucleic acid molecule may consist of at least two sequence parts that are derivable from two different genes, the 5′UTR element which is derivable from a TOP gene and the open reading frame and the 3′UTR which may be derivable from the gene encoding the desired protein product. More preferably, the artificial nucleic acid molecule consists of three sequence parts that are derivable from three different genes: the 5′UTR element which is derivable from a TOP gene, the open reading frame which is derivable from the gene encoding the desired gene product and the 3′UTR element which may be derivable from a gene that relates to an mRNA with an enhanced half-life, for example a 3′UTR element as defined and described below.
In some embodiments, the 3′UTR element consists of a histone stem-loop. In some embodiments, the 3′UTR element of the artificial nucleic acid molecule may comprise a histone stem-loop in addition to the nucleic acid sequence derived from the 3′UTR of a gene, such as of a gene providing a stable mRNA, such as of an albumin gene, an α-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, or a collagen alpha gene, such as a collagen alpha 1(I) gene as described above. Such artificial nucleic acid molecule according to the present invention, for example, may comprise in 5′-to-3′-direction a 5′UTR element, an ORF, a 3′UTR element, preferably comprising a polyadenylation signal, a histone stem-loop and an optional poly(A) sequence. It may also comprise in 5′-to-3′-direction a 5′UTR element as described above, an ORF, a 3′UTR element, e.g. comprising a polyadenylation signal, a poly(A) sequence and a histone stem-loop.
The term ‘a nucleic acid sequence which is derived from the 3′UTR of a [ . . . ] gene’ preferably refers to a nucleic acid sequence which is based on the 3′UTR sequence of a [ . . . ] gene or on a part thereof, such as on the 3′UTR of an albumin gene, an α-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, or a collagen alpha gene, such as a collagen alpha 1(I) gene, preferably of an albumin gene or an α-globin gene on a part thereof. This term includes sequences corresponding to the entire 3′UTR sequence, i.e. the full length 3′UTR sequence of a gene, and sequences corresponding to a fragment of the 3′UTR sequence of a gene, such as an albumin gene, α-globin gene, β-globin gene, tyrosine hydroxylase gene, lipoxygenase gene, or collagen alpha gene, such as a collagen alpha 1(I) gene, preferably of an albumin or α-globin gene. A fragment in this context preferably consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length 3′UTR, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full-length 3′UTR. Such a fragment, in the sense of the present invention, is preferably a functional fragment as described herein. The term ‘3′UTR of a [ . . . ] gene’ preferably refers to the 3′UTR of a naturally occurring gene, such as of a naturally occurring albumin gene, α-globin gene, β-globin gene, tyrosine hydroxylase gene, lipoxygenase gene, or collagen alpha gene, such as a collagen alpha 1 (I) gene, preferably of a naturally occurring albumin or α-globin gene.
The terms ‘variant of the 3′UTR of a [ . . . ] gene’ and ‘variant thereof’ in the context of a 3′UTR refers to a variant of the 3′UTR of a naturally occurring gene, such as a naturally occurring albumin gene, a naturally occurring α-globin gene, a naturally occurring β-globin gene, a naturally occurring tyrosine hydroxylase gene, a naturally occurring lipoxygenase gene, or a naturally occurring collagen alpha gene, such as a collagen alpha 1(I) gene, preferably to a variant of the 3′UTR of a vertebrate albumin gene, a vertebrate α-globin gene, a vertebrate β-globin gene, a vertebrate tyrosine hydroxylase gene, a vertebrate lipoxygenase gene, and a vertebrate collagen alpha gene, such as a vertebrate collagen alpha 1(I) gene, preferably to a variant of the 3′UTR of a mammalian albumin gene, a mammalian α-globin gene, a mammalian β-globin gene, a mammalian tyrosine hydroxylase gene, a mammalian lipoxygenase gene, and a mammalian collagen alpha gene, such as a mammalian collagen alpha 1(I) gene, or to a variant of the 3′UTR of a human albumin gene, a human α-globin gene, a human β-globin gene, a human tyrosine hydroxylase gene, a human lipoxygenase gene, and a human collagen alpha gene, such as a human collagen alpha 1(I) gene. Such variant may be a modified 3′UTR of a gene. For example, a variant 3′UTR may exhibit one or more nucleotide deletions, insertions, additions and/or substitutions compared to the naturally occurring 3′UTR from which the variant is derived. Preferably, a variant of a 3′UTR is at least 40%, preferably at least 50%, more preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% identical to the naturally occurring 3′UTR the variant is derived from. Preferably, the variant is a functional variant as described herein.
The term ‘a nucleic acid sequence which is derived from a variant of the 3′UTR of a [ . . . ] gene’ preferably refers to a nucleic acid sequence which is based on a variant of the 3′UTR sequence of a gene, such as on a variant of the 3′UTR of an albumin gene, an α-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, or a collagen alpha gene, such as a collagen alpha 1(I) gene, or on a part thereof as described above. This term includes sequences corresponding to the entire sequence of the variant of the 3′UTR of a gene, i.e. the full length variant 3′UTR sequence of a gene, and sequences corresponding to a fragment of the variant 3′UTR sequence of a gene. A fragment in this context preferably consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length variant 3′UTR, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full-length variant 3′UTR. Such a fragment of a variant, in the sense of the present invention, is preferably a functional fragment of a variant as described herein.
The terms ‘functional variant’, ‘functional fragment’, and ‘functional fragment of a variant’ (also termed ‘functional variant fragment’) in the context of the present invention, mean that the fragment of the 5′UTR or the 3′UTR, the variant of the 5′UTR or the 3′UTR, or the fragment of a variant of the 5′UTR or the 3′UTR of a gene fulfils at least one, preferably more than one, function of the naturally occurring 5′UTR or 3′UTR of the gene of which the variant, the fragment, or the fragment of a variant is derived. Such function may be, for example, stabilizing mRNA and/or stabilizing and/or prolonging protein production from an mRNA and/or increasing protein production from an mRNA, preferably in a mammalian cell, such as in a human cell. It is particularly preferred that the variant, the fragment, and the variant fragment in the context of the present invention fulfil the function of stabilizing an mRNA, preferably in a mammalian cell, such as a human cell, compared to an mRNA comprising a reference 5′UTR or lacking a 5′UTR and/or a 3′UTR, and/or the function of stabilizing and/or prolonging protein production from an mRNA, preferably in a mammalian cell, such as in a human cell, compared to an mRNA comprising a reference 5′UTR or lacking a 5′UTR and/or a 3′UTR, and/or the function of increasing protein production from an mRNA, preferably in a mammalian cell, such as in a human cell, compared to an mRNA comprising a reference 5′UTR or lacking a 5′UTR and/or a 3′UTR. A reference 5′UTR may be, for example, a 5′UTR naturally occurring in combination with the ORF. Furthermore, a functional variant, a functional fragment, or a functional variant fragment of a 5′UTR or of a 3′UTR of a gene preferably does not have a substantially diminishing effect on the efficiency of translation of the mRNA which comprises such variant of a 5′UTR and/or such variant of a 3′UTR compared to the wild type 5′UTR and/or 3′UTR from which the variant is derived. A particularly preferred function of a “functional fragment”, a “functional variant” or a “functional fragment of a variant” of the 3′UTR of a gene, such as an albumin gene, α-globin gene, β-globin gene, tyrosine hydroxylase gene, lipoxygenase gene, or collagen alpha gene, such as a collagen alpha 1(I) gene, in the context of the present invention is the stabilization and/or prolongation of protein production by expression of an mRNA carrying the functional fragment, functional variant or functional fragment of a variant as described above. A particularly preferred function of a “functional fragment”, a “functional variant” or a “functional fragment of a variant” of the 5′UTR in the context of the present invention is the protein production increasing function.
Preferably, the efficiency of the one or more functions exerted by the functional variant, the functional fragment, or the functional variant fragment, such as mRNA and/or protein production stabilizing efficiency and/or the protein production increasing efficiency, is at least 40%, more preferably at least 50%, more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, most preferably at least 90% of the mRNA and/or protein production stabilizing efficiency and/or the protein production increasing efficiency exhibited by the naturally occurring 5′UTR and/or 3′UTR of which the variant, the fragment or the variant fragment is derived.
In the context of the present invention, a fragment or part of the 3′UTR of a gene, such as an albumin gene, α-globin gene, β-globin gene, tyrosine hydroxylase gene, lipoxygenase gene, or collagen alpha gene, such as a collagen alpha 1(I) gene, or of a variant thereof preferably exhibits a length of at least about 40 nucleotides, preferably of at least about 50 nucleotides, preferably of at least about 75 nucleotides, more preferably of at least about 100 nucleotides, even more preferably of at least about 125 nucleotides, most preferably of at least about 150 nucleotides. Preferably, such fragment of the 3′UTR of a gene or of a variant of the 3′UTR of a gene is a functional fragment as described above.
In the context of the present invention, a fragment or part of the 5′UTR of a TOP gene or of a variant thereof preferably exhibits a length of at least about 20 nucleotides, preferably of at least about 30 nucleotides, more preferably of at least about 50 nucleotides. Preferably, such fragment of the 5′UTR of a TOP gene or of a variant of the 5′UTR of a TOP gene is a functional fragment as described above.
In some embodiments, the 3′UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a “functional fragment”, a “functional variant” or a “functional fragment of a variant” of the 3′UTR of a gene, such as of an albumin gene, α-globin gene, β-globin gene, tyrosine hydroxylase gene, lipoxygenase gene, or collagen alpha gene, such as a collagen alpha 1(I) gene, or of a variant thereof.
In some embodiments, the at least one 5′UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a “functional fragment”, a “functional variant” or a “functional fragment of a variant” of the 5′UTR of a TOP gene.
Preferably, the 3′UTR element of the artificial nucleic acid molecule according to the present invention increases the stability of the artificial nucleic acid molecule, e.g. increases the stability of an mRNA according to the present invention, compared to a respective mRNA (reference mRNA) lacking a 3′UTR element. Preferably, the at least one 3′UTR element of the artificial nucleic acid molecule according to the present invention increases the stability of protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective mRNA lacking a 3′UTR element. Preferably, the at least one 3′UTR element of the artificial nucleic acid molecule according to the present invention prolongs protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective mRNA lacking a 3′UTR element. Preferably, the at least one 3′UTR element of the artificial nucleic acid molecule according to the present invention increases the protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective mRNA lacking a 3′UTR element. Preferably, the at least one 3′UTR element of the artificial nucleic acid molecule according to the present invention does not negatively influence translational efficiency of an mRNA compared to the translational efficiency of a respective mRNA lacking a 3′UTR element. The term ‘respective mRNA’ in this context means that—apart from the different 3′UTR—the reference mRNA is comparable, preferably identical, to the mRNA comprising the 3′UTR element.
Preferably, the at least one 5′UTR element of the artificial nucleic acid molecule according to the present invention increases the stability of the artificial nucleic acid molecule, e.g. increases the stability of an mRNA according to the present invention, compared to a respective mRNA (reference mRNA) lacking a 5′UTR element or comprising a reference 5′UTR element, such as a 5′UTR naturally occurring in combination with the ORF. Preferably, the at least one 5′UTR element of the artificial nucleic acid molecule according to the present invention increases protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective mRNA lacking a 5′UTR element or comprising a reference 5′UTR element, such as a 5′UTR naturally occurring in combination with the ORF. The term ‘respective mRNA’ in this context means that—apart from the different 5′UTR—the reference mRNA is comparable, preferably identical, to the mRNA comprising the inventive 5′UTR element.
Preferably, the histone stem-loop of the artificial nucleic acid molecule according to the present invention increases the stability of the artificial nucleic acid molecule, e.g. increases the stability of an mRNA according to the present invention, compared to a respective mRNA (reference mRNA) lacking a histone stem-loop. Preferably, the histone stem-loop of the artificial nucleic acid molecule according to the present invention increases protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective mRNA lacking a histone stem-loop. The term ‘respective mRNA’ in this context means that—apart from the histone stem loop—the reference mRNA is comparable, preferably identical, to the mRNA comprising the a histone stem-loop.
Preferably, the at least one 5′UTR element and the at least one 3′UTR element act synergistically to increase protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, as described above.
Preferably, the at least one 5′UTR element and the histone stem-loop act synergistically to increase protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, as described above.
The term ‘stabilizing and/or prolonging protein production from an mRNA’ preferably means that the protein production from the mRNA is stabilized and/or prolonged compared to the protein production from a reference mRNA, e.g. lacking a 3′UTR element.
‘Stabilized protein expression’ in this context preferably means that there is more uniform protein production from the artificial nucleic acid molecule according to the present invention over a predetermined period of time, such as over 24 hours, more preferably over 48 hours, even more preferably over 72 hours, when compared to a reference nucleic acid molecule, for example, lacking a 3′UTR element. Thus, the level of protein production, e.g. in a mammalian system, from the artificial nucleic acid molecule comprising a 3′UTR element according to the present invention, e.g. from an mRNA according to the present invention, preferably does not drop to the extent observed for a reference nucleic acid molecule. For example, the amount of a protein (encoded by the ORF) observed 6 hours after initiation of expression, e.g. 6 hours post transfection of the artificial nucleic acid molecule according to the present invention into a cell, such as a mammalian cell, may be comparable to the amount of protein observed 48 hours after initiation of expression, e.g. 48 hours post transfection. Thus, the ratio of the amount of protein encoded by the ORF, such as of a reporter protein, e.g., luciferase, observed at 48 hours post initiation of expression, e.g. 48 hours post transfection, to the amount of protein observed 6 hours after initiation of expression, e.g. 6 hours post transfection, is preferably above 0.4, preferably above 0.5, more preferably above 0.6, even more preferably above 0.7, e.g. between about 0.4 and about 4, preferably between about 0.65 and about 3, more preferably between about 0.7 and 2 for a nucleic acid molecule according to the present invention. Thus, in one embodiment, the present invention provides an artificial nucleic acid molecule as described above, wherein the ratio of the (reporter) protein amount observed 48 hours after initiation of expression to the (reporter) protein amount observed 6 hours after initiation of expression, preferably in a mammalian expression system, such as in mammalian cells, is preferably between about 0.4 and 4, preferably between about 0.65 and about 3, more preferably between about 0.7 and 2.
‘Increased protein expression’ in the context of the present invention may refer to increased protein expression at one time point after initiation of expression compared to a reference molecule or to an increased total protein production within a certain time period after initiation of expression. Thus, the protein level observed at a certain time point after initiation of expression, e.g. after transfection, of the artificial nucleic acid molecule according to the present invention, e.g. after transfection of an mRNA according to the present invention, for example, 24, 48, or 72 hours post transfection, or the total protein produced in a time span of, e.g. 24, 48 or 72 hours, is preferably higher than the protein level observed at the same time point after initiation of expression, e.g. after transfection, or the total protein produced within the same time span, for a reference nucleic acid molecule, such as a reference mRNA comprising a reference 5′UTR element or lacking a 5′UTR element and/or 3′UTR element and/or a histone stem-loop. As set forth above, it is a particularly preferred function of the 5′UTR element and the histone stem-loop to effect an increase in protein production from the artificial nucleic acid molecule. Preferably, the increase in protein production effected by the 5′UTR element and the histone stem-loop compared to a reference nucleic acid molecule lacking such 5′UTR element and a histone stem-loop at a given time point post initiation of expression is at least 1.5-fold, more preferably at least 2-fold, more preferably at least 3-fold, more preferably at least 4-fold, more preferably at least 5-fold, even more preferably at least 10-fold, even more preferably at least 15-fold of the protein production observed for a reference nucleic acid molecule lacking the 5′UTR element and a histone stem-loop. The same holds preferably for the total protein production in a given time period, for example in a time period of 24, 48 or 72 hours post initiation of expression.
Said increase in stability of the artificial nucleic acid molecule, said increase in stability of protein production, said prolongation of protein production and/or said increase in protein production is preferably determined by comparison with a respective reference nucleic acid molecule lacking a 5′UTR element and/or a 3′UTR element and/or a histone stem-loop, e.g. an mRNA lacking a 5′UTR element and/or a 3′UTR element and/or a histone stem-loop, or a reference nucleic acid molecule comprising a reference 5′UTR element and/or a reference 3′UTR element, such as a 3′UTR and/or a 5′UTR naturally occurring with the ORF or a 5′UTR and/or a 3′UTR of a reference gene.
The mRNA and/or protein production stabilizing effect and efficiency and/or the protein production increasing effect and efficiency of the variants, fragments and/or variant fragments of the 3′UTR of an albumin gene as well as the mRNA and/or protein production stabilizing effect and efficiency and/or the protein production increasing effect and efficiency of the 3′UTR element, the at least one 5′UTR element, or the histone stem-loop of the artificial nucleic acid molecule according to the present invention may be determined by any method suitable for this purpose known to the skilled person. For example, artificial mRNA molecules may be generated comprising a coding sequence for a reporter protein, such as luciferase, and no 3′UTR and/or no 5′UTR and/or no histone stem-loop, a 5′UTR derived from a TOP gene and/or a 3′UTR derived from a gene as described above and/or a histone stem-loop as described above, a 5′UTR derived from a reference gene and/or a 3′UTR derived from a reference gene (i.e., a reference 3′UTR or a reference 5′UTR, such as a 5′UTR or a 3′UTR naturally occurring with the ORF), as 3′UTR a variant of a 3′UTR of a gene as described above, as 3′UTR a fragment of a 3′UTR of a gene as described above, or as 3′UTR a fragment of a variant of a 3′UTR of a gene as described above, as 5′UTR a variant of a 5′UTR of a TOP gene, as 5′UTR a fragment of a 5′UTR of a TOP gene, or as 5′UTR a fragment of a variant of a 5′UTR of a TOP gene. Such mRNAs may be generated, for example, by in vitro transcription of respective vectors such as plasmid vectors, e.g. comprising a T7 promoter and a sequence encoding the respective mRNA sequences. The generated mRNA molecules may be transfected into cells by any transfection method suitable for transfecting mRNA, for example they may be electroporated into mammalian cells, such as HELA or HDF cells, and samples may be analyzed certain time points after transfection, for example, 6 hours, 24 hours, 48 hours, and 72 hours post transfection. Said samples may be analyzed for mRNA quantities and/or protein quantities by methods well known to the skilled person. For example, the quantities of reporter mRNA present in the cells at the sample time points may be determined by quantitative PCR methods. The quantities of reporter protein encoded by the respective mRNAs may be determined, e.g., by ELISA assays or reporter assays such as luciferase assays depending on the reporter protein used. The effect of stabilizing protein expression and/or prolonging protein expression may be, for example, analyzed by determining the ratio of the protein level observed 48 hours post transfection and the protein level observed 6 hours post transfection. The closer said value is to 1, the more stable the protein expression is within this time period. Said value may also be above 1 if the protein level is higher at the later time point. Such measurements may of course also be performed at 72 or more hours and the ratio of the protein level observed 72 hours post transfection and the protein level observed 6 hours post transfection may be determined to determine stability of protein expression.
Preferably, the 3′UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to a nucleic acid sequence selected from SEQ ID NOs. 1369-1377 and 1434 and corresponding RNA sequences, wherein the variants of the sequences according to SEQ ID NOs. 1369-1377 and 1434 are preferably functional variants as described above. SEQ ID NOs. 1369, 1371 and 1434, variants thereof, and corresponding RNA sequences are particularly preferred.
The 3′UTR element of the artificial nucleic acid molecule according to the present invention may also comprise or consist of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to the nucleic acid sequence according to SEQ ID No. 1369-1377 and 1434 and of corresponding RNA sequences, wherein the fragment is preferably a functional fragment or a functional variant fragment as described above. Preferably, the fragment is as described above, i.e. being a continuous stretch of nucleotides representing at least 20% etc. of the full-length 3′UTR the fragment is derived from. Such fragment preferably exhibits a length of at least about 40 nucleotides, preferably of at least about 50 nucleotides, preferably of at least about 75 nucleotides, more preferably of at least about 100 nucleotides, even more preferably of at least about 125 nucleotides, most preferably of at least about 150 nucleotides.
For example, such fragment may exhibit a nucleic acid sequence according to SEQ ID Nos. 1378-1390, such as:







(SEQ ID No. 1378)







AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA


TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT


GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTTCT


TTAATCATTT TGCCTCTTTT CTCTGTGCTT CAATT


 







(SEQ ID No. 1379)







CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG


AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTTT


CTTTTTCGTT GGTGTAAAGC CAACACCCTG


 







(SEQ ID No. 1380)







AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA


TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT


GGTGTAAAGC CAACACCCTG TCTAAAAAAC


 







(SEQ ID No. 1381)







CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA


AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC


CAACACCCTG TCTAAAAAAC ATAAATTTCT


 







(SEQ ID No. 1382)







TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC


ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG


TCTAAAAAAC ATAAATTTCT TTAATCATTT


 







(SEQ ID No. 1383)







AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTTT


CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC


ATAAATTTCT TTAATCATTT TGCCTCTTTT


 







(SEQ ID No. 1384)







TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT


GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTTCT


TTAATCATTT TGCCTCTTTT CTCTGTGCTT


 







(SEQ ID No. 1385)







AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC


CAACACCCTG TCTAAAAAAC ATAAATTTCT TTAATCATTT


TGCCTCTTTT CTCTGTGCTT CAATTAATAA


 







(SEQ ID No. 1386)







ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG


TCTAAAAAAC ATAAATTTCT TTAATCATTT TGCCTCTTTT


CTCTGTGCTT CAATTAATAA AAAATGGAAA


 







(SEQ ID No. 1387)







CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA


AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC


CAACACCCTG TCTAAAAAAC ATAAATTTCT TTAATCATTT


TGCCTCTTTT CTCTGTGCTT CAATTAATAA A


 







(SEQ ID No. 1388)







TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT


GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTTCT


TTAATCATTT TGCCTCTTTT CTCTGTGCTT CAATTAATAA


A


 







(SEQ ID No. 1389)







CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC


ATAAATTTCT TTAATCATTT TGCCTCTTTT CTCTGTGCTT


CAATTAATAA A


 







(SEQ ID No. 1390)







AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC


CAACACCCTG TCTAAAAAAC






or the corresponding RNA sequence, or a nucleic acid sequence which is at least 40%, preferably at least about 50%, preferably at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%, even more preferably at least about 99% identical to said nucleic acid sequences or the corresponding RNA sequence. Thus, the at least one 3′UTR element of the artificial nucleic acid molecule according to the present invention may comprise or consist of a nucleic acid fragment as described above. Obviously, the thymidine nucleotides comprised in the fragments according to SEQ ID Nos. 1378-1390 may be replaced by uridine nucleotides.

Preferably, said variants, fragments or variant fragments are functional variants, functional fragments, or functional variant fragments as described above, exhibiting at least one function of the nucleic acid sequence according to SEQ ID Nos. 1369-1377 and 1434, such as stabilization of the artificial nucleic acid molecule according to the invention, stabilizing and/or prolonging protein expression from the artificial nucleic acid molecule according to the invention, and/or increasing protein production, preferably with an efficiency of at least 40%, more preferably of at least 50%, more preferably of at least 60%, even more preferably of at least 70%, even more preferably of at least 80%, most preferably of at least 90% of the stabilizing efficiency and/or protein production increasing efficiency exhibited by the nucleic acid sequence according to SEQ ID Nos. 1369-1377 and 1434. Preferably, variants, fragments or variant fragments are functional variants, functional fragments, or functional variant fragments exhibit the function of acting synergistically with the 5′UTR element to increase protein production from the artificial nucleic acid molecule.
Preferably, the 3′UTR element of the artificial nucleic acid molecule according to the present invention exhibits a length of at least about 40 nucleotides, preferably of at least about 50 nucleotides, preferably of at least about 75 nucleotides, more preferably of at least about 100 nucleotides, even more preferably of at least about 125 nucleotides, most preferably of at least about 150 nucleotides. For example, the 3′UTR may exhibit a length of about 50 to about 300 nucleotides, preferably of about 100 to about 250 nucleotides, more preferably of about 150 to about 200 nucleotides.
Furthermore, the artificial nucleic acid molecule according to the present invention may comprise more than one 3′UTR elements as described above. For example, the artificial nucleic acid molecule according to the present invention may comprise one, two, three, four or more 3′UTR elements, wherein the individual 3′UTR elements may be the same or they may be different. For example, the artificial nucleic acid molecule according to the present invention may comprise two essentially identical 3′UTR elements as described above, e.g. two 3′UTR elements comprising or consisting of a nucleic acid sequence which is derived from the 3′UTR of an albumin gene or an α-globin gene or from a variant of the 3′UTR of an albumin gene or of an α-globin gene, such as a nucleic acid sequence according to SEQ ID No. 1369, 1371, 1376, or 1434, functional variants thereof, functional fragments thereof, or functional variant fragments thereof as described above.
In a preferred embodiment, the artificial nucleic acid molecule comprises (a.) at least one 5′UTR element which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene encoding a ribosomal protein as described above, for example, encoding a ribosomal Large protein, or from a variant thereof, (b.) at least one open reading frame, (c.) at least one histone stem-loop as described herein, such as at least one histone stem-loop according to SEQ ID NOs. 1391-1433, optionally (d.) a poly(A) sequence or a poly(A) signal, optionally (e.) a poly(C) sequence, and optionally (f.) at least one 3′UTR element, preferably derived from a gene providing a stable mRNA, e.g., which comprises or consists of a nucleic acid sequence which is derived from the 3′UTR of an albumin gene or an α-globin gene, such as a sequence selected from the group consisting of SEQ ID NOs: 1369, 1371, and 1434 or a variant thereof as described herein.
Preferably, the sequence of elements of the artificial nucleic acid molecule in 5′-to-3′-direction is 5′-[at least one 5′UTR]-[ORF]-[optional at least one 3′UTR]-[optional poly(A) sequence]-[optional poly(C) sequence]-[at least one histone stem-loop]-3′.
In a particularly preferred embodiment, the artificial nucleic acid molecule comprises (a.) at least one 5′UTR element which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a ribosomal protein Large 32 gene (RPL32), a ribosomal protein Large 35 gene (RPL35), a ribosomal protein Large 21 gene (RPL21), an ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) gene, an hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD17B4), an androgen-induced 1 gene (AIG1), cytochrome c oxidase subunit VIc gene (COX6C), or a N-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variant thereof, preferably from a vertebrate ribosomal protein Large 32 gene (RPL32), a vertebrate ribosomal protein Large 35 gene (RPL35), a vertebrate ribosomal protein Large 21 gene (RPL21), a vertebrate ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) gene, a vertebrate hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD17B4), a vertebrate androgen-induced 1 gene (AIG1), a vertebrate cytochrome c oxidase subunit VIc gene (COX6C), or a vertebrate N-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variant thereof, more preferably from a mammalian ribosomal protein Large 32 gene (RPL32), a ribosomal protein Large 35 gene (RPL35), a ribosomal protein Large 21 gene (RPL21), a mammalian ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) gene, a mammalian hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD17B4), a mammalian androgen-induced 1 gene (AIG1), a mammalian cytochrome c oxidase subunit VIc gene (COX6C), or a mammalian N-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variant thereof, most preferably from a human ribosomal protein Large 32 gene (RPL32), a human ribosomal protein Large 35 gene (RPL35), a human ribosomal protein Large 21 gene (RPL21), a human ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) gene, a human hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD17B4), a human androgen-induced 1 gene (AIG1), a human cytochrome c oxidase subunit VIc gene (COX6C), or a human N-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variant thereof, wherein preferably the 5′UTR element does not comprise the 5′TOP of said gene, such as the sequence according to SEQ ID NO: 1368 or SEQ ID NOs 1452-1460 or a variant thereof, (b.) at least one open reading frame, (c.) at least one histone stem-loop, such as at least one histone stem-loop according to SEQ ID NOs. 1391-1433, optionally (d.) a poly(A) sequence and/or a poly(A) signal, optionally (e.) a poly(C) sequence, and optionally (f.) at least one 3′UTR element which comprises or consists of a nucleic acid sequence which is derived from an albumin gene or an α-globin gene, such as a sequence selected from the group consisting of SEQ ID NOs: 1369, 1371, and 1434 or a variant thereof as described herein.
In a particularly preferred embodiment, the artificial nucleic acid molecule according to the present invention comprises:

    (a.) at least one 5′UTR element which comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the nucleic acid sequence according to SEQ ID No. 1368 or SEQ ID NOs. 1452-1460, or a corresponding RNA sequence,
    (b.) at least one open reading frame,
    (c.) at least one histone stem-loop as described herein, such as a histone stem-loop sequence according to any one of SEQ ID NOs. 1391-1433, preferably a histone stem-loop sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or a corresponding RNA sequence, wherein preferably positions 6, 13 and 20 of the sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 1433 or the corresponding RNA sequence are conserved, i.e. are identical to the nucleotides at positions 6, 13 and 20 of SEQ ID NO. 1433,
    (d.) optionally, a poly(A) sequence or a poly(A) signal as described herein,
    (e.) optionally, a poly(C) sequence, and
    (f.) optionally, a 3′UTR element, preferably a 3′UTR element which is derived from a gene providing a stable mRNA, such as a 3′UTR element which comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to the nucleic acid sequence according to SEQ ID No. 1369, 1371, or 1434 or a corresponding RNA sequence.


Thus, in a particularly preferred embodiment, the present invention provides an artificial nucleic acid molecule comprising a 5′UTR element which comprises or consists of a nucleic acid sequence which has an identity of at least about 90% to the nucleic acid sequence according to SEQ ID No. 1368 or SEQ ID NOs. 1452-1460, or a corresponding RNA sequence, a histone stem-loop comprising a sequence which has an identity of at least about 90% to the sequence according to SEQ ID NO. 1434 or a corresponding RNA sequence, optionally a poly(A) sequence and/or a poly(A) signal as described herein, optionally a poly(C) sequence, and optionally a 3′UTR element which comprises or consists of a nucleic acid sequence which has an identity of at least about 90% to the nucleic acid sequence according to SEQ ID No. 1369, 1371 or 1434.
Preferably, the artificial nucleic acid molecule according to the present invention does not contain one or two or at least one or all but one or all of the components of the group consisting of: a sequence encoding a ribozyme (preferably a self-splicing ribozyme), a viral nucleic acid sequence, a histone stem-loop processing signal, in particular a histone stem-loop processing sequence derived from mouse histon H2A614 gene, a Neo gene, an inactivated promoter sequence and an inactivated enhancer sequence. Even more preferably, the nucleic acid according to the invention does not contain a ribozyme, preferably a self-splicing ribozyme, and one of the group consisting of: a Neo gene, an inactivated promotor sequence, an inactivated enhancer sequence, a histon stem-loop processing signal, in particular a histon-stem loop processing sequence derived from mouse histon H2A614 gene. Accordingly, the nucleic acid may in a preferred mode neither contain a ribozyme, preferably a self-splicing ribozyme, nor a Neo gene or, alternatively, neither a ribozyme, preferably a self-splicing ribozyme, nor any resistance gene (e.g. usually applied for selection). In an other preferred mode, the nucleic acid molecule of the invention may neither contain a ribozyme, preferably a self-splicing ribozyme, nor a histone stem-loop processing signal, in particular a histone stem-loop processing sequence derived from mouse histone H2A614 gene.
Furthermore, it is preferred that the inventive artificial nucleic acid molecule according to the present invention does not comprise an intron.
The artificial nucleic acid molecule according to the present invention may be RNA, such as mRNA, DNA, such as a DNA vector, or may be a modified RNA or DNA molecule. It may be provided as a double-stranded molecule having a sense strand and an anti-sense strand, for example, as a DNA molecule having a sense strand and an anti-sense strand.
The invention also provides an artificial nucleic acid molecule which is an mRNA molecule comprising a, 5′UTR element, an open reading frame, a histone stem-loop as described herein, an optional 3′UTR element as described herein and an optional poly(A) sequence.
The artificial nucleic acid molecule according to the present invention may further comprise a 5′-cap. The optional 5′-cap is preferably attached to the 5′-side of the 5′UTR element.
The invention provides an artificial nucleic acid molecule which may be a template for an RNA molecule, preferably for an mRNA molecule, which is stabilised and optimized with respect to translation efficiency. In other words, the artificial nucleic acid molecule may be a DNA or RNA which may be used for production of an mRNA. The obtainable mRNA, may, in turn, be translated for production of a desired peptide or protein encoded by the open reading frame. If the artificial nucleic acid molecule is a DNA, it may, for example, be used as a double-stranded storage form for continued and repetitive in vitro or in vivo production of mRNA.
Potential transcription systems are in vitro transcription systems or cellular transcription systems etc. Accordingly, transcription of an artificial nucleic acid molecule according to the invention, e.g. transcription of an artificial nucleic acid molecule comprising a 5′UTR element, an open reading frame, a histone stem-loop, a 3′UTR element, and a polyadenylation-signal, may result in an mRNA molecule comprising a 5′UTR element, an open reading frame, a histone stem-loop, a 3′UTR element and a poly(A) sequence.
For example, the artificial nucleic acid molecule according to the present invention may comprise a nucleic acid sequence corresponding to the DNA sequence







(SEQ ID No. 1377)









CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG



 



AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTTT



 



CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC



 



ATAAATTTCT TTAATCATTT TGCCTCTTTT CTCTGTGCTT



 



CAATTAATAA AAAATGGAAA GAATCTAGAT CTAAAAAAAA



 



AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA



 



AAAAAAAAAA AAAAAA.






Transcription of such a sequence may result in an artificial nucleic acid molecule comprising a corresponding RNA sequence.
Such artificial RNA molecule may also be obtainable in vitro by common methods of chemical synthesis without being necessarily transcribed from a DNA progenitor.
In a particularly preferred embodiment, the artificial nucleic acid molecule according to the present invention is an RNA molecule, preferably an mRNA molecule comprising in 5′-to-3′-direction a 5′UTR element as described above, an open reading frame, an optional 3′UTR element as described above, an optional poly(A) sequence, an optional poly(C) sequence, and a histone stem-loop as described herein.
In some embodiments, the artificial nucleic acid molecule comprises further elements such as an IRES-motif. An internal ribosome entry side (IRES) sequence or IRES-motif may separate several open reading frames, for example if the artificial nucleic acid molecule encodes for two or more peptides or proteins. An IRES-sequence may be particularly helpful if the mRNA is a bi- or multicistronic RNA.
Furthermore, the artificial nucleic acid molecule may comprise additional 5′-elements such as a promoter or enhancer sequence. The promoter may drive and or regulate transcription of the artificial nucleic acid molecule according to the present invention, for example of an artificial DNA molecule according to the present invention.
In preferred embodiments, the invention provides artificial nucleic acid molecules, preferably mRNA molecules, comprising in 5′-to-3′-direction at least one of the following structures:
5′-cap-5′UTR element-ORF-3′UTR element-histone stem-loop-poly(A) sequence
5′-cap-5′UTR element-ORF 3′UTR element-poly(A) sequence-histone stem-loop
5′-cap-5′UTR element-ORF-IRES-ORF-3′UTR element-histone stem-loop-poly(A) sequence
5′-cap-5′UTR element-ORF-IRES-ORF-3′UTR element-poly(A) sequence-histone stem-loop
5′-cap-5′UTR element-ORF-3′UTR element-poly(A) sequence-poly(C) sequence-histone stem-loop
5′-cap-5′UTR element-ORF-IRES-ORF-3′UTR element-poly(A) sequence-poly(C) sequence-histone stem-loop
5′-cap-5′UTR element-ORF-IRES-ORF-3′UTR element-histone stem-loop-poly(A) sequence-poly(C) sequence
More preferably, the inventive artificial nucleic acid molecule comprises or codes for (a.) a 5′UTR-element; (b.) an open reading frame, preferably encoding a peptide or protein; (c.) at least one histone stem-loop, optionally (d.) a poly(A) sequence and/or polyadenylation signal; (e.) optionally a poly(C) sequence; and (f.) optionally a 3′UTR element, preferably for increasing the expression level of an encoded protein, wherein the encoded protein is preferably no histone protein, no reporter protein and/or no marker or selection protein, as defined above. The elements (c.) to (f.) of the inventive artificial nucleic acid molecule may occur in the inventive artificial nucleic acid molecule in any sequence, i.e. the elements (a.), (b.), (c.), (d.), (e.) and (f.) may, for example, occur in the sequence (a.), (b.), (c.), (d.), (e.) and (f.), or (a.), (b.), (d.), (c.), (e.) and (f.), or (a.), (b.), (c.), (d.), (f.) and (e.), or (a.), (b.), (d.), (c.), (f.) and (e.), or (a.), (b.), (e.), (d.), (c.) and (f.), or (a.), (b.), (e.), (d.), (f.) and (c.), or (a.), (b.), (c.), (f.), (e.) and (d.) etc., wherein further elements as described herein, may also be contained, such as a 5′-CAP structure, stabilization sequences, IRES sequences, etc. Each of the elements (a.) to (f.) of the inventive artificial nucleic acid molecule, particularly b), may occur in di- or multicistronic constructs and/or each of the elements (a.), (c.) and (f.) may also be repeated at least once, preferably twice or more in the inventive artificial nucleic acid molecule. As an example, the inventive artificial nucleic acid molecule may comprise its sequence elements (a.), (b.), (c.) and optionally (d.) in e.g. the following order. In all cases the artificial nucleic acid molecule may additionally comprise one or more optional 3′UTR element(s) and/or a poly(C) sequence as defined herein:
5′UTR-ORF-histone stem-loop-3′; or
5′UTR-ORF-ORF-histone stem-loop-3′; or
5′ UTR-ORF-IRES-ORF-histone stem-loop-3′; or
5′ UTR-ORF-histone stem-loop-poly(A) sequence-3′; or
5′ UTR-ORF-histone stem-loop-polyadenylation signal-3′; or
5′ UTR-ORF-ORF-histone stem-loop-polyadenylation signal-3′; or
5′ UTR-ORF-histone stem-loop-histone stem-loop-3′; or
5′ UTR-ORF-histone stem-loop-histone stem-loop-poly(A) sequence-3′; or
5′ UTR-ORF-histone stem-loop-histone stem-loop-polyadenylation signal-3′; or
5′ UTR-ORF-histone stem-loop-poly(A) sequence histone stem-loop-3′; or
5′ UTR-ORF-poly(A) sequence-histone stem-loop-3′; or
5′ UTR-ORF-poly(A) sequence-histone stem-loop-histone stem-loop-3′; etc.
It is preferred that the above sequences comprise a poly(C) sequence. Preferably, this poly(C) sequence is located 5′ to the histone stem-loop, preferably between the poly(A) sequence and the histone stem-loop sequence.
In this context, it is particularly preferred that the inventive artificial nucleic acid molecule comprises or codes for a) a 5′UTR element, b) an open reading frame, preferably encoding a peptide or protein; c) at least one histone stem-loop, and d) a poly(A) sequence or polyadenylation sequence; preferably for increasing the expression level of an encoded protein, wherein the encoded protein is preferably no histone protein, no reporter protein (e.g. Luciferase, GFP, EGFP, β-Galactosidase, particularly EGFP) and/or no marker or selection protein (e.g. alpha-Globin, Galactokinase and Xanthine:Guanine phosphoribosyl transferase (GPT)).
The open reading frame of the artificial nucleic acid molecule is not particularly limited. For example, the open reading frame may encode a protein or peptide that may be used for therapy of a disease. The particular choice of the protein or peptide depends on the disease to be treated and is not the subject of the invention. Accordingly, the artificial nucleic acid molecule may be for use in treatment of a disease that is treatable with the protein or peptide that is encoded by the open reading frame. The open reading frame may also encode a protein or peptide that may be used as an antigen for vaccination. Again, the particular choice of the protein or peptide depends on the disease or infection to be prevented. Accordingly, the artificial nucleic acid molecule may be for use in prevention of a disease by inducing a specific immune response.
However, the encoded protein is preferably no histone protein. In the context of the present invention, such a histone protein is typically a strongly alkaline protein found in eukaryotic cell nuclei, which package and order the DNA into structural units called nucleosomes. Histone proteins are the chief protein components of chromatin, act as spools around which DNA winds, and play a role in gene regulation. Without histones, the unwound DNA in chromosomes would be very long (a length to width ratio of more than 10 million to one in human DNA). For example, each human cell has about 1.8 meters of DNA, but wound on the histones it has about 90 millimeters of chromatin, which, when duplicated and condensed during mitosis, result in about 120 micrometers of chromosomes. More preferably, in the context of the present invention, such a histone protein is typically defined as a highly conserved protein selected from one of the following five major classes of histones: H1/H5, H2A, H2B, H3, and H4′′, preferably selected from mammalian histone, more preferably from human histones or histone proteins. Such histones or histone proteins are typically organised into two super-classes defined as core histones, comprising histones H2A, H2B, H3 and H4, and linker histones, comprising histones H1 and H5.
In this context, linker histones, are preferably excluded from the scope of protection of the pending invention, preferably mammalian linker histones, more preferably human linker histones, are typically selected from H1, including H1F, particularly including H1F0, H1FNT, H1 FOO, H1 FX, and H1H1, particularly including HIST1H1A, HIST1H1B, HIST1H1C, HIST1H1D, HIST1H1E, HIST1H1T.
Furthermore, in some embodiments, core histones which are preferably excluded from the scope of protection of the pending invention, preferably mammalian core histones, more preferably human core histones, are typically selected from H2A, including H2AF, particularly including H2AFB1, H2AFB2, H2AFB3, H2AFJ, H2AFV, H2AFX, H2AFY, H2AFY2, H2AFZ, and H2A1, particularly including HIST1H2AA, HIST1H2AB, HIST1H2AC, HIST1H2AD, HIST1H2AE, HIST1H2AG, HIST1H2AI, HIST1H2AJ, HIST1H2AK, HIST1H2AL, HIST1H2AM, and H2A2, particularly including HIST2H2AA3, HIST2H2AC; H2B, including H2BF, particularly including H2BFM, H2BFO, H2BFS, H2BFWT H2B1, particularly including HIST1H2BA, HIST1H2BB, HIST1H2BC, HIST1H2BD, HIST1H2BE, HIST1H2BF, HIST1H2BG, HIST1H2BH, HIST1H2BI, HIST1H2BJ, HIST1H2BK, HIST1H2BL, HIST1H2BM, HIST1H2BN, HIST1H2BO, and H2B2, particularly including HIST2H2BE; H3, including H3A1, particularly including HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H31, HIST1H3J, and H3A2, particularly including HIST2H3C, and H3A3, particularly including HIST3H3; H4, including H41, particularly including HIST1H4A, HIST1H4B, HIST1H4C, HIST1H4D, HIST1H4E, HIST1H4F, HIST1H4G, HIST1H4H, HIST1H41, HIST1H4J, HIST1H4K, HIST1H4L, and H44, particularly including HIST4H4, and H5.
Preferably, the protein encoded by the open reading frame is no reporter protein (e.g. Luciferase, Green Fluorescent Protein (GFP), Enhanced Green Fluorescent Protein (EGFP), β-Galactosidase) and no marker or selection protein (e.g. alpha-globin, Galactokinase and Xanthine:guanine phosphoribosyl transferase (GPT)). Preferably, the artificial nucleic acid molecule of the invention does not contain a (bacterial) Neo gene sequence (Neomycin resistance gene).
Preferably, the ORF does not code for a protein selected from the group consisting of albumin proteins, α-globin proteins, β-globin proteins, tyrosine hydroxylase proteins, lipoxygenase proteins, and collagen alpha proteins.
In a preferred embodiment, the open reading frame does not code for human albumin, provided that the 3′UTR element is identical to the 3′UTR of human albumin. In some further embodiment, it is preferred that the open reading frame does not code for human albumin according to GenBank Accession number NM_000477.5 provided that the 3′UTR element is identical to the 3′UTR of human albumin. In some further embodiments, it is preferred that the open reading frame does not code for human albumin or variants thereof provided that the 3′UTR element is a sequence which is identical to SEQ ID No. 1369 or to a corresponding RNA sequence.
Furthermore, in some embodiments, it is preferred that the open reading frame does not code for a reporter protein selected from the group consisting of globin proteins, luciferase proteins, GFP proteins or variants thereof, for example, variants exhibiting at least 70% sequence identity to a globin protein, a luciferase protein, or a GFP protein.
Preferably, the artificial nucleic acid molecule, preferably the open reading frame, is at least partially G/C modified. Thus, the inventive artificial nucleic acid molecule may be thermodynamically stabilized by modifying the G (guanosine)/C (cytidine) content of the molecule. The G/C content of the open reading frame of an artificial nucleic acid molecule according to the present invention may be increased compared to the G/C content of the open reading frame of a corresponding wild type sequence, preferably by using the degeneration of the genetic code. Thus, the encoded amino acid sequence of the nucleic acid molecule is preferably not modified by the G/C modification compared to the coded amino acid sequence of the particular wild type sequence. The codons of a coding sequence or a whole nucleic acid molecule, e.g. an mRNA, may therefore be varied compared to the wild type coding sequence, such that they include an increased amount of G/C nucleotides while the translated amino acid sequence is maintained. In respect to the fact that several codons code for one and the same amino acid (so-called degeneration of the genetic code), the most favourable codons for the stability can be determined (so-called alternative codon usage).
Depending on the amino acid to be encoded by the coding region of the inventive nucleic acid molecule as defined herein, there are various possibilities for modification of the nucleic acid sequence, e.g. the open reading frame, compared to its wild type coding region. In the case of amino acids which are encoded by codons which contain exclusively G or C nucleotides, no modification of the codon is necessary. Thus, the codons for Pro (CCC or CCG), Arg (CGC or CGG), Ala (GCC or GCG) and Gly (GGC or GGG) require no modification, since no A or U/T is present.
In contrast, codons which contain A and/or U/T nucleotides may be modified by substitution of other codons which code for the same amino acids but contain no A and/or U/T. For example
the codons for Pro can be modified from CC(U/T) or CCA to CCC or CCG;
the codons for Arg can be modified from CG(U/T) or CGA or AGA or AGG to CGC or CGG;
the codons for Ala can be modified from GC(U/T) or GCA to GCC or GCG;
the codons for Gly can be modified from GG(U/T) or GGA to GGC or GGG.
In other cases, although A or (U/T) nucleotides cannot be eliminated from the codons, it is however possible to decrease the A and (U/T) content by using codons which contain a lower content of A and/or (U/T) nucleotides. Examples of these are:
The codons for Phe can be modified from (U/T)(U/T)(U/T) to (U/T) (U/T)C;
the codons for Leu can be modified from (U/T) (U/T)A, (U/T) (U/T)G, C(U/T) (U/T) or C(U/T)A to C(U/T)C or C(U/T)G;
the codons for Ser can be modified from (U/T)C(U/T) or (U/T)CA or AG(U/T) to (U/T)CC, (U/T)CG or AGC;
the codon for Tyr can be modified from (U/T)A(U/T) to (U/T)AC;
the codon for Cys can be modified from (U/T)G(U/T) to (U/T)GC;
the codon for His can be modified from CA(U/T) to CAC;
the codon for Gln can be modified from CAA to CAG;
the codons for Ile can be modified from A(U/T)(U/T) or A(U/T)A to A(U/T)C;
the codons for Thr can be modified from AC(U/T) or ACA to ACC or ACG;
the codon for Asn can be modified from AA(U/T) to AAC;
the codon for Lys can be modified from AAA to AAG;
the codons for Val can be modified from G(U/T)(U/T) or G(U/T)A to G(U/T)C or G(U/T)G;
the codon for Asp can be modified from GA(U/T) to GAC;
the codon for Glu can be modified from GAA to GAG;
the stop codon (U/T)AA can be modified to (U/T)AG or (U/T)GA.
In the case of the codons for Met (A(U/T)G) and Trp ((U/T)GG), on the other hand, there is no possibility of sequence modification without altering the encoded amino acid sequence.
The substitutions listed above can be used either individually or in all possible combinations to increase the G/C content of the open reading frame of the inventive nucleic acid sequence as defined herein, compared to its particular wild type open reading frame (i.e. the original sequence). Thus, for example, all codons for Thr occurring in the wild type sequence can be modified to ACC (or ACG).
Preferably, the G/C content of the open reading frame of the inventive artificial nucleic acid molecule as defined herein is increased by at least 7%, more preferably by at least 15%, particularly preferably by at least 20%, compared to the G/C content of the wild type coding region. According to a specific embodiment at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, more preferably at least 70%, even more preferably at least 80% and most preferably at least 90%, 95% or even 100% of the substitutable codons in the open reading frame of the inventive artificial nucleic acid molecule or a fragment, variant or derivative thereof are substituted, thereby increasing the G/C content of said open reading frame.
In this context, it is particularly preferable to increase the G/C content of the open reading frame of the inventive nucleic acid sequence as defined herein, to the maximum (i.e. 100% of the substitutable codons), compared to the wild type open reading frame.
Furthermore, the open reading frame is preferably at least partially codon-optimized. Codon-optimization is based on the finding that the translation efficiency may be determined by a different frequency in the occurrence of transfer RNAs (tRNAs) in cells. Thus, if so-called “rare codons” are present in the coding region of the inventive artificial nucleic acid molecule as defined herein, to an increased extent, the translation of the corresponding modified nucleic acid sequence is less efficient than in the case where codons coding for relatively “frequent” tRNAs are present.
Thus, the open reading frame of the inventive nucleic acid sequence is preferably modified compared to the corresponding wild type coding region such that at least one codon of the wild type sequence which codes for a tRNA which is relatively rare in the cell is exchanged for a codon which codes for a tRNA which is comparably frequent in the cell and carries the same amino acid as the relatively rare tRNA. By this modification, the open reading frame of the inventive artificial nucleic acid molecule as defined herein, is modified such that codons for which frequently occurring tRNAs are available may replace codons which correspond to rare tRNAs. In other words, according to the invention, by such a modification all codons of the wild type open reading frame which code for a rare tRNA may be exchanged for a codon which codes for a tRNA which is more frequent in the cell and which carries the same amino acid as the rare tRNA. Which tRNAs occur relatively frequently in the cell and which, in contrast, occur relatively rarely is known to a person skilled in the art; cf. e.g. Akashi, Curr. Opin. Genet. Dev. 2001, 11(6): 660-666. Accordingly, preferably, the open reading frame is codon-optimized, preferably with respect to the system in which the nucleic acid molecule according to the present invention is to be expressed, preferably with respect to the system in which the nucleic acid molecule according to the present invention is to be translated. Preferably, the codon usage of the open reading frame is codon-optimized according to mammalian codon usage, more preferably according to human codon usage. Preferably, the open reading frame is codon-optimized and G/C-content modified.
For further improving degradation resistance, e.g. resistance to in vivo degradation by an exo- or endonuclease, and/or for further improving protein production from the artificial nucleic acid molecule according to the present invention, the artificial nucleic acid molecule may further comprise modifications, such as backbone modifications, sugar modifications and/or base modifications, e.g., lipid-modifications or the like. Preferably, the transcription and/or the translation of the artificial nucleic acid molecule according to the present invention is not significantly impaired by said modifications.
Nucleotide analogues/modifications that may be used in the context of the present invention may be selected, for example, from 2-amino-6-chloropurineriboside-5′-triphosphate, 2-aminoadenosine-5′-triphosphate, 2-thiocytidine-5′-triphosphate, 2-thiouridine-5′-triphosphate, 4-thiouridine-5′-triphosphate, 5-aminoallylcytidine-5′-triphosphate, 5-aminoallyluridine-5 ‘-triphosphate, 5-bromocytidine-5’-triphosphate, 5-bromouridine-5′-triphosphate, 5-iodocytidine-5′-triphosphate, 5-iodouridine-5′-triphosphate, 5-methylcytidine-5′-triphosphate, 5-methyluridine-5′-triphosphate, 6-azacytidine-5′-triphosphate, 6-azauridine-5′-triphosphate, 6-chloropurineriboside-5′-triphosphate, 7-deazaadenosine-5′-triphosphate, 7-deazaguanosine-5′-triphosphate, 8-azaadenosine-5′-triphosphate, 8-azidoadenosine-5′-triphosphate, benzimidazole-riboside-5′-triphosphate, N1-methyladenosine-5′-triphosphate, N1-methylguanosine-5′-triphosphate, N6-methyladenosine-5′-triphosphate, O6-methylguanosine-5′-triphosphate, pseudouridine-5′-triphosphate, or puromycin-5′-triphosphate, xanthosine-5′-triphosphate. Particular preference is given to nucleotides for base modifications selected from the group of base-modified nucleotides consisting of 5-methylcytidine-5′-triphosphate, 7-deazaguanosine-5′-triphosphate, 5-bromocytidine-5′-triphosphate, and pseudouridine-5′-triphosphate.
Further, lipid-modified artificial nucleic acid molecules may typically comprise at least one linker which is covalently linked with the artificial nucleic acid molecule, and at least one lipid which is covalently linked with this linker. Alternatively, a lipid-modified artificial nucleic acid molecule may comprise at least one artificial nucleic acid molecule as defined herein and at least one, preferably bifunctional lipid which is covalently linked, preferably without a linker, with that artificial nucleic acid molecule. According to a third alternative, a lipid-modified artificial nucleic acid molecule may comprise an artificial nucleic acid molecule as defined herein, at least one linker which is covalently linked with that artificial nucleic acid molecule, at least one lipid which is covalently linked with this linker, and additionally at least one, preferably bifunctional lipid which is covalently linked, preferably without a linker, with the artificial nucleic acid molecule.
In a further aspect, the present invention provides a vector comprising

    (a.) at least one 5′-untranslated region element (5′UTR element) which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene;
    (b.) at least one open reading frame and/or at least one cloning site; and
    (c.) optionally, at least one histone stem-loop.


The cloning site may be suitable for accepting an open reading frame, i.e. an open reading frame coding for a protein or peptide to be expressed may be cloned into the vector via the cloning site.
The at least one 5′UTR element, the at least one ORF, and the at least one optional histone stem-loop are as described herein for the artificial nucleic acid molecule according to the present invention. The cloning site may be any sequence that is suitable for introducing an open reading frame or a sequence comprising an open reading frame, such as one or more restriction sites.
Thus, the vector comprising a cloning site is preferably suitable for inserting an open reading frame into the vector. Preferably, it may be suitable for inserting an open reading frame between the 5′UTR element and a desired 3′ structure such as a histone stem loop, a polyl(A) sequence, a polyadenylation signal and/or a 3′UTR element, more preferably it is suitable for insertion 5′ to the 3′ structure and 3′ to the 5′UTR element. For example the 3′ structure may comprise a histone stem-loop, a poly(A) sequence or a polyadenylation signal and/or a 3′UTR element as described above. Thereby the histone stem loop, the poly(A) sequence and/or the polyadenylation signal and the 3′UTR element may occur in any order that may be desired. Preferably, the cloning site or the ORF is located 5′ to the 3′UTR structure, preferably in close proximity to the 5′-end of the histone stem-loop, poly(A) sequence, polyadenylation signal and/or a 3′UTR element as described above. For example, the cloning site or the ORF may be directly connected to the 5′-end of the histone stem-loop, poly(A) sequence, polyadenylation signal and/or a 3′UTR element or they may be connected via a stretch of nucleotides, such as by a stretch of 2, 4, 6, 8, 10, 20 etc. nucleotides as described above for the artificial nucleic acid molecule according to the present invention. Preferably, the cloning site or the ORF is located 3′ to the 5′UTR element, preferably in close proximity to the 3′-end of the 5′UTR element. For example, the cloning site or the ORF may be directly connected to the 3′-end of the 5′UTR element or they may be connected via a stretch of nucleotides, such as by a stretch of 2, 4, 6, 8, 10, 20 etc. nucleotides as described above for the artificial nucleic acid molecule according to the present invention.
Preferably, the vector according to the present invention is suitable for producing the artificial nucleic acid molecule according to the present invention, preferably for producing an artificial mRNA according to the present invention, for example, by optionally inserting an open reading frame or a sequence comprising an open reading frame into the vector and transcribing the vector. Thus, preferably, the vector comprises elements needed for transcription, such as a promoter, e.g. an RNA polymerase promoter. Preferably, the vector is suitable for transcription using eukaryotic, prokaryotic, viral or phage transcription systems, such as eukaryotic cells, prokaryotic cells, or eukaryotic, prokaryotic, viral or phage in vitro transcription systems. Thus, for example, the vector may comprise a promoter sequence, which is recognizes by a polymerase, such as by an RNA polymerase, e.g. by a eukaryotic, prokaryotic, viral, or phage RNA polymerase. In a preferred embodiment, the vector comprises a phage RNA polymerase promoter such as an SP6 or T7, preferably a T7 promoter. Preferably, the vector is suitable for in vitro transcription using a phage based in vitro transcription system, such as a T7 RNA polymerase based in vitro transcription system. The vector may further comprise a poly(A) sequence and/or a polyadenylation signal and/or a poly(C) sequence as described above for the artificial nucleic acid molecule according to the present invention.
The vector may be an RNA vector or a DNA vector. Preferably, the vector is a DNA vector. The vector may be any vector known to the skilled person, such as a viral vector or a plasmid vector. Preferably, the vector is a plasmid vector, preferably a DNA plasmid vector.
In a preferred embodiment, the vector according to the present invention comprises or codes for the artificial nucleic acid molecule according to the present invention.
Preferably, a vector according to the present invention comprises a sequence according to SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461, SEQ ID NO. 1462, or a sequence according to SEQ ID NOs. 1368 or 1452-1460, a fragment thereof as described above, or a corresponding RNA sequence, or a sequence having an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%; even more preferably of at least about 99% to a sequence according to any one of SEQ ID NOs. 1-1363, SEQ ID NO. 1435, SEQ ID NO. 1461, SEQ ID NO. 1462, or a sequence according to SEQ ID NOs. 1368 or 1452-1460, a fragment thereof as described above, preferably a functional fragment thereof, or a corresponding RNA sequence.
Preferably, a vector according to the present invention comprises a sequence according to any one of SEQ ID Nos. 1369-1390 and 1434, a fragment thereof as described above or a corresponding RNA sequence, or a sequence having an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%; even more preferably of at least about 99% to a sequence according to any one of SEQ ID Nos. 1369-1390 and 1434 or a fragment thereof as described above, preferably a functional fragment thereof, or a corresponding RNA sequence.
Preferably, a vector according to the present invention comprises a sequence according to any one of SEQ ID Nos. 1391-1433 or a corresponding RNA sequence, or a sequence having an identity of at least about 75%, preferably of at least about 80%, more preferably of at least about 85%, even more preferably of at least about 90%; even more preferably of at least about 95% to a sequence according to SEQ ID Nos. 1433 as described above or a corresponding RNA sequence.
Preferably, the vector is a circular molecule. Preferably, the vector is a double-stranded molecule, such as a double stranded DNA molecule. Such circular, preferably double stranded DNA molecule may be used conveniently as a storage form for the inventive artificial nucleic acid molecule. Furthermore, it may be used for transfection of cells, for example, cultured cells. Also it may be used for in vitro transcription for obtaining an artificial RNA molecule according to the invention.
Preferably, the vector, preferably the circular vector, is linearizable, for example, by restriction enzyme digestion. In a preferred embodiment, the vector comprises a cleavage site, such as a restriction site, preferably a unique cleavage site, located immediately 3′ to the open reading frame or—if present—to the histone stem-loop, or—if present—to the poly(A) sequence or the polyadenylation signal, or—if present—to the 3′UTR element, or—if present—to the poly(C) sequence. Thus, preferably, the product obtained by linearizing the vector terminates at the 3′end with the 3′-end of the open reading frame, or—if present—with the 3′-end of the histone stem loop, or—if present—with the 3′-end of the poly(A) sequence or the 3′-end of the polyadenylation signal, or—if present—with the 3′-end of a 3′UTR element, plus some optional nucleotides, e.g. remaining from the restriction site after cleavage.
In a further aspect, the present invention relates to a cell comprising the artificial nucleic acid molecule according to the present invention or the vector according to the present invention. The cell may be any cell, such as a bacterial cell, insect cell, plant cell, vertebrate cell, e.g. a mammalian cell. Such cell may be, e.g., used for replication of the vector of the present invention, for example, in a bacterial cell. Furthermore, the cell may be used for transcribing the artificial nucleic acid molecule or the vector according to the present invention and/or translating the open reading frame of the artificial nucleic acid molecule or the vector according to the present invention. For example, the cell may be used for recombinant protein production.
The cells according to the present invention are, for example, obtainable by standard nucleic acid transfer methods, such as standard transfection methods. For example, the artificial nucleic acid molecule or the vector according to the present invention may be transferred into the cell by electroporation, lipofection, e.g. based on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or based on cationic polymers, such as DEAE-dextran or polyethylenimine etc.
Preferably, the cell is a mammalian cell, such as a cell of a human subject, a domestic animal, a laboratory animal, such as a mouse or rat cell. Preferably the cell is a human cell. The cell may be a cell of an established cell line, such as a CHO, BHK, 293T, COS-7, HELA, HEK etc. cell, or the cell may be a primary cell, such as a HDF cell, preferably a cell isolated from an organism. In a preferred embodiment, the cell is an isolated cell of a mammalian subject, preferably of a human subject. For example, the cell may be an immune cell, such as a dendritic cell, a cancer or tumor cell, or any somatic cell etc., preferably of a mammalian subject, preferably of a human subject.
In a further aspect, the present invention provides a pharmaceutical composition comprising the artificial nucleic acid molecule according to the present invention, the vector according the present invention, or the cell according to the present invention. The pharmaceutical composition according to the invention may be used, e.g., as a vaccine, for example, for genetic vaccination. Thus, the ORF may, e.g., encode an antigen to be administered to a patient for vaccination. Thus, in a preferred embodiment, the pharmaceutical composition according to the present invention is a vaccine. Furthermore, the pharmaceutical composition according to the present invention may be used, e.g., for gene therapy.
Preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, vehicles, fillers and/or diluents. In the context of the present invention, a pharmaceutically acceptable vehicle typically includes a liquid or non-liquid basis for the inventive pharmaceutical composition. In one embodiment, the pharmaceutical composition is provided in liquid form. In this context, preferably, the vehicle is based on water, such as pyrogen-free water, isotonic saline or buffered (aqueous) solutions, e.g. phosphate, citrate etc. buffered solutions. The buffer may be hypertonic, isotonic or hypotonic with reference to the specific reference medium, i.e. the buffer may have a higher, identical or lower salt content with reference to the specific reference medium, wherein preferably such concentrations of the afore mentioned salts may be used, which do not lead to damage of mammalian cells due to osmosis or other concentration effects. Reference media are e.g. liquids occurring in “in vivo” methods, such as blood, lymph, cytosolic liquids, or other body liquids, or e.g. liquids, which may be used as reference media in “in vitro” methods, such as common buffers or liquids. Such common buffers or liquids are known to a skilled person. Ringer-Lactate solution is particularly preferred as a liquid basis.
One or more compatible solid or liquid fillers or diluents or encapsulating compounds suitable for administration to a patient may be used as well for the inventive pharmaceutical composition. The term “compatible” as used herein preferably means that these components of the inventive pharmaceutical composition are capable of being mixed with the inventive nucleic acid, vector or cells as defined herein in such a manner that no interaction occurs which would substantially reduce the pharmaceutical effectiveness of the inventive pharmaceutical composition under typical use conditions.
The pharmaceutical composition according to the present invention may optionally further comprise one or more additional pharmaceutically active components. A pharmaceutically active component in this context is a compound that exhibits a therapeutic effect to heal, ameliorate or prevent a particular indication or disease. Such compounds include, without implying any limitation, peptides or proteins, nucleic acids, (therapeutically active) low molecular weight organic or inorganic compounds (molecular weight less than 5000, preferably less than 1000), sugars, antigens or antibodies, therapeutic agents already known in the prior art, antigenic cells, antigenic cellular fragments, cellular fractions, cell wall components (e.g. polysaccharides), modified, attenuated or de-activated (e.g. chemically or by irradiation) pathogens (virus, bacteria etc.).
Furthermore, the inventive pharmaceutical composition may comprise a carrier for the artificial nucleic acid molecule or the vector. Such a carrier may be suitable for mediating dissolution in physiological acceptable liquids, transport and cellular uptake of the pharmaceutical active artificial nucleic acid molecule or the vector. Accordingly, such a carrier may be a component which may be suitable for depot and delivery of an artificial nucleic acid molecule or vector according to the invention. Such components may be, for example, cationic or polycationic carriers or compounds which may serve as transfection or complexation agent.
Particularly preferred transfection or complexation agents in this context are cationic or polycationic compounds, including protamine, nucleoline, spermine or spermidine, or other cationic peptides or proteins, such as poly-L-lysine (PLL), poly-arginine, basic polypeptides, cell penetrating peptides (CPPs), including HIV-binding peptides, HIV-1 Tat (HIV), Tat-derived peptides, Penetratin, VP22 derived or analog peptides, HSV VP22 (Herpes simplex), MAP, KALA or protein transduction domains (PTDs), PpT620, prolin-rich peptides, arginine-rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1, L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides (particularly from Drosophila antennapedia), pAntp, plsl, FGF, Lactoferrin, Transportan, Buforin-2, Bac715-24, SynB, SynB(1), pVEC, hCT-derived peptides, SAP, or histones.
Furthermore, such cationic or polycationic compounds or carriers may be cationic or polycationic peptides or proteins, which preferably comprise or are additionally modified to comprise at least one —SH moiety. Preferably, a cationic or polycationic carrier is selected from cationic peptides having the following sum formula (III):

{(Arg)l;(Lys)m;(His)n;(Orn)o;(Xaa)x};  formula (III)

wherein l+m+n+o+x=3-100, and l, m, n or o independently of each other is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90 and 91-100 provided that the overall content of Arg (Arginine), Lys (Lysine), His (Histidine) and Orn (Ornithine) represents at least 10% of all amino acids of the oligopeptide; and Xaa is any amino acid selected from native (=naturally occurring) or non-native amino acids except of Arg, Lys, His or Orn; and x is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, provided, that the overall content of Xaa does not exceed 90% of all amino acids of the oligopeptide. Any of amino acids Arg, Lys, His, Orn and Xaa may be positioned at any place of the peptide. In this context cationic peptides or proteins in the range of 7-30 amino acids are particular preferred.

Further, the cationic or polycationic peptide or protein, when defined according to formula {(Arg)l;(Lys)m;(His)n;(Orn)o;(Xaa)x} (formula (III)) as shown above and which comprise or are additionally modified to comprise at least one —SH moiety, may be, without being restricted thereto, selected from subformula (IIIa):

{(Arg)l;(Lys)m;(His)n;(Orn)o;(Xaa′)x(Cys)y}  subformula (IIIa)

wherein (Arg)l;(Lys)m;(His)n;(Orn)o; and x are as defined herein, Xaa′ is any amino acid selected from native (=naturally occurring) or non-native amino acids except of Arg, Lys, His, Orn or Cys and y is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80 and 81-90, provided that the overall content of Arg (Arginine), Lys (Lysine), His (Histidine) and Orn (Ornithine) represents at least 10% of all amino acids of the oligopeptide. Further, the cationic or polycationic peptide may be selected from subformula (IIIb):

Cys1{(Arg)l;(Lys)m;(His)n;(Orn)o;(Xaa)x}Cys2  subformula (IIIb)

wherein empirical formula {(Arg)l;(Lys)m;(His)n;(Orn)o;(Xaa)x} (formula (III)) is as defined herein and forms a core of an amino acid sequence according to (semiempirical) formula (III) and wherein Cys1 and Cys2 are Cysteines proximal to, or terminal to (Arg)l;(Lys)m;(His)n;(Orn)o;(Xaa)x.

Further preferred cationic or polycationic compounds, which can be used as transfection or complexation agent may include cationic polysaccharides, for example chitosan, polybrene, cationic polymers, e.g. polyethyleneimine (PEI), cationic lipids, e.g. DOTMA: [1-(2,3-sioleyloxy)propyl)]-N,N,N-trimethylammonium chloride, DMRIE, di-C14-amidine, DOTIM, SAINT, DC-Chol, BGTC, CTAP, DOPC, DODAP, DOPE: Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC, DOGS: Dioctadecylamidoglicylspermin, DIMRI: Dimyristo-oxypropyl dimethyl hydroxyethyl ammonium bromide, DOTAP: dioleoyloxy-3-(trimethylammonio)propane, DC-6-14: O,O-ditetradecanoyl-N-(α-trimethylammonioacetyl)diethanolamine chloride, CLIP1: rac-[(2,3-dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammonium chloride, CLIP6: rac-[2(2,3-dihexadecyloxypropyl-oxymethyloxy)ethyl]trimethylammonium, CLIP9: rac-[2(2,3-dihexadecyloxypropyl-oxysuccinyloxy)ethyl]-trimethylammonium, oligofectamine, or cationic or polycationic polymers, e.g. modified polyaminoacids, such as β-amino acid-polymers or reversed polyamides, etc., modified polyethylenes, such as PVP (poly(N-ethyl-4-vinylpyridinium bromide)), etc., modified acrylates, such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc., modified Amidoamines such as pAMAM (poly(amidoamine)), etc., modified polybetaaminoester (PBAE), such as diamine end modified 1,4 butanediol diacrylate-co-5-amino-1-pentanol polymers, etc., dendrimers, such as polypropylamine dendrimers or pAMAM based dendrimers, etc., polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine), etc., polyallylamine, sugar backbone based polymers, such as cyclodextrin based polymers, dextran based polymers, chitosan, etc., silan backbone based polymers, such as PMOXA-PDMS copolymers, etc., blockpolymers consisting of a combination of one or more cationic blocks (e.g. selected from a cationic polymer as mentioned above) and of one or more hydrophilic or hydrophobic blocks (e.g. polyethyleneglycole); etc.
In this context, it is particularly preferred that the inventive artificial nucleic acid molecule or the inventive vector is complexed at least partially with a cationic or polycationic compound, preferably cationic proteins or peptides. Partially means that only a part of the inventive artificial nucleic acid molecule or the inventive vector is complexed with a cationic or polycationic compound and that the rest of the inventive artificial nucleic acid molecule or the inventive vector is in uncomplexed form (“free”). Preferably the ratio of complexed nucleic acid to:free nucleic acid is selected from a range. of about 5:1 (w/w) to about 1:10 (w/w), more preferably from a range of about 4:1 (w/w) to about 1:8 (w/w), even more preferably from a range of about 3:1 (w/w) to about 1:5 (w/w) or 1:3 (w/w), and most preferably the ratio of complexed nucleic acid to free nucleic acid is selected from a ratio of about 1:1 (w/w).
The pharmaceutical composition according to the present invention may optionally further comprise one or more adjuvants, for example, adjuvants for stimulating the innate immune system or for enhancing cellular uptake of the artificial nucleic acid molecule or vector. In this context, an adjuvant may be understood as any compound, which is suitable to initiate or increase an immune response of the innate immune system, i.e. a non-specific immune response. In other words, when administered, the inventive pharmaceutical composition preferably elicits an innate immune response due to the adjuvant, optionally contained therein. Preferably, such an adjuvant may be an adjuvant supporting the induction of an innate immune response in a mammal. Such an adjuvant may be, for example, an immunostimulatory nucleic acid, i.e. a nucleic acid that may bind to a Toll-like-receptor or the like, preferably an immunostimulatory RNA.
Such adjuvants, preferably such immunostimulatory nucleic acids, may induce an innate, i.e. unspecific, immune response which may support a specific, i.e. adaptive, immune response to the peptide or protein, i.e. the antigen, encoded by the artificial nucleic acid molecule of the pharmaceutical composition, preferably the vaccine.
The inventive pharmaceutical composition may also additionally comprise any further compound, which is known to be immunostimulating due to its binding affinity (as ligands) to human Toll-like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, or due to its binding affinity (as ligands) to murine Toll-like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12 or TLR13.
Further additives which may be included in the inventive pharmaceutical composition are, e.g., emulsifiers, such as, for example, Tween®; wetting agents, such as, for example, sodium lauryl sulfate; colouring agents; taste-imparting agents, pharmaceutical carriers; tablet-forming agents; stabilizers; antioxidants; preservatives etc.
The pharmaceutical composition according to the present invention preferably comprises a “safe and effective amount” of the components of the pharmaceutical composition, particularly of the inventive nucleic acid sequence, the vector and/or the cells as defined herein. As used herein, a “safe and effective amount” means an amount sufficient to significantly induce a positive modification of a disease or disorder as defined herein. At the same time, however, a “safe and effective amount” preferably avoids serious side-effects and permits a sensible relationship between advantage and risk. The determination of these limits typically lies within the scope of sensible medical judgment.
In a further aspect, the present invention provides the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for use as a medicament, for example, as vaccine (in genetic vaccination) or in gene therapy.
The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention are particularly suitable for any medical application which makes use of the therapeutic action or effect of peptides, polypeptides or proteins, or where supplementation of a particular peptide or protein is needed. Thus, the present invention provides the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for use in the treatment or prevention of diseases or disorders amenable to treatment by the therapeutic action or effect of peptides, polypeptides or proteins or amenable to treatment by supplementation of a particular peptide, polypeptide or protein. For example, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be used for the treatment or prevention of genetic diseases, autoimmune diseases, cancerous or tumour-related diseases, infectious diseases, chronic diseases or the like, e.g., by genetic vaccination or gene therapy.
In particular, such therapeutic treatments which benefit from a stable, prolonged and/or increased presence of therapeutic peptides, polypeptides or proteins in a subject to be treated are especially suitable as medical application in the context of the present invention, since the 5′UTR element in particular in combination with a histone stem-loop provides for increased protein expression from the ORF of the inventive nucleic acid molecule. Thus, a particularly suitable medical application for the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention is vaccination, for example against infections or tumours. Thus, the present invention provides the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for vaccination of a subject, preferably a mammalian subject, more preferably a human subject. Preferred vaccination treatments are vaccination against infectious diseases, such as bacterial, protozoal or viral infections, and anti-tumour-vaccination. Such vaccination treatments may be prophylactic or therapeutic.
Depending on the disease to be treated or prevented, the ORF may be selected. For example, the open reading frame may code for a protein that has to be supplied to a patient suffering from total lack or at least partial loss of function of a protein, such as a patient suffering from a genetic disease. Additionally, the open reading frame may be chosen from an ORF coding for a peptide or protein which beneficially influences a disease or the condition of a subject. Furthermore, the open reading frame may code for a peptide or protein which effects down-regulation of a pathological overproduction of a natural peptide or protein or elimination of cells expressing pathologically a protein or peptide. Such lack, loss of function or overproduction may, e.g., occur in the context of tumour and neoplasia, autoimmune diseases, allergies, infections, chronic diseases or the like. Furthermore, the open reading frame may code for an antigen or immunogen, e.g. for an epitope of a pathogen or for a tumour antigen. Thus, in preferred embodiments, the artificial nucleic acid molecule or the vector according to the present invention comprises an ORF encoding an amino acid sequence comprising or consisting of an antigen or immunogen, e.g. an epitope of a pathogen or a tumour-associated antigen, a 5′UTR element as described above, preferably a histone stem-loop as described herein, and optional further components, such as a 3′UTR element and/or a poly(A) sequence and/or a poly(C) sequence etc. as described herein.
In the context of medical application, in particular, in the context of vaccination, it is preferred that the artificial nucleic acid molecule according to the present invention is RNA, preferably mRNA, since DNA harbours the risk of eliciting an anti-DNA immune response and tends to insert into genomic DNA. However, in some embodiments, for example, if a viral delivery vehicle, such as an adenoviral delivery vehicle is used for delivery of the artificial nucleic acid molecule or the vector according to the present invention, e.g., in the context of gene therapeutic treatments, it may be desirable that the artificial nucleic acid molecule or the vector is a DNA molecule.
The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, intracranial, transdermal, intradermal, intrapulmonal, intraperitoneal, intracardial, intraarterial, and sublingual injection or infusion techniques.
Preferably, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention is administered parenterally, e.g. by parenteral injection, more preferably by subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, intracranial, transdermal, intradermal, intrapulmonal, intraperitoneal, intracardial, intraarterial, sublingual injection or via infusion techniques. Particularly preferred is intradermal and intramuscular injection. Sterile injectable forms of the inventive pharmaceutical composition may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may also be administered orally in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, e.g. including diseases of the skin or of any other accessible epithelial tissue. Suitable topical formulations are readily prepared for each of these areas or organs. For topical applications, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be formulated in a suitable ointment suspended or dissolved in one or more carriers.
In one embodiment, the use as a medicament comprises the step of transfection of mammalian cells, preferably in vitro transfection of mammalian cells, more preferably in vitro transfection of isolated cells of a subject to be treated by the medicament. If the use comprises the in vitro transfection of isolated cells, the use as a medicament may further comprise the (re)administration of the transfected cells to the patient. The use of the inventive artificial nucleic acid molecules or the vector as a medicament may further comprise the step of selection of successfully transfected isolated cells. Thus, it may be beneficial if the vector further comprises a selection marker. Also, the use as a medicament may comprise in vitro transfection of isolated cells and purification of an expression-product, i.e. the encoded peptide or protein from these cells. This purified peptide or protein may subsequently be administered to a subject in need thereof.
The present invention also provides a method for treating or preventing a disease or disorder as described above comprising administering the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention to a subject in need thereof.
Furthermore, the present invention provides a method for treating or preventing a disease or disorder comprising transfection of a cell with an artificial nucleic acid molecule according to the present invention or with the vector according to the present invention. Said transfection may be performed in vitro or in vivo. In a preferred embodiment, transfection of a cell is performed in vitro and the transfected cell is administered to a subject in need thereof, preferably to a human patient. Preferably, the cell which is to be transfected in vitro is an isolated cell of the subject, preferably of the human patient. Thus, the present invention provides a method of treatment comprising the steps of isolating a cell from a subject, preferably from a human patient, transfecting the isolated cell with the artificial nucleic acid molecule according to the present invention or the vector according to the present invention, and administering the transfected cell to the subject, preferably the human patient.
The method of treating or preventing a disorder according to the present invention is preferably a vaccination method and/or a gene therapy method as described above.
As described above, the 5′UTR element, preferably, the histone stem-loop, and optionally the poly(A)sequence and/or the 3′UTR element are capable of increasing protein production from an artificial nucleic acid molecule, such as an mRNA or vector, comprising these elements and an ORF, preferably in an at least additive, preferably in a synergistic manner. Thus, in a further aspect, the present invention relates to a method for increasing protein production from an artificial nucleic acid molecule comprising the step of associating the artificial nucleic acid molecule, preferably an ORF contained within the artificial nucleic acid molecule, with (i) at least one 5′-untranslated region element (5′UTR element) which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene as described above, preferably (ii) at least one histone stem-loop as described herein, and optionally one or more further elements, such as a poly(A)sequence and/or polyadenylation signal, and/or a poly(C) sequence, and/or a 3′UTR element, which comprises or consists of a nucleic acid sequence derived from the 3′UTR of a chordate gene, preferably a vertebrate gene, more preferably a mammalian gene, most preferably a human gene, or from a variant of the 3′UTR of a chordate gene, preferably a vertebrate gene, more preferably a mammalian gene, most preferably a human gene as described above.
Associating the artificial nucleic acid molecule or the vector with a 5′UTR element and preferably a histone stem-loop as well as optional further elements in the context of the present invention preferably means functionally associating or functionally combining an artificial nucleic acid molecule, e.g. comprising an ORF, such as an mRNA or a vector, with the 5′UTR element and optionally the histone stem-loop and/or the poly(A) sequence and/or the 3′UTR element. This means that the artificial nucleic acid molecule, preferably the ORF contained within the artificial nucleic acid molecule, the 5′UTR element and preferably the histone stem-loop and the optional further elements, such as the poly(A)sequence and/or the 3′UTR element as described above, are associated or coupled such that the function of the 5′UTR element and the histone stem-loop and the optional further elements, e.g. protein production increasing function, is exerted. Typically, this means that the 5′UTR element and the histone stem-loop and optionally the poly(A)sequence and/or the 3′UTR element are integrated into the artificial nucleic acid molecule, preferably into the mRNA molecule or the vector, such that the open reading frame is positioned between the 5′UTR element and the optional histone stem-loop and the optional poly(A)sequence and/or the optional 3′UTR element.
The product of said method is preferably the artificial nucleic acid molecule according to the present invention or the vector according to the present invention. Thus, e.g. the nature and sequence of the elements, such as the 5′UTR element, the histone stem-loop, the poly(A) sequence, the polyadenylation signal, the poly(C) sequence, and the 3′UTR element are as described above for the artificial nucleic acid molecule according to the present invention or the vector according to the present invention.
In a further aspect, the present invention provides the use of at least one 5′-untranslated region element (5′UTR element) which comprises or consists of a nucleic acid sequence which is derived from the 5′UTR of a TOP gene or which is derived from a variant of the 5′UTR of a TOP gene as described above, preferably at least one histone stem-loop, and optionally further elements, such as a poly(A)sequence and/or a polyadenylation signal, and/or a poly(C) signal), and/or a 3′UTR element which comprises or consists of a nucleic acid sequence derived from the 3′UTR of a chordate gene, preferably a vertebrate gene, more preferably a mammalian gene, most preferably a human gene, or from a variant of the 3′UTR of a chordate gene, preferably a vertebrate gene, more preferably a mammalian gene, most preferably a human gene as described above for increasing protein production from an artificial nucleic acid molecule, such as an mRNA or a vector.
The use according to the present invention preferably comprises associating the artificial nucleic acid molecule with the 5′UTR element, preferably the histone stem-loop and optional further elements, such as a poly(A)sequence or 3′UTR element etc., as described above.
The compounds and ingredients of the inventive pharmaceutical composition may also be manufactured and traded separately of each other. Thus, the invention relates further to a kit or kit of parts comprising an artificial nucleic acid molecule according to the invention, a vector according to the present invention, a cell according to the invention, and/or a pharmaceutical composition according to the invention. Preferably, such kit or kit of parts may, additionally, comprise instructions for use, cells for transfection, an adjuvant, a means for administration of the pharmaceutical composition, a pharmaceutically acceptable carrier and/or an pharmaceutically acceptable solution for dissolution or dilution of the artificial nucleic acid molecule, the vector, the cells or the pharmaceutical composition.



The following Figures, Sequences and Examples are intended to illustrate the invention further. They are not intended to limit the subject-matter of the invention thereto.
FIG. 1: shows the histone stem-loop consensus sequence generated from metazoan and protozoan stem-loop sequences (as reported by Dávila López, M., & Samuelsson, T. (2008), RNA (New York, N.Y.), 14(1), 1-10. doi:10.1261/rna.782308). 4001 histone stem-loop sequences from metazoa and protozoa were aligned and the quantity of the occurring nucleotides is indicated for every position in the stem-loop sequence. The generated consensus sequence representing all nucleotides present in the sequences analyzed is given using the single-letter nucleotide code. In addition to the consensus sequence, sequences are shown representing at least 99%, 95% and 90% of the nucleotides present in the sequences analyzed.
FIG. 2: shows the histone stem-loop consensus sequence generated from protozoan stem-loop sequences (as reported by Dávila López, M., & Samuelsson, T. (2008), RNA (New York, N.Y.), 14(1), 1-10. doi:10.1261/rna.782308). 131 histone stem-loop sequences from protozoa were aligned and the quantity of the occurring nucleotides is indicated for every position in the stem-loop sequence. The generated consensus sequence representing all nucleotides present in the sequences analyzed is given using the single-letter nucleotide code. In addition to the consensus sequence, sequences are shown representing at least 99%, 95% and 90% of the nucleotides present in the sequences analyzed.
FIG. 3: shows the histone stem-loop consensus sequence generated from metazoan stem-loop sequences (as reported by Dávila López, M., & Samuelsson, T. (2008), RNA (New York, N.Y.), 14(1), 1-10. doi:10.1261/rna.782308). 3870 histone stem-loop sequences from metazoa were aligned and the quantity of the occurring nucleotides is indicated for every position in the stem-loop sequence. The generated consensus sequence representing all nucleotides present in the sequences analyzed is given using the single-letter nucleotide code. In addition to the consensus sequence, sequences are shown representing at least 99%, 95% and 90% of the nucleotides present in the sequences analyzed.
FIG. 4: shows the histone stem-loop consensus sequence generated from vertebrate stem-loop sequences (as reported by Dávila López, M., & Samuelsson, T. (2008), RNA (New York, N.Y.), 14(1), 1-10. doi:10.1261/rna.782308). 1333 histone stem-loop sequences from vertebrates were aligned and the quantity of the occurring nucleotides is indicated for every position in the stem-loop sequence. The generated consensus sequence representing all nucleotides present in the sequences analyzed is given using the single-letter nucleotide code. In addition to the consensus sequence, sequences are shown representing at least 99%, 95% and 90% of the nucleotides present in the sequences analyzed.
FIG. 5: shows the histone stem-loop consensus sequence generated from human (Homo sapiens) stem-loop sequences (as reported by Dávila López, M., & Samuelsson, T. (2008), RNA (New York, N.Y.), 14(1), 1-10. doi:10.1261/rna.782308). 84 histone stem-loop sequences from humans were aligned and the quantity of the occurring nucleotides is indicated for every position in the stem-loop sequence. The generated consensus sequence representing all nucleotides present in the sequences analyzed is given using the single-letter nucleotide code. In addition to the consensus sequence, sequences are shown representing at least 99%, 95% and 90% of the nucleotides present in the sequences analyzed.
FIG. 6 shows the nucleotide sequence of a Photinus pyralis luciferase encoding nucleic acid molecule PpLuc(GC)-ag-A64. This artificial construct does not comprise a 5′UTR element or a histone stem loop. The coding region for PpLuc(GC) is depicted in italics. The sequence depicted in FIG. 6 corresponds to SEQ ID No. 1364.
FIG. 7 shows the nucleotide sequence of RPL32 PpLuc(GC)-ag-A64-C30-histoneSL. The 5′UTR of human ribosomal protein Large 32 lacking the 5′ terminal oligopyrimidine tract was inserted 5′ of the ORF. A histoneSL was appended 3′ of A64 poly(A). The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 7 corresponds to SEQ ID No. 1365.
FIG. 8 shows that the combination of the 5′UTR element derived from the 5′UTR of the TOP gene RPL32 and a histone stem-loop increases protein production from mRNA strongly. The effect of the combination of the 5′UTR element and the histone stem-loop on luciferase expression from mRNA was examined. To this end, different mRNAs were transfected into human dermal fibroblasts (HDF) by lipofection. Luciferase levels were measured at 24 hours after transfection. Luciferase was clearly expressed from mRNA having neither 5′UTR element nor histoneSL. Strikingly however, the combination of 5′UTR element and histoneSL strongly increased the luciferase level. The magnitude of the rise in luciferase level due to combining 5′UTR element and histoneSL in the same mRNA indicates that they are acting synergistically. Data are graphed as mean RLU±SD (relative light units±standard deviation) for duplicate transfections. RLU are summarized in Example 5.1.
FIG. 9 shows the nucleotide sequence of PpLuc(GC)ag-A64-histoneSL. A histoneSL was appended 3′ of A64 poly(A). The coding region for PpLuc(GC) is depicted in italics. The histone stem-loop sequence is underlined. The sequence depicted in FIG. 9 corresponds to SEQ ID No. 1464.
FIG. 10 shows the nucleotide sequence of rpl32-PpLuc(GC)-ag-A64. The 5′UTR of human ribosomal protein Large 32 lacking the 5′ terminal oligopyrimidine tract was inserted 5′ of the ORF. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 10 corresponds to SEQ ID No. 1463.
FIG. 11 shows the nucleotide sequence of rpl32-PpLuc(GC)-ag-A64-histoneSL. The 5′UTR of human ribosomal protein Large 32 lacking the 5′ terminal oligopyrimidine tract was inserted 5′ of the ORF. A histoneSL was appended 3′ of A64 poly(A). The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 11 corresponds to SEQ ID No. 1480.
FIG. 12 is a graphical representation of the effect of the 5′UTR element derived from the 5′UTR of the TOP gene RPL32, the histone stem-loop, and the combination of the 5′UTR element and the histone stem-loop on luciferase expression from mRNA. A variety of mRNAs were transfected into human dermal fibroblasts (HDF) by lipofection. Luciferase levels were measured at 8, 24, and 48 hours after transfection. Both, either the histone stem-loop or the 5′UTR element increase luciferase levels compared to mRNA lacking both these elements. Strikingly, the combination of 5′UTR element and histone stem-loop further strongly increases the luciferase level, much above the level observed with either of the individual elements, thus acting synergistically. Data are graphed as mean RLU±SEM (relative light units±standard error) for triplicate transfections. RLU are summarized in Example 5.2.
FIG. 13 shows the nucleotide sequence of rpl32-PpLuc(GC)-albumin7-A64-C30-histoneSL. The albumin7 3′UTR element replaced the alpha-globin 3′UTR element in the construct shown in FIG. 7 (which contains the rpl32 5′UTR element). The 5′UTR element sequence is underlined. The sequence depicted in FIG. 13 corresponds to SEQ ID No. 1481.
FIG. 14 shows the nucleotide sequence of rpl35-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of human ribosomal protein Large 35 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 13. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 14 corresponds to SEQ ID No. 1436.
FIG. 15 shows the nucleotide sequence of rpl21-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of human ribosomal protein Large 21 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 13. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 15 corresponds to SEQ ID No. 1437.
FIG. 16 shows the nucleotide sequence of atp5a1-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of human ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 13. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 16 corresponds to SEQ ID No. 1438.
FIG. 17 shows the nucleotide sequence of HSD17B4-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of human hydroxysteroid (17-beta) dehydrogenase 4 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 13. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 17 corresponds to SEQ ID No. 1439.
FIG. 18 shows the nucleotide sequence of AIG1-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of human androgen-induced 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 element sequence is underlined. The sequence depicted in FIG. 18 corresponds to SEQ ID No. 1440.
FIG. 19 shows the nucleotide sequence of COX6C-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of human cytochrome c oxidase subunit VIc lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 13. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 19 corresponds to SEQ ID No. 1441.
FIG. 20 shows the nucleotide sequence of ASAH1-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of human N-acylsphingosine amidohydrolase (acid ceramidase) 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 13. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 20 corresponds to SEQ ID No. 1442.
FIG. 21 is a graphical representation of the effect of the 5′UTR element derived from the TOP genes RPL32, RPL35, RPL21, ATP5A1, HSD17B4, AIG1, COX6C and ASAH1 on luciferase expression from mRNA. The mRNAs were transfected into human dermal fibroblasts (HDF) by lipofection. Luciferase levels were measured at 24, 48, and 72 hours after transfection. The 5′UTR elements strongly increase luciferase levels compared to mRNA lacking a 5′UTR element. Data are graphed as mean RLU±SEM (relative light units±standard error) for triplicate transfections. RLU are summarized in Example 5.3.
FIG. 22 shows the nucleotide sequence of rpl35-PpLuc(GC)-ag-A64. The 5′UTR of human ribosomal protein Large 35 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 10. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 22 corresponds to SEQ ID No. 1466.
FIG. 23 shows the nucleotide sequence of rpl21-PpLuc(GC)-ag-A64. The 5′UTR of human ribosomal protein Large 21 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 10. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 23 corresponds to SEQ ID No. 1467.
FIG. 24 shows the nucleotide sequence of atp5a1-PpLuc(GC)-ag-A64. The 5′UTR of human ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 10. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 24 corresponds to SEQ ID No. 1468.
FIG. 25 shows the nucleotide sequence of HSD17B4-PpLuc(GC)-ag-A64. The 5′UTR of human hydroxysteroid (17-beta) dehydrogenase 4 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 10. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 25 corresponds to SEQ ID No. 1469.
FIG. 26 shows the nucleotide sequence of AIG1-PpLuc(GC)-ag-A64. The 5′UTR of human androgen-induced 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 10. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 26 corresponds to SEQ ID No. 1470.
FIG. 27 shows the nucleotide sequence of COX6C-PpLuc(GC)-ag-A64. The 5′UTR of human cytochrome c oxidase subunit VIc lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 10. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 27 corresponds to SEQ ID No. 1471.
FIG. 28 shows the nucleotide sequence of ASAH1-PpLuc(GC)-ag-A64. The 5′UTR of human N-acylsphingosine amidohydrolase (acid ceramidase) 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 10. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 28 corresponds to SEQ ID No. 1472.
FIG. 29 shows the nucleotide sequence of rpl35-PpLuc(GC)-ag-A64-histoneSL. The 5′UTR of human ribosomal protein Large 35 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 11. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 29 corresponds to SEQ ID No. 1473.
FIG. 30 shows the nucleotide sequence of rpl21-PpLuc(GC)-ag-A64-histoneSL. The 5′UTR of human ribosomal protein Large 21 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 11. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 30 corresponds to SEQ ID No. 1474.
FIG. 31 shows the nucleotide sequence of atp5a1-PpLuc(GC)-ag-A64-histoneSL. The 5′UTR of human ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 11. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 31 corresponds to SEQ ID No. 1475.
FIG. 32 shows the nucleotide sequence of HSD17B4-PpLuc(GC)-ag-A64-histoneSL. The 5′UTR of human hydroxysteroid (17-beta) dehydrogenase 4 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 11. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 32 corresponds to SEQ ID No. 1476.
FIG. 33 shows the nucleotide sequence of AIG1-PpLuc(GC)-ag-A64-histoneSL. The 5′UTR of human androgen-induced 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 11. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 33 corresponds to SEQ ID No. 1477.
FIG. 34 shows the nucleotide sequence of COX6C-PpLuc(GC)-ag-A64-histoneSL. The 5′UTR of human cytochrome c oxidase subunit VIc lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 11. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 34 corresponds to SEQ ID No. 1478.
FIG. 35 shows the nucleotide sequence of ASAH1-PpLuc(GC)-ag-A64-histoneSL. The 5′UTR of human N-acylsphingosine amidohydrolase (acid ceramidase) 1 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 11. The coding region for PpLuc(GC) is depicted in italics. The 5′UTR element sequence and the histone stem-loop sequence are underlined. The sequence depicted in FIG. 35 corresponds to SEQ ID No. 1479.
FIG. 36 is a graphical representation of the effect of 5′UTR elements derived from 5′UTRs of the TOP genes RPL35, RPL21, ATP5A1, HSD17B4, AIG1, COX6C and ASAH1, the histone stem-loop, and the combination of 5′UTR elements and histone stem-loop on luciferase expression from mRNA. The different mRNAs were transfected into human dermal fibroblasts (HDF) by lipofection. Luciferase levels were measured at 8, 24, and 48 hours after transfection. Both, either the histone stem-loop or the 5′UTR elements increase luciferase levels compared to mRNA lacking both these elements. Strikingly, the combination of 5′UTR elements and histone stem-loop further strongly increases the luciferase level, much above the level observed with either of the individual elements, thus acting synergistically. Data are graphed as mean RLU±SEM (relative light units±standard error) for triplicate transfections. The synergy between 5′UTR elements and histone stem-loop is summarized in example 5.4.
FIG. 37 shows the nucleotide sequence of mrpl21-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of murine ribosomal protein Large 21 lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 13. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 36 corresponds to SEQ ID No. 1443.
FIG. 38 shows the nucleotide sequence of mrpl35A-PpLuc(GC)-albumin7-A64-C30-histoneSL. The 5′UTR of murine ribosomal protein Large 35A lacking the 5′ terminal oligopyrimidine tract replaced the rpl32 5′UTR element in the construct shown in FIG. 13. The 5′UTR element sequence is underlined. The sequence depicted in FIG. 37 corresponds to SEQ ID No. 1444.
FIG. 39 is a graphical representation of the effect of the 5′UTR elements derived from 5′UTRs of mouse TOP genes on luciferase expression from mRNA. mRNAs containing either a mouse or a human 5′UTR element were transfected into human dermal fibroblasts (HDF) by lipofection. Luciferase levels were measured at 24, 48, and 72 hours after transfection. Mouse 5′UTR elements strongly increase luciferase levels compared to mRNA lacking a 5′UTR element, similarly as the human 5′UTR element. Data are graphed as mean RLU±SEM (relative light units±standard error) for triplicate transfections. RLU are summarized in Example 5.5.





    SEQ ID No. 1-1363. 1435, and 1461-1462 sequences comprising 5′UTRs of TOP genes
    SEQ ID No. 1364 PpLuc(GC)-ag-A64 (FIG. 6)
    SEQ ID No. 1365 RPL32-PpLuc(GC)-ag-A64-C30-histoneSL (FIG. 7)
    SEQ ID No. 1366 fragment of the 5′UTR of human ribosomal protein Large 32
    SEQ ID No. 1367 fragment of the 5′UTR of human ribosomal protein Large 32
    SEQ ID No. 1368 5′UTR of human ribosomal protein Large 32 lacking the 5′ terminal oligopyrimidine tract
    SEQ ID No. 1369 Human albumin 3′UTR
    SEQ ID No. 1370 3′UTR of Homo sapiens hemoglobin, alpha 1 (HBA1)
    SEQ ID No. 1371 3′UTR of Homo sapiens hemoglobin, alpha 2 (HBA2)
    SEQ ID No. 1372 3′UTR of Homo sapiens hemoglobin, beta (HBB)
    SEQ ID No. 1373 3′UTR of Homo sapiens tyrosine hydroxylase (TH)
    SEQ ID No. 1374 3′UTR of Homo sapiens arachidonate 15-lipoxygenase (ALOX15)
    SEQ ID No. 1375 3′UTR of Homo sapiens collagen, type I, alpha 1 (COL1A1)
    SEQ ID No. 1376 albumin7 3′UTR
    SEQ ID No. 1377 Human albumin 3′UTR+poly(A) sequence
    SEQ ID No. 1378 Human albumin 3′UTR fragment 1
    SEQ ID No. 1379 Human albumin 3′UTR fragment 2
    SEQ ID No. 1380 Human albumin 3′UTR fragment 3
    SEQ ID No. 1381 Human albumin 3′UTR fragment 4
    SEQ ID No. 1382 Human albumin 3′UTR fragment 5
    SEQ ID No. 1383 Human albumin 3′UTR fragment 6
    SEQ ID No. 1384 Human albumin 3′UTR fragment 7
    SEQ ID No. 1385 Human albumin 3′UTR fragment 8
    SEQ ID No. 1386 Human albumin 3′UTR fragment 9
    SEQ ID No. 1387 Human albumin 3′UTR fragment 10
    SEQ ID No. 1388 Human albumin 3′UTR fragment 11
    SEQ ID No. 1389 Human albumin 3′UTR fragment 12
    SEQ ID No. 1390 Human albumin 3′UTR fragment 13
    SEQ ID NO. 1391 Sequence according to formula (Ic)
    SEQ ID NO. 1392 Sequence according to formula (IIc):
    SEQ ID NO. 1393 Sequence according to formula (Id):
    SEQ ID NO. 1394 Sequence according to formula (IId)
    SEQ ID NO. 1395 Sequence according to formula (Ie)
    SEQ ID NO. 1396 Sequence according to formula (IIe)
    SEQ ID NO. 1397 Sequence according to formula (If)
    SEQ ID NO. 1398 Sequence according to formula (IIf)
    SEQ ID NO. 1399 Sequence according to formula (Ig)
    SEQ ID NO. 1400 Sequence according to formula (IIg)
    SEQ ID NO. 1401 Sequence according to formula (Ih)
    SEQ ID NO. 1402 Sequence according to formula (IIh)
    SEQ ID NO. 1403 Sequence according to formula (Ic)
    SEQ ID NO. 1404 Sequence according to formula (Ic)
    SEQ ID NO. 1405 Sequence according to formula (Ic)
    SEQ ID NO. 1406 Sequence according to formula (Ie)
    SEQ ID NO. 1407 Sequence according to formula (Ie)
    SEQ ID NO. 1408 Sequence according to formula (Ie)
    SEQ ID NO. 1409 Sequence according to formula (If)
    SEQ ID NO. 1410 Sequence according to formula (If)
    SEQ ID NO. 1411 Sequence according to formula (If)
    SEQ ID NO. 1412 Sequence according to formula (Ig)
    SEQ ID NO. 1413 Sequence according to formula (Ig)
    SEQ ID NO. 1414 Sequence according to formula (Ig)
    SEQ ID NO. 1415 Sequence according to formula (Ih)
    SEQ ID NO. 1416 Sequence according to formula (Ih)
    SEQ ID NO. 1417 Sequence according to formula (Ih)
    SEQ ID NO. 1418 Sequence according to formula (IIc)
    SEQ ID NO. 1419 Sequence according to formula (IIc)
    SEQ ID NO. 1420 Sequence according to formula (IIc)
    SEQ ID NO. 1421 Sequence according to formula (IIe)
    SEQ ID NO. 1422 Sequence according to formula (IIe)
    SEQ ID NO. 1423 Sequence according to formula (IIe)
    SEQ ID NO. 1424 Sequence according to formula (IIf)
    SEQ ID NO. 1425 Sequence according to formula (IIf)
    SEQ ID NO. 1426 Sequence according to formula (IIf)
    SEQ ID NO. 1427 Sequence according to formula (IIg)
    SEQ ID NO. 1428 Sequence according to formula (IIg)
    SEQ ID NO. 1429 Sequence according to formula (IIg)
    SEQ ID NO. 1430 Sequence according to formula (IIh)
    SEQ ID NO. 1431 Sequence according to formula (IIh)
    SEQ ID NO. 1432 Sequence according to formula (IIh)
    SEQ ID NO. 1433 Example histone stem-loop sequence
    SEQ ID NO. 1434 Center, α-complex-binding portion of the 3′UTR of an α-globin gene
    SEQ ID NO. 1435 ATP synthase lipid-binding protein, mitochondrial (atp5g2)
    SEQ ID NO. 1436 RPL35-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 14)
    SEQ ID NO. 1437 RPL21-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 15)
    SEQ ID NO. 1438 ATP5A1-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 16)
    SEQ ID NO. 1439 HSD17B4-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 17)
    SEQ ID NO. 1440 AIG1-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 18)
    SEQ ID NO. 1441 COX6C-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 19)
    SEQ ID NO. 1442 ASAH1-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 20)
    SEQ ID NO. 1443 mRPL21-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 37)
    SEQ ID NO. 1444 mRPL35A-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 38)
    SEQ ID NO. 1445 RPL35-PpLuc(GC)-A64-C30-histoneSL
    SEQ ID NO. 1446 RPL21-PpLuc(GC)-A64-C30-histoneSL
    SEQ ID NO. 1447 ATP5A1-PpLuc(GC)-A64-C30-histoneSL
    SEQ ID NO. 1448 HSD17B4-PpLuc(GC)-A64-C30-histoneSL
    SEQ ID NO. 1449 AIG1-PpLuc(GC)-A64-C30-histoneSL
    SEQ ID NO. 1450 COX6C-PpLuc(GC)-A64-C30-histoneSL
    SEQ ID NO. 1451 ASAH1-PpLuc(GC)-A64-C30-histoneSL
    SEQ ID NO. 1452 5′UTR of human ribosomal protein Large 35 (RPL35) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1453 5′UTR of human ribosomal protein Large 21 (RPL21) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1454 5′UTR of human ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1455 5′UTR of human hydroxysteroid (17-beta) dehydrogenase 4 (HSD17B4) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1456 5′UTR of human androgen-induced 1 (AIG1) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1457 5′UTR of human cytochrome c oxidase subunit VIc (COX6C) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1458 5′UTR of human N-acylsphingosine amidohydrolase (acid ceramidase) 1 (ASAH1) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1459 5′UTR of mouse ribosomal protein Large 21 (mRPL21) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1460 5′UTR of mouse ribosomal protein large 35A (mRPL35A) lacking the 5′ terminal oligopyrimidine tract
    SEQ ID NO. 1461 Mouse ribosomal protein Large 21 (mRPL21)
    SEQ ID NO. 1462 Mouse ribosomal protein large 35A (mRPL35A)
    SEQ ID NO. 1463 RPL32-PpLuc(GC)-ag-A64 (FIG. 10)
    SEQ ID NO. 1464-PpLuc(GC)-ag-A64-histoneSL (FIG. 9)
    SEQ ID NO. 1465-PpLuc(GC) albumin7-A64-C30-histoneSL
    SEQ ID NO. 1466 RPL35-PpLuc(GC)-ag-A64 (FIG. 22)
    SEQ ID NO. 1467 RPL21-PpLuc(GC)-ag-A64 (FIG. 23)
    SEQ ID NO. 1468 atp5a1-PpLuc(GC)-ag-A64 (FIG. 24)
    SEQ ID NO. 1469 HSD17B4-PpLuc(GC)-ag-A64 (FIG. 25)
    SEQ ID NO. 1470 AIG1-PpLuc(GC)-ag-A64 (FIG. 26)
    SEQ ID NO. 1471 COX6C-PpLuc(GC)-ag-A64 (FIG. 27)
    SEQ ID NO. 1472 ASAH1-PpLuc(GC)-ag-A64 (FIG. 28)
    SEQ ID NO. 1473 RPL35-PpLuc(GC)-ag-A64-histoneSL (FIG. 29)
    SEQ ID NO. 1474 RPL21-PpLuc(GC)-ag-A64-histoneSL (FIG. 30)
    SEQ ID NO. 1475 atp5a1-PpLuc(GC)-ag-A64-histoneSL (FIG. 31)
    SEQ ID NO. 1476 HSD17B4-PpLuc(GC)-ag-A64-histoneSL (FIG. 32)
    SEQ ID NO. 1477 AIG1-PpLuc(GC)-ag-A64-histoneSL (FIG. 33)
    SEQ ID NO. 1478 COX6C-PpLuc(GC)-ag-A64-histoneSL (FIG. 34)
    SEQ ID NO. 1479 ASAH1-PpLuc(GC)-ag-A64-histoneSL (FIG. 35)
    SEQ ID NO. 1480 RPL32-PpLuc(GC)-ag-A64-histoneSL (FIG. 11)
    SEQ ID NO. 1481 RPL32-PpLuc(GC) albumin7-A64-C30-histoneSL (FIG. 13)


EXAMPLES
1. Preparation of DNA-Templates
A vector for in vitro transcription was constructed containing a T7 promoter followed by a GC-enriched sequence coding for Photinus pyralis luciferase (PpLuc(GC)) and an A64 poly(A) sequence. The poly(A) sequence was followed by a restriction site used for linearization of the vector before in vitro transcription. mRNA obtained from this vector accordingly by in vitro transcription is designated as “PpLuc(GC) A64”.
This vector was modified to include untranslated sequences 5′ or 3′ of the open reading frame. In summary, vectors comprising the following mRNA encoding sequences have been generated:

    SEQ ID No. 1364 PpLuc(GC)-ag-A64 (FIG. 6)
    SEQ ID No. 1365 RPL32-PpLuc(GC)-ag-A64-C30-histoneSL (FIG. 7):
    SEQ ID NO. 1436 RPL35-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 14)
    SEQ ID NO. 1437 RPL21-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 15)
    SEQ ID NO. 1438 ATP5A1-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 16)
    SEQ ID NO. 1439 HSD17B4-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 17)
    SEQ ID NO. 1440 AIG1-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 18)
    SEQ ID NO. 1441 COX6C-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 19)
    SEQ ID NO. 1442 ASAH1-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 20)
    SEQ ID NO. 1443 mRPL21-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 37)
    SEQ ID NO. 1444 mRPL35A PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 38)
    SEQ ID NO. 1445 RPL35-PpLuc(GC) A64-C30-histoneSL
    SEQ ID NO. 1446 RPL21-PpLuc(GC) A64-C30-histoneSL
    SEQ ID NO. 1447 ATP5A1-PpLuc(GC) A64-C30-histoneSL
    SEQ ID NO. 1448 HSD17B4-PpLuc(GC) A64-C30-histoneSL
    SEQ ID NO. 1449 AIG1-PpLuc(GC) A64-C30-histoneSL
    SEQ ID NO. 1450 COX6C-PpLuc(GC) A64-C30-histoneSL
    SEQ ID NO. 1451 ASAH1-PpLuc(GC) A64-C30-histoneSL
    SEQ ID NO. 1463 RPL32-PpLuc(GC)-ag-A64 (FIG. 10)
    SEQ ID NO. 1464-PpLuc(GC)-ag-A64-histoneSL (FIG. 9)
    SEQ ID NO. 1465-PpLuc(GC)-albumin7-A64-C30-histoneSL
    SEQ ID NO. 1466 RPL35-PpLuc(GC)-ag-A64 (FIG. 22)
    SEQ ID NO. 1467 RPL21-PpLuc(GC)-ag-A64 (FIG. 23)
    SEQ ID NO. 1468 atp5a1-PpLuc(GC)-ag-A64 (FIG. 24)
    SEQ ID NO. 1469 HSD17B4-PpLuc(GC)-ag-A64 (FIG. 25)
    SEQ ID NO. 0.1470 AIG1-PpLuc(GC)-ag-A64 (FIG. 26)
    SEQ ID NO. 1471 COX6C-PpLuc(GC)-ag-A64 (FIG. 27)
    SEQ ID NO. 1472 ASAH1-PpLuc(GC)-ag-A64 (FIG. 28)
    SEQ ID NO. 1473 RPL35-PpLuc(GC)-ag-A64-histoneSL (FIG. 29)
    SEQ ID NO. 1474 RPL21-PpLuc(GC)-ag-A64-histoneSL (FIG. 30)
    SEQ ID NO. 1475 atp5a1-PpLuc(GC)-ag-A64-histoneSL (FIG. 31)
    SEQ ID NO. 1476 HSD17B4-PpLuc(GC)-ag-A64-histoneSL (FIG. 32)
    SEQ ID NO. 1477 AIG1-PpLuc(GC)-ag-A64-histoneSL (FIG. 33)
    SEQ ID NO. 1478 COX6C-PpLuc(GC)-ag-A64-histoneSL (FIG. 34)
    SEQ ID NO. 1479 ASAH1-PpLuc(GC)-ag-A64-histoneSL (FIG. 35)
    SEQ ID NO. 1480 RPL32-PpLuc(GC)-ag-A64-histoneSL (FIG. 11)
    SEQ ID NO. 1481 RPL32-PpLuc(GC)-albumin7-A64-C30-histoneSL (FIG. 13)


2. In Vitro Transcription
The DNA-template according to Example 1 was linearized and transcribed in vitro using T7-Polymerase. The DNA-template was then digested by DNase-treatment. mRNA transcripts contained a 5′-CAP structure obtained by adding an excess of N7-Methyl-Guanosine-5′-Triphosphate-5′-Guanosine to the transcription reaction. mRNA thus obtained was purified and resuspended in water.
3. Luciferase Expression by mRNA Lipofection
Human dermal fibroblasts (HDF) were seeded in 24 well plates at a density of 5×104 cells per well. The following day, cells were washed in opti-MEM and then transfected with 50 ng per well of Lipofectamine2000-complexed PpLuc-encoding mRNA in opti-MEM. As a control, mRNA not coding for PpLuc was lipofected separately. mRNA coding for Renilla reniformis luciferase (RrLuc) was transfected together with PpLuc mRNA to control for transfection efficiency (20 ng of RrLuc mRNA per well). 90 minutes after start of transfection, opti-MEM was exchanged for medium. 24, 48, 72 hours after transfection, medium was aspirated and cells were lysed in 200 μl of lysis buffer (25 mM Tris, pH 7.5 (HCl), 2 mM EDTA, 10% glycerol, 1% Triton X-100, 2 mM DTT, 1 mM PMSF). Lysates were stored at −20° C. until luciferase activity was measured.
Alternatively, HDF were seeded in 96 well plates one to three days before transfection at a density of 104 cells per well. Immediately before lipofection, cells were washed in opti-MEM. Cells were lipofected with 25 ng of PpLuc-encoding mRNA per well complexed with Lipofectamine2000. In some experiments, mRNA coding for Renilla reniformis luciferase (RrLuc) was transfected together with PpLuc mRNA to control for transfection efficiency (2.5 ng of RrLuc mRNA per well). 90 minutes after start of transfection, opti-MEM was exchanged for medium. At various time points post transfection, medium was aspirated and cells were lysed in 100 μl of lysis buffer (Passive Lysis Buffer, Promega). Lysates were stored at −80° C. until luciferase activity was measured.
4. Luciferase Measurement
Luciferase activity was measured as relative light units (RLU) in a BioTek SynergyHT plate reader. PpLuc activity was measured at 15 seconds measuring time using 50 μl of lysate and 200 μl of luciferin buffer (75 μM luciferin, 25 mM Glycylglycin, pH 7.8 (NaOH), 15 mM MgSO4, 2 mM ATP). RrLuc activity was measured at 15 seconds measuring time using 50 μl of lysate and 200 μl of coelenterazin buffer (40 μM coelenterazin in phosphate buffered saline adjusted to 500 mM NaCl).
Alternatively, luciferase activity was measured as relative light units (RLU) in a Hidex Chameleon plate reader. PpLuc activity was measured at 2 seconds measuring time using 20 μl of lysate and 50 μl of luciferin buffer (Beetle-Juice, PJK GmbH). RrLuc activity was measured at 2 seconds measuring time using 20 μl of lysate and 50 μl of coelenterazin buffer (Renilla-Juice, PJK GmbH).
Results
5.1 the Combination of 5′UTR Elements Derived from 5′UTRs of TOP Genes and Histone Stem-Loop Increases Protein Expression Strongly.
To investigate the effect of the combination of a 5′UTR element derived from a 5′UTR of a TOP gene and a histone stem-loop (histoneSL) on protein expression from mRNA, mRNAs with different UTRs were synthesized: mRNAs either lacked both 5′UTR element and histoneSL, or contained both 5′UTR element and histoneSL. Luciferase-encoding mRNAs or control mRNA were transfected into human dermal fibroblasts (HDF). Luciferase levels were measured at 24 hours after transfection (see following Table 1 and FIG. 8).










TABLE 1







mRNA
RLU at 24 hours



















control RNA
588



PpLuc(GC)-ag-A64
12246



RPL32-PpLuc(GC)-ag-A64-C30-histoneSL
319840










Luciferase was clearly expressed from mRNA having neither 5′UTR element nor histoneSL. Strikingly however, the combination of 5′UTR element and histoneSL strongly increased the luciferase level. The magnitude of the rise in luciferase level due to combining 5′UTR element and histoneSL in the same mRNA indicates that they are acting synergistically.
5.2 the Combination of 5′UTR Elements Derived from 5′UTRs of TOP Genes and Histone Stem-Loop Increases Protein Expression from mRNA in a Synergistic Manner.
To investigate the effect of the combination of a 5′UTR element derived from a 5′UTR of a TOP gene and histone stem-loop on protein expression from mRNA, mRNAs with different UTRs were synthesized: mRNAs either lacked both 5′UTR element and histone stem-loop, or contained either a 5′UTR element or a histone stem-loop, or both 5′UTR element and histone stem-loop. Luciferase-encoding mRNAs were transfected into human dermal fibroblasts (HDF). Luciferase levels were measured at 8, 24, and 48 hours after transfection (see following Table 2 and FIG. 12).










TABLE 2






RLU at 8
RLU at 24
RLU at 48


mRNA
hours
hours
hours


















PpLuc(GC)-ag-A64
13110
25861
14362


PpLuc(GC)-ag-A64-histoneSL
88640
97013
57026


rp132-PpLuc(GC)-ag-A64
155654
212245
102528


rp132-PpLuc(GC)-ag-A64-
301384
425825
161974


histoneSL












Luciferase was clearly expressed from mRNA having neither 5′UTR element nor histone stem-loop. Both, either the histone stem-loop or the 5′UTR element increased luciferase levels compared to mRNA lacking both these elements. Strikingly however, the combination of 5′UTR element and histone stem-loop further strongly increased the luciferase level, much above the level observed with either of the individual elements. The magnitude of the rise in luciferase level due to combining 5′UTR element and histone stem-loop in the same mRNA demonstrates that they are acting synergistically.
The synergy between 5′UTR element and histone stem-loop was quantified by dividing the signal from mRNA combining both elements by the sum of the signal from mRNA lacking both elements plus the rise in signal effected by the 5′UTR element plus the rise in signal effected by the histone stem-loop. This calculation was performed for the three time points individually and for total protein expressed from 0 to 48 hours calculated from the area under the curve (AUC) (see following Table 3).












TABLE 3





rp132
histone
RLU
Δ RLU
RLU predicted (additive)
synergy



S















8h












—
—
13110





—
+
88640
75530




+
—
155654
142544




+
+
301384

231184
1.30







24 h












—
—
25861





—
+
97013
71152




+
—
212245
186384




+
+
425825

283397
1.50







48 h












—
—
14362





—
+
57026
42664




+
—
102528
88166




+
+
161974

145192
1.12







AUC 0-48 hours












—
—
846881





—
+
3688000
2841119




+
—
7343000
6496119




+
+
14080000

10184119
1.38









The synergy thus calculated specifies how much higher the luciferase level from mRNA combining 5′UTR element and histone stem-loop is than would be expected if the effects of 5′UTR element and histone stem-loop were purely additive. This result confirms that the combination of 5′UTR element and histone stem-loop effects a markedly synergistic increase in protein expression.
5.3 5′UTR Elements Derived from 5′UTRs of TOP Genes Increase Protein Expression from mRNA.
To investigate the effect of 5′UTR elements derived from 5′UTRs of TOP genes on protein expression from mRNA, mRNAs with one of different 5′UTR elements were synthesized. In addition, mRNAs contained the albumin? 3′UTR element. Luciferase-encoding mRNAs were transfected into human dermal fibroblasts (HDF). Luciferase levels were measured at 24, 48, and 72 hours after transfection (see following Table 4 and FIG. 21).










TABLE 4





5′UTR
RLU at 24 hours
RLU at 48 hours
RLU at 72 hours


















none
114277
121852
68235


rpl32
332236
286792
114148


rpl35
495917
234070
96993


rpl21
563314
352241
156605


atp5a1
1000253
538287
187159


HSD17B4
1179847
636877
299337


AIG1
620315
446621
167846


COX6C
592190
806065
173743


ASAH1
820413
529901
198429









Luciferase was clearly expressed from mRNA lacking a 5′UTR element. Strikingly however, all 5′UTR elements strongly increased the luciferase level.
5.4 the Combination of 5′UTR Elements Derived from 5′UTRs of TOP Genes and Histone Stem-Loop Increases Protein Expression from mRNA in a Synergistic Manner.
To investigate the effect of the combination of 5′UTR elements derived from the 5′UTRs of TOP genes and histone stem-loop on protein expression from mRNA, mRNAs with different UTRs were synthesized: mRNAs either lacked both 5′UTR element and histone stem-loop, or contained a histone stem-loop, or contained one of different 5′UTR elements derived from 5′UTRs of TOP genes, or contained both one of different 5′UTR elements and a histone stem-loop. In addition, mRNAs contained the alpha-globin 3′UTR element. Luciferase-encoding mRNAs were transfected into human dermal fibroblasts (HDF). Luciferase levels were measured at 8, 24, and 48 hours after transfection (see FIG. 36). Luciferase was clearly expressed from mRNA having neither 5′UTR element nor histone stem-loop. The histone stem-loop increased the luciferase level. All 5′UTR elements also increased the luciferase level. Strikingly however, the combinations of 5′UTR element and histone stem-loop further strongly increased the luciferase level, much above the level observed with either of the individual elements. The magnitude of the rise in luciferase level due to combining 5′UTR element and histone stem-loop in the same mRNA demonstrates that they are acting synergistically.
The synergy between 5′UTR element and histone stem-loop was quantified by dividing the signal from mRNA combining both elements by the sum of the signal from mRNA lacking both elements plus the rise in signal effected by the 5′UTR element plus the rise in signal effected by the histone stem-loop. This calculation was performed for total protein expressed from 0 to 48 hours calculated from the area under the curve (AUC) (see following Table 5).










TABLE 5







TOP 5′UTR
Synergy with histone stem-loop









35 L
2.50



21 L
3.25



atp5a1
3.00



HSD17B4
3.55



AIG1
1.52



COX6C
3.19










The synergy thus calculated specifies how much higher the luciferase level from mRNA combining 5′UTR element and histone stem-loop is than would be expected if the effects of 5′UTR element and histone stem-loop were purely additive. The luciferase level from mRNA combining 5′UTR element and histone stem-loop was up to more than three times higher than if their effects were purely additive. This result confirms that the combination of 5′UTR element and histone stem-loop effects a markedly synergistic increase in protein expression.
5.5 5′UTR Elements Derived from 5′UTRs of Mouse TOP Genes Increase Protein Expression from mRNA.
To investigate the effect of TOP 5′UTR elements derived from 5′UTRs of mouse TOP genes on protein expression from mRNA, mRNAs with two different mouse 5′UTR elements were synthesized. In addition, mRNAs contained the albumin7 3′UTR element. Luciferase-encoding mRNAs were transfected into human dermal fibroblasts (HDF). For comparison, mRNA containing the human rpl32 5′UTR element was transfected. Luciferase levels were measured at 24, 48, and 72 hours after transfection (see following Table 6 and FIG. 39).










TABLE 6





5′UTR
RLU at 24 hours
RLU at 48 hours
RLU at 72 hours


















none
114277
121852
68235


rpl32
332236
286792
114148


mrpl21
798233
351894
139249


mrpl35A
838609
466236
174949









Luciferase was clearly expressed from mRNA lacking a 5′UTR element. Both mouse 5′UTR elements strongly increased the luciferase level, similarly as the human 5′UTR element.
Sequences:








Homo sapiens alpha-2-macroglobulin (A2M):



(Seq ID No: 1)



gctccttctttctg



caacatg


 


Homo sapiens acyl-CoA dehydrogenase, C-4 to C-12 straight chain


(ACADM):


(Seq ID No: 2)



ggctctctttccgcgctgcggtcagcctcggcgtcccacagagagggccagaggtggaaa



cgcagaaaaccaaaccaggactatcagagattgcccggagaggggatg


 


Homo sapiens arylsulfatase E (chondrodysplasia punctata 1)


(ARSE):


(Seq ID No: 3)



cttcctcttcttgatcggggattcaggaaggagcccaggagcagag



gaagtagagagagagacaacatg


 


Homo sapiens Bruton agammaglobulinemia tyrosine kinase


(BTK):


(Seq ID No: 4)



tgtccttcctctctggactgtaagaatatgtctccagggccag



tgtctgctgcgatcgagtcccaccttccaagtcctggcatctcaatgcatctgggaagc


tacctgcattaagtcaggactgagcacacaggtgaactccagaaagaagaagctatg


 


Homo sapiens complement component 2 (C2):


(Seq ID No: 5)



tgac



cttttccctcccgcggctctctacctctcgccgcccctagggaggacaccatg


 


Homo sapiens cyclin-dependent kinase 4 (CDK4):


(Seq ID No: 6)



gggcctctctagcttgcggcctgtgtctatggtcgggccctctgcgtccagctgctccg



gaccgagctcgggtgtatggggccgtaggaaccggctccggggccccgataac


gggccgcccccacagcaccccgggctggcgtgagggtctcccttgatctgagaatg


 


Homo sapiens


cytochrome P450, family 17, subfamily A, polypeptide


1 (CYP17A1):


(Seq ID No: 7)



agctcttctactccactgctgtctatcttgcctgccggcacc



cagccaccatg


 


Homo sapiens endoglin (ENG):


(Seq ID No: 8)



cttcctctacccggttgg



caggcggcctggcccagccccttctctaaggaagcg


catttcctgcctccctgggccggccgggctggatg


 


Homo sapiens excision repair cross-complementing rodent repair


deficiency, complementation group 3 (ERCC3):


(Seq ID No: 9)



tcttctctctgctgctgtagctgccatg



 


Homo sapiens excision repair cross-complementing rodent repair


deficiency, complementation group 5 (ERCC5):


(Seq ID No: 10)



ctgtctttcttccgggaggcggtgacagctgctgagacgtgttgcagccagag



tctctccgctttaatgcgctcccattagtgccgtcccccactggaaaac


cgtggcttctgtattatttgccatctttgttgtgtaggag


cagggagggcttcctcccggggtcctaggcggcggtgcagtccgtcgtagaagaatt


agagtagaagttgtcggggtccgctcttaggacgcagccgcctcatg


 


Homo sapiens ferritin, light polypeptide (FTL):


(Seq ID No: 11)



cgtcccctcgcagttcggcggtcccgcgggtctgtctcttgcttcaacagtgtttggacg



gaacagatccggggactctcttccagcctccgaccgccctccgatttcctctccgcttgc


aacctccgggaccatcttctcggccatctcctgcttctgggacctgccagcaccgttttt


gtggttagctccttcttgccaaccaaccatg


 


Homo sapiens galactosylceramidase (GALC):


(Seq ID No: 12)



ccgcctccctgggcgccggagtcatgtgacccacacaatg



 


Homo sapiens gap junction protein, alpha 1, 43 kDa (GJA1):


(Seq ID No: 13)



ttttctttcattagggggaaggcgtgaggaaagtaccaaacagcagcggag



ttttaaactttaaatagacaggtctgagtgcctgaactt


gccttttcattttacttcatcctccaaggagttcaatcacttggcgtgacttcac


tacttttaagcaaaagagtggtgcccaggcaacatg


 


Homo sapiens gap junction protein, beta 1, 32 kDa (GJB1):


(Seq ID No: 14)



cattctctgggaaagggcagcagcagccaggtgtggcag



tgacagggaggtgtgaatgaggcaggatg


 


Homo sapiens glucose-6-phosphate isomerase (GPI):


(Seq ID No: 15)



cgctccttcctcctcggctcgcgtctcactcagtgtaccttctagtcccgccatg



 


Homo sapiens


hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/


enoyl-CoA hydratase (trifunctional


protein), alpha subunit (HADHA):


(Seq ID No: 16)



ctgtcctcttcagctcaa



gatg


 


Homo sapiens hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA


thiolase/enoyl-CoA hydratase (trifunctional


protein), beta subunit (HADHB):


(Seq ID No: 17)



gggccctttctgggcag



gacccgccccttggtcccgcagagccttggtacttggacctgaaccttgctccga


gagggagtcctcgcggacgtcagccaagattccagaatg


 


Homo sapiens complement factor H (CFH):


(Seq ID No: 18)



cttccttttgcag



caagttctttcctgcactaatcacaattcttggaagaggagaactggacgtt


gtgaacagagttagctggtaaatgtcctcttaaaagatccaaaaaatg


 


Homo sapiens sarcoglycan, gamma


(35 kDa dystrophin-associated glycoprotein) (SGCG):


(Seq ID No: 19)



agccctttctccagggacagttgctgaagcttcatcctttgctctcattctg



taagtcatagaaaagtttgaaacattctgtctgtggtagagctcgggccagctgtag


ttcattcgccagtgtgcttttcttaatatctaagatg


 


Homo sapiens lipase A, lysosomal acid, cholesterol esterase


(LIPA):


(Seq ID No: 20)



ggtcccctatccgcaccccggcccctgagagctggcactgcgactcgaga



cagcggcccggcaggacagctccagaatg


 


Homo sapiens lipoprotein lipase (LPL):


(Seq ID No: 21)



ccccctcttcctcctcctcaagggaaagctgcccacttctagctgccctgccatcccctt



taaagggcgacttgctcagcgccaaac


cgcggctccagccctctccagcctccggctcagccggctcatcagtcggtccgcgcctt


gcagctcctccagagggacgcgccccgagatg


 


Homo sapiens mutL homolog 1, colon cancer, nonpolyposis type 2


(E. coli) (MLH1):


(Seq ID No: 22)



ggctcttctggcgccaaaatg



 


Homo sapiens Niemann-Pick disease, type C1 (NPC1):


(Seq ID No: 23)



cttccttcctgaccggcgcgcg



cagcctgctgccgcggtcagcgcctgctcctgctcctccgctcctcctgcgcggggtgct


gaaacagcccggggaagtagagccgcctccggggagcccaaccagccgaac


gccgccggcgtcagcagccttgcgcggccacagcatg


 


Homo sapiens peroxisomal biogenesis factor 12 (PEX12):


(Seq ID No: 24)



gcgcctctcttccgccaggcatcccagaggtcctggtggtttcatttccgggtgcggctt



ctgtcataaagcggagacctcccttcaaacgtggcgtcgtgggttgttt


gcgcctcgcctggggtcagcgagcaaggacgggcgcgggcggggatactcaaa


gccaacagctggagtcagcccttgtgtcccgggctcacagtggcac


gactgaatcctcagagtcggctggcttttgagctctcacgattggggag


gagggggcgtttctggttcgcagctccagag


gattgcgttccttcccccatacctgtcccccacagtcacgctctgccctgacgtgcag


catttgacaagttaccccctcgccacatactacttccacccacgtccgagttaacttt


gttcttaaccttcttgagactaccctcggcctccaggtctttttttcccag


ttcatttttgcccataagattgagtttcgagtttcagatatcatgcagaaagtttac


ctttaagactgagcacccatctgatactcttcctcccgaaaaagttcatgctcacgaga


gagtttgtgggaaaagtgaaagccagtacacgcaggaaactatg


 


Homo sapiens peroxisomal biogenesis factor 6 (PEX6):


(Seq ID No: 25)



cgctccttcaccctcctcgttggtgtcctgtcaccatg



 


Homo sapiens phosphofructokinase, muscle (PFKM):


(Seq ID No: 26)



gagccttctt



gtcagcatctgttagtggaggttgggaagcctctcctccttccccctccctcttt


gcctccac


ctggctcctccccatgttcgtccatcacccctcccccctttcccaaggacaatctgcaa


gaaagcagcggcggaggagagctaagactaaaagagtggatcatg


 


Homo sapiens serpin peptidase inhibitor, clade A (alpha-


1 antiproteinase, antitrypsin), member 1 (SERPINA1):


(Seq ID No: 27)



ctgtctcctcagcttcaggcaccaccactgacctgggacagtgaatcgacaatg



 


Homo sapiens phosphatase and tensin homolog (PTEN):


(Seq ID No: 28)



agttctctcctctcggaagctgcagccatgatggaagtttgagagttgagccgctgtgag



gcgaggccgggctcaggcgagggagatgagagacggcggcggccgcggcccggagcccct


ctcagcgcctgtgagcagccgcgggggcagcgccctcggggagccggccggcctgcggcg


gcggcagcggcggcgtttctcgcctcctcttcgtcttttctaaccgtgcagcctcttcct


cggcttctcctgaaagggaaggtggaagccgtgggctcgggcgggagccggctgaggcgc


ggcggcggcggcggcacctcccgctcctggagcgggggggagaagcggcggcggcggcgg


ccgcggcggctgcagctccagggagggggtctgagtcgcctgtcaccatttccagggctg


ggaacgccggagagttggtctctccccttctactgcctccaacacggcggcggcggcggc


ggcacatccagggacccgggccggttttaaacctcccgtccgccgccgccgcaccccccg


tggcccgggctccggaggccgccggcggaggcagccgttcggaggattattcgtcttctc


cccattccgctgccgccgctgccaggcctctggctgctgaggagaagcaggcccagtcgc


tgcaaccatccagcagccgccgcagcagccattacccggctgcggtccagagccaagcgg


cggcagagcgaggggcatcagctaccgccaagtccagagccatttccatcctgcagaaga


agccccgccaccagcagcttctgccatctctctcctcctttttcttcagccacaggctcc


cagacatg


 


Homo sapiens solute carrier family 3 (cystine,


dibasic and neutral amino acid transporters, activator


of cystine, dibasic and neutral amino acid transport), member


1 (SLC3A1):


(Seq ID No: 29)



cctcccttactgcaggaaggcactccgaagacataagtcggtga



gacatg


 


Homo sapiens aldehyde dehydrogenase 3 family, member A2


(ALDH3A2):


(Seq ID No: 30)



ccgcctcccactccccagcgcccccggaccgtgcagttctctgcag



gaccaggccatg


 


Homo sapiens bleomycin hydrolase (BLMH):


(Seq ID No: 31)



gtttctcccagcctcagcctccccgccgccgccgccgccgccgccgccgagccggtttcc



tttttccggcgctccgggtgcgagagacaggtcgggccccctaggcagcgagccg


cagcgcaatcccggcgctcgcccaaggaccctggaagctaccgttaccccgccggg


cagcgtgggcgccatg


 


Homo sapiens cathepsin K (CTSK):


(Seq ID No: 32)



cctcctcctcttacccaaattttccagccgatcactggagctgacttccg



caatcccgatggaataaatctagcacccctgatggtgtgcccacacttt


gctgccgaaacgaagccagacaacagatttccatcagcaggatg


 


Homo sapiens GM2 ganglioside activator (GM2A):


(Seq ID No: 33)



gcttctttgcg



taaccaatactggaaggcatttaaaggcacctctgccgccacagaccttgcag


ttaactccgccctgacccacccttcccgatg


 


Homo sapiens hydroxysteroid (17-beta) dehydrogenase 4


(HSD17B4):


(Seq ID No: 34)



ccgcctcctcctgtcccgcagtcggcgtccagcggctctgctt



gttcgtgtgtgtgtcgttgcaggccttattcatg


 


Homo sapiens neutrophil cytosolic factor 2 (NCF2):


(Seq ID No: 35)



ctctctctgcttctttccttttctctctcatggtagggttatgagtcagttgccaaaagg



tggggacatttcctgatgcatttgcaacactgagaagttatcttaagggaggctgggccc


cattctactcatctggcccagaaagtgaacaccttgggggccactaaggcagccctgcta


ggggagacgctccaacctgtcttctctctgtctcctggcagctctcttggcctcctagtt


tctacctaatcatg


 


Homo sapiens 3-oxoacid CoA transferase 1 (OXCT1):


(Seq ID No: 36)



cagcctcctcctgcctcaccgcccgaagatg



 


Homo sapiens sulfite oxidase (SUOX):


(Seq ID No: 37)



ccgccccttctcgagaactcg



cagagctgggctggtaaaattgcagtgctgaagacactggacccg


caaaaggctgtccctcccaaacctgggattctgggctcactgagttcacctgcgag


tcagccctacctgcactgctctggtctagtacaaacaggctgctggcattgagggac


ggagtctccaactcctggcctctagcagtcctcctgtgtaggtctcccaaagtgctag


tgtgtccggaattggtgggttcttggtctcactgacttcaagaatgaagccgcg


gaccctcgcagtctgctacaatg


 


Homo sapiens albumin (ALB):


(Seq ID No: 38)



ttttctcttctgtcaacccca



cacgcctttggcacaatg


 


Homo sapiens arylsulfatase A (ARSA):


(Seq ID No: 39)



ctccctctagcgccttccccccggcccgactccgctggtcagcgccaagtgacttac



gcccccgaccctgagcccggaccgctaggcgaggaggatcagatctccgctcga


gaatctgaaggtgccctggtcctggaggagttccgtcccagoccgcggtctcccgg


tactgtcgggccccggccctctggagcttcaggaggcggccgtcagggtcggggag


tatttgggtccggggtctcagggaagggcggcgcctgggtctgcggtatcggaaa


gagcctgctggagccaagtagccctccctctcttgggacagacccctcggtcccatg


 


Homo sapiens elastin (ELN):


(Seq ID No: 40)



ctccctccctctttccctcacagccgac



gaggcaacaattaggctttggggataaaacgaggtgcggagagcgggctgggg


catttctccccgagatg


 


Homo sapiens hemoglobin, alpha 2 (HBA2):


(Seq ID No: 41)



cactcttctggtcccca



cagactcagagagaacccaccatg


 


Homo sapiens hexosaminidase B (beta polypeptide) (HEXB):


(Seq ID No: 42)



cttcctctgatccgggccgggcgggaagtcgggtcccgaggctccggctcggcagac



cgggcggaaagcagccgagcggccatg


 


Homo sapiens mannosidase, alpha, class 2B, member 1


(MAN2B1):


(Seq ID No: 43)



cggcctttccagggccggggaaccccaggaggaagctgctgagccatg



 


Homo sapiens recombination activating gene 2 (RAG2):


(Seq ID No: 44)



cac



tctctttacagtcagccttctgcttgccacagtcatagtgggcagtcag


tgaatcttccccaagtgctgacaattaatacctggtttagcggcaaagattcaga


gaggcgtgagcagcccctctggccttcagacaaaaatctacgtaccatcagaaactatg


 


Homo sapiens CD53 molecule (CD53):


(Seq ID No: 45)



tctccttttacacaaatagccccg



gatatctgtgttaccagccttgtctcggccacctcaaggataatcac


taaattctgccgaaaggactgaggaacggtgcctggaaaagggcaagaatatcacgg


catg


 


Homo sapiens Fc fragment of IgG, low affinity IIIa, receptor


(CD16a) (FCGR3A):


(Seq ID No: 46)



tggtccctttagggctccggatatctttggtgacttgtc



cactccagtgtggcatcatg


 


Homo sapiens interleukin 1, beta (IL1B):


(Seq ID No: 47)



aaac



ctcttcgaggcacaaggcacaacaggctgctctgggattctcttcagccaatcttcatt


gctcaagtgtctgaagcagccatg


 


Homo sapiens CD4 molecule (CD4):


(Seq ID No: 48)



ctgtctctcttcatttaagcac



gactctgcagaaggaacaaagcaccctccccactgggctcctggtt


gcagagctccaagtcctcacacagatacgcctgtttgagaagcagcgggcaagaaagac


gcaa


gcccagaggccctgccatttctgtgggctcaggtccctactggctcaggcccctgcctcc


ctcggcaaggccacaatg


 


Homo sapiens serpin peptidase inhibitor, Glade A (alpha-


1 antiproteinase, antitrypsin), member 5 (SERPINA5):


(Seq ID No: 49)



agccctctgccctttctgagcccgagggactgccacctccactgtgtgcacactcagc



tacgggacacatttcaggtatccaaggcagcagaggtgag


tgggtcccccgagctctgtgaccttatgctccacactaactctgg


cagagcctccgtttcctcatagaacaaagaacagccaccatg


 


Homo sapiens vitronectin (VTN):


(Seq ID No: 50)



tgccctccttccctgtctctgcctctccctcccttcctcaggcatcagagcgga



gacttcagggagaccagagcccagcttgccaggcactgagctagaagccctgccatg


 


Homo sapiens aldehyde dehydrogenase 9 family, member A1


(ALDH9A1):


(Seq ID No: 51)



ccgcccctcccgcggccccgcccctcccgcggcccgtcagcctctgccgcg



gagctgcgtccgccactcatg


 


Homo sapiens annexin A1 (ANXA1):


(Seq ID No: 52)



cttcctttaaaatcc



tataaaatcagaagcccaagtctccactgccagtgtgaaatcttcagagaa


gaatttctctttagttctttgcaagaaggtagagataaagacactttttcaaaaatg


 


Homo sapiens


ATPase, Na+/K+ transporting, alpha 1 polypeptide


(ATP1A1):


(Seq ID No: 53)



ttttctctctgattctccagcgacaggacccggcgccgggcactgag



caccgccaccatg


 


Homo sapiens


ATPase, Na+/K+ transporting, alpha 2 polypeptide


(ATP1A2):


(Seq ID No: 54)



ctttctctgtctgccagggtctccgactgtcccagac



gggctggtgtgggcttgggatcctcctggtgacctctcccgctaaggtccctcagccac


tctgccccaagatg


 


Homo sapiens calcium channel, voltage-dependent, beta 3 subunit


(CACNB3):


(Seq ID No: 55)



ccctccttcgcgctctctcgctccctgccgccgcccgcagggctgcggggctcggtggca



tctcccgggcgcggcccgcagtcctt


gcccctgcctccgggccgctcccgcccccggcgccgctcgctcccccgacccg


gactcccccatg


 


Homo sapiens cholinergic receptor, nicotinic, alpha 7 (neuronal)


(CHRNA7):


(Seq ID No: 56)



gtgcctctgtggccgcaggcgcaggcccgggcgacagccga



gacgtggagcgcgccggctcgctgcagctccgggactcaacatg


 


Homo sapiens


cytochrome P450, family 51, subfamily A, polypeptide


1 (CYP51A1):


(Seq ID No: 57)



gcttctctcgttccgtcgattgggaggagcggtggcgac



ctcggccttcagtgtttccgacggagtgaatg


 


Homo sapiens glutamate decarboxylase 1 (brain, 67 kDa)


(GAD1):


(Seq ID No: 58)



atctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaac



gaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcg


gatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcg


cagagccgagcctgtttctgcgccggaccagtcgaggactctggacag


tagaggccccgggacgaccgagctgatg


 


Homo sapiens gamma-glutamyl carboxylase (GGCX):


(Seq ID No: 59)



aattctcctggcggcctccgttcagacgcggcagctgtgacccacctgcctcctccg



cagagcaatg


 


Homo sapiens glutamate receptor, metabotropic 3 (GRM3):


(Seq ID No: 60)



tcccctctttccccaacctcctccctctcttctactccacccctccgttttcccac



tccccactgactcggatgcctggatgttctgccaccgggcagtggtccagcgtg


cagccgggagggggcaggggcagggggcactgtgacaggaagctgcgcgcacaagtt


ggccatttcgagggcaaaataagttctcccttggatttggaaaggacaaagccagtaa


gctacctcttttgtgtcggatgaggaggaccaaccatgagccagagcccgggtg


caggctcaccgccgccgctgccaccgcggtcagctccagttcctgccaggagtt


gtcggtgcgaggaattttgtgacaggctctgttagtctgttcctcccttattt


gaaggacaggccaaagatccagtttggaaatgagagaggactagcatgacacatt


ggctccaccattgatatctcccagaggtacagaaacaggattcatgaagatg


 


Homo sapiens guanylate cyclase 1, soluble, alpha 3


(GUCY1A3):


(Seq ID No: 61)



ggttcctttggggtgatcaaagagggagacacagacacagagagacaaaggcaaggagga



ctgtctgggagccacgcgggcgatacagtttccgaggcacgccgcgtcccgcctagcctg


ttgaacaggtagacatgagcgacccaagctgcggatttgcgaggcgcgccctggagctgc


tagagatccggaagcacagccccgaggtgtgcgaagccaccaagtcaagttcctaacgag


tcttcagaggaggcagcaggaagctcagagagctgcaaagcaaccgtgcccatctgtcaa


gacattcctgagaagaacatacaagaaagtcttcctcaaagaaaaaccagtcggagccga


gtctatcttcacactttggcagagagtatttgcaaactgattttcccagagtttgaacgg


ctgaatgttgcacttcagagaacattggcaaagcacaaaataaaagaaagcaggaaatct


ttggaaagagaagactttgaaaaaacaattgcagagcaagcagttgcagcaggagttcca


gtggaggttatcaaagaatctcttggtgaagaggtttttaaaatatgttacgaggaagat


gaaaacatccttggggtggttggaggcacccttaaagattttttaaacagcttcagtacc


cttctgaaacagagcagccattgccaagaagcaggaaaaaggggcaggcttgaggacgcc


tccattctatgcctggataaggaggatgattttctacatgtttactacttcttccctaag


agaaccacctccctgattcttcccggcatcataaaggcagctgctcacgtattatatgaa


acggaagtggaagtgtcgttaatg


 


Homo sapiens 3-hydroxy-3-methylglutaryl-CoA reductase


(HMGCR):


(Seq ID No: 62)



ggctccttccgctccgcgactgcgttaactg



gagccaggctgagcgtcggcgccggggttcggtggcctctagtgagatctggag


gatccaaggattctgtagctacaatg


 


Homo sapiens IMP (inosine 5′-monophosphate) dehydrogenase 2


(IMPDH2):


(Seq ID No: 63)



aggtctctgcggcgcggtcctcggagacacgcggcggtgtcctgtgtt



ggccatg


 


Homo sapiens leukotriene A4 hydrolase (LTA4H):


(Seq ID No: 64)



acttcctttcccggcgtgcaccgcgaatccctcctcctcttctttac



ctctctccctcctcctcaggttctctatcgacgagtctggtagctgagcgttgggctg


taggtcgctgtgctgtgtgatcccccagagccatg


 


Homo sapiens neuropeptide Y receptor Y1 (NPY1R):


(Seq ID No: 65)



ccttctttaa



taagcaggagcgaaaaagacaaattccaaagaggattgttcagttcaagggaatgaa


gaattcagaataattttggtaaatggattccaatatggggaataagaataa


gctgaacagttgacctgctttgaagaaacatactgtccatttgtctaaaa


taatctataacaaccaaaccaatcaaaatg


 


Homo sapiens pyruvate dehydrogenase (lipoamide) beta (PDHB):


(Seq ID No: 66)



cggcccctctgttgtcgtttggcagcggatagaggacacgaccaagatg



 


Homo sapiens ribosomal protein L36a-like (RPL36AL):


(Seq ID No: 67)



cttccctttcctgttaggcgagagctgcgaaaggcga



gagctgcgaagggccaggtgtcgggcgctgtttctcgttttcatcatataga


caaaacagccctgctgcaaagatg


 


Homo sapiens ATPase, Ca++ transporting, type 2C, member 1


(ATP2C1):


(Seq ID No: 68)



gcttcttctcacgccgggagcaggctcccgcctcgcac



cgctgccccgcgag


cagctcctcttctcccgaggcgcgcggggcgcccccgcgagccccgcggctga


gaccccgcagcctggaggagggctgtccggggcttt


ggatgctgctgctaggggtggtgggagcagccgtgggacgcgtggccgg


gagcgggggtgacagcctgggattccgggggcttctcttcctt


gtcctcctcctctcctctctattcccagtgtggccgtggctgacactaaagacttt


gtagccatcaacccgagtgcagtttcgatggaaaatg


 


Homo sapiens UDP-glucose pyrophosphorylase 2 (UGP2):


(Seq ID No: 69)



ccgcctctttcattgaagaaatttaagttcgtgtggttttaccttttccgggagtctcca



gctggccctcatttgtgtccggagctcaggagttcccaaaccgactcagtcgcaccaagt


ttccgtcttttggaattggggaaggagtttctttctttcttttcttttttcttgagccag


ttttaatcgctttgaataaatactcccttaagtagttaaatataggaggagaaagaatac


atcggttgttaaagcaggagaggaagagagacctgccctgtagcgtgactcctctagaaa


aaaaaaaaaaaagccggagtattttactaagcccctaaaatg


 


Homo sapiens ATPase, Na+/K+ transporting, beta 1 polypeptide


(ATP1B1):


(Seq ID No: 70)



cctcctcctgctcctgccttggctcctccgccgcgcgtctcgcac



tccgagagccgcagcggcagcggcgcgtcctgcctgcagagagccaggccggagaa


gccgagcggcgcagaggacgccagggcgcgcgccgcagccacccaccctccggac


cgcggcagctgctgacccgccatcgccatg


 


Homo sapiens glycoprotein M6B (GPM6B):


(Seq ID No: 71)



ctgtctttatggaccag



taggcagagcgaaattgacgctgacaagacttttgcatcttggaagggactg


taatctactgtagtgaagaacagagcctctcaatcagacgggtgtaaataagagac


ggaggggagtccaaaagaaaaggaagaggaggaaaaacaagtgtgtgttggggg


gaacagggggaaaagcatttttggtggatggtatg


 


Homo sapiens wntless homolog (Drosophila) (WLS):


(Seq ID No: 72)



gctcctttaa



gcgtccacaggcggcggagcggccacaatcacagctccgggcattgggg


gaacccgagccggctgcgccgggg


gaatccgtgcgggcgccttccgtcccggtcccatcctcgccgcgctccagcac


ctctgaagttttgcagcgcccagaaaggaggcgaggaaggagggagtgtgtgagag


gagggagcaaaaagctcaccctaaaacatttatttcaaggagaaaa


gaaaaagggggggcgcaaaaatg


 


Homo sapiens flavin containing monooxygenase 3 (FMO3):


(Seq ID No: 73)



ttttctctttcaaactgcccagacggttggacaggacgtagacacacagaagaaaa



gaagacaaagaacgggtaggaaaattaaaaaggttaccatg


 


Homo sapiens multiple C2 domains, transmembrane 1 (MCTP1):


(Seq ID No: 74)



cagcctcttttgccggtattcagtgaagaaagcaagtctaaatatgcagttctctcac



tggagtgaaagatgttttgttcatttctaatcaactatg


 


Homo sapiens structural maintenance of chromosomes 4 (SMC4):


(Seq ID No: 75)



ccgcctctcggcgagcccgccctcttctgaagaggcgtttctggaccac



tgagccccgcctcccactgtgagcggaaccctac


cgtttttaaaaaaatctttttcaaaacttgccaggttgtctttccaaatatttttaa


taatagtgctgctgctgtagaccacagagaaaagaatccctcgctcttccttttcac


ttagtagaaacttctaccgcgtaggtcccgccaggagttcgcgcatgcgcag


gagcgacaataagatggcggtgataatcgccgcactttttttcaaattagtg


gatcccagaaatcattgcgcgcatttgtaacgaatttccgttcgagttt


gtattttaggcgccattttcgagtgaaggacccggagccgaaacaccggtaggagcggg


gaggtgggtactacacaaccgtctccagccttggtctgagtggactgtcctgcagcgac


catg


 


Homo sapiens GLE1 RNA export mediator homolog (yeast)


(GLE1):


(Seq ID No: 76)



tggccttcccggcggctgattcgagggcttgtttggtcagaaggggggcgtcagagaagc



tgccccttagccaaccatg


 


Homo sapiens tripartite motif containing 6 (TRIM6):


(Seq ID No: 77)



gag



tctttcggcctgggtggaggacgcggctgcttcaagtcctt


ggctctgatccaggccacagattccaggattctacaggcaggaaacatctta


gaaatcagggttgggcaggcaggagccaggagagtagctacaatg


 


Homo sapiens ecotropic viral integration site 2A (EVI2A):


(Seq ID No: 78)



tatccttttttactgcagatttactttaaggctcatattctccaagtc



tattctgctttaaaaagaagacaagaaaagaagtggtttatcaaaatcac


gttataatcagattttgaccaagcattttgtaagtatacaaatgtcagccaatgacata


taacaaccatttcttataaaaccttgatgttcaaaagcctgactagcagtggcatccatg


 


Homo sapiens heterogeneous nuclear ribonucleoprotein L


(HNRNPL):


(Seq ID No: 79)



tgctcttttcgatccgggacggccggtcaggctcgccgccgagctgga



gaactacgatgacccgcacaaaacccctgcctccccagtt


gtccacatcaggggcctgattgacggtgtggtggaagcagaccttgtggaggcctt


gcaggagtttggacccatcagctatgtggtggtaatg


 


Homo sapiens mitochondrial translational initiation factor 2


(MTIF2):


(Seq ID No: 80)



cattcttccgggtccagaaggtgatctccgcccgtgctcagaatccaggggcccggggct



gtagattccttgacaaggatatcctagcggcgaaacaacaccgtactgggagtcagaac


gtctgggttctagtcttgactgccattaactagcggtatgacattggagaagctttttt


gacccttctggatttccgtttccttttctgtaaaatgaggagcttggaagatccg


gaaaatgaggcccataggaaacaagtgacttgctgagtccagataacac


tgactgtcagagagaaacatg


 


Homo sapiens


nuclear factor of kappa light polypeptide gene enhancer


in B-cells inhibitor, zeta (NFKBIZ):


(Seq ID No: 81)



tggcctcctctt



gccacgaggtcagacggcgagttcttaga


gaaaaaggctgcttagctgctgcttatcatgtaac


ctcaaaaggaaactgatcgtctttctcatgctgtcacgtactt


gggttattatcgctgattacagctggaaacaattgatttgctcttacgtattt


gtgtgacttgactcttcaaacacaaaggttaacaggaa


gatctcgagggccctggctgaacttcaccttttggctttctt


ggcctgatgctgaactctcgaggttgagccccatatg


 


Homo sapiens


v-erb-b2 erythroblastic leukemia viral oncogene homolog


3 (avian) (ERBB3):


(Seq ID No: 82)



atccctccccg



gactccggctccggctccgattgcaatttgcaacctccgctgccgtcgccgcag


cagccaccaattcgccagcggttcaggtggctctt


gcctcgatgtcctagcctaggggcccccgggccggactt


ggctgggctcccttcaccctctgcggagtcatg


 


Homo sapiens podoplanin (PDPN):


(Seq ID No: 83)



ccgcctcctcgggagagataaatg



 


Homo sapiens ribonucleotide reductase M1 (RRM1):


(Seq ID No: 84)



gcgccccttt



gtgcgtcacgggtggcgggcgcgggaaggggatttggattgttgcgcctctgctctgaa


gaaagtgctgtctggctccaactccagttctttcccctgagcagcgcctggaac


ctaacccttcccactctgtcaccttctcgatcccgccggcgctttagagccgcag


tccagtcttggatccttcagagcctcagccactagctgcgatg


 


Homo sapiens solute carrier family 2 (facilitated


glucose transporter), member 4 (SLC2A4):


(Seq ID No: 85)



gcgtcttttcccccagccccgctccaccagatccgcgggagccccac



tgctctccgggtccttggcttgtggctgtgggtcccatcgggcccgccctcgcac


gtcactccgggacccccgcggcctccgcaggttctgcgctccaggccggagtcaga


gactccaggatcggttctttcatcttcgccgcccctgcgcgtccagctcttctaagac


gagatg


 


Homo sapiens steroid-5-alpha-reductase, alpha polypeptide 1


(3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)


(SRD5A1):


(Seq ID No: 86)



aaccctttctgcagagtcccggcagtgcgggactccgg



tagccgcccctccggtagccgcccctcctgcccccgcgccgccgccctatatgtt


gcccgccgcggcctctggggcatggagcacgctgcccagccctggcgatg


 


Homo sapiens thromboxane A synthase 1 (platelet) (TBXAS1):


(Seq ID No: 87)



gttcccttttctacctgcagagcacggttcccataagggcggcga



gatcagcctcctgtctcatctggaagaccaccactctggggtctcagaggaatg


 


Homo sapiens transketolase (TKT):


(Seq ID No: 88)



ctatctctgtgtgtccgcgtgtgcgcccggtccccgcctgccgcaccatg



 


Homo sapiens


tumor necrosis factor receptor superfamily, member


1A (TNFRSF1A):


(Seq ID No: 89)



cctcctcctccagctcttcctgtcccgctgttgcaacac



tgcctcactcttcccctcccac


cttctctcccctcctctctgctttaattttctcagaattctctggactgaggctccag


ttctggcctttggggttcaagatcactgggaccaggccgtgatctctatgcccgag


tctcaaccctcaactgtcaccccaaggcacttgggacgtcctggacagaccgag


tcccgggaagccccagcactgccgctgccacactgccctgagcccaaatgggggagtga


gaggccatagctgtctggcatg


 


Homo sapiens tubulin, beta 2A class IIa (TUBB2A):


(Seq ID No: 90)



ag



gtctctgcgcagcccagcccgccggtccacgccgcgcac


cgctccgagggccagcgccacccgctccgcagccggcaccatg


 


Homo sapiens actin, beta (ACTB):


(Seq ID No: 91)



tcgccttt



gccgatccgccgcccgtccacacccgccgccagctcaccatg


 


Homo sapiens adenylosuccinate synthase (ADSS):


(Seq ID No: 92)



ggctccttcttcctctgcatgtggctggcggccgcagagcagttcagttcgctcac



tcctcgccggccgcctctccttcgggctctcctcgcgtcactggagccatg


 


Homo sapiens alanyl (membrane) aminopeptidase (ANPEP):


(Seq ID No: 93)



cgttctctgcctggcctgaggctccctgagccgcctccccaccatcaccatg



 


Homo sapiens beaded filament structural protein 1, filensin


(BFSP1):


(Seq ID No: 94)



gcctcctttctttctcagcccagacctggccctctggagagggtttt



ggagtcctgggtaggcagggtacctcaggcagcaggcagcacacctt


ggatgtgagctgaatggattttcaaatttcacagaaggagcctccatgctgga


gaaagtatgtatg


 


Homo sapiens basic transcription factor 3 (BTF3):


(Seq ID No: 95)



cggcctccctttagctgccatctt



gcgtccccgcgtgtgtgcgcctaatctcaggtggtccacccgagaccccttgagcac


caaccctagtcccccgcgcggccccttattcgctccgacaagatg


 


Homo sapiens


complement component 1, q subcomponent binding protein


(C1QBP):


(Seq ID No: 96)



ttgtcctttgcatctgcacgtgttcgcagtcgtttccgcgatg



 


Homo sapiens calsequestrin 1 (fast-twitch, skeletal muscle)


(CASQ1):


(Seq ID No: 97)



tttcctttcttaatatggcgatgagctcttaggccagtgtggggac



cggggctgaggtgccctggacactggaggagggggagggaaggagcccctgg


gagcctggggtagaagtgtaggaggtgggaggattccggcccg


catggagctgtcctggcctcagaaggttatccgtctctcctgccaaccatggaga


catatttagacaggaccaggtggggactgaggggtgccaatttcaggggg


cagctccggttccctccccgccccctgctcctattcctccacctgaccctttttccctt


ggctctgtcggcagtttctccaggacccagcagtgccctctgtccac


tgctctgggccattccccaatcccccctcccacttgagcccctaactcagaatctgg


gacccaggggcccctccctaccccagctaacctcttctggaccagga


gagccaacccagatcccactacctccatg


 


Homo sapiens caveolin 3 (CAV3):


(Seq ID No: 98)



gtctctctgcccctctctgccccaagtattttcagccccagccggccacacagctcg



gatctcctcctgtggatccccccagctctgcgatg


 


Homo sapiens serpin peptidase inhibitor, clade H


(heat shock protein 47), member 1, (collagen


binding protein 1) (SERPINH1):


(Seq ID No: 99)



aggtctttggctttttttggcggagctggggcgccctccggaagcgtttccaactttcca



gaagtttctcgggacgggcaggagggggtggggactgccatatatagatcccgggagcag


gggagcgggctaagagtagaatcgtgtcgcggctcgagagcgagagtcacgtcccggcgc


tagcccagcccgacccaggcccaccgtggtgcacgcaaaccacttcctggccatg


 


Homo sapiens CD68 molecule (CD68):


(Seq ID No: 100)



tttcctcctttccaaga



gagggctgagggagcagggttgagcaactggtgcagacagcctagctggacttt


gggtgaggcggttcagccatg


 


Homo sapiens cell division cycle 20 homolog (S. cerevisiae)


(CDC20):


(Seq ID No: 101)



gggtccctttctgtcccctgagcac



cgtcgcctcctttcctccagggctccgtaggcaccaactg


caaggacccctccccctgcgggcgctcccatg


 


Homo sapiens cadherin 13, H-cadherin (heart) (CDH13):


(Seq ID No: 102)



gagcctctcctcaaagcctggctcccacggaaaatatgctcagtgcagccgcgtg



catgaatgaaaacgccgccgggcgcttctagtcggacaaaatg


 


Homo sapiens regulator of chromosome condensation


(RCC1) and BTB (POZ) domain containing protein 2 (RCBTB2):


(Seq ID No: 103)



cgctcccttcgtttccgtctcggccgggcacccgagcg



catcccgccgaggccgggccgtttcagggg


gaggcgccaactcatcgcggcgccgggcccctgaccgtgcagtaaccgctacccag


gaggcggagcggacaaggctccggcctgcgaggagtcacattaactttgctctagaaga


caactttacaaggatctaaaaggaacaggattaaagatgactgaa


tactgggttccagaaatttaaaacaatcagcttagcaaatcatatattcttctgtg


gagctgagaattgatgtccgctcttccccgtgatttggaactttccaatcccaga


gaaaagttgacaaagggactgcccaggactgagtccatatg


 


Homo sapiens cold inducible RNA binding protein (CIRBP):


(Seq ID No: 104)



ccccccctcactcgcgcgttaggaggctcgggtcgttgtggtgcgctgtcttcccgctt



gcgtcagggacctgcccgactcagtggccgccatg


 


Homo sapiens LIM domain binding 2 (LDB2):


(Seq ID No: 105)



cctcctctcctctccctctcctctcctgctatagagggctccgacagcag



ttcccagccagcgtgttcagcctgcctgcctgcctgcctctgtgtgtgtgtgagcgtgtg


tgcgtgcgtctactttgtactgggaagaacacagcccatgtgctctgcatggac


gttactgatactctgtttagcttgattttcgaaaagcaggcaagatg


 


Homo sapiens chloride channel, nucleotide-sensitive, 1A


(CLNS1A):


(Seq ID No: 106)



ctgcctcttccagggcgggcggtgtggtgcacgcatt



gctgtgctccaactccctcagggcctgtgttgccgcactctgctgctatg


 


Homo sapiens collapsin response mediator protein 1 (CRMP1):


(Seq ID No: 107)



cctcctccttctcccgccctcctcgccgatccgggcggtgctggcagccg



gagcggcggcgggcgggccgagcagccggggcagccgcgcgtgggcatccac


gggcgccgagcctccgtccgtgtctctatccctcccgggccttt


gtcagcgcgcccgctgggagcggggccgagagcgccggttccagtcagacagccccg


caggtcagcggccgggccgagggcgccagagggggccatg


 


Homo sapiens catenin (cadherin-associated protein), delta 1


(CTNND1):


(Seq ID No: 108)



ttgcctttggctgggtgcaacttccattttaggtgttggatctgagggg



gaaaaaaaagagagagggagagagagagaaagaagagcaggaaagatcccgaaaggag


gaagaggtggcgaaaaatcaactgccctgctggatttgtctttctcagcacctt


ggcgaagccttgggtttctttcttaaaggactgatttttagaactccacattt


gaggtgtgtggcttttgaagaaaatgtatgtactgacgggaaaaggaggataa


gcaagtcgaatttttgtcttacgctctctccttcctgcttcctcctt


gctgtggtggctgggatgcttcttccatgattttttgaatcta


gactgggctgttctctgtgttaaaccaatcagttgcgaccttctcttaacag


tgtgaagtgagggggtctctctccctccttctccttcctctgtgattcac


cttcctttttaccctgccctgcggcggctccgccccttaccttcatg


 


Homo sapiens diacylglycerol kinase, alpha 80 kDa (DGKA):


(Seq ID No: 109)



ccgtcccctccagcccagctcgggctccagctccagcgccggcgcttcagctgcgac



cgcgagccctctcaagcaagatataacttccccaagtcacacagtggtatcagagctaa


gaatgggacccagatatgactgatctagttctgttccaaaaccgtgctgtatta


tattaacgcctaccctctgaagaggtccaagcaacggaagtactactacgaa


gctgcctttctggccatccttgagaaaaatagacagatgagttcctgccagtgag


tccctaggcctccatctctctcccttgctgtaccaccttcaccac


catccatgcgaccccaagagccttaatgactctagaagagactccaggcaggggaa


gctgaaaggacctttcactccctacttttggccagggccttctgtgccacctgccaa


gaccagcaggcctaccctctgaagaggtccaagcaacggaagtactactacgaa


gctgcctttctggccatccttgagaaaaatagacagatg


 


Homo sapiens aspartyl-tRNA synthetase (DARS):


(Seq ID No: 110)



cgatctttctg



gagccgcacctccacgcggagtccgagcgcgtgtgctgagaccccagggtcgg


gagggcggagactgggagggagggagaagcccctttggcctgccttacggaa


gcctgcgagggagggtggtgtccactgcccagttccgtgtcccgatg


 


Homo sapiens dynein, cytoplasmic 1, intermediate chain 2


(DYNC1I2):


(Seq ID No: 111)



agttcttctcgatcgtgtcagtttgtaaggcgagggcggaagttggat



tcctggcctgagaatattaggcgtagttttccagtttttggcaaagcggaaa


tacttaaggcccctgggttgactgggttctttgttttatctaccggcttctgctttac


gacaggtcacaaacatg


 


Homo sapiens dedicator of cytokinesis 1 (DOCK1):


(Seq ID No: 112)



tttcctccccatcctgtcgcggctcgaaaggaatggaaaatggcggcctagacgcggag



tttcctgcccgacccgcggcggctccggcggcgccatg


 


Homo sapiens dihydropyrimidinase-like 2 (DPYSL2):


(Seq ID No: 113)



ctctctcttttttttccgccctagctggggctgtgttggaggagaggaagaaagagaga



cagaggattgcattcatccgttacgttcttgaaatttcctaatagcaagaccagcgaa


gcggttgcacccttttcaatctt


gcaaaggaaaaaaacaaaacaaaacaaaaaaaacccaagtccccttcccggcagttttt


gccttaaagctgccctcttgaaattaattttttcccaggagagagatg


 


Homo sapiens developmentally regulated GTP binding protein 2


(DRG2):


(Seq ID No: 114)



tgttctctttggcttccgggcgcacgctactctgtcgccgccgtcagaccg



gaattgccggtgccgccgccaccgctgtctgtgcgcccacctctgctgctaccatg


 


Homo sapiens


eukaryotic translation elongation factor 1 alpha


1 (EEF1A1):


(Seq ID No: 115)



cgttctttttcgcaacgggttt



gccgccagaacacaggtgtcgtgaaaactacccctaaaagccaaaatg


 


Homo sapiens


eukaryotic translation elongation factor 1 gamma


(EEF1G):


(Seq ID No: 116)



tctcctctttccccctcccttctctcccgggcggcttactttgcgg



cagcgccgagaaccccaccccctttctttgcggaatcaccatg


 


Homo sapiens


eukaryotic translation initiation factor 2, subunit


3 gamma, 52 kDa (EIF2S3):


(Seq ID No: 117)



atttccttcctcttttggcaacatggcgggc



 


Homo sapiens eukaryotic translation initiation factor 4B


(EIF4B):


(Seq ID No: 118)



gggtcttttgcgttctctttccctctcccaacatg



 


Homo sapiens


eukaryotic translation initiation factor 4 gamma,


2 (EIF4G2):


(Seq ID No: 119)



tattcttttgaagattcttcgttgtcaagccgccaaagtg



 


Homo sapiens epithelial membrane protein 1 (EMP1):


(Seq ID No: 120)



cttcccctcagtgcggtcacatacttccagaagagcggaccagggctgctgccagcac



ctgccactcagagcgcctctgtcgctgggacccttcagaactctcttt


gctcacaagttaccaaaaaaaaaagagccaacatg


 


Homo sapiens fibrillarin (FBL):


(Seq ID No: 121)



cgctcttttccacgtgcgaaagccccg



gactcgtggagttgtgaacgccgcggactccggagccgcacaaaccagggctcgccatg


 


Homo sapiens exostoses (multiple)-like 2 (EXTL2):


(Seq ID No: 122)



ctgtccctt



gctccaggcgctcactttgcgggcggcactttttccaggttgttaatccagctaatgga


gaaggatagatgcacgctacttggtttagaaaaaaaaacaaaaatgagcaaacgagac


gccccttccgttttatgataactaagctgcagggaaataaatcggctggccctactg


caatctactgcactcgagaaacatcacagaaaattctttgatttatcttaa


tagtgacaagtgagcctgcttctgtcaattactgaagctataaggagat


tttttaaaaattaaacttcaacacaatg


 


Homo sapiens solute carrier family 37 (glucose-


6-phosphate transporter), member 4 (SLC37A4):


(Seq ID No: 123)



ccgcctctgttcaggacactgggtccccttggagcctccccaggcttaatgattgtccag



aaggcggctataaagggagcctgggaggctgggtggaggagggagcagaaaaaacccaac


tcagcagatctgggaactgtgagagcggcaagcaggaactgtggtcagaggctgtgcgtc


ttggctggtagggcctgctcttttctaccatg


 


Homo sapiens GDP dissociation inhibitor 2 (GDI2):


(Seq ID No: 124)



agccctcccctcctcgctccctcccctcctctccccgcccag



ttcttctcttcccgtctgaggtggcggtcggtctcgcctt


gtcgccagctccattttcctctctttctcttcccctttccttcgcgcccaa


gagcgcctcccagcctcgtagggtggtcacggagcccctgcgccttttcctt


gctcgggtcctgcgtccgcgcctgccccgccatg


 


Homo sapiens


UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,


polypeptide 1 (B4GALT1):


(Seq ID No: 125)



cacccttcttaaagcggcggcgggaagatg



 


Homo sapiens GDP-mannose 4,6-dehydratase (GMDS):


(Seq ID No: 126)



ggccctccctgcac



ggcctcccgtgcgcccctgtcagactgtggcggccggtcgcgcggtgcgctctccctccc


tgcccgcagcctggagaggcgcttcgtgctgcacacccccgcgttcctgccggcac


cgcgcctgccctctgccgcgctccgccctgccgccgaccgcacgcccgccgcgggacatg


 


Homo sapiens histone deacetylase 2 (HDAC2):


(Seq ID No: 127)



ggccccctcctcgcgagttggtgccgctgccacctccgattccgagctttcggcac



ctctgccgggtggtaccgagccttcccggcgccccctcctctcctcccac


cggcctgcccttccccgcgggactatcgcccccac


gtttccctcagcccttttctctcccggccgagccgcggcggcagcagcagcagcagcag


cagcaggaggaggagcccggtggcggcggtggccggggagcccatg


 


Homo sapiens protein arginine methyltransferase 2 (PRMT2):


(Seq ID No: 128)



gggccttcccggctgacggcctgcgtgcactgcgcttgcgcgggtt



gagggcggtggctcaggctcctggaaaggaccgtccacccctccgcgctggcggtgtg


gacgcggaactcagcggagaaacgcgattgagagcagtgtgtggattacactatcactg


gaaaaatacgaattgagaagaaggaaaagactggaagatgcagacctt


ggttcctgttagtggaaacactgtaaggtcccagaaatggaaaagaaaatgaaa


taaatcagcagttatgaggcagagcctaagagaactatg


 


Homo sapiens immunoglobulin (CD79A) binding protein 1


(IGBP1):


(Seq ID No: 129)



gttcctctctccccaagatg



 


Homo sapiens


eukaryotic translation initiation factor 3, subunit


E (EIF3E):


(Seq ID No: 130)



actcccttttctttggcaagatg



 


Homo sapiens activated leukocyte cell adhesion molecule (AL-


CAM):


(Seq ID No: 131)



gtccctctactcagagcagcccggagaccgctgccgccgctgccgctgctaccaccgctg



ccacctgaggagacccgccgcccccccgtcgccgcctcctgcgagtccttcttagcacct


ggcgtttcatgcacattgccactgccattattattatcattccaatacaaggaaaataaa


agaagataccagcgaaaagaaccgcttacacctttccgaattactcaagtgtctcctgga


aacagagggtcgttgtccccggaggagcagccgaagggcccgtgggctggtgttgaccgg


gagggaggaggagttgggggcattgcgtggtggaaagttgcgtgcggcagagaaccgaag


gtgcagcgccacagcccaggggacggtgtgtctgggagaagacgctgcccctgcgtcggg


acccgccagcgcgcgggcaccgcggggcccgggacgacgccccctcctgcggcgtggact


ccgtcagtggcccaccaagaaggaggaggaatatg


 


Homo sapiens acyloxyacyl hydrolase (neutrophil) (AOAH):


(Seq ID No: 132)



ttttctttatcctgcagtctttacctcagcagaaccgcacac



cacagactccctccagctctttgtgtgtggctctctcagggtccaacaagagcaa


gctgtgggtctgtgagtgtttatgtgtgcttttattcacttcacac


ttattgaaaagtgtgtatgtgagagggtggggtgtgtgtgtcaaagagagtgaggaaga


gaaggagagagagatcaattgattctgcagcctcagctccagcatccctcagttgg


gagcttccaaagccgggtgatcacttggggtgcatagctcggagatg


 


Homo sapiens ADP-ribosylation factor 1 (ARF1):


(Seq ID No: 133)



ccgccccttacccggcgtgccccgcgcccggaggcgctgac



gtggccgccgtcagagccgccatcttgtgggagcaaaaccaacgcctggctcggagcag


cagcctctgaggtgtccctggccagtgtccttccacctgtccacaagcatg


 


Homo sapiens ADP-ribosylation factor 6 (ARF6):


(Seq ID No: 134)



gcgccttttccggcagcggcggcggcagaactgggaggaggagttggaggccg



gagggagcccgcgctcggggcggcggctggaggcagcgcaccgagttcccgcgag


gatccatgacctgacggggccccg


gagccgcgctgcctctcgggtgtcctgggtcggtggggagcccagtgctcg


caggccggcgggcgggccggagggctgcagtctccctcgcggtgagaggaaggcggag


gagcgggaaccgcggcggcgctcgcgcggcgcctgcggggggaagggcag


ttccgggccgggccgcgcctcagcagggcggcggctcccagcgcag


tctcagggcccgggtggcggcggcgactggagaaatcaagtt


gtgcggtcggtgatgcccgagtgagcggggggcctgggcctctgcccttag


gaggcaactcccacgcaggccgcaaaggcgctctcgcggccga


gaggcttcgtttcggtttcgcggcggcggcggcgttgttggctgaggggacccgg


gacacctgaatgcccccggccccggctcctccgacgcgatg


 


Homo sapiens ras homolog family member A (RHOA):


(Seq ID No: 135)



cgccctcccgccgccgcccgccctcgctctctcgcgc



taccctcccgccgcccgcggtcctccgtcggttctctcgttagtccac


ggtctggtcttcagctacccgccttcgtctccgagtttgcgactcgcggac


cggcgtccccggcgcgaagaggctggactcggattcgttgcctgagcaatg


 


Homo sapiens ras homolog family member G (RHOG):


(Seq ID No: 136)



cggcctcccgctctcacttccttctcgagcccggagccgctgccgccgcccccagctccc



ccgcctcggggagggcaccaggtcactgcagccagaggggtccagaagagagaggaggca


ctgcctccactacagcaactgcacccacgatg


 


Homo sapiens


ATP synthase, H+ transporting, mitochondrial F1 complex,


O subunit (ATP5O):


(Seq ID No: 137)



ctctcttcccactcgggtttgaccta



cagccgcccgggagaagatg


 


Homo sapiens B lymphoid tyrosine kinase (BLK):


(Seq ID No: 138)



ccac



ctctgtctgctgccggcagaaagccacaagccatgaaaactgattgagatgagaa


gaattcatctgggactggcttttgctttaggatggtgttggaagttgctcgtt


gtcgctaggagcctgctccactgtaagggtgtcaggatctgaagagc


tatggtgaaacaccactgaagcattgccaaggatg


 


Homo sapiens B-cell translocation gene 1, anti-proliferative


(BTG1):


(Seq ID No: 139)



gcatctcttcgcctctcggagctggaaatgcagctattga



gatcttcgaatgctgcggagctggaggcggaggcagctggggaggtccgagcgatgtgac


caggccgccatcgctcgtctcttcctctctcctgccgcctcctgtctcgaaaa


taacttttttagtctaaagaaagaaagacaaaagtagtcgtccgcccctcac


gccctctcttcctctcagccttccgcccggtgaggaa


gcccggggtggctgctccgccgtcggggccgcgccgccgagccccagccgccccgggccg


cccccgcacgccgcccccatg


 


Homo sapiens calcium modulating ligand (CAMLG):


(Seq ID No: 140)



cggcctctag



tcatcgccctcgcagcggcggccaacatcaccgccactgccacccctcccagactgtg


gacgggaggatg


 


Homo sapiens calnexin (CANX):


(Seq ID No: 141)



aggcctcttggttctgcggcacgtgac



ggtcgggccgcctccgcctctctctttactgcggcgcggggcaaggtgtgcgggcgg


gaaggggcacgggcacccccgcggtccccgggaggctagagatcatg


 


Homo sapiens calpain 2, (m/II) large subunit (CAPN2):


(Seq ID No: 142)



cgac



ctttctctgcgcagtacggccgccgggaccgcagcatg


 


Homo sapiens caveolin 1, caveolae protein, 22 kDa (CAV1):


(Seq ID No: 143)



gcgcctttttttccccccatacaatacaagatcttccttcctcagttcccttaaa



gcacagcccagggaaacctcctcacagttttcatccagccacgggccagcatg


 


Homo sapiens CD1d molecule (CD1D):


(Seq ID No: 144)



cgacctctttgcagctcg



cacagctaagggcgagggcgcccttcggcagaagcagcaaaccgccggcaa


gcccagcgaggagggctgccggggtctgggcttgggaattggctggcacccagcg


gaaagggacgtgagctgagcggcgggggagaagagtgcgcaggtcagagggcggcgcg


cagcggcgctccgcgaggtccccacgccgggcgatatg


 


Homo sapiens CD22 molecule (CD22):


(Seq ID No: 145)



tctcctttt



gctctcagatgctgccagggtccctgaagagggaagacacgcggaaacaggctt


gcacccagacacgacaccatg


 


Homo sapiens CD37 molecule (CD37):


(Seq ID No: 146)



cttcctctttt



ggggttcttcctttctctctcagctctccgtctctctttctctctcagcctctttctttc


tccctgtctcccccactgtcagcacctcttctgtgtggtgagtggaccgcttaccccac


taggtgaagatg


 


Homo sapiens CD38 molecule (CD38):


(Seq ID No: 147)



gcctctctctt



gctgcctagcctcctgccggcctcatcttcgcccagccaaccccgcctggagccctatg


 


Homo sapiens CD48 molecule (CD48):


(Seq ID No: 148)



cggcctttttctagccaggctctcaactgtctcctgcgttgctgggaagttctg



gaaggaagcatg


 


Homo sapiens chromogranin B (secretogranin 1) (CHGB):


(Seq ID No: 149)



cttcctttccgcacaggggccgccgagcggggccatg



 


Homo sapiens chloride channel, voltage-sensitive 3 (CLCN3):


(Seq ID No: 150)



ttccccttccgtgggtcagggccggtccggtccggaacctgcagcccctttcccag



tgttctagttcgcccgtgacccggaataatgagcaaggagggtgtggtgggttgaaa


gccatcctactttactcccgagttagagcatggattcagttttagtcttaagggg


gaagtgagattggagatttttatttttaattttgggcagaagcaggtt


gactctagggatctccagagcgagaggatttaacttcatgttgctcccgtgttt


gaaggaggacaataaaagtcccaccgggcaaaattttcgtaacctctgcggtagaaaac


gtcaggtatcttttaaatcgcgatagttttcgctgtgtcaggctttcttcggtg


gagctccgagggtagctaggttctaggtttgaaacagatgcagaatccaaaggcagcg


caaaaaacagccaccgattttgctatgtctctgagctgcgagataatcagacagc


taaatg


 


Homo sapiens colipase, pancreatic (CLPS):


(Seq ID No: 151)



ttccccttccgtgggtcagggccggtccggtccggaacctgcagcccctttcccag



tgttctagttcgcccgtgacccggaataatgagcaaggagggtgtggtgggttgaaa


gccatcctactttactcccgagttagagcatggattcagttttagtcttaagggg


gaagtgagattggagatttttatttttaattttgggcagaagcaggtt


gactctagggatctccagagcgagaggatttaacttcatgttgctcccgtgttt


gaaggaggacaataaaagtcccaccgggcaaaattttcgtaacctctgcggtagaaaac


gtcaggtatcttttaaatcgcgatagttttcgctgtgtcaggctttcttcggtg


gagctccgagggtagctaggttctaggtttgaaacagatgcagaatccaaaggcagcg


caaaaaacagccaccgattttgctatgtctctgagctgcgagataatcagacagc


taaatg


 


Homo sapiens cytochrome c oxidase subunit IV isoform 1


(COX4I1):


(Seq ID No: 152)



ctacccttttccgctccacggtgacctccgtgcggccgggtgcgggcg



gagtcttcctcgatcccgtggtgctccgcggcgcggccttgctctcttccggtcgcgg


gacaccgggtgtagagggcggtcgcggcgggcagtggcggcagaatg


 


Homo sapiens cytochrome c oxidase subunit VIIc (COX7C):


(Seq ID No: 153)



ctttcttttcagtccttgcgcaccggggaacaaggtcgtgaaaaaaaaggtcttggtgag



gtgccgccatttcatctgtcctcattctctgcgcctttcgcagagcttccagcagcgg


tatg


 


Homo sapiens activating transcription factor 2 (ATF2):


(Seq ID No: 154)



cagccttttcctccaggggtgctttgtaaacacggctgtgctcagggctcgcgggtgac



cgaaaggatcatgaactagtgacctggaaagggtactagatggaaacttga


gaaaggactgcttattgataacagctaaggtattcctggaagcagagtaaataaa


gctcatggcccaccagctagaaagtattcttgccatgagaaaaagaatgtga


taagttattcaacttatg


 


Homo sapiens casein kinase 1, alpha 1 (CSNK1A1):


(Seq ID No: 155)



agatccctttcccagagtgctctgcgccgtgaagaagcggctcccggggactggggg



cattttgtgttggctggagctggagtaacaagatggcgtcgtccgcggag


tgacaggggtccctctgggccggagccggcggcagtggtggcagcgg


tatcgccgccctagctcaccgcgccccttttccagcccgcgacgtcgccgcgcaa


gcgaggcagcggcggccgccgagaaacaagtggcccagcctggtaaccgccgagaa


gcccttcacaaactgcggcctggcaaaaagaaac


ctgactgagcggcggtgatcaggttcccctctgctgattctgggccccgaaccccgg


taaaggcctccgtgttccgtttcctgccgccctcctccgtagccttgcctagtgtag


gagccccgaggcctccgtcctcttcccagaggtgtcggggctt


ggccccagcctccatcttcgtctctcaggatg


 


Homo sapiens catenin (cadherin-


associated protein), beta 1, 88 kDa (CTNNB1):


(Seq ID No: 156)



aa



gcctctcggtctgtggcagcagcgttggcccggccccgggagcggagagcgaggg


gaggcggagacggaggaaggtctgaggagcagcttcagtccccgccgagccgccaccg


caggtcgaggacggtcggactcccgcggcgggaggagcctgttcccctgagggtattt


gaagtataccatacaactgttttgaaaatccagcgtggacaatg


 


Homo sapiens dCMP deaminase (DCTD):


(Seq ID No: 157)



ccgcctcctcccccgacttccttccctgagcacggcggcggcggggacgagcac



cggcctgcgcgcggagccggcaccggatgacccaacatg


 


Homo sapiens damage-specific DNA binding protein 1, 127 kDa


(DDB1):


(Seq ID No: 158)



ctgtcttttcgcttgtgtccctctttctagtgtcgcgctcgagtcccgac



gggccgctccaagcctcgacatg


 


Homo sapiens desmin (DES):


(Seq ID No: 159)



ctgtctcccctcgccgcatccac



tctccggccggccgcctgcccgccgcctcctccgtgcgcccgccagcctcgcccgcgccg


tcaccatg


 


Homo sapiens deoxyhypusine synthase (DHPS):


(Seq ID No: 160)



cgttccctacttcctgtgctcttgcggagacgcgcgcgtcggggtttaac



gcgtttctgggccgccgtaagcccggcctaggggcagctttgactcgagagccggc


tataggcgcatg


 


Homo sapiens dihydrolipoamide S-acetyltransferase (DLAT):


(Seq ID No: 161)



caccctttcggatgcctcccctagaaccctaccactttccacccctttccgtctgttatt



tctcccaaacttgcgcccgcacaggcccctctggaacactcctgccccgtagtgcccctc


gtccccgctccgtagagaaagagcgtgcgtgccgcgcatttctggcctggggagcgggtg


gagtaaacctgcgggaaccattttacgacaacgtgcggctgtgcggtgtggctgacggca


acgccgctgctcttggagaggtcactccggagacggcgttggttttggggtgtggggggt


tggtggcactatg


 


Homo sapiens down-regulator of transcription 1, TBP-binding


(negative cofactor 2) (DR1):


(Seq ID No: 162)



ccttccctggcatctggagggaccaccgtt



gccgcgtcttcggcttccacgatctgcgttcgggctacgcggccacggcggcagccac


tgcgactcccactgtgcctggctctgtccatattag


ttcccaggcggccgtcgccgttccagcagcggcagcggcagcggcagcggcg


gacatgttgtgaggcggcggcgcgggtgtctgaaggatggtttggccgaggcggcgg


caacggctgctggcggcggcggcagcggcagcggggcctcgggctctata


gagccgagcccgctgggtacccgcccggtaccgcggcgaggccagtgcccctggatctt


gcctctgctccgacgccgttggggaccagttaggcgacagcgcccgcccctctgag


gagacacgaaggtggttccccagccgctcaaatttccggaccac


cgcgctttcccctcctcagcctgggctgtgctctctctagaatcctcgggcccccac


tttcttcccaaactcatcctaaatctctcacacacgcgagtgttcccagccctcaa


gccagctgctcctccgttcattttctgcaccctcttcgcaaagcaccccccgggatcac


tctccgagggcgactttttgagaaatctcggtggagtagtggaccagagctggggag


tttttaaaagccggggcgcgagaaacaggaaggtactatg


 


Homo sapiens endothelin receptor type A (EDNRA):


(Seq ID No: 163)



ttttctttttcgtgcgagccctcgcgcgcgcgtacagtcatcccgctggtctgac



gattgtggagaggcggtggagaggcttcatccatcccacccggtcgtcgccggg


gattggggtcccagcgagacctccccgggagaagcagtgcccaggaggttttctgaa


gccggggaagctgtgcagccgaagccgccgccgcgccggagcccgggacac


cggccaccctccgcgccacccaccctcgccggctccggcttcctctggcccaggcgccgc


gcggacccggcagctgtctgcgcacgccgagctccacggtgaaaaaaaagtgaaggtg


taaaagcagcacaagtgcaataagagatatttcctcaaatttgcctcaagatg


 


Homo sapiens


eukaryotic translation elongation factor 1 alpha


2 (EEF1A2):


(Seq ID No: 164)



cagtccctctggctgagacctcggctccggaatcactg



cagcccccctcgccctgagccagagcaccccgggtcccgccagcccctcacactcccag


caaaatg


 


Homo sapiens eukaryotic translation elongation factor 2


(EEF2):


(Seq ID No: 165)



cgttctcttccgccgtcgtcgccgccatcctcggcgcgactcgcttctttcggttctac



ctgggagaatccaccgccatccgccaccatg


 


Homo sapiens eukaryotic translation initiation factor 4A2


(EIF4A2):


(Seq ID No: 166)



ctgtcttttcagtcgggcgctgagtggtttttcggatcatg



 


Homo sapiens egf-like module containing, mucin-like, hormone


receptor-like 1 (EMR1):


(Seq ID No: 167)



gtttcttttctttgaatgacagaactacag



cataatg


 


Homo sapiens enolase 2 (gamma, neuronal) (ENO2):


(Seq ID No: 168)



gcgcctcctccgcccgccgcccgggagccgcagccgccgccgccactgccac



tcccgctctctcagcgccgccgtcgccaccgccaccgccaccgccactaccac


cgtctgagtctgcagtcccgagatcccagccatcatg


 


Homo sapiens esterase D (ESD):


(Seq ID No: 169)



ccgccttttacttcggcccgcttcttctggtcactccgccaccgtagaatcgcctac



catttggtgcaagcaaaaagcaatcagcaattggacaggaaaagaatg


 


Homo sapiens Finkel-Biskis-Reilly murine sarcoma virus


(FBR-MuSV) ubiquitously expressed (FAU):


(Seq ID No: 170)



cttcctctttctcgactccatcttcgcggtagctgggaccgccgttcagtcgccaatatg



 


Homo sapiens Friend leukemia virus integration 1 (FLI1):


(Seq ID No: 171)



ctgtctctttcgctccgctacaacaacaaacgtgcacaggggagtgaggg



cagggcgctcgcagggggcac


gcagggagggcccagggcgccagggaggccgcgccgggctaatccgaaggggctgcgagg


tcaggctgtaaccgggtcaatgtgtggaatattggggggctcggctgcagacttggc


caaatg


 


Homo sapiens fibromodulin (FMOD):


(Seq ID No: 172)



gccccttttcacaatatttgattag



gaatttggggcgggaccctggtctggcacaggcacgcacactctcag


tagactctttcactcctctctctcttcctctctcacac


gttctccaacccaaggaggccagacagagggacgtggtcac


tctctgaaaagttcaacttgagagacaaaatg


 


Homo sapiens ferritin, heavy polypeptide 1 (FTH1):


(Seq ID No: 173)



cgttcttcgccgagagtcgtcggggtttcctgcttcaacagtgcttggac



ggaacccggcgctcgttccccaccccggccggccgcccatagccagccctccgtcac


ctcttcaccgcaccctcggactgccccaaggcccccgccgccgctccagcgccgcg


cagccaccgccgccgccgccgcctctccttagtcgccgccatg


 


Homo sapiens glyceraldehyde-3-phosphate dehydrogenase


(GAPDH):


(Seq ID No: 174)



cgctctctgctcctcctgttcgacagtcagccgcatcttctttt



gcgtcgccagccgagccacatcgctcagacaccatg


 


Homo sapiens glycyl-tRNA synthetase (GARS):


(Seq ID No: 175)



caccctctctg



gacagcccagggccgcaggctcatg


 


Homo sapiens glutamic-oxaloacetic transaminase 2, mitochondrial


(aspartate aminotransferase 2) (GOT2):


(Seq ID No: 176)



ctgtccttaccttcagcaggagccggttccctgtgtgtgtgtccgctcgccctctgctcc



gtcctgcggctgcccactgccctcctacggtccaccatg


 


Homo sapiens


general transcription factor IIF, polypeptide 1,


74 kDa (GTF2F1):


(Seq ID No: 177)



gcgcctcttccggttac



cttttcccagcgccagaggcgcctagggttggggtcctcgctcaggcacaga


gacccgacaccgagcggcggcttccccgggatcgagggacgcgcacgccagaggagac


gaaaggaacccgggtcggaccagatcggaaccactgaccattgcccatg


 


Homo sapiens glycogen synthase 1 (muscle) (GYS1):


(Seq ID No: 178)



cggcctccttctgcctaggtcccaacgcttcggggcaggggtgcggtcttgcaa



taggaagccgagcgtcttgcaagcttcccgtcgggcaccagctactcggccccg


caccctacctggtgcattccctagacacctccggggtccctacctggagatccccg


gagccccccttcctgcgccagccatg


 


Homo sapiens major histocompatibility complex, class I, C


(HLA-C):


(Seq ID No: 179)



cattctccccagaggccgagatg



 


Homo sapiens


major histocompatibility complex, class II, DP beta


1 (HLA-DPB1):


(Seq ID No: 180)



gctccctttagcgagtccttcttttcctgactg



cagctcttttcattttgccatccttttccagctccatg


 


Homo sapiens 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble)


(HMGCS1):


(Seq ID No: 181)



ctgtcctttcgtggctcac



tccctttcctctgctgccgctcggtcacgcttgctctttcaccatg


 


Homo sapiens hippocalcin (HPCA):


(Seq ID No: 182)



ccgccttccctgcgcag



tcggtgtctccgcgtcgctgggtgggacttggctcggcggccatg


 


Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2


(HSD17B2):


(Seq ID No: 183)



ctcccttctt



gactctctgttcacagaactcaggctgcctccagccagcctttgcccgctagactcac


tggccctgagcacttgaaggtgcagcaagtcactgagaatg


 


Homo sapiens heat shock 60 kDa protein 1 (chaperonin)


(HSPD1):


(Seq ID No: 184)



ctgtccctcactcgccgccgacgacctgtctcgccgagcgcacgcctt



gccgccgccccgcagaaatg


 


Homo sapiens intercellular adhesion molecule 3 (ICAM3):


(Seq ID No: 185)



ccgccttttcccctgcctgcccttcgggcacctcaggaaggcaccttcctctgtca



gaatg


 


Homo sapiens inositol polyphosphate-1-phosphatase (INPP1):


(Seq ID No: 186)



cgtcctctggccgcgcctgcggccgcacgcccagcgcccctcgcctaacctcgcgcccgg



gccgcgcctcctcctcctcctgctccccgccgcttccgtttctcgagggaaaggctgctg


cctcctgctctgtcctcatccccggcttagctgacggcccagagggtgggtgccaattcc


accagcagctgcaactgaaaagcaaggttcagaaatg


 


Homo sapiens interferon regulatory factor 2 (IRF2):


(Seq ID No: 187)



gtttcctctccttgttttgctttcgatctggactgttctcaggcaagccggggag



taacttttagttttgctcctgcgattattcaactgac


gggctttcatttccatttcacataccctagcaacacttataccttgcggaatt


gtattggtagcgtgaaaaaagcacactgagagggcaccatg


 


Homo sapiens inter-alpha-trypsin inhibitor heavy chain 2


(ITIH2):


(Seq ID No: 188)



ttttcttcttttttcttctttcttaaagcgaactg



tactcctctgctgttcctttgaacttggttcagtaggaagaagtga


tatcctccccagaccatctgctttggggagcttggcaaaactgtccagcaaaatg


 


Homo sapiens karyopherin (importin) beta 1 (KPNB1):


(Seq ID No: 189)



ccgccttcctccctccctcgctccctccctgcgcgccgcctctcac



tcacagcctcccttccttctttctccctccgcctcccgagcac


cagcgcgctctgagctgcccccagggtccctcccccgccgccagcagcccattt


ggagggaggaagtaagggaagaggagaggaaggggagccggaccgactacccaga


cagagccggtgaatgggttt


gtggtgacccccgccccccaccccaccctcccttcccacccgacccccaacccccatccc


cagttcgagccgccgcccgaaaggccgggccgtcgtcttaggaggag


tcgccgccgccgccacctccgccatg


 


Homo sapiens karyopherin alpha 3 (importin alpha 4) (KPNA3):


(Seq ID No: 190)



ctctccccctcctccccctcccgctccaagattcgccgccgccgccgccgcagccgcag



gagtagccgccgccggagccgcgcgcagccatg


 


Homo sapiens keratin 19 (KRT19):


(Seq ID No: 191)



gctcctcccgcgaatcg



cagcttctgagaccagggttgctccgtccgtgctccgcctcgccatg


 


Homo sapiens laminin, beta 1 (LAMB1):


(Seq ID No: 192)



attcccttcttt



gggctcgggggctcccggagcagggcgagagctcgcgtcgccggaaaggaagacgggaa


gaaagggcaggcggctcggcgggcgtcttctccactcctctgccgcgtccccgtggctg


cagggagccggcatg


 


Homo sapiens ribosomal protein SA (RPSA):


(Seq ID No: 193)



ctgtcttttccgtgc



tacctgcagaggggtccatacggcgttgttctggattcccgtcg


taacttaaagggaaattttcacaatg


 


Homo sapiens lymphocyte cytosolic protein 1 (L-plastin)


(LCP1):


(Seq ID No: 194)



ttttctttcctggctgatgatttgtcattctagtcacttcctgcctt



gtgaccacacacccaggcttgacaaagctgttctgcagatcagaaa


gaaggggttcctggtcatacaccagtactaccaaggacagcttttttcctgcaa


gatctgttacctaaagcaataaaaaatg


 


Homo sapiens lectin, galactoside-binding, soluble, 1


(LGALS1):


(Seq ID No: 195)



ccatctctctcgggtggagtcttctgacagctggtgcgcctgcccgggaacatcctcctg



gactcaatcatg


 


Homo sapiens SH2 domain containing 1A (SH2D1A):


(Seq ID No: 196)



ttctctcttttttgcacatctggctgaactgggagtcaggtggttgactt



gtgcctggctgcagtagcagcggcatctcccttgcacag


ttctcctcctcggcctgcccaagagtccaccaggccatg


 


Homo sapiens mannosidase, alpha, class 2A, member 1


(MAN2A1):


(Seq ID No: 197)



tgttcctttcccctccgcttctctgac



ctagctgcgcggccccggcccgggagctgccgaacccgcgcctcccctgggtgaggag


gacacgcctgccctcgtcgagaaaacttttcctgccgactcagttggggcggcggtgg


caggaagtgcgggcagcgacctctcctccgcctgccccgcgcgccctgccg


gaggtcggcgctgagcttgcgatcaagtttgtgggggccccccttcccagtt


gccggcgagtctcgcctcgagaggggcgcccgaccccggggagggcgg


caggccagggcgaaggccaagggcgtgtggtggcgccggagactaggtgcggag


caaggcggggactcgcacccgcatccgagagcgcggaggtcgcgcagcccggga


gaagggagcctccggcggctgcttcctagagtccacagtgcgctgtctccttt


ggctgaggagagtgtcctggccccgagtctatcgaggaaaatg


 


Homo sapiens myelin basic protein (MBP):


(Seq ID No: 198)



ccgcctcttttcccga



gatgccccggggagggaggacaacaccttcaaagacaggccctctgagtccgac


gagctccagaccatccaagaagacagtgcagccacctccgagagcctggatgtgatg


 


Homo sapiens melanocortin 1 receptor (alpha


melanocyte stimulating hormone receptor) (MC1R):


(Seq ID No: 199)



cattcttcccaggacctcagcgcagccctggcccaggaaggcaggagacagaggccag



gacggtccagaggtgtcgaaatgtcctggggacctgagcagcagccaccagggaa


gaggcagggagggagctgaggaccaggcttggttgtgagaatccctgagcccaggcgg


tagatgccaggaggtgtctggactggctgggccatgcctgggctgac


ctgtccagccagggagagggtgtgaggg


cagatctgggggtgcccagatggaaggaggcaggcatgggg


gacacccaaggccccctggcagcaccatgaactaagcaggacacctggaggggaa


gaactgtggggacctggaggcctccaacgactccttcctgcttcctggacaggactatg


 


Homo sapiens malic enzyme 1, NADP(+)-dependent, cytosolic


(ME1):


(Seq ID No: 200)



gggcctttcccagtgcggccgccgccgccacagctgcagtcagcac



cgtcaccccagcagcatccgccgcctgcac


cgcgcgtgcggcccgccccggcctgaccccgccgccgaacccggcgccagccatg


 


Homo sapiens myocyte enhancer factor 2C (MEF2C):


(Seq ID No: 201)



agctctctgctcgctctgctcgcagtcacagacacttgagcacacgcgtacacccagaca



tcttcgggctgctattggattgactttgaaggttctgtgtgggtcgccgtggctgcatgt


ttgaatcaggtggagaagcacttcaacgctggacgaagtaaagattattgttgttatttt


ttttttctctctctctctctcttaagaaaggaaaatatcccaaggactaatctgatcggg


tcttccttcatcaggaacgaatgcaggaatttgggaactgagctgtgcaagtgctgaaga


aggagatttgtttggaggaaacaggaaagagaaagaaaaggaaggaaaaaatacataatt


tcagggacgagagagagaagaaaaacggggactatg


 


Homo sapiens mannosyl (alpha-


1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase


(MGAT1):


(Seq ID No: 202)



agcccttcttggggaagtcagctacccagcagcctgtag



tcctcggctacccaccctcaccgcctggggtcccatggtgagacagctgggtggg


catcaggcttctgcagagggccaggccggagggagctgggcgagggag


tggggctggctcctggcttgcaccggcctcgtggaatccaggcctcagac


ctgatcgctggcgaaactggctctgtgcgctg


gagcccctggtcttctgcgtctgtcctcctcccggccagactttactcctggctcagcga


caggtatttgctatggaagagctgtccctccctcccctcggtgggcctgggtccac


ctccacctcctcttcaggtccgcaccttcctcccctttaaaacaccagccgggcg


cagacccgttctaggcttttccatggtgcttccgccaaagcttgtgaccgag


tccttcccgcctagggctggtgggcctcccctgctgg


taggtctctcttcgctttctttactcagaactgaagctctcattccccacccac


caaggaaaaacaaaagggaagaagccacagctggccccggcttgctttgg


cacaggtgtttccccccggccccccgtcggg


caccctggttcctgttctgtccctgccccac


gcgaccctggggctcccacccgggctcctcagcctcccctgggttggggtggggg


gactggctcccagcccttggcctagggtttggtgaacgcctttcctg


gactgcgggcccacttcaggcgcggctccaggctgggcagctgcgctg


gagggccgagggcaggggtggggtcgggcgtccaccctcagggttgcgccagggagccg


gaaagccgactcccgaagttggggtcctgggaaaacttgggtcctgggttgactgagaa


gcggcggggaaaggaggcgggccaggaggagggggcctggcggac


gccggccggggggcggggcgcggcggggctgtcggtcacgcccctcag


tccgccccgccccgccccgcctgccggggaagggccacgtt


gcccgcccggccgtccggccccggcgcgccgcagaaagggctggcgag


tcgaaaggcgaggcggccgcggcagcgcttgggacgcgcctgggcac


cgggctcgctccctgcgccccggagcaggccaagttcggggccaggacgtcgggaggac


ctggtgcatggctgcctcctaatcccatagtccagaggaggcatccctaggactgcggg


caagggagccgggcaagcccagggcagccttgaac


cgtcccctggcctgccctccccggtgggggccaggatg


 


Homo sapiens


mitogen-activated protein kinase kinase kinase 11


(MAP3K11):


(Seq ID No: 203)



ctgcctcccgcccccggggccaaagtacaaagggaggaggaa



gaagggagcggggtcggagccgtcggggccaaaggagacggggccaggaacaggcag


tctcggcccaactgcggacgctccctccaccccctgcgcaaaaagacccaaccggagtt


gaggcgctgcccctgaaggccccaccttacacttggcgggggccg


gagccaggctcccaggactgctccagaaccgagggaagctcgggtccctccaa


gctagccatggtgaggcgccggaggccccggggccccacccccccggcctgaccacac


tgccctgggtgccctcctccagaagcccgagatgcggggggccgggagacaacac


tcctggctccccagagaggcgtgggtctggggctgagggccagggcccg


gatgcccaggttccgggactagggccttggcagccagcgggggtggggaccacggg


cacccagagaaggtcctccacacatcccagcgccggctcccggccatg


 


Homo sapiens membrane protein, palmitoylated 1, 55 kDa


(MPP1):


(Seq ID No: 204)



ccgccttctccgcagccccgcaggccccgggccctgtcattcccagcgctgccctgtctt



gcgttccagtgttccagcttctgcgagatg


 


Homo sapiens v-myc myelocytomatosis viral oncogene homolog


(avian) (MYC):


(Seq ID No: 205)



ggccctttataatgcgagggtctggacggctgag



gacccccgagctgtgctgctcgcggccgccac


cgccgggccccggccgtccctggctcccctcctgcctcgagaaggg


cagggcttctcagaggcttggcgggaaaaagaacggagggagggatcgcgctgag


tataaaagccggttttcggggctttatctaactcgctgtagtaattccagcga


gaggcagagggagcgagcgggcggccggctagggtggaagagccgggcgag


cagagctgcgctgcgggcgtcctgggaagggagatccggagcgaa


tagggggcttcgcctctggcccagccctcccgctgatcccccagccagcggtccg


caacccttgccgcatccacgaaactttgcccatagcagcgggcgggcactttgcactg


gaacttacaacacccgagcaaggacgcgactctcccgacgcggggaggc


tattctgcccatttggggacacttccccgccgctgccag


gacccgcttctctgaaaggctctccttgcagctgcttagacgctg


 


Homo sapiens nuclear cap binding protein subunit 1, 80 kDa


(NCBP1):


(Seq ID No: 206)



tggcctctcggttccgcggcgcaccggagggcagcatg



 


Homo sapiens necdin homolog (mouse) (NDN):


(Seq ID No: 207)



cttcctctccag



gaatccgcggagggagcgcaggctcgaagagctcctggacgcagaggccctgccctt


gccagacggcgcagacatg


 


Homo sapiens NADH dehydrogenase (ubiqui-


none) 1 beta subcomplex, 5, 16 kDa (NDUFB5):


(Seq ID No: 208)



ccttcttcctcctgcccgtagtagccatg



 


Homo sapiens NADH dehydrogenase (ubiqui-


none) Fe-S protein 4, 18 kDa (NADH-coenzyme Q reductase)


(NDUFS4):


(Seq ID No: 209)



ccgtcctttcatcctggcgtttgcctgcagcaagatg



 


Homo sapiens


nuclear factor of kappa light polypeptide gene enhancer


in B-cells 2 (p49/p100) (NFKB2):


(Seq ID No: 210)



tgccccttccccggccaa



gcccaactccggatctcgctctccaccggatctcacccgccacacccg


gacaggcggctggaggaggcgggcgtctaaaattctgggaagcagaacctggccg


gagccactagacagagccgggcctagcccagagacatg


 


Homo sapiens non-metastatic cells 2, protein


(NM23B) expressed in (NME2):


(Seq ID No: 211)



gcccctcctccgccgccggctcccgggtgtggtggtcgcac



cagctctctgctctcccagcgcagcgccgccgcccggcccctccagcttcccggaccatg


 


Homo sapiens nucleophosmin (nucleolar


phosphoprotein B23, numatrin) (NPM1):


(Seq ID No: 212)



gcgtcctttccctggtgtgattccgtcctgcgcggttgttctctggagcagcgttctttt



atctccgtccgccttctctcctacctaagtgcgtgccgccacccgatg


 


Homo sapiens 5′-nucleotidase, ecto (CD73) (NT5E):


(Seq ID No: 213)



cattccttttgtagaaaaacccgtgcctcgaatgaggcgagactcagagag



gacccaggcgcggggcggacccctccaattccttcctcgcgcccccgaaagagcggcg


caccagcagccgaactgccggcgcccaggctccctggtccggccgggatgcggccgg


tacccgctccccgccgggaacaacctctccactcttcctg


cagggagctggtgccagccgacagccgcgccagggccgctccgggtaccagggtcg


gatcgggtgacgtcgcgaacttgcgcctggccgccaagccggcctccaggctgaa


gaaggacccgccccggccttgacccgggccccgcccctccagccggggcac


cgagccccggccctagctgctcgcccctactcgccggcac


tcgcccggctcgcccgctttcgcacccagttcacgcgccacagctatg


 


Homo sapiens phosphatidylethanolamine binding protein 1


(PEBP1):


(Seq ID No: 214)



gcgtcttcccgagccag



tgtgctgagctctccgcgtcgcctctgtcgcccgcgcctggcctaccgcggcac


tcccggctgcacgctctgcttggcctcgccatg


 


Homo sapiens poly(A) binding protein, cytoplasmic 1


(PABPC1):


(Seq ID No: 215)



gcttccccttctccccggcggttagtgctgagagtgcggag



tgtgtgctccgggctcg


gaacacacatttattattaaaaaatccaaaaaaaatctaaaaaaatcttttaaaaaaccc


caaaaaaatttacaaaaaatccgcgtctcccccgccgga


gacttttattttttttcttcctcttttataaaataacccggtgaagcagccgagac


cgacccgcccgcccgcggccccgcagcagctccaagaaggaaccaagagac


cgaggccttcccgctgcccggacccgacaccgccaccctcgctccccgccggcagccgg


cagccagcggcagtggatcgaccccgttctgcggccgttgagtag


ttttcaattccggttgatttttgtccctctgcgctt


gctccccgctcccctccccccggctccggcccccagccccggcac


tcgctctcctcctctcacggaaaggtcgcggcctgtggccctgcgggcagccgtgccga


gatg


 


Homo sapiens proprotein convertase subtilisin/kexin type 2


(PCSK2):


(Seq ID No: 216)



cgctctttctctccggtacacacagctccccacattcg



cacccctgcccgcgcgccgggccgcctgactgcacggcttcccctccagccagatgctg


gagaacacacactgattcgctgctttccaagaccctgttcagtctctttctctata


caaagatttttttaaaaactatatataagaattctttatttgcaccctccctccgag


tcccctgctccgccagcctgcgcgcctcctagcaccacttttcactcccaaagaaggatg


 


Homo sapiens phosphogluconate dehydrogenase (PGD):


(Seq ID No: 217)



gggtctttccctcactcgtcctccgcgcgtcgccgctcttcggttctgctctgtccgccg



ccatg


 


Homo sapiens phosphoglucomutase 1 (PGM1):


(Seq ID No: 218)



cgctcccctttcccctcccgccggacctgccaggaggtgggctggcgcg



gagggagggccctgtcccctgtccctttaaggaggagggccaaacgccggcctagag


tgcggcgtagcccccacccgccgtgccctcaccccagagcagctg


cagcctcagccggccgcccctccgccagccaagtccgccgctctgacccccggcag


caagtcgccaccatg


 


Homo sapiens solute carrier family 25 (mitochondrial


carrier; phosphate carrier), member 3 (SLC25A3):


(Seq ID No: 219)



cggcctctgtgagccgcaacctttccaagggagtggtt



gtgtgatcgccatcttagggagtgagtgtggccgggccttctcctgtggcgggtgtggg


gagcggagcccagagctcctgtggggccgctgctttggcggtgggcccagccgggag


cagcctctttcgaaggccgccgtgacctcttcaagggcgtggagacgg


gaaggaaaaggccccggttggggttccagggcgccggtaacgttaaccggcgcctt


gcctgtcctctaaccgtcgctccctcctcccctagaaagatg


 


Homo sapiens pim-1 oncogene (PIM1):


(Seq ID No: 220)



cctcccctttactcctggctgcggggcgagccgggcgtctgctg



cagcggccgcggtggctgaggaggcccgagaggagtcggtggcagcggcggcggcgg


gaccggcagcagcagcagcagcagcagcagcagcaaccac


tagcctcctgccccgcggcgctgccgcacgagccccac


gagccgctcaccccgccgttctcagcgctgcccgaccccgctggcgcgccctcccgccgc


cagtcccggcagcgccctcagttgtcctccgactcgccctcggccttccgcgccagccg


cagccacagccgcaacgccacccg


cagccacagccacagccacagccccaggcatagccttcgg


cacagccccggctccggctcctgcggcagctcctctgggcac


cgtccctgcgccgacatcctggaggttgggatg


 


Homo sapiens pyruvate kinase, muscle (PKM2):


(Seq ID No: 221)



ggatctcttcgtctttgcagcgtagcccgagtcggtcagcgccggaggtgagcggtg



caggaggctacgccatcagtccccaccaagggccagtcgcccggctagtgcg


gaatcccggcgcgccggccggccccgggcacgcaggcagggcggcgcag


gatccagggcgtctgggatgcagtggagctcagagagaggagaacggctcctcac


gcctggggcctgctcttcagaagtccccagcgccgttccttccagatcaggacctcag


cagccatg


 


Homo sapiens pleiomorphic adenoma gene-like 1 (PLAGL1):


(Seq ID No: 222)



cggcctcctcggcgcagccatcctcttggctgccgcgggcggcaaagcccacggcatctg



ccatttgtcattcagcccgtcggtaccgccccgagccttgatttagacacggctggggcg


tgctctggcctcactctccgggcgggtgctggacggacggacggacggggcagccgtgct


cacagctcagcagcgcggggccttggcgcgcggggcgcttccccgggtcgccgtcatggc


cgcggaggtggcacgcccgagcggcctcgcctgagctccgggggtcgtcgccccgcaggg


attgctgtcacgtctaatgtggctgctgcctcgtgtcacatctgaaactcatctgtacct


cacttagaaagtggttctgattagacaagacttttcgttgcagtcgacagaaacctaatg


ggaccattgaagaattccaaacaggtatttgcataggaatcagaggagttaatcttgtct


cttctcacaggtttgaatcttcagacaaacttctgggaggactcggtccctgcctcgcag


cagatgttccctgtcactcagtaggcatatg


 


Homo sapiens phospholipase D2 (PLD2):


(Seq ID No: 223)



tgctctcttggctccggaacccccgcgggcgctggctccgtctgccagggatg



 


Homo sapiens proteolipid protein 2 (colonic


epithelium-enriched) (PLP2):


(Seq ID No: 224)



cccccttcccggccagacggcggg



caagacagctgggtgtacagcgtcctcgaaaccacgagcaagtgag


cagatcctccgaggcaccagggactccagcccatgccatg


 


Homo sapiens pinin, desmosome associated protein (PNN):


(Seq ID No: 225)



cag



tcctttcgcgcctcggcggcgcggcatagcccggctcggcctgtaaagcagtctcaa


gcctgccgcagggagaagatg


 


Homo sapiens phosphoribosyl pyrophosphate amidotransferase


(PPAT):


(Seq ID No: 226)



ggtccttccacgtgctttcggcggcgacatg



 


Homo sapiens


protein phosphatase 1, catalytic subunit, gamma isozyme


(PPP1CC):


(Seq ID No: 227)



tgttcttctcgtggttccagtggggagagaaggag



gaagtagggagcggggtggcaggggggggacccgccgcggctgctgccaccgccgccac


caccgcctctgctcgtggcgtgggaaaggaggtgtgag


tcccgggcgcgagccggcggcggcgccgctgcgggagggtcggcggtgggaaggcgatg


 


Homo sapiens protein phosphatase 1, regulatory subunit 8


(PPP1R8):


(Seq ID No: 228)



cggtcttccagtttcccggcgtgcttagggcgcgccaaatgggagggg



gagacgcaagatg


 


Homo sapiens protein phosphatase 6, catalytic subunit


(PPP6C):


(Seq ID No: 229)



cggcctccgccgctgccgccgccgctgctacagccgccgccgccgctgtt



gccgcggcttgttattcttaaaatg


 


Homo sapiens protein kinase C substrate 80K-H (PRKCSH):


(Seq ID No: 230)



ctttctttctgcagcaggaaccgcggctgctggacaagaggggtgcggtggatactgac



ctttgctccggcctcgtcgtgaagacacagcgcatctccccgctg


taggcttcctcccacagaacccgtttcgggcctcagagcgtctggtgagatg


 


Homo sapiens mitogen-activated protein kinase 6 (MAPK6):


(Seq ID No: 231)



cgccccctcttcctcgccctctctcgcgggtcggggttacatggcggcgactgcggcaaa



gcgagagcctcggagacgccgctgccgccagcacagccggagacctgagccgacactggg


ggcagtccgcgagccccgcactctctcgatgagtcggagaagtcccgttgtatcagagta


agatggacggtagctttgattgtgattgtggtgagctggagccacctgatcactaacaaa


agacatcttctgttaaccaacagccgccagggcttcctgttgaaataaatatatagcaac


aaaggaaaaaaagaagcaaaacggaaatagtgcttaccagcaccttagaatgatgctgct


caggaccagtccaacactgaatgtatctgcactgtgaggagaatgttcatagaagcctgt


tgtgtgcatatttattcacatttttgttaaatgttaaatcgtttagcacggtaatctgag


tgcacagtatgtcatttcattccgtttgagtttcttgttttcgttaaatgtctgcagagt


tgctgcccctttcttgaactatgagtactgcaatctttttaattctcaatatgaatagag


ctttttgagctttaaatctaaggggaactcgacaggcctgtttggcatatgcaatgaaca


tcaagaaaccatcttgctgtggaagcataattatttttcttctccctttttgaaagatct


ttccttttgatgccagttttcttccttgtttacacaagttcaatttgaaaggaaaaggca


atagtaagggtttcaaaatg


 


Homo sapiens phosphoribosyl pyrophosphate synthetase 2


(PRPS2):


(Seq ID No: 232)



cctccccttccctacatctagccgccgcgctttcccgctcccgcagcag



cagcctcccgcgtcgctgtcgctgttgcctccgccac


ctcctccgccgccgcgcgcccctcggagttccgcgccccaccatg


 


Homo sapiens


phosphoribosyl pyrophosphate synthetase-associated


protein 1 (PRPSAP1):


(Seq ID No: 233)



ttgcctctggctctgaggcggcggcgccgggcgctgcgaaggctcggccgctgtag



tcagtggtgtggggtgcgcaagggcacggacctcggagctctccccgcttgcgccgag


tttctcagcgccttccccacccaaaccggggtctcgcagtcggaagcactcagagtg


cagccccgcgcggggccggtcgtaaccgcgccgcgggccggacgatg


 


Homo sapiens proteasome (prosome,


macropain) subunit, beta type, 5 (PSMB5):


(Seq ID No: 234)



ag



ttctttctgcccacactagacatg


 


Homo sapiens proteasome (prosome,


macropain) 26S subunit, non-ATPase, 13 (PSMD13):


(Seq ID No: 235)



tgttcttctgtgccgggggtcttcctgctgtcatg



 


Homo sapiens protein tyrosine phosphatase, receptor type, N


(PTPRN):


(Seq ID No: 236)



cagcccctctggcaggctcccgccagcgtcgctgcggctccggcccgg



gagcgagcgcccggagctcggaaagatg


 


Homo sapiens RAB3A, member RAS oncogene family (RAB3A):


(Seq ID No: 237)



ctccctttgcaggacgtcacggaggactg



caggggcctgagccgctgctgccgccgccgccgcgcagccccacatcaacgcac


cggggtcctgtcaccgccaccgccaaaaaagtcaccgccgctagggtcgccgtt


gcatcggtgcagggcaagatg


 


Homo sapiens


RNA binding motif, single stranded interacting protein


2 (RBMS2):


(Seq ID No: 238)



ctctctctctctctctctcgctcgttccctaacattaaaga



gaaaatg


 


Homo sapiens


reticulocalbin 1, EF-hand calcium binding domain


(RCN1):


(Seq ID No: 239)



gcgcccctctgctccggctcggggcgggcactggcggagggactggccag



tcccctcctccgcgccggccccaaccctgtcgctgccgccgcgctccgag


tccccattcccgagctgccgctgtt


gtcgctcgctcagcgtctccctctcggccgccctctcctcgggacgatg


 


Homo sapiens radixin (RDX):


(Seq ID No: 240)



ccgccttttcccgcg



gaggcgccgagcggccatattgcg


gagctgtctgcggtggcggcggcgcctctcgtctcccgcggcccagcgctcgcaccac


cgcttctccctccctgtcgcagccgcgccgccgcgcagcgccccagccacac


gccggcgggcagaagccgcccgctctccggaaagtgataacagaattcattgaagtgga


gaatttttaaagaaggtaacaaaaagagaaagaaaatg


 


Homo sapiens replication factor C (activator 1) 1, 145 kDa


(RFC1):


(Seq ID No: 241)



tcgccttcttgcacttcgcgggagaagttgtt



ggcgcgaatggatcctgagcctcgataacagattcctcaac


cggcccacccgccagccagccagcgccttcatcctggggctgcgatg


 


Homo sapiens ring finger protein 4 (RNF4):


(Seq ID No: 242)



gcatctttctcgag



gagctctcctgggcggctgaagaaggagcttcttctccggag


tgcgccggcggtggcgcctgcggacctaactagctccaggttaggccgagctttgcgg


gaaagcagcggacttgaaaatactggaaatctgtccggatccaaattattttgcaa


gccagatgagtaaccagagggcatgaaaggttgagaacatttgacttccctgcaaac


cttggtatagatcacttccttttctgtaggaaaggaaaggcaccaaagagcacaatg


 


Homo sapiens ribophorin I (RPN1):


(Seq ID No: 243)



tgctcttcccggtcatg



 


Homo sapiens ribosomal protein S27a (RPS27A):


(Seq ID No: 244)



cgttcttccttttcgatccgccatctgcggtggagccgccaccaaaatg



 


Homo sapiens secreted and transmembrane 1 (SECTM1):


(Seq ID No: 245)



cttcctttagcgtgaaccgcgggtgcggtgcctcccgtgaaaataataaattcac



cgtcacgcttgttgtgaacgcgggtggttcccgaaacttggaggcttcccg


taaacccagctccttcctcatctgg


gaggtgggtcccgcgcgggtccgccgcctcctccctggcccctccctctcgtgtctttca


ttttcctggggctccggggcgcggagaagctgcatcccagaggagcgcgtccaggagcg


gacccgggagtgtttcaagagccagtgacaaggaccaggggcccaagtcccaccagc


catg


 


Homo sapiens small glutamine-rich tetratricopeptide repeat


(TPR)-containing, alpha (SGTA):


(Seq ID No: 246)



ctttcttttgcg



caggcgtcgcgccctggggccggggccgggcggcaccgcggtgcgcaagcgcaac


cgtcggtgggtcggggatcggtcgcctgagaggtatcacctcttctgggctcaagatg


 


Homo sapiens


SH3 domain binding glutamic acid-rich protein like


(SH3BGRL):


(Seq ID No: 247)



agttctccttccaccttcccccacccttctctgccaac



cgctgtttcagcccctagctggattccagccattgctg


cagctgctccacagcccttttcaggacccaaacaaccgcagccgctgttcccaggatg


 


Homo sapiens solute carrier family 1 (glutamate/


neutral amino acid transporter), member 4 (SLC1A4):


(Seq ID No: 248)



cgccctcctacttccccgtctgcgtccgcgttcgcggctcccgttt



gcatcatccccgtctgcgtccgcgttcgcggctcccgttt


gcatcatctccagccggcggctgctccagggaggctgggcgcgatcctctccgcccgcgg


ctccaacccgcactctgcgcctctcctcgcctttctcgcac


ctgctcctgcgccaggcccggagacccccggggcggcttcccagaacctgcggag


cacaactggccgaccgacccattcattgggaaccccgtcttttgccagagcccac


gtcccctgccacctctagctcggagcggcgtgtagcgccatg


 


Homo sapiens


small nuclear RNA activating complex, polypeptide


2, 45 kDa (SNAPC2):


(Seq ID No: 249)



ctgcctctttctgagcggcatg



 


Homo sapiens sorting nexin 1 (SNX1):


(Seq ID No: 250)



ctatctctcga



taaagttgttgttgcggcttccgccgcgggtggaagaagatg


 


Homo sapiens signal recognition particle 54 kDa (SRP54):


(Seq ID No: 251)



ctatctctcatctttccgctcttagctgggagtgctccgcctagtcac



ttttcttaaggtggctcgtcgaggcctgacttcttccccgaaatcacgtccctaga


cagcctcctattttaccactaactttactcctgcagttattcagcggtag


gaaactgaaaccaaaaaccagtgtaagcaagtaaacatctaaactgtttcag


gagccgcgtagaaggaacgcggcggtgtgccccggaagcggaagtagattctcctata


gaaaggctggactacgcggagtggtgacgtttcctcattgggcggaaggttcgctgg


cactccgttggtcttccagctggtgggagttgacgacgtggtgctgggcgttgg


gaccctactttatctagttcgggaagttgggttgtggggtcat


acctgtctgtctgctcccagctttcttgggtttcttccgac


ggcgtggggcctcgctaaggaattcccggcccctcagggccac


ggctttagcggtgtcttttgcgagttcttcgtaagtacatcttaaagctgtcaagatg


 


Homo sapiens signal sequence receptor, beta (translocon-


associated protein beta) (SSR2):


(Seq ID No: 252)



cggtctttcggatgctgac



gctctcttcctgtctttgtggctccggaaaggcgtttgggatgccaacgatg


 


Homo sapiens


signal transducer and activator of transcription


6, interleukin-4 induced (STAT6):


(Seq ID No: 253)



ttttctttttggtggtggtggtg



gaaggggggaggtgctagcagggccagccttgaactcgctggacagagctacagac


ctatggggcctggaagtgcccgctgagaaagggagaagacagcagaggggtt


gccgaggcaacctccaagtcccagatcatg


 


Homo sapiens suppressor of Ty 4 homolog 1 (S. cerevisiae)


(SUPT4H1):


(Seq ID No: 254)



tgttcttcccatcggcgaagatg



 


Homo sapiens transcription factor 7


(T-cell specific, HMG-box) (TCF7):


(Seq ID No: 255)



ggtccttcccctaaaacttggcactgccgatactcccagcccgttccttcccaagtcagg



aacttgcaggggaccccttggcaattctttttctctcaagagcagacagccttcagtccc


agccgctgccagggctggtgtgtctgacccagctgtggtttttccaggcctgaaggcccc


ggagtgcaccagcggcatg


 


Homo sapiens TEA domain family member 4 (TEAD4):


(Seq ID No: 256)



cagtctcctccccgaggtgccggtggccccgccgccac



tccctccggctccctccctcccgccgcggcgcgcatctcattccagccctcattccgcg


cattccagcgtcctcctcgcacactcgaggccagggggcgggagggccg


cagctccggcgccgccgcgtcccgccaggtgagaggcgcccgcgcccgccg


cacccgccggcgccctcacgggccgcgcgccccacgccgccgcagccgac


cgctcgcgccgcgtgctcggctgctcttttctttccgccgcccgcgttcccgcctt


ggacctctgcgctccgacgcgctccgtcccgac


ctctggcttccctccgcgctccggcgctgctcgctgcccctctcccgcttccctcctgtc


cgccccgcgctcccctcctcgctcccggttgactcactcctccaggaa


tagggatccccgtgttttcccgtcagtcccattctgg


gaaaactcctccctccgcgcgctccgctccgctccgctgggcgcac


cggggccggtcggcgcggggtgggcttggccccgcggccccgccttcac


tgcgccgcccgtcggccccggccggagcccggctctgcgcgctgac


gccctgtcgtccccgcagaacgatcgccgcggccggaagagttggcgctcggggcg


gactccttggaactggcttagcgcacccatcccaccttcccgcaccctgggaccggtcg


gaacgagctgattgcccgctacatcaagctccggacagggaagacccgcaccaggaa


gcaggtctccagccacatccaggtgctggctcgtcgcaaagctcgcga


gatccaggccaagctaaaggaccaggcagctaaggacaaggccctgcagagcatg


 


Homo sapiens G protein-coupled receptor 137B (GPR137B):


(Seq ID No: 257)



ttttctttcctccagtctcggggctgcaggctgagcgcgatgcgcgga



gacccccgcgggggcggcggcggccgtgagccccgatg


 


Homo sapiens tumor protein, translationally-controlled 1


(TPT1):


(Seq ID No: 258)



cggccttttccgcccgctcccccctccccccgagcgccgctccggctgcac



cgcgctcgctccgagtttcaggctcgtgctaagctagcgccgtcgtcgtctcccttcag


tcgccatcatg


 


Homo sapiens ubiquitin A-52 residue ribosomal protein


fusion product 1 (UBA52):


(Seq ID No: 259)



ctatcttctttttcttcagcgaggcggccgagctgacg



caaacatg


 


Homo sapiens ubiquinol-cytochrome c reductase core


protein II (UQCRC2):


(Seq ID No: 260)



cggcctccgccaccatcttgctttcctttaatccggcagtgac



cgtgtgtcagaacaatcttgaatcatg


 


Homo sapiens ubiquitin specific peptidase 1 (USP1):


(Seq ID No: 261)



ctgcctttcgtgtctctgcagcgtggagactggaaccggcaatttcaaaggacgccacgt



tcaatcgcagcgctggcgcgggcggaggctaaaacacgggggtcctgagactgaggaaaa


cgcgccaagttcccctcggtggcggagtgctaaagaccctagcggttcaggcgttcggcg


agcggggccgctgcttgttgcgctcctggctctcccggggcgggcgcagatgggcgccgc


tcccgggatgtagttggtgttggtgcaagacgggagcgagcggcggtcggggttcccgct


cttgggagcggatggtcactcccccgcggggagggcgagccgaccagattttcctggggc


cggggacccggcgggctcggggcagggactcacctgtcgcacccacactcattcgggttg


gacttgccggcgtcaccgccgcggacttcgctttgggccatgaccagatataattggtga


ttacaactttcctctataaattaactcttgacactccttgggatttgaagaaaaaaatg


 


Homo sapiens voltage-dependent anion channel 2 (VDAC2):


(Seq ID No: 262)



gtgtctccttcacttcgccctccagctgctggagctgcagcccgac



cgcgagcgtgccaagcggcttcagcagctagcggagcggtggcggcggcccccctcag


gacaccaccagattcccctcttcccgcggcctcgccatg


 


Homo sapiens vimentin (VIM):


(Seq ID No: 263)



gcctcttctccgggagccagtccgcgccac



cgccgccgcccaggccatcgccaccctccgcagccatg


 


Homo sapiens very low density lipoprotein receptor (VLDLR):


(Seq ID No: 264)



ccccctccccgctgctcaccccgctctccggccgccgccggtgcgggtgctccgctac



cggctcctctccgttctgtgctctcttctgctctcggctccccaccccctctcccttccc


tcctctccccttgcctcccctcctctgcagcgcctgcattattttctgcccg


caggctcggcttgcactgctgctgcagcccggggaggtggctgggtgggtggggagga


gactgtgcaagttgtaggg


gagggggtgccctcttcttccccgctcccttcccccgccaactccttcccctccttctcc


ccctttcccctccccgcccccaccttcttcctcctttcggaaggactggtaactt


gtcgtgcggagcgaacggcggcggcggcggcggcggcggcaccatccaggcgggcac


catg


 


Homo sapiens wingless-type MMTV integration site


family, member 10B (WNT10B):


(Seq ID No: 265)



agtcctttgctcgccggcttgctagctctctcgatcac



tccctcccttcctccctcccttcctcccggcggccgcggcggcgctggggaa


gcggtgaagaggagtggcccggccctggaagaatgcggctctgacaaggg


gacagaacccagcgcagtctccccacggtttaagcagcactagtgaa


gcccaggcaacccaaccgtgcctgtctcggaccccgcacccaaaccactg


gaggtcctgatcgatctgcccaccggagcctccgggcttcgacatg


 


Homo sapiens CCHC-type zinc finger, nucleic acid


binding protein (CNBP):


(Seq ID No: 266)



cagcctctaccttgcgagccgtcttccccaggcctgcgtccgag



tctccgccgctgcgggcccgctccgacgcggaagatctgactgcagccatg


 


Homo sapiens zinc finger protein 43 (ZNF43):


(Seq ID No: 267)



gggccttt



gtctctggctgcagttggagctctgcgtctcgtcttcgttcttctgtgtcctctgctgct


agaggtccagcctctgtggctctgtgacctgcgggtattgggggatccacagctaagac


gccaggaccccccggaagcctagaaatg


 


Homo sapiens zinc finger protein 74 (ZNF74):


(Seq ID No: 268)



cagtccttttgtgggagtccggtctgtccacttgccggtccctcagaccgtcggcggtct



ctgtccgcttcgggacctgtccgctggtcgctccgcgtccgatggctcctggccgcggaa


ccttaggcctggccctggtctccgagcgcgggttcgccgggaggagcgtgtggcgggggt


gtgccggggcgtgagtgcgccgagcatggggctgagcctggtgtggggagtgggtatctg


cggagccggcctgaaccccacctcagccgggcgcggggagggggctccgtgcgtgtgatc


gtgcagctgtgagcgcgtggccgccccgcggggctccgctgcaggcccctcagccccagg


agcagtactcgctcttcagggcctgccctggatcctggaggctacacagctgcccactcc


tcctggggaggctgccgtggaggccatg


 


Homo sapiens zinc finger protein 85 (ZNF85):


(Seq ID No: 269)



gggccttt



gtctctcgctgcagcctgagctctaggtcttgttttccctgcttt


gtgttttctgctcgtggacgcccagcctctgtggccctgtggcctgcaggtattggga


gatccacagctaagacgccgggaccccctggaagcctagaaatg


 


Homo sapiens zinc finger protein 91 (ZNF91):


(Seq ID No: 270)



gggccttt



gtctctcgctgccgccggagtttccaggtctcgacttcac


tgctctgtgtcctctgctccaggaggcccagcctgtgtggccctgtgacctg


caggtattggagagccacagctaagatg


 


Homo sapiens zinc finger protein 141 (ZNF141):


(Seq ID No: 271)



gggtcttt



gcgtctggctactaccagaccgcgggttaggggcttcatctctctgcgttctcagtt


gtgggaggccttggtgattcggccacagcctcagcctccgtcgctctgtgacctgcggg


tattggatgattggtagctaagactcccgaatacttcagaagtggggaaatg


 


Homo sapiens zinc finger protein 205 (ZNF205):


(Seq ID No: 272)



tgttctttctagctctgaaatagaaaatg



 


Homo sapiens transmembrane protein 187 (TMEM187):


(Seq ID No: 273)



ctcccttttcggagatttgaatttcccccagcgaggcgagtgaggcgaaatacccg



tatggtgatagctggccttttcgcgccaatactgaaaaaggcagaac


gttcctccgctggcgccagccaatcagcaggactcctgccttccttcggggcaaggtcg


cagcatctgcctcggaaatcacgaaatcacggggcttctttctgctggctcagccgg


gaggcccagagtgttctgcagaggctgcgtattgaaggctgctctctgaa


gctccctgccccaggtcacgccgccggttccagatg


 


Homo sapiens histone cluster 2, H2be (HIST2H2BE):


(Seq ID No: 274)



acttcttttcttggctaagccgcgtttgtactgtgtcttaccatg



 


Homo sapiens solute carrier family 25 (mitochondrial


carrier; oxoglutarate carrier), member 11 (SLC25A11):


(Seq ID No: 275)



ccgcctttgcgctgcgcgcctgcgcccgcgccggcttccagcgggtgtcggacctga



gagctggaggggcgtgcgcgcgccctcgctctgttgcgcgcgcggtgtcacctt


gggcgcgagcggggccgcgcgcgcacgggacccggagccgagggccattgagtggcgatg


 


Homo sapiens tyrosylprotein sulfotransferase 2 (TPST2):


(Seq ID No: 276)



cctcccccttccccggctggggcggctggagagccgggagtcgctgggtgcgtggggctg



cctcgccgcgtctcgccacgggctctgccagcagacagccttggcacacaggcacaaggg


ctggagcccagagatgagagtgcccaagggagatgtgagcctggcgggctgcccgctaac


ctgtcgctgaagccccagaagcgggccctcaggccaggcctaccctgcctccggcccag


catg


 


Homo sapiens sorbin and SH3 domain containing 2 (SORBS2):


(Seq ID No: 277)



aagcctcttttatacatctcttcagggaagagagaagcaatgggcatgttagtata



caatgatcacagccacgcaggcctgcaagctgccttttggacaggctgtt


gactgccgttccaattagctgattggagaatgtggaatgcagagtgataatgctgcata


tctgctatcaggcagcagcaaaggtttttgtcttgggaaggcaagctttccctgcaa


tattatctcagcagctccctagctgcttaccctgaaaacgagggatccaaac


ggagggtgttgcactctgctaacgctggtcctgtgcgtggctgtggcatatgagcgg


caggtctgaaaaagcaggtgtgtgctgggacgggcactggactggaacgcaggcggac


gctctcgggtttacctgcttcctgttaacagattgtgggctcccagggcatatgtctg


cacgctgaggccgaggcggagaaggggcttcctgagcgtcccagtacactgacagaga


cacttggattggacttaatcttaaacctctggagttcaagac


cttttaaaaagggctaaataaacaatctctacatgtaaaaggccactgactcc


tacttcctctgtatagagcaactgttgaactcagctgcctgtaggaaaactgaa


gactttaataacaaactctccaaggtgaaaatg


 


Homo sapiens G protein-coupled receptor 65 (GPR65):


(Seq ID No: 278)



gtttctcttcttgacttgatgcaggcacagatttatcaagctcctcag



tcaacaaacacatcaccggaagaaatatggaaggaaaggaattttaaaaggaaatac


caatctctgtgcaaacaaagccttgtatattcatgtttgcaccaatctactgtgagat


ttatgaagaaaaacaaattgcggacaactctctatgtacacttacaaatgcctcagtt


gatgcttgtgggctgtttgtcagcgttctgtga


taatgaacacatggacttctgtttattaaattcagttgacccctttagccaattgccag


gagcctggatttttacttccaactgctgatatctgtgtaaaaatt


gatctacatccaccctttaaaagcattgatgaattaattagaactttagacaacaaa


gaaaaattgaaaaagaattctcagtaaaagcgaattcgatgttcaaaacaaactacaaa


gagacaagacttctctgtttactttctaagaactaatataattgctac


cttaaaaaggaaaaaatg


 


Homo sapiens nipsnap homolog 1 (C. elegans) (NIPSNAP1):


(Seq ID No: 279)



gggccttcctgcaacctttgcggctccaacatg



 


Homo sapiens inhibitor of kappa light polypeptide gene


enhancer in B-cells, kinase complex-associated protein (IKBKAP):


(Seq ID No: 280)



gcttctttgcagcgcttcagcgttttcccctggagggcgcctccatcctt



ggaggcctagtgccgtcggagagagagcgggagccgcggacagagacgcgtgcg


caattcggagccgactctgggtgcggactgtgggagctgactctggg


tagccggctgcgcgtggctggggaggcgaggccggacgcacctctgttt


gggggtcctcagagattaatgattcatcaagggatagttgtacttgtctcgtgg


gaatcacttcatcatg


 


Homo sapiens COP9 constitutive photomorphogenic homolog subunit


3 (Arabidopsis) (COPS3):


(Seq ID No: 281)



ctgccttcgccgctcgggccgcccgggggaaaacatg



 


Homo sapiens pirin (iron-binding nuclear protein) (PIR):


(Seq ID No: 282)



ccgcctcctctaggccgccggccgcgaagcgctgagtcacggtgaggctactg



gacccacactctcttaacctgccctccctgcac


tcgctcccggcggctcttcgcgtcacccccgccgctaaggctccaggtgccgctaccg


cagcgtgagtacctggggctcctgcaggggtccactagccctccatcctc


tacagctcagcatcagaacactctctttttagactccgatatg


 


Homo sapiens THO complex 5 (THOC5):


(Seq ID No: 283)



ccttccttacttccggttctc



tatggtgcgcgggcaagctttgctccgcctccggcag


tggcttactcccggtgccaggttcttggagctgtgaggaggaacaaccatg


 


Homo sapiens RuvB-like 1 (E. coli) (RUVBL1):


(Seq ID No: 284)



gggccttt



gcaaaattgccctagtaacggccgcatggtaactcaggcgccgggcgcac


tgtcctagctgctggttttccacgctggttttagctcccggcgtctgcaaaatg


 


Homo sapiens Kruppel-like factor 7 (ubiquitous) (KLF7):


(Seq ID No: 285)



tttcctttttagttgactgaaacaaaacaaaacaaaagggccactg



gatgtctgccttcttggggggtgagccaga


cagactgacaaacaaacagccccaactgtgttcgggggagggtttcgcctcccgtttt


gcccggcagcagcagcatg


 


Homo sapiens USO1 vesicle docking protein homolog (yeast)


(USO1):


(Seq ID No: 286)



gctccccttttgccttcaaccttcgagccgccacgtaatgccac



gtccccgcgcatgcgcatcttggccgctgctggcggctgtttccgggcttagagggctg


gagtggccgccgagttggaggcggtggtggcagcagtaggagtgtgtagagtgcgg


gattgggggccaggccctgcggagggcgggggaagttgtcttcttttttttccg


gaggggccggtaaacctggtggctgaacggcaagatg


 


Homo sapiens unc-5 homolog C (C. elegans) (UNC5C):


(Seq ID No: 287)



cccccttttggcccctgcctttggagaaagtggagtgtggcgcttggtt



gtcgttatttcttcggactgcttcgcggtgcacggattcagcttctgcccag


tggggctttcagctgtttgcgcgtctctctgtccccctcccctccccccggcacac


ctctgtctacgatg


 


Homo sapiens RNA terminal phosphate cyclase domain 1


(RTCD1):


(Seq ID No: 288)



gcttcttccgctttctcgtcaggctcctgcgccccaggcatgaac



caaggtttctgaactactgggcgggagccaacgtctcttctttctcccgctctggcg


gaggctttgtcgctgcgggctgggccccagggtgtcccccatg


 


Homo sapiens eukaryotic translation initiation factor 3, subunit


A (EIF3A):


(Seq ID No: 289)



ggctccttcctttccgtctctggccggctgggcgcgggcgactgctggcgaggcgcgtgg



gaccttacgctggttccccttcgtctcctctcccggcccgggccactagagagttcgctg


acgccgggtgagctgagcctgccgccaagatg


 


Homo sapiens eukaryotic translation initiation factor 3, subunit


D (EIF3D):


(Seq ID No: 290)



gtttcctcttttcctggtttctcaagagtgctgctgctaac



gcggtccccggcacgcaccatctgttgccatcccggccggccgaggccattgcagat


tttggaagatg


 


Homo sapiens eukaryotic translation initiation factor 3, subunit


F (EIF3F):


(Seq ID No: 291)



ccgcctccttctttctcgacaagatg



 


Homo sapiens eukaryotic translation initiation factor 3, subunit


G (EIF3G):


(Seq ID No: 292)



cgctctctggccgggcttgggctgcgtggagaatactttttg



cgatg


 


Homo sapiens eukaryotic translation initiation factor 3, subunit


H (EIF3H):


(Seq ID No: 293)



gtttctctttcttcctgtctgcttggaaagatg



 


Homo sapiens eukaryotic translation initiation factor 3, subunit


I (EIF3I):


(Seq ID No: 294)



aaaccttttccggtcttactcacgttgcggccttcctcgcgtca



cagccgggatg


 


Homo sapiens eukaryotic translation initiation factor 3, subunit


J (EIF3J):


(Seq ID No: 295)



ctccctctcacacacgctcacacccggctcgagatg



 


Homo sapiens poly(A) binding protein, cytoplasmic 4 (inducible


form) (PABPC4):


(Seq ID No: 296)



ccgcctctctccgccccgggtcgctgccgcctccgccgctttcgggcttcgcagcctgag



gaaaaaaagagaaaaagataaaaaaaatctgaaaacgcttcaaaatcctgaaaaaaaaaa


aggaaaagaaaaaacgaatcctcggagaacccgcggggaagtcactttcgtacgcttccg


gcctgccccgcgcccgccgccgcagcgcttggcgtccgtcggtctccgtccgtcggtccg


ggggtgagccgcccgcccggcccgccgtgccctccccccgctcgggccccgagccccgcg


ccccgcgcctgccccggcgcaccacgtgtccgtgctgcccttcgccgcccgcccggggct


cgccgagtcggcgcccacaaagatttggtttccctctgccccggcggttgtaatcttaaa


ccgccggagcccgaggcctatatttatagagaaacgcgtgtccccgaggccgccgtgggc


agcgtccggtcgcctcttaaaggatttttacccttcggaaggggattccccgtttaattt


ttttcctactttgattttttgaaatttggagcttcgcaccaggaccgcggagaagtgcaa


agtcgcggggagggccgtattgtgcggagagccttttgtctgcggtgctgcggccgtggg


agccggcccccgcctcccgtttccgtcccgtctccaagcccgccgactccagctcgtcct


cgccgcgccggtgccacctgtgagccgcggcgcgggcccgggctccgaaggcgccccttt


gtcctgcggcgggcccgataagaagtcctcctggcggggctcggggtggtggggggcggg


gagatg


 


Homo sapiens receptor-interacting serine-threonine kinase 2


(RIPK2):


(Seq ID No: 297)



agctctttcgcggcgctacggcgttggcaccagtctctagaaaa



gaagtcagctctggttcggagaagcagcggctggcgtgggccatccggg


gaatgggcgccctcgtgacctagtgttgcggggcaaaaagggtctt


gccggcctcgctcgtgcaggggcgtatctgggcgcctgagcgcggcgtgggagccttgg


gagccgccgcagcagggggcacacccggaaccggcctgagcgcccgggaccatg


 


Homo sapiens neuropilin 1 (NRP1):


(Seq ID No: 298)



ctttcttttctccaagac



gggctgaggattgtacagctctaggcggagttggggctcttcggatcgcttagat


tctcctctttgctgcatttccccccacgtcctcgttctcccgcgtctgcctgcg


gacccggagaagggagaatg


 


Homo sapiens guanine monphosphate synthetase (GMPS):


(Seq ID No: 299)



tggtcttctctcccgcggcgctggggcccgcgctccgctgctgtt



gctccattcggcgcttttctggcggctggctcctctccgctgccggctgctcctcgac


caggcctccttctcaacctcagcccgcggcgccgacccttccgg


caccctcccgccccgtctcgtactgtcgccgtcaccgccgcggctccggccctggccc


cgatg


 


Homo sapiens far upstream element (FUSE) binding protein 1


(FUBP1):


(Seq ID No: 300)



ttttctttctttcttagctgttagctgagaggaagtctctgaacaggcgg



cagcggctcttatagtgcaaccatg


 


Homo sapiens eukaryotic translation initiation factor 2B, subunit


5 epsilon, 82 kDa (EIF2B5):


(Seq ID No: 301)



gatccttttt



gtcccctactgcgtgcggtggcagcttccttgcggaagtggtgaccgtgagagaagaa


gatg


 


Homo sapiens eukaryotic translation initiation factor 2, subunit


2 beta, 38 kDa (EIF2S2):


(Seq ID No: 302)



gtttcctttcgctgatgcaagagcctag



tgcggtggtgggagaggtatcggcagggg


cagcgctgccgccggggcctggggctgacccgtctgacttcccgtccgtgccgagcccac


tcgagccgcagccatg


 


Homo sapiens adaptor-related protein complex 1, sigma 2 subunit


(AP1S2):


(Seq ID No: 303)



cctcccctctccgcctaa



gcctgccctatgccagccgggtgtcctccccacagcaccacggcttctcttcctcag


cacggcgacaggggcttccccttcgccgccgccgccgccgccggccaa


gctccgccgcgcccgcggcccgcggccgccatg


 


Homo sapiens suppression of tumorigenicity 13 (colon


carcinoma) (Hsp70 interacting protein) (ST13):


(Seq ID No: 304)



cgcccccttctgcgcggtcacgccgagccagcgcctgggcctggaaccgggccgtagccc



ccccagtttcgcccaccacctccctaccatg


 


Homo sapiens solute carrier family 7 (cationic


amino acid transporter, y+ system), member 7 (SLC7A7):


(Seq ID No: 305)



ctccctttcttaaatgcttggggtgagagagaagagaggctagggtggggcatggag



gacacagagagagagagtgctgtgtattccttccccgc


tactgtcctgtcctcagctaacttgctctgggacagcttccccagggctacagatactg


cactcagctgactgtcctttcttctgggcccctggtcccagagcagagctgacaaagga


gattcctgagagagcaccttcttatcacagaaagtgctgagccaa


gagctcctagctgccccttttgcagatgtgaagggccagtgaacctt


ggacccagatggttgcttaatactcctttccccctccctcactccttccttt


gcgggctgcctcacctcctccacccttcttgcttaaatccataggcattt


gtctggccttcccttttactgctggctgggaaggaggagcatcagaccacagatcctg


gaaggcacttctctccctgactgctgctcacactgccgtgagaacctgcttatatccag


gaccaaggaggcaatgccaggaagctggtgaagggtttcctctcctccaccatg


 


Homo sapiens paired box 2 (PAX2):


(Seq ID No: 306)



ctcccttttctcctcaagtcctgaagttgagtttgagaggcgacac



ggcggcggcggccgcgctgctcccgctcctctgcctccccatg


 


Homo sapiens 5-aminoimidazole-4-carboxamide ribonucleotide for


myltransferase/IMP cyclohydrolase (ATIC):


(Seq ID No: 307)



agccctcctacctgcg



cacgtggtgccgccgctgctgcctcccgctcgccctgaacccagtgcctgcagccatg


 


Homo sapiens ATP synthase, H+ transporting, mitochondrial


F1 complex, alpha subunit 1, cardiac muscle (ATP5A1):


(Seq ID No: 308)



ccttcttt



gcggctcggccattttgtcccagtcagtccggaggctgcggctgcagaagtac


cgcctgcggagtaactgcaaagatg


 


Homo sapiens cyclin G1 (CCNG1):


(Seq ID No: 309)



cggccccttcggctccgagctgaccctgatcagggccgagtt



gtctcggcggcgctgccgaggcctccacccaggacag


tccccctccccgggcctctctcctcttgcctacgagtcccctctcctcg


taggcctctcggatctgatatcgtggggtgaggtgagcaggcccggggagggtggttac


cgctgaggagctgcagtctctgtcaagatg


 


Homo sapiens cadherin 16, KSP-cadherin (CDH16):


(Seq ID No: 310)



agctctcttcttgcttggcagctggaccaagggagccagtcttgggcgctg



gagggcctgtcctgaccatg


 


Homo sapiens cyclin-dependent kinase inhibitor 1B


(p27, Kip1) (CDKN1B):


(Seq ID No: 311)



ttttcttcttcgtcagcctcccttccaccgccatattgggccactaaaaaaagggggctc



gtcttttcggggtgtttttctccccctcccctgtccccgcttgctcacggctctgcgact


ccgacgccggcaaggtttggagagcggctgggttcgcgggacccgcgggcttgcacccgc


ccagactcggacgggctttgccaccctctccgcttgcctggtcccctctcctctccgccc


tcccgctcgccagtccatttgatcagcggagactcggcggccgggccggggcttccccgc


agcccctgcgcgctcctagagctcgggccgtggctcgtcggggtctgtgtcttttggctc


cgagggcagtcgctgggcttccgagaggggttcgggctgcgtaggggcgctttgttttgt


tcggttttgtttttttgagagtgcgagagaggcggtcgtgcagacccgggagaaagatg


 


Homo sapiens chimerin (chimaerin) 2 (CHN2):


(Seq ID No: 312)



tctcctcttcttcctttgtgtgtgcgcgagcggagttggggcggagggagaagggg



gaggtcgctctgtctgtccgtctcccgccgcctctgcccggtc


tactcgaagtgcggcgggagaggcgggagcccaggagagggtgcgg


gagctggcggggcggctcggagctgccaggacgccctggtcccagccgcgcacaggg


gagcgtggacggcagaggggctcggcgggagccga


gatccgcccgtcccggctgcccctcggcctccctctgctcccac


ctaccccctgacacccatagaaaagcgtgcaaaggcgcggagcgggacggaaac


cacaaataaatagcggcggcggcagcgcgtcatctggtggagcaggaagtg


caggcagagtccggaggctggtgctttctgcgcgtccccaggacttt


gccatgggctgggggccgcggaggctgcgagcggccgggcgaggg


cagcggcggcggcgtccgcaccggggctgagcgagcagcgacgcgaggggcgcgcgga


gatg


 


Homo sapiens citrate synthase (CS):


(Seq ID No: 313)



gggcctccttgag



gaccccgggctgggcgccgccgccggttcgtc


tactctttccttcagccgcctcctttcaacctt


gtcaacccgtcggcgcggcctctggtgcagcggcggcggctcctgttcctgccg


cagctctctccctttcttacctccccaccagatcccgga


gatcgcccgccatggctttacttactgcggccgcccggctcttgggaac


caaggcacccagtggcaagtactagctgagcatttgggagatgcttgtcttactt


ggctgttgcttctcctgctgctggggaaaaggaatgcatcttgtcttgttctt


gcagcccggcatgccagtgcttcctccacgaatttgaaagacatattggctgacctga


tacctaaggagcaggccagaattaagactttcaggcagcaacatggcaagac


ggtggtgggccaaatcactgtggacatg


 


Homo sapiens cathepsin S (CTSS):


(Seq ID No: 314)



atttcttttcaagtcaatt



gaactgaaatctccttgttgctttgaaatcttagaagagagcccac


taattcaaggactcttactgtgggagcaactgctggttctatcacaatg


 


Homo sapiens deoxynucleotidyltransferase, terminal (DNTT):


(Seq ID No: 315)



cagtctccctcccttctggagacaccaccagatgggccagccagaggcagcag



cagcctcttcccatg


 


Homo sapiens dual specificity phosphatase 3 (DUSP3):


(Seq ID No: 316)



cgctctccgcctcgcttgctcctgccgggcgtgcagggccccgccgccgccatg



 


Homo sapiens coagulation factor II (thrombin)


receptor-like 2 (F2RL2):


(Seq ID No: 317)



catcctttccctgcggaggaccagggcaagtttcctgcctgcacggcacaggagagcaaa



cttctacagacagaccaaggcttccatttgctgctgacacatggaactgaggtgaaattg


tgctccatgattttacagatttcataacgtttaagagacgggactcaggtcatcaaaatg


 


Homo sapiens Fc fragment of IgG, receptor, transporter, alpha


(FCGRT):


(Seq ID No: 318)



cgtcctctcagcatg



 


Homo sapiens guanylate binding protein 2, interferon-inducible


(GBP2):


(Seq ID No: 319)



ttacctctttttcttgtctctcgtcaggtctctgacattgacagagcctg



gacgttggaggaagccccaggacgttggaggggtaaagtaaaagtccacagttac


cgtgagagaaaaaagagggagaaagcagtgcagccaaactcggaagaaaagagaggag


gaaaaggactcgactttcacattggaacaaccttctttccag


tgctaaaggatctctgatctggggaacaacaccctggacatg


 


Homo sapiens G protein pathway suppressor 1 (GPS1):


(Seq ID No: 320)



cgctctttctcccttcagcagccagccagctctgtgtcagggtcggggggtg



cagaaagtcaggacagaatg


 


Homo sapiens general transcription factor IIF, polypeptide 2,


30 kDa (GTF2F2):


(Seq ID No: 321)



gttcctcttttcctcggttcccagtgttctgg



caggtaaggaacgccggctcttcgcctctcagcgcggcttgtcctttgttccggac


gcccgctcctcagccctgcggctcctggggtcgctgctgcatcccgcacgcctccac


cggctgcagacccatg


 


Homo sapiens glycogenin 1 (GYG1):


(Seq ID No: 322)



cgctccctcccggtgccggcttctctgagtcaccaac



ctgaggctgccccggccgcctgcgcacccggcagcaccatg


 


Homo sapiens heat shock 70 kDa protein 9 (mortalin) (HSPA9):


(Seq ID No: 323)



agctctttgccgtcggagcgcttgtttgctgcctcgtactcctccatttatccgccatg



 


Homo sapiens iron-responsive element binding protein 2


(IREB2):


(Seq ID No: 324)



cttccttctttcctcccttgccag



tccgcctgtcttcctccccgtcttccctgcccggcctcccccttcttcccccgctggccc


cctccccggagggataatatggtctccggcgatg


 


Homo sapiens origin recognition complex, subunit 1 (ORC1):


(Seq ID No: 325)



ccaccttcttttcatttctagtgagacacacgctttggtcctggctttcggcccgtag



ttgtagaaggagccctgctggtgcaggttagaggtgccgcatcccccg


gagctctcgaagtggaggcggtaggaaacggagggcttgcggctagccggaggaa


gctttggagccggaagccatg


 


Homo sapiens RAB1A, member RAS oncogene family (RAB1A):


(Seq ID No: 326)



cattcctttctttcgattacccgtggcgcggagagtcagggcggcggctgcggcagcaag



ggcggcggtggcggcggcggcagctgcagtgacatg


 


Homo sapiens cytohesin 2 (CYTH2):


(Seq ID No: 327)



gagtcttttcagcgctgag



gactggcgctgaggaggcggcggtggctcccggggcgttt


gagcgggctcacccgagcccgcgggccaacgcggatccaggcccgactggcgggac


cgccccggattccccgcgggccttcctagccgccatg


 


Homo sapiens COP9 constitutive photomorphogenic homolog subunit


2 (Arabidopsis) (COPS2):


(Seq ID No: 328)



atttctcctccccctcccggccaagatg



 


Homo sapiens solute carrier family 9 (sodium/


hydrogen exchanger), member 3 regulator 1 (SLC9A3R1):


(Seq ID No: 329)



ggtcctctctcggctcctcgcggctcgcggcggccgacggttcctgggacacctgctt



gcttggcccgtccggcggctcagggcttctctgctgcgctcccggttcgctggacgg


gaagaagggctgggccgtcccgtcccgtccccatcg


gaaccccaagtcgcgccgctgacccgtcgcagggcgagatg


 


Homo sapiens peptidase (mitochondrial processing) beta


(PMPCB):


(Seq ID No: 330)



ctaccttccttctagcagaaatg



 


Homo sapiens RAB3D, member RAS oncogene family (RAB3D):


(Seq ID No: 331)



cggcccttcctccgccttctgggcggagcccgcgcgggatccgggtggctg



caggctgctggcttctgcggctgcggggtcggggtcgcggccagggccaagccg


cagcgagttcacaggcggaacccctgcaggcggcgccccctacgcgaggtcacccctgg


gaaggagcgcagcccacccggcccctccgcatccgagcaggac


gcccgtctcctctccctgaggatttcaggtctccctgtcccaggaggcttgtgccaa


gatg


 


Homo sapiens ATP-binding cassette, sub-family B (MDR/TAP):


(Seq ID No: 332)



tcttctctcggttcctctttcctcgctcaagatg



 


Homo sapiens N-acylsphingosine amidohydrolase (acid


ceramidase) 1 (ASAH1):


(Seq ID No: 333)



ggctcttctttgcctctgctggagtccggggag



tggcgttggctgctagagcgatg


 


Homo sapiens cytochrome c oxidase subunit VIc (COX6C):


(Seq ID No: 334)



ttttcctttagtcaggaaggacgttggtgttgaggttagcatacgtatcaaggacag



taactaccatg


 


Homo sapiens COX15 homolog, cytochrome c oxidase assembly protein


(yeast) (COX15):


(Seq ID No: 335)



gcttctcttttccttggcggaggagggagac



cacagagccctgggttgtggaagaggtggctgttccctgtcatcagtatg


 


Homo sapiens c-src tyrosine kinase (CSK):


(Seq ID No: 336)



cccccttcccccgcctttcttccctccgcgacccgggccgtgcgtccgtccccctgcctc



tgcctggcggtccctcctcccctctccttgcacccatacctctttgtaccg


caccccctggggacccctgcgcccctcccctcccccctgaccgcatggaccgtcccg


caggccgctgatgccgcccgcggcgaggtggcccggaccgcagtgccccaaga


gagctctaatggtaccaagtgacaggttggctttactgtgactcggggac


gccagagctcctgagaagatg


 


Homo sapiens versican (VCAN):


(Seq ID No: 337)



gagcctttctggggaa



gaactccaggcgtgcggacgcaacagccgagaacattaggtgttgtggacaggagctgg


gaccaagatcttcggccagccccgcatcctcccgcatcttccagcaccgtcccg


caccctccgcatccttccccgggccaccacgcttcctatgtgacccgcctgggcaac


gccgaacccagtcgcgcagcgctgcagtgaattttccccccaaactgcaataa


gccgccttccaaggccaagatg


 


Homo sapiens dystroglycan 1 (dystrophin-


associated glycoprotein 1) (DAG1):


(Seq ID No: 338)



gcgcctcttaggctt



ggcggtggcggcggcggcagcttcgcgccgaatccccggg


gagcggcggtggcggcgtcctggggccaggaggagcgaacac


ctgccgcggtcctcccgccggcgctgggctctgtgtgctccgggatggagcaggtgtg


cagagggtgagaacccagctctgggaccaagtcacttgcttccttacttagcaagac


tatcgacttgagcaaacttggacctgggatg


 


Homo sapiens DEAD (Asp-Glu-Ala-Asp) box helicase 5 (DDX5):


(Seq ID No: 339)



ccccctcttttggttacagacgtgagggctctttggagacgtaaacatctccgag



tggcgagggtgggcggggctgggcttgggaaagggcggggtggcttgcttgaggtgtg


gaaagaccagaagaaggtgaggtcaagagagtg


cagaatgaggcattccaatggtgggtgggccctgacctgagagagtggcgcggg


gaggggtgaaagcgcggcgatcctggaacgccagcgggcgttgcggcc


tatgcgcgaggggcggggcgattaggtcatagagcggctcccagcgttccctgcggcg


taggaggcggtccagactataaaagcggctgccggaaagcggccggcac


ctcattcatttctaccggtctctagtagtg


cagcttcggctggtgtcatcggtgtccttcctccgctgccgcccccg


caaggcttcgccgtcatcgaggccatttccagcgacttgtcgcacgcttttctata


tacttcgttccccgccaaccgcaaccattgacgccatg


 


Homo sapiens desmoplakin (DSP):


(Seq ID No: 340)



gctcctctgcgccctt



gccgccctccgagccacagctttcctcccgctcctgcccccggcccgtcgccgtctccgc


gctcgcagcggcctcgggagggcccaggtagcgagcagcgacctcgcgagccttccg


cactcccgcccggttccccggccgtccgcctatcctt


ggccccctccgctttctccgcgccggcccgcctcgcttatgcctcggcgctgagccgctc


tcccgattgcccgccgacatg


 


Homo sapiens glutamyl-prolyl-tRNA synthetase (EPRS):


(Seq ID No: 341)



cttcctttcgcggggtcctccgtagttctggcacgagccaggcgtactgacaggtggac



cagcggactggtggagatg


 


Homo sapiens acyl-CoA synthetase long-chain family member 4


(ACSL4):


(Seq ID No: 342)



gctcctcctcgtcccagcgctagcgggcacgcggttcctttttgcgagctttccgagtgc



caggcgccggccggctgcgaagacgcggtgggccgcccctccgattgaaatcacagaaga


tattcgtgttcttcttaagagaaaaagaggacattttagctttctcagttgaaggcgtac


tttattgtcggcttccaaagattactaacttttatctgtatcactaagattgaactgcct


tggctgtactgctattcttactgctgcttctattattgccttcttcagcacaataaggct


ttcaaaagccaaagaataacaagaaataagcaccattttagaagcctttccactatg


 


Homo sapiens fibroblast activation protein, alpha (FAP):


(Seq ID No: 343)



tggtccttttcaacggttttcacagatccagtgacccacgctctgaagacagaatt



agctaactttcaaaaacatctggaaaaatg


 


Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-


acetylgalactosaminyltransferase 3 (GalNAc-T3) (GALNT3):


(Seq ID No: 344)



ctgcctctccaggcaacgcgggaggcccagcgggaaggcaggaggcggcggcggaggag



gagctctactgagccgcaactgtggcgacagcaaccggagtcgcagccgccgccacctg


cacctggcgcctagcccac


gtccagcgcctgcccggccgccgcttcccgccaccctgccctgcccacccgccaggtact


accattaaagataccttcttctcagcaaatctatgataaaaaatataagtaacagaa


gaagaaataactgttatttgtcaagtgacaagcttttaatgtcagaatg


 


Homo sapiens glypican 3 (GPC3):


(Seq ID No: 345)



acgtctcttgctcctcagggccac



tgccaggcttgccgagtcctgggactgctctcgctccggctgccac


tctcccgcgctctcctagctccctgcgaagcaggatg


 


Homo sapiens interleukin enhancer binding factor 2, 45 kDa


(ILF2):


(Seq ID No: 346)



acgcctcttcagttgtctgctactcagaggaaggggcggtt



ggtgcggcctccattgttcgtgttttaaggcgccatg


 


Homo sapiens nucleosome assembly protein 1-like 1 (NAP1L1):


(Seq ID No: 347)



gggtcttttttagcgccatctgctcgcggcgccgcctcctgctcctcccgctgctgctgc



cgctgccgccctgagtcactgcctgcgcagctccggccgcctggctccccatactag


tcgccgatatttggagttcttacaacatg


 


Homo sapiens asparaginyl-tRNA synthetase (NARS):


(Seq ID No: 348)



cgctctctgatgcaacgccggaatcgcggaaaccgccggtgcacgttggagtcataa



gacggcgtcggtgttgcagtctgtgtccttggaggtgaccagggccactgcaggcatg


 


Homo sapiens NADH dehydrogenase (ubiquinone)


1 alpha subcomplex, 10, 42 kDa (NDUFA10):


(Seq ID No: 349)



cgtcccctt



gggtccttgatcctgagctgaccgggtagccatg


 


Homo sapiens NADH dehydrogenase (ubiquinone)


Fe—S protein 2, 49 kDa (NADH-coenzyme Q reductase)


(NDUFS2):


(Seq ID No: 350)



ttctccttcccgcagtctgcagccggagtaagatg



 


Homo sapiens NADH dehydrogenase (ubiquinone)


Fe—S protein 5, 15 kDa (NADH-coenzyme Q reductase)


(NDUFS5):


(Seq ID No: 351)



catcctttacggcaggcgtccgcgtcgctagctagtcgttctgaa



gcggcggccagagaagagtcaagggcacgagcatcgggtagccatg


 


Homo sapiens phosphoenolpyruvate carboxykinase 2 (mitochondrial)


(PCK2):


(Seq ID No: 352)



ccctcctttttaa



gcgcctcccgccagcctctgctgtggctcgcttcgccgcgctccctccttccccgccttc


catacctccccggctccgctcggttcctggccaccccgcagcccctgcccaggtgccatg


 


Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin),


member 6 (SERPINB6):


(Seq ID No: 353)



ctcccttcgcgctccggacgggcgacgg



tagctcgagacccgggactccgcccgcctccccgcgagtattt


gaggtccggggcggctccggcgcctctgcccgccgttctgctcgctcgctccccgctctg


gagtctgccatcatg


 


Homo sapiens Rab geranylgeranyltransferase, alpha subunit


(RABGGTA):


(Seq ID No: 354)



ttctctcctcagacttcaagggctaccactggacccttcccctgtctt



gaaccctgagccggcaccatg


 


Homo sapiens Rab geranylgeranyltransferase, beta subunit


(RABGGTB):


(Seq ID No: 355)



ctctctcctttccctgttagacatg



 


Homo sapiens small nuclear ribonucleoprotein polypeptide A


(SNRPA):


(Seq ID No: 356)



agttctctccgcacgcgggctggagaagcgggtcctacgcacgctttgtt



gtcgcgctttgcctccgtccttgcccctactcccgccttacctgacttccttttcggag


gaagatccttgagcagccgacgttgggacaaaggatttgga


gaaacccagggctaaagtcacgtttttcctcctttaagacttacctcaacacttcactc


catg


 


Homo sapiens sterol regulatory element binding transcription factor


2 (SREBF2):


(Seq ID No: 357)



cgccctttctgtgcggcgcccgggcgcaac



gcaaacatggcggcgggtggcacccgtcggtgaggcggtgccgggcgggggtt


gtcgggtgtcatgggcggtggcgacggcaccgcccccgcgtctccctgagcgggacgg


cagggggggcttctgcgctgagccgggcgatg


 


Homo sapiens translin (TSN):


(Seq ID No: 358)



ctgccctttggac



gcgcgcctcggttccgaacgcagcggacggcgcctcaggcagcgcggcg


gacagcccgtcctccggcgcgccgcgagcctcggaggaccctagcgacggtcgtggcg


taagaccggggggacgcggcggtagcggcggccgttgcgattgattgcgctggtt


gcctgcggcgtccacttccttggccgcccttgctacactggctgattgttgtg


cagccggcgccatg


 


Homo sapiens Fanconi anemia, complementation group G


(FANCG):


(Seq ID No: 359)



ccaccctttctcgaggctgtggcctccgcgagagccgagcgggccgcaccgccggccgtg



cgactgccccagtcagacacgaccccggcttctagcccgcctaagcctgtttggggttgc


tgactcgtttcctccccgagtttcccgcgggaactaactcttcaagaggaccaaccgcag


cccagagcttcgcagacccggccaaccagaggcgaggttgagagcccggcgggccgcggg


gagagagcgtcccatctgtcctggaaagcctgggcgggtggattgggaccccgagagaag


caggggagctcggcggggtgcagaagtgcccaggcccctccccgctggggttgggagctt


gggcaggccagcttcacccttcctaagtccgcttctggtctccgggcccagcctcggcca


ccatg


 


Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B


(DDX39B):


(Seq ID No: 360)



ttccctccttcgtcgctgtt



gctgccgccatacgcgctctccctgtttagctcttctgttagaaatagtatcttt


gttttcctttgctgttcctcaatcccctactcttcaccccttgttttcacctatttt


gcgagaacccatccagatcccccttcccttcttcccctgccggcccagttatg


 


Homo sapiens RAB11A, member RAS oncogene family (RAB11A):


(Seq ID No: 361)



ccgccctttcgctcctcggccgcgcaatg



 


Homo sapiens SPARC-like 1 (hevin) (SPARCL1):


(Seq ID No: 362)



agctctttcccttttggtttgcaagcactgcctgtaaagccctcgcatga



gaggccagcctgctagggaaatccaggaatctgcaacaaaaacgatgacagtctgaaa


tactctctggtgccaacctccaaattctcgtctgtcacttcagacccccactagtt


gacagagcagcagaatttcaactccagtagacttgaatatgcctctgggcaaagaa


gcagagctaacgaggaaagggatttaaagagtttttcttgggtgttt


gtcaaacttttattccctgtctgtgtgcagaggggattcaacttcaatttttctgcag


tggctctgggtccagccccttacttaaagatctggaaagcatg


 


Homo sapiens cyclin B2 (CCNB2):


(Seq ID No: 363)



ctcccttttcag



tccgcgtccctccctgggccgggctggcactcttgccttccccgtccctcatg


 


Homo sapiens cytochrome c oxidase subunit VIIa polypeptide 2 like


(COX7A2L):


(Seq ID No: 364)



ggtccttctctggggcggtcgcgttggcagcggatgcgggaagc



cggactctgggcgtcatg


 


Homo sapiens lysophosphatidic acid receptor 2 (LPAR2):


(Seq ID No: 365)



cgccctctcagcaacccgcacagggcgcacccggacgctctaccgctcccgccgcag



tcgccgggccatgggcctcgagcccgccccgaacccccgcgagcccgcctt


gtctgcggcgtgactggaggcccagatg


 


Homo sapiens adaptor-related protein complex 4, mu 1 subunit


(AP4M1):


(Seq ID No: 366)



cgttcttttgttccggggccgcagggcgggg



caggcccgactttcgccgtcttcttgtctactctccagaacggccatg


 


Homo sapiens budding uninhibited by benzimidazoles 3 homolog


(yeast) (BUB3):


(Seq ID No: 367)



cttcctctccgcctccttcgcctagcctgcgagtgttctgagggaagcaaggaggcggcg



gcggccgcagcgagtggcgagtagtggaaacgttgcttctgaggggagcccaagatg


 


Homo sapiens DEAD (Asp-Glu-Ala-Asp) box helicase 21 (DDX21):


(Seq ID No: 368)



ctacctcttcctctccacgcggttgagaagaccggtcggcctgggcaacctgcgctgaa



gatg


 


Homo sapiens solute carrier family 33 (acetyl-


CoA transporter), member 1 (SLC33A1):


(Seq ID No: 369)



tgctctctgccgcatt



gatagcagcgagagctggaggtgttgggtcgggagaccagccgttcgatcccgccg


caggtaggagctggtttccatcctggcaccacggcacacac


ctccagcctcgagcccggcgctgctgcccgggggtctccttcaggctctttgac


gccgttccagggggcacctatccaggcatcctctgggcctctagccagag


gactggctcccggcttcagcactccgggctgcagtaa


gaagtgcccttatcgctctgagccctgccaccatcccgtgaaccac


cgaaaccctggtccagcgcgacagccttggacctgggactggacggatccaaaac


gctcagcctcggccccccacagacggggctctgcatcgtctctgatatg


 


Homo sapiens G protein-coupled receptor 37 like 1 (GPR37L1):


(Seq ID No: 370)



tgctcttcctgggctggctgtctcctgctcatccagccatg



 


Homo sapiens neuronal regeneration related protein homolog


(rat) (NREP):


(Seq ID No: 371)



ctgtctttctagcatgttgccctttttcaaccacattt



gtgtttcaggtgtagagaggagagagagtgaacagggagcggggcttttgtctgtt


ggtctccctggactgaagagagggagaatagaagcccaagactaagattctcaaaatg


 


Homo sapiens vesicle-associated membrane protein 3 (cellubrevin)


(VAMP3):


(Seq ID No: 372)



gcttctctgctgaccctctctcgtcgccgctgccgccgccg



cagctgccaaaatg


 


Homo sapiens synaptosomal-associated protein, 29 kDa


(SNAP29):


(Seq ID No: 373)



cctccttctgtttcccagaccgagagccgcgccggcaccatg



 


Homo sapiens lon peptidase 1, mitochondrial (LONP1):


(Seq ID No: 374)



ccccctcttctccgcgtaggcccagctccctgaagcggctgtttcgagccac



gcgcccatcgggtaccgaggcacgcgccgggcgtcacgtgcgtttcgcggcgagcg


gaaatgacgcgagttgtgtgagccgccagtatggccgggctatg


 


Homo sapiens kinesin family member 3B (KIF3B):


(Seq ID No: 375)



ctgtctctccccatccggggcagcggg



gaatggctgagccaggggttcgccgcccccgccgccgccgccgccgccgccgccgccgcc


gccgcccgctttcggctcgggcctcaggaccgtagcatcctgagacattttgaatt


gacacttctcaagatttgactggatcagagttcatcatg


 


Homo sapiens transmembrane 9 superfamily member 2 (TM9SF2):


(Seq ID No: 376)



cttcctttatctctggcggccttgtagtcgtctccgagactccccacccctccttccctc



ttgaccccctaggtttgattgccctttccccgaaacaactatcatg


 


Homo sapiens cytosolic iron-sulfur protein assembly 1


(CIAO1):


(Seq ID No: 377)



gagcctctgtcggccgcggaagcctggagtgggcggtacgcagac



gcgcgcggtgagacccgctgtctgctcagcggactctgcccgcccccac


ctccccctgcgtcgggccgacatg


 


Homo sapiens GRB2-related adaptor protein 2 (GRAP2):


(Seq ID No: 378)



caccctctttcagagtggtacatggaagacagcacaaagtg



gatccatactctgaaatgcagtaactctgatgcttgaatttgtctcccttctt


gccagaaaggattctaataactcggtgtcaaagccaaga


cataaactcaaccccttctcttccaaaagcttcacgttacagcatg


 


Homo sapiens leupaxin (LPXN):


(Seq ID No: 379)



gtacctttctcggggtgtctgcg



taactgcccagacttgccttggtttggtcagatgacacctcctctgg


gactggctagccagcgttcatg


 


Homo sapiens SH3-domain binding protein 5 (BTK-associated)


(SH3BP5):


(Seq ID No: 380)



tttcctctgctccgccgcggccggaggtatccg



catcggcgagctgcgtctcccgggtgtcggccccggcggctccccgac


cgtgcccggctgtggcgaggcggctccagcccagcctgtgg


cagccgcgacccccggggcgctccggagcccactgcgcggcgcgcgtgccggctgcctg


catg


 


Homo sapiens phosphatidylinositol glycan anchor biosynthesis,


class B (PIGB):


(Seq ID No: 381)



ctttcttccgccttaggaaggtggcggccagggatg



 


Homo sapiens lipopolysaccharide-induced TNF factor (LITAF):


(Seq ID No: 382)



cggcccttttctcggggcgcccgagaggccagctcagacctcccggctcgacaggcggcg



cgggcggcggtgagtgcggcgcggggacgccggggcgcggggaccagcgggagacagcgg


ggggccggtggcgccagcacctgctgggggccccgggcactgagcccttggctggggcct


cctgggatgccagggggcgcgggtcgggtcgcgggcatcgaggcgcggcggagggcgtgg


gggcccggccggggcggggtccggcctcccagcgctggtcccggccgcgtctccggttgg


gttcagctcctgcgtcccagagtggcccgatcgcgcgtggcggggtcgtccggcccccac


ccgaacgagcgcccttcgcggcccgccgcgtccccctccccggagaggacggcccctggg


ctttttagaaaaaggcgcgattctctctagtgactcaggttgagatttccagaaatatcc


cccgggggttcagaaacaaaaccaaaacaaacaaaaaaaccccaacgaattcccaaatgc


tatttgccaaacatttgacttctaggggcgcgggtacccgcgtttctctccctgcccccg


cgacttcgcgcaagatccgggaaggacacccgaggcccctgggagaccctggggaggtga


aaatcagagagcgaagcgggccgtggcccctaggcctgacccctccccgcggggtaaggc


gggcaccccgcgagcgcaggggtcctcttactgctgatggcacccagctctgggcccaga


cgccgctcaccgtccaccgccggtgctgggtaaaatg


 


Homo sapiens etoposide induced 2.4 mRNA (EI24):


(Seq ID No: 383)



ccaccccttcggctctgggccccgcctcgtggtgccggctggttcttcgcgctcgcccga



cttcccagcggccccgtgcggcccgggcatgcccagtgcgggcg


cagcggccccggccctggaagcgccccggcggagctggcctgcggtgggctagggg


cagggccggagccgcggcggcggagctgtggatccttcatgatgagagatttggg


gacacttctctctcctgtgtgtagttgatagtttggtggtgaagagatg


 


Homo sapiens chromosome 14 open reading frame 2 (C14orf2):


(Seq ID No: 384)



tgacctttccgagttggctgcagattt



gtggtgcgttctgagccgtctgtcctgcgccaagatg


 


Homo sapiens peroxiredoxin 6 (PRDX6):


(Seq ID No: 385)



attcctccgcgcgctgg



gacaggctgcttcttcgccagaaccaaccggttgctt


gctgtcccagcggcgccccctcatcaccgtcgccatg


 


Homo sapiens solute carrier family 29 (nucleoside


transporters), member 1 (SLC29A1):


(Seq ID No: 386)



ctctcttccgcccggcggcccacac



cggtcaggcccggcgcgggctgcgctctccagctgtggctatggccccagccccga


gatgaggagggagagaactaggggcccgcaggcctgggaatttccgtcccccac


caagtccggatgctcactccaaagtctcag


caggcccctgagggagggagctgtcagccagggaaaaccgagaacaccatcaccatg


 


Homo sapiens heterogeneous nuclear ribonucleoprotein F


(HNRNPF):


(Seq ID No: 387)



cgaccttcctgccgggccgggcggtccgaggctgctggagtgccgtgag



caggccgcgggaacgtcgccgtcacctt


gtctcggggcctcggcgctgcttcccgccaaaacacgtttac


cgcgcgcccgggcctcccaccttgcggaagggaccccaccaccacttggatttctgtt


gcaggttgagaacaaaaacatgcacctggagtttccccggagccctctgcgtggtt


gagcttcggtggaatttcggggctcttggctgccagccgcgcttgcctggtag


caacagaaaccagtcctgctcgcctccgtggacatttcattac


catccagaagtgtctcccactgaaggcatccgtggttgtttttaagccacaaaaaa


gccacacccaagatcacctgacacccaccctgacaagtgtccatg


 


Homo sapiens islet cell autoantigen 1, 69 kDa (ICA1):


(Seq ID No: 388)



ccgcccctttccctcgccttcggctgacgctgacgtcggatgagtgatccggagggac



gctccgaccgcggccgggaggctcctgggggccggggctccgaggttataa


tataacttatcctctcatgcttttttcctgccccttctccccaaatcatcaacaa


tagaagaagaagaaaacatg


 


Homo sapiens PWP2 periodic tryptophan protein homolog


(yeast) (PWP2):


(Seq ID No: 389)



gtgtctctgtgggcggccgccgggttgagctgcggcacacgtg



cgacggccgtgatg


 


Homo sapiens glutaminyl-tRNA synthetase (QARS):


(Seq ID No: 390)



gtttcttttag



tttccggtgtctctgcaatg


 


Homo sapiens stearoyl-CoA desaturase (delta-9-desaturase)


(SCD):


(Seq ID No: 391)



cggcctctgtctcctccccctcccgcccttacctccacgcgggac



cgcccgcgccagtcaactcctcgcactttgcccctgcttggcagcgga


taaaagggggctgaggaaataccggacacggtcacccgtt


gccagctctagcctttaaattcccggctcggggacctccacgcac


cgcggctagcgccgacaaccagctagcgtgcaaggcgccgcggctcagcgcgtac


cggcgggcttcgaaaccgcagtcctccggcgaccccgaactccgctccg


gagcctcagccccctggaaagtgatcccggcatccgagagccaagatg


 


Homo sapiens fragile X mental retardation, autosomal homolog 1


(FXR1):


(Seq ID No: 392)



cggcctttgcggttccaacatg



 


Homo sapiens musculin (MSC):


(Seq ID No: 393)



tagccttttcaaaaggcgcagcttac



cgcggtgcgcgcggattctggacttgggcgccaactcgtagtccac


gctccccggggtcagcagaggggcgctcacgctctcgccacccac


ctcgctttctcaccccgcgcttcccggcctgggtttttagtcttcctt


ggagcgctctctggcctccgcctccgccagggagcggaaggcggagacagcga


gactggccaggggggaggaaagaggacgcgtgtgggcaagggggacaacgggatg


 


Homo sapiens RNA binding motif protein 8A (RBM8A):


(Seq ID No: 394)



cgacctttcccctctgcgacagtttcccgaggtacctagtgtctgagcggca



cagacgagatctcgatcgaaggcgagatg


 


Homo sapiens heparan sulfate (glucosamine)


3-O-sulfotransferase 1 (HS3ST1):


(Seq ID No: 395)



ggtcctctgcgccctgg



cagccaggagtcgccgccacgaccgccgggtctcag


tgggtgcctgcgccttctccccgcccgcctgccccgggccatccagaaacttgctc


tacccgccgcgggtgctcggcagtgctgcccatggcccagcccaggagcc


tatttagggcgccggacgggctggacagaggcgcggctcagtaattgaaggcctgaaac


gcccatgtgccactgactaggaggcttccctgctgcggcac


ttcatgacccagcggcgcgcggcccagtgaagccaccgtggtgtccagcatg


 


Homo sapiens solute carrier family 12 (potassium/


chloride transporters), member 6 (SLC12A6):


(Seq ID No: 396)



ctgtctctt



gtaggcagggatcacagtctgaaacgacagcaaggaa


gaggtaggcagggaaaactaactggaaggaagtttaaatacagaaagag


caaagtattatctaactataacaatg


 


Homo sapiens apelin receptor (APLNR):


(Seq ID No: 397)



cttcctccagggtctgga



gaacccagaggcagctcctcctgagtgctgggaaggactctggg


catcttcagcccttcttactctctgaggctcaagccagaaattcaggctgcttgcagag


tgggtgacagagccacggagctggtgtccctgggaccctctgcccgtcttctctccac


tccccagcatg


 


Homo sapiens calpain 1, (mu/I) large subunit (CAPN1):


(Seq ID No: 398)



cgctcttcctggttgggccctgccctgagctgccaccgggaagccagcctcagggactgc



agcgacccccaaacacccctcccccaggatg


 


Homo sapiens cyclin C (CCNC):


(Seq ID No: 399)



cttcctttcgccgtcgccgccgcggagcg



gagtcgagccgagctgatttgatcgaggagcgcggttaccggacgggctgggtc


tatggtcgctccgcgggccgctccgccggctggtgcttttttatcagggcaa


gctgtgttccatg


 


Homo sapiens glutamate dehydrogenase 1 (GLUD1):


(Seq ID No: 400)



cttcctccctagtcgcggggagtctgagaaagcgcgcctgtttcgcgaccatcacgcac



ctcccctccgcttgtggccatg


 


Homo sapiens guanine nucleotide binding protein-like 1


(GNL1):


(Seq ID No: 401)



cctccttcctcgccgccggggcgccctctcggtgccactggctctcac



gtgccagtagcccaccccgcatcatcctctcgcctcgctcctggagggaagtgacta


tatctcccccgtccgccttccatcgccgccgcggcgg


taattctgtcgggcccgcccgctgacgtcac


ctgctagccccgcctcctctagggtcccgggcccctgcggcgggggctgccccgggggg


cagtcagttgaggcggcgggagctcggcggagggcgggccaggtgactggtccgggc


catg


 


Homo sapiens lysophosphatidic acid receptor 4 (LPAR4):


(Seq ID No: 402)



aggcctttttgtgtcctgtttgctaaaggcatgcgggctacagcattcaagagagggag



tcgttaacaaagggaaagagataaatgtaaataa


gctcacatttacagaatgagcggtttgcagtaaaaagctgcggcagcccagagtctgc


tactttaggctgggctaacctttccctg


taaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatggataaaaatatgcac


ttccaaagggcgagttgcccatttacatgtttattagctaattatctacaggcatcag


cacattctctcatctagcacactctttcttggggaggaaaatatttcctaccggtcca


tagtgtcagagtggtgaacccctgcagccagcaggcctcctgaaaaaaaagtccatg


 


Homo sapiens G protein-coupled receptor kinase 5 (GRK5):


(Seq ID No: 403)



gctcctctttgcagagggggaaactcttgggctgagagcaggaataatgcgg



taggcaaggcgggctgctggctcccccggctccggcagcagcggcggcagcccgag


cagcggcagcagcagcggcagcaccccaggcgctgacagccccgccggccggctccgtt


gctgaccgccgactgtcaatg


 


Homo sapiens glutamic-pyruvate transaminase (alanine


aminotransferase) (GPT):


(Seq ID No: 404)



agccctttctgtccctcccag



tgaggccagctgcggtgaagagggtgctctcttgcctggagttccctctgctac


ggctgccccctcccagccctggcccactaagccagacccagctgtcgccattcccac


ttctggtcctgccacctcctgagctgccttcccgcctggtctgggtagagtcatg


 


Homo sapiens hydroxyacyl-CoA dehydrogenase (HADH):


(Seq ID No: 405)



gggtctcctcgctgtcgccgccgctgccacaccatg



 


Homo sapiens high density lipoprotein binding protein


(HDLBP):


(Seq ID No: 406)



tcttctcctttaccaagatggcggcttgtccctgtttcgccacagttcctaccttatgag



ctcggttttcttatgcttataagagtggaacagcaaaagctgg


caggctgacagaggcggcctcaggacggaccttctggctactgaccgtttt


gctgtggttttcccggattgtgtgtaggtgtgagatcaaccatg


 


Homo sapiens histidine triad nucleotide binding protein 1


(HINT1):


(Seq ID No: 407)



gttcctcccttcttccgagcctctcctctggccgccgcgcgggagagagg



ccgagatg


 


Homo sapiens heat shock 70 kDa protein 1A (HSPA1A):


(Seq ID No: 408)



ctacctttttcgagagtgactcccgttgtcccaaggcttcccagagcgaacctgtg



cggctgcaggcaccggcgcgtcgagtttccggcgtccggaaggaccgagctcttctcgcg


gatccagtgttccgtttccagcccccaatctcagagcggagccgacagagag


cagggaaccggcatg


 


Homo sapiens nucleolin (NCL):


(Seq ID No: 409)



cagtctttcgcctcag



tctcgagctctcgctggccttcgggtgtacgtgctccgggatcttcag


cacccgcggccgccatcgccgtcgcttggcttcttctggactcatctgcgccactt


gtccgcttcacactccgccgccatcatg


 


Homo sapiens nuclear factor, interleukin 3 regulated


(NFIL3):


(Seq ID No: 410)



ccgcccctttctttctcctcgccggcccgagagcaggaacacgataac



gaaggaggcccaacttcattcaataaggagcctgacggatttatcccagacgg


tagaacaaaaggaagaatattgatggattttaaaccagagtttttaaagagcttgagaa


tacggggaaattaatttgttctcctacacacatagatagggtaaggttgtttctgatg


 


Homo sapiens protein phosphatase 1, regulatory subunit 3C


(PPP1R3C):


(Seq ID No: 411)



cagtctctcccagcgaccgccgcgggggcaaggcctg



gagctgtggttcgaatttgtg


caggcagcgggtgctggcttttagggtccgccgcctctctgcctaatg


 


Homo sapiens protein tyrosine phosphatase, non-receptor type


14 (PTPN14):


(Seq ID No: 412)



agttctttccaactttttctcggcggagtgagcgcagcgggcgcagactcgggggcaggt



tgctgtgcttctccgggctcagccgcctgctctcctggctcaggtcctcggggagcccta


gacagacatcaagtggccactggcgctccttcccctcccagctgagccatcctccccggc


ctcctcgggcgggacagccccgtgcttaggtttttctccttttctcccccggtgcgcctc


tgctcggactctcgcgccgggatcgcggcggaaacctccctcccctttcgcctcctgcgg


ctccttcccttcgcccctcctccgccagtcactggaatcaattccgtggggaatcggctc


cgccgccgcgaaggacagcctttccgcgcgggactccggggcgccacgggggccatgtaa


gcagctatcttccagagggccacactgggcatggacacccttttccctgcctggaggagc


acaggtgatagtgtaattttccagtcacgaaactgctaaggccatctcaggggcgtgtgc


gccaggataggcgggcggcgtccgaggaccacatagccatg


 


Homo sapiens selenoprotein P, plasma, 1 (SEPP1):


(Seq ID No: 413)



ctttcttttaagttgataacaatcagctcaggggtttgctctgcttgcaaggtcactgca



agaatgaacattgaactttggactatacctgaggggtgaggtaaacaacaggactataaa


tatcagagtgtgctgctgtggctttgtggagctgccagagtaaagcaaaga


gaaaggaagcaggcccgttggaagtggttgtgacaaccccagcaatg


 


Homo sapiens serine hydroxymethyltransferase 2 (mitochondrial)


(SHMT2):


(Seq ID No: 414)



agctcttctcgcgcatgcgttctccgaac



ggtcttcttccgacagcttgctgccctagaccagagttggtggctggac


ctcctgcgacttccgagttgcgatg


 


Homo sapiens tyrosine kinase with immunoglobulin-like and EGF-


like domains 1 (TIE1):


(Seq ID No: 415)



tttcctcttcctccccagcaccgacccacactgac



caacacaggctgagcagtcaggcccacag


catctgaccccaggcccagctcgtcctggctggcctgggtcggcctctggagtatg


 


Homo sapiens coiled-coil domain containing 6 (CCDC6):


(Seq ID No: 416)



cctcctttccccagcccgccgcggccatg



 


Homo sapiens nuclear receptor coactivator 4 (NCOA4):


(Seq ID No: 417)



ggacctttcgcactcgggtcaggggtaaagcagcctgtcgcttgccgggcagc



tggtgagtcggtgacctggcctgtgaggagcagtgaggagaatg


 


Homo sapiens chromatin assembly factor 1, subunit B (p60)


(CHAF1B):


(Seq ID No: 418)



gtgcctctgactgtccgggtccctccagcatttt



gcagctttctcctgtcttgaagaagtagaacggtgcccgagaaac


gtttttccccttcgagactcaggaggatgaaagtcatcacttgtgaaatagcctgg


cacaacaaggagcccgtgtacagcctggacttccagcatg


 


Homo sapiens 3′-phosphoadenosine 5′-phosphosulfate synthase 1


(PAPSS1):


(Seq ID No: 419)



agccccgccccgctcgctggcctgccctcctcttgctaccctcccggcg



cagagaaccccggctgctcagcgcgctccgcggtcatg


 


Homo sapiens Fas apoptotic inhibitory molecule 3 (FAIM3):


(Seq ID No: 420)



tgccctcctcttgctaccctcccggcgcaga



gaaccccggctgctcagcgcgctccgcggtcatg


 


Homo sapiens N-acetylated alpha-linked acidic dipeptidase 2


(NAALAD2):


(Seq ID No: 421)



cagcctcctgccagcgcgctctctgtttctctgcagccccgaa



gctcgcgaatgtagcaggcgccccaagctcggtcctcaagaagccatggcg


gaatccaggggccgtctgtacctttggatgtgcttggctgctgcgctgg


catctttcctgatgggatttatggtgggtaagt


 


Homo sapiens abl-interactor 1 (ABI1):


(Seq ID No: 422)



ctgtctctttaacgcgagag



gaagcgatgcagaggggtggaaaatg


 


Homo sapiens potassium voltage-gated channel, Isk-related family,


member 3 (KCNE3):


(Seq ID No: 423)



cttccttttctgccttctctcctgctttctagctctgggctttcccagctccgaagtcaa



tactgagatcccagatgtgtccagagacatcctgaagaggctcgggggtggag


gagccttagtgtgtccacaaagggactcctgaaactgactgagagccagt


 


Homo sapiens target of myb1 (chicken)-like 1 (TOM1L1):


(Seq ID No: 424)



ggccctctggcgctaccatg



 


Homo sapiens ubiquitin-like modifier activating enzyme 2


(UBA2):


(Seq ID No: 425)



cgcccttcccccacccgcttccggccgcggctcggttctcccgcctccgcctccgccgcg



gctcgtggttgtcccgccatg


 


Homo sapiens scavenger receptor class B, member 2 (SCARB2):


(Seq ID No: 426)



ctccctccttgcagttggatccctggcgggtgcggcccggcccggcccgtgagcggcg



cacagaatg


 


Homo sapiens insulin induced gene 1 (INSIG1):


(Seq ID No: 427)



actcctcctttcccccgccccgcctccgttcgga



gagccggcgggcgggcgcctctcggccaggaagcgcctcttggacgcgtgtgaccgatg


 


Homo sapiens kinesin family member C3 (KIFC3):


(Seq ID No: 428)



aggcctcttctgaggctctaggtgccccagtagcagggccttctgcagcaaggccgg



gaactgctgcaccattggtgtgttttaccttaagggactccaggcagcttccttgctgg


gaagatattcatttgctggggtggggctgggggtgcagaggtaggaagtgctgtggcta


gaaggcggcctggccagcgagtaggtggtggagcgagtgagagcgtgtgcgctg


taaacagtgtgagtgcatg


 


Homo sapiens LIM domain kinase 2 (LIMK2):


(Seq ID No: 429)



aggcctcttctgaggctctaggtgccccagtagcagggccttctgcagcaaggccgggaa



ctgctgcaccattggtgtgttttaccttaagggactccaggcagcttccttgctgggaag


atattcatttgctggggtggggctgggggtgcagaggtaggaagtgctgtggctagaagg


cggcctggccagcgagtaggtggtggagcgagtgagagcgtgtgcgctgtaaacagtgtg


agtgcatgtgcgccagcgcgtgcaaggacacggtaagggatgtacatgtattgtctcgtg


agtaagagcttgtgtgtgtgttgggatgggaagacacgtactggtatgagagcccgcgtg


agaagtgtatgtgtgagtactcgcgtggaagttttgcactcgggtttgaggctgtgcaaa


agtacgcatggctcaccaggtgtggggctgtgtgggctgcctcgtgtgtgccagcccgtg


tgcaggcctgttttgtgagagccttcagggaacgcatgagcacgtgtgccagtgcgagtg


cgggacgcggggaggcgggagagaccgagtgggaggccccgcgaaggagtgggagtggga


gtgggagtgccggcgggagacctgcgggggcgcgcccgggctgacgcgtgcgcgccagtg


cgcgtgagtgcgggcgcgcgccgccgccccccgccggggtcggagccggttgccatggga


acgcgccgcggcccgagttaatcatttcctgtggaaagtgtgcgggaggggcgcgagcgg


gctggccgaggaggaggcggcggcgtggagctgcctcctgccggcgggccgggccgggcc


gagccccgggcgctgcggcgacgcctggatcctgcctccgccaggccggctgcctggtgc


cccgaggaggctgctgagccccaggccatg


 


Homo sapiens lectin, mannose-binding, 1 (LMAN1):


(Seq ID No: 430)



cctcctccgcgttccagaatccaagatg



 


Homo sapiens MRE11 meiotic recombination 11 homolog A


(S. cerevisiae) (MRE11A):


(Seq ID No: 431)



cgttctctcccgcggaattcaggtttac



ggccctgcgggttctcagaggcaagttcagaccgtgttgttttcttttcac


ggatcctgccctttcttcccgaaaagaagacagcctt


gggtcgcgattgtggggcttcgaagagtccagcagtgggaatttctagaattt


ggaatcgagtgcattttctgacatttgagtacagtacccaggggttcttggagaagaac


ctggtcccagaggagcttgactgaccataaaaatg


 


Homo sapiens nascent polypeptide-associated complex alpha subunit


(NACA):


(Seq ID No: 432)



cttccttctgcaacaggcgtgggtcac



gctctcgctcggtctttctgccgccatcttggttccgcgttccctgcacag


taagtactttctgtgccgctactgtctatccgcagccatccgcctttctttcgggctaa


gccgccccggggactgagagttaaggagagttggaggctttactgggccacagggttcc


tactcgcccctgggcctccggacaaaatggggtctgcggttggtgtcctggcaaaa


gcagggtagaagggctgcggggcgggcccagaatccgagcctgcagagatgggagcag


ttgcagtgttgagggcggaagaggagtgcgtcttgttttgggaactgcttcacag


gatccagaaaaggaaatg


 


Homo sapiens claudin 11 (CLDN11):


(Seq ID No: 433)



cgcccttcgccgctgagctcg



cagcctccggcgcccacctccacctccag


tgtcccgcctcgggccgtcgccctccagcggctcgcgagcgtgggagacgtacctggg


caggcactgtccagcccaggcccaggcacagccgtgaggggcgaggcacggg


gacatcctggcggccaccatg


 


Homo sapiens retinoblastoma binding protein 4 (RBBP4):


(Seq ID No: 434)



ccgcccctcccgcaacgctcgaccccaggattcccccggctcgcctgcccgccatg



 


Homo sapiens acyl-CoA synthetase medium-chain family member 3


(ACSM3):


(Seq ID No: 435)



ccctcttctttagactgccacgaggaaaaagcagatgtga



gaactcaaggttcagggctgctcttctaagaaacaagtctgcca


taatctccatctgtgttggaatctgttaactaatgaactggtctctgtg


caaatcctgagtgctaaagcttccaacaagactgatg


 


Homo sapiens syndecan binding protein (syntenin) (SDCBP):


(Seq ID No: 436)



cgctctcttacactcgggcctcagaagtccgtgccagtgaccg



gaggcggcggcggcgagcggttccttgtgggctagaagaatcctgcaaaaatg


 


Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1):


(Seq ID No: 437)



agtccttctcattccttgcccccgcccaaggctctcttcaccttccccgcgggggtcctc



tcgttttctgtctcccaaatgctggcttcccgcctttcctcccccgcttatttacttaat


taaggccctggggctgcaccccaccggcagctccttcgggggtgtggccgaagagctccg


agggcggggctgaccgagccatattcgggcgtggccggtggtgattggtgagggcggggc


ctgccgcagggggcggggcctgcaggtttggcccccgcagggagcgcagctggcgccgct


gggagctggtggcgcggcgcaggtcccggccgagtgtggcgcagcagtggcggcgcttcc


cattcgccatgcgccgggggtgggtgcccgaaggttgcatgatggaatttgaacattact


tcaagaggttttgtattttggattagttaattgggtttgtcctctgctgactgtttcttc


ggatgcattttttggtgtgctcttgagggattaaatg


 


Homo sapiens Wolf-Hirschhorn syndrome candidate 2 (WHSC2):


(Seq ID No: 438)



cgtccttccggctctcggctttgccacaaagcttcccgaagacgcggccgctacccgga



gacgcggtcgccacccagaagcgctctcccgggaagccccgctcgtgggaccgcgccac


ctgcgccgcctctgcggcccgcagcccgacgggcgccgccatgtt


ggggtcctagcgagggacgcgtaggtgtcttcataagatg


 


Homo sapiens nuclear receptor subfamily 1, group H, member 3


(NR1H3):


(Seq ID No: 439)



cagtccttttgcaagagctgctaagagcgctgggtaaggagaggaaggg



gagagacatggaacttggctggtctgcagggaaatgccactgttttggccgggag


tagggggcgggagtggcgggagagggggtggccggctggggaggagccagcctggtgga


gaagctgccctgtgggcgggggtgaggaggggagggctgtggtcaccaggcag


gaaggaggggtggcctgacccctcggcagtccctcccctcagcctttccccaaattgc


tacttctotggggctccaggtcctgcttgtgctcagctccagctcactggctggccac


cgagacttctggacaggaaactgcaccatcctcttctcccagcaagggggctccaga


gactgcccacccaggaagtctggtggcctggggatttggtgggtctgctccttag


 


Homo sapiens glypican 6 (GPC6):


(Seq ID No: 440)



cctcctttctccttccctctt



gcctccagtgactgtctccaggatttctctcttcctatttcaggag


gactctcacaggctcccacagcctgtgttaagctgaggtttcccctagatctcg


tatatccccaacacatacctccacgcacacacatccccaagaacctcgagctcacac


caacagacacacgcgcgcatacacactcgctctcgcttgtccatctccctcccgggg


gagccggcgcgcgctcccacctttgccgcacactccggcgagccgagcccg


cagcgctccaggattctgcggctcggaactcg


gattgcagctctgaacccccatggtggttttttaaacac


ttcttttccttctcttcctcgttttgattgcaccgtttccatctgggggctagaggag


caaggcagcagccttcccagccagcccttgttggctt


gccatcgtccatctggcttataaaagtttgctgagcgcag


tccagagggctgcgctgctcgtcccctcggctggcagaagggggtgacgctggg


cagcggcgaggagcgcgccgctgcctctggcgggctttcggcttgaggggcaaggtgaa


gagcgcaccggccgtggggtttaccgagctggatttgtatgttgcaccatg


 


Homo sapiens peptidylprolyl isomerase F (PPIF):


(Seq ID No: 441)



cggccttctgggcgcgcgcgacgtcagtttgag



ttctgtgttctccccgcccgtgtcccgcccgacccgcgcccgcgatg


 


Homo sapiens ARP1 actin-related protein 1 homolog A, centractin


alpha (yeast) (ACTR1A):


(Seq ID No: 442)



agttccttccccagaaggaga



gattcctctgccatg


 


Homo sapiens tripartite motif containing 28 (TRIM28):


(Seq ID No: 443)



ggctctttctgcgagcgggcgcgcgggcgagcggttgtgcttgtgctt



gtggcgcgtggtgcgggtttcggcggcggctgaggaagaagcgcgggcggcgccttcgg


gaggcgagcaggcagcagttggccgtgccgtagcagcgtcccgcgcgcggcggg


cagcggcccaggaggcgcgtggcggcgctcggcctcgcggcggcggcggcgg


cagcggcccagcagtt


ggcggcgagcgcgtctgcgcctgcgcggcgggccccgcgcccctcctccccccctgggcg


cccccggcggcgtgtgaatg


 


Homo sapiens aminoadipate-semialdehyde synthase (AASS):


(Seq ID No: 444)



cggccttccatcccagtttcttctaggaattcggagcctcccctgcagcgactcggaa



gattcgaggcggcgggggacaagtcggcgccccagagcggacgagtcaccaggtgtcaa


gatg


 


Homo sapiens cornichon homolog (Drosophila) (CNIH):


(Seq ID No: 445)



ccgcctttctccgctggcaacggcgccgctccccgctcctcctccccagccatg



 


Homo sapiens M-phase phosphoprotein 10


(U3 small nucleolar ribonucleoprotein) (MPHOSPH10):


(Seq ID No: 446)



ctcccttcccttgcatgctgcattgtgtcgggagttgctgacagccatg



 


Homo sapiens ubiquitin specific peptidase like 1 (USPL1):


(Seq ID No: 447)



ccgccttcctagtggagacgcgagtgggggaggagcagtccgaggggaacgtgggtt



gaacgttgcaactagggtggagatcaagctggaacaggagttccgatcgacccggtac


caagaaggggagtgcccgcggcagggttcattgaaaaaatccttagtga


tattgacatgtctcaagtgacataaattagccaatgactcggaatg


 


Homo sapiens solute carrier family 23 (nucleobase


transporters), member 1 (SLC23A1):


(Seq ID No: 448)



tggccttt



gtcaagtcatcccctcttctcctcaggaactgctcaaacctgtgccccaaagatg


 


Homo sapiens splicing factor 3b, subunit 4, 49 kDa (SF3B4):


(Seq ID No: 449)



ggatctctttcgccatg



 


Homo sapiens DnaJ (Hsp40) homolog, subfamily A, member 2


(DNAJA2):


(Seq ID No: 450)



ctgtctccctcggcctgtgccgccgccgacgccgctt



gtgggcccgactccgctctgtctgcttcgccaccttctccccgagcac


tgcccggccggccgccatg


 


Homo sapiens calicin (CCIN):


(Seq ID No: 451)



catcctctcttccaccctctcttctccctggtcaaccgctctgcaaacaac



catcaatctgatcccacaggcctgagaaagtctgctctccagtac


ctgctgctgatctgtttcagccgacaagaggcaccatg


 


Homo sapiens mannosidase, beta A, lysosomal (MANBA):


(Seq ID No: 452)



ctgcctttcgatctctccacatctcggtggcgcgggatctcaagatg



 


Homo sapiens microtubule-associated protein 1B (MAP1B):


(Seq ID No: 453)



aatcctttctcctgccgcagtggagaggagcggccggagcgagacac



ttcgccgaggcacagcagccggcaggatg


 


Homo sapiens malate dehydrogenase 1, NAD (soluble) (MDH1):


(Seq ID No: 454)



gagccttttctcgctaacaccgctcgccctctccgagtcagttccgcggtagaggtgac



ctgactctctgaggctcattttgcagttgttgaaattgtccccgcagttttcaatcatg


 


Homo sapiens microfibrillar-associated protein 1 (MFAP1):


(Seq ID No: 455)



gtttctctatcagtcgcgcagctgtgttcgcggactcaggtg



gaaggaatttcttctcttcgttgacgttgctggtgttcactgtttggaattag


tcaagtttcgggaatcaccgtcgctgccatcaacatg


 


Homo sapiens chaperonin containing TCP1, subunit 3 (gamma)


(CCT3):


(Seq ID No: 456)



ggttctctctctccagaaggttctgccggttcccccagctctggg



tacccggctctgcatcgcgtcgccatg


 


Homo sapiens tubulin, alpha 1a (TUBA1A):


(Seq ID No: 457)



caacctctcctcttcgtctccgccatcagctcggcagtcgcgaagcagc



aaccatg


 


Homo sapiens CD164 molecule, sialomucin (CD164):


(Seq ID No: 458)



ctttctcccgaacgccagcgctgaggacacgatg



 


Homo sapiens cysteine-rich secretory protein 3 (CRISP3):


(Seq ID No: 459)



ctctctctgcaccttccttctgtcaatagatg



 


Homo sapiens SMYD family member 5 (SMYD5):


(Seq ID No: 460)



cggcctccatgtgcgac



gtgttctccttctgcgtgggcgtggcgggccgcgcgcgggtctccgtg


gaagtccgtttcgtgagcagcgccaaggtgaggtcggggcgggtcctgccgg


gagcctctccccagtccggccatg


 


Homo sapiens kelch repeat and BTB (POZ) domain containing 10


(KBTBD10):


(Seq ID No: 461)



ctgcctttttacagctagacctgtgtgctg



caaggagctaaggccttcagtgtccccttccttacccaggtttctcacagaatg


 


Homo sapiens aldo-keto reductase family 1, member A1 (aldehyde


reductase) (AKR1A1):


(Seq ID No: 462)



ccgccccttgcaccgcccacgtggccagcgccacctgcctcattgtgcccaggagttctc



caaacccgcgctgcggagtgagtgaccaagttccggccagttcgacctcgaggatccaga


ggtggagacggtactacctcccagctctgttttccatccccttcaggtccttcctcggga


ggcggcgaaggcggtccaccctgcgcgtgatcctttatgcccggcccctgcccctccctc


cgggtggaacttccccctcaccgccagacttaagctgaggatcgttggatctctggcggg


gtgcagaactgagcccaggccacagtaccctattcacgctctgtgcttgtgccaaggttt


caagtgatcctcccgcctcagcctgcccaggtgctgagattacatgtatgagccactgca


cctggaaaggagccagaaatgtgaagtgctagctgaaggatgagcagcagctagccaggc


aaagggggcaatg


 


Homo sapiens TRK-fused gene (TFG):


(Seq ID No: 463)



tgttcttcccccacctgccac



gtacagagcccaagttctcgctaggcttgtt


gggtcagcgcgattggccggggcccgcgcgagcctgcgagcgaggtgcggcggtcgcgaa


gggcaaccgagggggccgtgaccaccgcctccccgcgacgccccagtccag


tggcctcgcgtccgcccattcagcggagacctgcggagaggcggcggccgcggcctccg


caagccgtctttctctagagttgtatatatagaacatcctggagtccaccatg


 


Homo sapiens 3′(2′), 5′-bisphosphate nucleotidase 1 (BPNT1):


(Seq ID No: 464)



catccttctcaaaagacttattgacagtgccaaagctcggtactggacacaac



gagggacctgggtctacgataacgcgcttttgctcctcctgaagtgtctttggtccaac


gttgttccagagtgtaccatg


 


Homo sapiens guanine nucleotide binding protein (G protein):


(Seq ID No: 465)



ttttctctctctctttcactgcaaggcggcggcaggagaggttgtggtgctag



tttctctaagccatccagtgccatcctcgtcgctgcagcgacacac


gctctcgccgccgccatg


 


Homo sapiens major histocompatibility complex, class II, DM alpha


(HLA-DMA):


(Seq ID No: 466)



caccctctcggggagggagttggggaagctgggttggctgggtt



ggtagctcctacctactgtgtggcaagaaggtatg


 


Homo sapiens transmembrane protein 50B (TMEM50B):


(Seq ID No: 467)



tctccttcctgcgcgcgcgcctgaagtcggcgtgggcgtttgaggaagctgggatacag



catttaatgaaaaatttatgcttaagaagtaaaaatg


 


Homo sapiens lactoperoxidase (LPO):


(Seq ID No: 468)



cagtctttcctgctaa



gcctcagcgtctcctccaa


gccacatcaaaatctttccttctgggcctttcccagaagtgaattcttgctg


gaaggtataaaagaccagctcctccaagcagagcaactccctggctgccgtgaaaaga


caaggcactgggcagtgatg


 


Homo sapiens NEL-like 2 (chicken) (NELL2):


(Seq ID No: 469)



ctgcctttacaaca



gagggagacgatggactgagctgatccgcaccatg


 


Homo sapiens nucleobindin 1 (NUCB1):


(Seq ID No: 470)



cgccctctgcggtgaaggaga



gaccacactgccatg


 


Homo sapiens paired box 9 (PAX9):


(Seq ID No: 471)



aagcctctttcatcggggcacagacttccttttacttcttccttttgccctctcgcctcc



tcctcctgggaagaagcggaggcgccggcggtcggccgggatagcaacaggccgggccac


tgaggcggtgcggaaagtttctgtctgggagtgcggaactggggccgggttggtgtactg


ctcggagcaatg


 


Homo sapiens cyclin-dependent kinase 16 (CDK16):


(Seq ID No: 472)



cgccctttattcttgctcggcctcgccacagagag



caaatcagattggctgggcgacaacctcaaagggcggggctgcacacgttcactacgg


gaatgaggtagcggtggagggggcagttgggcggggataggccgtcctagctaaggtgg


taaaggccaataactcttcaggctgcctctcctcgaaaagtcatcttctcgcgaac


ctttaaaatgccttcctccccaagcacctcaagggactagaactgagtgcttcattt


gtcttttttcctccttgcaaaagtcccgtttgccaccatggggatgtaccaagtgagac


cgagtagggggaacgagtggtgattgacgcgccaggttactggccactgctcac


ctaggcgctagcaaacttctgccaagatcggaactgagtactaaacagcctccacag


ttctccctggtgccgtctccggcttggcgccg


catcctcctctgggctcgcgatggccgcgtcccctcccgctgcggacgggtcctttgg


tacatg


 


Homo sapiens serpin peptidase inhibitor, clade E (nexin,


plasminogen activator inhibitor type 1), member 2 (SERPINE2):


(Seq ID No: 473)



ctgcctctttccggctgtgaccctcctcgccgccgccgctt



ggctgcgtcctccgactccccgcgccgccgagaccaggctcccgctccggttgcggccg


caccgccctccgcggccgccccctggggatccagcgagcgcggtcgtccttggtg


gaaggaaccatg


 


Homo sapiens pancreatic lipase-related protein 1 (PNLIPRP1):


(Seq ID No: 474)



aactcctttccccctgctgtgacgtacaggtgaggtaaacag



tactgaagtccagggcgtcggtgctcactgctctggcaatgcccggtga


gactgaattatgtttaaatttattgtagatg


 


Homo sapiens peripherin (PRPH):


(Seq ID No: 475)



ggctccttcccagcccccggcctagctctgcgaacggtgactgcccatccttggccg



caatg


 


Homo sapiens RAD21 homolog (S. pombe) (RAD21):


(Seq ID No: 476)



gacccttttcccctccccgggccacccagcccgcccaactcccagcggagag



caaggttttcttctgttttcatagccagccagaacaatg


 


Homo sapiens signal sequence receptor, delta (SSR4):


(Seq ID No: 477)



ttttcttttcctctaggcagagaagaggcgatg



 


Homo sapiens tissue factor pathway inhibitor (lipoprotein-


associated coagulation inhibitor) (TFPI):


(Seq ID No: 478)



ctccctcttt



gctctaacagacagcagcgactttaggctggataatagtcaaattcttac


ctcgctctttcactgctagtaagatcagattgcgtttctttcag


ttactcttcaatcgccagtttcttgatctgcttctaaaagaagaagtagagaaga


taaatcctgtcttcaatacctggaaggaaaaacaaaataacctcaactccgtttt


gaaaaaaacattccaagaactttcatcagagattttacttagatg


 


Homo sapiens ubiquinol-cytochrome c reductase binding protein


(UQCRB):


(Seq ID No: 479)



gcttctctttctggtcaaaatg



 


Homo sapiens mitogen-activated protein kinase kinase kinase 12


(MAP3K12):


(Seq ID No: 480)



ccgccttttgtgctgcggccgcggagcccccgagggcccagtgttcac



catcataccaggggccagaggcgatg


 


Homo sapiens sushi-repeat containing protein, X-linked


(SRPX):


(Seq ID No: 481)



tggtctcttcggtctcctgccgcccccgggaa



gcgcgctgcgctgccgaggcgagctaagcgcccgctcgccatg


 


Homo sapiens aminopeptidase puromycin sensitive (NPEPPS):


(Seq ID No: 482)



ccccctctccctccctcctt



gcgggccctcctccccttccctcccctccgcccccttccccg


taggcagcccgcccgccagtccgcccgcac


cgcctccttcccagcccctagcgctccggctgggtctctcccccgccccccaggctcccc


cggtcgctctcctccggcggtcgcccgcgctcggtggatg


 


Homo sapiens fibulin 5 (FBLN5):


(Seq ID No: 483)



tcgccttctgcccgggcgctcg



cagccgagcgcggccggggaagggctctcctcccagcgccgagcactgggccctgg


cagacgccccaagattgttgtgaggagtctagccagttggtgagcgctgtaatctgaac


cagctgtgtccagactgaggccccatttgcattgtttaacatactta


gaaaatgaagtgttcatttttaacattcctcctccaatt


ggtttaatgctgaattactgaagagggctaagcaaaaccaggtgctt


gcgctgagggctctgcagtggctgggaggaccccggcgctctccccgtgtcctctccac


gactcgctcggcccctctggaataaaacacccgcgagccccgagggcccagag


gaggccgacgtgcccgagctcctccgggggtcccgcccgcgagctttcttctcgccttcg


catctcctcctcgcgcgtcttggacatg


 


Homo sapiens lysophospholipase I (LYPLA1):


(Seq ID No: 484)



cgctcttccttccgcttgcgctgtgagctgaggcggtgtatg



 


Homo sapiens high mobility group nucleosomal binding domain 4


(HMGN4):


(Seq ID No: 485)



tcgtcttctctgtcttagggctggtgctggccctgcccac



gcctagggctccggcgcgtcacgggcctcagctgggattcccgcgcccctcggac


ggccacgagactcggacatctttccaggaacagcgtgaggaggacagaa


gcacccaacaggactgctcaagccacctgcgaacactgctgctaccatg


 


Homo sapiens eukaryotic translation initiation factor 3, subunit


M (EIF3M):


(Seq ID No: 486)



agttcccttttccggtcggcgtggtcttgcgagtggag



tgtccgctgtgcccgggcctgcaccatg


 


Homo sapiens Sec23 homolog A (S. cerevisiae) (SEC23A):


(Seq ID No: 487)



cctcctcttgacgtggcagaggcggcgccagccatg



 


Homo sapiens cartilage associated protein (CRTAP):


(Seq ID No: 488)



cgtcctctttcctttccttctccctccccttttcccttccttcgtcccttccttccttcc



tttcgccgggcgcgatg


 


Homo sapiens vesicle amine transport protein 1 homolog


(T. californica) (VAT1):


(Seq ID No: 489)



ccgcccctcccgctggatcccg



cagccgcggctcttcccgacgcgttccgccttccccagctgtgcac


tctccatccagctgtgcgctctcgtcgggagtcccagccatg


 


Homo sapiens importin 7 (IPO7):


(Seq ID No: 490)



gcttctctttcctttcgcgccggtt



gccgctgcggagcgcggcgggtccatgtgcgcagtgagtggcgctattcctggcccag


tagcacccgagccccgggtttgaccgagtccgcgctgcgatg


 


Homo sapiens ATG7 autophagy related 7 homolog


(S. cerevisiae) (ATG7):


(Seq ID No: 491)



gctcctttgcgcacgcgcgccgcttcccagtgg



caagcgcgggcaggaccgcgttgcgtcatcggggcgcgcgcctcagaga


gagctgtggttgccggaagttgagcggcggtaagtgagccgcggcgggcgagggtgtag


tggggtcttgctgggccggttttggaggcctggag


tcaaggggcgagctcgccagggagggcgagggtcacagcaagtctcag


gatcctcctctgccagtttctgggtggtccttcctcctccagggactcactgat


tccggctggcgcccttcgtctgtagccgcgtcccctcagactggttcag


tccggggtcttctgacttggaagctcgtgctgat


ttcctaagtcagcccctcctgtcctcttggtaggcagtgctcagaatcttcagtgtt


ggaacacgggagatgggacatttggattcccagcctggctgtgtctggattt


gctgtctctggcacgttccttccccatctaagctgcttttccatctgcaaaatgg


gaatgataatccgccatttgtttaagtgaggaggttaaataagtttactttctgagaaa


gaagattctcgattccttggttacagggttagaaactaatg


 


Homo sapiens dynactin 2 (p50) (DCTN2):


(Seq ID No: 492)



cgctcccttt



gccgccgccttagcccgggacccgaacccagcctctcccctacccgaacac


cggccccggctccaccgaggcccgggtcccccagcccgtctcgccgccgccatg


 


Homo sapiens acidic (leucine-


rich) nuclear phosphoprotein 32 family, member B


(ANP32B):


(Seq ID No: 493)



agcccccttttccctccatggtttctctccgctcccgtgagtaactt



ggctccgggggctccgctcgcctgcccgcacgccgcccgccacccaggac


cgcgccgccggcctccgccgctagcaaacccttccgacggccctcgctgcgcaagccgg


gacgcctctcccccctccgcccccgccgcggaaagttaagtttgaagaggggggaa


gaggggaacatg


 


Homo sapiens protein C receptor, endothelial (PROCR):


(Seq ID No: 494)



acttctcttttccctagactgcagccagcggagcccgcagccggcccgagccag



gaacccaggtccggagcctcaacttcaggatg


 


Homo sapiens actin related protein 2/3 complex, subunit 1A,


41 kDa (ARPC1A):


(Seq ID No: 495)



cgctccctctgggcttccgtcctccgcccgcgcccgacggagcctgttcgcgtcgactgc



ccagagtccgcgaatcctccgctccgagcccgtccggactcccccgatcccagctttctc


tcctttgaaaacactaagaataatg


 


Homo sapiens chaperonin containing TCP1, subunit 4 (delta)


(CCT4):


(Seq ID No: 496)



aggcccccttctccgcctccgcctcctcccgacgccggcgccgctttctg



gaaggttcgtgaaggcagtgagggcttaccgttattacac


tgcggccggccagaatccgggtccatccgtccttcccgagccaacccagacacagcg


gagtttgccatg


 


Homo sapiens Niemann-Pick disease, type C2 (NPC2):


(Seq ID No: 497)



gcttctttcccgagcttggaacttcgttatccgcgatg



 


Homo sapiens phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole


succinocarboxamide synthetase (PAICS):


(Seq ID No: 498)



acccctcttttctagagttctgcctcgcttcccggcgcggtcgcagccctcagcccac



ttaggataatg


 


Homo sapiens ST6 (alpha-


N-acetyl-neuraminy1-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide


alpha-2,6-sialyltransferase 2 (ST6GALNAC2):


(Seq ID No: 499)



ctcccttctgcctgggacgtcagcggacggggcgctcgcgggccggggctgtatg



 


Homo sapiens polymerase (RNA) III


(DNA directed) polypeptide C (62 kD) (POLR3C):


(Seq ID No: 500)



aagccctttccgaggatggcaaaggatctgggaatgcttctccaaagatatgtggatgga



cgaaataggtctctggtgatactgaggcggggtggggacggggaggcaaagacttggctt


cttaggaattggaagaaataagtaaacaatgtttggtagcaatttgtaataaggaagtaa


tcataaaattaactacgtccgtttctgattgtgtcaactttgtcaaggagtagaagttta


agaattgaatactgtcctgcaaacaacgtaacctcatctcctgtttgacacaccctgttg


agaagcagtcctttacctcctaaatttctttttcgaaattatcatttcctttatggactg


agaataacactgcctgttcactcccaccgagctgtgaacagtgaccttaattcttccaag


cagggaagtgtagaaactaaggtctgtgacagaccgcaaaatcatctcccaatctttaag


gaaaatcagaatcacgcataatcccatagagataaatttgatgcatagtcttttcctatg


catacatttttcctttttttttacaataattgaatttttatattttttcagcttgcttct


gtcacttaatatattatgagtaattttttttggttttttttgttttggagacagaatctc


gcactgtcgcccgggttggagtgcagtggcgcgatctcggctcactgcaacctctgcctc


ccggcttcaagcgattctcctgtctcagcctccctagtagctgggattacaggcacccgc


caccacgcccagctaatttttttgtgtgtttttagtagagaaggggtttcactatattgg


ccaggctggtctcaaactcctgacctcatgatacgcccacctcggtctcccaaagtgcta


ggattacaggcctgagccaccgcgccagcctattatgaataattttctacatgaatacgc


atcgtactaaataactttaaatgttggtgtagtatgccattgtatgggtatggcatcatt


tattgttagacgttagattgtttccactaagtcggtattataaagagaactaatgacttc


attattattagctttttctttctttggacacaatatccaaaaagaaattgttgtttcaaa


gatatgcaagatttttaaggctttttgatatgtattgtcaaattgccctccagaaagaat


acatgaatttacactcagcagctctgcttccagcgtgaaagactttctattgtaccattt


tggtgttttttccctagctctcagactccccagtacaatg


 


Homo sapiens influenza virus NS1A binding protein


(IVNS1ABP):


(Seq ID No: 501)



gtgtctcccggtcgcgcgtg



gaggtcggtcgctcagagctgctgggcgcag


tttctccgcctgctgcttcggcgcggctgtatcggcgagcgagcgagttcccgcgag


ttctcggtggcgctcccccttcctttcagtctccacggactggcccctcgtccttc


tacttgaccgctcccgtcttccgccgccttctggcgctttccgttgggccgat


tcccgcccgcttcctcctgcttcccatcgaagctcta


gaaatgaatgtttccatctcttcagagatgaaccagat


tatgatgcatcattatcacagaagaaattcgtgtctatagcttttaaggacttgat


tacatcattttcaagcctgatagttttggaatcaccattagagcttaagacacac


ctgccttcatttcaaccacctgtcttcataccctgacgaagtgcaccttttaacac


tcctttgtccttggattacttaagagttcccagaaatacatttgccaccaacagag


tagccaaatttataaggaaaaatg


 


Homo sapiens thioredoxin interacting protein (TXNIP):


(Seq ID No: 502)



acccctctttttctccaaaggagtgcttgtggagatcggatcttttctccagcaatt



gggggaaagaaggctttttctctgaattcgcttagtgtaaccagcggcg


tatattttttaggcgccttttcgaaaacctagtagttaatattcattt


gtttaaatcttattttatttttaagctcaaactgcttaagaatac


cttaattccttaaagtgaaataattttttgcaaaggggtttcctcgattt


ggagctttttttttcttccaccgtcatttctaactcttaaaaccaactcagttccat


catg


 


Homo sapiens ecotropic viral integration site 2B (EVI2B):


(Seq ID No: 503)



ttttcctttcttagccaaatcaccaaaatgtccagttagaacaagaatttagcattctg



caaaagaagttaacagctgagataacgaggaaatattctgaaatg


 


Homo sapiens guanine nucleotide binding protein


(G protein), alpha inhibiting activity polypeptide 3


(GNAI3):


(Seq ID No: 504)



ggttcttctgggcgctaagggagctgacggagagggccaccgcccagcaa



tagacggtgcctcagcctgccgagccgcagtttccgtggtgtgagtgag


tccgggcccgtgtcccctctcccgccgccgccatg


 


Homo sapiens polymerase (DNA directed), eta (POLH):


(Seq ID No: 505)



cggcccttcgcagcgggcgcgctgtcagacctcagtctggcggctgcatt



gctgggcgcgccgctctcgtctgatccctgctggggacggttgcccgggcag


gatcctttacgatcccttctcggtttctccgtcgtcacagggaa


taaatctcgctcgaaactcactggaccgctcctagaaaggcgaaaagatattcag


gagcccttccattttccttccagtaggcaccgaacccagcattttcggcaac


cgctgctggcagttttgccaggtgtttgttaccttgaaaaatg


 


Homo sapiens solute carrier family 2 (facilitated


glucose transporter), member 1 (SLC2A1):


(Seq ID No: 506)



cgctctctggcaagaggcaagaggtagcaacagcgagcgtgccggtcgctagtcgcgggt



ccccgagtgagcacgccagggagcaggagaccaaacgacgggggtcggagtcagagtcgc


agtgggagtccccggaccggagcacgagcctgagcgggagagcgccgctcgcacgcccgt


cgccacccgcgtacccggcgcagccagagccaccagcgcagcgctgccatg


 


Homo sapiens zinc finger protein 138 (ZNF138):


(Seq ID No: 507)



gggtcttt



gtctcgctgcagcgggtgctgcaggtctggccttcacttttctgcgtcctcttactccta


gaggcccagcctctgtggcgctgtgatctggttattgggagattcacagctaagac


gccaggatcccccggaagcctagaaatg


 


Homo sapiens ubiquitin specific peptidase 3 (USPS):


(Seq ID No: 508)



ctttctttgacgcaagggctcgagacgcagccgccgtcggccgagcgcccggctagaa



gcgacaccagacggagcctccggagttcctccgcccccacctcgccgggtcctg


gagccgcagtcctcccagctgccctcctcgtggccatg


 


Homo sapiens influenza virus NS1A binding protein


(IVNS1ABP):


(Seq ID No: 509)



ctgtcttttctccagtttgagcgggggtgtcgggagcaggcgga



gagctttcctgcgaggctgtggaagcagtgaacactcttctcagcggctcgcctcccag


cagtgctattttttgccatccgccctcacccccagcacacgcgctcgcacacacac


gcacgcacgcacacacacacacacacacactcacacagagacctctctgggtttcttt


gccttgagtctcccggggctgtgagaagccaggcgcatctcaaaccgagctgg


cagctccaggctccggagccatgccctgcacggaccctcgtctttaccacgctcctgag


gaatgaaaggaacccagggaccctcagaaggcagcagtgatgcggaccaaccccccg


gagcctgcacccttccgagggccataggcgacccagggaactggaga


gagctccagaaaggaaatcccagctttcccaaagtccctgtggatgctgacaaaagga


gacctgaatttttggaagagcctgtactaggttacccggctgcagagtgat


tttcccctccggcactgactctccccctccaacccccagccgtccagagtaccatgaa


gaattatg


 


Homo sapiens guanine nucleotide binding protein


(G protein), beta 5 (GNB5):


(Seq ID No: 510)



ttccctctccgctgcgtccccgcgcgaagatg



 


Homo sapiens chaperonin containing TCP1, subunit 8 (theta)


(CCT8):


(Seq ID No: 511)



cttcctccgcggtcttccgagcggtcgcgtgaactgcttcctgcaggctgg



ccatg


 


Homo sapiens prostaglandin E synthase 3 (cytosolic)


(PTGES3):


(Seq ID No: 512)



cgctctttccgcgcggtg



cattctggggcccgaggtcgagcccgccgctgccgccgtcgcctgagggaagcgagaa


gaggccgcgaccggagagaaaaagcggagtcgccaccggagagaagtcgactccctag


cagcagccgccgccagagaggcccgcccaccagttcgcccgtccccctgccccgttca


caatg


 


Homo sapiens zinc finger protein 266 (ZNF266):


(Seq ID No: 513)



ttttcttcctggtggcgtttgggcttaatacagctttggcgaggtcggatgacgggtggg



agccagcggtggaaggggtggcgaaagtaccggtttgccccaggccgccgaggggcctcc


ttagagagaccttgcctgctccgctcgcgtccgccggggccgcgcgggtcctcctggcgc


cgccaggttcaaaaagccactcgagttgtcactgcgacggccctgggccaggagccgttt


cgggatctgtcaaacaacgagttttcgtcgttcgaatcaggttgactggtccttcatccc


cccaatctcccgtacctggcgagtccagctcgtcgcggcaatgctaagaaaagagtgata


tgcaagctgagaccaaaaatatggtatgatttagccatactgaaggggaaggaaataaga


gctgggcaaagcattctgtgaattggctgactccacttctatggtgagagagaggagtgc


atcaaagattactcccagtagagatggtttcagcatgttggccagtctggtctcagactc


ctgacctcaagtgatccacccacctcggcctcccaaaatgctgggattacaggtataagc


cactgtgcctggccaaagataccgttaaccctggataaagagaatggaggttacctctgt


ccgtgtagattcctaagctgtcctggagtgatccttggagtaaaggaaaggtgctttgaa


gcacattcagccatcagccctgtgggatggcagccactgatttgtcctatggtctttaca


gggacccagtctgccttcaagaaaagacagaagtagaaagggtggtggctgactgtctga


caaattgttatcaggtatgcaggaagtatatccttctccaaaatatcatacttgcatcac


caggtagacacatttccttctacacagaattatcttcagagcttcttaaagcaaataaag


cctgcttcaaggactgagtccctagtcgaattcccggaaggagtggagcctgtcatattg


tgtttatctagcatctgctcaagagtgtgctgcagtggagggaaatcagatgacctccca


gtctggttgtgttacatacaatcatgtgtaagaagtgccattcaagccgtgtcactggag


gggactgacagtgagattcagtgacttttgatgatctggctgtggacttcaccccagaag


aatggactttactggacccaactcagagaaacctctacagagatgtgatg


 


Homo sapiens methylenetetrahydrofolate dehydrogenase


(NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase


(MTHFD2):


(Seq ID No: 514)



gcttccctcccggcgcagtcaccggcgcggtctatg



 


Homo sapiens chemokine (C-C motif) receptor 9 (CCR9):


(Seq ID No: 515)



cttcctttctcgtgttgttatcgggtagctgcctgctcagaacccacaaa



gcctgcccctcatcccaggcagagagcaacccagctctttccccagacactga


gagctggtggtgcctgctgtcccagggagagttgcatcgccctccacagagcaggctt


gcatctgactgacccaccatg


 


Homo sapiens heat shock 105 kDa/110 kDa protein 1 (HSPH1):


(Seq ID No: 516)



cctccccttttgggtcggtagttcagcgccggcgccggtgtgcgagccgcggcagag



tgaggcaggcaacccgaggtgcggagcgacctgcg


gaggctgagccccgctttctcccagggtttcttatcagccagccgccgctgtccccgggg


gagtaggaggctcctgacaggccgcggctgtctgtgtgtccttctgagtgtcagag


gaacggccagaccccgcgggccggagcagaacgcggccagggcagaaagcggcggcag


gagaagcaggcagggggccggaggacgcagaccgagacccgaggcggaggcggac


cgcgagccggccatg


 


Homo sapiens StAR-related lipid transfer


(START) domain containing 10 (STARD10):


(Seq ID No: 517)



tggtcctttcttttatgattcacaaggaatgaccctcttcatcgcctctcctaattcagt



cctcacaacagtccttttacaaatgggacaacaggttagaggaagtcaggcagatttcca


gcatcatagagagtaaaggaccagggaaggatcaggattcaaggactgcacccaggctct


gcttccagcttgctgtgtgactttgggtaattttgttcccttagggaactgagctttctc


atttgtaaatgcaaacaggctgttgggaggatcaaatgagatccaggggtgaaaacagct


tagtttactttcaggaatttacccacgcggtatataaaggcaaaatattattatagtcag


gtgattgtagattgaggaacccatttcctcattctgcaaattgcaaacctgagggcccaa


agagggacaggggcttgccccaggtctcagcaggctgtgagcaagagctaaagcctaatc


ctcctgcctttgggcctggagcccttccttgtaccccaggggtcagtgtctttgttggat


acaggcttagattgactgactgtaccctgagaacctaggggagtccctgttcccaattct


tctcctacccccaccttggcctgatggaggaagaccctgctgtgttgagatgagcaccag


agccaagaagctgaggaggatctggagaattctggaggaagaggagagtgttgctggagc


tgtacagaccctgcttctcaggtcccaggaaggtggcgtcagcatctgcagccgcgtcga


cgttgtcggagcctccgcggaggacccaggagagccggactaggaccagggccctgggcc


tccccacactccccatg


 


Homo sapiens UTP14, U3 small nucleolar ribonucleoprotein, homolog


A (yeast) (UTP14A):


(Seq ID No: 518)



ctttccttcggcttccgttcttggtccatgtgaga



gaagctggctgctgaaatg


 


Homo sapiens SUB1 homolog (S. cerevisiae) (SUB1):


(Seq ID No: 519)



ggttctctgtcagtcgcgagcgaacgaccaagagggtgttcgactgcta



gagccgagcgaagcgatg


 


Homo sapiens minichromosome maintenance complex component 5


(MCM5):


(Seq ID No: 520)



ccgcctcttgtttttcccgcgaaactcggcggctgagcgtggaggttctt



gtctcccctggtttgtgaagtgcggaaaaccagaggcgcagtcatg


 


Homo sapiens RNA binding motif (RNP1, RRM) protein 3 (RBM3):


(Seq ID No: 521)



tactctttatcaatcgtcttccggcgcagccccgtccctgtttttt



gtgctcctccgagctcgctgttcgtccgggttttttacgttttaatttccaggactt


gaactgccatg


 


Homo sapiens KDEL


(Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor


1 (KDELR1):


(Seq ID No: 522)



ctccccctctcgctctcctccctcttcccggctccagctccgccgccagctccagccttt



gctccccctcccaaagtcccctccccggagcggagcgcac


ctagggtccctcttccgtccccccagcccagctacccgttcagaccagcagcctcggggg


gcacccccccgccagcctgcctccctcccgctcagccctgccagggttccccagccatg


 


Homo sapiens StAR-related lipid transfer


(START) domain containing 3 (STARD3):


(Seq ID No: 523)



agatcttcttccgctctgaggcgctactgaggccgcggagccggactgcggtt



ggggcgggaagagccggggccgtggctgacatggag


cagccctgctgctgaggccgcgccctccccgccctgaggtgggggcccaccaggatg


 


Homo sapiens heterogeneous nuclear ribonucleoprotein A0


(HNRNPA0):


(Seq ID No: 524)



cggcctctttgtgtggtgcccagataggggagcggaggtggcggcggcggcggtagcggt



ggccttggttgtcttccagtctcctcggctcgccctttagccggcaccgctccccttccc


tcccccttcctctcttccttccttccctccccttccctttttcccttccccgtcggtgag


cggcgggggtggctccagcaacggctgggcccaagctgtgtagaggccttaaccaacgat


aacggcggcgacggcgaaacctcggagctcgcagggcgggggcaaggcccgggccttgga


gatg


 


Homo sapiens chromobox homolog 1 (CBX1):


(Seq ID No: 525)



ggctctttt



gttcggctgaggggagggccgttggccggggcctgcggtacgccgcttcagtgagggac


gccactgcggccacccggcttgctgccttcctgggcgccactcccccaggcgacccgac


gcgacgcgccagcagcgcagcaccgattcctctcgggctctt


gggcgctgctctgaggtgaggagcccgctggaggcgggagagctgggg


gagggggcgcggcggcggcggcggcgggagccctgcgtgagggaac


gcgctttcgaggcggaggttaggagcggg


gagcgcgcccgggtccagcgtcctgcttctccgcttcccgcgctgagctcttcgcctgtc


gctgaggcgtcggtgccagctgcgtgaaggatgga


gagggcggggcgcgaatcctgagccagagactgagtgcttgggggtgggccgagcactt


gggggccgctcttcggggcccgggtggtctggaacaatgttgctt


ggctgggcggctgcgggatagggcggaaggggacaggcttgaggcttgga


taggcgtgaggaggcgcatacgaccgcacaacccgaggtttgtaactgtattcggaa


gacgccgggtccggctgggactgccagaggaacctggctttgcaggactacggaggag


taacgtcgagtgaattggaagagggcccagggccgcacaagcagcgtcaccctttacac


cagaaagctggcgggcactatg


 


Homo sapiens myeloid/lymphoid or mixed-lineage leukemia


(trithorax homolog, Drosophila); translocated to, 11


(MLLT11):


(Seq ID No: 526)



cgcccttcttaggaggggctgcattgcagggggagag



tgaactgacagactcagtcactgaagagggaaaaggagtgagaagacaaagccgtcaaa


gccccaacagctttgtatttctccagcccggcgcagaccccggagctcccgaggcac


tccctccatctttggaacacgccagtaattgattgataacaggaagctatg


 


Homo sapiens interferon-induced protein 44-like (IFI44L):


(Seq ID No: 527)



ttttctttctttcctagagtctctgaagccacagatctcttaa



gaactttctgtctccaaaccgtggctgctcgataaatcagacagaacag


ttaatcctcaatttaagcctgatctaacccctagaaacagatatagaacaatg


 


Homo sapiens cyclin I (CCNI):


(Seq ID No: 528)



acttcttcctcccttcccctctcttcccctccctccccagccttccccgcgagcggacgc



ggcagcgcctctgtctcgctttttcttatttttcccccctttcccctttctttttttttt


tttcttttcttttctcccctccccccctttcaccatttcccctcggaggcgctttccccg


ggcaggggcagagccggtctcaccccccgcctctccccggcccccgccgccctatggcga


gagggagccccctcccaacccgggctcgagcggcggcggcctcaggccgggggtcatcat


ggaactaattcgctgaccgacccagcggccgcagccgtgcgtcccgctcgagcgccagcg


cccgcgcccgcgccccccgatccgcttcccctttctccctcctcagttggccgagtcgtc


ccgcgcgcaccgcctccgcgcgcctatgagaatgaggtggtaacgggcccccggatgacc


ccgcgtcaccactgtgaggcctacagctctgccggggaggaggaggaggaggaagaggag


gagaaggtagctacagcaagctgggtagcaggcagatccaaaggatatcatg


 


Homo sapiens methionyl aminopeptidase 2 (METAP2):


(Seq ID No: 529)



cattccctcgcgctctctcgggcaacatg



 


Homo sapiens leukocyte immunoglobulin-like receptor, subfamily


B (with TM and ITIM domains), member 4 (LILRB4):


(Seq ID No: 530)



gtctcttt



gtcctgccggcactgaggactcatccatctgcacagctggggcccctgggaggagacgc


catg


 


Homo sapiens destrin (actin depolymerizing factor) (DSTN):


(Seq ID No: 531)



gggtctctcggtcccgcagccgtgaggaggacggtctgcat



actcgctgcccgccggctccctcccccgcgtccctgcgaccgccgcggcgaagatg


 


Homo sapiens eukaryotic translation initiation factor 2D


(EIF2D):


(Seq ID No: 532)



gggcccttttcgcggccgggccccagcatggctgcccccac



ggctgagggcctggcagctgctgcgccctcgctttctt


gacattccctggcttctgtgctctcttccccaggccaccccagcagacatg


 


Homo sapiens histamine N-methyltransferase (HNMT):


(Seq ID No: 533)



ctgtctttctcagaaaaccaaatatg



 


Homo sapiens ras-related C3 botulinum toxin substrate 1


(rho family, small GTP binding protein Rac1) (RAC1):


(Seq ID No: 534)



gtttctctgcagttttcctcagctttgggtggtggccgctgccgggcatcggcttccag



tccgcggagggcgaggcggcgtggacagcggccccggcacccagcgccccgccgcccg


caagccgcgcgcccgtccgccgcgccccgagcccgccgcttcc


tatctcagcgccctgccgccgccgccgcggcccagcgagcggccctgatgcaggccatca


agtgtgtggtggtgggagacggaaacaagaatctcagtgtaacccgag


caaaatcgcgcgtctcagcgttgcttgtatagagctgtaggtaaaacttgcc


tactgatcagttacacaaccaatgcatttcctggagaatatatccctactgtcttt


gacaattattctgccaatgttatg


 


Homo sapiens signal recognition particle 72 kDa (SRP72):


(Seq ID No: 535)



tcgtctcctccaagatg



 


Homo sapiens zinc finger protein 33B (ZNF33B):


(Seq ID No: 536)



ccgcctttccttttgtttgtctcacgttttgcgtgggaggcggtcccgggat



ttcaggggtctaccggctctcttatggcgaatgcaacccgaagagagagtgagctg


tatcttcagagttgtctccgtctttccaagaacagaacaaaatg


 


Homo sapiens zinc finger protein 16 (ZNF16):


(Seq ID No: 537)



gcctcctttccaa



gcgcgacccgttgaggtccttgtcatg


 


Homo sapiens zinc finger protein 33A (ZNF33A):


(Seq ID No: 538)



ccgcctttccttttgtttttctcaggttttgcgtgggaggcggtcccgggatttcaaggg



tctacgcgcttttctatggcgaatgcaacccgacgagggagtgggctgtatcttcagagt


tgtctccgtctttccaagaacagaacaaaatg


 


Homo sapiens butyrophilin, subfamily 3, member A3 (BTN3A3):


(Seq ID No: 539)



ctttctttttcctttcttcggaatgagagactcaaccataatagaaagaatggagaac



tattaaccaccattcttcagtgggctgtgattttcagaggggaatactaa


gaaatggttttccatactggaacccaaaggtaaagacactcaaggacagacatttttgg


cagagctgctcactccttgctcagctcagttttctgtgctt


ggaccctctgggcccatcctggccatg


 


Homo sapiens butyrophilin, subfamily 2, member A2 (BTN2A2):


(Seq ID No: 540)



ctctttgggatgctttgttgtctggtggtgactgtgcccatgggtgagttgtatcg



gaaaatcgtcatgtgaggatcagaggggaaaa


gaaaacagaggcctctggtctctgcctgccctgggtgctcatg


 


Homo sapiens nudix (nucleoside


diphosphate linked moiety X)-type motif 21 (NUDT21):


(Seq ID No: 541)



acgcctcctcttgcgctgtcctgttaatggcgggcagtagccgctgaggggattgcaga



taaccgcttcccgcacggggaaagtctaccctgcctgccac


tttctgctcgccgtcagcgccggagctcgccagcatg


 


Homo sapiens stathmin-like 2 (STMN2):


(Seq ID No: 542)



tgctctttctctagcac



ggtcccactctgcagactcagtgccttattcag


tcttctctctcgctctctccgctgctgtagccggaccctttgccttcgccac


tgctcagcgtctgcacatccctacaatg


 


Homo sapiens katanin p60 (ATPase containing) subunit A 1


(KATNA1):


(Seq ID No: 543)



caccctcttccgccgctcccgcccagcgacctcgctcccggggcgac



gccccgcgtgcgccagagtcgccgaggtcgtccccggcaccg


gaagtgaccctggcgggtttgtcttcaaattctcggcgagcaggagccgcgccgg


caggtggtgttgacgattgaactgggcagtactggggccgtgagcggagag


caaagtgggctggactgggtcaggccctccttcctcgctgccgggatctccac


tccgccaatcccctgtgcctggcgttgggcggtttcccgaggagcttgggccgccg


cagcttacagttgaacatg


 


Homo sapiens butyrophilin, subfamily 3, member A2 (BTN3A2):


(Seq ID No: 544)



ctttctctttttcctttcttccggatgagaggctaagccataatagaaagaatgga



gaattattgattgaccgtctttattctgtgggctctgattctccaatgggaatac


caagggatggttttccatactggaacccaaaggtaaagacactcaaggacaga


catttttggcagagcatagatg


 


Homo sapiens CLK4-associating serine/arginine rich protein


(CLASRP):


(Seq ID No: 545)



cggcctttcatttccgcttccggtgcgggccgcgcgcgagcg



cagcggtgggaggcggcgaccagccggttgaggccccaggcttggcctcaccacaatg


 


Homo sapiens clathrin, light chain A (CLTA):


(Seq ID No: 546)



ctccctcctggcgcttgtcctcctctcccagtcggcaccacagcggtggctgccgggcgt



ggtgtcggtgggtcggttggtttttgtctcaccgttggtgtccgtgccgttcagttgccc


gccatg


 


Homo sapiens NADH dehydrogenase (ubiquinone)


flavoprotein 1, 51 kDa (NDUFV1):


(Seq ID No: 547)



gcgtctctatcgcgccag



ttcctcagcctcagtgctatgaaggtgacagcgtgaggtgacccatctggcccgccg


cgatg


 


Homo sapiens signal sequence receptor, gamma (translocon-


associated protein gamma) (SSR3):


(Seq ID No: 548)



gggcctttgcccgcctt



ggcggccggctctacgttccctgttctcgcctgcagctccgccatg


 


Homo sapiens valosin containing protein (VCP):


(Seq ID No: 549)



gcttcccttccgatgattcggctcttctcggctcagtctcagcgaagcgtctgcgac



cgtcgtttgagtcgtcgctgccgctgccgctgccactgccactgccacctcgcg


gatcaggagccagcgttgttcgcccgacgcctcgctgccggtgggaggaagcga


gagggaagccgcttgcgggtttgtcgccgctgctcgcccaccgcctggaa


gagccgagccccggcccagtcggtcgcttgccaccgctcg


tagccgttacccgcgggccgccacagccgccggccgggagaggcgcgcgccatg


 


Homo sapiens zinc finger protein 195 (ZNF195):


(Seq ID No: 550)



gggccttt



gtcccgacagagctccacttcctgtccccgcggctctgtgtcccctgctagccg


taggtcgtgtgacccgcaggcaccgggagatccagaagtgaaacgccaggctctctg


gaggccaggagatg


 


Homo sapiens testis-specific kinase 2 (TESK2):


(Seq ID No: 551)



cag



tctttcgcggcccgggagctcagcagagctaccagctgccctgttggcttcgctggtcg


gatcgtcctcctggccccgccaaacaggcggggg


gagcggccccgactgtggggccatggcagtag


tctcctcgttcgccgccgccgctagcctagctgag


tcgccggcttctgcgctaggggctcccaccgcctccgcaggctaaggagccgctgccac


caacgagctgtgagggttactatgctccctctttgccgccgtctcctcctctt


gcccgcgcaggcacccctctggctgctcagtcctgcctcagtgtcaaaccagaaga


gaagtaaaattcaacaaaaatttatgtgtggagttccttcttaaaagaa


gaaaaaagtgattatttagactatg


 


Homo sapiens family with sequence similarity 107, member A


(FAM107A):


(Seq ID No: 552)



agccctccttgctagtctgggacttcccggtggagtgaggaacccag



caacacgctcctgacttcccttcccaaggactcgacctgagaaggacacagcag


tctctgaatttcatgctctcctctttgatgtgaagaaaatgaaaagctgaacagttgtg


gaactgtggatagagttagacaataaggccgccatg


 


Homo sapiens serine/threonine kinase receptor associated protein


(STRAP):


(Seq ID No: 553)



ccctccctccctttccctccctcgtcgactgttgcttgctggtcgcagactccctgaccc



ctccctcacccctccctaacctcggtgccaccggattgcccttcttttcctgttgcccag


cccagccctagtgtcagggcgggggcctggagcagcccgaggcactgcagcagaagagag


aaaagacaacgacgaccctcagctcgccagtccggtcgctggcttcgccgccgccatg


 


Homo sapiens mitochondrial ribosomal protein L3 (MRPL3):


(Seq ID No: 554)



ctttctttccgtcgcagagagcatcggccggcgaccgttccggcggccatt



gcgaaaacttccccacggctactgcgtccacgtggcggtggcgtggggactccctgaaa


gcagagcggcagggcgcccggaagtcgtgagtcgagtcttcccgggctaatccatg


 


Homo sapiens zinc fingers and homeoboxes 1 (ZHX1):


(Seq ID No: 555)



ctcccttccccctccgcccccggacggccgctggggcgcgcgcctctcctcg



cacccccaccctgagtccccacactccgcggggccaccgagctgctgaggccccttt


gcgggcccgccgagcggttccgggtttagggttcacaggtcagagtt


gactccctgaaaagtgcagccggtttgaaatgcaagatggcggcggcgtggcgctga


gaggcgcggcggcccctgcaggagaagacagactgctgctttggacctgttgg


taatgatggcctgagctaaacatctaactagaagggatacccttccatttcaaa


gaacagaatgctaaggaagctgtggcaagtgattggagtt


gtgcttcaaaaatttcagaaattcagcagtattttatctgccaacaataa


gctctttacttgattgcaccatgagaaagctgctaatgagacttgttgag


cacaaaaatggacttgaagaaccaaaagccattgttttcaaatgaagaacactgaacag


ttttaagcctcgatgctttttaatcaccactgagcttttcctcataacatcagaatg


 


Homo sapiens calcium binding protein P22 (CHP):


(Seq ID No: 556)



ccttccttccctccctccttccctcctgtcgccgtctcttctggcgccgctgctcccg



gaggagctcccggcacggcgatg


 


Homo sapiens ecdysoneless homolog (Drosophila) (ECD):


(Seq ID No: 557)



ctttctctcaggatttccgctggcttcaggttccggtcaggcgtcgg



gacagagcctgatccaggcttcggcggccggtggcagctctcgatcagctctcgcag


tcggagaggcggctaaggaaaggtgccacagcagagacgcgaaggagaggccctagaac


cttttcaaagaagaatg


 


Homo sapiens V-set and immunoglobulin domain containing 4


(VSIG4):


(Seq ID No: 558)



gagcctctttggtagcaggaggctggaagaaaggacagaagtagctctgg



ctgtgatg


 


Homo sapiens prohibitin 2 (PHB2):


(Seq ID No: 559)



tgccctttctttcgccagccttac



gggcccgaaccctcgtgtgaagggtgcagtacctaagccggagcgggg


tagaggcgggccggcacccccttctgacctccagtgccgccggcctcaagatcagacatg


 


Homo sapiens signal transducer and activator of transcription


1, 91 kDa (STAT1):


(Seq ID No: 560)



ctgccttttctcctgccgggtagtttcgctttcctgcgcagagtctgcggaggggctcgg



ctgcaccggggggatcgcgcctggcagaccccagaccgagcagaggcgacccagcgcgct


cgggagaggctgcaccgccgcgcccccgcctagcccttccggatcctgcgcgcagaaaag


tttcatttgctgtatgccatcctcgagagctgtctaggttaacgttcgcactctgtgtat


ataacctcgacagtcttggcacctaacgtgctgtgcgtagctgctcctttggttgaatcc


ccaggcccttgttggggcacaaggtggcaggatg


 


Homo sapiens heat shock protein 90 kDa alpha (cytosolic),


class B member 1 (HSP90AB1):


(Seq ID No: 561)



agctctctcgagtcac



tccggcgcagtgttgggactgtctgggtatcggaaagcaagcctacgttgctcac


tattacgtataatccttttcttttcaagatg


 


Homo sapiens cancer susceptibility candidate 3 (CASC3):


(Seq ID No: 562)



cgttctccgtaagatg



 


Homo sapiens nuclear cap binding protein subunit 2, 20 kDa


(NCBP2):


(Seq ID No: 563)



gcttctctgcactatg



 


Homo sapiens non-POU domain containing, octamer-binding (NO-


NO):


(Seq ID No: 564)



cgctcttttctcgggacgggagaggccgtgtagcgtcgccgttactccgagga



gataccagtcggtagaggagaagtcgaggttagagggaactgggaggcacttt


gctgtctgcaatcgaagttgagggtgcaaaaatg


 


Homo sapiens lectin, galactoside-binding, soluble, 9


(LGALS9):


(Seq ID No: 565)



atttctttgttaagtcgttccctctacaaaggacttcctag



tgggtgtgaaaggcagcggtggccacagaggcggcggagagatg


 


Homo sapiens chaperonin containing TCP1, subunit 5 (epsilon)


(CCT5):


(Seq ID No: 566)



cggtctccgccggttggggggaagtaattccggttgttgcaccatg



 


Homo sapiens haloacid dehalogenase-like hydrolase domain containing


1 (HDHD1):


(Seq ID No: 567)



cttcctcctcgcccccacccagacccagaaggcgccaccatg



 


Homo sapiens glutamate dehydrogenase 2 (GLUD2):


(Seq ID No: 568)



cttccttcctagtcgcggggagtctgagaaagcgcacctgttccgcgaccgtcac



gcacccctcctccgcctgccgcgatg


 


Homo sapiens general transcription factor IIIC, polypeptide 3,


102 kDa (GTF3C3):


(Seq ID No: 569)



ggttctctgtcccggttcctggggttgcacagacagaccct



gtaaacatg


 


Homo sapiens general transcription factor IIIC, polypeptide


5, 63 kDa (GTF3C5):


(Seq ID No: 570)



gggtccctcgctggctagtaggagagactggtgcttgccccgcccggtggactaactcgc



ttaattttaaataaaaagtcgaggacacggcggtcgttttcccgaagacatgggccctcc


catgggccatttgctccctggaggccctcgcgtcttgctgagcccggggagttaggatga


cgcgagcggtgagggagcccggaacgattccttcgcggaacaattgaggcgaggcctttg


ggagtactttgtgggacggaccctggcgggccctgccagacgcacagggatg


 


Homo sapiens ancient ubiquitous protein 1 (AUP1):


(Seq ID No: 571)



ccgccttcccaagagcccctgcggccgggcgcgaaaatggcggcggcggcgac



ggccgggcgctcctgaagcagcagttatg


 


Homo sapiens coatomer protein complex, subunit gamma 2


(COPG2):


(Seq ID No: 572)



cggccttcctgcagcctcttccgctcgccggctgcggcgcctgggac



ggttgcggtgggtctgggcgctgggaagtcgtccaagatg


 


Homo sapiens apoptosis antagonizing transcription factor


(AATF):


(Seq ID No: 573)



cggtctctggcggagtcggggaatcggatcaaggcgagaggatccgg



cagggaaggagcttcggggccgggggttgggccgcacatttacgtgcgcgaagcggag


tggaccgggagctggtgacgatg


 


Homo sapiens integrator complex subunit 6 (INTS6):


(Seq ID No: 574)



tctcctctttctccaccacctcgggccccggtgtccccggccagcactatg



 


Homo sapiens F-box and leucine-rich repeat protein 4


(FBXL4):


(Seq ID No: 575)



tcttccttccgggtcgcgctaggccgggcttgcggcggttgtgccg



catctagagagtcggggagccgcccccg


cacccaggccttctcgcgctgcctggtcgctggtgaa


gcccgcggcgcgcgcctctcccggaccctgcagggtaaaagaatgtcacatgtcag


catttgtacctgaagtcagcatgcaaagttcagggtacctggatgaatgccaactttt


gcatttcccatgtgtatcctgtgaccattctatctgggaacatccttcaaagag


ttcatgcatcttactgaggacacctgaccttttgaagcttcataattcacatctagatg


 


Homo sapiens guanine nucleotide binding protein


(G protein), gamma 3 (GNG3):


(Seq ID No: 576)



gctccttctag



catccttcatccttcaggtaccagccatccagacagtgcttgagctgcagaaactga


gaccagacctctggcctggccctccccaggggcctcctttcgtatagtcactgcttctg


catcagatactttcagctgcaactccctactgggtgggg


cacccatttcaggcagaaggttttggtaccctccactgaccctacacccagggctgc


tactgccgcttgtggcttcaggatg


 


Homo sapiens histidyl-tRNA synthetase 2, mitochondrial (putative)


(HARS2):


(Seq ID No: 577)



aggccttttgttcctgtcccggaaagccggcgtcctgccgcg



cgatg


 


Homo sapiens interleukin enhancer binding factor 3, 90 kDa


(ILF3):


(Seq ID No: 578)



cctcctcctcctcttctcgccattgcagttggacccagcagcccggcgcg



caccgcgtggcttttgggggcagaccccggcgggctgtggcag


gagggcggcggcggcggctgcggtcgaagaaggggacgccgacaagagtt


gaagtattgataacaccaaggaactctatcacaatttgaaaagataagcaaaagttt


gatttccagacactacagaagaagtaaaaatg


 


Homo sapiens polymerase I and transcript release factor


(PTRF):


(Seq ID No: 579)



gtttcctctgctctccgctctcgcccgctagctctcctcccttccgctcctgcttctctc



cgggtctcccgctccagctccagccccacccggccggtcccgcacggctccgggtagc


catg


 


Homo sapiens 5′-3′ exoribonuclease 2 (XRN2):


(Seq ID No: 580)



tgccctctgccgctgctcccgtctctttggttac



gctcgtcagccggtcggccgccgcctccagccgtgtgccgctatg


 


Homo sapiens 2-hydroxyacyl-CoA lyase 1 (HACL1):


(Seq ID No: 581)



ccgcctcttccttcccgttgtttaaggcagttggttgccctcctgtccgtcagaggtg



cagtaccagaggtggcgtgctgccgatttcgcgtttgccttgctggatgattccgctt


gtttgccggctgcgtgagtgcttagagcttttcggtggaagatg


 


Homo sapiens zinc finger protein 346 (ZNF346):


(Seq ID No: 582)



ggctctctac



cggtgagggtttgcggggaagatg


 


Homo sapiens microtubule-associated protein, RP/EB family, member


3 (MAPRE3):


(Seq ID No: 583)



cagtctctgtgcgttgaagccggagac



cgcggcggcctcagcgaggaccctccgccccggagccgccggccggagccg


cagcctctgccgcagcgcccccgccacctgtcccctccccctccgcctccgccg


gagccgcctcgtgcactctggggtatg


 


Homo sapiens splicing factor 3b, subunit 3, 130 kDa (SF3B3):


(Seq ID No: 584)



gtgcctttttccgccgcgcgccaccagaatgtccctgtcttgaggtctaatggcggac



gccagtatgttggagttggtggtggcttaagttttgaagggaggtagcatccgttgga


tatccacaccatccttctcgctgcaggctttcttggactccgtactgttggtgtaac


caaggcctggaggtctgggtggctcaggtttcctgcagccatg


 


Homo sapiens spondin 2, extracellular matrix protein


(SPON2):


(Seq ID No: 585)



ctgcctctcgctggaggccaggccgtgcagcatcgaagacaggag



gaactggagcctcattggccggcccggggcgccggcctcgggcttaaa


taggagctccgggctctggctgggacccgac


cgctgccggccgcgctcccgctgctcctgccgggtgatg


 


Homo sapiens solute carrier family 13 (sodium/


sulfate symporters), member 4 (SLC13A4):


(Seq ID No: 586)



ttttcttttctgctttgcaggcccaggctcaaggcaaattataagtagggaaccaatttg



agggaaagacatgtgaacagagttaaggtaccacgtcctgggagcgaccagcagccccac


ctgaagtccgcatgcaactctgacaagctcaggtgcttgttttaaggaaaggggctacta


gagtcttaccaacagcgagcccaggtgggagatgaaacaggtactccccaaaataggtca


tccgagggaggaaaactgatggagagcacaatgtgctctgagcgtttttaatgtttttaa


gcttttaaatgatttcttcaaggccgagcagcagcagcaaaggtgtggcttaaaggatta


agggggtttctgctgacacctagaatgaagttactctattactaatcaagccgagaggag


gcccactatgcccccgtttatcatcctttcccagttcctttttgctggtcacaaaacgat


gctcatcaatcccacctaaagcaggaggccaggagcccagcctcttgtagaaacagcgag


ggtataactgccctcccgttctgcccccaagacgaaggaggactctcggaagccaagaaa


ggtttaagaagtctttctggatagagagcagtgcccaggcaggaagcctttcgccggcag


agcggggtccaaggacgagctggagaggacagaggcgcgatg


 


Homo sapiens PRP6 pre-mRNA processing factor 6 homolog


(S. cerevisiae) (PRPF6):


(Seq ID No: 587)



attcctttccttcctagccttggtcgtcgccgc



caccatg


 


Homo sapiens eukaryotic translation initiation factor 3, subunit


K (EIF3K):


(Seq ID No: 588)



ccacctcttcctgttcccgtccttgaggacgccgtgccgggtcag



tgttagcctccagccctggttgtggaaggcgacagaagtcatg


 


Homo sapiens ataxin 10 (ATXN10):


(Seq ID No: 589)



ccccctcccccgcggcgccgtctcctcctcccgcctgaggcgagtctgggctcagccta



gagctctccggcggcggcgcagcttcagggcagcgcgggctg


cagcggcggcggcggttagggctgtgtagggcgaggcctcccccttcctcctcgccatcc


tactcctccctcctcgtcatcctcccccttcgtcctcctcgccttcctcctcctcgtcag


gctcgacccagctgtgagcggcaagatg


 


Homo sapiens secretogranin III (SCG3):


(Seq ID No: 590)



cttccttcctcac



ttcctctgcaggagggagcgagagtaaagctacgccctggcgcgcag


tctccgcgtcacaggaacttcagcacccacagggcggacagcgctcccctctacctgga


gacttgactcccgcgcgccccaaccctgcttatcccttgaccgtcgagtgtcaga


gatcctgcagccgcccag


tcccggcccctctcccgccccacacccaccctcctggctcttcctgtttttactcctcct


tttcattcataacaaaagctacagctccaggagcccagcgccgggctgtgacccaa


gccgagcgtggaagaatg


 


Homo sapiens polymerase (DNA directed), mu (POLM):


(Seq ID No: 591)



cttccttccgtctcgctcggagtttccctctgcgttcgctccgcgctgctg



gaggctgtcgtcccaatg


 


Homo sapiens epsin 1 (EPN1):


(Seq ID No: 592)



cctccttctgtt



gcttcccgtctcctcggcggctcccctcccccgcccggctctccgcgccccttctgggcg


gcggggcggcggagccgtcggcgtgcggccctcctt


gcgttcgtgcgtgcgcccgtggcccggcgcacgtcccgcgacaccgaggccgagcgggg


cagggggctgaccgccatgaccccccagagcccggcgtgagggggccga


gatgcggtgacctgccagcacctgccgcagccttcgtccgggag


tcgccccatctctccacgcatcggggccctgtgccccttgctgctgcagccgggcac


catg


 


Homo sapiens Sec61 alpha 1 subunit (S. cerevisiae)


(SEC61A1):


(Seq ID No: 593)



gtgtctctcggcggagctgctgtgcagtggaacgcgctgggccgcggg



cagcgtcgcctcacgcggagcagagctgagctgaagcgggacccggagcccgag


cagccgccgccatg


 


Homo sapiens Obg-like ATPase 1 (OLA1):


(Seq ID No: 594)



cgttctctcctccttcctccccgcctccagctgccggcaggacctttctctcgctgccgc



tgggaccccgtgtcatcgcccaggccgagcacgatg


 


Homo sapiens sorting nexin 12 (SNX12):


(Seq ID No: 595)



ag



gcctctgtcccccaccccctttccccggtcccaggctctccttcggaaagatg


 


Homo sapiens LAG1 longevity assurance homolog 2


(S. cerevisiae) (LASS2):


(Seq ID No: 596)



cggcctttttttcccggctgggctcgggctcagctcgactgggctcggcgggcggcggcg



gcggcgccggcggctggcggag


gagggagggcgagggcgggcgcgggccggcgggcgggcggaagagggagga


gaggcgcggggagccaggcctcggggcctcggagcaaccacccgagcagacggag


tacacggagcagcggccccggccccgccaacgctgccgccggctactccctctt


gatgccctcccctttgcccctcactcaggatg


 


Homo sapiens cytohesin 4 (CYTH4):


(Seq ID No: 597)



tcatcttttcccca



gaggcgtcggaatg


 


Homo sapiens transportin 2 (TNPO2):


(Seq ID No: 598)



aattctctctcttt



ggctccctccttccgcgcgagtctctggagaagccgcagcgcgagtt


gccgccgctgctgcccggggccgggtaagtgggcctcactcagagcccgaccctctt


ggccccggcttgcgtcgacccccgccgggcac


cgagcctgcgccgcgcgcggcccgggcgtcggggccgcgcccgaccgggaaaggccgg


gaagccggttgggcccgatcctcctggcagctagaacgggccgggcgggggaggggg


gaaccgagcagagcttagggggtggggcctcggagccaggccatgtcggggctcctcaa


gaagagggccagtgggactgctggggtcgggctggaggggatctgattgggggaa


gcgtctggggactgcttggggcctgattgggggacgtcgcgaggatcggcttgcctt


gcgccatg


 


Homo sapiens makorin ring finger protein 1 (MKRN1):


(Seq ID No: 599)



gggcctttgctgtgtgggataaacagtaatg



 


Homo sapiens vinculin (VCL):


(Seq ID No: 600)



ctgtctcttcgccggttcccggccccgtg



gatcctacttctctgtcgcccgcggttcgccgccccgctcgccgccgcgatg


 


Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 38


(DHX38):


(Seq ID No: 601)



cctccttttcctgcccccagactagaggcgggatgtag



tctcttaggctaagagtgattggtcacaaggagactcg


gaagtgtctgatcagagccccagaggaggccttgagagcctgttggcgtac


cgttccacacttggatccaggaatcgggcgtgttccaggctgctctctatggtagcttt


gggcggatagagggggcgcgcaaagtattaagggacaa


taatggccgctttcaaggtgtggattttggctccttgagcctgtctgagcgaggggtgg


cagcgccggcgccccagaatccgggacagaagggtcccaagagtcgcgcttggtgaga


gaaatcccagatcctgtgatg


 


Homo sapiens osteoglycin (OGN):


(Seq ID No: 602)



catcctctaagcttttaaatattgcttcgatggtctgaatttttatttccagggaaaaag



agagttttgtcccacagtcagcaggccactagtttattaacttccagtcaccttgatttt


tgctaaaatg


 


Homo sapiens NIN1/RPN12 binding protein 1 homolog


(S. cerevisiae) (NOB1):


(Seq ID No: 603)



gctcccctctcacgcagccaacatg



 


Homo sapiens nudix (nucleoside


diphosphate linked moiety X)-type motif 5 (NUDT5):


(Seq ID No: 604)



catccttttagcaccgcgagaggcgccggtgtttcgagccgtggcaccgg



catcggctgacactgctgcctccagctag


ttatttcgtcctcttccgttcttcacccctacaccttggaggtgaacttctcac


ctgagggctgtaaagactcgtttgaaaatg


 


Homo sapiens WD repeat domain 91 (WDR91):


(Seq ID No: 605)



cgtccctcaccgcac



cacccctaaagacgctagcgctgcgatg


 


Homo sapiens nuclear transcription factor Y, gamma (NFYC):


(Seq ID No: 606)



gggcctctgcattgcccgactccgtaggagcgcgggggcggctcctgctcttcctg



gactcctgagcagagttgtcgagatg


 


Homo sapiens protein phosphatase 2, regulatory subunit A, alpha


(PPP2R1A):


(Seq ID No: 607)



ccgcccttccttcttctcccagcattgccccccccacgtttcag



cacagcgctggccgcagtctgacaggaaagggacggagccaagatg


 


Homo sapiens vesicle-associated membrane protein 2 (synaptobrevin


2) (VAMP2):


(Seq ID No: 608)



ccatctttccgtcccgggcagccagcgccagtcg



gagccagcgcgagccgccgccgccatcac


tgccgctgccaagtcctccacccgctgcccccgccatg


 


Homo sapiens transmembrane protein 5 (TMEM5):


(Seq ID No: 609)



gat



tctctttccgcccgctccatggcggtggatgcctgactggaagcccgagtgggatg


 


Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase


3 (B3GNT3):


(Seq ID No: 610)



aactctttcttcggctcgcgagctgagaggag



caggtagaggggcagaggcgggactgtcgtctgggggagccgcccag


gaggctcctcaggccgaccccagaccctggctggccaggatg


 


Homo sapiens SEC11 homolog A (S. cerevisiae) (SEC11A):


(Seq ID No: 611)



gcgccctttcccctgccggtgtcctgctcgccgtccccgccatg



 


Homo sapiens RUN and SH3 domain containing 1 (RUSC1):


(Seq ID No: 612)



ctccctccccgcgccccgtcctctcccgccctacaggccctagcagggcaggcgggaggt



gagcgcggccatcccgctcccggagttccgggatcctggagtccgtagttcgtggtcctt


cgccggtgtccccggagcccagcggctgtggatg


 


Homo sapiens aryl hydrocarbon receptor interacting protein-like


1 (AIPL1):


(Seq ID No: 613)



cctccctttctcctgcagccatg



 


Homo sapiens tumor necrosis factor, alpha-induced protein 8


(TNFAIP8):


(Seq ID No: 614)



cctccttttctcccgccggctctaacccgcgctt



ggctaaggtccgcgggaacccgtgagccaccgagagagcaga


gaactcggcgccgccaaacagcccagctcgcgcttcagcgtcccggcgccgtcgcgccac


tcctccgatg


 


Homo sapiens staphylococcal nuclease and tudor domain containing


1 (SND1):


(Seq ID No: 615)



gcgtctctttcgctccgtgtcccgctgctgctcctgtgagcgcccggcgag



tccgtcccgtccaccgtccgcagctgg


tagccagcctgcccctcgcctcgactccctttcaccaacaccgacacccacattgacac


ctccagtccggccagccgctccactcgttgcctttgcatctccacacatg


 


Homo sapiens DNA segment on chromosome 4


(unique) 234 expressed sequence (D4S234E):


(Seq ID No: 616)



cgccctctttt



ggtcgccccctccccaacccagcactaaggagcaccctgctctggtctccgccac


cacccagcgcctcctggacccatccccccaaacccttgaacgtcctcag


gacccccaggtgagcgcggcgcgctgcgggcggggaccctctctgcacctccccg


cacccctgggggtcgctctgtccctacggtccccgcctcccctttctcctttctaa


gcgcctcgcgcccaggccgccgcccggggtggcgcagcccg


cagccctcccgctccgggcgccctccgccgctccga


gaccccctgggggcgcgtcctctcccgctcccctgttccctcccccggctcagggcgggc


gcgtggtcccaggggaggctcccgcccagccccgcactccttt


gtgcggccgggcgggcgctgcgtcaaggtggaggcgcggccacacgcgcg


cacccacccgcgcgcacccagcccccgggagaggcaggaagggaggcggcggcgcgag


gaggagggagcggccgtg


gagcccaatcgttcgctccccttcccgggtccgcgcgcggcgccgcctccgccatt


gctgcgagcaggagcaggagacgcggagctcggagcgctcagctgacctgccg


gagccgggcgtgggctgcagcctcggagctcccggaacgatg


 


Homo sapiens growth hormone inducible transmembrane protein


(GHITM):


(Seq ID No: 617)



acgtcctttcgatgttgcgtcatgcagtgcgccggag



gaactgtgctctttgaggccgacgctaggggcccg


gaagggaaactgcgaggcgaaggtgaccggggaccgagcatttcagatctgctcgg


tagacctggtgcaccaccaccatg


 


Homo sapiens stress-associated endoplasmic reticulum protein


1 (SERP1):


(Seq ID No: 618)



tttccttcctctttcactccgcgctcacggcggcggccaaagcggcggcgacggcggcgc



gagaacgacccggcggccagttctcttcctcctgcgcacctgccccgctcggtcagtcag


tcggcggccggcgcccggcttgtgctcagacctcgcgcttgcggcgcccaggcccagcgg


ccgtagctagcgtctggcctgagaacctcggcgctccggcggcgcgggcaccacgagccg


agcctcgcagcggctccagaggaggcaggcgagtgagcgagtccgaggggtggccggggc


aggtggtggcgccgcgaagatg


 


Homo sapiens ADP-ribosylation factor interacting protein 1


(ARFIP1):


(Seq ID No: 619)



cggtctcctcacttccggcttcgctgctcttggttctggttctg



gaggctgggttgagaggtcgccggtccgactgtcctcggcggttggtcagtgtgaattt


gtgacagctgcagttgctccccgcccccgagcagccgaggagtctaccatg


 


Homo sapiens tumor necrosis factor receptor superfamily, member


21 (TNFRSF21):


(Seq ID No: 620)



ccgccccttcggcgccaccac



gtgtgtccctgcgcccggtggccaccgactcagtccctcgccgaccagtctgggcagcg


gaggagggtggttggcagtggctggaagcttcgctatgggaagttgttccttt


gctctctcgcgcccagtcctcctccctggttctcctcagccgctgtcggaggagag


cacccggagacgcgggctgcag


tcgcggcggcttctccccgcctgggcggccgcgccgctggg


caggtgctgagcgcccctagagcctcccttgccgcctccctcctctgcccggccgcag


cagtgcacatggggtgttggaggtagatgggctcccggcccgggaggcggcggtg


gatgcggcgctgggcagaagcagccgccgat


tccagctgccccgcgcgccccgggcgcccctgcgagtccccggttcagccatg


 


Homo sapiens sushi-repeat containing protein, X-linked 2


(SRPX2):


(Seq ID No: 621)



ccccctcttctgcagcagacggactgag



ttcctctaatccctgtgttccttctcccccatctttctaaaacccttctctgagagag


gaataactatagcttcagggataatatagctttaaggaaacttttggcagatgtggac


gtcgtaacatctgggcagtgttaacagaatcccggaggccgggacagaccaggagccac


tcgttctaggaatgttaaagtagaaggttttttccaattgatgagaggagcagagag


gaaggagaaagaggaggagagagaaaaagggcacaaaatacca


taaaacagatcccatatttctgcttcccctcacttttagaagttaatt


gatggctgacttctgaaagtcactttcctttgccctgg


tacttcaggccatatacatcttttcttgtctccataatcctccctttcaaggatg


 


Homo sapiens HIV-1 Tat specific factor 1 (HTATSF1):


(Seq ID No: 622)



ac



ctccctttctctgctcagctccagcgtcatttcggcctcttag


ttcttctgaaccctgctcctgagctaggtaggaaacatg


 


Homo sapiens trafficking protein particle complex 2


(TRAPPC2):


(Seq ID No: 623)



gggtctcttccgcggaaactgacattgcgtttccgttgtcggcctcccactgcaggagcc



atatattgaagaccatg


 


Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide


N-acetylgalactosaminyltransferase 5 (GalNAc-T5) (GALNT5):


(Seq ID No: 624)



ccaccttttcttgggcttgtaggaaggtggacatgggctcccggagacaagacaagtga



tatgttgaactgttcggtggctggaatcaactgctcctggagtgacctaaggccag


tgtttatcagaacttagccagggccagccaagcaggcacagatgctctgc


tatgaaatgccacgcaggcagagactgacaagcggtaggaactgagctttcccctt


ggactgctgcttcctgctgtgttcaggggagggggtcactttctgg


caactctgctgctgctgctgctgctgctgctacttcagcttcctctccactcaaggtaa


gcaggctaagggagggcaggctgctagggaaagctttgtaccatg


 


Homo sapiens transmembrane protein 97 (TMEM97):


(Seq ID No: 625)



tggcccctcttctcacatcagcgggtccaggcccaaccgacagactatg



 


Homo sapiens EH-domain containing 2 (EHD2):


(Seq ID No: 626)



cgtcctccccgctccgggccccacccggctcagacggctccggacgggaccgcgag



cacaggccgctccgcgggcgcttcggatcctcgcgg


gaccccaccctctcccagcctgcccagcccgctgcagccgccagcgcgccccgtcgg


cagctctccatctgcacgtctctccgtgaaccccgtgagcggtgtgcagccaccatg


 


Homo sapiens tubulin tyrosine ligase-like family, member 4


(TTLL4):


(Seq ID No: 627)



cgccctcttcttccagactctcggtctgtccgctgggggcgcgcgcggtgtgtgg



caggcggcagcggcgctggcggccgagtgcgcttgtcacgcgtggcggtgcgtggtt


gctaggggcgcctgaggctgccgggtagcccagcaggccgagggaggaagtagcgtg


gagccggtgccgagccggggcgaagctggatcccctagatagactgtcttcaagctcac


tgatattttcctctgcttgatccattgtgctgttgagagcctctag


taaatttttcagactgacagacttcaaggatgcagctgctactaccggaggtgtgtgg


caccttacctcagcaaggccatgagaccgtgtggccatgatgtgggcccctcatg


 


Homo sapiens basic leucine zipper and W2 domains 1 (BZW1):


(Seq ID No: 628)



acctctccctcctcctggcgttagttccggtcgcagaggagacaccgccgcagtt



gccggtacatcggggatttctggctctttcctcttcgccttaaattcgggtgtcttt


tatg


 


Homo sapiens centrosomal protein 57 kDa (CEP57):


(Seq ID No: 629)



ttgccctttctgtgtaagctgtgagcgtaggcggccctgagggggtgtgtt



gcaggggtttccaagcccagcaccagcaccctt


gcccttttccatcaggggttcagcctagggtccccgctggtgggcggctcccgagtctt


ggagaagagcacgagaacctagaccgcccccgaagtgcggagaccccctggg


caggctgaaagatg


 


Homo sapiens family with sequence similarity 115, member A


(FAM115A):


(Seq ID No: 630)



ctgccctttgcctcctgggcggagaagctgcttcctcctgggaacaaccgcctcccgctc



ctagcaggttgctactgccccgaacccgcgctgcagggaacagcggggcaaacagtgagt


ggggttcagcgtagactctggaccaggagaggcccgcggtgaccgaggcctgggccccgg


aaaccaatagagccatg


 


Homo sapiens ATG13 autophagy related 13 homolog


(S. cerevisiae) (ATG13):


(Seq ID No: 631)



agccctctttcaccccccccccccggccattac



cgaagcggatgaaaacaaacactaacgatggcggcgccgggaagcgac


cggctgctgggcttaaggcgggagtgaccgcttaaccagtgagggaagcactgaa


gagcgccagtcgacgtgggtgcgacaactcgcggagtcttaggagcaaaac


gtctggggcctgcgagccaggacccttctgaagccttaggtgtctatcggcgacgtg


tacggtcactgcagctccggagcgcggaaccctcagccag


gaggcgcggctggtcggtcccaggtcccggcctccgtaatgagagcccggaaccac


tctttgtgccgcagcttcgcagcatcttggactcaagtgat


tctcctgcctcagcctcctgagtagctgggactacagattcctataggcaatg


 


Homo sapiens sorting nexin 17 (SNX17):


(Seq ID No: 632)



ccgccttcccacatcg



gatcgcagggctcccaaaatggcgagtgaggctgcggggactcgctgagcagcg


gagggggagcgtgcagagccgctgcggccctcacagtccg


gagcccggccgtgccgtgccgtagggaacatg


 


Homo sapiens phytanoyl-CoA 2-hydroxylase interacting protein


(PHYHIP):


(Seq ID No: 633)



cgttctttctcccttctctgcctctctctcctccacgctgctttgat



ttcgctcttgcctctcttcttgcgctgctcagctgggaacatcgtctcaccaggggcag


cagcgacgcgctgcacagccagacaggagctggctgcggggcatggaagcagcctcctt


ggcagccgggagaggagcaagcgcacgccac


tgcccgtgacccaggcgtccggctgctgtcccctgccggggagctcatccac


gcagaggtctctccctgtcctccctgcgagcttttcctctgcagagcccagtg


gagccagtccccacaggagacaaccctgacgggagcatg


 


Homo sapiens translocase of outer mitochondrial membrane 20 homolog


(yeast) (TOMM20):


(Seq ID No: 634)



cggcctttctgtgttcctggcccgcggccgtcgggtgtgagctgcgccgac



cgctctgagggttcgtggcccaccgctccttcgcggtccctgccgccaccgtccac


gctcagcgttgtagagaagatg


 


Homo sapiens KIAA0141 (KIAA0141):


(Seq ID No: 635)



cggcctttctagccgctgtcccaagggtt



ggtctcgcgctttcggctgcgagctctctgtggtgctggcagcgacatg


 


Homo sapiens janus kinase and microtubule interacting protein


2 (JAKMIP2):


(Seq ID No: 636)



ctccctcctttaaacagcttctccgggtctcagcatgggcttccagggcagcgattgagg



agaccttaccaaggagcaccacacagtagatgctgagacatcgtactccaggataagaaa


cagtaacatggcagcacctgcttgaaagaaattaaaaaccaacagactccatttagaaag


gaacaatg


 


Homo sapiens EPM2A (laforin) interacting protein 1


(EPM2AIP1):


(Seq ID No: 637)



cctcctctccccttgcggcctttctaacgttggccctgctcttgtgg



cctcccgcagaatg


 


Homo sapiens centrosomal protein 170 kDa (CEP170):


(Seq ID No: 638)



cggtcttt



gccgttaccgctatgtgtggggcgtgtgtggaataacgttattgcccagcg


gagctgagggccccggagctcgaccgcagcggcagcgacgacaacagcggcgacgac


gacgacgacgaggtggggggaggacggcgtgcgagagactcacgggacgcgac


gcgccccgcctcccccgtccggtccctctctccacggtaaggggatgacgtagcttt


gccaaagacttagaagctaagcagaaaatg


 


Homo sapiens suppressor of Ty 7 (S. cerevisiae)-like


(SUPT7L):


(Seq ID No: 639)



aggcctctcgaggtccagacagccgcccagcccgctctgcgacgcag



cagtgaatagtgtggtacctccttgtctcggttcaggtccagac


ctccccgtcttccggctgccctgaacgtcaggcgacctcag


gaccctgtgattggcgcctgcgccggcggaccgtgaccgaggaaacccctg


gagggacttgggcattccttgggctccgtgcctgttcttcgtgctcctttcggg


caaggatctcacattatcagtctttgaccgacacagaatgcctggcatttga


taaatgtttgttgaacttgaagagacatatggacaatg


 


Homo sapiens non-SMC condensin I complex, subunit D2


(NCAPD2):


(Seq ID No: 640)



ttttccttttcatttcagcctgactgccggaatcagagccgcgggtga



gatccccagccctgtgagcctgtaggagtagaatg


 


Homo sapiens ring finger protein 10 (RNF10):


(Seq ID No: 641)



ggttctttga



gatgctgtttggcgactcgtcgccattcccggag


caggtcggcctcggcccaggggcgagtatccgttgctgtgtcggagacactag


tccccgacaccgagacagccagccctctcccctgcctcgcggcggga


gagcgtgtccggccggccggccggcggggctcgcgcaac


ctccctcgcctccccttcccccgcagcctccgccccgccaggcccggcccg


gactcccgagccccggcctcctcgtcctcggtcgccgctgccgccgggcttaacagcccc


gtccgccgcttctcttcctagtttgagaa


gccaaggaaggaaacagggaaaaatgtcgccatgaaggccgagaac


cgctgccgccgccgacccccgccggccctgaac


gccatgagcctgggtccccgccgcgcccgctccgctccgactgccgtcgccgccgaggcc


cccgttgatg


 


Homo sapiens PAN2 poly(A) specific ribonuclease subunit homolog


(S. cerevisiae) (PAN2):


(Seq ID No: 642)



agcccttcttgattggaagaagcgcctcg



gaccccggtccttggcgccgtagtggttaggttgagccctaggcgtggggga


gaactggggaaactggaatttcccgcggagctgacagcgctt


gcgctccccctactcgttctaattccacgcgctccaaaatatccgccatgga


gaaatcttggccaggatgtccattctaggcccatcggtgctgtcttgctgaaggtt


gggtcaggcatctaaagggactgtggtaagggagggtgtgacacaggtgtaa


gctgccatcgtcatcatg


 


Homo sapiens CD302 molecule (CD302):


(Seq ID No: 643)



gctcctctccggccgcg



cagccgctgccgcccacccgcacccgccgtcatg


 


Homo sapiens NSA2 ribosome biogenesis homolog


(S. cerevisiae) (NSA2):


(Seq ID No: 644)



gactctttcctgtcccggcctgcgtggtgtgggcttgtgggtctttga



gacccgaaaattgagagcgttttcgcac


tccagcggctgctcctggcggctctgcggccgtcaccatg


 


Homo sapiens DIS3 mitotic control homolog (S. cerevisiae)


(DIS3):


(Seq ID No: 645)



acgccttttgctggaagagcgctgctggggttaggattctgcgcggcgagg



caagatg


 


Homo sapiens caspase recruitment domain family, member 8


(CARD8):


(Seq ID No: 646)



cctcctctgcgagcgttatttcaaaagaagttgagaaccagagaaac



cgacctaaggggattctcccatttggcccgtcctaccctaaagtcaccac


ctgctgcttttctggagcgcttaccagtgaccaagaggaacagaacacagag


cagcctggcagtgtccaagcaacaagcctccgctcctccttcctg


caccctggggctcctgaaactcacatgggtaaaaaagatacagtaaagacataaatac


cacatttgacaaatg


 


Homo sapiens epsin 2 (EPN2):


(Seq ID No: 647)



ccgcctctcgagcgctgccggtggccg



cagcggcgcacccacgccggcccggaggagcagagtgttcatttctgtgtcgggcacag


tgctaagtgctgggtgctcactggtgatgaggcagatgaaggttaccaaacttgtg


gacaggagcctcatatcagagacgtggacctcactg


tagcctggtcatggcttccagcttttcgaatctgaggctccaaaggaggaaatgac


cattcagggatcttactccagcttgattacggagactgaaccttcatagggtgcgcac


ttaccaaggacaggaaggtttctctgtttgaagggctttaaacttataacaaagaaaa


taaaaatg


 


Homo sapiens pyridoxal-dependent decarboxylase domain containing


1 (PDXDC1):


(Seq ID No: 648)



ccgcctctcaaccatcaggttcggcagcccgcggcgccgcctgg



cagctcctcctcttctccgccccgccggccgcgggcgcgggggac


gtcagcgctgccagcgtggaaggagctgcggggcgcgggaggaggaagtagagcccgg


gaccgccaggccaccaccggccgcctcagccatg


 


Homo sapiens nicotinamide nucleotide adenylyltransferase 2


(NMNAT2):


(Seq ID No: 649)



ccttcctttctccctctgcagacacaacgagacacaaaaaga



gaggcaacccctagaccaccgcgaaggacccatctgcaccatg


 


Homo sapiens mitochondrial ribosomal protein S27 (MRPS27):


(Seq ID No: 650)



tgttccttttggtacgctccaagatg



 


Homo sapiens leucine-rich repeats and calponin homology


(CH) domain containing 1 (LRCH1):


(Seq ID No: 651)



tcccctccttccagcgcctttcggtggagcactgcggcac



tcagcccgagctgccgttttcccctcgcggggaacgctgtgacccccccgcag


gagcggcggggcggggtgggggggcccgggagaagatg


 


Homo sapiens PAS domain containing serine/threonine kinase


(PASK):


(Seq ID No: 652)



gctcctttccgtggtgtgtagccggcttggcgtgaccctcgcctgatccagttgttagag



ttggaagcttggcagttggcctcccttcttcccatg


 


Homo sapiens megalencephalic leukoencephalopathy with subcortical


cysts 1 (MLC1):


(Seq ID No: 653)



cttcctttcctagttgggttctgacagctccgaggcag



tggtttacacaaccaacacgaaacatttctacgatccacccgattcctcccctcattga


tattcaggaagcagctctccttcccctgccttcagctcaagtttgctgagctttt


gtttcatttgtgaatacttcttgctggaagtccctcacccagagaccagtgctcccaac


ggcagagcagcgggggagataaagaactggtgacacgtggctgtacattcag


cacagctgtggtgtccccaagtgccatg


 


Homo sapiens RRS1 ribosome biogenesis regulator homolog


(S. cerevisiae) (RRS1):


(Seq ID No: 654)



ctttcttttccggattgggcatcccggcatctg



cacgtggttatgctgccggagtttgggccgccactgtaggaaaagtaacttcagctg


cagccccaaagcgagtgagccgagccggagccatg


 


Homo sapiens formin binding protein 4 (FNBP4):


(Seq ID No: 655)



cgctctctgctcgcgcttgggctcgcgatg



 


Homo sapiens peptidylprolyl isomerase domain and WD repeat containing


1 (PPWD1):


(Seq ID No: 656)



gcgccttttctgacgatgcgaacaacatg



 


Homo sapiens sorting and assembly machinery component 50 homolog


(S. cerevisiae) (SAMM50):


(Seq ID No: 657)



ccgccttctgccctcagcagcagac



gctctgtcccgcccgggcagctctgcgaggcagcggctggagagggaaccatg


 


Homo sapiens Yip1 domain family, member 3 (YIPF3):


(Seq ID No: 658)



gcttctcctttttgtgttccggccgatcccacctctcctcgaccctggacgtctac



cttccggaggcccacatcttgcccactccgcgcgcggggctagcgcgggtttcagcgac


gggagccctcaagggacatg


 


Homo sapiens tectonin beta-propeller repeat containing 1


(TECPR1):


(Seq ID No: 659)



caccctcttgcccggtccccgggagggccggtccgctcctcccggac



gccgaggacctaccaccgcgacttcgccccgcccggcgcgggcccag


gaccctgatgtcgcttttgaacagcccctgcacctggcagccagcgagctactgtag


taggcattgccgactgtttgcataccggatgggagtgacagtgtaatagaaaaacaa


gcaagaaaccttttaggtaggactcctaaggctcagaggaagttacctccagccgctgc


catg


 


Homo sapiens DDB1 and CUL4 associated factor 12 (DCAF12):


(Seq ID No: 660)



ccttccctttcccggctcaagtccttcctctctctttcctttctttccgcctatcttttt



tctgctgccgctccgggtccgggccattttccgggccgggcgcactaaggtgcgcggccc


cggggcccagtatatgacccgccgtcctgctatccttcgcttcccccgccccatgtggct


gcggggccgcggcggcgctgcccactatg


 


Homo sapiens chromosome 3 open reading frame 17 (C3orf17):


(Seq ID No: 661)



ccgcctttcgtaagtccccccgcctcgcatg



 


Homo sapiens LETM1 domain containing 1 (LETMD1):


(Seq ID No: 662)



caac



ctcttctctcccgcttctctcgctgtgaagatg


 


Homo sapiens chordin-like 2 (CHRDL2):


(Seq ID No: 663)



ctcccttctgctggac



cttccttcgtctctccatctctccctcctttccccgcgttctctttccac


ctttctcttcttcccaccttagacctcccttcctgccctcctttcctgcccac


cgctgcttcctggcccttctccgaccccgctctagcagcagac


ctcctggggtctgtgggtt


gatctgtggcccctgtgcctccgtgtccttttcgtctcccttcctcccgactccgctccc


ggaccagcggcctgaccctggggaaaggatg


 


Homo sapiens CCR4-NOT transcription complex, subunit 10


(CNOT10):


(Seq ID No: 664)



actcctctagccggaacctgggggcccggagccggggtaggcacagag



ttgtcctcggaggtccaggacagcggccagcccggcggcgggagtcagggccacgccac


ctgcagggaagaacccgagtcgaagcgggaagatg


 


Homo sapiens THUMP domain containing 3 (THUMPD3):


(Seq ID No: 665)



cttcctctt



gcagttgaggccggcgccgagccggacttcaggcggatctcgtggcggagcccatctt


gctccctctcccaggcctttacccgctccctaggattcccgggccctgtaggtgggag


ttgggagacgacagtactgcttttaaagagacagtgttagggatcttggaa


gcacagccaacatg


 


Homo sapiens nipsnap homolog 3A (C. elegans) (NIPSNAP3A):


(Seq ID No: 666)



gctcctttccactcgggaaaccttcagaggagtctcagaaaggacac



ggctggctgcttttctcagcgccgaagccgcgccatg


 


Homo sapiens CAP-GLY domain containing linker protein 3


(CLIP3):


(Seq ID No: 667)



gcccctccctctccgcccccaccccctgtcggcgtctgggcctcgtccccttctctctgt



ctcccttgcctcccccatcacgtcccctgacaccgacaccccattgctcccacag


tctccccagtctccactttggtccccagcgctgtctgcccgaggattt


gcctgaaggctgcccccaactctgcacccgccccccgagggccaccgaggaccatg


 


Homo sapiens ring finger protein 167 (RNF167):


(Seq ID No: 668)



cacccttcccgaagtttttctgtcac



ctgtgttaggctccgtcccctttccgcgttttatccccgtaccagaaaaggata


catttagtgcctcccacccagctccactaaacgggttggatatctcattctttgagtt


ggtgttccttccccggcgcccccatgtagctgggaagtgggacctgggggtggtt


ggacccctgggatcctaaaggaggggcagggagggcgcagaactccgcttctgctcctt


gctaccaggacgcgcggcctcctcagcctctttcctcccgctgccatg


 


Homo sapiens polymerase (RNA) II


(DNA directed) polypeptide M (POLR2M):


(Seq ID No: 669)



cgttcttccgggaaaatggcgactcccgctcgtgccccggagtcaccgccgtccgcggat



ccggcgctag


tagcggggcctgccgaggaagccgagtgcccgccgccgcgccagcctcagcccgcgca


gaatg


 


Homo sapiens dihydroxyacetone kinase 2 homolog


(S. cerevisiae) (DAK):


(Seq ID No: 670)



tcgcctctttccgccagcgcccgcaggacccg



gatgagagcgcacgcttcggggtctccgggaagtcgcggcgccttcggatgtggcg


gatgcggccgtgagccggcgggggaggtgctgctgctgcctccactg


tactcagacccaggtagcacaggattgtccatcctccagcagctcagtgcaac


ggtgtgaactcagcctgtttcagagcctccacaccatg


 


Homo sapiens RNA polymerase II associated protein 1 (RPAP1):


(Seq ID No: 671)



cgatctctgcggggcaagatggcggcgcccagacaggcctggagcacggatgaataa



gagggaacccccacacggagacactgctggagagagtcgtactggggaggcagctggag


cagcaagatg


 


Homo sapiens torsin A interacting protein 1 (TOR1AIP1):


(Seq ID No: 672)



cctcctctttggtgcctccagccaggaggcgggagcgatccacag



cagctgacccagctcaggcactgcctctctcacagccctcaagacacac


catgggcccagaggcaggtttgctacacagcagcgacgac


gcaggcggcggccccagcgactcgcaactgcctccctgaccacagcggccac


cgcccaacacccccgagaagccatcgccaccaccggcaggagaacctagggtccataaa


gccatcttcgcgatcgactaaagctacgtcaacaactatg


 


Homo sapiens SERPINE1 mRNA binding protein 1 (SERBP1):


(Seq ID No: 673)



ccccctctctcggcccggccatcttgtgggaagagctgaagcaggcgctctt



ggctcggcgcggcccgctgcaatccgtggaggaacgcgccgccgagccaccatcatg


 


Homo sapiens N-acetyltransferase 9 (GCN5-related, putative)


(NAT9):


(Seq ID No: 674)



caccctttctgcgggggacgatttcgtcggtggtaggctgctaccatg



 


Homo sapiens ribosomal L1 domain containing 1 (RSL1D1):


(Seq ID No: 675)



gcgcctcttcacgaggtggaaacaagatg



 


Homo sapiens SH3 domain containing, Ysc84-like 1


(S. cerevisiae) (SH3YL1):


(Seq ID No: 676)



cttcctcttcctgggcagcctcgggacggggcg



ccgcggccgggcgggcagcatg


 


Homo sapiens methylmalonic aciduria (cobalamin


deficiency) cblD type, with homocystinuria (MMADHC):


(Seq ID No: 677)



acttcctttgcctgctcaccgccagcgtaggtgctaccac



cgctgccgtcgccgccgccattttgatggcaggaagagtccggttctgggacagctg


gagacagtggtggtgactgaaataactttaccaaaggaaagctattttgcgaac


tatcttctccagcggagatg


 


Homo sapiens glioma tumor suppressor candidate region gene 2


(GLTSCR2):


(Seq ID No: 678)



agttcttcctttgacaagatg



 


Homo sapiens DDB1 and CUL4 associated factor 8 (DCAF8):


(Seq ID No: 679)



cagtcttctcgagcacatcgtcgcaaacggggccggaaagcgtggcag



cgcaggcgcaagcgcagagagcggaggcggtggtggtggcggccgctggccagttcctt


cagtgaatctacagacctattttctcaggagctcagcctggccttacttcagtga


taaaaggaggaaaggctggctacagcaaacatcattcaagatg


 


Homo sapiens UBX domain protein 1 (UBXN1):


(Seq ID No: 680)



ctttcttctcgtcggtgttcccggctgctatagagccgggtgagagagcgag



cgcccgtcggcgggtgtcgagggcgggttgcctcgcgct


gacccttcccgccctccttctcgtcacacaccaggtccccgcggaag


ccgcggtgtcggcgccatg


 


Homo sapiens antizyme inhibitor 1 (AZIN1):


(Seq ID No: 681)



ccgccttctcacac



tttcaggctct


gatcgcggccgcagtttttccttttttcttctgccgtcgccttctctgcctcttct


catcctttctcgctctgctgctctgcagtgtgacgagtccgaatcctcttcccacccag


cccgcgcctttcttcttttgcctgcgctgttctatttctccttcggccgccgccgccac


tgctgcacacagctggtgtcggtgccgcgcttttacccccaagtcgttcccgcagcc


tatggcccaggccgccttgggtatttctgctcaaggtaaccacatccctctt


taaaaattccgccgaaaaagagaagacgctttacccgactctttgggccgttatct


cacggcgaactttctgaccaagtatacaactacccagagggcctaggagaagtgctgta


tagagagcagttcgacttcaacgctgagccaccttgggaacctagctgatgatag


gggggttccatctcccaacttgtccatggaggtcttcacttcagaaatccaagactca


tattcatccagcttggtgtcaagtgggctgttgctgccagaattatcttgtgattattt


gagagatgtatcagtttcttctgaagtacaatcaactgtagaagcctttgtag


cagtttgttgcatattctaaggacccagacatag


gcttggtggcccgtctcttgtctttcctggtttatgactttcggctttgtg


gaatacggctgagatg


 


Homo sapiens cell division cycle 40 homolog (S. cerevisiae)


(CDC40):


(Seq ID No: 682)



gcctcttcttcttccgccctggcagggtctccgca



gaagatttgttgccgtcatg


 


Homo sapiens stathmin-like 3 (STMN3):


(Seq ID No: 683)



gcgcctctccag



cctccgcaggcccaaccgccgccagcaccatg


 


Homo sapiens nudix (nucleoside


diphosphate linked moiety X)-type motif 13 (NUDT13):


(Seq ID No: 684)



tttcctcttttgtgctgattcctgaggactaggaaggtgccccgaaaagaattcagaga



cctgacaatg


 


Homo sapiens calcium homeostasis modulator 2 (CALHM2):


(Seq ID No: 685)



ctctcttttctggagttagattagtctgaagccgccaccagccccaggcccccgtgcaga



agaaaagcgggagggaacggcggaggccgccgctgccctgcaccgccctcctggaggcca


cttggagagtccggccccgaggaggccatggccacaagtgcccacagctggccccaggtt


gccagcgtcgctacagcccagaccaaggcagaataatctccggatgagctggtggcaccg


ctgagcctttggtctcaccagggcttcctgttgctggcaggcggggtggagcggagctgc


tgggaggctgctggataggagaggggtcacggctgcggaagaggaggttcttcgggacac


ccgtggatggacacggcaaggaaacaccaggccaaccacagctggggataaaatagcaca


accacaccctgccgtccagcgcctcccagcctgtgccccttcctagtaccaccagcaacc


atcaatcccgtctcctcctgcctcctctcctgcaatccaccccgccacgactatcgccat


g


 


Homo sapiens NMD3 homolog (S. cerevisiae) (NMD3):


(Seq ID No: 686)



tcttctctgtggcggagacagccaggttggcagctgacgggacagccggggtc



tattttgttgcgggttttcagcaaatccagggctggtctggaggcgcgaaaact


taaggcatacagaacgatg


 


Homo sapiens ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit


H (ATP6V1H):


(Seq ID No: 687)



gcgcctctgtcattc



tactgcggccgccctggcttccttctacctgtgcggccctcaacgtctccttggtgcgg


gacccgcttcactttcggctcccggagtctccctccactgctcagacctctggacct


gacaggagacgcctacttggctctgacgcggcgccccag


cccggctgtgtccccggcgccccggaccac


cctccctgccggctttgggtgcgttgtggggtcccgaggattcgcgagatttgtt


gaaagacattcaagattacgaagtttagatg


 


Homo sapiens DPH5 homolog (S. cerevisiae) (DPH5):


(Seq ID No: 688)



gggccttttctctgcacggagccggcgcttttgcagttgcttctgcg



gaaaggtggtagttaagaatttgtaaaggccagagaactacctacgattctctcag


cggtctctcttctcctcaagtttgaaatg


 


Homo sapiens polymerase (RNA) I polypeptide D, 16 kDa


(POLR1D):


(Seq ID No: 689)



cctcctccctccttccgtcctccgcgccttccgtcggtcggtccttgcttcctgcttcgc



ctccgcgcctcgcgctatgggacagagcccccgatccgccagcaccacctgaggatcca


gaaaccgccccagcgatg


 


Homo sapiens HMP19 protein (HMP19):


(Seq ID No: 690)



ctgtcctttcagcaccacaag



ctcgggctgaggagggaggactcctggccgtcctcctcctcttcaaattggctt


gaatcttctctgaccccccacgagtgcagcacagtctgggaagaaaggcgtaaggatg


 


Homo sapiens adiponectin receptor 1 (ADIPOR1):


(Seq ID No: 691)



gcgccccttccggcgcggggagggcgct



gaagatcggggccgctcggccgcaggccgcctccagcgccgcgggatgtagcgcgggg


gaccgcggcccccagcagagcccgcctgcccggcttgtctaccatcagagggaga


tctctgccccctggggctgagagaccccaacctttccccaagctgaag


ctgcagggtattgaggtaccagccagatg


 


Homo sapiens SH3-domain GRB2-like endophilin B1 (SH3GLB1):


(Seq ID No: 692)



ttttcccttgggacccgggtccacacggcggggtcgcccgtccatctccggctcgcccgc



ggggcccatcgtcgacgttagcggccgttctccgagccgactgacccatccttggcgctg


ccgccgcgcgcttgttctcctccctcgccccgccttcatcctccccgttcacggaaacga


cagctgcggctgcggggctggcgccgcctccctccacctaccacgtctgccctcgccgct


ctagccctgcgccccagcccggccgcggcacctccgcctcgccgccgctaggtcggccgg


ctccgcccggctgccgcctaggatg


 


Homo sapiens anterior pharynx defective 1 homolog A


(C. elegans) (APH1A):


(Seq ID No: 693)



gtcccctcttcggcttccgtagaggaagtggcgcg



gaccttcatttggggtttcggttcccccccttccccttccccggggtctgggggt


gacattgcaccgcgcccctcgtggggtcgcgttgccaccccacgcggactccccag


ctggcgcgcccctcccatttgcctgtcctggtcaggcccccaccccccttcccacct


gaccagccatg


 


Homo sapiens RNA binding motif protein, X-linked 2 (RBMX2):


(Seq ID No: 694)



ctgcctttcccgggcgctgattcctgagtgctgagcgcgaacccgaggagatg



 


Homo sapiens family with sequence similarity 82, member B


(FAM82B):


(Seq ID No: 695)



atctcctttagccccgcccgcctccgtagctgcct



gaagtagtgcagggtcagcccgcaagttgcaggtcatg


 


Homo sapiens UTP11-like, U3 small nucleolar ribonucleoprotein,


(yeast) (UTP11L):


(Seq ID No: 696)



tgatcttttccaaggctgtacagacatg



 


Homo sapiens chromosome 14 open reading frame 166


(C14orf166):


(Seq ID No: 697)



cgccctctcgccgcgtcgccggtgcctgcgcctcccgctccac



ctcgcttcttctctcccggccgaggcccgggggaccagagcgagaagcggggaccatg


 


Homo sapiens transmembrane emp24 protein transport domain containing


5 (TMED5):


(Seq ID No: 698)



gcttctctttcggagggagtgttcgccgccgccgcggccgc



cacctggagtttcttcagactccagatttccctgtcaaccacgaggagtccagagag


gaaacgcggagcggagacaacagtacctgacgcctctttcagcccgggatcgccccag


cagggatg


 


Homo sapiens coatomer protein complex, subunit zeta 1


(COPZ1):


(Seq ID No: 699)



gtttcttttgcggctccacgtcggcaccagctgcggggcaagat



 


Homo sapiens mitochondrial ribosomal protein S16 (MRPS16):


(Seq ID No: 700)



ggttctttctgtgtttgttctctgccctgccaaggccgtagag



ctggtgcgtgcgggtagcggggctctccgaggagccgcacgccggcggcaccatg


 


Homo sapiens charged multivesicular body protein 3 (CHMP3):


(Seq ID No: 701)



ctacctccttttccgcgggccccgcccaggcggctgcccgtgacctgcctgggcgcgggg



aactgaaagccggaaggggcaagacgggttcagttcgtcatggggctgtttggaaagacc


caggagaagccgcccaaagaactgatatccaaagagaagaagaaaaagtgaaacgatctg


tgaaagatgctgccaagaagggccagaaggatgtctgcatagttctggccaaggagatg


 


Homo sapiens RNA binding motif protein 7 (RBM7):


(Seq ID No: 702)



cgaccttttggccaggttagggagggggcgacgctgagatg



 


Homo sapiens eukaryotic translation initiation factor 3, subunit


L (EIF3L):


(Seq ID No: 703)



cgctctttccggcggtgctcgcaagcgaggcagccatg



 


Homo sapiens zinc finger protein 706 (ZNF706):


(Seq ID No: 704)



ccttcctttccctccggcgtcctctcccggccctctcgcgctgcac



tgtctctccgacgcaagactgtcccggcccggatatg


 


Homo sapiens androgen-induced 1 (AIG1):


(Seq ID No: 705)



cgccctccttgccgcccag



ccggtccaggcctctggcgaacatg


 


Homo sapiens interleukin-1 receptor-associated kinase 4 (I-


RAK4):


(Seq ID No: 706)



cgccccttcgcggcgcttcctagttcggctggttcttctgtcgccggctt



cagcagcccgcgcccgggcaggaatagaagatg


 


Homo sapiens transmembrane protein 66 (TMEM66):


(Seq ID No: 707)



cgttccttcgccgccgccaggggtagcggtgtagctgcgcagcgtcgcgcgcgctac



cgcacccaggttcggcccgtaggcgtctggcagcccggcgccatcttcatcgagcgc


catg


 


Homo sapiens carboxypeptidase Q (CPQ):


(Seq ID No: 708)



ccgcctctcggccccgcggcctggccggcaagcagggctgcagtcacggggcggcgcg



gagggccccagcccagtcaggggtgtggccgccgccaccgtaaggctaggccgcgagct


tagtcctgggagccgcctccgtcgccgccgtcagagccgccctatcagattatct


taacaagaaaaccaactggaaaaaaaaatg


 


Homo sapiens hydroxysteroid (17-beta) dehydrogenase 12


(HSD17B12):


(Seq ID No: 709)



cgctcttttcattcacgaaggtagtgaggcctagtggaaagccatg



 


Homo sapiens protein phosphatase methylesterase 1 (PPME1):


(Seq ID No: 710)



cctcccctcgatg



 


Homo sapiens HemK methyltransferase family member 1 (HEMK1):


(Seq ID No: 711)



ccccctttccggcaggctactgggctccgcccacacacctcccggcctggttcctaaacg



ccagctcggagcaatccccttgggctggagccaaatccctgctgtgattttaaggaagac


cggcaggtccgggcccccaagggtcaaccccacacacatccccgcactttcctgtatgca


ggcctgcgagcgtagagggagtggaattcacagcctccccacccatccgcaggggtctcc


tgggaggaacccaccagcgataggaacactgaagctgggctacggcgtccgcccgagcct


tttcttaaaggcgccgaccccggaagcggggcgtccgagggagcgcgcgacgggccacgc


acgtccgggcgtccagttcggggcagcttctccggctggtgggtgggtggggcagccttt


caggcagggtggcaaccaactatatctgaggaccagagccattttggggcaccagagctt


gtgacctctccatctccacccagctgggtccaggggccactctcagcactcacctcagca


gctgacatcataaagcagacttgggaacctggaagcactctggagaacctttccctgaga


catg


 


Homo sapiens N(alpha)-acetyltransferase 38, NatC auxiliary subunit


(NAA38):


(Seq ID No: 712)



cgccctttcagttctgcttgctgtcggcaccgctgcgttacccg



gaaccgccgggccgaacagcatg


 


Homo sapiens cleavage and polyadenylation specific factor 3, 73 kDa


(CPSF3):


(Seq ID No: 713)



ggttcttccttttttatttaccggtggctgtgcttccaatttag



gaagaccccggcgacctgttcctcacccccgcttcgccctcacactttcgggatg


 


Homo sapiens dynactin 4 (p62) (DCTN4):


(Seq ID No: 714)



tcgcctcctccctccccaa



gatg


 


Homo sapiens hydroxysteroid (17-beta) dehydrogenase 11


(HSD17B11):


(Seq ID No: 715)



gttcctccttgctctcgcccctactctttctggtgttagatcgagc



taccctctaaaagcagtttagagtggtaaaaaaaaaaaaaaacacaccaaacgctcg


cagccacaaaagggatg


 


Homo sapiens YTH domain family, member 2 (YTHDF2):


(Seq ID No: 716)



tag



tctttccaggtgttagtcgaaac


ctcgtggtgcgaccctggtcgtcccaaaccccctaggccttaatcctggggcggtggggg


cggggaggccgtgagcacggcttccgctcctccaatccgccagagggcg


cagcggccggcctctcccttcccggggttcttcgcgccgggccccttccgcgtgggtgag


tgaatgtgagag


tcagcgctcgcgccgcgcgcgccgcccgcctccgctgttcggcgctctgctttaggcggt


ggggggcgggcgcgcgcgtaaaagcatagagacgggcattgagctcttgggcta


gagcgtcgccgagtcggagccg


gagcctgagccgcgcgctgtgtctccgctgcgtccgccgaggcccccgag


tgtcagggacaaaagcctccgcctgctcccg


cagccggggctcatctgccgccgccgccgcgctgaggagag


ttcgccgccgtcgccgcccgtgaggatctgagagccatg


 


Homo sapiens tubulin, epsilon 1 (TUBE1):


(Seq ID No: 717)



agctctctag



cagagcgccgttgctgggggaatgcagaagcggccgcgggctagcaagctcccg


gagccggcggcgcaccaccatg


 


Homo sapiens ubiquitin interaction motif containing 1


(UIMC1):


(Seq ID No: 718)



cctccttttcttcctcagcgggtccgcggcccgctactctccgggaggggcgcttcccga



cgccaaggtaggcctctcccgacgccggggcggcccttcctgatgccggggtgtgtctct


cgcgacgcgggggtgggctccggacgccggggctggccttgccgaagtcgggggtgggtc


cctccggacgccgaagtgggctcgggatgcggggctgggaccctcccgattccggggcgg


attccggacgccgggaccggccattactggtgccgggttgggcttctccagatgccgggg


ctgggtccttcccaaggttgagacaaaaggatg


 


Homo sapiens TNF receptor-associated protein 1 (TRAP1):


(Seq ID No: 719)



ccgccccttcccatcgtgtacggtcccgcgtggctgcgcgcggcgctctgggag



tacgacatg


 


Homo sapiens cereblon (CRBN):


(Seq ID No: 720)



cagcctcctttgcgggtaaacagacatg



 


Homo sapiens ribosomal L24 domain containing 1 (RSL24D1):


(Seq ID No: 721)



cttcctctcaagcttggcgtttgtttggtggggttacacgcgggttcaacatg



 


Homo sapiens leucine carboxyl methyltransferase 1 (LCMT1):


(Seq ID No: 722)



taccctcttctgtt



gctttctccctgtggctcgcgccgtcccccgccgcccgtcgaccccgcttccatgtccct


ggcggacacagctcccaggaacctccacgcccatggccactaggcagagggaatcctc


tatcacctcctgctgttccacctcgagctgcgacgcagacgacgagggcgtgcgcgg


cacctgcgaagatg


 


Homo sapiens RAB14, member RAS oncogene family (RAB14):


(Seq ID No: 723)



cccccttcttttgtggtccggcccattgcgagggtgacaggaaaccctgtg



cagggagcgccgccatcttggaccagcccgaggaagatactgagggagcacaggagcag


tcaccgctgccactgctactgccgctactgctgccggcgcgtctgcac


ctctcggcctgccagtgtacctgccggcgcctcggtcgac


cgcccccgccccctctcccgctgcgtccgcactcctgttcctggtcctgac


gcccccctcccgcccggaaagctgcccagccaccagcaaccccccagtgccaccatg


 


Homo sapiens Enah/Vasp-like (EVL):


(Seq ID No: 724)



cttccttttcctgttt



ggttttaagtaggctataaaaatcaagtt


gctgtcttcagagggtctgtggtcctctgatcaacataggctggtgggagtacag


gactcgcctcctcagggttccctgtgctgccacttttcagccatg


 


Homo sapiens LIM domain and actin binding 1 (LIMA1):


(Seq ID No: 725)



ctctcttcccctctccctctccctctgccgggtggatgctttctccatgtgg



caaggctgtaactgttcacagctgtctgaaacagcagtggaccaggagcagcttggag


ttttaactttcattttacaaagaacaacatgtttgaatgtttcag


caggcaagttataactggcatctacttcttgttcttctagaacac


cgaaaatctctcccagcactttagaaaggggaccctgactgtgttaaagaagaagtgg


gagaacccagggctgggagcagagtctcacacagactctctacggaacagcagcactga


gattaggcacagagcagaccatcctcctgctgaagtgacaagccacgctgcttctg


gagccaaagctgaccaagaagaacaaatccaccccagatctagactcaggtcac


ctcctgaagccctcgttcagggtcgatatccccacatcaaggacggtgaggatcttaaa


gaccactcaacagaaagtaaaaaaatg


 


Homo sapiens ubiquitin-fold modifier conjugating enzyme 1


(UFC1):


(Seq ID No: 726)



gtttctcttgcgccctggtccaagatg



 


Homo sapiens coatomer protein complex, subunit beta 1


(COPB1):


(Seq ID No: 727)



cacccccttccacgtcagccaaggactctggagccgccgccgccgctgctgcggttcata



gccggagtagacggagccgcagtagacggatccgcggctgcaccaaaccactgcccctcg


gagcctggtagtgggccacaa


gcccccagtcccagaggcgtggtgggtcgggcagagtcggaagaactggctttctagctg


gaagatgcggaaggggagcgactaggccgcttgcgtctgggcctggcagaagggaccgga


ttttctggcatccttaaatcttgtgtcaaggattggttataatataaccagaaaccatg


 


Homo sapiens transmembrane protein 9 (TMEM9):


(Seq ID No: 728)



gggtctttt



gcggctgcagcgggcttgtaggtgtccggctttgctggcccagcaagcctgataagcatg


 


Homo sapiens shisa homolog 5 (Xenopus laevis) (SHISA5):


(Seq ID No: 729)



ctttctttttctccaaaaggggaggaaattgaaactgagtggcccacgatgggaa



gaggggaagcccaggggtacaggaggcctctgggtgaaggcagaggctaacatg


 


Homo sapiens transmembrane protein 69 (TMEM69):


(Seq ID No: 730)



gtgcctttccagtggacctgggctgttgttgcggttgttttccttctctccgtgcaac



gctggcaagtctcaaagtcgccacagaaacatgcccctgattcag


tgcctctgcttagctgtaacatgttaatcagaactacctggcatcttcctgaacaa


gactttcaataggggccagtatg


 


Homo sapiens kelch repeat and BTB (POZ) domain containing 4


(KBTBD4):


(Seq ID No: 731)



agatcttcttccgggcggacgtggagccggaagcggaggttccgggctc



cgggatg


 


Homo sapiens pipecolic acid oxidase (PIPOX):


(Seq ID No: 732)



cgtcctttagccgg



gagcctgtctttgcttgcctttgcctttgaggctctgtggctgtggggctgagtggcat


catg


 


Homo sapiens blocked early in transport 1 homolog


(S. cerevisiae)-like (BET1L):


(Seq ID No: 733)



agctctttccccgcgactgcgccac



gtctgaggcggctgtggccgcgtcggtgtccgcgtcgaggagccggggcagggcacgatg


 


Homo sapiens zinc finger protein 581 (ZNF581):


(Seq ID No: 734)



ttctctctttcggccggcgccgccagttcctgggg



cacacccagaggtccccttctcgccgccgcctgcaactgcgaggg


tagcccggggccgcttggagtcgcccggacctgagaggctgctgcac


tgggcctcagccagccctccggatg


 


Homo sapiens armadillo repeat containing, X-linked 1


(ARMCX1):


(Seq ID No: 735)



cgtccttctaatcctagtcttcgtttggtccggttgcactcttcctatagcccagagggc



gagagggcctgtggcctgggggaaggaggacgaggttctgcctggatcccagcagtagga


cgctgtgccatttgggaacaaaggaatagtctgcctggaatccctgcagatcttggggcc


ggaggccagtccaacccttggagcaggaagaaacgcaaagttgtcaagaaccaagtcgag


ctgcctcagagccggcccgcagtagctgcagactccgcccgcgacgtgtgcgcgcttctc


tgggccagagcgagcctgttttgtgctcgggttaagagatttgtcccagctataccatg


 


Homo sapiens spastic paraplegia 21 (autosomal


recessive, Mast syndrome) (SPG21):


(Seq ID No: 736)



cggcctcccgcacgcaccgcgcagcctgctgtgcccgtgggtcccgag



tgctccgccgcccgccccgacccgggcccagccgcctccacggcccgcgctcgtactg


gagcgaagagcggcctcctgaaggaggggaagggacgtgggggcggccacggcaggat


taacctccatttcagctaatcatg


 


Homo sapiens staufen, RNA binding protein, homolog 1 (Drosophila)


(STAU1):


(Seq ID No: 737)



tctcccttttttccttcttccttcccctcctcgccgccac



cgcccaggaccgccggccgggggacgagctcggagcagcagccagagtttattaaccac


ttaacctctcagaactgaacaaagacaacattgttcctggaac


gccctctttttaaaaaagaaagcataacccctactgtagaactaaatgcactgtgcatg


 


Homo sapiens adducin 2 (beta) (ADD2):


(Seq ID No: 738)



cggccttttgtcagcgcg



cagggccaggagagctctcatttcctcccagcctcgtgcgg


gaaatggctttaattctgacggcagggctgtgagggactagcgggaacccgagcctttt


gtcaaggaactgcggcgtcggtggccagtcatccccgccgccgcggagccgctgcac


tgctgggggatctcccagcagctctgacgagcgcgggctgcagcatgggcagaaaac


gctgccctgcagattagctgggtggattttttaagcgcaccccaccccccaaaccca


taaaataacaaaaccaacccgcagtggccgaccggagatagctaagatgccgcgcag


gagtttccacctggatgtttgaggttgtgtagatgtggccggcacccttgagagtg


gagctagggggtgcagactgagcagtgaacagaaggagcctt


ggacagggctgggccagcctcccgagttccaggagcgaattgcaaacccaccgg


gaaaatg


 


Homo sapiens WD repeat domain 1 (WDR1):


(Seq ID No: 739)



ccgccttccggctccag



tccccgggctcggcctcggcgaggtgtaattcgcagcgcgggccggccccg


gaggctctcggcgagcgcggcgcggtaacaagtgggcgaggatg


 


Homo sapiens family with sequence similarity 20, member A


(FAM20A):


(Seq ID No: 740)



cgacctctacttccac



ctctggccccaagtacagcgccagctgcggcctcgggagcgcccgcgggggtgcccgtg


caccggccgcgcctcctccctggcgcgggactcggccgcagctgcctcggaccccgg


cacgatcgtgcacaacttttcccgaaccgagccccggactgaaccggctggcgg


cagccacagcgggtcgagctccaagttgcaggccctcttcgcccacccgctgtacaac


gtcccggaggagccgcctctcctgggagccgaggactcgctcctggccagccag


gaggcgctgcggtattaccggaggaaggtggcccgctggaacaggcctcag


ttcctgcttttgaaaggaagagggggagtctgtgacccctgaggcctcctt


gcaactctgttttccaagctttgcacatcttccgaatttcttcttcaaagtc


taccctaatgaaatatcagacaattttccaagtgtgcttcatgaacttctgg


gaggtgcttcacagtttctgcaaatgattgattgaattttcactttgaaaaaa


tatactttaaggcgacacaagatg


 


Homo sapiens kelch domain containing 4 (KLHDC4):


(Seq ID No: 741)



ttttctttcctggtgtcccgtcgcggcttgggacccggcaagatg



 


Homo sapiens calcium channel flower domain containing 1


(CACFD1):


(Seq ID No: 742)



tgctccctctcccacaaggcagcgcgccggctcggacgcggccggctac



cgagccctttgtgagggctgtgagctgcgcctgacggtggcaccatg


 


Homo sapiens zinc finger, CCHC domain containing 8 (ZCCHC8):


(Seq ID No: 743)



gaatcttttccacagcccaaaatg



 


Homo sapiens kelch-like 24 (Drosophila) (KLHL24):


(Seq ID No: 744)



gtttccttt



gttgtgagctgcggcagagactggtggctggaggagacgccggcgctggagag


tgcgctgcgccgcccgccgctgagggaccgcggggttagccactgctggctgcttccag


tgttcgccgagaggtaccgggggtgacagctccgggaccggccgaaaggcgaggaac


cggtgtggaaattaaaagaacacacatattttgactggggctttgatcaac


caaatgctaaaaagccacataaagaagatccctaatagtcatttctcaacaattata


tagtcaactgatgtaacaatg


 


Homo sapiens FtsJ homolog 3 (E. coli) (FTSJ3):


(Seq ID No: 745)



ctccccctttccaccatg



 


Homo sapiens dymeclin (DYM):


(Seq ID No: 746)



gcttccctcttctctcgccgcctcctggcctccgcaccgacgcggcccgggctg



gagccgagccggggccgagctgcaggccggaccggagccggatctgtacccgctgagac


gtggaaacatggaggcctgagccggtgtgcgccac


ctgggctgcggcggcgacagcgacttctcctgacccctctgccaccctcccatccgtccg


cgggtccgtggagctggagcagatcccccagccggctgagacaggttgtctttt


ggaaatgcaggtttaaggacaaattatctgcttaagctagaagatg


 


Homo sapiens zinc finger protein 280D (ZNF280D):


(Seq ID No: 747)



cctcctctttctcctcctcctcagggctccagtcaggccgatccgctccgctcac



ggaaggaaaacagaaataacttgctggcttgtctggag


tcacatgtacttaggtgacaatttacagaaagtcatctctgcagcttgatg


 


Homo sapiens ankyrin repeat domain 10 (ANKRD10):


(Seq ID No: 748)



cgttccttt



gtgctgcggcggcggcttctcgagtcctccccgac


gcgtcctctaggccagcgagccccgcgctctccggtgacggaccatg


 


Homo sapiens SWT1 RNA endoribonuclease homolog


(S. cerevisiae) (SWT1):


(Seq ID No: 749)



ctctcctttggcttggggctccggagttgccac



tgccgccggcgctggtaagcttttcaggatg


 


Homo sapiens leucine rich repeat containing 49 (LRRC49):


(Seq ID No: 750)



tgacctctttcgggtctctttgaatctccgctgtagcgtcacctggaaggcagatctaac



agagaacctggactgtctcctatcatg


 


Homo sapiens F-box and leucine-rich repeat protein 12


(FBXL12):


(Seq ID No: 751)



ccgccttctggacttggtcttagttcccagtcgcggccaaatcac



gcctcagccacctcccgcaagcctctcactgcctcagccacgctttccaggctggtttct


ggtccccatccgcggctggtccggccctgggaccgaatcacttcccagcgagaggaaggt


caaatttctcgaccggctacgggaaggtcgcggccgccgccctgtcagccgcctcggcgc


ccccaggacccctcgggtctctttaaccggaagcggaagtgcgtgtcggcgggatcatg


 


Homo sapiens WD repeat domain 55 (WDR55):


(Seq ID No: 752)



cagtccttctcagcatg



 


Homo sapiens zinc finger protein 3 (ZNF3):


(Seq ID No: 753)



cgttcttt



gttctgtccccggtgtgtgggtctgtgacagggtccaacagggcctggtccgtgtccggt


cccccaaatctgtcgtccctgcccccaggcattgg


catcaacaaaagtcagaattcccgggaacttgaacagaggctgctaaattcccag


taattgctcctttggccttctagggactgacttcaaagaaggaaggaaa


gaatcaggcagtgcttcctcattctcttttaaaacccgcttcccgctgagtctg


cacccaggagaccagagagcaccttgcccttccatg


 


Homo sapiens tetratricopeptide repeat domain 27 (TTC27):


(Seq ID No: 754)



ggttcttctcctaggcggaagccagaccaga



gagcgtgcgtgtttttcccagggtgccccgcgctgctgttatggccgcctcctt


gaggtagtatccgcacatggaattctagggccgcaggtgtatttacgg


taactgtcgccactagatttcagcgcctttggactctcctgttttcactttcttttgtt


gactcccgtgtggccctcgtgggagcctgttttggctgcagcggtgtctggggtgatg


 


Homo sapiens THUMP domain containing 1 (THUMPD1):


(Seq ID No: 755)



gtttctctttcctctcagtttgcgcacaccatg



 


Homo sapiens ankyrin repeat and KH domain containing 1


(ANKHD1):


(Seq ID No: 756)



tgctcttctcgttcccgagatcagcggcggcggtgaccgcgag



tgggtcggcaccgtctccggctccgggtgcgaacaatg


 


Homo sapiens syntabulin (syntaxin-interacting) (SYBU):


(Seq ID No: 757)



cctcctcctggacggcggcagcggcggcgcgaggagccggcgggcagcggcgcgatg



 


Homo


sapiens coiled-coil-helix-coiled-coil-helix domain containing


3 (CHCHD3):


(Seq ID No: 758)



gcgccttctccttgcttctgggggtcgtggcctt



gctcccgctgtgcgggaaaagaatccaggcccttccac


gcgcgtgtgggtgcgggggccccgaagtgctcgtggttccccgctaggtctccgctgggg


caggaaccggaatcatg


 


Homo sapiens HAUS augmin-like complex, subunit 4 (HAUS4):


(Seq ID No: 759)



cctccttcgtcgcggcctctagtgcactttcggctccttccccttcccgggcctttcagc



ttggtctttccgggcctcgcttcccccagcccctgcgcccggcccgaacgagaggttccg


gagccccggcgcgggcgggttctggggtgtagacgctgctggccagcccgccccagccga


ggttctcggcaccgccttgagagcttcagctgccccaggattagaatcccaagaaaatca


aatg


 


Homo sapiens solute carrier family 41, member 3 (SLC41A3):


(Seq ID No: 760)



ccgcctctttcccgccgccgcctgggaggg



gacccgggctgccaggcgcccagctgtgcccagatg


 


Homo


sapiens phosphatidylinositol glycan anchor biosynthesis,


class V (PIGV):


(Seq ID No: 761)



cttcctttccagcctcccgccctcgtctgcttccggccctgtggcctggtggggctctg



caggctccctcgggagtggtccttgggccgtggcccctctgg


gaggcctgagggagctcaatcctggtagcaacacccctgaattcctggtggtgaaag


gatg


 


Homo sapiens poly (ADP-ribose) polymerase family, member 16


(PARP16):


(Seq ID No: 762)



agttcctttatccctgggcccaac



ctccccgccgacccgcggtccaggcctcggtctctctcttcggcggcgagccgcggccca


gaccccggcagaggacacttgtcggcac


gttctcacccctgtcatctcagccccctgcctagctccaccccaggcttgg


gaacccggcccctgacggcccattgtccgcgggcccagcccccgcgctgaacgcac


gctcgcccttgcccctaaccagcgcgtctaccccggcaacgcgcagtgacctgggatg


 


Homo sapiens thioredoxin-like 4B (TXNL4B):


(Seq ID No: 763)



gtttcttttctgcgcttgtgcgttttctgttcggtttccttcccgctagcggggccac



gagggttgctaggcaacagcccctgggtgacttggtcttagggtcctgtccggctt


ggggctgatgaaaggagctgtccgcgcccgggctcttccgagaagtggtt


gctgacagccacaaagtgaaagggagtgaggcggcgtggacgagtaaggagtgacag


tgaggattcacatttgggttatttcaagatg


 


Homo sapiens slingshot homolog 3 (Drosophila) (SSH3):


(Seq ID No: 764)



cgtccttcctggtcctgcgggtccaggactgtccgcggggtt



gagggaaggggccgtgcccggtgccagcccaggtgctcgcggcctggctccatg


 


Homo sapiens zinc finger protein 692 (ZNF692):


(Seq ID No: 765)



ctccctctggggcgcgggcctcagttccgggctacagcagccgacgccgagaggcac



cgtttcttcttaaaagagaaacgctgcgcgcgcgaggtgggcccctgtcttccag


cagctccgggcctgctcgctaggcccgggaggcgcaggcgcaggcgcag


tgggggtgagggcgcgtgggggcgcacagcctctggtgcacatg


 


Homo sapiens tRNA-histidine guanylyltransferase 1-like


(S. cerevisiae) (THG1L):


(Seq ID No: 766)



tggccctttcctttccgcgtgtagaatg



 


Homo sapiens solute carrier family 25, member 38 (SLC25A38):


(Seq ID No: 767)



tctccccttctacagagttcctccggcgcttcctccaccccgggatacacagaacctcat



ctcctacggtgctgaagcctgcagcagggcaggatgggcaggagagcagagccgcggagt


ctgcggcgcgggtgaagagcggcgcgtaattcccgcagcaagattgttccgcgcccgcag


cccctggactagcaggatccgaaccccggcggctgcgtgcttataggcgcagacgtcaga


gagcccgcggcttaaagcgcgtcgcctggctagcgccaccccctagccttcttcaaggcc


tccagggctgggcccaagcgcccgtcgacggcaccctgggcccagaggactcgcgggcct


catctccaatg


 


Homo sapiens WD repeat domain 13 (WDR13):


(Seq ID No: 768)



agttctttctga



tagcaggcagccatcttgcctggagcctgagaaagggaggagagacagaaggaac


cggcgacagtggtctcagggccgctccggggggcctcaagaaccggaggcagccccg


gaggtggtccccgatcccgggctatgctcttggatctgagaagggaaggcg


gagggcggcggggacaagatgggtggagaatgtcaagcaaggaatgctaggcgggg


gaggggcgttgctatggcgactggg


gaggggcggtgtctgttctgaatcgctgtgtgtcacccgggcgctgcccaggaaggg


cagggctggggtgatgaccatggtaacacccgggggggag


ttcgtgacatctccggcgcggagggactcgatgtctatggcaatggtcgcctggtg


gaagggacggaactagatcccttcgctcgggacgctcacattccaggcccttgtcctg


caggctgccgcgggcggacacgccagaggaggaggccggggaatg


 


Homo sapiens chromosome 1 open reading frame 123 (C1orf123):


(Seq ID No: 769)



ccgccttttacgacgcgccggaaagcaacggcaagggcggcagccagcaccgggcgga



gagggctaccatg


 


Homo sapiens chromosome 20 open reading frame 11 (C20orf11):


(Seq ID No: 770)



ctgcctccttctactcgggcgccccggcggccgccacctctccccagcccagga



gaggctgcggagccgcagccgcccagaccgcgcagcgcgggaggcaggttccgcac


gaaataaatcagaatg


 


Homo sapiens zinc finger protein 446 (ZNF446):


(Seq ID No: 771)



ttcccctttt



ggggacagatcccgaagttcgagcatccctcgga


taggccgggtgtcaggcctggtctctcaggcccgtccaggcccatcttgacgattccaa


gaccacccccttgagcaagaatg


 


Homo sapiens mitofusin 1 (MFN1):


(Seq ID No: 772)



ccgccctttgccac



tccccctgcctcctctccgcctttaacttctcgggaagatgaggcagtttgg


catctgtggccgagttgctgttgccgggtgatagttggagcggagacttagcataatg


 


Homo sapiens phosphotyrosine interaction domain containing 1


(PID1):


(Seq ID No: 773)



agtcctctcgcagctgcgccaggacagccggcgcgcggccgtgcccacaagttgccggca



gctgagcgccgcgcctcctcctgctcgcagccccctacgcccacccggcggcggtggcca


gcgccaggacgcacatcccgcggacaccgaccccagatgtaaagcgggaccccagcccct


cgccccccggcgcgatcgacagtctcgccagcgtctcctctgccaaaacccagggctgga


agatgtggcagccggccacggagcgcctgcaggagagatttgcagacacagaagcggcac


agagaaggccattgtgaagatcaaggcagaaaccggagttatggcatcataagccaag


gaatg


 


Homo sapiens pleckstrin homology domain interacting protein


(PHIP):


(Seq ID No: 774)



tttcctcctcctcctcctccgcctccgccgccgttgcttgaatggtggagccgaagctcg



gctcgtgaacacacactgacagctatagggcaggcggcggcaccgtccccgcttcccctc


ggcggcggggtgtcccgtcggcggccctgaagtgacccataaacatg


 


Homo sapiens LIM and senescent cell antigen-like domains 2


(LIMS2):


(Seq ID No: 775)



tggcctttttt



gggcgtctccctgctccgcggcccgggctggcgggcgggcgctcggctggcggctgcag


cagcagagggagacccgcggcaaccccggcaacccagggctcggcgtcgctgccaccatg


 


Homo sapiens SCY1-like 2 (S. cerevisiae) (SCYL2):


(Seq ID No: 776)



aggtcttttag



tctttttccccctcccttactcttcgtccccggtccctcccctccccacccctttccttc


tagctccgacgtttgcggccgcgggggcggcggaggatatggagtaaagccagagtcag


tggccaggcacgaaggcagagcaggaacagccaggaggcgtttattaggggggcggggg


gaaagagccccagcaccgcccctcctggaagaaggaagaggtaagtgaccggccgccgg


caccgaccgacctccctcaccggcggctctctcgcctgggctcccggagccggcgag


gagggaatggag


gactcgcgcccgggttaggcctcccagggccgctcaggctggtgggtgtt


gcctggtgacgggcctgccggcggccggccgggcgatcggcggtcggcgcccgcgcaaa


gcggggctggacgagcagcgagctccggggagcggatccgagagggccgag


tcctcgaaagaggccttgaggcgacgggagacccgggatcgaagtcagctgccg


gagggagagccccccatgccggctcgagagctcgggtttcggtggtggagaacgtag


tacctttcggggacattggacactactctaggaccgggtaactataactacccaa


tattgcagccatg


 


Homo sapiens ring finger protein 31 (RNF31):


(Seq ID No: 777)



caccctctctcctagtacttcctgttctcggctaaccctggcgctgggccgggggctg



gagagtgaccgtggtctgagtgacctggggcggctgcgtgggccggggtgggcctcaaa


gccgggcaccagacgg


gaggggcggcgctcgggccgcgcgctgcccgcgccgggtcctggcgggcggcgaggctgg


ggctgactcctgcctcaggatg


 


Homo sapiens mediator complex subunit 9 (MED9):


(Seq ID No: 778)



cgac



ctctggctaacctacccccggagccatg


 


Homo sapiens ATP5S-like (ATP5SL):


(Seq ID No: 779)



cggccccttccggttacgaaac



cttagcaagatg


 


Homo sapiens GPN-loop GTPase 2 (GPN2):


(Seq ID No: 780)



tctccttttgcgcgacacggtctcagctgttccgcctgaggcgagtgacgctggccgcca



acgaggtatacgtactgggaccctcgccctcagtctcgtctccggcgcggctacctgccc


cgttttccctgtgagttgacctgctccgggccgcgggccgccaatg


 


Homo sapiens transmembrane protein 48 (TMEM48):


(Seq ID No: 781)



cggtctcctg



tacgccctagactaggggccgccatctccatg


 


Homo


sapiens ankyrin repeat and zinc finger domain containing


1 (ANKZF1):


(Seq ID No: 782)



ttgtcctcttcgctgctccgtagtgacggggattgttgtgtt



gcagaaatccggcaatcgacctgaggacttgcgagccgctcagctcccgggacgttt


ggagctgctgctaaataatttctgctcagccatg


 


Homo sapiens notchless homolog 1 (Drosophila) (NLE1):


(Seq ID No: 783)



ggctctttctcctccacgtggggacgcaggatg



 


Homo sapiens cell division cycle associated 8 (CDCA8):


(Seq ID No: 784)



cgctctctctcactggcacagcgaggttttgctcagcccttgtctcgggaccg



cagcctccgccgagcgccatg


 


Homo sapiens polymerase (RNA) III


(DNA directed) polypeptide E (80 kD) (POLR3E):


(Seq ID No: 785)



cgctcccccccac



gtgtccgccggagtttctccaccagcaacatggccgccgcctgagagga


gagccgggccgccgccgtctctgcagcccgcgggtaactgggccgtt


gccgccgtccgcgctcggcccccgcggaga


gatcgagctgaaggactgcgcggctggctctcctctagtatg


 


Homo sapiens armadillo repeat containing 1 (ARMC1):


(Seq ID No: 786)



gagcctttgcccgccagcgccttcgctctttggctccctgagttagtccggttgctt



gcgatcgccgcggccggggctgcgaaccgaagggctcgctccgcgccgcctgggtctc


tacctcatccgtaggtgtggccctgatggtgtggcaggctctggactcctaaagctctg


gagcgaatttaagattttattcatgtgcatggcatagaagatg


 


Homo sapiens transmembrane protein 33 (TMEM33):


(Seq ID No: 787)



ccgtctttctg



gaaacaccgctttgatctcggcggtgcgggacaggtac


ctcccggctgctgcgggtgccctggatccagtcggctgcaccaggcgagcga


gacccttccctggtggaggctcagagttccggcagggtg


catccggcctgtgtgtggcgcgaggcagggaagccgg


tacccgggtcctggccccagcgctgac


gttttctctcccctttcttctctcttcgcggttgcggcgtcgcagacgctag


tgtgagcccccatg


 


Homo sapiens pyridoxamine 5′-phosphate oxidase (PNPO):


(Seq ID No: 788)



ccttccttccccggggtagaagtccagggtgagaaatt



ggttccgaactcaaaggaacccagtgccgggccacagccgggtcac


gtggccggcggccccccatg


 


Homo sapiens golgi phosphoprotein 3-like (GOLPH3L):


(Seq ID No: 789)



attccttctctgcatcgaaggatcaggaagtttgtgctctctgcgtggctaagtttttca



cctactaggacgggggtggggtggggagaacaggtgtccttctaaaatacagcacaagct


acagcctgcgtccagccataacccaggagtaacatcagaaacaggtgagaatg


 


Homo sapiens regulator of chromosome condensation


(RCC1) and BTB (POZ) domain containing protein 1 (RCBTB1):


(Seq ID No: 790)



cgctcctcctcttcgctgccggtgggcaccgccgctcgctcgcacttctgcgcccatt



ggagcttcggagatccctgcggtcccgcgggacggcgcggcagcagctgacctcgcaga


caggatcttgctctcttgcccagactggaatacagtggtgtgaacacggctcactg


cagcctcaacctcctggactcagagatgtcggcttatttataggaattgcttgaa


gccagagtcatg


 


Homo sapiens leprecan-like 1 (LEPREL1):


(Seq ID No: 791)



cgtccctttaa



gagcggctggccaggcacggcctccgcctctcagtacgcggagcgccggcggtcac


ctggggctcgcggagcggccagatcgcggcggag


tcggcgcgcttccccgagggaaggtgggagaggggacccggacgcgaggtgccccgaa


gccctctcgagcgtaaccgtcccgcgcctctctgaggcggaggatg


 


Homo sapiens hedgehog acyltransferase (HHAT):


(Seq ID No: 792)



ctgtctctt



ggctcaggcttggaggcctccgagcagcaacatcgtcccaattataccccgttggag


catcttcagatcttccactcttttcacaacgcaatcaaaatcttcgtacccatttt


gcagtagtgatctctgtaagttgctttacaattcataaagtttattctattt


gatcttcactctaatttacaaagaaaagcagggaagtctatttctgttttacagaggtg


tacagggaggctcacaggggctaagttcacacagtaagccctcgaagctgccagggctg


caaagcccaccctctttccaccgcaccgaactacctcctttcgcctacaaaac


gtaggtggggaccactggtgttggaatgacggcccacctcgag


tttcaggtgacttccactctgcaattaacttgcaggcagccccagacctg


caatgaacacacgggtgggggagagatatgcacgccagggtcagtgggaac


caacagccgaggggtgagcggggctaggggccccgggccgccggcggggcaaac


gcggttcagaaacgcaggccgcgctctggcccgccccctgcagcagcac


ggcctgctcgccatcgcccggagagcgccgcgggttcccgagtccgggcgcg


gagggcgcgcgggcacggcggcaggggcgtgctcggaggac


gcgcgctgcgctgctcctccaaagggcagctccgggggaaagagggtggcgtcccggg


gaagcccgcagccgccgccgatgtcgctgggactcggaagtgccgaaagaggggtgtt


gggaactcgcggcgcgcgtgaacgttgccgtcgccgccgcccgggacagcccgga


gaaactctcagcgtaggcatcgggaaccttcgtgccaaggagccatg


 


Homo sapiens chromosome 11 open reading frame 57 (C11orf57):


(Seq ID No: 793)



cctcctttttctcccaaaccacttcttcccccctaccccccgccacgcgaggctgcggcg



cacggtatgggtgtgtttgtgtgtatttgtgtggggagggcgtttggagggaaggttacc


gggagctccgaggccgctggggaacagggatcccggtgacaaagatggggatatttcctc


tgtcttccacttggaaacctcaacccccgcttcaggctccctagatactttctggggccc


aaccgaaggccgtagccatccaaagcgttcccagcctttctggggagtgaaacttacccc


cggggttcgtcctagaggagcgtgagcggggaatgcccaggtcaaccgggctgtccgaat


tccgccccggctcagcctccggcctcagtccgggagagagatctgcctgtcggtctgggc


tgggggaaacgcggcagtggcctgggccacaggtgagggcagagtaaccagtgggaaggc


tgcgttttcacgaaggactcgggtgaagctgcagagctgcctttgagccctgactccttg


gcttcctgggtcggaggagatcttgtaatggagtggttcttcgtctcactagcaagatgc


ctgatttcctcaggatcaagggattgaagaatg


 


Homo sapiens high mobility group 20A (HMG20A):


(Seq ID No: 794)



agtccttcgccg



cattggggcaaaataatcccttcatttttgtgaaggtaccgtggaaaa


tatttcatttttcttctcaccggagcaattgtaaatgctatgcggtaagaggagttac


ctgtggaaaggtggttaagagattaggtaaagaaaaggaaaggacaccaaaa


taaagtgctgcggaagaatttttgtccagctgtgagacgacgag


tgcgtgaagtgaaggcgattgagaggggctgagggaattgtcctctgtg


gaagggactttcttttggccctaggccccttcctgcccctgtcgtcagcagagtctc


tacaaggaagataacggactgtaaaattctataaagcaaagctacacatcacttgacac


catacaccatcttggttacataatgaagagagatg


 


Homo


sapiens checkpoint with forkhead and ring finger domains,


E3 ubiquitin protein ligase (CHFR):


(Seq ID No: 795)



atgtctctt



gacagcggcggcggcgcagccggttccgggttcggcgcggggcggggatgtgaatcc


cgatg


 


Homo sapiens nucleoporin 133 kDa (NUP133):


(Seq ID No: 796)



ccatctcttcccttaggtgtttaagttccgcgcgcaggccaggctgcaacctgac



ggccagatccctcgctgtcctagtcgctgctccttggagtcatg


 


Homo sapiens CNDP dipeptidase 2 (metallopeptidase


M20 family) (CNDP2):


(Seq ID No: 797)



cttccttccaagaaccttcgagatctgcggtct



ggggtctggttgaaagatg


 


Homo sapiens oxoglutarate dehydrogenase-like (OGDHL):


(Seq ID No: 798)



gcaccccttccgcgcagccccctgacctgcagcctccggacctcgctgcagcgcg



gacccggcccgcccgcccgaatg


 


Homo sapiens transmembrane protein 30A (TMEM30A):


(Seq ID No: 799)



ccgcctcttccgctctacagcg



gaggtggctgtggcggtggcgctggtggctgcggcggcggcggcgg


cagcggcgctcgagcggttcctgtcagggtcagccggcgggccccctgggtggtccac


ctgcaaatcgcggagcggcgccccagggatcgatg


 


Homo sapiens elongation protein 2 homolog (S. cerevisiae)


(ELP2):


(Seq ID No: 800)



gcgtctcttgtttgtgcggctgaccagttggcgacatg



 


Homo sapiens WD repeat domain 12 (WDR12):


(Seq ID No: 801)



cgttcttttctttgtatttccgcctctcgcctctctctaaaagccgcagttagaggcgag



atttaggaaaaacctctgccgagtgagcctctggttgggaatatgtatgagaaaaaaaaa


ctggcaaggcgttagtcaagcaaagctgaaggcagaggaaatttgatatctggctggagt


ctagaggatttaatgcaaataagatactctgagggcagcgtggcaaaaaaagactacaat


tcccggtggtcacagcgtttgagaagcgatgctttctgagacttgtagtaactaggagct


gtgtttgaactatccaggctcaggacagcctcttgaaaaaaaattttttattaataaagc


ggatttgagtgggatctttttcctaatcgattacgggcccacacgtatgggaagaattct


aacaatgattaaagggacatgctacctttacgactatccttttctaatcgatgactccta


aatctaggagtaggtagtcgatgtttgtggtctgggcgtctgtagaagggcaacctcgtg


ctttctgcagaggagaccggagggcagaaggcagagtccaggcttagactgcagttcctc


gcttacctgtgcagtctaattttgagctgcctctttgtagtcttaaaaggcaggagcttc


gtgttgtgggtctgctaacccgtacgtttccgtgggcaagtcgtgtgtactcctcgc


catg


 


Homo sapiens tetratricopeptide repeat domain 17 (TTC17):


(Seq ID No: 802)



cgacctcttcaagatggcgggcgccgga



gactagcttccgcttccggtgtgagcggcccggccgggggggcaagatg


 


Homo sapiens proline rich 11 (PRR11):


(Seq ID No: 803)



ttttctttatggcgtggga



gaggccacagcccggactccatcgactcccccggctcttagactaaaatcatg


 


Homo sapiens TBC1 domain family, member 23 (TBC1D23):


(Seq ID No: 804)



ctccctctttcttcccctctggggaagctcagtgctggacttccgaagaccttttac



gacattgagtctcggagttggtctcagcgccggatccacttttcggcaaagtgacgtg


gacgtcaacagcaatg


 


Homo sapiens leucine rich repeat neuronal 3 (LRRN3):


(Seq ID No: 805)



gctcctctctggggagtggagggtgttcagttattaatgaccgctgagcaggcagcac



catgtcagtgtgacaactgatcgggtgaacgatgcaccactaaccac


catggaaacaaggaaaaataaagccagctcacaggatctctcttcactggattga


gagcctcagcctgccgactgagaaaaagagttccaggaaaaagaaggaatcccggctg


cagcctcctgccttcctttatattttaaaatagagagataagattgcgtgcatgtgtg


catatctatagtatatattttgtacactttgttacacagacacacaaatgcac


ctatttataccgggcaagaacacaaccatgtgattatctcaaccaaggaactgag


gaatccagcacgcaaggacatcggaggtgggctagcactgaaactgcttttcaa


gcatcatgctgctattcctgcaaatactgaagaagcatgggatttaaa


tattttacttctaaataaatgaattactcaatctcctatgaccatctatacat


actccaccttcaaaaagtacatcaatattatatcattaaggaaatagtaac


cttctcttctccaatatgcatgacatttttggacaatgcaattgtggcactggcac


ttatttcagtgaagaaaaactttgtggttctatggcattcatcatttgacaaatgcaa


gcatcttccttatcaatcagctcctattgaacttactagcactgactgtg


gaatccttaagggcccattacatttctgaagaagaaagctaagatg


 


Homo sapiens MIS18 binding protein 1 (MIS18BP1):


(Seq ID No: 806)



ggccctctctccgcgcggagccgagccggaactgcggcag



tctctccctgccaggctcttcatccaaggtttctgtggatcccttctgaagttc


tatctgaaaattgcgcttaagtgaattttctgttagaagaacttggttgctactttctt


gtcaagatg


 


Homo sapiens LMBR1 domain containing 1 (LMBRD1):


(Seq ID No: 807)



ccgcccctttaacctttagggtgcgcgggtgcagtatatctcgcgctctctcccctttcc



ccctcccctttccccaccccgggcgctcaggttggtctggaccggaagcgaagatg


 


Homo sapiens ST6 (alpha-


N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide


alpha-2,6-sialyltransferase 1 (ST6GALNAC1):


(Seq ID No: 808)



cttcctctagaacccgacccaccaccatg



 


Homo sapiens spermatogenesis associated 7 (SPATA7):


(Seq ID No: 809)



gctcctcttttccagtcctccactgccggggctgggcccggccgcgggaaggac



cgaaggggatacagcgtgtccctgcggcggctgcaagaggactaagcatg


 


Homo sapiens docking protein 5 (DOK5):


(Seq ID No: 810)



cctcctccttcctcctcctcctcctccttcttctcctccttctcggccgggag



gaggcagggctggatccctcagccgccgccgctcctcctcctggcaggccggccgcg


gagtcagctgac


gccggcgctccagcctcgcctccccgcgccgcgctctgcgctccccgaaagtggctg


caagccggccgcccactgtcagggttggggggacaga


gaaagtgatgtgcgccttctaaagcctcgcccagcgccgccgaagcagcttcac


ctctccaactttctcccaccgactgcttgtctt


gaccctgccctccaccctccccagagccacttcgggtgcgcgctcttggg


taaagggggggtcaccggctgtctgggatg


 


Homo sapiens glycosyltransferase 8 domain containing 1


(GLT8D1):


(Seq ID No: 811)



tctcctccatcgcctgcagtaagggcggccgcggcgagcctttgaggg



gaacgacttgtcggagccctaaccaggggtatctctgagcctggtgggatccccg


gagcgtcacatcactttccgatcacttcaaagtggttaaaaactaatattta


tatgacagaagaaaaagatg


 


Homo sapiens cullin-associated and neddylation-dissociated 1


(CAND1):


(Seq ID No: 812)



tggccttttgccctagggagcgagtgcggagcgagtgggagcgagac



ggccctgagtggaagtgtctggctccccgtagaggcccttctgtac


gccccgccgcccatgagctcgttctcacgcgaacagcgccgtcgttaggctggctctg


tagcctcggcttaccccgggacaggcccacgcctcgccagggaggggg


cagcccgtcgaggcgcctccctagtcagcgtcggcgtcgcgctgcgaccctggaagcgg


gagccgccgcgagcgagaggaggagctccagtggcggcggcggcggcggcagcgg


cagcgggcagcagctccagcagcgccagcaggcgggatcgaggccgtcaacatg


 


Homo


sapiens BRICK1, SCAR/WAVE actin-nucleating complex subunit


(BRK1):


(Seq ID No: 813)



cgctcttcctcaggcggcggccatg



 


Homo sapiens zinc finger CCCH-type containing 15 (ZC3H15):


(Seq ID No: 814)



cggtcttcctcctcgtcctgccgcagggccagaacccctgacggtattcagctgcgcg



taagtctggccggtgccatctgtctccgcaatg


 


Homo sapiens polo-like kinase 1 substrate 1 (PLK1S1):


(Seq ID No: 815)



cggtctccttcggcaaccccggccgaacggccacccagaggctgtgctgagctggcgcag



cggcagcagcatg


 


Homo sapiens dysbindin (dystro-


brevin binding protein 1) domain containing 2 (DBNDD2):


(Seq ID No: 816)



gtttctttcctacgcagccgctcctgccgccgtggtcgctggagcttt



gcctctctaggccggcagcgcctctcctccatggtcctgtctgtcagcgctgttttgg


gagcccgccggtgaggccgggccacgctcagacacttcgatcgtcgagtctgtcac


tgggcatg


 


Homo sapiens KIAA1704 (KIAA1704):


(Seq ID No: 817)



gattctttttggatagggttgac



gttcgtggatagactcatatctgtgaccagtgtccgccaccgcggatg


 


Homo sapiens solute carrier family 25, member 37 (SLC25A37):


(Seq ID No: 818)



ccccctccctgcccacctcctgcagcctcctgcgccccgccgagctggcggatg



 


Homo sapiens myoneurin (MYNN):


(Seq ID No: 819)



cgtcctcccaagatggcggagacagag



tgaagaaactgtgttccccccttgggttgctatcgatcaagggtaaaattccattctga


tatcaaaatg


 


Homo sapiens vacuolar protein sorting 33 homolog B (yeast)


(VPS33B):


(Seq ID No: 820)



gcttctttttctggtagaaggcggggttctcctcgtacgctgcggag



tctctgcggggtgtagaccggaatcctgctgacgggcagagtg


gatcagggagggagggtcgagacacggtggctgcaggtctgaga


caaggctgctccgaggtagtagctctcttgcctggaggtggccattcattcctggag


tgctgctgaggagcgagggcccatctggggtctctg


gaagtcggtgcccaggcctgaaggatagcccccctt


gcgcttccctgggctgcggccggccttctcagaac


gaagggcgtccttccaccccgcggcgcaggtgaccgctgccatg


 


Homo sapiens zinc finger, C4H2 domain containing (ZC4H2):


(Seq ID No: 821)



aggcctctccaagcccctaccgcacaggctcatagccccaagcccggaggaggtggc



tacattgtgtctattgtatcccttggctggtgtatttgtacatctctcgggac


gtgaaattgacagtgaaaagtatg


 


Homo sapiens BAI1-associated protein 2-like 1 (BAIAP2L1):


(Seq ID No: 822)



cttcctctggcggcgtccggccgcttctcctctgctcctcgaa



gaaggccagggcggcgctgccgcaagttttgacattttcgcagcggagacgcgcgcggg


cactctcgggccgacggctgcggcggcggccgaccctccagagccccttag


tcgcgccccggccctcccgctgcccggagtccggcggccac


gaggcccagccgcgtcctcccgcgcttgctcgcccggcggccgcagccatg


 


Homo sapiens solute carrier family 25, member 40 (SLC25A40):


(Seq ID No: 823)



cgtccttctcgcgcctcgctctggccctgcaggttgtgtttccgcctctaccccgcctcc



attccgttgctctctcagtctcagacccgggctctcggtccgccgcttcaggtcttggcg


cagcctcagagagttggcgcggctctgtgttgaccaaacctagtggatgcagttagcgcc


ggagcccggccccgcccgtcaccagggttattcccgccttctaggtttgccaggactgcc


ggccctgcagctgccttctgccccaggtttttggctactgatgttacaaacaataaaata


ttggagcatagagttgaagaacagactcaaaccaggtttttatttaattagt


taaaaatatg


 


Homo sapiens protocadherin alpha subfamily C, 2 (PCDHAC2):


(Seq ID No: 824)



tttccttttccctccccctggagctgtagcggcagcagcagcaggaa



gccgagccgggttgagcgactcggaggcgagcggaggagctggaatatggggag


tcagcgaggacggtggggccaggagcccttgggagggcctac


ggagggagcggccccaggcgctttctagagcgtgagcggtgggggagcaggcg


cagggtggcacgagcggaggcggggcccgggcgtggggcacggctggggaa


gctgccgcctccggccctgcccggctgcctccgccgcggccagtggctatg


 


Homo sapiens chondroitin polymerizing factor 2 (CHPF2):


(Seq ID No: 825)



gttcctttttgggttagctttggcagtattgagttttacttcctcctctttttagtg



gaagacagaccataatcccagtgtgagtgaaattgattgtttcatttattaccgtttt


ggctgggggttagttccgacaccttcacagttgaagagcaggcagaaggagtt


gtgaagacaggacaatcttcttggggatgctggtcctggaa


gccagcgggcctcgctctgtctttggcctcatt


gaccccaggttctctggttaaaactgaaagcc


tactactggcctggtgcccatcaatccattgatccttgaggctgtgcccctgggg


cacccacctggcagggcctaccaccatg


 


Homo sapiens thioredoxin-related transmembrane protein 3


(TMX3):


(Seq ID No: 826)



gcttctcttccgctccgggtcggctccgtttccctttccgggcggg



caggcggcggaccccagtgtctttatccctcttttgcacagtcagcttctg


cagctctcccgggctagcatg


 


Homo sapiens ras homolog family member F (in filopodia)


(RHOF):


(Seq ID No: 827)



cgacctcttggctccgctagtgcccggcgcgccgccgccagtgctgcgggc



tccgggcaatg


 


Homo sapiens amyloid beta


(A4) precursor protein-binding, family B, member 1 interacting


protein (APBB1IP):


(Seq ID No: 828)



ctttctctcaggaaactccactcccaactgacaggtgctatttccagccagtcctatgct



gttgcaaatagtgagtccatgaatgccctctgccgtgtgcattacttattttcatcagca


gatcttcgtaacacactcctggaagtgggatgacggggtcaaaaggcgaatccatacata


agttaaatagatattgctcaattctcttccacggggttcagaccattttggatttctacg


agcaatgaagacagtgctattcctctacaccctggccggccaactgagcgtggttaaacg


tggggagggaggagggtgaggttaccaacctgatggttgagaaagggcctccgcccagcg


cgcccttcctccacccccacccgagagacagctgaactccggccgggacgcgcgtgttgc


cagtccagccctgcaccgcgtcccctgagggcgggctgcaggcggccgggaagccttgca


caaccggcccaaaagaggaagcccagaaagtgctgaagtaaacactttgggagaccgttg


caacataaagcggcctctcagtctttggtggaaccatcactaggccccaatcccttagtc


cctcttgcgtcgaggctgcaaaatggttccattcgccaggagacgctcctgagagaaggg


cgcgcgcggcacaggggccttccttgcacctcggagcaaagcagctcggatagcgccaca


cgtctgcgcgctgcgtgggaagggcagggctgacagcacttcctccccggggcagcgacc


tggagcccgggtgcggcagtctgcaccgcgcgtcgctttcccggccggagtctcgccgcc


ttcccgcgccccgcagcgccccgcagagcagtcgagatg


 


Homo sapiens roundabout, axon guidance receptor, homolog 4


(Drosophila) (ROBO4):


(Seq ID No: 829)



ccttccctcttcactgtgagctcagagcagcag



gacaaagtgctcgggacaaggacatagggctgagagtagccatg


 


Homo


sapiens translocase of outer mitochondrial membrane 7 homolog


(yeast) (TOMM7):


(Seq ID No: 830)



acctcctttccctttcggattcccgacgctgtggtt



gctgtaaggggtcctccctgcgccacacggccgtcgccatg


 


Homo


sapiens major histocompatibility complex, class II, DR alpha


(HLA-DRA):


(Seq ID No: 831)



ttttcttttattcttgtctgttctgcctcactcccgagctc



tactgactcccaacagagcgcccaagaagaaaatg


 


Homo sapiens protein arginine methyltransferase 8 (PRMT8):


(Seq ID No: 832)



cctcctctactatctcggtatcaccaaacccttgccggctcttatg



 


Homo sapiens adducin 3 (gamma) (ADDS):


(Seq ID No: 833)



ctgcctcttatgaagcaa



tactagagaggaaaaacaaaacccattcctttaagaaagattccgcctcctctcataa


gcaagcgcctaatggtaattgtagagtttactaagtcaaacacttactactcagcatt


gagagaa


gctgctgctgctaatgctgctgctgctgctgccgccgccgccgctgctgctgctgctgtt


ggtctgaggctgcagtaggtttctgtgcagcattgcagaatccacacctaga


gaacagaagacacagacacgtacgtctactacccttgttagaaggaagcttt


ggatcttcggtggataacaagagtaatccacagacttaaaacatg


 


Homo sapiens BarH-like homeobox 1 (BARHL1):


(Seq ID No: 834)



agccctttt



ggatctaatgcgcagaggaggtt


ggcccagagctcccgggctcccccaaggctgaactccgtccaaggtgcccg


caggctccctgcccgccttccccatgccagcccgcagctaggggcagggg


cagcggcggctggggttgggggtgggtggggagcttttggggaggacaggtcgcagctt


ggctatg


 


Homo sapiens intraflagellar transport 46 homolog (Chlamydomonas)


(IFT46):


(Seq ID No: 835)



ttatctttttgcctagcgactgacaacaggctggttgctt



ggcgtggaatcctaaagtggcctggctttgagactggagtga


gaccccagccctaggctggggttctttccattatagaggagacggattcagaagggc


tacagaccaaggttgttgaaaaccagacatatgatgagcgtctagagattaac


gactccgaagaggttgcaagtatttatactccaaccccaagacac


caaggacttcctcgttctgcccatcttcctaacaaggctatg


 


Homo sapiens carbonic anhydrase X (CA10):


(Seq ID No: 836)



cccccttttcgggag



gagggaggcagggacttgcaggcaagagttgcacctggtctaggaacctgcagagaaaa


gaactctggggtaagtagtgttctggcactggcacggaaaggggtaaagggtgggggg


catgagagggacgaaatggagagggcagggaatgaattatgcaaaaaaatctccaa


tatttcgcagcggagggagagcacagcacagcactcccaggatgag


tcctgcctgggtctcccgcgccgaacccgcagcacgaagttctttttaagaaga


gaaactcgaaaatcctggagggtaacagaggcagccagggcggggcggagtgcg


gaggcggctgccagggactggggccgaggcggcggccaaggtggcctgaa


gctgtgacacccagcctcctcctcctcctcctcatggccgcgctcagcctcac


ctccccgcccgggcctcctgcctccgcccccgggtgccgggctgcggagctgacgctgg


gacgcccggcggcggcgaggacgctcacctggccaa


gcctccttctcctcctccccctcccgcccccacctgtcctcctcctctctgagttgg


gaagcgtagggatccgtaggcgaggaaataacgacccctgcagttgtattgcg


gaaaatctcgacagcggcgctagttgcgggcgatggaa


gccaggcaactgggggttctggggagttcaggaaaatagcagaggagcag


gaagggcgcgcgcgacctggagagtctgtgtgcccccaccgcgccccag


tccccggggcccagcccttcccctcggcgccctggacgcactgccggaacccggctga


gaggctgcaggctgcgcgcggacctggggagcagggagggtcggcg


gaggctgccggcggctggcggtttcgggcaa


taatccctgcctctctttctctgtgtgtctgctgtgtctgctccttccccgccccccg


gaagcaggagaagaactgccccggagcgcagcagccaccctccgac


catgccccggtgaggggggcggacttcgagggcaacttgccgcg


gactgcctgggcttagccagcgagctacgcgctcccgggagcccggaattgcacggcg


cagcccggcggggggctatcgtctatgtcttcttggggcgccagac


gaatcggggtctcgtttttgctggaagagcccagtgtt


ggtggcttcaggtggctgctgccgccgccgccgccgccgccgctgctag


tgcggtttccgccgctggtgcgaagagaagagacacgcgagcggggagac


ctccaaggcagcgaggcatcggacatgtgtcagcacatctggggcg


cacatccgtcgagcccgaggggagatttgccggaacaattcaaactgcga


tattgatcttgggggtgactgtccctggccggctgtcgggtgggagtgcgagtgtgcac


tcgctcggaagtgtgtgcgagtgtg


tatgtgtgtgtgccgtgtcgggctccccccttccccccgttttcccgtcgag


tgatgcacttggaatgagaatcagaggatg


 


Homo sapiens dual specificity phosphatase 22 (DUSP22):


(Seq ID No: 837)



cctcctccctgtaacatgccatagtgcgcctgcgaccacac



ggccggggcgctagcgttcgccttcagccaccatg


 


Homo sapiens olfactomedin-like 3 (OLFML3):


(Seq ID No: 838)



gttccttctactctgg



caccactctccaggctgccatg


 


Homo sapiens phosphoribosyl transferase domain containing 1


(PRTFDC1):


(Seq ID No: 839)



ccgtcttcccttcccgcgttccccgggagaaacatg



 


Homo sapiens translocase of outer mitochondrial membrane 22


homolog (yeast) (TOMM22):


(Seq ID No: 840)



cctcctttccgcttccggtgtccccta



cagtcatg


 


Homo sapiens arrestin, beta 1 (ARRB1):


(Seq ID No: 841)



gctcctcctgctggctggg



gattttccagcctgggcgctgacgccgcggacctccctgcgaccgtcgcggaccatg


 


Homo sapiens cytokine induced apoptosis inhibitor 1 (CIA-


PIN1):


(Seq ID No: 842)



cctcctctcgcgagaggcgcaaggcgtggagtcgacggctggagagaa



gccgggagcgagcccaggcggcagtcttgattcccttttggccagcag


tttttaggtctgtcagtactgcactgcaagaatg


 


Homo sapiens leucine zipper transcription factor-like 1


(LZTFL1):


(Seq ID No: 843)



taccctccttccccattttctgtggtccaac



taccctcggcgatcccaggcttggcggggcac


cgcctggcctctcccgttcctttaggctgccgccgctgcctgccgccatg


 


Homo sapiens phospholipid scramblase 4 (PLSCR4):


(Seq ID No: 844)



agccctcccttccgcgcgcttactttgtttataactt



gaaaaatcctctccgtctcccttccctgcctcctttcctttccctttcctctgccag


tacaactagacccggcgtctggcgtccccggtgcccagcattctgcggggcaggcggat


taattggaattcttcaaaatg


 


Homo


sapiens ectonucleoside triphosphate diphosphohydrolase 7


(ENTPD7):


(Seq ID No: 845)



cctccttccggctgggcaaggggccgcggggagcagctcgggactgaac



cgagaggtgccgaaggaaccggcgggccgcttgatcccgctgcagacgtagga


gatgcctgggacaaggaggccaccttctcagggcaaaagaaaaa


gaaggtgacaggcgttgagaccaccgaagggaacccatg


 


Homo


sapiens fascin homolog 3, actin-bundling protein, testicular


(Strongylocentrotus purpuratus) (FSCN3):


(Seq ID No: 846)



agttctctctgg



gaacatctggtgggtactacaggccctattccaggccctatggcctgtggaacctcac


cacgggggggagggctgggccagacggagacatcacctgtggtgtcagccccatg


 


Homo sapiens X-prolyl aminopeptidase (aminopeptidase


P) 1, soluble (XPNPEP1):


(Seq ID No: 847)



cctccttcgcgccggcccttccgcgggtgatcagctggtctgcgctcccctgac



gtgggctggggcacgtcaccgccgaatg


 


Homo sapiens REX4, RNA exonuclease 4 homolog (S. cerevisiae)


(REXO4):


(Seq ID No: 848)



gggtctcttccggagtcttttcctggac



ggggtccctgcggtgggtgtgtttcggcctggcctgggcaggcgctt


gtgctgccagggcgccgggcccggg


gaggccggggtctcgggtggccgccggcccaggcgctggacggcagcaggatg


 


Homo sapiens LYR motif containing 4 (LYRM4):


(Seq ID No: 849)



ttttctttccaaaatg



 


Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 24


(DDX24):


(Seq ID No: 850)



ggttcttcactcgcgactgacggagctgcggtggcgtctccacacgcaac



catg


 


Homo sapiens transmembrane protein 159 (TMEM159):


(Seq ID No: 851)



ccttcttcctcttgttcctcctcctgcctctcttcgcttcgcctgcaaac



gcggtgggggctgctcggcggtcaggagcaggttaccctccgtctgcatgcccac


catcaaggtatgaggatggtagaagctctcgtcgaaccagatggatgaagaccactaac


ggcttttgtttcctctggtaacagcaagagacagagcgacatgagagattggac


cgcgggctgcactggagaatttactggtaggataattcatccctaaaga


gattgaagtgagcttcagaatg


 


Homo sapiens NDRG family member 4 (NDRG4):


(Seq ID No: 852)



cggcctccgcccctg



cagccgcgggcacgcggaggggctcctggctgcccgcacctg


cacccgcgcgtcggcggcgccgaagccccgctccccgcctgcgcgtctgtctcgtccg


catctccgcggcctcctgctccacgacgtgaccatg


 


Homo


sapiens pre-B-cell leukemia homeobox interacting protein


1 (PBXIP1):


(Seq ID No: 853)



ttttcttctcgggctgcaaacaaagggaagcctgcaacaagttaa



gctgaagaccgaagcaagagctggttcaggtggcagccacagcagcctcagggac


ctcagcaactatg


 


Homo sapiens twisted gastrulation homolog 1 (Drosophila)


(TWSG1):


(Seq ID No: 854)



ctgtctctttaaggtgcccgaggctcgcgggcgctgcgctgaggggac



ggcgggaggcgcggcctggcctcgcactcaaagccgccg


cagcgcgccccgggctcggccgacccggcggggatctaggggtgggcgacttcgcgg


gaccgtggcgcatgtttcctgggagttactgatcatcttctttgaagaaacatg


 


Homo sapiens zinc finger protein 286A (ZNF286A):


(Seq ID No: 855)



gtccccttt



gtgaggcccgggatgggaggtgcccggttcccccagggacagcttcaagcgg


tagggacagacatctgag


gacccagcctcagggatgctgtccccgggcttccaggctccagcgccgtag


gactgaggcagactccacggtgagaaaga


gacccgatctaacccaggcctttcatcagagcccaggagggaaggcaggaagtgggac


cacgaggcccggggggcttctaactcgtctggccagggagatctgaattggggtgaa


gagcagaatctccagaacaaggaggaggtggtgatcatg


 


Homo sapiens S100 calcium binding protein A14 (S100A14):


(Seq ID No: 856)



gctcctcctgtctt



gtctcagcggctgccaacagatcatgagccatcagctcctctggggccagc


tataggacaacagaactctcaccaaaggaccagacacagtgggcaccatg


 


Homo sapiens ANKHD1-EIF4EBP3 readthrough (ANKHD1-EIF4EBP3):


(Seq ID No: 857)



tgctcttctcgttcccgagatcagcggcggcggtgaccgcgagtgggtcggcac



cgtctccggctccgggtgcgaacaatg


 


Homo sapiens KIAA1143 (KIAA1143):


(Seq ID No: 858)



ctgtctttacccagagctaccatg



 


Homo sapiens neuroligin 4, X-linked (NLGN4X):


(Seq ID No: 859)



ctctctttttctt



gcagaaccgtctctctcccttctctgtctcttagcacagagctcttattcagccac


tagcttggcccttcctgcttcaattgtaatgcttgttctgcccgtccacagac


tattggcggcagaaacaacgaatttcctccaaactaggcggtgttggtggctctt


gcattcctctggatgaggaaatctagttggggggttccagaaggg


gaaggctcctgggctttcaatacatcctcctgaatcatacctcgtttcgggttcccta


gaaaaatctggacgtgtaaaaagaactcttaacggccgatgcagctcttccaaa


gctaaggctgccttggagttttcataagaaattgtccctggaggtgtt


ggatgatcacagcttccttggagcattgcagttgctggaatccagtttcaggat


taagggagggctgcctccttgcaatgggctgccaagaaaacggctgtgctt


gttcttaacctcaggctctgtctgtgatcagtctgagagtctctcccaggtc


tactgctccctggaaagccctatctctctgcaggctcgcctctgggctttgtctcctt


ggagccacatcactgggacagctgtggatgtggatgcagatttgaaccatg


 


Homo sapiens mitochondrial antiviral signaling protein


(MAVS):


(Seq ID No: 860)



ccgcctcctcgctgcgg



gaagggtcctgggccccgggcggcggtcgccaggtctcagggccgggggtacccgag


tctcgtttcctctcag


tccatccacccttcatggggccagagccctctctccagaatctgagcagcaatg


 


Homo sapiens serine incorporator 1 (SERINC1):


(Seq ID No: 861)



ctgtctccatctt



gtctgtatccgctgctcttgtgacgttgtggagatg


 


Homo sapiens KIAA1324 (KIAA1324):


(Seq ID No: 862)



cctcccctttttttccgccttctgccagcagaagcagcagccgcagcacctgagccgc



tactgccgctcactcaggacaacgctatg


 


Homo sapiens synaptotagmin IV (SYT4):


(Seq ID No: 863)



ggacctccctcttt



gcctcctccctgttccaggagctggtgccctgggctctgcgctgtt


gttttcagcgctccgaaagccggcgcttgagatccaggcaagtgaatccagccaggcag


ttttcccttcagcacctcggacagaacacgcagtaaaaaatg


 


Homo


sapiens pyruvate dehyrogenase phosphatase catalytic subunit


2 (PDP2):


(Seq ID No: 864)



cttccttctggagctgggtcctgactagggac



cgcctgggtgaggtgaggacctggtggccgcagttgtggcactgtgcg


caggcgctgaactgaccggacggagcgggcggctgtggcctcgccagctggtttaaaaa


tatccttttttgctgaaggaacacatttgctggtatagtttcagaatg


 


Homo sapiens gephyrin (GPHN):


(Seq ID No: 865)



ctatcctttcctctcagtcctgccatctagctgccttgggtctcgcgctccgcagagcgt



tccgacactctccggcctcgttctgccgcctccgcgcgctctccccgtgcggccaccgcg


ccccccaagcttgcctccttcttgccggacttggggccgcgcgccctgactccttcccct


cccgcggacccgcgcactcccggcgcggcctctcccccacgcaggccaccgtgcactctg


tggcctccccctccttccccgctctcctcgcgcttctctggctccctagctgtcgcgctc


tcctcggcgagcgcgctcccggcccgcgcgctccgggctccggtttctcccggctcctgt


cagtgcggtgactgcgctgggaaacatg


 


Homo sapiens deltex homolog 2 (Drosophila) (DTX2):


(Seq ID No: 866)



ccttctcctgagagtcggagccacagccagagccctgcccaggccgagccggagctg



cagcccgagcgcggtggtgccctcagccccgtcctctt


gtcctcctcagcctcggtgccttggaatttgtgtcgctgagtcagcaagcctttcagat


ttgcccggtttttgttgtttgtggtttgtatcaagatgg


gaactcaaacaagtcattcctcctaaggagctggtgtcttcatccagaagggacagttt


gtgccagctctccagagagaaaaggatctggtactgttctggagtggcctgtagcaga


cactgaaccaccagccagctgcatttgttgtcctggaagtcattgccaactctgccag


tcacactggggtccccagagaagtcaagatctgccggaggcgctgggcaatgaccccgg


gactccaggccagaggggtctgaagctgtttgggaaagcagcgggactccttgggaa


gatg


 


Homo sapiens melanoma antigen family E, 1 (MAGEE1):


(Seq ID No: 867)



ctgcctttttcaccacctctaatttcagcttcagcagttgcttggaactttggttctgg



cagcagcagcaacatcattaccgctagcggcagttttgtgccgaggcacctacacac


ctcccgtcctctctgccagatcgcgggcctgtcggtgtctgctcctacacgccaac


gccggtgggcaggaccatg


 


Homo sapiens G protein-coupled receptor 107 (GPR107):


(Seq ID No: 868)



cgccctttcaccccggacgtgggcgggagaggaagcggctggtgatgctg



gaacaaacatg


 


Homo sapiens PDZ and LIM domain 1 (PDLIM1):


(Seq ID No: 869)



cgctctttctccgacagctgccgggggtgccctgcaa



gctgttccgcgcgtcctgcccgtctgtccccgcgggtcgtcgcccgccacagccgcgc


catg


 


Homo sapiens thymosin beta 10 (TMSB10):


(Seq ID No: 870)



cgctcttttgtttctt



gctgcagcaacgcgagtgggagcaccaggatctcgggctcggaacgagactgcac


ggattgttttaagaaaatg


 


Homo sapiens phospholipid scramblase 1 (PLSCR1):


(Seq ID No: 871)



agacccttttcagacccttttccggctgacttctgagaaggttgcgcag



cagctgtgcccggcagtctagaggcgcagaagaggaa


gccatcgcctggccccggctctctggaccttgtctcgctcgggagcggaaacagcgg


cagccagagaactgttttaatcatg


 


Homo


sapiens eukaryotic translation elongation factor 1 beta 2


(EEF1B2):


(Seq ID No: 872)



gggtcctttttcctctcttcagcgtggggcgcccacaattt



gcgcgctctctttctgctgctccccagctctcggatacagccgacaccatg


 


Homo sapiens pyrophosphatase (inorganic) 1 (PPA1):


(Seq ID No: 873)



ggctctctccttgtcagtcggcgccgcgtgcgggctggtggctctgtggcagcggcggcg



gcaggactccggcactatg


 


Homo


sapiens X-ray repair complementing defective repair in Chinese


hamster cells 5 (double-strand-break rejoining)


(XRCC5):


(Seq ID No: 874)



ggctctttccgctatctgccgcttgtccaccggaagcgagttgcgacac



ggcaggttcccgcccggaagaagcgaccaaagcgcctgaggaccggcaacatg


 


Homo sapiens GATA zinc finger domain containing 1 (GATAD1):


(Seq ID No: 875)



gatccctttcccagtcctgcttcccag



tgcctcgggccagggaatcctggcctccgcctgcggagccggcg


gaacccgcttcccgcctccacggggcagcgccagcggcctggtcctttcaccgg


cagctccgtgccgacgctctcaccgctcttcctatcgccgggagtggcgggccgac


cagggggcggccgggctac


cgtccgccattcccgtgtctctgcgcccgcgggggccgcccgagccggccaccatg


 


Homo sapiens enolase-phosphatase 1 (ENOPH1):


(Seq ID No: 876)



ccgccttttccag



ttccaggtgtgcagaagtgtcctctccccacgcgcggcgggctgcactt


ggtcgctggctccgagatcgcgcggggccgccggaagcccaagacggtaccgggggccg


cagccgcagccggcgccgccctccgccctccccaacagcaggccgagtcccgtag


catccggtagggaaatg


 


Homo


sapiens regulation of nuclear pre-mRNA domain containing


1B (RPRD1B):


(Seq ID No: 877)



agctctttccgggggcccggggaactactctcctt



gcctcgctctgtctccttcgaagtgctctgcgcgaggttcagagcggccgccgcctccaa


agggacggttttctagagctccgacgcctctcggtgcccctctgctccggccctt


gccctttgacctcgctctcgcggcagggtgagaggtcgggtggccatctt


gtggcggcggcgcgggcggctgttactgcggagacccatcccctcccccttctcg


cacccctggcagtctgtcagtcggtaaaaagtcccg


cagcctgtcaggtgaggccccggcctcgtgccgtcgctcttcccgccgcac


tgggcggcccaggccgctccctgccgggcctcactgccgccaccatg


 


Homo sapiens family with sequence similarity 60, member A


(FAM60A):


(Seq ID No: 878)



ctatctttctagacaaggcagttgaggaggagggagcgcttgagggg



gactggcctggcgtgcactccgcacctcggggacattattgcgcgtggaac


ggctgcttttggaaggcacaacttcctgaatggaccatgactcccaccaaa


gatccctgtctctgattcaccaaacagcttcaaccctgaaaccaggacgagaagtt


gacaacatctgagtggacagctaattgacctaagacttcagaccagac


tattgcccagaagaaaagatg


 


Homo sapiens MID1 interacting protein 1 (MID1IP1):


(Seq ID No: 879)



gggccttttatctcggtgctgccgggggaggcgggaggaggagacaccaggggtggccct



gagcgccggcgacacctttcctggactataaattgagcacctgggatgggtagggggcca


acgcagtcaccgccgtccgcagtcacagtccagccactgaccgcagcagcgcccttgcgt


agcagccgcttgcagcgagaacactgaattgccaacgagcaggagagtctcaaggcgcaa


gaggaggccagggctcgacccacagagcaccctcagccatcgcgagtttccgggcgccaa


agccaggagaagccgcccatcccgcagggccggtctgccagcgagacgagagttggcgag


ggcggaggagtgccgggaatcccgccacaccggctatagccaggcccccagcgcgggcct


tggagagcgcgtgaaggcgggcatccccttgacccggccgaccatccccgtgcccctgcg


tccctgcgctccaacgtccgcgcggccaccatg


 


Homo sapiens transmembrane protein 35 (TMEM35):


(Seq ID No: 880)



ctctcccttt



gtcattctagctgcctgctgcctccg


cagcgtccccccagctctccctgtgctaactgcctgcaccttggacagagcgggtgcg


caaatcagaaggattagttgggacctgccttggcgaccccatg


 


Homo sapiens Fc fragment of IgG, low affinity IIa, receptor


(CD32) (FCGR2A):


(Seq ID No: 881)



cttcctcttttctaagcttgtctcttaaaacccactggacg



ttggcacagtgctgggatg


 


Homo sapiens tribbles homolog 2 (Drosophila) (TRIB2):


(Seq ID No: 882)



ctttctctttttgtttggcttctaacgcgttgggactgag



tcgccgccgtgagctccccgaagactgcacaaactac


cgcgggctcctccgccccgtctgcgattcggaagccggcctgggggtcgcgtcgg


gagccctggcgctgcagctccgcaccttagcagcccgggtactcatccagatccac


gccggggacacacacacagagtaactaaaagtgcggcgattctg


cacatcgccgactgctttggggtaacaaaaagacccgagttgcctgccgaccgag


gacccccgggagccgggctcggagcagacgaggtatccggcggcgcccattt


gggggcttctaactctttctccac


gcagcccctcttctgtcccctcccctctcgctcccttttaaaatcagtggcac


cgaggcgcctgcagccgcactcgccagcgactcatctctccagcgggttttttttt


gtttgtcgtgtgcgatcctcacactcatg


 


Homo sapiens family with sequence similarity 3, member A


(FAM3A):


(Seq ID No: 883)



cgtcctctccgggggcggagcgggtcggcgggcctgacagggaac



ctccctgaccgagcccacgtctccccacggccagagaaatctccggcccggcccg


catcgccagcccccaggcccggaggaacggcccgagcccaggagaac


cacatcttcgtcccagccccggaggctcctgtgggcaagatcgtgagccaac


gggttcctgaggcccctcctggccaggcagggtttccccgcgcgtttccgag


gagccctgcctggccgggcggctggacaaacaggtcgtagcac


cgatcgcgcccgcccccagcaggggtcccgcacaggctt


gcccctgacccccacccaaacctgtccttccgctttgcccccaaacagtgcactt


gccggcggtcccaacccagcaggagaagtggacatg


 


Homo sapiens exocyst complex component 4 (EXOC4):


(Seq ID No: 884)



ggctctccccgcgtccaagatg



 


Homo sapiens ELOVL fatty acid elongase 5 (ELOVL5):


(Seq ID No: 885)



gcgccttcctcttcccatcgcgcgggtcctagccaccggtgtctccttctacatccgcct



ctgcgccggctgccacccgcgctccctccgccgccgccgccttgctgctgctcaaagctg


ctgccgccccttgggctaaaaggttttcaaatg


 


Homo sapiens apolipoprotein B mRNA editing enzyme, catalytic


polypeptide-like 3G (APOBEC3G):


(Seq ID No: 886)



ctttctctttccctttgcaattgcctt



gggtcctgccgcacagagcggcctgtctttatcagaggtccctctgccagggg


gagggccccagagaaaaccagaaagagggtgagagactgaggaagataaa


gcgtcccagggcctcctacaccagcgcctgagcaggaagcgggaggggccatgactac


gaggccctgggaggtcactttagggagggctgtcctaaaaccagaagcttggag


cagaaagtgaaaccctggtgctccagacaaagatcttagtcgggactagccggccaag


gatg


 


Homo sapiens gamma-aminobutyric acid (GABA) B receptor, 1


(GABBR1):


(Seq ID No: 887)



gctcctcctcctcccctccgtcggtcagtcagtccgcgaggagag



tccgcggtggcggcgacggtggcgagagccgcgggggccgtaggaagccaac


cttccctgcttctccggggccctcgccccctcctccccacaaaatcagggatggaggcgc


ctccccggcaccctcttagcagccctccccaggaaaagtgtcccccctgagctcctaac


gctccccaacagctacccctgccccccacgccatg


 


Homo sapiens cofilin 2 (muscle) (CFL2):


(Seq ID No: 888)



cctccttctcctcccag



tgccacagagccgaagcccgagctgccgccgcagccacagccgagggcactatg


 


Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 35


(DHX35):


(Seq ID No: 889)



tgaccttttaccccaacatg



 


Homo


sapiens resistance to inhibitors of cholinesterase 8 homo


log A (C. elegans) (RIC8A):


(Seq ID No: 890)



ccgccttccccggcgcgccatg



 


Homo sapiens FK506 binding protein 10, 65 kDa (FKBP10):


(Seq ID No: 891)



ag



ttctttgtagtgcctccctcagactctaacacactcagcctggccccctcctcc


tattgcaaccccctcccccgctcctcccggccaggccagctcag


tcttcccagcccccattccacgtggaccagccagggcgggggtagggaaagaggacag


gaagagggggagccagttctgggaggcggggggaaggaggtt


ggtggcgactccctcgctcgccctcactgccggcggtcccaactccaggcaccatg


 


Homo sapiens small ArfGAP 1 (SMAP1):


(Seq ID No: 892)



cctcctcccgttccagctgccgctgccgcttcctgggctgag



tccgcccgcggtcccggcggcgccaggtgcgttcac


tctgcccggctccagccagcgtccgccgccgccg


tagctgccccaggctccccgccccgctgccgagatg


 


Homo sapiens chromosome 14 open reading frame 93 (C14orf93):


(Seq ID No: 893)



cctcctttttgcacacacacgaatacaaagagccatacgaccttcggatgccggaaggtc



cttctgaatcccttccctgttccttaggttgcactagtcgggggttccatgctggggggc


agaaggaatgctctctaccgtctgaaaccgttcatcaggaaggccttgatttgtgatgtg


ctaggagagcacaggatctgcaaatagaaggcacctgtctcccttctgcaggccgaggag


aggccgccatggactgtgtgcttcttcatggcttgtttactcttctttcacagaccctac


agcttggggcctgggctcctctgaccatcctcattgagaaaggaaagtgagtccagagaa


gttgatgcttcctacctgttggagcggcccagcagtgtaagcgtggttgttactgcccca


tccgccatg


 


Homo sapiens brevican (BCAN):


(Seq ID No: 894)



cgccctcttccgaatgtcctgcggccccagcctctcctcacgctcgcgcag



tctccgccgcagtctcagctgcagctgcaggactgagccgtgcacccggagga


gacccccggaggaggcgacaaacttcgcagtgccgcgacccaaccccagccctggg


tagcctgcagcatg


 


Homo sapiens H2.0-like homeobox (HLX):


(Seq ID No: 895)



cggcctctcttcctcag



tgcgggcggagaagcgaaagcggatcgtcctcggctgccgccgccttctccgg


gactcgcgcgcccctccccgcgcgcccacccacccagtccggctggactgcgg


cagccgcgcggctcaccccggcaggatg


 


Homo


sapiens v-rel reticuloendotheliosis viral oncogene homolog


A (avian) (RELA):


(Seq ID No: 896)



ccgcctctggcgaatggctcgtctgtagtgcac



gccgcgggcccagctgcgaccccggccccgcccccgggaccccggccatg


 


Homo sapiens zinc finger protein 277 (ZNF277):


(Seq ID No: 897)



cctcccttttcttttctgccgggtaatg



 


Homo


sapiens globoside alpha-1,3-N-acetylgalactosaminyltransferase


1 (GBGT1):


(Seq ID No: 898)



cttcctcttttctgtctggcccgcggccccgctgcctgccctgctccaggctccac



ctgcgccgccgatcgcccgggtatcgcgggggcccaggccagctgag


tccgttttccgcgccggggtggcgcccctccaaccgtcctaacgccgggccggcag


caaggagtgttcctgggacctcagagaccaggctcagagcctgacatccctgcgaggg


gacagcctcatccgcccaggccagtgggggtctctacaagtgcccaggctcaggtg


cagcccccagcaatg


 


Homo


sapiens FXYD domain containing ion transport regulator 6


(FXYD6):


(Seq ID No: 899)



ggtcctcctgggagtctcggaggggaccggctgtgcagacgccatg



 


Homo sapiens nuclear RNA export factor 3 (NXF3):


(Seq ID No: 900)



tcctctc



tatgcttggggaaggaacttcctgtaagcaaggcttgaggcttgctctcgccttcgtcag


cagccctcctcaatcttctccaaactcccgtccccaggccacacagattctcctcaaga


gagccctataaggacattggtaaaatg


 


Homo sapiens chromosome 14 open reading frame 133


(C14orf133):


(Seq ID No: 901)



attcccttccgcccccttctctaagctgcacagcctgaatagaagggctggtccagcggc



ggcggaggctggcgctgtcctgagagggagggctctgtgcggaagagtcagggcgaccct


tgggcgctggagtacgcttgggactggggctgcgagtgagcaccagcgattggttcggaa


gcggacatttggttcagaacgagcatttaactctgccagggatccgctgggctctgacga


ctgcggtagatccatggcttcctggacgttcacccgtagagtcatcctagcttaactctt


gttccctggtctcagttcacaagcctcacctgtatcttcctggctcggaagataattgaa


accaagtctgacttctcaatg


 


Homo sapiens X-prolyl aminopeptidase (aminopeptidase


P) 3, putative (XPNPEP3):


(Seq ID No: 902)



ctttctcttcccgacgcgtgag



ttaggccgtaatg


 


Homo sapiens death inducer-obliterator 1 (DIDO1):


(Seq ID No: 903)



ggccctctggcaagatggctgctgcggaggcgttggagcgcggaaatctggaaccgg



gatggcgacgtctacactgagtcggaggcgaaggagcttactccacgg


gaacagcctctagataatctgagttgttgaaaatacgaagcctgttactcgtgaacag


tggctgacaacagtgttgttgtgagcctggctgtctgctt


ggacccagaggtttcgtctgccagggtttttggttgtatttaggat


ttcagggaaaagtgtccaagctttcagtgttggagcaggtatg


 


Homo sapiens PERP, TP53 apoptosis effector (PERP):


(Seq ID No: 904)



cggcctcttcgcttttgtggcggcgcccgcgctcgcaggccac



tctctgctgtcgcccgtcccgcgcgctcctccgacccgctccgctccgctccgctcggcc


ccgcgccgcccgtcaacatg


 


Homo sapiens tubulointerstitial nephritis antigen-like 1


(TINAGL1):


(Seq ID No: 905)



tcctctcttgactttgagcgtccggcggtcgcagagccaggaggcg



gaggcgcgcgggccagcctgggccccagcccacaccttcaccagggcccaggagccac


catg


 


Homo sapiens eukaryotic translation initiation factor 4H


(EIF4H):


(Seq ID No: 906)



ggttcctctcggagcggagacggcaaatg



 


Homo sapiens non-SMC condensin I complex, subunit G (NCAPG):


(Seq ID No: 907)



ccccctctcgcgggaattatttgaacgttcgagcggtaaa



tactccctggggctgtcatagaagactactcggagagcgctgcctctgggtt


ggcgggctggcaggctgtagccgagcgcgggcaggactcgtcccgg


cagggttccagagccatg


 


Homo sapiens MMS19 nucleotide excision repair homolog


(S. cerevisiae) (MMS19):


(Seq ID No: 908)



tatcccctcccacggtctctagttcgcgttatg



 


Homo sapiens DnaJ (Hsp40) homolog, subfamily C, member 1


(DNAJC1):


(Seq ID No: 909)



ctgcctctacagctgtgtgtaggcctgggggcgagggtcttcggaac



gtagcgctggctgcggccccgcccgcctacccacccgcccgtccgg


cagccggctcccgccgcctccgcgctctgtctggggccagccac


ctggcgggccgctccggtgcgcctgcccgcgcttttcac


tgacaggcgctgttccccacagccagcgccgcccgccacgtcccagctctcggccaac


ggagctgcgcggcgggtgacctttccgagcccagcgcgatg


 


Homo sapiens stimulated by retinoic acid gene 6 homolog


(mouse) (STRA6):


(Seq ID No: 910)



ctaccctttcatctctgcaactccttcctccctgggcctcccttctggtgtgtctgtggg



tctgtctaggtgggcttgggaaaggggaaggaaggggcgtctctttaggcagctcagact


ggacaagccttcttt


gaaaatggtcctttgaacacacgcctgctggtggttggtcagacagatgcgccagcgg


gagccccggggccccaaggggacagctatctctgcaggaccagtgcgatg


 


Homo sapiens 5-azacytidine induced 2 (AZI2):


(Seq ID No: 911)



cagccccttttccggctgagagctcatccacacttccaatcactttccggag



tgcttcccctccctccggcccgtgctggtcccgacggcgggcctgggtctcgcgcgcg


tattgctgggtaac


gggccttctctcgcgtcggcccggcccctcctgcctcggctcgtccctccttccagaac


gtcccgggctcctgccgagtcagaagaaatgggactccctccgcgacgtgcccggag


cagctcccttcgctgtggaagcggcggtgtcttcgaagaaaccggaa


gcccgtggtgacccctggcgacccggtttgttttcggtccgtttccaaacac


taaggaatcgaaactcggcggccttgggggcggccctacgtagcctggcttctggttgt


catg


 


Homo sapiens polymerase (RNA) I polypeptide E, 53 kDa


(POLR1E):


(Seq ID No: 912)



acgccttttccggcccg



cagcgcggcctgggctcccgcgtgtttaaaagtgcgctt


gtggctgctgctgtcttaactcctgtgcttggcggacagacaggcgagatg


 


Homo sapiens mitochondrial ribosomal protein S25 (MRPS25):


(Seq ID No: 913)



agtcctttctcgtcgctgctcggctcgcggcccgtggggtcggccccgccaccgtt



gccgccatg


 


Homo sapiens TRM2 tRNA methyltransferase 2 homolog A


(S. cerevisiae) (TRMT2A):


(Seq ID No: 914)



cggcctccgccgcacgcgctggcggactaagag



tggctggcgaagcgagcggccggcgcgggcccctggcgggcgggcggtacagccccaa


gcctgagacccggacctgagcatcgcaggttcgagtcccgccccgcctggggcgaa


gccgggggtggcggcgacctcgcggcgttgcaccggctctgtgagcac


ctcccctctgagcacttcccttgtgacaggccacttcccttgtgacaggcccaggac


gaggtggccaggcggcccccatggcgtccctggtctaggcggagaaccgcctgggcgatg


 


Homo sapiens lipid phosphate phosphatase-related protein type


2 (LPPR2):


(Seq ID No: 915)



ccctccctccacctcggagtctgcgcggcgcggccaggcccggccgaccgcgtctcggtc



ttcgcgtctgccagcctggctggcagtccgtctgtccatcccgccgcgccggggcagtct


aggcggagcgggggctcaggcggcggcggcctcgacgcgagtgagtgtcgtggttggggt


gctggacccagagtgcctaccctcgcctgcctgggcctcagtttccacatctgcacaatg


ggggtgaccatccctgccctgctggctgccaggagcggctgtgagtcttcaggcgtggat


gcagcctgggggaagccatagggcgctttcacaggcctggccttcaccatg


 


Homo sapiens chromosome 11 open reading frame 1 (C11orf1):


(Seq ID No: 916)



gaaccttttttcacctcgtctgaaatg



 


Homo


sapiens microtubule associated monoxygenase, calponin and


LIM domain containing 1 (MICAL1):


(Seq ID No: 917)



cgccctcccacccgctcagac



ctggttgccagcccaacaggaagcggcccctcccggcttcggagccgccgccac


tcatctctgcccagctgctgccctccccaggaggcctccatg


 


Homo sapiens kinesin light chain 2 (KLC2):


(Seq ID No: 918)



gctcctttaaggcagcgaacgggccaagagaagcgtgtttcgccccctccgacgccac



cgaggtagcggcttcacctttaaggcggcgcgggggctgctgggaaggccggcgg


gatggaggcggcgggaccggctcgcgggtgcgggtccgggtgaagcgg


gaggcagccagagtcggagccgggcccgagcaccaggcg


caggcccggcgcccgcctgcccgcaccctcgtcctcacagacgccacagccatg


 


Homo sapiens DNA cross-link repair 1B (DCLRE1B):


(Seq ID No: 919)



acttcctttttctgcccactctgg



taacttattgctctgctgggctctttcccttagggtctctggccctgttcttgccccag


catgacttttatcgggacgccgttgtggaagcctcacgcaggagccctgcccccgtgga


gaagatcccactggtgactccaaccctaccaccatg


 


Homo sapiens armadillo repeat containing, X-linked 5


(ARMCX5):


(Seq ID No: 920)



gctcctcccactgccgttgtgggtaacgcggacgtggaagaac



ctcgtctgcggaggaaaaggtagatgttaaatggtaactacgcgcgaggttctgag


gagccctgggaacaggaaggagaaaagaataccaaaagtgacaacagtttgccaatcg


cagtctttaatctgataaagcggttatctcgtcttgagtcccaggtgccgag


tcaatccccatacacagccgccgccattgcctcgagtcctt


gtgtctgactgtctgttcctgctgctgtatgacacagcacctcgaggcaaggaaataa


gaaaactgcctctgatccaagcagagaaggtctgcctgtagatctgctgtagggctt


gtcaccattggaagcaaggtcctacttcagtggcagatctggtggccttggag


tggctgaagaccaccaccctccacagggctgggcccatgcacagccatccttccctac


cttgagtgagcttcctctgcatgttttctatatcactggcagagcctgtagtt


ggaaaggggacagagtgactactggactttgtgtgaaaacaccaaccgg


gacaaaacttcagtcaaggctgagacgggtgggggtatataacttgtccttac


gttaaacttggaacatg


 


Homo sapiens chromosome 12 open reading frame 43 (C12orf43):


(Seq ID No: 921)



aatcctttgcggtggttcaagatg



 


Homo sapiens vacuolar protein sorting 33 homolog A


(S. cerevisiae) (VPS33A):


(Seq ID No: 922)



ggtcctcccgtaggaaccggcggactcggtt



ggcgttgtggggcagggggtggtggagcaagatg


 


Homo sapiens arginine/serine-rich coiled-coil 2 (RSRC2):


(Seq ID No: 923)



gggcctcctcgcctttgtgccatccgggtctctcgcgcgagcgatttagtctgaggcgaa



gcttcggagcggccggtactgttgaaagcgacaagtggaggcgccgctctagcggccggg


actctgaactatggcggctagtgatacagagcgagatggactagccccagaaaagacatc


accagatagagataagaaaaaagagcagtcagaagtatctgtttctcctagagcttcaaa


acatcattattcaagatcacgatcaaggtcaagagaaagaaaacgaaagtcagataatga


aggaagaaaacacaggagccggagcagaagcaaagagcgtgcttatgcgcgaagagactg


aactgaagacgctgcagactcagatagcaaaataataagcctacttcatgataagggaag


aagacatgaatccaaagataaatcctctaagaaacataagtctgaggaacataatgacaa


agaacattcttctgataaaggaagagagcgactaaattcatctgaaaatggtgaggacag


gcacaaacgcaaagaaagaaagtcatcaagaggcagaagtcactcaagatctaggtctcg


tgaaagacgccatcgtagtagaagcagggagcggaagaagtctcgatccaggagtaggga


gcggaagaaatcgagatccagaagcagagagaggaagaaatcgagatccagaagcaggga


aagaaaacggcggatcaggtctcgttcccgctcaagatcaagacacaggcataggactag


aagcaggagtaggacaaggagtaggagtcgagatagaaagaagagaattgaaaagccgag


aagatttagcagaagtttaagccggactccaagtccacctcccttcagaggcagaaacac


agcaatg


 


Homo sapiens integrator complex subunit 3 (INTS3):


(Seq ID No: 924)



ccgccttcccaccccccgcccttccactatggccgcttctgtgtggtgtggggagac



gctggtcctccccgtcctcccatagcgcttattgcctcaccctcaccccctaggggccg


gatccaaaggcgctgcactccccaagccttggggcatcagccaggaaggtttcctac


ctcctaattcaggggcaggactcctcttttccccccacggggaaaa


gaggcagaaacttaggggtttccctcctttcttagggtcagacgctcttagggtccac


ttcttcaggggcggaagcctctcctacccttcccataggggcacaggcctttaccccac


tgtacttcggagccaacgcctttccctcagcactgccaccccagagtcaggacccagag


gactgtgccttcgcccccaacgcaggcgcggccttttggagaggagggaggagtgga


gaggacaggggcccttgctctcccctccccaacttgttcctcttgccccccag


tccctggcaatccagagatcccgatatctaggactgtccatccatccactccctgac


cttttcccggctcctggctgcagccatg


 


Homo sapiens spermatogenesis associated, serine-rich 2


(SPATS2):


(Seq ID No: 925)



tctcctttcctcttctcagacccgggagcgtccgggacgcggagcccg



gagctggggcgacgaggcgattgcgggggcctgggctagctgctggctaccaatattc


tactttctgtctctatgaatgtgactaccctggttacctcatataatctccctg


gaaaaggagacatgaatgtctgcaatgatacttcctgacaagaagttgatacaa


gaaaaggaaaggagattaacagctagtgagcagaatttcgaacagcaggatttcg


tattttttgcttccaactgcacacttccgttgcccacttttaaatcagagatac


ctacactcaaaacccagacaaggcaaaaggatacttttcttgtatattttttga


gatcgaagaaacgacaatg


 


Homo sapiens fibroblast growth factor receptor 1 (FGFR1):


(Seq ID No: 926)



ccgcccctttcacctcctggctccctcccgggcgatccgcgcccctt



gggtctcccctcccttccctccgtccgcgtctcctgcgccccctccctgcgctcgtcccg


ccgctcttcccgccgcccaacttttcctccaactcgcgctcgg


gagctggcgaggcggcggcggctcctcaggtcagtttgaaaaggaggatcgagctcac


tgtggagtatccatggagatgtggagccttgtcaccaacctctaactgcagaactgg


gatg


 


Homo sapiens FUN14 domain containing 2 (FUNDC2):


(Seq ID No: 927)



ctccctcttccgctgccgccgtgggaatg



 


Homo sapiens ganglioside induced differentiation associated


protein 1-like 1 (GDAP1L1):


(Seq ID No: 928)



cctccttctttcctgcctctgattccgggctgtcatg



 


Homo sapiens chromosome 19 open reading frame 43 (C19orf43):


(Seq ID No: 929)



agtcctttgcgcggcacctggcgacaaaatg



 


Homo sapiens MIS12, MIND kinetochore complex component, homolog


(S. pombe) (MIS12):


(Seq ID No: 930)



ccctctcttctccaccagccaacgtccgggaaaaacgag



taagtacaggttccttctgccaatccccgccggccacagctaactttcccgcccggcccc


tttctgtcataattgaggtgtccacaaccagccaatcaggaacgcgagag


tatcccgcgtttgctttcgctcgccgaggcgcgtatcagtcggaattttggg


gagccaaccgcgccgtctgtccctggcaagccagcggcggtttaaaggaggtggcgg


gaagcctgtgtgtgcttcaaatcgtcaccctcatggtcgctccggtaagtgctgcgggg


cagcattttctctgaggaggagcggggacgggcgagactggcataa


gcgtcttcgcgagggagcaaggcggcctgtgggtcggcctcaccccggcctccgac


ctgaagatcccagcatgcagcgcgggcgcggggcccgacggaagccgggagccggccg


gaagcagttcctgcgctctggcttctgggtcctgtcctgcgcgatcgcggggtcttaga


cagctcaactcgccgagatgacctgggcacctctgcgttgaatcggcaaa


tactgatcaagccgcatttattctgctctcaggaactctaagtctagcagagaa


gatgaggcggtagaagttcatcaatggcttggctggaggacaagcaaattgaggacatt


ggcaacggagtgatcaaaatgatagatcatgaggcctaaaatgaataaggaaagaaga


gaagtggcagaggctgagaacagaaagagagggtggaggggctgtaaatcttgaa


gattagggtataatatgagtatatgggtaagaattggaagaattgtgtaggaggcag


tagtcaaaaagtagaagcagtttggaagagtagttacaaatatcaa


gagccaggtggctaaaaggtggagctataggtcattgaagctcaagaaactgag


tctctagggcattggttaagtcatctgtctagacttcaaagttgtctaggatga


taattcagaagactgatctgtgccaaagtcacaggtttttcac


gactgaaaacaacatagcaaaataagccaagatg


 


Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 50


(DDX50):


(Seq ID No: 931)



cttcctttcacgctgtcgctgcccgtaggtggttgtggccactgtgcccg



gagggaggcggcggtggccagtaatg


 


Homo sapiens chromosome 7 open reading frame 25 (C7orf25):


(Seq ID No: 932)



cggcctctgcgtgcacgcgcctgcgtgctcgcgctcgcggttctggcgctgccggaa



taatgctgacagcatg


 


Homo sapiens KxDL motif containing 1 (KXD1):


(Seq ID No: 933)



ccgccctttcctgtcgtgacttaacgcacgcaagcggctccagggtacgtccccgccac



gcgcgctcgcaggatcggtgcgtggtgacgtttcgccggcgcgggcgccatcccggaa


gcgcgagcaaggccgccagatgtgcaggcagcggaggaggagaaagagatg


 


Homo sapiens defective in sister chromatid cohesion 1 homolog


(S. cerevisiae) (DSCC1):


(Seq ID No: 934)



acttctttcttgcccgccaagcccgcagccacccgggcgcggcgggactcctagacccgg



cgctgcgatg


 


Homo sapiens zinc finger protein 426 (ZNF426):


(Seq ID No: 935)



cgttccttttgtgacgccggctgtgagcgcctgagagtctttttgcctttcagagttaag



gcctcactggcctgggaaaataattgctgccttttgcatccgcgttggctccgtccccag


gatcttcccggttcagggacctggcgatttctgagtgttccggaatcccaataaccctgt


ttaaagaggaatggagattgccactgtccatttagattaatgaggtgtcctgaagtgatg


gtgacatcaatgaaaggagggttctgacacgttctcacctcgcgggatg


 


Homo sapiens TATA box binding protein


(TBP)-associated factor, RNA polymerase I, D, 41 kDa (TAF1D):


(Seq ID No: 936)



caacccttttcttccgcacggttggaggaggtcggctggttatcgggagtt



ggagggctgaggtcgggagggtggtgtgtacagagctctaggacaccaggccag


tcgcgggttttgggccgaggcctgggttacaagcagcaagtgcgcggttggggccac


tgcgaggccgttttagaaaactgtttaaaacaaagagcaattgatg


 


Homo sapiens PHD finger protein 1 (PHF1):


(Seq ID No: 937)



ccgcctcctcctcctgccgctgccgctgctttggctgctgcgtcat



acgccccagagccgccgggacggaggggctgggcctggggaccccccggcctccgcctg


cacgcccccccacgcccggacgtgccctctccgcgcgggggactcgcctaggtctcc


tacgtctgcccctgcccggctcccggcggccccagctgtcaccggcccccccaggatg


caatg


 


Homo sapiens family with sequence similarity 134, member A


(FAM134A):


(Seq ID No: 938)



cccccttccgcctgacgcgcccccggcggcggccgcg



cagccctggctcctcgcgggctcgggcggcggctgcggcggggctatg


 


Homo


sapiens membrane bound O-acyltransferase domain containing


7 (MBOAT7):


(Seq ID No: 939)



ccgcctcctttccggagcccgtctgttccccttcgggtccaaa



gcttttggctcctccttgttccgagcccgaaggcccgccccttcacgtactcg


gagctcggatcccagtgtggacctggactcgaatcccgtt


gccgactcgcgctctcggcttctgctccggggcttcttccctgcccgcccggggccctga


ccgtggcttcttccccggcctgatctgcgcagcccggcgggcgcccagaaggag


caggcggcgcgggggcgcgctgggcgggggaggcgtggccggagctgcggcggcaa


gcgggctgggactgctcggccgcctcctgcccggcgagcagctcagaccatg


 


Homo sapiens major facilitator superfamily domain containing


11 (MFSD11):


(Seq ID No: 940)



acgccccttttttgctcagccgtcagccccgtctccgtctgaagagtgcttctgccctca



tttgcctctccctgtgaccccggccccctcagactccgctgcgtcgtctctcggccccgt


ccagccgttcctgactgctcttcgccggagtccgcttcccaaccccctttcgccagagcc


cgagagctccgtcggctctgcgtcctggcggattgtcagtggcttcgccccgaggagagc


tgactgccctgggctgctgcctccggcagagctgagccaaaatg


 


Homo sapiens thiamine triphosphatase (THTPA):


(Seq ID No: 941)



ctcccttccccctctgtgggtcccgcgaggagactctcgggctttgaggtgagacctgaa



gttccgctggccggtagtgtagcaggaaagggcaggtcctcccgggtcgtgagccagtag


cctcctggggtggcaaggtgtagagaggggggcgttgaaaggacacccgctacccggcct


gctttctaggggtctctttggattgaggacatcagcagcagtggaagggattttactgga


gacctgtcactgtcagagccttaaaatatcaccgacggggccttaatgtcaccgaggtag


agagaaaagggcagtagccctagagactattgcgacacag


tgtgcccctcataagtttttccagggaggggttctgtactgagttgacgccccag


gagctgagcaccaggctttgcatccttgggaactcagcaaacgtttgttcagccaatt


gcaggtagcatg


 


Homo sapiens acyl-CoA synthetase short-chain family member 3


(ACSS3):


(Seq ID No: 942)



tactcccttccctcaggccccaggaagttgcaagagtaccatttgtcg



cacactcggggaccgcgggtggccggaggagatg


 


Homo sapiens chromosome 6 open reading frame 211 (C6orf211):


(Seq ID No: 943)



gctcctccttcgcggcggtaccgcctctgtttctgcggcgattgaacagccgagcttt



gcggccgggatcgcggaaagtgatg


 


Homo sapiens transmembrane protein 204 (TMEM204):


(Seq ID No: 944)



atttcctctctgctgagagccagggaaggcgagctctgcgcacacgggcgtccctgcag



cagccactctgctttccaggaccggccaactgccctg


gaggcatccacacaggggcccaggcagcacagaggagctgtgaacccgctccacac


cggccaccctgcccggagcctggcactcacagcaggccggtgctaaggag


tgtggcgcgggctcgactcccactgctgccggcctcccgagtgactctgttttccac


tgctgcaggcgagaagaggcacgcgcggcacaggccggcctccgcttcccgggaagac


ggcgcactcctggccctgggttcttgctgctgcccaccctctgctccctgg


gatgggccccgaggcgagcagcttcagcacaggcctggccctgctccaggtgcag


gaaggaggataaggccgggccgagaggcggcacacctggac


catcccatgggcctccgcccgcgccgccccgaggatgag


tggtgatgtcctctagccacccctagcagcgtcggctctccctggacgtgcggccgcg


gactgggacttggctttctccggataagcggcggcaccggcgtcagcgatg


 


Homo sapiens DEAR (Asp-Glu-Ala-His) box polypeptide 40


(DHX40):


(Seq ID No: 945)



tcgtctttcccctcccatctcctcagatcggtggacgtgctcgcctccac



tcggggccaggtctatg


 


Homo sapiens importin 4 (IPO4):


(Seq ID No: 946)



cctccccttttcggcccag



tagcggcggctcagttgctgccatg


 


Homo sapiens N-acetyltransferase 10 (GCN5-related) (NAT10):


(Seq ID No: 947)



ccttctctttcggagttgttccgtgctcccacgtgcttccccttctccactggctgg



gatcccccgggctcggggcgcagtaataatttttcaccatg


 


Homo sapiens lin-28 homolog A (C. elegans) (LIN28A):


(Seq ID No: 948)



aaccctttgccttcggacttctccggggccagcagccgcccgaccaggggcccggggcca



cgggctcagccgacgaccatg


 


Homo


sapiens CAP-GLY domain containing linker protein family,


member 4 (CLIP4):


(Seq ID No: 949)



cggcctttcctccgcgcccccgcgtccccagccggccgctccgagaggacccggag



gaggcaggtggctttctagaagatg


 


Homo sapiens zinc finger, AN1-type domain 1 (ZFAND1):


(Seq ID No: 950)



ccgccccttacggcgccggagagatg



 


Homo sapiens GTPase, IMAP family member 6 (GIMAP6):


(Seq ID No: 951)



cctccctttttctacttccgaggctgcaaagtgcaacagcagactcttctgactcag



gaaggccggtgctcctacccacttcctgttcctccatctccagcggacac


tgctctttcaagggcaggtctccagcccagctctctgaaaacattttgctgaaaa


tataagcaaacatcggccttgtcctccttgtgttcatacactgtggaa


gcttttctctgcctcctccgtgagagtgcgtggccgggagaccagaaac


gtggtcctttctcttgcctgtgagctggtgcagagatg


 


Homo sapiens thioredoxin domain containing 15 (TXNDC15):


(Seq ID No: 952)



cttcctccggctggcagcacgactcgcgtagccgtgcgccgattgcctctcggcctggg



caatg


 


Homo sapiens asparagine-linked glycosylation 9, alpha-1,2-mannosyltransferase


homolog (S. cerevisiae) (ALG9):


(Seq ID No: 953)



aattcttttttccccaggcttgccatg



 


Homo sapiens glutathione S-transferase, C-terminal domain containing


(GSTCD):


(Seq ID No: 954)



acttccctttttccggtccgccggattatgaatgac



ggccggcgcgagtattttccacataaggtggctgtcgtttttctcctggcgtotgtg


gaggcgagtggtctgcgggcagcagctcccagaggcagccttggaattccagctcg


gactgggcgggaaggcgcaggcggcccaggtcgccgacacgctcac


gcaccctccctgcctggccgcgcctctgcgaccaggtgacccaatgaaagaagaaaatg


 


Homo sapiens CXADR-like membrane protein (CLMP):


(Seq ID No: 955)



actcctttttctttccaaacagggaaaagtgttccacgaagcgg



tagcgcctttccgcctcgcgttttcctccctgaccctggtcccggctcccgtccgggcgc


cagctggtggggcgagcgccgggagcccatctgcccccaggggcac


ggggcgcggggccggctcccgcccggcacatggctgcagccacctcgcgcg


caccccgaggcgccgcgcccagctcgcccgaggtccgtcggaggcgcccggccgccccg


gagccaagcagcagctgagcggggaagcgcccgcgtccggggatcgggatg


 


Homo sapiens nonhomologous end-joining factor 1 (NHEJ1):


(Seq ID No: 956)



cctcctcttgcggtggggggaaagcggcctcttactctaggcctttcggtttgcgcgagc



gggcaggaaagcgtgcgtgcggctaagagagtgggcgctctcgcggccgctgacgatg


 


Homo sapiens gametogenetin binding protein 2 (GGNBP2):


(Seq ID No: 957)



cctccttcttccactccccgcggcgcgagcggctgactgcccgtagaggaaac



gacattcggagctgcgctcccgcccaggccggccctgacgcgggcctcgtcagccag


taacagggagcagaggtgggagttagcgaggcgaccacgaaaacggtgaaggtcggaac


cgacagcctcctccgagaagggcaggagctgggaggaggcggcagcggcggcgg


cagaaacagcagcggcggcggcggcggcagctgggaggaggtggtgacggtggcaacgg


cagcgtcggggacgatg


 


Homo sapiens zinc finger protein 672 (ZNF672):


(Seq ID No: 958)



ctttctcttttagccccgcctgcttcccggctccagctggggccggagaggctgag



tggttggtacgctgctcgctggcctcccagtcttcccagcaaccggtgacac


tgcccgcgccagactgaccactagccgacgcgggcgagagggacaggagcgtgac


ctccccatcccgaggggccggacgctcgggcgcctccccgctccccccactcg


gaggccgcgcgcgccgttagccccttcctcgctcccccgccccagtcccgcagtccgg


gaggcgggggtcggcagccggctgagtgggaaccgcgcggtgtctgaggaggcag


tcggcgaccggtttccacttcaagcgtgacccttttgcctgtgggatgagctccag


catggggtgaggtacagaagagagacttgaagagcgtgccttgggactcaa


gcgccaaacctgtaccctagcgagtgtcctactccgcatccg


taatggaaggaaatgcacatcttactccagaggcacaagaggaggacatcccatgcggc


tactcctgcccagcgtggtggggcagcagaagctccagagcccagacttgcaggctcac


ggtgcagggtgaacctggccacagctcaccctggaacagccacaatgtctgcccctta


gagaagaaccctgaaatcagaccagtttttgcggcctccccctttcctctctgttacag


tgccctttccaggccttaagagaagtaaaacttagctgcagcgccaggaggtg


gaccccagagtgtgagtggcacgcttccctgtgaacccgtcctcaccatg


 


Homo sapiens N(alpha)-acetyltransferase 60, NatF catalytic subunit


(NAA60):


(Seq ID No: 959)



ccgcctccgtcccggctgcggcccctgccggttacataactcgtt



gcgggctccgcgcggtcccacttcccggctcccttcgcctccag


gatgcgctgagccctacaacacccccagcggccgccggctcccccacgaggtgtgaatg


 


Homo sapiens transcription elongation factor A (SII)-like 4


(TCEAL4):


(Seq ID No: 960)



tgccctctgtccccgcggctgggtctcgtctgctccggttcctgggctcctaattctt



ggtccagcttcttccaggtcagtgtgcgggccttccacgctgccagcggaacactg


gaatggcggaaggggaacgggtctgcgcgtctgttgttcccagcgctctgcgaa


gcctgaaaaggaggagcaacctgtccagaatccccgcaggacaggaaaaggaggg


gaaatctcgacatg


 


Homo sapiens progestin and adipoQ receptor family member VI


(PAQR6):


(Seq ID No: 961)



tcccctttgtctccccactccccgcccaggcctggcccgcctgcctggccactcttcctc



catcagcctggctggcagcagccttggactccgcccgtggagccctgggcctgttgaccc


accagcttaggagcacccaccaagctctgggtaaggaagctcaccttctggggctcttct


gggaaaatagaggtcaacgtggaggtaccaggccaccatgctcagtctcaagctgcccca


acttcttcaagtccaccaggtcccccgggtgttctgggaagatggcatcatgtctggcta


ccgccgccccaccagctcggctttggactgtgtcctcagctccttccagatgaccaacga


gacggtcaacatctggactcacttcctgcccacctggtgaggggaggctctgccccaggc


cgcggccttgagctcagagggggtacccaggcgggcagggaccgtccaggcccacgggct


gcagcggcagtcgcgggggtccgcggcggcctgagcacgcgcccgccgcaggtacttcct


gtggcggctcctggcgctggcgggcggccccggcttccgtgcggagccgtaccactggcc


gctgctggtcttcctgctgcccgcctgcctctaccccttcgcgtcgtgctgcgcgcacac


cttcagctccatg


 


Homo sapiens DENN/MADD domain containing 2D (DENND2D):


(Seq ID No: 962)



catccttcttgctcaaccactgggtgcacaggatggaaacttctattccctctctg



gaagacagcgcgtggcttggcttcacagagttgtggctggagaccgaa


gcagcccctttctcaggcttactgtcaccagtctgtctgtgttaggggagaggggag


tccgctctgtcctgaaggcccagagatg


 


Homo sapiens family with sequence similarity 188, member A


(FAM188A):


(Seq ID No: 963)



ccttcttctttcctgcctcaccttccaattcgttt



gccgccgccgtcccgcagctgctgtttccggagttgccccttccccatgttccgggg


caggagtccgcaaagcgaagatccgcccgccggttcctcatcatg


 


Homo sapiens neurensin 2 (NRSN2):


(Seq ID No: 964)



ccgcctttgctcggcggagacag



caggcagagagatgaggaaactgagacccagaaaggtggaagcacttgtctaaggtcac


gcctccaggaagcagtgtgtccacgactccag


tccaagtggtcaggctccagagcccacagtcccaggggtccatg


 


Homo sapiens tripartite motif containing 46 (TRIM46):


(Seq ID No: 965)



agccctcctcacacccccactgggctcctgcattaagcccggggttcgcagccg



cagccgggatcgggcacccaggggcgggcgggcacggtagggccatg


 


Homo sapiens target of EGR1, member 1 (nuclear) (TOE1):


(Seq ID No: 966)



catcctctctgggaatttaccgatgcccagaacgcccttctttcccccacac



gaccctctcctagtctaactcctgggcgtgctttaagctcagctcaggcagcgtcac


cttctctggaaagcccaaacccagccaccccactacccgctacccgcggcccac


gctgatgaagacagcagaacacggaggccccgcgttcccgccgcgagagcaggaga


gaaagattacctcccgcgagctctagcgcgcccggctttccggcgcac


tccagggggcgtggctcgggtccacccgggctgcgagccggcagcacaggccaa


taggcaattagcgcgcgccaggctgccttccccgcgccggacccgggacgtctgaac


ggaagttcgacccatcggcgacccgacggcga


gaccccgccccatccccgactgcctgaaccgcgccaggagacggaccgcaagtccagcg


tacccacagacgactcaggcgggagacgagcggtgtcatg


 


Homo sapiens DBF4 homolog B (S. cerevisiae) (DBF4B):


(Seq ID No: 967)



cgttcttttaggggtggagccggcaggaaatttaaactgaagccgcggccgaaaacgcca



agagattgatgctgtagctgccctgagataaccaggactgtggaatcgggaa


gagctcatggagctcgcgaatgtaatacggaggcctctgaggaaggagtac


ggaggccgagaaggagccggcatttgatg


 


Homo sapiens myc target 1 (MYCT1):


(Seq ID No: 968)



atttccttttatg



 


Homo sapiens myosin XIX (MYO19):


(Seq ID No: 969)



ggttcctttcctcactgcacgctctt



gcccctcctcttttctctcctgcccgtgttcttcccgccgcctgac


ctggcccgcccgcctttccagtctggccgggcgggggcctgaagcacggcggctcgggcc


gtgggaccgtgttcacaccctttccagaaattcttggctggtaaccgcgaaaccgactgg


agcaggagctgggagaactggagaaaactgctctaatctcacttgactccagctaggagc


tgatgctgcatcgtaataacatttgcagagcgctttcacaggcgctggagtgacttgtct


gagattcctccagaactgagccctttgttggaaccataccccagcccatggtcccatgac


taggtggatagtactccttgtacctcctgcaacccagaaccctggctgaccactttgaag


gaggatg


 


Homo sapiens KIAA0226-like (KIAA0226L):


(Seq ID No: 970)



cctcccctttctgctgttaccgggagcgcggtggccacggaacgctgcccg



gagccgcgcgagggaggacccgacgcgcggcgtttacccagcgcagcgttccac


cgctcgggtttggctggataaaataaaaaatggggatattgacctcctgtcactactg


catggactttgatggtttccaatcattactttctcctctgtgtcaatctgcctcttcga


gaaattcatactcctgaatagctctccagacccccagctggccatgtggtgag


ttcagggcccaaatcaagtagtaccagcaatcagggaactcctatctgtttt


gaatggattcacaccagccacaagcctggaaagatg


 


Homo sapiens MUS81 endonuclease homolog (S. cerevisiae)


(MUS81):


(Seq ID No: 971)



ctccctcttcccccgccccgccctgggccaggtgttcgaatcccgactccagaactggcg



gcgtcccagtcccgcgggcgtggagcgccggaggacccgccctcgggctcatg


 


Homo sapiens zinc finger protein 430 (ZNF430):


(Seq ID No: 972)



gggccttt



gtccctcgctgtggcctgagctccaggtctcgtcttcagcgctctgtgtcctctgctcct


agaggtccaggctctgtggccctgtgacccgcaggtattgggagatctacagctaagac


gccaggaacccctggaagcctagaaatg


 


Homo sapiens mutS homolog 5 (E. coli) (MSH5):


(Seq ID No: 973)



gctcctttt



gcaggctcgtggcggtcggtcagcggggcgttctcccacctg


tagcgactcaggttactgaaaaggcgggaaaacgctgcgatggcggcagctgggggag


gaggaagataagcgcgtgaggctggggtcctggcgcgtggttggcagaggcagaga


cataagacgtgcac


gactcgccccacagggccctcagaccccttccttccaaaggagcctccaagctcatg


 


Homo sapiens proline rich 3 (PRR3):


(Seq ID No: 974)



gccccttcctcac



taccctccaaatcccgctgcagccattgccgcagacacgatg


 


Homo sapiens sirtuin 2 (SIRT2):


(Seq ID No: 975)



cgccctttaccaacatggctgctgac



gccacgccttctgggactcgtagtccggtcctcgcgcgctttcttac


ctaactggggcgctctgggtgttgtacgaaagcgcgtctgcggccgcaatgtctgctga


gagttgtagttctgtgccctatcacggccactcccatttctggtgccgtcacgg


gacagagcagtcggtgacaggacagagcagtcggtgacgggacacagtggttggtgac


gggacagagcggtcggtgacagcctcaagggcttcagcaccgcgcccatgg


cagagccagaccgactcagattcagactctgagggaggagccgctggtggagaagca


gacatg


 


Homo sapiens KIAA1715 (KIAA1715):


(Seq ID No: 976)



ttgtctctctgtcagtggcggctgctgcctgctctggaggcaggctgggcggtggcggcc



gagactggcgggggtggacgcccgggccgggctgcgcccgcttctt


gcagctgtgaattcctttggacaattgatgatatttatcattgtgcccagtttc


tacaaataaaagatg


 


Homo sapiens proline-rich transmembrane protein 1 (PRRT1):


(Seq ID No: 977)



ctgccttcatctctccatctctgcgctgctgccggctgcgccatccag



cacccagactccagcaccggccgaggacccccactccggctg


cagggaccctgtcccagcgagaccgcaggcatg


 


Homo sapiens t-complex 1 (TCP1):


(Seq ID No: 978)



ccgccccttccccggagcctcac



ttccgtcacagtcctgtttctctccctgtt


gtccctgcctctttttccttcccgccgtgccccgcggccgggccggggcagccgggaa


gcgggtggggtggtgtgttacccagtagctcctgggacatcgctcgggtacgctccac


gccgtcgcagccactgctgtggtcgccggtcggccgaggggccgcgatactggtt


gcccgcggtgtaagcagaattcgacgtgtatcgctgccgtcaagatg


 


Homo sapiens Yip1 domain family, member 5 (YIPF5):


(Seq ID No: 979)



cgttcttt



ggccctgtgacacgtagcaacggggctggttcagggtctgaaacagagtttgggggtt


gtttgggattagtgaagctactgcctttgccgccagcgcagcctcagagtttgat


tatttgcaatg


 


Homo sapiens glucose-fructose oxidoreductase domain containing


2 (GFOD2):


(Seq ID No: 980)



cctccctttccagagcccccagttccttagaaac



caggcggcgcgttcccggtggcggcgccctggactcccgggcccgcg


catccccgccagccttccttaaggcggatgggtggcccccgagaccccgtcg


gacccatggtttccagtgcagcgcggagtgggcgatgccagcgtgccag


gagccatgtctgaccaggacgtttggaagatcatatccatgccagaggctcttgtgag


gagatgagttggtaaagagagaggctgggatg


 


Homo sapiens apolipoprotein L, 2 (APOL2):


(Seq ID No: 981)



ttccctttcgaattccagggtatatctgggaggccggaggacgtgtctggttattacaca



gatgcacagctggacgtgggatccacacagctcagaacagttggatcttgctcagtctct


gtcagaggaagatcccttggacaagaggaccctgccttggtgtgagagtgagggaagagg


aagctggaacgagggttaaggaaaaccttccagtctggacagtgactggagagctccaag


gaaagcccctcggtaacccagccgctggcaccatg


 


Homo sapiens microtubule-associated protein 4 (MAP4):


(Seq ID No: 982)



ccgcctccctgcgccccgcccctccggctagctcgctggctcccggctcctcccgac



gtctcctacctcctcac


ggctcttcccggcgctctcctggctcccttctgccccagctccgtctcggcggcggcggg


cagttgcagtggtgcagaatg


 


Homo sapiens exonuclease NEF-sp (LOC81691):


(Seq ID No: 983)



cttccttcttt



gccaggcagacgcccgttgtagccgttggggaaccgttgagaatccgccatg


 


Homo sapiens ST6 (alpha-


N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide


alpha-2,6-sialyltransferase 5 (ST6GALNAC5):


(Seq ID No: 984)



ctgtctctaatctctg



caacagccgcgcttcccgggtcccgcggctcccgcgcgcgatctgccgcggccggctgct


gggcaaaaatcagagccgcctccgccccattacccatcatggaaaccctccag


gaaaaagtggccccggacgcgcgagcctgaggattctgcacaaaagaggtgcccaaaatg


 


Homo sapiens heterogeneous nuclear ribonucleoprotein A1


(HNRNPA1):


(Seq ID No: 985)



tgctcctttctgcccgtggacgccgccgaagaa



gcatcgttaaagtctctcttcaccctgccgtcatg


 


Homo sapiens zinc finger protein 93 (ZNF93):


(Seq ID No: 986)



gggtccttt



gtctctcggtgcagccggagctccaggtctcctcttcactactctgtgtcctgtgctcc


tacaggcccagcctctgtggccctgtgacctgcaggtattgggagatccacagctaaga


caccaggacccctggaagcctagaaatg


 


Homo sapiens N-terminal EF-hand calcium binding protein 3


(NECAB3):


(Seq ID No: 987)



cggcctctagccacaccgagtccgccgcggcgtccagggtcggcag



caaccgcagccgagcccgagcgggtggcggcgccatg


 


Homo sapiens splicing factor 3b, subunit 5, 10 kDa (SF3B5):


(Seq ID No: 988)



cattcttctgcgacggcgcggacctggagcttccgcgcggtggcttcactctcctg



taaaacgctagagcggcgagttgttacctgcgtcctctgacctgagagcgaaggggaaa


gcggcgagatg


 


Homo sapiens INO80 complex subunit B (INO80B):


(Seq ID No: 989)



gtcccctttcctcgcaggacctcatg



 


Homo sapiens polyamine modulated factor 1 binding protein 1


(PMFBP1):


(Seq ID No: 990)



ctttcttcctcttggcttatattagggataggggatgtggttt



gttacaaaggatgagtattttgatagcttctcattccttgaactattctg


caggtttataacaaagctcagaaaatactaaaggttaaaggagaattga


gagctgccaaggaaatg


 


Homo sapiens pseudouridylate synthase 3 (PUS3):


(Seq ID No: 991)



cttcctttctcggaaacgcggcgcggccggctgccggaaaacagggcagacctgtatggt



tcgtttattcctggggttgtcatatcatg


 


Homo sapiens heterogeneous nuclear ribonucleoprotein D


(AU-rich element RNA binding protein 1, 37 kDa) (HNRNPD):


(Seq ID No: 992)



tattcttttttagtgcagcgggagagagcgggagtgtgcgccgcgcgagagtgg



gaggcgaagggggcaggccagggagaggcgcaggagcctttgcagccac


gcgcgcgccttccctgtcttgtgtgcttcgcgaggtagagcgggcgcgcgg


cagcggcggggattactttgctgctagtttcggttcgcggcagcggcgggtgtag


tctcggcggcagcggcggagacactagcactatg


 


Homo sapiens GABA(A) receptor-associated protein like 1


(GABARAPL1):


(Seq ID No: 993)



atttctccatctggctctcctctacctccaggcaggctcacccga



gatccccgccccgaaccccccctgcacactcggcccagcgctgttgcccccggagcg


gacgtttctgcagctattctgagcacaccttgacgtcggctgagggagcgg


gacagggtcagcggcgaaggaggcaggccccgcgcggggatctcggaagccctgcggtg


catcatg


 


Homo sapiens chromosome 22 open reading frame 13 (C22orf13):


(Seq ID No: 994)



ccttcctttccccagtgttgagcgcggtctcgcctccgcttcctcctcac



tccgcctgccggctgggaaactagggcaccagtacgatagttccggcaccggaaaa


gagggctgatgactgggcccgggggccgccgcaacgacccttggggccggcaaa


gagccagagagggtgctcacacttccaagcaccccacaccaaggacaggctggacgg


caaggcggagacgcggggcttgggccctcagaccggggacagcaggaggtt


gggccaagggccaggacttcccgtcacaatttcatttgttgatcccggcac


cgccaggtaaggggggccctgagtgaggctaggtatctggtacgga


taaagttaggtatagagtagagcggctgcccgctcagggttatccctaaagacagtt


ggaggagagttgcttggggcctcggggatgcactgggcgggatcagggcttacacctag


gactggcaaaagagcgggacccggcagaggcggggcttgccgaagggacgagcctc


tattcaggaaatgcacgagctttggggcggggctcaaa


gaaaggggcggggcttccggggcccgcgtcctggtgagctgcgcgtctgcgcgag


gattgggcgagagggtggggccactcaacgctgaggcggcgaatggccggag


cagacttaaatcaagaggctggggacctctaagatcaaagttt


ggggcggggcctaaggagggggcggggcctccagattcgagacctg


gaagggctggggcggcgcttggggcggccctgccgccgcctcccgttctcccctccg


cagcggcggcggtggcggagaaggaactcgacacgcaccgac


cgccctcccgccccagccgaagcggaagctg


tagcccgctctgggccggggccatgggcgccccgcgccgcccgggtcatg


 


Homo sapiens lon peptidase 2, peroxisomal (LONP2):


(Seq ID No: 995)



ggctctttttgacagcccccagtgcgaaaggctgccagcatg



 


Homo sapiens RNA binding motif protein 4B (RBM4B):


(Seq ID No: 996)



ggttctctctgacgtgggagccgccgtcgctgccgccacccggaggctcttgtcaggatg



 


Homo sapiens protocadherin alpha 3 (PCDHA3):


(Seq ID No: 997)



aggtctttctccacaaaagaaataacagcgtgcattacgtattcagatactgctttgctt



catcctctctaaaatttaacaccgaggagtttaagaaatgaaga


taaggaactcgaattatttttaaactttggatcaatgtaaaggcaatctaatattt


ggaaaatacttgcaatg


 


Homo sapiens RAB34, member RAS oncogene family (RAB34):


(Seq ID No: 998)



gcctctccttgggccccttctctccccctttcccctccctgctggttcctgg



catcgccagatgctgcgcagcagtctccgattccccatcac


caattcggctggcgtctccgagaccgcggactcccgtagggtccccgtggccccgagtt


gtagtcgggacaccccggccgcgggtgatcgtcgggtctccac


gcgcccgggtcgctgacgcggatccggcctcggcgccttctcagggcgccctg


caaggccgcaggcaggatg


 


Homo sapiens cell division cycle associated 7 (CDCA7):


(Seq ID No: 999)



gctcctcctgctgtgggaccgctgaccgcgcggctgctccgctctccccgctccaa



gcgccgatctgggcacccgccaccagcatg


 


Homo sapiens ArfGAP with GTPase domain, ankyrin repeat and PH


domain 3 (AGAP3):


(Seq ID No: 1000)



gggtcttttaggagagcactgctgcagccggcagtgga



gagcctgggcagggagacagggagaaaactccggcagcagggtggtctctagggctgac


ctcggagcctggggacaggggagcctatgccgcactgaaggcgggacgctgtaagcgag


gagcagctgggcctgggcggactcctcggccaatcagcctcggtcagcag


caccctcaggcgcagggcactgtttgggcattgcctaga


gatccgacaccccgcccagatcagcgcagggaggcgaaagcgacagccgggcgcgggag


gagaccaggg


cagctgtcccctccgcgagggtggccctcgaggcaatgcgggtgggggctggtgag


gaggcggaagggccgaggctgagtgggaggggccggggcgccagggctg


gagcgcgcggctcgggggtggaggctg


cagagccagcgagcgagcgaggggcgggggcgcccgggccggcgcgcag


gaggggcgggggcggcggggaggggggctcgggctgcgtgtgccg


gagccggcgggggcggcggtgcgtgcgcatgacgcggggg


gagggcctgggccgcgcgctcccggtcccgttgttgttgccgctg


gaggctgctccgaggcagcgggatcacggcgctgggaagcgctcgg


cagcggcggccacagcgtgcgcggcggcgcctcctggcctcggcctccggcccccggccc


ccggctccatgcgctagccccgcgccgccagcccagtag


tcccggccccgccagccccgcgctcccgctcgccgctgccgccgccgccgccgccgccgc


ctccgccgcgccgccccgggcccgcctcgggccccacggctccgaagccatg


 


Homo sapiens potassium channel tetramerisation domain containing


10 (KCTD10):


(Seq ID No: 1001)



ctgcctctctcagtccgggtttggagactcctgcgtcctc



cgacttttcatg


 


Homo sapiens cyclin B1 (CCNB1):


(Seq ID No: 1002)



cattctctgcgaccggcagccgccaatgggaagggagtgagtgccacgaacaggccaata



aggagggagcagtgcggggtttaaatctgaggctaggctggctcttctcggcgtgctgcg


gcggaacggctgttggtttctgctgggtgtaggtccttggctggtcgggcctccggtgtt


ctgcttctccccgctgagctgctgcctggtgaagaggaagccatg


 


Homo sapiens eukaryotic translation initiation factor 2A, 65 kDa


(EIF2A):


(Seq ID No: 1003)



gtttctctttccgggacaacatg



 


Homo sapiens protocadherin gamma subfamily B, 7 (PCDHGB7):


(Seq ID No: 1004)



cagcctctagcctgggattccctgcgcagccaacaacagaaaagaaaac



cagctcccacacagaggctcccggctgcgcagaccttgcccagcacac


cagattgccagctccgagacccgg


gactcctcctgtcctgggccgaatgctcttttagcgcggtagagtgcac


tttctccaactggaaaagcggggacccagcgagaacccgagcgaacgatg


 


Homo sapiens acyl-CoA dehydrogenase family, member 11


(ACAD11):


(Seq ID No: 1005)



ggctctttcggcttccttcctcgctgggccggctaaacccggccgcag



cagcaccggggtgataagtgtccagggcaggaggccagcgatgttgccttgctaac


cgggtatctaagagaaacagggtctttttattcttaggctcgacagtctgac


ggccctttttctgaacgggaccctgcaggtcttccgcctgctgttgcattaaattt


gggggtggaagaggcttctgcgttgttccttacccgcaacgatgaccatggcttt


gccttctttaaaattgaggcctccaactctgacgctgactggagaatt


gaaacccgaacacacattgggctcttttggcacttgactagagctaaaacctcgggat


tcagcgggcaagcgttgctcagcaacggcgcgtaggctgtgtgcggttggctg


gagccagaccccaccccggcctcggcccatgctctagaggggacgtt


gccccaatcctgaaggacttcggcactcgagacctgtggatgccgcgtt


gctgtggcctgcgggggtgatcatg


 


Homo sapiens zinc finger, CCHC domain containing 7 (ZCCHC7):


(Seq ID No: 1006)



ccgtccctctacgcgttttggttcccggttggtgcttcctgttcgcagctgcggcac



ttcaaggttactgactttttatg


 


Homo sapiens zinc finger, MYND-type containing 12 (ZMYND12):


(Seq ID No: 1007)



gggcctttctggacttggactccttgggagtcgtttctcggccatttgacccgtgg



gacttgtgggttttgtgctgctttttctttctttcttccccttttccaacttcag


caatacacccagatgttagtcgagtcacgtcccgccgccctctgcccttgaaatgctgg


caagtacgcagccccgcgatcgtcacgtgacgccggggttcagcgtatccttgctggg


caaccgtcttagagaccagcactgctggctgcaccatg


 


Homo sapiens forty-two-three domain containing 1 (FYTTD1):


(Seq ID No: 1008)



cgctccctcggtgcggcgggctgcgtgcgcgagtgggaggtgg



caggcctgcgactccggccttgtccgcgcccgctctcggcgcgacgtctccagccatg


 


Homo sapiens SH3-domain GRB2-like (endo-


philin) interacting protein 1 (SGIP1):


(Seq ID No: 1009)



ctccctttctctcagcatcttcttggtagcctgcctgtaggtgaagaagcaccagcagca



tccatggcctgtcttttggcttaacacttatctcctttggctttgacagcggacggaata


gacctcagcagcggcgtggtgaggacttagctgggacctggaatcgtatcctcctgtgtt


ttttcagactccttggaaattaaggaatgcaattctgccaccatg


 


Homo sapiens GTPase activating Rap/RanGAP domain-like 3


(GARNL3):


(Seq ID No: 1010)



cagccctttttgcaaatg



 


Homo sapiens DCN1, defective in cullin neddylation 1, domain containing


5 (S. cerevisiae) (DCUN1D5):


(Seq ID No: 1011)



gagcctcttgctt



gctgtgactggtggagctgccgcgctgtccgcgttatctcctcccggtgagaacgaac


cgcagtgtccaccggcgaggagccagccctgtcccggtcagagaaagacgacgagga


tacctgg


gagcgggcggcggccgggctgggccgcgccggtgcgggctggcgactctgctcctccgct


tgctgctgtctctgggaactgggtgccagcgctgaggggcttccagcg


gacagggacccccttccccggctcccctgcccaccctgccggggagggcggaagatg


 


Homo sapiens alkB, alkylation repair homolog 7 (E. coli)


(ALKBH7):


(Seq ID No: 1012)



tgccctctctcatgaccccgctccgggattatg



 


Homo sapiens nitric oxide associated 1 (NOA1):


(Seq ID No: 1013)



ccgccccttt



ggagctacttcctcatg


 


Homo sapiens BTB (POZ) domain containing 10 (BTBD10):


(Seq ID No: 1014)



tcgcctcttcgcattgtgagctctcgcggtaagaggctgaggagccggcctgcaac



ctgccggggcggctccgctacgcgcagccgcctcagtggcttcctccacagccac


ctccggagggatctggctgaggaggaagtggaggtgtcactggccccggccttt


gccccaatcttgtgtgggcactgaagggggactacaggttcgagagttatgggtgc


tacatgtgtgctttcagagcagtagtgtgaggaagcttggagtgggatg


 


Homo sapiens zinc finger protein 397 (ZNF397):


(Seq ID No: 1015)



cggtcttt



gtggcttgcagctcggggtgggtggctcatttcctggccgctcctgggcttcgcggaaa


gaagagattactcacactccttcgcaagcacagaaccagttgtactgagcttttt


gctaagctgtttcagccaagaatg


 


Homo sapiens mitochondrial ribosomal protein L45 (MRPL45):


(Seq ID No: 1016)



gctcccttcccggcggcctttgcgggaacaagatg



 


Homo sapiens AKT1 substrate 1 (proline-rich) (AKT1S1):


(Seq ID No: 1017)



cttccttctccatattgtatactggaattgaagccaaggaggtaccattttgctcgaggg



catggcctaagccggtcagctaaggccatgttaatacggggctgtcccatctctctgcgg


ggcgcgacagctggaagagccgaacggataagagaagaggaggtgagaggagctgtacac


cacaagaggcactgagggactcaggataacgggatgaagccgtcagtgcccccagaaacg


aagcggccccggacgaatttctgagtcaccgtcgcgagaaagcgggctgagccgccattt


tgaagcctggcaaaccgaagcaagaaatgctgccgtgttggatctttgccagccttcgtg


ccgaatgggagcaggttggagggagggagagccaatatacactatgggctgattaagccc


ggttggctgccatgttgttaacgagcaccgatttcctctacttttgtcgaagaagtttat


tgtgggtcagggacgtcaggtcgcttgccttcgtttactgtggtcatgattgagcatatg


aggacggccattattgttgggggcaaatggaaatgctctaggcggggccatttttcttag


gggcaagctgtcgtcacccttgtcaactggttcggatgaagcccctgtggccgccatctt


gatctcgggcggccccgataagggaggcggagtgtgcggagaggaggcggggcaactgcg


cggacgtgacgcaaggcgccgccatgtcttttgagggcggtgacggcgccgggccggcca


tgctggctacgggcacggcgcggatg


 


Homo sapiens transmembrane protein 101 (TMEM101):


(Seq ID No: 1018)



ctgccctttcccaagatg



 


Homo sapiens eukaryotic translation elongation factor 1 delta


(guanine nucleotide exchange protein) (EEF1D):


(Seq ID No: 1019)



ggccctccctttcatcagtcttcccgcgtccgccgattcctcctcctt



ggtcgccgcgtccttggctggcgttagagacagggtttcaacgtgttagccag


gatggtctcagtctccagaccctgtgatccgcccgcctcggcctcccaaagtgttgg


gattacaggtgtgagccaccgtgcctggccgaggctccttcttttatg


 


Homo sapiens ADP-ribosylation factor GTPase activating protein


2 (ARFGAP2):


(Seq ID No: 1020)



cgccctccccgccgtggattggcccgcggcgg



gacccgtcagccgcggttgtgtctgggaaggagagaaaatg


 


Homo sapiens junctophilin 4 (JPH4):


(Seq ID No: 1021)



atttctctcctccctgggggtctcagtg



catctccttctcctctctgcctgcctcctccctcaccgaagggttagcg


gacacccatccttttctgcttggggaccccaccaccacccgcaacac


tgccgctgtctcttcttcaccgtatccttctc


tacccaccctcttctctcttctcttctccctgcccctttaaatctgcctggcccagcctc


ccccgtgatgctgggatggagcaaacattgatttgtgctgggatggaatcggaatttt


gatttatttttcctctcccaaccataagaagaaaaaaataataaaaacaccccctctt


gagagccccctcccccttt


gcatccagctcccagctcttcttccctatctccatccaaggcagat


tttttcccctacactattctcatcttcccccacccttgccactac


ctcgcccccccacccagcctgctcctccagctggggagagaggggactctccg


gactcccccacctttcctctctgggttggagcagtctctccggaaggggagggggctt


ggcttgtccgggcgaggtgggagtggaggtatcctgccatggatgctgtgccggg


gaggcagcctgagccccagcccacatgagacgccgaagaaccgggg


cagaggggtcctgacagcagccagggaaacgggtgccctacgat


tctgcccagccccctctcaggacccccaaactgccatccacactcgacac


ttcggggttctagccactcag


gatgagggtccggccctgcctgccctcgctggggcccccccgcccggccccggtctaact


gcccccgccccgaggcctcgcccggctccaaggcccccagcaggctctccagtcccag


gatgcgctgagccgccggggggctgaggccgcgccaactacatgcatg


 


Homo sapiens embryonal Fyn-associated substrate (EFS):


(Seq ID No: 1022)



ttttctttctcctcctccaaccttggcggaggccac



gactcaggcgccacagctgggggctagaggccgcggaccatggtgcggggcagccac


cgctgaagtcagcaaaaccgagcctggcctgaggcaggctgcgcgggaggccaaagc


catg


 


Homo sapiens GH3 domain containing (GHDC):


(Seq ID No: 1023)



cgctccttctttctggccggatgtgtgctgagacccagag



tcacccaggggtctccgtcacgtgccaggagtaggcagaagtgggctgtgacagatcag


gaaacagagctcagtgcagcccactaaattgctcagggccctacagctaacaagcgg


cagaggcaggatctgcactcaggagctgcttggagatg


 


Homo sapiens acrosin binding protein (ACRBP):


(Seq ID No: 1024)



ggctctctctgcggcttggcccgttagaggcggcttgtgtccacgggacgcgggcg



gatcttctccggccatg


 


Homo sapiens jagunal homolog 1 (Drosophila) (JAGN1):


(Seq ID No: 1025)



ag



ttctcttcacggagccgcgcggctgcgggggcgcaaatagggtcagtgggccgctt


ggcggtgtcgttgcggtaccaggtccgcgtgaggggttcgggggttctgggcaggca


caatg


 


Homo sapiens ligand of numb-protein X 1, E3 ubiquitin protein


ligase (LNX1):


(Seq ID No: 1026)



gttcctttcctgggcatcagcttgcctgctctcagcctaa



gctctctcgccaaccgtggtggctccttgcgttcctacatcctctcatctga


gaatcagagagcataatcttcttacgggcccgtgatttattaac


gtggcttaatctgaaggttctcagtcaaattctttgtgatctactgattgtggggg


catggcaaggtttgcttaaaggagcttggctggtttgggccctt


gtagctgacagaaggtggccagggagaaggcagcacactgctcggagaatg


 


Homo sapiens cyclin-dependent kinase 2 interacting protein


(CINP):


(Seq ID No: 1027)



tctccttctacggatatctgtggaccttatg



 


Homo sapiens splA/ryanodine receptor domain and SOCS box containing


2 (SPSB2):


(Seq ID No: 1028)



gcttctttccgcccggctccttcagaggcccggcgac



ctccagggctgggaagtcaaccgagctcccttccaggtcaatccaaactg


gagctcaactttcagaagagaaagacgccccagcaagcctctttcggggag


tcctctagctcctcacctccatg


 


Homo sapiens Berardinelli-Seip congenital lipodystrophy 2


(seipin) (BSCL2):


(Seq ID No: 1029)



cctcctcctttcctccctctactctgacacagcacttag



cacctgaatcttcgtttctctcccagggaccctccattttccatatccag


gaaaatgtgatgcgccacaggtatcagcgtctggatcgccacttcac


gttttagccacaagtgactcagtggaagatccagagtcaacagaggctcgtcaggaa


gatg


 


Homo sapiens tubulin, alpha 1c (TUBA1C):


(Seq ID No: 1030)



caccctttcactacttctcccccggactccttggtagtctgttagtgggagatccttgtt



gccgtcccttcgcctccttcaccgccgcagaccccttcaagttctagtcatg


 


Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 9


(AGPAT9):


(Seq ID No: 1031)



tttccttcctctcttcccttcgcagaggtgag



tgccgggctcggcgctctgctcctggagctcccgcgggactgcctggg


gacagggactgctgtggcgctcggccctccactgcggacctctcctgag


tgggtgcgccgagtcatg


 


Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 1


(lysophosphatidic acid acyltransferase, alpha) (AGPAT1):


(Seq ID No: 1032)



gcccctttctttccttcgcttcctcttttagagaatgtccggattgctattggacttt



ggagcgtatggctccaaatcaactcattggctaaaacttgac


ggaaaatggtggttaggtggccagaatg


 


Homo sapiens abhydrolase domain containing 14B (ABHD14B):


(Seq ID No: 1033)



cggcctcttcccagcgttcctcctccggccccaggtcaccgccagcac



gcgcctgcttcccgtctgcgcgagtccacgcagctccccagatcaagaa


gctgaggccccaggttacacactaaagtaaatggcagaggcagaaataacac


ctatgtcctcctgaccccaaggcatgttcttaaagttctggaaacctcctg


gaggcttccttgctgctcctctgggactgccaccctggg


cagggtgttctgtggcccctcatcatcgtggttttgaaccacaggcccttcaccag


cacagcagcagcaggcatg


 


Homo sapiens protein tyrosine phosphatase, non-receptor type 5


(striatum-enriched) (PTPN5):


(Seq ID No: 1034)



catcctcccgccagcctgcccgcctgctcgccggcgcccggagcccgctctggccgctt



gctttttgctgagaaagcttcctgccctggaagatggcacccttccccatccagacac


cttgggaatg


 


Homo sapiens carbonyl reductase 4 (CBR4):


(Seq ID No: 1035)



cttcctccttttcac



ggcgtcttgcattactattgtgcggctgcaggaggtgtcgagcggcgttattttttttt


gcggtttgcctttttttttcttttttttttttttggaaccgcggttgtttaaaa


gcctgagggaacctggagaggggctcccactccctaccctctttcctccgagttt


gtgactccgagatg


 


Homo sapiens zinc finger CCCH-type containing 10 (ZC3H10):


(Seq ID No: 1036)



ggctctttgtcgaagctagaggaccggcaggcggcagcagcaactacggcggcggcgg



cagaacccagcagcgatgtggaggtggagacccacaggagccccggacttcacctgagc


tacctcagtggtcaccaagagtggcaagataaagaaaaccctgagttgggcgggaccag


gatg


 


Homo sapiens poly (ADP-ribose) polymerase family, member 10


(PARP10):


(Seq ID No: 1037)



ccgtctttcagtttcacttttgttttcctgctcccagcagggttaggcttgctgaggggc



aggcacaggagtcctggctgagctcatggcctgaggctgcctagcggccacggggaatg


 


Homo sapiens RNA pseudouridylate synthase domain containing 4


(RPUSD4):


(Seq ID No: 1038)



ccgcccttccttgtaagatg



 


Homo sapiens family with sequence similarity 73, member B


(FAM73B):


(Seq ID No: 1039)



ctgcccttccgcagcgatggcatcccgggtgag



tatcggccccggccgagcccccaaggcgggcgggcagcgcggcagggccgggactt


gagcggaggaccgagtaggcgcaggtgtccgggcccaacaggaccag


gaaggtgtcggggttggaatgagtgggtacccgggccggggacggtgcga


gagggtgccttgcttgggagcggaacgagaaggtactt


gggtcagggaggtgatgcccgggcctggaacgtggcggggattggagcaggcgcg


caggtacccgatccgaggcggggagagcacccgggatggaaggag


caggcgtgcgggccgtgagcggcgccagagggtacctggctctgtg


gaggggccctctggtatgtgtgtccctgtccttctggggcgtggatggtgcctgg


gacccagctggcaaccagttgaagacgttctccttggaagctcttggccctgag


gactttgcctggggcattggccctgccatg


 


Homo sapiens protein phosphatase 1, regulatory subunit 15B


(PPP1R15B):


(Seq ID No: 1040)



gcgtctcttccggcgtctaggggggtgtcctgccggcgcgcgggccctgcggccatttt



gggcttcgcttccaccgcaccagccggcctacccagtccttccggtatcgcgtt


gctcaggggcttttcaaccctctgtcagtcggaaaaccatcgccgaggccgtggggg


gactcctatccatggtgttgaagcgtcgagccgactagggaacctccttccccgccag


gatggaagtcgcatcagtcgccgcc


tattgcgcgggctgttcttccctgtgttctgccgcccgctgccg


cattcgctgccctctgtggcttttctgctggctcgaagatcggcctggagcagcgac


gccaccgctgggcaaggccgagactctgtaggcttcctccgaatcccgtcgac


ctccagccgctgagcgccgcggccctacctgagagactgtcaagaaaaaggagatg


 


Homo sapiens family with sequence similarity 104, member A


(FAM104A):


(Seq ID No: 1041)



ccctctcttcgcggagcggcgccgcgtagcttccatccgccagctgc



catg


 


Homo sapiens PRP38 pre-mRNA processing factor 38


(yeast) domain containing A (PRPF38A):


(Seq ID No: 1042)



agccctttacactac



ggtgtttccggcttcaagatggtcgcctaagctgtttagtgaaacttcttccac


ctttctccattcctctaggtgctttttctgaacctg


gatgtgaggcattaaaggatccgacggaaatagaattgaaggcattctaaaatg


 


Homo sapiens synaptotagmin-like 1 (SYTL1):


(Seq ID No: 1043)



cctcctccgtgtgggg



cagctgctggctgggctgcctgttgagtcagccttcttccctcac


ggctcttctcccggtccctgaaactcggctgccaggggagctggagccac


ctgcgaaggtgtcctcccatactggacccctacaggaagctccgtgtgcccagctgggg


cacagccccagctgatg


 


Homo sapiens ubiquitin associated and SH3 domain containing B


(UBASH3B):


(Seq ID No: 1044)



gctccttttcctttttgatccattcaaaaattactcatt



gcaaattcccggactgctaggcgaggagagggaagggggcggaggagacagggctactg


caggcgcagagctgggggcagccgggggcccgagtggctgaggctggtcccg


cagcggccgcttgccggcgttctggctcctgtggcctcaccaggaagcgtcagag


tcccgacactggggaagctcg


gagcgccgcctccgctgccgccgcctcctgcctggctctgggtccccgagccccctcccc


tggcccagcccgactccctcctccttcccgaac


catccggctcgggctccttccctggcgatggctggccgctgagccatg


 


Homo sapiens transmembrane protein 241 (TMEM241):


(Seq ID No: 1045)



ccgtctctgggcggctgctgccgctgccgctgctgctgctgcgggggtcgggcggcggcc



aggggatttgggcaggcaccgtggatccccgagaaggggacgagttgacagatg


 


Homo sapiens ataxia, cerebellar, Cayman type (ATCAY):


(Seq ID No: 1046)



gagcctctgccagccctgagctgggaagaagcagctacctcggaggcagggcgcg



caggcgggcggcgatgagagggggcgcagccgcagccccgcgctggggagcccac


cgctaaccctgcaccccacccacccctgcacaaaagagctggcgggcgctggccac


gtcgccctgggtgaccttcctcggatgcagaatccgcccctgcgag


catcctcttcctcctaggctctgaaggccoggggagcgtgagcgatgcccagctg


cacccgggcagggctcgcctttgtttgccagtaaggaggagaggctgtctcagctg


cagaggggtcatccctgcttcaagccagtgcctcttcccagctcccatg


 


Homo sapiens ELL associated factor 1 (EAF1):


(Seq ID No: 1047)



attcctctctcacccccacgcagaggagagaacttgcttctg



gacccgggtgggtgccggctcggctctccttgtcttccagagcggtggcccggaa


gcacagtcctcccagacgccagcgccagaagctcggatcgcggctgcaccggga


gagcgccgatctgggtgcgaggcaggtgcggggccatg


 


Homo sapiens tripartite motif containing 5 (TRIM5):


(Seq ID No: 1048)



gttcctctaggaaaattcctttgtgcagatcaggcccgtggattggtgag



tgaatcctaaccacgtcttccctggcctgtcttcactcttctccccagaatcaccac


ttctgcactggtgtctgaaggtgtattgagtgattttgtggagggcagaagtag


gaagtctttgggacaaaactgtatttaccttgggatctgtgaacaagaggaacctcag


cagccaggacaggcaggagcagtggaatagctactatg


 


Homo sapiens wingless-type MMTV integration site family, member


3A (WNT3A):


(Seq ID No: 1049)



cgccctctcgcgcggcgatg



 


Homo sapiens chromosome 16 open reading frame 45 (C16orf45):


(Seq ID No: 1050)



ctccctccctgcagcccgcaacgggaatggagtaaagggagacccgtcgacctggccac



ggggatcagcgatg


 


Homo sapiens zinc finger protein 502 (ZNF502):


(Seq ID No: 1051)



cattcttccggtttcagaagttaaggctggtgtcctggccccagtccacctctgggagcg



cctgcgccgctccgcggagagtccgtggatctcacagtgaaaaatgtttgctgacccttg


acattgacaaactgctgacagctcagatgatccatgattggaaggatgtggtcatcacca


agatgtctttctttctccggttcccagttttccagacctgaagtgttttccaatcaaa


gcgaagagacgatctgtggatg


 


Homo sapiens armadillo repeat containing 6 (ARMC6):


(Seq ID No: 1052)



ggctctcttgcgcaagcgcgctgtccgcttcttctgggcggacgctctg



gaggcaaaacatttccctgctgggggcggcgaccaccgtgagcgtcccggaaggggcgg


caaagacgcctccgtcgcgcacgaggtggcctcgttggctttacctt


ggttcgcggtcgtccttggttatcgtgagcgtccgcgagtctctgggaggccaa


gcctaggggcgccacagcgcctgcgcgcgtacggcggccggaaggggcta


gaggcggctccctgggtgacaaccgcgcgccccacctttccccacgtggccgcgaagacc


ggctcaggagcatctatcggctgcacgccaacatcaacacaggcgaagatg


 


Homo sapiens post-GPI attachment to proteins 3 (PGAP3):


(Seq ID No: 1053)



gctcctcccccggcggcgagccagggagaaaggatg



 


Homo sapiens histone cluster 3, H2a (HIST3H2A):


(Seq ID No: 1054)



tgccctctt



gtttttagtctcgcttttcggttgccgttgtcttttttccttgactcggaaatg


 


Homo sapiens ethanolaminephosphotransferase 1


(CDP-ethanolamine-specific) (EPT1):


(Seq ID No: 1055)



ggctctcctaccttctcggg



cagcccagtctttgccatccttgcccagccggtgtggtgcttgtgtgtcacagcctt


gtagccgggagtcgctgccgagtgggcgctcagttttcgggtcgtcatg


 


Homo sapiens F-box and leucine-rich repeat protein 5


(FBXL5):


(Seq ID No: 1056)



ccgcctctgccccgcggcgagggtgtctatgga



gaggcggcggccgcggctgctgaggcggaggctgaggcag


tggcgatggcgccctttcctgaagaagtggacgtcttcaccgccccacactggcg


gatgaagcagctggtggggctctactgcgacaagctttctaaaac


caatttttccaacaacaacgatttccgtgctcttctgcagtctttgtatgc


tactttcaaggagttcaaaatgcatgagcagattgaaaatgaatacattattggttt


gcttcaacaacgcagccagaccatttataatgtacattctgacaataaactctccga


gatgcttagcctctttgaaaagggactgaagaatgttaagcctactactgttgactg


gaagccttaccaataacataaaacaatcgaataacaattatttcatgtatta


tatgtaaaatatatatactggattcttacagtaagaatgaatatgaacag


ttaaattatgcaaaacaactgaaagagagattggaggcttttacaagagat


tttcttcctcacatg


 


Homo sapiens major histocompatibility complex, class II, DP


alpha 1 (HLA-DPA1):


(Seq ID No: 1057)



ctgcctccactcggcctcagttcctcatcactgttcctgtgctcacagtcatcaattata



gaccccacaacatg


 


Homo sapiens secretory carrier membrane protein 1 (SCAMP1):


(Seq ID No: 1058)



tcgtctctctctctgcgcctgggtcgggtgggtgacgccgagagccagagagatg



 


Homo sapiens chromosome 15 open reading frame 57 (C15orf57):


(Seq ID No: 1059)



ccgcccctcccgatttcctccgggctacaggcgacagagctgagccaa



gcgtttactgggcagctgttacggtaagtgaggaggggctggggtgcccagcgtttt


ggatctcccactctggcccggccccggaataccacatagaggccttgggacctgat


tcatcccgtccagacagccctagagacctgagcgactgaggcctgggatctggacgccg


gaatttcctgcgtggttctggacgccctgccctgggctcagattccaaatg


 


Homo sapiens WD repeat and FYVE domain containing 2 (WDFY2):


(Seq ID No: 1060)



cctcctcttgtagtggcgccggcttgcatcccaggtcgtggcggttttggtgcctgaagc



agggagcgcggagtcgttcccgagagaggcggccaggctatgctcgccggtttccggcgt


tccgctccggccagccagagtctctgtctcaac


ctgtgtccgtgctccagcagtctcctcagcccggccccgcggcgcggtt


ggcggcggcgccccaggcgcgccccctcctccgatg


 


Homo sapiens topoisomerase (DNA) I, mitochondrial (TOP1MT):


(Seq ID No: 1061)



cgctctttcccggaggctggcagatg



 


Homo sapiens intraflagellar transport 122 homolog (Chlamydomonas)


(IFT122):


(Seq ID No: 1062)



ctttccctttcggacatgcgcgctcggagcaaggcgccctcg



cactcagcttaccgcgcatgtacgttgccaggggtaacgcaggtagccaaagtggctt


gtggagtggcgaccgttagtgaggcggttgctgagacagacgctgaggcgggtaggag


gagcccgagccgtaagggaagccgtgatg


 


Homo sapiens mitochondrial ribosomal protein L53 (MRPL53):


(Seq ID No: 1063)



agttcttccggggcggaggtcaccatg



 


Homo sapiens T-cell activation RhoGTPase activating protein


(TAGAP):


(Seq ID No: 1064)



ccgccccttcgcttataatgcagagcatgtgaagggagac



cggctcggtctctctctctcccagtggactagaaggagcagagag


ttatgctgtttctcccattctttacagctcaccggatgtaaaagaactctggctaga


gaccctccaaggacagaggcacagccacacgggagtgaaatccacccctggacag


tcagccgcaatactgatgaagctgagaagcagccacaatgcttcaaaaacactaaac


gccaataatatggagacactaatcgaatgtcaatcagagggtga


tatcaaggaacatcccctgttggcatcatgtgagagtgaagacagtattt


gccagctcattggacattctcactattctatgccttaaaggcccttcaacggaaggga


tattcaggagagcagccaacgagaaagcccgtaaggagctgaaggag


gagctcaactctggggatgcggtggatctggagaggctccccgtgcac


ctcctcgctgtggtctttaaggacttcctcagaagtatcccccggaagctactttcaa


gcgacctctttgaggagtggatg


 


Homo sapiens phosphoserine aminotransferase 1 (PSAT1):


(Seq ID No: 1065)



ggtcctccttggctgactcaccgccctggccgccgcaccatg



 


Homo sapiens CD97 molecule (CD97):


(Seq ID No: 1066)



ccccctccttcataaagtcctggcctcgggacagcctgcacagctgcctagcctgtggag



acgggacagccctgtcccactcactctttcccctgccgctcctgccggcagctccaac


catg


 


Homo sapiens protein tyrosine phosphatase, non-receptor type 2


(PTPN2):


(Seq ID No: 1067)



cgctctccccggatcgtgcggggcctgagcctctccgccggcg



caggctctgctcgcgccagctcgctcccgcagccatg


 


Homo sapiens chromosome 20 open reading frame 112


(C20orf112):


(Seq ID No: 1068)



gcccctctccccgggcagccgcggcggcagcagcagcagcagcagctggagctgtggggc



tgtcaccgccgcccgccccgctcactcgcggatcccgaccgcccatctccgcctcgcttc


cagcccaggatgagacttctgtgagcagcgaggattttgatatg


 


Homo sapiens APEX nuclease (multifunctional


DNA repair enzyme) 1 (APEX1):


(Seq ID No: 1069)



cacccttctttgtgctcgggttag



gaggagctaggctgccatcgggccggtgcagatacggggttgctcttttgctcataa


gaggggcttcgctggcagtctgaacggcaagcttgagtcaggacccttaattaa


gatcctcaattggctggagggcagatctcgcgagtagggcaacgcggtaaaaa


tattgcttcggtgggtgacgcggtacagctgcccaagggcgttcgtaacgggaatg


 


Homo sapiens intermediate filament family orphan 1 (IFFO1):


(Seq ID No: 1070)



tttcctcttgagccatcatgcacatctgactgcagccccagcgagcccttccttcctt



gtctgactgctcttcttctcgatttcttcttgttctgccttctcggttt


gcagccctgacccccgctgtgtgtctggccctt


ggtgactgtccgtgtttctgttcctgtcatt


gtaactgtgacttttctctctgtctgcccccccttcc


tactggttcatgcttctcccccattcccaccctctctgcccggcctcccgctcccgccct


ttctcctcatgcacccggcctcgtctctgtagtctctgcactt


gtctcccattaaggtcccatccatg


 


Homo sapiens neuralized homolog 2 (Drosophila) (NEURL2):


(Seq ID No: 1071)



cagtcttcctcccgccccttctttggtccctacggac



ctggggggcggtggcggtcaatgccgggtcaaggtccgcgggcctcgcagatcg


tagcccgggcgcacgcgatcagatgatcctgttgtggacggctaagttgtaggcgg


gatggctgagaaagcggcgctaggacccccgggcagaggctcggggaagggag


tcaggggggaaatgccttacaaggtcgccttgcggtcaccatcatt


gcccgccgcccaaaatagcccccggcgccagctggcctgccctatggccgagagatg


 


Homo sapiens drebrin 1 (DBN1):


(Seq ID No: 1072)



ctccctctttccctccctcctcctccgtccgcccgtccgtccgcgcgtctgtccgttcgg



cccggtccggcccgaagcatg


 


Homo sapiens WW domain containing adaptor with coiled-coil


(WAC):


(Seq ID No: 1073)



cagcctcccttatttagtccgcgatggcttccctcgcgccccaccgtcctcttccggaag



gcggctccctccctgcgcagcccggagcccctgagatcagcctcgagcaggcgcccgagc


gagactatccctaaacgggaacggcggtggccgactcgcgagtgaggaaaagaaggaaag


ggcagactggtcgcgaagagaagatccaggcctcagaggaggagaaaggccggagccagc


cgaggtttgccgagggcggtgttccggacccgcgcggtgcggggaggaaggccgagggtg


ggagaggaggggcccggcggaaactgccgaggtttcccgaaggcggcagcgtccgagttg


cccggatgtagttggtggagcggcagcggcggcaccagcggcggcggcggcggcgggagg


aggaggaggagaagaaggaccaggcggcggcagcagcggcggcggcggggggaggagggg


aggaggcggcggagcaggaggaggagaaggcggaggaggcagtcgctctccgcggggctg


agccggacgcgtcgtcttgcccccctccccccggttcgcggtgccgccgtgtagttggcg


ccgctgccccggctgagagtgagcgtggtgtcgacggagggagatggcccgggagcgccg


gcgccagtaactgggagctgatgagagtcgccgagggcgcgccgggcccaggtgccgggg


ctgcccgccgcccgccgccgccgccgcctgcgcgcccgcccgcctttcgcggccgctctc


ccccctccccgacacacactcacaggccgggcattgatg


 


Homo sapiens kelch-like 6 (Drosophila) (KLHL6):


(Seq ID No: 1074)



cgctccttcag



tctcgatg


 


Homo sapiens GTPase, IMAP family member 1 (GIMAP1):


(Seq ID No: 1075)



cagccttctgcactcacagccgaagggaaagcagcaggttggggcttctt



gtggccaacttcagagcctgtcaccaggaaaggtaagcatg


 


Homo sapiens RAB24, member RAS oncogene family (RAB24):


(Seq ID No: 1076)



cgccctctagccccctcccgcgggagtcgcggcgctgcgggtaggagccgggttgcgg



gagaccccaggttcggttgggattcccagccagaacggagcttaagccggg


caggcgagcgaatgacggagtagcgagctgcacggcggcgtgctgcgctgttgaggac


gctgtcccgcgcgctcccaggccgccccgaggcttggggtcttcgaagga


taatcggcgcccggggccgaacagcgggggcacacggggcgctgccgaagtg


caaggccacggccagagctcgagcccgacgcgctgtctggagtcgtaggaccctgac


gtggctgaagcggccccgggagcatg


 


Homo sapiens adaptor-related protein complex 2, alpha 1 subunit


(AP2A1):


(Seq ID No: 1077)



agccctccccgcggccggctcggctcctt



ggcgctgcctggggtcctttccgcccggtccccgctt


gccagcccccgctgctctgtgccctgtccggccaggcctggagccgacaccaccgccat


catg


 


Homo sapiens copine IV (CPNE4):


(Seq ID No: 1078)



ctccctcttttctcag



taccctcctctttactctccgagttaactgagagccgac


ctgacatctccaacattttcaccctcttcccccacccccatcaccgagaatggag


tcagggtttccggagagaccgaactctgctctcagcacctttcccagccgctgtt


gctaaactgacctcggaggacgagaggggaaggaggtgcgacgccccttacatcag


tacataactaccacaccaaccacctccacttcaaagccggatttt


gcatcctgggggcgggacagacctcgtcccgggctgaattctctctccactcttcga


gattggcacacccagaatg


 


Homo sapiens synaptosomal-associated protein, 25 kDa


(SNAP25):


(Seq ID No: 1079)



ctgtctttccttccctccctgctcggcggctccaccacagttgcaacctgcagaggcccg



gagaacacaaccctcccgagaagcccaggtccagagccaaacccgtcactgaccccccag


cccaggcgcccagccactccccaccgctaccatg


 


Homo sapiens cAMP responsive element binding protein 3-like 4


(CREB3L4):


(Seq ID No: 1080)



aggtctcttgactctttccgccttt



gtttacaaccctgccatgatctccctcttgcaaaagcgagggc


tacagaacaggcattcaggagtcctgtgctccag


tcacagccttttctgttcttcagctaggagacaccaaaccctcaggaagatttacta


tagctaagagaaaactgcagcagaaagggcgcggctacctacttcttaaattccgttt


gtggaccctcagactcttagtcccctactcccagatacagcggccctac


cgtggctcctggcaaggtggcatccacttttgtagtaagcatg


 


Homo sapiens leucine-rich pentatricopeptide repeat containing


(LRPPRC):


(Seq ID No: 1081)



ctgtccttctggcggagcgtgcttcccgctgcggggacgttcgagcaatg



 


Homo sapiens zinc finger protein 418 (ZNF418):


(Seq ID No: 1082)



cgttctctgg



tagcgaccattttggttaatgttgggtgtgtttctgcggtttgtgaggtga


gaggcgctggagctatgggtccgaaccgcggtgtctgaacccagaaggtgaagag


tccttcttgctgcacagaggcagatcttaggccccgtaacggcgcccgccgctcccgg


cagtgctttccccgcgtactcgg


gatggcggcggccgcgctgaggctcccggctcaggcatcatctggctgcaaagaaga


gaacacactgtgtttgagggaggaggaaggaggatcagagtttaaactcctgccataatg


 


Homo sapiens tetratricopeptide repeat domain 14 (TTC14):


(Seq ID No: 1083)



gtttcttccgcttcctgtaccacccggctcaagtagcggacacggaacagggaac



tatcagcccgtcggcctccgggccctgcattctctagccatg


 


Homo sapiens BMP binding endothelial regulator (BMPER):


(Seq ID No: 1084)



agcccttttcgactgtgagctgcggcagctgagcagaggcggcggcgcgggacctgcag



tcgccagggattccctccaggtgacgatg


 


Homo sapiens zinc finger protein 384 (ZNF384):


(Seq ID No: 1085)



cccccttttcgtttccggcgctcccgccttctctccgcagagctcttctctgagcctgtt



ggggggagggaggggggcgtggaggaactggggttcgcgggagcacgagctgcagcacca


cttccgggtgagtgcaaggggagggcagcaaggagggggggccacccactacctcgcgcc


cccgccctgcgggtgtctcgcgcgcgttccgtgcgtgtgagtgtgtgggtctgtctcgct


ccagaagtgcgtgcccgcgcgctgcgccttgcgctttttcccctccctcgccccttcctg


gtcctcccaccctcctcggctccctcctttcccagcaaacgccgcccctcccgcgccctg


gctcaggctctggcgccgccgcagccgtcgccgcccgaaagttcaggagccctggaaagg


agaaggaataagacggcaggaggaagagagagagagggtagaatg


 


Homo sapiens RAD51-like 3 (S. cerevisiae) (RAD51L3):


(Seq ID No: 1086)



ctctcctttctcctccggcagccagcgcgcctgtgtcctctctaggaaggggtaggggag



gggcgtctggagaggaccccccgcgaatgcccacgtgacgtgcag


tccccctggggctgttccggcctgcggggaacatg


 


Homo sapiens CD99 molecule-like 2 (CD99L2):


(Seq ID No: 1087)



gctcctcctcccgctcctcctcggcctccccttcgggcgctctcgcgctaactgtgctcc



tccggggccctccgcctgctcccagccatg


 


Homo sapiens glucosamine-6-phosphate deaminase 2 (GNPDA2):


(Seq ID No: 1088)



gcgcctttatctgcatccgggtccgtgggattcgcgctccac



tggtcagctggggtcgctctcgggtggttgggtgttgctt


gttcccgctgttccagcgtcgaagaaccattgggtctgccggtttgaacttgttctg


gaagctgtgcgtcaccgtaatg


 


Homo sapiens methionyl-tRNA synthetase 2, mitochondrial


(MARS2):


(Seq ID No: 1089)



ccgcctcctccgcttgcggccggtctgcaccatg



 


Homo sapiens chromosome 12 open reading frame 57 (C12orf57):


(Seq ID No: 1090)



tttcctttccgctcccaggggcgttgggaacggttgtaggac



gtggctctttattcgtgagttttccatttacctccgctgaacctagagcttcagac


gccctatg


 


Homo sapiens tRNA-yW synthesizing protein 3 homolog


(S. cerevisiae) (TYW3):


(Seq ID No: 1091)



ggaccttttcggccaccgctcgcttcaa



tatggctgcccccagggagagacgaggctaccatgaaggagccgagcgcagaccctgag


tccgtcacccatg


 


Homo sapiens Sp1 transcription factor (SP1):


(Seq ID No: 1092)



ctccctcctccttacccccccctccctgtccggtccgggttcgctt



gcctcgtcagcgtccgcgtttttcccggccccccccaacccccccggacag


gacccccttgagcttgtccctcagctgccaccatg


 


Homo sapiens histidine triad nucleotide binding protein 3


(HINT3):


(Seq ID No: 1093)



cgccctctagtggcagccggttttgaggccggcctccggcttt



gaagttcctcaccgcgtctccttccctctccccaaagcctggatcac


cgcccagcgtcaggcgaggggcgacgtctcgaggtaaaacggaggaggtgcgggacgcg


gagactgcgcgggcccggtagccctgga


gaggccgaggctctaggccgcgaggggcgggtgcaatg


 


Homo sapiens M-phase specific PLK1 interacting protein


(MPLKIP):


(Seq ID No: 1094)



agttctctgcggagggccggttgatacagttccggtgggagaac



gcggctgcgaggttttcggctttggctcctgatatg


 


Homo sapiens palmitoyl-protein thioesterase 2 (PPT2):


(Seq ID No: 1095)



cacccttccccccgccaccgtgggttccagacttgggataagtaaacagcgggtggagcg



aggcctacggacccaggccaggtgggagtctgcactcttcaaggggcctgggctgctgct


cacgggtattaaagaactccgcgttgttcatggctgaggcgatgcattaggaagatcctg


gacctagagaacaagtcccccgaacgctgagttggaggcgggacttcgggtgcgcgttgg


cgggagcatg


 


Homo sapiens BCL2-like 14 (apoptosis facilitator) (BCL2L14):


(Seq ID No: 1096)



aagcctcttttcaggctgagtcctaaacctgaagaaagttta



gagcctggggctctaaactacctgagtctttccaaacgacaagccaagaagacctgtt


gaaagtttcctcttaagtttcgtggagagagactcaggtatagaaa


tatccttactgccacctgacctgaagcagaagaaatcacagacagcttccagac


caggcccaacatg


 


Homo sapiens galactose mutarotase (aldose 1-epimerase)


(GALM):


(Seq ID No: 1097)



acgccccttctcctgtaaacttgggtcgcctctagcttagcgagcgctg



gagtttgaagagcgggcagtggctgcacacgccaaactttccctatg


 


Homo sapiens carboxymethylenebutenolidase homolog (Pseudomonas)


(CMBL):


(Seq ID No: 1098)



cttccttcccttccccgactttgcagat



ttctcttcccccaggcctccctcctccacctctccgccccctccgggctt


ggctctcccaggaggctacgactggagccactggtcccgcag


gatccccgcgtcctcggtcgccgcgtccacgtccctctcgcgtccccgcccggcgccac


gccgcctcctctgggttcggcctccgcgcggtgcagcgcagtctcaggccgcgggacaa


gcccgacttaaatctctgcaatg


 


Homo sapiens chromosome 7 open reading frame 31 (C7orf31):


(Seq ID No: 1099)



cgtccttctcccgcccccgcccctgcctgccagctccaccgggccgtaggtgcggac



gacctcaaaattcctcggcccgcgaaggccgccagctgcggggaggggaggg


gaggcgcggtcccg


cagcgcccccaggctcatgtcccaggtatgtccagacccccgaggcaccgcttgcaggg


cagtgacagcccgtgaggctcggcctcgacccctggcacccttggtcccagctac


gccggctcctggccttcccccaagtccgagagagaggtgggattctccccgacgcagtt


ggaaaccgggaatcccctttagggtcccgttcgtgctgcactactgactccaccatctg


caaagggattcttgtccagaatccccgaaggctttaggacagcgcttattttgtt


gaatgaagagtctctaattttcggaaagaccacaggctaaaagtcaagtt


gtgcctttttagccaagaagcatg


 


Homo sapiens secretory carrier membrane protein 5 (SCAMP5):


(Seq ID No: 1100)



cggcctttcggcagccgaacggccgcggcagttcaggacaaagaggtgtggg



caggccactgggccagctggtaacatcatg


 


Homo sapiens mitogen-activated protein kinase 10 (MAPK10):


(Seq ID No: 1101)



tgctcctttcggttgccatagcaaccccattccccaagccctctgtccgtctcctctggt



aggttccacaatggtacaggcagcatcacgctgcacaatggtttccaggcagtgaaagag


ggtgattcagcaagccactcttcttctattttctttaacctccccttcactttttatttt


tatgggggtgggtggtgcttgctatatgcttacctttttcttttcttttttcatttttac


aaatttccttttttgtcctcacccctcaattcctaggggcttgagtgagtttaagattgg


gttttcttggaaatcacctgtccatcgttaattttaaacaatctccatatctccaaagaa


tctcttccatgttagtctggaatgtggttaatgaaaaacaagtagggaggatttctgggg


caaacactgccggatcaggatcgtagttctcaggcacggaatggctagtgtgagaaacac


caacagcaggcccatctcagatcttcactatggcaacttatgcaagaaactgttgaatta


gacccgtttcctatagatgagaaaccatacaagctgtggtatttatgagcctccatttct


tatactactgcagtgaaccaacattggatgtgaaaattgccttttgtcaggtgtgtgttc


cttacaggtaaaacaagggattcgataaacaagtggatgtgtcatatattgccaaacatt


acaacatg


 


Homo sapiens beta-site APP-cleaving enzyme 2 (BACE2):


(Seq ID No: 1102)



cgtcctccccgccgccgccggtcccggtgcgcgcccatccctgcccg



cagccccgcgcgccggccgagtcgctgagccgcggctgccggacgggacgggac


cggctaggctgggcgcgccccccgggccccgccgtgggcatg


 


Homo sapiens SWI/SNF related, matrix associated, actin dependent


regulator of chromatin, subfamily d, member 1 (SMARCD1):


(Seq ID No: 1103)



acgccttttccgctagtcgccccgctctatccca



tagtctcgctgccctgagcctcccgtgccggccggccggccgggg


gaacaggcgggcgctcggggggcgctcggggggcggggggag


ttccggttccggttctttgtgcggctgcatcggcggctccgggaagatg


 


Homo sapiens family with sequence similarity 175, member A


(FAM175A):


(Seq ID No: 1104)



cgtcctcttgtgtagcctgaggcggcggtagcatg



 


Homo sapiens adenosine deaminase domain containing 1 (testis-


specific) (ADAD1):


(Seq ID No: 1105)



aggcctcttttgaaa



gatgcggccctgaccctgtgaacctcgcgcagagcggcctgaagcgagaggtt


gaggctgggaggtgagaaaatg


 


Homo sapiens acyl-CoA synthetase short-chain family member 2


(ACSS2):


(Seq ID No: 1106)



gcccctctacggaggccccgcctctagttcggcctgttttctcag



tcccggcacccgccgcgaccgcaaaggcggccgcggttctaggaacttgacgtgatg


 


Homo sapiens multiple coagulation factor deficiency 2


(MCFD2):


(Seq ID No: 1107)



cttcccttactcaccggtgtccggaaaggtgaac



gctgcgctcgggctgcctcgcctgttacctccgccgccgggcatg


 


Homo sapiens SPOC domain containing 1 (SPOCD1):


(Seq ID No: 1108)



gctccttttcagctagtgggtggaaccccaggagggaaaactcagggaa



gcccagggcccgtgttgtgcttttggcccaggtaggtggacagacatg


 


Homo sapiens LY6/PLAUR domain containing 1 (LYPD1):


(Seq ID No: 1109)



agttccttcagtctcagccgccaactccggaggcgcggtgctcggcccgggagcgcgagc



gggaggagcagagacccgcagccgggagcccgagcgcgggcgatgcaggctccgcgagcg


gcacctgcggctcctctaagctacgaccgtcgtctccgcggcagcagcgcgggccccagc


agcctcggcagccacagccgctgcagccggggcagcctccgctgctgtcgcctcctctga


tgcgcttgccctctcccggccccgggactccgggagaatg


 


Homo sapiens cytochrome b5 domain containing 1 (CYB5D1):


(Seq ID No: 1110)



cattctttcatactgcctcctcccttgtttttctgtctcagagaga



tagtctgtcctaaatatcccatgtagcccaggccactgaattaaaacggagcg


tattcgttctctgccccaccccgcaactcctgaaagcggcgcaactcaattactt


gatccttatatgccccacgcgggactcatactacgtttcccgtgaacacgtgcag


tccaaaccccgcccctgatatttatctcagtggacggtggccg


gaaaaggacaatggtttccatgtcagcggataaacgctctcccctcggctcccggac


gcgacggaggtcgtagtagtagtgagtacgtgctgaggagcaaaggagtaaccaaga


gatccagtgaccgacagagcaagagccatg


 


Homo sapiens synaptoporin (SYNPR):


(Seq ID No: 1111)



tctcctcctttgcttcataaaaa



gagggacaagtggctggtgctgtggacagagaagctttatttttagtatgagacaac


ctctattttctttcaggagagggaagttggattatcaattcttttgtaaatg


 


Homo sapiens heterogeneous nuclear ribonucleoprotein U-like 1


(HNRPUL1):


(Seq ID No: 1112)



ccccccctttcccccttcgcctcctgacaggaaaggtttaagggg



gacagagccctgggaggccgggccgggctcgggggccaccccgggggcccgggccatg


 


Homo sapiens schlafen family member 5 (SLFN5):


(Seq ID No: 1113)



ggttctctgctctggacttgggaggctccgttgcctgctcccggagggagac



gcgctgccgaggagaacccagcgggagaacatttcaggataggaa


taggccaagtgctgagaagatg


 


Homo sapiens MAS-related GPR, member F (MRGPRF):


(Seq ID No: 1114)



ccatctcttccagcaggagagggctctactctgagctcc



tattttccaaggctccgggccgcgctcggcgctggcctgctgccccggcgggtccgccgg


ccggaggcgggagtcacaggaagagccctccacaaaaggaggcctcggcggatcag


gacagctgcaggtgggtgtgcagactggtgagctgccagcaggggcccagac


gcgccaggcctggagatg


 


Homo sapiens ubiquitin-like domain containing CTD phosphatase


1 (UBLCP1):


(Seq ID No: 1115)



cggtctctcagcggccggtttctgcgtccgctgccgcaggttccac



cgcgctccaggtatttttttttctgaaggaaagctgcttcctcatatgtttcaagaatg


 


Homo sapiens Rab interacting lysosomal protein-like 2


(RILPL2):


(Seq ID No: 1116)



cctccttttccgttgtcccttcgcgccccaaaccacatcctggagcg



cactctccagcgtggctggcagcggggacggtgcgccggggcgcaggcccaagag


tcgcgtgcgcggccccttgcaccatccccccgggcccacccccgggccgcgctgattggg


caggtagggactctgcccagcggaaagttttgggtgccgggaggaagtctaacctttgg


gagactccaagacagcagctccgaggtcggcgggggtctgggtggccatg


 


Homo sapiens zinc finger with UFM1-specific peptidase domain


(ZUFSP):


(Seq ID No: 1117)



acttcttttccgtgggagtaaggaagtgcttttgaatgaggtactgagggccaaggtgtt



ggaagttcctaattctttcctcggttaactgtgaaactctgcgtattgggaaggcctggc


ctcagtcatcaggccaggagaggtactggacgccgcgcacgcactcgtctgccagcgagg


cccaaaggggaagcctagcggagctcagtgtggcagctgctggcctctgggccgctactt


gtcaataccatg


 


Homo sapiens mitogen-activated protein kinase kinase 5


(MAP2K5):


(Seq ID No: 1118)



ccgccttcctcctcctcctctcgccgctaccgccgtcgccgccgccg



cagccgccgccggtccgcgcggcctcgggtggccg


gagctcagcctgcgcgcgccgcgccctgtgtctccgggtggggcagaa


gactcgccccttgaacctcccgcggggactctccgtggtgtggcggccctggggctcttt


cttaatagccccggactgagtcccctccagtcgaggaccctctcctagtccactgacgag


cggtggacacctgccgctgtatctcccccaaaccgagtccttgccctgctgcctcctcat


acccacacggcggcagagaccttcaccatagcgttcgctcaactccagaaccttccgacc


tccgctagttcctgcgggcctttgcccgcttcccggtgcaccctccccgggagacacctc


agacccccgacagcctgggcaggctcggtgcctgcgggtgcgttcctgatcacccctccc


ctcttccctccccctcatcctccattcccttgttttcaccctctgtcctctgcccgtcac


tccccttgtcacctcttggagccccctcctaaccagcggccagtgggtttcccatacccc


aggatgtgagcctctttaacctgtaatg


 


Homo sapiens solute carrier family 2 (facilitated


glucose transporter), member 12 (SLC2A12):


(Seq ID No: 1119)



cactcttctttag



catgctattatggggaaagtgaccactcctgggagcgggggtggtcggggcggttt


ggtggcggggaagcggctgtaacttctacgtgaccatg


 


Homo sapiens mitochondrial ribosomal protein L30 (MRPL30):


(Seq ID No: 1120)



cttcctctgctctgcttcccttcggag



gaaaatttcaggctgaaggtttagcgggtgccgcctctaaagagagcaatcactacact


tatg


 


Homo sapiens tripartite motif containing 11 (TRIM11):


(Seq ID No: 1121)



gctcctcttcctgccggcatccgggatccctacgtcccgcgtcccccgagcgctcg



gagcctacgcgcccagcgctaccgaaacccagagtcctgcgccctggag


tccccgcgccccggagcccgagcacccgggagtcccgagcctcgcgccccggag


tgcccgagcctgcgccgccgcacccgga


taccccgcgtccccgcgagctgccgaggccgcccgccgccgccccgcggacagtac


cgccttcctcccctctgtccgcgccatg


 


Homo sapiens proline-rich transmembrane protein 2 (PRRT2):


(Seq ID No: 1122)



ctccctccctagctgacttgctccctcccgggctgcggctgctgcaaaagccagcagcgg



cagcgggagctgtccggaggccggcgtcgagggtttgccgctgtctctgctattccatcc


tccccataggggctctctcccctctcccatctcaagatg


 


Homo sapiens zinc finger protein 626 (ZNF626):


(Seq ID No: 1123)



cggcctttgtctctcgctgcagtcagagctccaggtctggttcttctcctaaaggcccag



gctgtgtggccccgtgtcctgcaggtattgggagatccacagctaagacaccgggacctc


ctggaagccaaaaatg


 


Homo sapiens solute carrier family 25, member 43 (SLC25A43):


(Seq ID No: 1124)



cggtcttccgggcccgggtcggggctcgatg



 


Homo sapiens crystallin, zeta (quinone reductase)-like 1


(CRYZL1):


(Seq ID No: 1125)



ggctctctgacgaaggactggaaggtggcggtggtgaaggtg



caggccgttggggcggctcagaggcaggtgactatg


 


Homo sapiens mitogen-activated protein kinase kinase kinase


7 (MAP3K7):


(Seq ID No: 1126)



ctgcctctacccccgccacggatcgccgggtagtaggactgcgcggctccaggctgaggg



tcggtccggaggcgggtgggcgcgggtctcacccggattgtccgggtggcaccgttcccg


gccccaccgggcgccgcgagggatcatg


 


Homo sapiens septin 6 (SEPT6):


(Seq ID No: 1127)



ctttctctttgtcggag



gagctcctctgtttcctgtgcagtagctcccgttgcggcggcacccgtgg


cagccctggcggacgcaggagcgatg


 


Homo sapiens myotrophin (MTPN):


(Seq ID No: 1128)



ctgcctctcctcggccaggcggaac



ctctctgctgggcccggtggccgcaaaagaactttctttctcccgcccgaac


ggtcgccgcggccaactgcctcgcccgcctgg


cagcctaaccctccttctcttcttctcctctccggcttcgcgcggccctgcctccctctc


gcccggcggcatccgcttgctgctgccaccgcctcctcatcttctgcccggccaac


cggcctgccccgctgcagtgatg


 


Homo sapiens annexin A11 (ANXA11):


(Seq ID No: 1129)



ccctcccttgcactgcctctgg



cacctggggcagccgcgcccgcggagttttccgcccggcgctgac


ggctgctgcgcccgcggctccccagtgccccgagtgccccgcgggccccgcgagcgg


gagtgggacccagcccctaggcagaacccaggcgccgcgcccgggacgcccgcggaga


gagccactcccgcccacgtcccatttcgcccctcgcgtccggag


tccccgtggccagggattattggacctgcctggtttaaactattgtcttagttaatttt


gtgctgctctaacaaaatatcacagactgagtaatttataagcaatagtagcttattt


ggctcacagttctggaggctgagaagatcgtgaggctgcatctggcaagggccttctt


gctgcttcataacatggcagaagacatcatgcgggtgtgtgtctggggaaga


gacttacagaagtggagttgctgagtcaaagatctaaccatg


 


Homo sapiens RNA binding protein, fox-1 homolog


(C. elegans) 1 (RBFOX1):


(Seq ID No: 1130)



ttttctttctttcctctcccggcgttgatgag



tgcttggctcctgacagaagggatttggctcccagctttgtagttcggaagaagtt


gggtctatagatttccccctaactctccattgatgtgttgagcttcagagggaataa


taactctacgtaaagcatg


 


Homo sapiens prefoldin subunit 5 (PFDN5):


(Seq ID No: 1131)



cttcctcttcgttaagtcggccttcccaacatg



 


Homo sapiens high mobility group AT-hook 1 (HMGA1):


(Seq ID No: 1132)



cgctctttttaagctcccctgagccggtgctgcgctcctctaattgggactccgagccgg



ggctatttctggcgctggcgcggctccaagaaggcatccgcatttgctaccagcggcggc


cgcggcggagccaggccggtcctcagcgcccagcac


cgccgctcccggcaacccggagcgcgcaccgcaggccggcggccgagctcgcg


catcccagccatcactcttccacctgctccttagagaagggaagatg


 


Homo sapiens zinc finger protein 323 (ZNF323):


(Seq ID No: 1133)



cggccttt



gcggttgatcggtcattggggtgctgcagccccgccacctgttccgtagctt


gccggtgccccgaaggtgtcttctcctaaggaagat


taaatcagaaaattttaaatcacagttatccctttacttaaagccagagtaa


gccttccaaattaaccccaggaatg


 


Homo sapiens tumor protein p53 inducible protein 3 (TP53I3):


(Seq ID No: 1134)



ctttctcttctcttagcagcacccagcttgcccacccatgctcaagatgggcgggatgcc



agcctgttacataaatgtgccaaaagcctggccatgcctggaaaatggaccaatccgccc


gccaagaggttgggtctcgttccctagaga


gaaggaagtttcctctccttgaagtgagagctagaatcgcactttctgtcaagctgaga


gaaagactcttttccagaggctaaaaggacaagaaaatctgatttgctt


gcttctaactttgcgttttaaagggggaaggaggaaaggaaagagggg


gagggtggttctgcttagccccacccctccggc


taccccaggtccagccgtccattccggtggaggcagaggcag


tcctggggctctggggctcgggctttgtcaccgggacccgcaggagccagaaccac


tcggcgccgcctggtgcatgggaggggagccgggccaggaacaatatg


 


Homo sapiens ceramide synthase 5 (CERS5):


(Seq ID No: 1135)



ccgcctccccgcgggttccgttggctgtggcggcagctgacgctt



gtggcggcggtggcttcggggtgggcgtaagatg


 


Homo sapiens TRAF3 interacting protein 2 (TRAF3IP2):


(Seq ID No: 1136)



tgttcttctacttacctgggcccggagaaggtggagggagacgagaagccgccga



gagccgactaccctccgggcccagtctgtctgtccgtggtggatctaagaaactagaatg


 


Homo sapiens Smith-Magenis syndrome chromosome region, candidate 7


(SMCR7):


(Seq ID No: 1137)



ggtccttcac



gttccattcccaggctggtctgagctccggggccgtggtcccgctgcctcctccggtcgt


cgtgcggaagctgcgacgcaggcagaccatg


 


Homo sapiens mitochondrial ribosomal protein L10 (MRPL10):


(Seq ID No: 1138)



cattcttccggtggagatggctgcggccgtggcggg



gatgctgcgagggggtctcctgccccaggcgggctagagtgcagtggcatg


 


Homo sapiens proteasome (prosome,


macropain) subunit, alpha type, 1 (PSMA1):


(Seq ID No: 1139)



acttctctgtagatcgctgagcgatactttcggcagcacctccttgattctcagttttgc



tggaggccgcaaccaggcccgcgccgccaccatg


 


Homo sapiens sorting nexin 5 (SNX5):


(Seq ID No: 1140)



cggtctttctctagac



gcgtcttgctgggagagtgtccgttgcttcccgtccgtgtcgcggccctgcggtt


ggcggcctcctcgtggagcggagcaaggccaggcggcccctgctcgagtcccgcgtcgc


catg


 


Homo sapiens zinc finger protein 276 (ZNF276):


(Seq ID No: 1141)



gggccccctccgcgcgtactgcgggccccacgggtgttagtggcgggggcggcagagtcc



gggtgggttgtcgcgacggagccgggcctcttcgccgtcttgagacggggctggcgagaa


gggcccctcacggagttgccatgggcgtctaaccgcggcagccaggcccctctctacgtg


agaccccggcccccctcccctttctgcagcccgcccgccacctgcgcgccgcgtggcctc


cgccggcgcctgcccgccccgcgcctccgtctcccacggagcaggccgggctctcgc


catg


 


Homo sapiens zinc finger protein 561 (ZNF561):


(Seq ID No: 1142)



ccatcttttccggcgctggctcctctccgtcagtgcggtttcgcctttatggtggtg



gagtctgcccaggctgtggaccgcaaataaccctgtacaaagaggaatgga


gattgcctctatccacctagattcataagctggcctgaggtgatcttgg


catcaaggaagggatgcacatcatcacaccatcagcttcagagaatg


 


Homo sapiens mucin 7, secreted (MUC7):


(Seq ID No: 1143)



ctttctcttctttt



gcttctagttaccatcctcaaaggattggctaaaagcaagcaactg


gattgaacaccctaagaagaaagattcacactgcaccaggagacatcagaaagaatg


 


Homo sapiens threonyl-tRNA synthetase (TARS):


(Seq ID No: 1144)



gcgcctttcgattgcatcagctggtccagccgaggccaagtcccgggcgctagcccac



ctcccacccgcctctt


ggctcctctcctctaggccgtcgctttcgggttctctcatcgcttcgtcgttcgccaatg


 


Homo sapiens ATPase, Na+/K+ transporting, alpha 3 polypeptide


(ATP1A3):


(Seq ID No: 1145)



cagcctctgtgcggtgggaccaacggacggacggacggacgcgcgcac



ctaccgaggcgcgggcgctgcagaggctcccagcccaa


gcctgagcctgagcccgccccgaggtccccgccccgcccgcctggctctctcgccgcg


gagccgccaagatg


 


Homo sapiens chromosome 11 open reading frame 46 (C11orf46):


(Seq ID No: 1146)



cgtcctctcagtggtagcgcggggactggctgggaagcggtcggtcgag



tgtggcctgtgtggactcgcatcttgcccgaagccgggcggaggagagctcaa


gctaagggtgatcagcccatgacctaaacctccagacaaaataaaacggaaaattt


gctagaatcaagaatg


 


Homo sapiens chromosome 17 open reading frame 45 (C17orf45):


(Seq ID No: 1147)



tgaccttttcattcccgttgttatggaggtaggctctctaggaatctgggagtagtagct



ggggggcaagagcaaataaagagctcgagcttctgtggtctctggggagatg


 


Homo sapiens AHA1, activator of heat shock 90 kDa protein ATPase


homolog 2 (yeast) (AHSA2):


(Seq ID No: 1148)



gggccttctggcagtttctgg



gagctgcgaacgcgccgccccggggctcggcggccggaaacgctggcttcg


gagccttaggcgccgcggcctttccttgttttccgcccagtccac


gccgccatggccaagtggggccaggggaacccccactggatcgtggaggagcgggag


gacgggaccaacgtgaacaactggcgctggcgcggctggcggcggcctccttccgg


gatctggggagggccgggccgcgg


gagccggggctgccctggggtctgtgcggggccgcggggccagggggtcagggggccgcc


ccccctcagctgctggacgcagggctcggccttcgcctctcggctcgggagagtcctt


gagtacggagaccggctaggagggttgcagctgcctctttttgaaagttgggtt


gggccccaagagtgacttccgacagacctttccactcccac


cgtctgtggcctgagggccttcccttctcctcccgcccacccctctggatgtttcggg


gagttagaagggagctggattgagagactgtgttaggggcgggggtatggaacgtagtg


gaaagggcagaaatttggatctcagttcgcgcccaccccg


caggcgcctcccgcgagccgggccctctgtgagtgagacaagctccccttcctttac


gcgcctcacctggcgcgtggggagaggtcggcagccctccgccgcagaacctccg


gaagggatgtcctctgccctgcgcctctggccggggctgtggtccctccaggccgtcgag


gggatgctgaggccggtccccagaggagcatgacttggctggtccggag


gagctctgagggcatgggcaatcttggctcgctgcaacctcagcttccagagttcaa


gcgagtctcctgcttcagcctcatgagtagctgggactacagatgcgtgccactac


gtccgtctgatgtttgtatttttagtagagacagggtttcaccatgtt


ggtcaggctgctctcgaactccagatctcgtgatccgcccgcctgggcctacta


aagtgctgggattacaggcgtgagctagatctgactttctagtgtcctagcctt


ggcccgatggacatgtcatttctctcagctcgtttctgtcccctaaagtgagaa


tattgcctgggaagattacattagacgatgtatatgcgaagacacttgatagctgg


tattgtcatgattctgattagttcactactgctactttccctgtggcctaggctttgcc


tatttccagtgggcgagctagctagatcctcctcccttaaataagccag


tgtttttaagacagaatactacttgcatagtggacaataatatcttaaagaactgag


caggatgaaaagaatttgatagaaagcaggtttgaggagcacattggaggttgg


caggtttcgaggctgcttgagaggacttgggccgatctgggctgggcttggac


gtgaccctggcacccaggcaggtggatcccagctggggcttccattcac


gactttctggtccctggcaggacagagcgggatgccaccagctt


gtccaaagggaagttccaggagctcctggtgggcatcgttgtggagaatgac


gctggccgcggcgagatcaacgagttgaagcaggtggaaggggaggcttcgtgcag


cagccgcaaaggaaagctgattttcttctatgagtggaacatcaaactgggctg


gaaaggcatcgttaaagaatctggagtgaagcacaagggattgattgaaa


tacccaatctttctgaggaaaatgaagtagatgacactgagaatttacaacgggaatg


 


Homo sapiens GrpE-like 2, mitochondrial (E. coli) (GRPEL2):


(Seq ID No: 1149)



ctgcctctcagcccaaattggaaacatg



 


Homo sapiens xyloside xylosyltransferase 1 (XXYLT1):


(Seq ID No: 1150)



ccgcccctttcatggccgccgcctggcgccggggctaagtggccgccggcgtccgggtac



ccgagggctctcccgcgttgctggcaccgctggcgccgcggtctcgtagcgcatg


 


Homo sapiens chromosome 7 open reading frame 60 (C7orf60):


(Seq ID No: 1151)



cctcctctggctgctgcctccgcagctccctcctcctaccccacctcctccatctggg



gagcgtctgcgggggcctgaggggcggcggcggcggcggcggctgcgatatg


 


Homo sapiens tetratricopeptide repeat domain 39B (TTC39B):


(Seq ID No: 1152)



ccctcctttgcgctgggctgagcccagagccgagagcaggggtcggctctgag



ttccctgcttggtttttgggtggcagcagccagaggaggaatatg


 


Homo sapiens motile sperm domain containing 2 (MOSPD2):


(Seq ID No: 1153)



cacccttctctgtctacctctgggcgggactgccgggtgatgaga



tactcggtcggcgacggtagaacgggcgacggcgacaaccgcaatcacatccacgac


ggtgatcatg


 


Homo sapiens major facilitator superfamily domain containing 6-


like (MFSD6L):


(Seq ID No: 1154)



ggcccctttcggtccaacggcaggac



ctgggggctgtggccgggggcggccgttgacctggtgaccgcggcgccgccccagac


cgggggcgcagtcccactcgctccgagccccggtcccccaagcctccctcccgggtac


ctggggccgcgcccgccctgcgcccagctccgccctccgtcggcccaggcctgacagagc


ccggcagccatg


 


Homo sapiens consortin, connexin sorting protein (CNST):


(Seq ID No: 1155)



cttcctctctagccgccagtgctc



tatgctccgcggtcgcgggccgccagcctccagccggccagccgcgaggggtgcg


cagagggaggcggggcggaaaggcgagaggtgtctcctccaccggagccagggga


gacccgagcaagctccgtgacagcacgtcggccgccatgtcgccgagtggggctg


gaaacagacccggcgcccagcggtagccctccttgcgcctccgattcccaga


catggaaggtctttaatgtaactttaaatggttcaccaaaggatgctctaatg


 


Homo sapiens zinc finger protein 92 (ZNF92):


(Seq ID No: 1156)



gggccttt



gtctctcgctgcagccggcgctccacgtctagtcttcactgctctgcgtcctgtgctga


taaaggctcgccgctgtgaccctgttacctgcaagaacttggaggttcacagctaagac


gccaggaccccctggaagcctagaaatg


 


Homo sapiens DnaJ (Hsp40) homolog, subfamily C, member 18


(DNAJC18):


(Seq ID No: 1157)



cccccttctctttcagcctcgggcacgggggaggctcggcggac



ctgctgattgggaaccgatatg


 


Homo sapiens polymerase (RNA) I polypeptide D, 16 kDa


(POLR1D):


(Seq ID No: 1158)



cctcctccctccttccgtcctccgcgccttccgtcggtcggtccttgcttcctgcttcgc



ctccgcgcctcgcgctatgggacagagcccccgatccgccagcaccacctgaggatccag


aaaccgccccagcgatg


 


Homo sapiens ring finger protein 182 (RNF182):


(Seq ID No: 1159)



ac



ctccctcccctcccaggcgccgccgcagccg


gagcggctcccgggccctgggccgccgccggccaggaagaaatacttgtgttggctg


catttccagggatgctaccagagctcaaggctgtcacctggtcttgcccagaa


gagccgttcttagaggcaggacttgatgaaggctttcctgctgatggaataggttt


gctagagctggccttggaattagaacccttcatgtggcctttataaatatgcgttt


gagacagagttatatgcagaagttgaaaatgcctggaagatttctggtttctttcac


tacttatcctgcctttttgcatcgctgccagatttggatgatatgatattcagagggg


caccttaatcaaagccattcttcaacaagacccacctggcataa


gattgcacacataattcaagatg


 


Homo sapiens transmembrane protein 18 (TMEM18):


(Seq ID No: 1160)



cctcctctgtg



gattctggccaggccgggttcggcggttgctgtgagagcgggcttcccaacaccatg


 


Homo sapiens Hermansky-Pudlak syndrome 4 (HPS4):


(Seq ID No: 1161)



ag



gcctctctgccgcgcgcgcaggtacggggcagaagtcg


caggtacccagctgctgcccacatttctggtccagagtcccgaaccccgagcactgg


gatgcctggctactccgagccaaggcactgatgtttgaactggaaacttcaaaac


gtttaataagagtcttcaggatgggtttgaactagacaagctagaaatttcttta


gaacaccagctctagcatgcatctcccacttttggctttcctggagaggagcttgaa


gaggtggttctgcagacagccacagtgatacttaggaaaccagaggaatggattt


gacttttctgctaggattctctgttatagtttctccctgagttgtaagaggcatggaaa


tatacatgaaactgaagaacctgcaaggaagggaagtggaactttccatgctgag


tgaaaactaaccaagtggcagttgtgactgaaaacactgaaacctaccacgtccagat


tcactggattgggggatagaggaacggtcacagctagggagaaagaagtgataccg


gaaaagaaaacctaaatgaagagaatgaggatgactgcacagtagatg


 


Homo sapiens PTK7 protein tyrosine kinase 7 (PTK7):


(Seq ID No: 1162)



agctccttttcctgagcccgccgcgatg



 


Homo sapiens kelch repeat and BTB (POZ) domain containing 6


(KBTBD6):


(Seq ID No: 1163)



agttctcctgggcgcctagcattgtcgcccacgctgcag



tagcggcttctgcggctccaagccagcgggtcctgtgaaggcgagcagacgcgga


gaaaggacgcgggagtgagagagggtgagtcagccactgtctaaacgataacgg


gaggcggctctgcggggtagggttgaattcag


taaatgggctcgtgctgctgtctcttcggagacgctgc


tatcttagcgtcagcgagggaaggttgaggaggagccagagccgggtcctg


cagcgtttctcgccatcagcgcccgtcgccatctccaccatg


 


Homo sapiens sperm antigen with calponin homology and coiled-coil


domains 1 (SPECC1):


(Seq ID No: 1164)



ctttctttgactggagcggacccgccggacgcaac



cgcctcgccagccggagccagcgcgagctcggcacggtggacacccggtccgaggccgg


caagccggctggtgcccgagtcggccaagcatg


 


Homo sapiens ST6 (alpha-


N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgal


actosaminide alpha-2,6-sialyltransferase 3 (ST6GALNAC3):


(Seq ID No: 1165)



ggtccccttatttggatctgcgggaatgtgggctggagaggtcctgccgtggtac



cagcctccagcctgcccccaggactgcccctgacccaggcgcgcccgctgctcggtgg


caggagggccggcggagcgccatg


 


Homo sapiens transportin 1 (TNPO1):


(Seq ID No: 1166)



gattctctttgttccg



cagccatttcaggccccggacaggaggcag


tgccgcttcggccgaaggcccgagcgcccgaggcgtctgggatg


 


Homo sapiens heat shock 70 kDa protein 8 (HSPA8):


(Seq ID No: 1167)



cttccttcgttattggagccaggcctacaccccagcaaccatg



 


Homo sapiens hyaluronoglucosaminidase 1 (HYAL1):


(Seq ID No: 1168)



ggctccttcctccaggagtctctggtgcagctggggtg



gaatctggccaggccctgcttaggcccccatcctggggtcaggaaatttggagga


taaggcccttcagccccaaggacatcctggctgccatacctgctcctgacttctcagggc


tggcagtcatcgactgggaggcatggcgcccacgctgggccttcaactgggacac


caaggacatttaccggcagcgctcacgggcactggtacaggcacag


caccctgattggccagctcctcaggtggaggcagtagcccaggaccag


ttccagggagctgcacgggcctggatg


 


Homo sapiens STE20-related kinase adaptor alpha (STRADA):


(Seq ID No: 1169)



agtcctcccggtcgccccactgcgcatggcacgttgcgtactcccctcccagcaac



cggtctggcggcggcgcggcagtaaaactgaggaggcggagccaagac


ggtcggggctgcttgctaactccaggaacaggtttaagtttttgaaactgaagtaggcc


tacacagtaggaactcatg


 


Homo sapiens transmembrane protein 161B (TMEM161B):


(Seq ID No: 1170)



ccctctctttcgctgtttgagagtctctcggctcaaggaccgggaggtaagaggtttgg



gactgccccggcaactccagggtgtctggtccacgacctatcctaggcgccatg


 


Homo sapiens Usher syndrome 1C (autosomal recessive, severe)


(USH1C):


(Seq ID No: 1171)



ggctctttccagctcctggcagccgggcacccgaaggaacgggtcgtg



caacgacgcagctggacctggcccagccatg


 


Homo sapiens interleukin 12 receptor, beta 1 (IL12RB1):


(Seq ID No: 1172)



cag



tcttttctccttgctcagcttcaatgtgttccggagtggggacggggtggctgaac


ctcgcaggtggcagagaggctcccctggggctgtggggctctacgtggatccgatg


 


Homo sapiens Meis homeobox 2 (MEIS2):


(Seq ID No: 1173)



atcccttcctctcttttctgttcgccctcttctccctgctctttttccctttccaccccc



ctcctctgttctccctcacctcctgcgccccctcccccttcccgggttctgacagtac


gatgagctgccccattacggcgggatg


 


Homo sapiens G elongation factor, mitochondrial 2 (GFM2):


(Seq ID No: 1174)



ttttcttttcgtttagatacattgccttttgcctaggctggcgtcgagactt



gaggccgttgcagactttggcgcggctcgcgcctcctgcttcaagagcccagcggtga


gagctggcctgcggcacgcggcctaatgccagacagtaacagtttggaggatcaagatg


 


Homo sapiens lamin A/C (LMNA):


(Seq ID No: 1175)



gagccttt



gccccggcgtcggtgactcagtgttcgcgggagcgccgcacctacac


cagccaacccagatcccgaggtccgacagcgcccggcccagatccccacgcctgccag


gagcaagccgagagccagccggccggcgcactccgactccgagcag


tctctgtccttcgacccgagccccgcgccctttccgggacccctgccccgcggg


cagcgctgccaacctgccggccatg


 


Homo sapiens calcium/calmodulin-dependent protein kinase II delta


(CAMK2D):


(Seq ID No: 1176)



cgctctttctctcgccgcgccgtcttgaa



gccgcgcgggctcgtgagcagcgcgaggccgccaaggtgcctcgcttcgccg


gagccgctgccgcccgccggagggaagccggcctcgggcgcgcacgctcgtcg


gagccccggcgcgccccgcgcctgagcctgctgacagcggccgctgggctcaggctgtcc


gctctgggctccgcggcctcggccccgctgcactccacctccgccccctcg


gactccctcccctctgcttctactcctcctgctccagtgcggatcgtttcg


caactgcttgccac


tcgtcccgtgcctggctgtttttccatttcccggccccctcttcttgag


tactttaccccctgcatttggggacagggactggaaaaggggcgggtggagcgtccag


tggagaagaaggaagcgaggcccgcaggaggaggaggatcggcggactgtggggagga


gaccccacgccaccctttctggtcatctcccctcccgccccgcccctgcgcacac


tccctcgcgggcgagctactttcggaccaggaaagtaa


gagcggccctgggtgacagcgccgcggggccag


tcccggggttagccgcgcgtctgctcgcttctggtccgtcgcgctcccagccaggg


cacagcccggaccgaggatg


 


Homo sapiens calcium/calmodulin-dependent protein kinase II gamma


(CAMK2G):


(Seq ID No: 1177)



ccgtctcctcctcttgctccctcggccgggcggcggtgactgtg



caccgacgtcggcgcgggctgcaccgccgcgtccgcccgcccgccagcatg


 


Homo sapiens interleukin 15 (IL15):


(Seq ID No: 1178)



ttttcttttcgccaggggttgggactccgggtggcaggcgcccgggggaatcccagctga



ctcgctcactgccttcgaagtccggcgccccccgggagggaactgggtggccgcaccctc


ccggctgcggtggctgtcgccccccaccctgcagccaggactcgatggagaatccattcc


aatatatggccatgtggctctttggagcaatgttccatcatgttccatgctgctgacgtc


acatggagcacagaaatcaatgttagcagatagccagcccatacaagatcgttttcaact


agtggccccactgtgtccggaattgatgggttcttggtctcactgacttcaagaatgaag


ccgcggaccctcgcggtgagtgttacagctcttaaggtggcgcatctggagtttgttcct


tctgatgttcggatgtgttcggagtttcttccttctggtgggttcgtggtctcgctggct


caggagtgaagctacagaccttcgcggaggcattgtggatggatggctgctggaaacccc


ttgccatagccagctcttcttcaatacttaaggatttaccgtggctttgagtaatgagaa


tttcgaaaccacatttgagaagtatttccatccagtgctacttgtgtttacttctaaaca


gtcattttctaactgaagctggcattcatgtcttcattttgggatgcagctaatataccc


agttggcccaaagcacctaacctatagttatataatctgactctcagttcagttttactc


tactaatgccttcatg


 


Homo sapiens protein O-fucosyltransferase 1 (POFUT1):


(Seq ID No: 1179)



gtccctccttccctccccgactgtgcgccgcggctggctcgggttcccgggccgacatg



 


Homo sapiens calpain 3, (p94) (CAPN3):


(Seq ID No: 1180)



cac



tctctttctctctccctctggcatgcatgctgctggtaggagacccccaagtcaacatt


gcttcagaaatcctttagcactcatttctcagga


gaacttatggcttcagaatcacagctcggtttttaagatggacataacctgtacgac


cttctgatgggctttcaactttgaactggatgtggacac


ttttctctcagatgacagaattactccaacttcccctttgcagttgcttcctttcctt


gaaggtagctgtatcttattttctttaaaaagctttttcttccaaagccacttgccatg


 


Homo sapiens PTK2B protein tyrosine kinase 2 beta (PTK2B):


(Seq ID No: 1181)



agcccttttactcagccacagcctccggagccgttgcacacctac



ctgcccggccgacttacctgtacttgccgccgtcccggctcacctggcggtgcccgag


gagtagtcgctggagtccgcgcctccctgggactg


caatgtgccgatcttagctgctgcctgagaggatg


 


Homo


sapiens ST6 beta-galactosamide alpha-2,6-sialyltranferase


1 (ST6GAL1):


(Seq ID No: 1182)



cttccttccttctccagtcccttccac



tgtgcgtcttctgtcccccgttcttccccagcggacccctctttcgagactccctag


tggggtccccagctcccgggcgatcctgcccttgccgagcgcgttttctggagtcac


ctgggggaggggagtcctgggcagggccgggctggggaagacgcctggggcac


tgcccggcgttaacaaagggagccgataccgaccggcgtgggcgcg


gagcgggcggccgccaccgagcgtgctgagcaaccgcagcctccgcggccgagagtg


cagcgagcaaggggagagccagttgcgcagagccctgcaaccagcagtccaggga


gaagtggtgaatgtcatggagcccagctgaaatggactggccccctt


gagcctgtcccaagccctggtgccaggtgtccatccccgtgctgagatgagtttt


gatcatcctgagaaaaatgggccttggcctgcagacccaataaac


cttccctcccatggataatagtgctaattcctgaggac


ctgaagggcctgccgcccctgggggattagccagaagcagatgatcatgacgcag


tcctgaggtttaatggggcacccacagccaacttccaacaagatgtgggcacaaaaac


taccattcgcctgatg


 


Homo


sapiens ubiquitin-conjugating enzyme E2Q family member 2


(UBE2Q2):


(Seq ID No: 1183)



ctccccttccgcgcccggctccccttccgcgcccctcccgccggagat



gaggggaagatg


 


Homo sapiens membrane magnesium transporter 1 (MMGT1):


(Seq ID No: 1184)



gcttcttttgctgggctgctgctccttcggcatcatg



 


Homo sapiens PAP associated domain containing 4 (PAPD4):


(Seq ID No: 1185)



cggtcttccgggtgtctttgacagggttttctacgccgctttttcggcgactttttgctc



ttccgctttttgccaccgcccccaaccttctatatccttgcagcccctac


cttttcttgtgttgctcctcccctggcagccgtgaggggggttagatctcagccg


gagccggagctgggcctagctgtcccacgggccaccactacctcctttggttcggga


gaaagctacgaccaagtacgcccagctcgggccttagaacttctgaacgggcag


tgcgggtaggccctgcttagcccttcccggaggacacctgaccaaaagaggaaga


tagtcttgggacccttgcatggtgtttcaaagggtggtgaagaactaaggtagaa


gaatacatgttcacttccagtgaacaagagcatg


 


Homo sapiens chromosome 3 open reading frame 23 (C3orf23):


(Seq ID No: 1186)



ctcccttctggtgtactgggtgggaggtggaactagtcggacaaagccctcgcgtcg



gacccttgccagaactcaattaatggatgcctcgaagttgacgtacatatatattca


gaaatg


 


Homo


sapiens mucosa associated lymphoid tissue lymphoma translocation


gene 1 (MALT1):


(Seq ID No: 1187)



cgccccttt



gcgcggctggcgcggccagccggccaggctcccctcggcaaacctgtctaatt


ggggcggggagcggagcttcctcctctgagggccgtgccgcgctgccagattt


gttcttccgcccctgcctccgcggctcggaggcgagcg


gaaggtgccccggggccgaggcccgtgacggggcgggcgggagccccggcag


tccggggtcgccggcgagggccatg


 


Homo


sapiens UDP glycosyltransferase 3 family, polypeptide A2


(UGT3A2):


(Seq ID No: 1188)



ctacctctacccacagccagtgcctttggcgcactgaggtg



cacagggtcccttagccgggcgcagggcgcgcagcccaggctgagatccgcggcttccg


tagaagtgagcatg


 


Homo


sapiens sodium channel, voltage-gated, type IV, beta subunit


(SCN4B):


(Seq ID No: 1189)



cctcctctcgctctctgcccgctaactttcccgagccccgac



cggcggcgcagagctccggggtagctttgtggccgaacgccgacctcgggcgga


gagcgcggctgtgcccagtatcccatccccgcgacccccgcgcgctccggagagaacag


gactatg


 


Homo sapiens JAZF zinc finger 1 (JAZF1):


(Seq ID No: 1190)



tcccctctgcctcccggtggctcctcgctctccttccatctctctcgccccctctccctc



cgtcccgtcctcgccgctcccctcaccccgcctctctccccctcccccagcccctcctct


cctcaccccacccggcctccctccctccctcgcccgcccggcgctcgcagagccgacac


caggggggctctcgatgtagcaccatg


 


Homo sapiens chromosome 15 open reading frame 55 (C15orf55):


(Seq ID No: 1191)



ttcccttccttggatccctgtgcacctactggagccaggttactctgggtcctggac



ctgactgcctcattctggaggcttccagacagccacagttagtgcccaaacctgagag


gatg


 


Homo sapiens ras homolog family member C (RHOC):


(Seq ID No: 1192)



cgccctctcttcctgcagcctgggaacttcagccggctggagccccaccatg



 


Homo sapiens CTP synthase II (CTPS2):


(Seq ID No: 1193)



cattctctttccttttccttctctcctgagcgctcctgcagttcctggggcgtag



taggggatccacaagcgtttgtgaccagtgaagttctttacaagggtgagatctgcac


gggaggacccgagcgagggtctcggcttgccaggaagccggggttccccgggaagcgtg


gagttcacccgcgcactcgaagtgcctttgcaaaattatatctgggtgttgg


cacccagccactattctgccaatg


 


Homo sapiens PRP4 pre-mRNA processing factor 4 homolog B


(yeast) (PRPF4B):


(Seq ID No: 1194)



agctcttttccttcttcctccacttcccctaccctccac



cgtccgggagccgccgccaccgccgccgaggagtcaggaagttcaagatg


 


Homo sapiens molybdenum cofactor synthesis 2 (MOCS2):


(Seq ID No: 1195)



gcgcctttgcggccgtgattcggtcccgctgtcctaggcgg



gatggtgccgctgtgccaggtaagggtggcgggtgtgcgtgcgggcctgggtgcg


gagccctcctcgacgtgtctctcccgccctttccctccacatacccagccttggtcag


tcggacctccccactagcccccaacctggccggcgtctt


gggttcgggggcgcccccgcccccgcccccgggcccttcctgtctccgggctttactgcg


actgccccagcagaagtcgggtcctctccgagaactcttgtcagctcacggcag


caaggacggactcgttctgaaggcgcctccaccttttatgaccacctctttcccagat


tattcgttttgatgaagctaaaattttaatctaaaaagaaatgcacctcatgga


gaattcttgtgaagaactgtgcttcatctgtggatttctacacccttgatcattt


gcaaacctgtaattatttcgtaaagagttgtttgcacggagtgacaggtt


gaagtattgtattttgcaaaaagtgctgaaataacaggagttcgttcagagac


catttctgtgcctcaagaaataaaagcgttgcagctgtggaaggagata


gaaactcgacatcctggattggctgatgttagaaatcagataatattt


gctgttcgtcaagaatatg


 


Homo sapiens cat eye syndrome chromosome region, candidate 1


(CECR1):


(Seq ID No: 1196)



tttcctttttccggaggggagatg



 


Homo sapiens solute carrier family 13 (sodium-


dependent citrate transporter), member 5 (SLC13A5):


(Seq ID No: 1197)



ctgcccctcactcgtctcgcccgccagtctccctcccgcgcgatg



 


Homo sapiens armadillo repeat containing, X-linked 3


(ARMCX3):


(Seq ID No: 1198)



agtccttcttgtcctggtcgttgttcccgtctgagtaccagctccccactgccctgaggg



cgggccggcctgcggcggagggaaaaaggaagaggagaaggaaattgtcccgaatccctg


cagtgggtccaagcctctcccgggtggccagtctttctgtaggttgcggcacaacgccag


gcaaaagaagaggaaggaatttaatcctaatcggtggaggtcgatttgagggtctgctgt


agcaggtggctccgcttgaagcgagggaggaagtttcctccgatcagtagagattggaaa


gattgttgggagtggcacaccactagggaaaagaagaaggggcgaactgcttgtcttgag


gaggtcaacccccagaatcagctcttgtggccttgaagtggctgaagacgatcaccctcc


acaggcttgagcccagtcccacagccttcctcccccagcctgagtgactactctattcct


tggtccctgctattgtcggggacgattgcatg


 


Homo sapiens armadillo repeat containing, X-linked 2


(ARMCX2):


(Seq ID No: 1199)



cgtcctcctctgggtaccaactctattgcg



cagctcgctgccgtgcgtttaacccaggcgaggaggaggaggagaaaattcccccagat


tcgggcaggcccgcaccccacattccgtcctgttttgagaggaggagggaagagaaa


taaacgtggcagcgcatagaaggccagcagggagactgctttccagacac


ctccggcccacacagccgttcaccccccgtcttttcagtcctg


gaaaaggaattcggtctgtccttaggatgaagctctaactgaactgaagtaagga


gaaacagccttgaatctttggagggtctgtcttccttttgggctctgtgcaactgcagc


tacagtggaaaaaagcaaactgctcttgatcccaggccctgcctaagcctcag


cagaacttgtaagcctaaactgaagagcctcacccggacgagcaggcatcccttaac


cttaagcaatccagttccacgccctggatcagtgaataaccccagctgcaccatg


 


Homo sapiens UBA domain containing 2 (UBAC2):


(Seq ID No: 1200)



cgccctctggggctccgagcccggcgggaccatgttcaccagcaccggctccag



tgggctctgtgagtaccggcctccgccatcctggctgccccctacac


gccaccctaggcacctctttgaggaggctggggcagcggggaccctcgggtttgccg


gaggtggtggggccgaccctccagacccgcgtccgaaccctgctagttcccggtctt


gggggtcagcggaaaccgcccccatttcggcctggaggggcgaatggggacaaa


gccccgccgcccgccccgaccccacctggtatccccaggtgctctgcccaggag


tctcttggggccgctgcaagtggg


caggtgccctggtgttctcgtgggccggccccaggccctttgcg


gagcgtgtgccgcgctgaaggaaggggccgtcccccttac


catgccccattcttttaggcttgggggaccgaactaactccccccgcccccactt


gcaaagttcagcctccgctttagaagctgacctctcagtttcacttggatg


 


Homo sapiens cancer susceptibility candidate 4 (CASC4):


(Seq ID No: 1201)



cctcctccctcggccggccctggggccgtgtccgccggg



caactccagccgaggcctgggcttctgcctgcaggtgtctgcggcgaggcccctaggg


tacagcccgatttggccccatg


 


Homo sapiens protein phosphatase, Mg2+/Mn2+ dependent, 1G


(PPM1G):


(Seq ID No: 1202)



cgctccctcacagctcccgtcccgttac



cgcctcctggccggcctcgcgcctttcaccggcacctt


gcgtcggtcgcgccgcggggcctgctcctgccgcgcg


cacccccggggcttcggctccggcacgggtcgcgcccagctttcctgcac


ctgaggccgccggccagccgccgccatg


 


Homo sapiens StAR-related lipid transfer


(START) domain containing 13 (STARD13):


(Seq ID No: 1203)



ctttctttttaaaaatcgctgggtctgttgagctgtcctgggctgggtgcctt



gctctttgactgagactggagacagacggcaacagccacaggcagactgaggtggcaa


taggaaatctgccgagatg


 


Homo sapiens tubulin, beta class I (TUBB):


(Seq ID No: 1204)



gattctcccgcctcccagccccggcgcacgcgcgccccgcccagcctgctttccctccgc



gccctcccctctcctttctccctctcagaaccttcctgccgtcgcgtttgcacctcgctg


ctccagcctctggggcgcattccaac


cttccagcctgcgacctgcggagaaaaaaaattacttattttcttgccccatacat


accttgaggcgagcaaaaaaattaaattttaaccatg


 


Homo


sapiens cytochrome P450, family 4, subfamily X, polypeptide


1 (CYP4X1):


(Seq ID No: 1205)



tttccttcttcccgcgagtcagaagcttcgcgagggcccaga



gaggcggtggggtgggcgaccctacgccagctccgggcgggagaaa


gcccaccctctcccgcgccccaggaaaccgccggcgttcggcgctgcgcagagccatg


 


Homo sapiens doublecortin (DCX):


(Seq ID No: 1206)



ttttctttctctcag



catctccacccaaccagcagaaaaccggtgagtggggcttttaagtgattttcaagaa


gaatgtaacagatgtcaaacgggaaaagcacaaggcaaa


gcctgctctctctgtctctctgtctcctcttctccttttttgccttattctatccgat


tttttccctaagcttctacctgggattttcctttggaaaagtctctgaggttccac


caaaatatg


 


Homo


sapiens protein phosphatase 2, regulatory subunit B′, gamma


(PPP2R5C):


(Seq ID No: 1207)



ttgtctttttttttttaaactaaaatggaggctggtttctt



gccttaaggagcccattgcctttcccgctgaagtctagatg


 


Homo sapiens solute carrier family 9, subfamily B (cation


proton antiporter 2), member 2 (SLC9B2):


(Seq ID No: 1208)



ccacctttccgggg



gaagccacgcgcaccaggcatcgcacgcggctctgcacccgcgccgccggac


ctgaaacccggcggagggcacacggggctgccgctgcgggccccggac


caacccatgcttactccggagcctgtaccggcgccgacgggtcggac


ctccctgcgcggtgtcgcccagcgggttcgtgcgaaaggcggggccgactacac


gcggtgccgcgccctgagaccgtttatctgcagtcaac


gcagcctcccggctcagcctgggaagatgcgcgaatcgg


gaaccccagagcgcggtggctagac


cgggctccgccgcctcccccacagcccctttcctaatcgttcagac


ggagcctggtcgacttcgccgga


gactgccagatctcgttcctcttccctgtgtcatcttcttaattataaataatg


 


Homo sapiens hypoxia inducible factor 1, alpha subunit (basic


helix-loop-helix transcription factor) (HIF1A):


(Seq ID No: 1209)



caccctcttcgtcgcttcggccagtgtgtcgggctgggccctgacaagccacctgagga



gaggctcggagccgggcccggaccccggcgattgccgcccgcttctctctagtctcac


gaggggtttcccgcctcgcacccccacctctggactt


gcctttccttctcttctccgcgtgtggagggagccagcgcttaggccg


gagcgagcctgggggccgcccgccgtgaagacatcgcggggaccgattcaccatg


 


Homo sapiens interleukin 21 receptor (IL21R):


(Seq ID No: 1210)



cctcctcttcctccccactctgcacatgcggctgggtggcagccagcggcctcaga



cagacccactggcgtctctctgctgagtgaccgtaa


gctcggcgtctggccctctgcctgcctctccctgagtgtggctgacagccac


gcagctgtgtctgtctgtctgcggcccgtgcatccctgctgcggccgcctggtac


cttccttgccgtctctttcctctgtctgctgctctgtgggacacctgcctg


gaggcccagctgcccgtcatcagag


tgacaggtcttatgacagcctgattggtgactcgggctgggtgtggat


tctcaccccaggcctctgcctgctttctcagaccctcatctgtcacccccac


gctgaacccagctgccacccccagaagcccatcagactgcccccagcacac


ggaatggatttctgagaaagaagccgaaacagaagatgaggcaatgaggctgcga


gaggtagagtgattttccctcggtgactcaactgggacgtagcaggtcgggcagtcaa


gccaggtgaccccatg


 


Homo sapiens DDB1 and CUL4 associated factor 4 (DCAF4):


(Seq ID No: 1211)



tggtctttccgggtccttgcacgcttcgctccaactcctgcagagctgagccggaggg



gaatccggaagggacacgctgaacaggtctgactcccgggcagcacagcccgctcac


gattccggccacggtgatgacgagtctccgtcaacctcgtctggcacagctgggac


ctcctctgtgccagagctacctgggttttactttgaccctgaaaagaaacgc


tacttccgcttgctccctggacataacaactgcaaccccctgacgaaagagag


catccggcagaaggagatg


 


Homo sapiens oxidation resistance 1 (OXR1):


(Seq ID No: 1212)



ccgcctctt



gtgaggcgcgcggagccgcctcccctgggtcaggtctgatgggccggtgggcgcgctag


tggtggccgccaccgccgaaaccgtcgacctcctgggccccag


ttccgcgtccagccccgcggcagcatg


 


Homo sapiens cut-like homeobox 1 (CUX1):


(Seq ID No: 1213)



ccccctctctat



cagccgctcactccgtctcaatatgtctcaagatg


 


Homo sapiens atlastin GTPase 1 (ATL1):


(Seq ID No: 1214)



ctcccttttcctccccac



tccttcccaccagcgccacagcaacatcctcagag


tctgagcgaactgcgcccagcgcgggcacggagcctcccaccgccagcaac


ctgcggccccggagaaggcagcgagcgcagtgacagcgcctcaccgccaccagctcctg


gaccaccatg


 


Homo sapiens chemokine-like factor superfamily 5 (CKLFSF5):


(Seq ID No: 1215)



ctgccttctctcccggggccctgtgggcaagcctcctgcttcac



tttcaggtttctcgaagtgccttcttgctcctgtctgtttccccatcctgccagat


ttctgtttctcttgctgggcttttggcagtagggggctgtgttggtgggccctacgaa


gatg


 


Homo sapiens transmembrane emp24 protein transport domain containing


7 (TMED7):


(Seq ID No: 1216)



aggccttttccgcttctcttttacctccccaggtccgcccgtctgcgcccctcacaggaa



gccggagggtcgctctgatcccgaatctcccacaggcgtgaacctgctctgctgtgtatc


tttgcggggtggcctgcgctgaggcctgccgcgcgcggtgagtccgcgcagacctgaccc


tgcgtctcgcagctcggttgaggccgccgccgccttctcgggatg


 


Homo sapiens ubiquitin-conjugating enzyme E2D 3 (UBE2D3):


(Seq ID No: 1217)



cttcctttac



cttcctcccatggtctccttccggttctcgatgcttctctgagcctaagggtttccgcca


ctcgttcaccctccccccagctcatgatcctcctccctcccccgccctcctggtccaatc


tccgatctgtttagtaagaaggtgctgttccgagaagaaggaaaagggcttgacac


gtattcactcggccccggacgtgggaagcaa


gccgtctggcttcggcctcacatcggtcttgtgctcgggacggcggcgttggcg


gactgatccgcggcggtgaagagaggccgggaagttaaacttgtagccaccac


ctccgctcttcccgtcaccctcgcccccacttcgggccgaaagcacgg


tacagaggctgttggtggctttgccacgccaccccacccaccccg


gatcgcggctgtcttaagggacctggattcatcaggggctcttcggggcctgtgcgag


tgctgatctgctccgtttttgcaaaaggcgcctgtgtctggcagagctggtgtgagac


gagacaatcctgccccgccgccgggataatcaagagttttggccggacctttgagcata


caccgagagagtgaggagccagacgacaagcacacactatg


 


Homo sapiens zinc finger protein 595 (ZNF595):


(Seq ID No: 1218)



tttcctctggctcctgcgagggctt



ggtttagggcttcagctctctgcgttctcggctccgggaggcctcggtgat


tcagccacagcctctgcctcccgttgctctgtgacctgagggtattggacaattt


gtagctaagactcccggataccctgaagtcgggaaatg


 


Homo


sapiens acyl-CoA synthetase medium-chain family member 2B


(ACSM2B):


(Seq ID No: 1219)



tgctctcttccaaggctgtaggagttctggagctgctggctggagag



gagggtggacgaagctctctccagaaagacatcctgagaggacttggcagcctg


cagatggcctattgtgggaccttgtgatcatgcctgaacatg


 


Homo sapiens SRSF protein kinase 2 (SRPK2):


(Seq ID No: 1220)



tttccctttatagcaccattgaatcccagtcctaacagaagtactgcgaatctt



gtggcctcattctgaacaaaagggattagagaagaaaaatctcttgatataaggctt


gaaagcaagggcaggcaatcttggttgtgaatattttctgatttttccagaaatcaa


gcagaagattgagctgctgatg


 


Homo sapiens synaptophysin-like 1 (SYPL1):


(Seq ID No: 1221)



tgcccttcctcgccac



cgggctgctctggtctcgtcggtcccctcctccgccccgtcgtcctgactctctctccct


cctttcctcagaggatg


 


Homo sapiens thioredoxin reductase 1 (TXNRD1):


(Seq ID No: 1222)



aaccctttcac



ctcagttttcttcactccggcatttgcagcagagcgaaaggtggtcgag


tcctgaaggagggcctgatgtcttcatcattctcaaattcttgtaa


gctctgcgtcgggtgaaaccagacaaagccgcgagcccagggatgggagcacgcgggg


gacggcctgccggcggggacgacagcattgcgcctgggtgcagcagtgtgcgtctcggg


gaagggaagatattttaaggcgtgtctgagcagacggg


gaggcttttccaaacccaggcagcttcgtggcgtgtgcggtttcgacccggtcacacaaa


gcttcagcatgtcatgtggcttatcaggagggcagacttcaaaagctactaaaaatg


 


Homo sapiens minichromosome maintenance complex component 7


(MCM7):


(Seq ID No: 1223)



tgtccttccgcgcggcggccgcggagagagctgcggcccgggggggcgtgcctgggatcc



ggagcttcgctcgggcccgggaaaggcggcagtgggctgggatcgcggtgtctctgggtg


tgatggccaatggctggactggctcccgccctgggcggaggaatcccgagctgtgaagcg


gctggaatccgggcccatgtgcttctttgtttactaagagcggaagcgatggcgggagcg


ggggtggggtgcggtggcggggtgcggtggcggaggtcccggtgaaatcaggggctaagg


ggacccaaagaaggcgggggatcataggggtggaaagaaagctgagaaccttgagaccgg


agtgtgaggggccaacggggaagggcgctagaattttaaactaaagtagggaccggaatt


cccctggggagatgttggatggccctgtgcactgccacgggctctttattcttcgctggt


tagaaacagacttgtgaaaaagagttatgcccactttggggagacttcgaaaaggttaag


aagttcttacaagagttctaccaggatgatgaactcgggaagaagcagttcaagtatggg


aaccagttggttcggctggctcatcgggaacaggtggctctgtatgtggacctggacgac


gtagccgaggatgaccccgagttggtggactcaatttgtgagaatgccaggcgctacgcg


aagctctttgctgatgccgtacaagagctgctgcctcagtacaaggagagggaagtggta


aataaagatgtcctggacgtttacattgagcatcggctaatgatggagcagcggagtcgg


gaccctgggatggtccgaagcccccagaaccagtaccctgctgaactcatgcgcagattg


tgagtggtctctgtcgggaaagatgtagggattggttctccaggatcttgtttgtgactg


ttttctccccttagtgagctgtattttcaaggccctagcagcaacaagcctcgtgtgatc


cgggaagtgcgggctgactctgtggggaagttggtaactgtgcgtggaatcgtcactcgt


gtctctgaagtcaaacccaagatg


 


Homo sapiens pre-B-cell colony enhancing factor 1 (PBEF1):


(Seq ID No: 1224)



tttccccctctccccctcctccgccgaccgagcagtgacttaagcaac



ggagcgcggtgaagctcatttttctccttcctcg


cagccgcgccagggagctcgcggcgcgcggcccctgtcctccggcccgagatg


 


Homo


sapiens cyclin B1 interacting protein 1, E3 ubiquitin protein


ligase (CCNB1IP1):


(Seq ID No: 1225)



ctttctttccctctccgttttggtgggctggtt



gaagatgaaatccactgaggagggaagtccagcaccctgtgtgccag


tccagaactggcccatctgtagaccccctgaaaatcatatgggcttggatttgga


tattctcaacagaaagggttaaaggctgatggtacctaaagcctggtacttgaatttt


gatcaagataagctgccttaagttctcttcattacacaaatgatcctagataattgata


gatcctgtggttcaactggatttctagatagaagctggattcatgtgatgccagaggag


taaaatttcaagagactgaaaccagatctgagtttcgctgttccagtctggacctcttt


ggtgctgtaaatcctggatatactgtagatgag


tactgcgtttttcttttatggcctctcttcagcttctggagacctcactatcctattatg


 


Homo sapiens STEAP family member 3, metalloreductase


(STEAP3):


(Seq ID No: 1226)



ccgccttcgccgcggaccttcagctgccgcggtcgctccgagcggcgggccgcagagatg



acatttattcattttatgcatcctgggttctactggtcgtcccacctcagttcctgtagc


aaagagacttgagtctgagccactaattatcacccgtgaggtttcctccccgagcaggaa


gcagcaggccagagctgcgctctctcagtgcactctccaaccaagcatcagtcaccactc


ccggtccagcccctgtggccaagagctggcgtgcaggctgcgggaggcagctggctgtgc


aagaccctggcagggccctcgcctcctgagaaaccgagagtcagaaccaaagccaggctg


tcctggttggagactgagccagaaagggtggctcacctcacggtgaggctgtcgagtgac


ctgagagcctcagaccctcacgtcagccggatg


 


Homo sapiens nicotinamide nucleotide transhydrogenase (NNT):


(Seq ID No: 1227)



tgttcttccgggttggaggcgcagcgccgcggggcccaa



gcccgggtctgccagcgcgacgtcctctcgcggccctcaggg


cacagcccaaggctgtcagcctcccggcccagtgatttgccttcaaggaaactggggag


tcagaaaattgggaactcatatcaacatg


 


Homo sapiens SHC


(Src homology 2 domain containing) transforming protein 1


(SHC1):


(Seq ID No: 1228)



gtccctctccctccccag



gacttctgtgactcctgggccacagaggtccaaccaggctaagggcctgggga


taccccctgcctggcccccttgcccaaactggcaggggggccaggctgggcag


cagcccctctttcacctcaactatg


 


Homo sapiens bromodomain containing 8 (BRD8):


(Seq ID No: 1229)



cggcccttcca



gaccgtctctcctcagggttggagacttcggggccaagatg


 


Homo sapiens ring finger protein 13 (RNF13):


(Seq ID No: 1230)



tcgcctctttag



taggtcgggtgagtgtagtgtgcagggaagagac


gcgtcagcgccagggccaggcccgcccgggggcagcccggcagccgaatcttgggc


tactctgtcccaacagccggagcagatcagaccgac


cggccctgcccgctcggtcccgcgccctccagaccctacggtctccgtttctagggg


cacatggttagcggcaggcgcccacagccaatccacttt


gccagcctgccccttcctctgccaagagcagcttcttcagccgcgctccagttccg


cagacgcctgccccaccctgctcttcccttccagggaagacggatcacgcggccaa


gaacgagactcgcaaactgggcatttctccgagccgggctagagcaagtagcga


gactccgcgtgagagtgggaaagagccttaacaggcaaccatgttgcccag


tgggttttctgtgcctttgggtgcggaccaatgaggcgcgtggggcgg


gacttccgcttcgcctaggtgttgtcgtccctgctag


tactccgggctgtgggggtcggtgcggatattcagtcatgaaatcaggg


tagggacttctcccgcagcgacgcggctggcaagactgtttgtgttgcgggggccg


gacttcaagagagaaagagagagtgggcagacatcgaagccaaacagcagtatcccg


gaagcactcatgcaactttggtggcggccactcagttttctctgccagtgtctggtgat


tttacaacgagatg


 


Homo sapiens aldolase A, fructose-bisphosphate (ALDOA):


(Seq ID No: 1231)



ccgcctcctgcgccgccccttccgaggctaaatcggctgcgttcctctcggaac



gcgccgcagaaggggtcctggtgacgagtcccgcgttctctccttgaatccac


tcgccagcccgccgccctctgccgccgcaccctgcacacccgcccctctcctgtgccag


gaacttgctactaccagcaccatg


 


Homo sapiens LY6/PLAUR domain containing 6 (LYPD6):


(Seq ID No: 1232)



cgctccttccctgagctcccgggctccggcagcgcgctggcggggcgccgcatt



gcacactctgggggcgccgcagtgttcgtgggatggggcagcgggctg


cagctggcggccggaatccgcgcgcagcccgggtgcaagttctctcctgttgccctgag


tgcccactcccaggccctctgtatgagtgacacttcagtctgccatg


 


Homo sapiens butyrophilin, subfamily 3, member A1 (BTN3A1):


(Seq ID No: 1233)



cagtctctgctttctttttcctttcttccagaaggagatttaaccatagtagaaa



gaatggagaactattaactgcctttcttctgtgggctgtgattttcagaggg


gaatgctaagaggtgattttcaatgttgggactcaaaggtgaagacac


tgaaggacagaatttttggcagaggaaagatcttcttcggtcaccatacttgag


ttagctctagggaagtggaggtttccatttggaattc


tatagcttcttccaggtcatagtgtctgccccccaccttccagtatctcctga


tatgcagcatgaatg


 


Homo sapiens lipoic acid synthetase (LIAS):


(Seq ID No: 1234)



ctgtcctttcccgg



gagttagcgatccctcaacccctgcactgcgctagtcctaaagaggaaatg


 


Homo sapiens C-type lectin domain family 7, member A


(CLEC7A):


(Seq ID No: 1235)



gattctcttttgtccacagacagtcatctcaggagcagaaagaaaa



gagctcccaaatgctatatctattcaggggctctcaagaacaatg


 


Homo sapiens CD247 molecule (CD247):


(Seq ID No: 1236)



actccttttctcctaac



cgtcccggccac


cgctgcctcagcctctgcctcccagcctctttctgagggaaaggacaagatg


 


Homo sapiens myeloid zinc finger 1 (MZF1):


(Seq ID No: 1237)



aa



gcctttctccattttgcggtctaggaagtagcagaggccccttcctgtagggagtt


gccatggagacgcggtggggcaccgacggagttctaatgacggccgtgattggtgcag


gatcctgctaatctcaggaaggcccgtagagaagtgaggaaaacgtggtgggggg


catgcgcgatctggtaggcggtgctgccgtctgttgtacctgagaggcttgcg


catgccgacgcacggattcgaggcggggagcatgggaagaagcggccaggagtatgac


ctgatcattgcgaccaccgctaggggaagggaggagagggtgtagaaacggggac


gagggtgggggaagggcaaggaggcgctcgagctggtgcgcggagcatcctgggagac


gtagtccagcgggagggggaagtcgaagactgcgcgtgctcaggagcgcg


gagcggcccgctgagcgcagaggggcagacactggcctcagatacctgacctgg


taccctctatg


 


Homo sapiens E2F transcription factor 6 (E2F6):


(Seq ID No: 1238)



cctcctctttttccgtctgcgtcgggagctcccgggcac



gtgaggccgtgccgcgtttactggcgggcgggacggcctagccgggcggcgcctcggag


gaagccgcggaccccttaggtgctgggccctt


ggaaatcggcgcgtggggggcggtgctcgagctgagcgcgagagggcggga


gagctcgtggggtgcgaggggagcaggacgcccggccgggcagcatg


 


Homo sapiens purinergic receptor P2Y, G-protein coupled, 10


(P2RY10):


(Seq ID No: 1239)



cttcctctttcaacaacaaatgtgtcagttatcagcaggatccatgccgccagagtaaag



ctttctaccctttactccctgcaaagaaacaagagtgcttatcccagctaagctccaggg


taatgttatcatgacagcttcaacttttagaccacaggcaaatgctttgttaaaactcta


tgctggtcattcccttcaggatttggcactcaccaacatacccttctttcaagtgaaaag


gcatctcttttaatggtcctgacctttggaataggaagcatgtaccctggacagagcact


tcaaactagaggaaccataaatccatg


 


Homo sapiens chromosome 9 open reading frame 85 (C9orf85):


(Seq ID No: 1240)



catccttttgcctgctcccggcgaggggtggctttgatttcggcgatg



 


Homo sapiens ERGIC and golgi 3 (ERGIC3):


(Seq ID No: 1241)



cgtcccctttccggccggtccccatg



 


Homo sapiens ankyrin repeat domain 46 (ANKRD46):


(Seq ID No: 1242)



ccctcccctccgcccgtcaccgcctccttgaa



gctgccgctgtcgctgctgctcgttcgagtcgcagatccttgccagcacattacagaa


tatttttgttgaaccttcttgagaattcagagaaactgctgagtgaccactgaac


gaaaagatctaatcttaaggcttacgcctcactttgatgcccaggctggag


tgctgtggctcaatcacagctcatcgcaacctcgac


ctcccgggctcaagtgatcctctcacctcagcgtcccgaacaggcgtgttccatccac


cacatcagaacaatg


 


Homo sapiens Ras and Rab interactor-like (RINL):


(Seq ID No: 1243)



tcctctctccacttcctgctactgcaggcctctcctccga



gaacagaggccaggtcatgactcactggcttcctgcaacctgac


gatggcccagccagaagacaaggcac


ctgaagtccccacagagggggtgaggtgaacaaagcagacag


gacccctctaggggtcctcagcaccctagagccacttactcgcctgcagag


gacatggggggtgtggcatgtgccagagctggatacccaggatgcggaggccctt


gtggggctgtggccactagggagtttcttggtcacaggac


gtgaccccagccaggccctggtgttgaggtcaggacctttaccaggagaagtcaatac


ctaccagatccagaagattcccagaggtgtgtccctggaatcctccaacctctgcatg


 


Homo sapiens embigin (EMB):


(Seq ID No: 1244)



ccgccttttcttcagcgtcctacccgcgg



cactggctgcgagcgccgggccacctgcgagtgtgcgcagggactctg


gacacccgcggcggcgagctgagggagcagtctccacgaggacccaggcg


gaccctctggcgccatg


 


Homo sapiens MMS22-like, DNA repair protein (MMS22L):


(Seq ID No: 1245)



ccgcctttccggagcgcgggcgcgcggtggcgggaatttcgcctgtttgcggttta



gaccccaaagattcctgttggtggtctgggtcacaggaggcaggtttcgggagctg


gaaatgtgagcgggtacgacaggcaccgcgggtaaccgacgccccgggtccttgctg


cagccgggtacgcgggataccggcaccccgccttctccgcccgag


tgctgccaggcgtgggcctggaatctcttcacaccttctctttggagcccttaatga


tacgacgaaccccaagtgtttcagaacatgaagtaaacaatg


 


Homo sapiens chromosome 19 open reading frame 54 (C19orf54):


(Seq ID No: 1246)



actcctttcctttttccagtggttatcgcggcgcccaccggcctctgatctctgagtctt



ctccaacccacagacgttttttgttgctctggttccaggaccttctccacaactaggcca


ttttccctgccaggtgtcctttttgacctcttgacctctgactcaaagggcctgctcccc


ctcatgtcttcggcctggagaagagccagctcctgaaggaggcctttgataaggccggcc


cggtccccaagggcagagaagatgtgaagaggcttctgaaactacacaaggaccggttcc


gaggtgacctgcggtggatcctcttctgtgcagacctgccgtccctcatccaagaaggcc


ctcaatg


 


Homo sapiens zinc finger protein 621 (ZNF621):


(Seq ID No: 1247)



cgcccttccggctcggcctttagttagtgaccagctcctcggcgttctg



cagagcgtgggtttcagcgagttctac


gtgccaggtccgcccggtgccggcttcctcgctgcccctggcggctcgtcagcccccac


tacccctgaacttggtcccaatggcggcccgcccctccttcacccggaccgtggg


catctgggcctcgccgaagccgtcaaggtggctgctcgggcttcta


gagcccgtgtccagccctttgccaccgaggcctgatcctcttttctgccctaaa


gaacttgccctgacagcctctggctcccgctcttgaggatcttgctt


gtccaaacccagaagacagtgcatgaagccaggggacatccgccatg


 


Homo sapiens family with sequence similarity 73, member A


(FAM73A):


(Seq ID No: 1248)



ccgccttctccatg



 


Homo sapiens RNA binding motif protein 43 (RBM43):


(Seq ID No: 1249)



ccgcccttttcttcgtagcctccaagggagctggaacaaaaaacgaaaccaaaac



ctgcctgctcgctcctctccccatcgcctgcgttccgctggtt


gtgggctttctgcggccgctgagggcgcgtctcccctccgccatg


 


Homo sapiens spermatogenesis and centriole associated 1


(SPATC1):


(Seq ID No: 1250)



caccctccttcagcccaggcaaggcctggggccctggg



cagcctccaggtgcagtgccctcccgtgggccgcacccttgccactgccccagggcatg


 


Homo sapiens carbonic anhydrase XIII (CA13):


(Seq ID No: 1251)



ctttctcttccttccaccccgagggaccatg



 


Homo sapiens transglutaminase 2


(C polypeptide, protein-glutamine-gamma-glutamyltransferase)


(TGM2):


(Seq ID No: 1252)



cgctctccgcctcggcagtgccagccgccagtggtcgcactt



ggagggtctcgccgccagtggaaggagccaccgcccccgcccgaccatg


 


Homo sapiens NOP2/Sun domain family, member 4 (NSUN4):


(Seq ID No: 1253)



atttcctttcccttttttcgctcgtgtcccgccgggtggcgctcaccacctccccg



gaacacgcgagtctcctgtcgcggttccggtcggaattaccccgtggagcacgccga


tatg


 


Homo sapiens mitochondrial ribosome recycling factor (MRRF):


(Seq ID No: 1254)



gagtctttccttagtaacctgggcgatagctgtggatgtttccaaggattgtcttcagt



catg


 


Homo sapiens PHD finger protein 17 (PHF17):


(Seq ID No: 1255)



cttcctccataacaagccaaacgccagaccgagagtgcctccgtgcgcgagtgcccggtg



tgtgcgcgccggcgagagcaggggcccgcccggctccccgcccgccgcggcccgaactca


tgcagctccgagcgagcgagcggcgcccagcccagcgcctcggccgaacccctccgcagc


aggctgcctgctgtttcccggggagatcatg


 


Homo sapiens prolylcarboxypeptidase (angiotensinase C)


(PRCP):


(Seq ID No: 1256)



cctccttttcgccctcccacccgcactgcagtctccagcctgagccatg



 


Homo sapiens proteolipid protein 1 (PLP1):


(Seq ID No: 1257)



aagcccttttcatt



gcaggagaagaggacaaagatactcagagagaaaaagtaaaagaccgaa


gaaggaggctggagagaccaggatccttccagctgaacaaagtcagccacaaa


gcagactagccagccggctacaattggagtcagagtcccaaagacatg


 


Homo sapiens coiled-coil domain containing 80 (CCDC80):


(Seq ID No: 1258)



cagccttctcactcctcactgagtccactctgaacgtgctaaaatgg



gaaggaggcggtgttttgctgatctgttaaattcttagtgaagtttccttgatttccag


tggctgctgttgtttgagtttggtttggagcaaaactgaggtagtcctaacatttctgg


gactgaatccaggcaagagaaagaagaaaaagaagaagaaaaagaggag


gaaaaaggtagggagaaataaagggaggagagaagcacagtgaaa


gaaaaaaaaagtcccttttcgacatcacattcctgtgttttccctcagcctg


gaaaacatattaatcccagtgcttttacgcccggaaacaaagagactaagccagac


tatgggggaaagggagataagaaggatcctggaactttaaagagggaaagagtgagat


tcagaaatcgccaggactggactttaagggacgtcctgtgtcagcacaagggactgg


cacacacagacacacgagaccgaggagaaactgcagacaaatggagatacaaagactta


gaaggacagctcctttcacctcatcctacttgtccagaaggtaaaaaga


cacagccagaaagaaaaggcatcggctcagctctcagatcaggacaggctgtg


gatctgtggcggtactctgaaagctggagctgcagcacacccctttt


gtattgctcaccctcggtaaagagagagagggctgggaggaaaagtagttcatctag


gaaactgtcctgggaaccaaacttctgatttcttttgcaaccctctgcattccatctc


tatgagccaccattggattacacaatg


 


Homo sapiens chromosome 20 open reading frame 44 (C20orf44):


(Seq ID No: 1259)



cgacctctttgcgcctgcgccccccttgccagtctttcgccggcaaaaggaggac



gtagaaaaggggacaccggaaactcactcttcacccggaaatggttattgaggaacatg


 


Homo sapiens tryptophanyl tRNA synthetase 2, mitochondrial


(WARS2):


(Seq ID No: 1260)



cgcccttctcaagatg



 


Homo sapiens myotubularin related protein 2 (MTMR2):


(Seq ID No: 1261)



ctttccctgtgctgcccctgccgcgcgatggagaagagctcgagctgcgagagtcttggc



tcccagccggcggcggctcggccgcccagcgtggactccttgtccagttaatgtgttaag


agccattgacatttgaagatcatcagaagtgaagataaaacatctcaaaaattataattg


cctccacttctcattcagagaattcagtgcatacaaaatcagcttctgttgtatcatcag


attccatttcaacttctgccgacaacttttctcctgatttgaggagggagtctcgctcta


tcccctaggctggagtgcattggcgccatctcggctcatttgcaacctctgtctcccggg


ttcaagcgattctcctgcctcagcttcccgaggagctgggattacaggtcctgagggagt


ctaacaagttagcagaaatg


 


Homo sapiens reticulon 3 (RTN3):


(Seq ID No: 1262)



cgccctctagctgcgctcggctgag



tcagtcagtctgtcggagtctgtcctcggagcaggcggagtaaagggactt


gagcgagccagttgccggattattctatttcccctccctctctcccgccccg


tatctcttttcacccttctcccaccctcgctcgcgtagccatg


 


Homo sapiens G protein-coupled receptor 56 (GPR56):


(Seq ID No: 1263)



gtccctccctctccgcactagctgtctgccctgccctgccgtaggagatgggctgg



gagcctcccacgctctccagctcactcggcaggcagcggggaccagggctgg


caggttaagcctctgggggtggatcctgaaaggtggtccagccgcctggccctgcgtgg


gaccctccacctggcagcagacagggtctcgctctgtcacacaggctggagtgcag


tggtgtgatcttggctcatcgtaacctccacctcccgggttcaagtgat


tctcatgcctcagcctcccgagtagctgggattacaggtggtgacttccaagag


tgactccgtcggaggaaaatg


 


Homo


sapiens immunoglobulin superfamily containing leucine-rich


repeat (ISLR):


(Seq ID No: 1264)



gctcctccctgccgcctcctctcagtg



gatggttccaggcaccctgtctggggcagggagggcacaggcctg


cacatcgaaggtggggtgggaccaggctgcccctcgccccagcatccaagtcctccctt


gggcgcccgtggccctgcagactctcagggctaaggtcctctgttgcttttt


ggttccaccttagaagaggctccgcttgactaagagtagcttgaaggaggcaccatg


 


Homo sapiens glycoprotein M6A (GPM6A):


(Seq ID No: 1265)



atttcttttccccattttaaatgcaaagcaagactt



gtgaatcatagtgtctctgctcctgggattcagac


caaatttccccccaaaattctcaggctatttgtttgaatacctgcttacagtgg


tacacaatgggcagctttgagaagaaaaattgataatcttcacggaagagtaattt


gaatgaaattacacttgacagcctgtctccaagcaaacaagaggaac


gagggagcctgagctaagctctgaggacttgcccaagccactgctgtt


ggagcttcccaggaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaacaccag


tttttccaacatctaattgagcttttgattaattccgtgtaccagattctactgaa


gaaaggtagccatg


 


Homo sapiens splicing factor 1 (SF1):


(Seq ID No: 1266)



ctccctcttt



gtgcgtctcgcgccgccgccgcccgccgcgtgagaggacgggctccgcgcgctccgg


cagcgcattcgggtcccctccccccgggaggcttgcgaaggagaagccgccgcagag


gaaaagcaggtgccggtgcctgtccccgggggcgccatg


 


Homo sapiens cell cycle associated protein 1 (CAPRIN1):


(Seq ID No: 1267)



ccgcccctcgcgacccagagggctgctggctggctaagtccctcccgctcccggctctcg



cctcactaggagcggctctcggtgcagcgggacagggcgaagcggcctgcgcccac


ggagcgcgcgacactgcccggaagggaccgccacccttgccccctcagctgcccac


tcgtgatttccagcggcctccgcgcgcgcacgatg


 


Homo sapiens hypothetical protein FLJ90297 (LOC388152):


(Seq ID No: 1268)



ctgccctcttgcgtgccccggccacccccgggcggcttgtagccggtgcgcggggtggct



ggggctacgtgcagagctgtcgcggagccggaacagcagcggtgaagcccctcggctcgg


ccgagaccgccgtgcccattgctcgcctcggttgccgccgctttagccgcagccgctgct


gccgccgccgggggagaggcagcctattgtctttctccgcggcgaaggtgaggagctgtc


tcggctcggcccgcgggggagccccgggagccgcacggagatggaggaggacatctggac


agtgagcaggaggcgcctcggcccatg


 


Homo sapiens kelch-like ECH-associated protein 1 (KEAP1):


(Seq ID No: 1269)



cgccctctccccgcctccttttcgggcgtcccgaggccgctccccaaccgacaaccaa



gaccccgcaggccacgcagccctggagccgaggccccccgacggcg


gaggcgcccgcgggtcccctacagccaaggtccctgagtgccagaggtggtggtgtt


gcttatcttctggaaccccatg


 


Homo sapiens F-box protein 38 (FBXO38):


(Seq ID No: 1270)



ctccctctcaaccacaa



taacaggcggagggtcggcgtaggtactttgaactcaagtaaacaaaagggaagat


tttctcgttgatactggagactgcacaacaatg


 


Homo sapiens musculoskeletal, embryonic nuclear protein 1


(MUSTN1):


(Seq ID No: 1271)



agatcttttccagcagctgctgcctgccagagaggcgccttcaga



gacccagcgcttacacaatacccaccatg


 


Homo sapiens QKI, KH domain containing, RNA binding (QKI):


(Seq ID No: 1272)



cctcctctccggcggcggcggcggcggcggcgggcggagtgagctgcggagcctg



gaatatg


 


Homo


sapiens protein phosphatase 1, catalytic subunit, beta isoform


(PPP1CB):


(Seq ID No: 1273)



gggcctctctt



gtttatttatttattttccgtgggtgcctccgagtgtgcgcgcgctctcgc


tacccggcggggagggggtggggggagggcccgggaaaagggggagtt


ggagccggggtcgaaacgccgcgtgacttgtaggtgagagaacgccgagccgtcgccg


cagcctccgccgccgagaagcccttgttcccgctgctgggaaggagag


tctgtgccgacaagatg


 


Homo sapiens methyltransferase like 21B (METTL21B):


(Seq ID No: 1274)



cagcctc



taccccgctccggatccgggatctgagcgccggccgcggtgcccaggcactccctt


ggcgggccggatg


 


Homo sapiens adaptor-related protein complex 3, mu 1 subunit


(AP3M1):


(Seq ID No: 1275)



cggccttctcggcttctccagcttcggtaggagag



gatccggcgccgaatcactgactggcacaggtgttgggatagtgtctcactt


ggtcacccaggctggagtgcagtggcgcaatcttagctctc


tacagcgtcgatcttcctcctgggctcaagcaattctcctgcttcatcctcctgagtac


ctaggactacagaaaatg


 


Homo sapiens muscleblind-like splicing regulator 1 (MBNL1):


(Seq ID No: 1276)



cagtcttttcactgcagctgaatgagttgtggcgcccacaatgctcccatgacaaggagc



tgacaagttccattttccgtcgcgggcatcttggaatcatgactcccacaatgccttggg


cacttggtcgacagtggggccgcctctgaaaaaaaaatgtgagaggttggtactaagaag


tgcctttcctgacgtctctgctgcttggaaccgcttctagagcagtctctgcttttgcct


tgcttgctgccagctagactgtgacgacagcacatccaccctccacctctagcccagaca


cccccatttctacttataatcaagagaaaagctctaagtatctggcattgccctaggctg


ctttagtgttaaaagaaaagtttgctgaaaaagtaagatatcttctgccaggaaatcaag


gaggaaaaaaaaaatcattttctcgattttgctctaaactgctgcatctgtctatgccaa


actaatcaataccgattgcaccaccaaactccattgcaaattcagctgtgaggagattcc


ctttcagacaactttgctgaaagcagcttggaaattcggtgtcgaagggtctgccacgtt


ttcatgcttgcattttgggctccaaattggcactgggaaggggttactgagagcacaagg


ctgataccaggccctacttttaaacgttcatctacttacaatcctagtatttctctaaaa


accaaaacctctttgaattaacagtttcatgctgtgaatttctagtgggagatcttttcc


ttgatattgacgacacaattttccatgtacttttaaagcagggagtggggaaaagtattt


tgaggggacattttcatcatcagttcagctttttttttttggttgttgctcttttttggg


ggggttgggtttgttggtttcactgaaacatttaactacctgtaaaatctaaacatg


 


Homo


sapiens lipid phosphate phosphatase-related protein type


1 (LPPR1):


(Seq ID No: 1277)



cagccttttgctctttcctttcattaaacaaacaggagatcctgaaac



ctggaccctgtgcaagctgcagcgccaggaggaggcagcggaggaagcagagcgcgg


gatgggcgcccagcggcatctgtgatcccgcgcacctccgccccacgggcgcgcg


cacaaacacggacacacacatacacacactcgcgcacacactcgcacaaacacacac


tcgtacacgcccgcgccgctcgctcgccggcttgctctcccacgcaagcggaatgcag


cagcgcctggagagcgtgtctcggaccgccgcctgaatgtacctcgctcccgggagccg


gacggcccagtagggcgcactggaggacgctccgctgcgggagcctggacagttttt


gacggtgcagtcttgctatatggtgtgagaaatg


 


Homo sapiens muscleblind-like splicing regulator 2 (MBNL2):


(Seq ID No: 1278)



ctgtctttgcttcatcatctgaaggtaaaattttccagatacggcagac



ggctttcagagtacaataaacagggaatgagaac


tatttacatggaagtttctttctcatgatgcggtggagaagcctcggccactt


ggttctgccagatgttcctggggttactgtaaatgg


gaaggacaggcagagctaaacaaggtttatcatttaaaagtgcctgtgtgaagtcac


ttttgctggaaaactgcagcttgggagctttctttgtattcacatcccac


tcttctgtcaagtacactttaccctgaccttatgagtggatgaagatacctcagtt


gtctgactttgccaattgcttaatttcagaatttaaaaaggggaaa


gaaaaacatcctgctaaaatatgaacatctgagtgtcttattttccaacatcgtcaa


tagctgtgagcgtcagcattaaatattctcccaaggagtgccatgatattgaagtcac


tttattaataacagctgtatctgcaaaacagtcaagagactcggacgttgaaagccaga


gatgacactgagcatgcttttattgcggcctaccatctttaagtgg


gacatattgattgatgagtgattgcctgtccatacactctctcatcatcctgttcctt


ggattggacttcactaagcaatttatcactcaccttcagacttacatgtgggag


ttttcacaacagtagttttggaatcattagaacttggattgat


ttcatcatttaacagaaacaaacagcccaaattactttatcaccatg


 


Homo sapiens chromosome 3 open reading frame 25 (C3orf25):


(Seq ID No: 1279)



gcgcctttcgcacgacttggagttacggtttatctgataccgcggtacccctacgcaa



gcaagcccacatcgacacacattcacacacgcccttcagcaccccctcccagcaccac


gaccatg


 


Homo sapiens testis expressed 19 (TEX19):


(Seq ID No: 1280)



cctcctcctttccctgggtgcccacatgaacagagacaccaggatgctctcctgagacca



cagcaactgcagaagctgaagacatttccagaagttcaagcttccaccctctg


caggtccccactgagctgggacccaggtcatccaccccaccccaaatccctgga


taggaaacccctttctcctcctgctccttgtccccttcatccctgccgcccagcatcc


tactggcctcagcacctgtggccagaccgtccaagatcctctgaaggcccagctcttgct


gtccaccccggcagtaggcaggcagcctggccatg


 


Homo sapiens protein kinase C, beta (PRKCB):


(Seq ID No: 1281)



gcctccctcccccg



cagctggggccagcggtgccaagcgcagctggacgagcggcagcagctgggcgag


tgacagccccggctccgcgcgccgcggccgccagagccggcgcaggggaa


gcgcccgcggccccgggtgcagcagcggccgccgcctcccgcgcctccccggcccg


cagcccgcggtcccgcggccccggggccggcacctctcgggctccggctccccgcgcg


caagatg


 


Homo sapiens protein kinase N1 (PKN1):


(Seq ID No: 1282)



ccctccctccgcgcggg



gacccctggcgggcggcaggaggacatg


 


Homo sapiens hemochromatosis type 2 (juvenile) (HFE2):


(Seq ID No: 1283)



ccttctctggttccctgacctcagtgagacagcagccggcctggggacctgggggaga



cacggaggaccccctggctggagctgacccacagagtagggaatcatggctggagaatt


ggatagcagagtaatgtttgacctctggaaacatcac


ttacagggcttccggtcaaaattcactaggtaggagggtcatcagctgggaagaac


cggcgcctgggaaacctggctggataggtatg


 


Homo sapiens ribosomal protein L9 (RPL9):


(Seq ID No: 1284)



cgttctttcttt



gctgcgtctactgcgagaatg


 


Homo sapiens ribosomal protein L3 (RPL3):


(Seq ID No: 1285)



cggcctcttcggcgg



gatttgatggcgtgatg


 


Homo sapiens ribosomal protein L4 (RPL4):


(Seq ID No: 1286)



acttccttttcctgtgg



cagcagccgggctgagaggagcgtggctgtctcctctctccgccatg


 


Homo sapiens ribosomal protein L5 (RPL5):


(Seq ID No: 1287)



tggcccttttcccaccccctagcgccgctgggcctgcaggtctctgtcgagcagcggac



gccggtctctgttccgcaggatg


 


Homo sapiens ribosomal protein L6 (RPL6):


(Seq ID No: 1288)



aattctctttcccatcttgcaagatg



 


Homo sapiens ribosomal protein L7 (RPL7):


(Seq ID No: 1289)



cttcctctttttccggctggaaccatg



 


Homo sapiens ribosomal protein L7a (RPL7A):


(Seq ID No: 1290)



ctttcctttctctctcctcccgccgcccaagatg



 


Homo sapiens ribosomal protein L11 (RPL11):


(Seq ID No: 1291)



ctttctcttcctgctctccatcatg



 


Homo sapiens ribosomal protein L12 (RPL12):


(Seq ID No: 1292)



cggcctctcggctttcggctcggaggaggccaaggtgcaacttccttcggtcgtcccgaa



tccgggttcatccgacaccagccgcctccaccatg


 


Homo sapiens ribosomal protein L13 (RPL13):


(Seq ID No: 1293)



gcttcctttccgctcggctgttttcctgcgcaggagccgcagggccgtaggcagccatg



 


Homo sapiens ribosomal protein L23 (RPL23):


(Seq ID No: 1294)



acttccttttttcttttttccggcgttcaagatg



 


Homo sapiens ribosomal protein L18 (RPL18):


(Seq ID No: 1295)



cgttctctctttccg



gacctggccgagcaggaggcgccatcatg


 


Homo sapiens ribosomal protein L18a (RPL18A):


(Seq ID No: 1296)



acttcctttt



gcgggtggcggcgaacgcggagagcacgccatg


 


Homo sapiens ribosomal protein L19 (RPL19):


(Seq ID No: 1297)



agctctttcctttcgctgctgcggccgcagccatg



 


Homo sapiens ribosomal protein L21 (RPL21):


(Seq ID No: 1298)



gcctctttcctttcggccggaaccgccatcttccagtaattcgccaaaatg



 


Homo sapiens ribosomal protein L22 (RPL22):


(Seq ID No: 1299)



ac



ctccctttctaactccgctgccgccatg


 


Homo sapiens ribosomal protein L23a (RPL23A):


(Seq ID No: 1300)



agacccttttca



caagatg


 


Homo sapiens ribosomal protein L17 (RPL17):


(Seq ID No: 1301)



cgctcttcctctttccctaagcagcctgagggttgactg



gattggtgaggcccgtgtggctacttctgtggaagcagtgctgtagttactggaaga


taaaagggaaagcaagcccttggtgggggaaagtatggctgcgatgatgg


catttcttaggacacctttggattaataatgaaaacaactactctctgag


cagctgttcgaatcatctgatatttatactgaatgagttactgtaagtac


gtattgacagaattacactgtactttcctctaggtgatctgtgaaaatg


 


Homo sapiens ribosomal protein L24 (RPL24):


(Seq ID No: 1302)



ttctctctttcttttcgccatcttttgtctttccgtggagctgtcgccatg



 


Homo sapiens ribosomal protein L26 (RPL26):


(Seq ID No: 1303)



agttctcttcccttttgcggccatcaccgaagcgggagcggccaaaatg



 


Homo sapiens ribosomal protein L27 (RPL27):


(Seq ID No: 1304)



ctttccttttt



gctggtagggccgggtggttgctgccgaaatg


 


Homo sapiens ribosomal protein L30 (RPL30):


(Seq ID No: 1305)



aagtctttcctttctcgttccccggccatcttagcggctgctgttggtt



gggggccgtcccgctcctaaggcaggaagatg


 


Homo sapiens ribosomal protein L27a (RPL27A):


(Seq ID No: 1306)



ccttcctttttcgtctgggctgccaacatg



 


Homo sapiens ribosomal protein L28 (RPL28):


(Seq ID No: 1307)



cttcctctttccgtctcaggtcgccgctgcgaagggagccgccgccatg



 


Homo sapiens ribosomal protein L29 (RPL29):


(Seq ID No: 1308)



cagcccctttctcttccggttctaggcgcttcgggagccgcggcttatggtgcagacatg



 


Homo sapiens ribosomal protein L31 (RPL31):


(Seq ID No: 1309)



cgctcttcctttccaacttggacgctgcagaatg



 


Homo sapiens ribosomal protein L32 (RPL32):


(Seq ID No: 1310)



ccgtcccttctctcttcctcggcgctgcctacggaggtggcagccatctccttctcgg



catcatg


 


Homo sapiens ribosomal protein L35a (RPL35A):


(Seq ID No: 1311)



cgtccttctcttaccgccatcttggctcctgtggaggcctgctgggaacgg



gacttctaaaaggaactatg


 


Homo sapiens ribosomal protein L37 (RPL37):


(Seq ID No: 1312)



ccttctcttccggtctttctggtctcggccgcagaagcgagatg



 


Homo sapiens ribosomal protein L37a (RPL37A):


(Seq ID No: 1313)



gcgtctcttcctttctgggctcggacctaggtcgcggcgacatg



 


Homo sapiens ribosomal protein L38 (RPL38):


(Seq ID No: 1314)



cgttctttttcgtccttttccccggttgctgcttgctgtgagtgtctctagggtgatac



gtgggtgagaaaggtcctggtccgcgccagagcccagcgcgcctcgtcgccatg


 


Homo sapiens ribosomal protein L39 (RPL39):


(Seq ID No: 1315)



ccctcctcttcctttctccgccatcgtggtgtgttcttgactccgctgctcgccatg



 


Homo sapiens ribosomal protein, large, P0 (RPLP0):


(Seq ID No: 1316)



ag



gcccttctctcgccaggcgtcctcgtggaagtgacatcgtctttaaaccctgcgtgg


caatccctgacgcaccgccgtgatg


 


Homo sapiens ribosomal protein, large, P1 (RPLP1):


(Seq ID No: 1317)



cggtccttccgaggaagctaaggctgcgttggggtgaggccctcac



ttcatccggcgactagcaccgcgtccggcagcgccagccctacactcgcccgcgccatg


 


Homo sapiens ribosomal protein, large, P2 (RPLP2):


(Seq ID No: 1318)



ccttccttttcctccctgtcgccaccgaggtcgcacgcgtgagacttctccgccgcctcc



gccgcagacgccgccgcgatg


 


Homo sapiens ribosomal protein S3 (RPS3):


(Seq ID No: 1319)



acttcctttcctttcagcggagcgcggcggcaagatg



 


Homo sapiens ribosomal protein S3A (RPS3A):


(Seq ID No: 1320)



ccgccctttt



ggctctctgaccagcaccatg


 


Homo sapiens ribosomal protein S4, X-linked (RPS4X):


(Seq ID No: 1321)



ggtcctctttccttgcctaacgcagccatg



 


Homo sapiens ribosomal protein S4, Y-linked 1 (RPS4Y1):


(Seq ID No: 1322)



gat



tctcttccgtcgcagagtttcgccatg


 


Homo sapiens ribosomal protein S5 (RPS5):


(Seq ID No: 1323)



ttttcttcccag



ttaaaagtgttggcccgcggcgcgcggcctcttcctgtctgtac


cagggcggcgcgtggtctacgccgagtgacagagacgctcaggctgtgttctcaggatg


 


Homo sapiens ribosomal protein S6 (RPS6):


(Seq ID No: 1324)



ggccctcttttccgtggcgcctcggaggcgttcagctgcttcaagatg



 


Homo sapiens ribosomal protein S7 (RPS7):


(Seq ID No: 1325)



gggtctcttcctaa



gccggcgctcggcaagttctcccaggagaaagccatg


 


Homo sapiens ribosomal protein S8 (RPS8):


(Seq ID No: 1326)



gtttctctttccagccagcgccgagcgatg



 


Homo sapiens ribosomal protein S9 (RPS9):


(Seq ID No: 1327)



gcgcctctttctcag



tgaccgggtggtttgcttaggcgcagacggggaagcggagccaacatg


 


Homo sapiens ribosomal protein S10 (RPS10):


(Seq ID No: 1328)



gctccttcctttccagccccggtaccggaccctgcagccgcagagatg



 


Homo sapiens ribosomal protein S11 (RPS11):


(Seq ID No: 1329)



ctgcccctttctttttttcaggcggccgggaagatg



 


Homo sapiens ribosomal protein S12 (RPS12):


(Seq ID No: 1330)



ag



gcctctttccctgccgccgccgagtcgcgcggaggcggaggcttgggtgcgttcaagat


tcaacttcacccgtaacccaccgccatg


 


Homo sapiens ribosomal protein S13 (RPS13):


(Seq ID No: 1331)



cgctctcctttcgtt



gcctgatcgccgccatcatg


 


Homo sapiens ribosomal protein S15 (RPS15):


(Seq ID No: 1332)



cgatctcttctgag



gatccggcaagatg


 


Homo sapiens ribosomal protein S15a (RPS15A):


(Seq ID No: 1333)



cgtcctctttccgccatctttccgcgccggtgagtagcactctctga



gagctccaatttcatccgtctgccatcggcgccatcctgcaatctaagccacaatg


 


Homo sapiens ribosomal protein S16 (RPS16):


(Seq ID No: 1334)



ctttccttttccggttgcggcgccgcgcggtgaggttgtctagtccacgctcggagc



catg


 


Homo sapiens ribosomal protein S19 (RPS19):


(Seq ID No: 1335)



cgttccctttcccctggctggcagcgcggaggccgcacgatg



 


Homo sapiens ribosomal protein S20 (RPS20):


(Seq ID No: 1336)



ccacccctttctttttgaggaagacgcggtcgtaagggctgaggatttttggtccgcac



gctcctgctcctgactcaccgctgttcgctctcgccgaggaacaagtcggtcaggaa


gcccgcgcgcaacagccatg


 


Homo sapiens ribosomal protein S21 (RPS21):


(Seq ID No: 1337)



gcttcctttctctctcgcgcgcggtgtggtggcagcaggcgcagcccagcctcgaaatg



 


Homo sapiens ribosomal protein S23 (RPS23):


(Seq ID No: 1338)



gcttctctctttcgctcaggcccgtggcgccgacaggatg



 


Homo sapiens ribosomal protein S25 (RPS25):


(Seq ID No: 1339)



gcttccttttt



gtccgacatcttgacgaggctgcggtgtctgctgctattctccgagcttcgcaatg


 


Homo sapiens ribosomal protein S26 (RPS26):


(Seq ID No: 1340)



ccgtctcctctctccggtccgtgcctccaagatg



 


Homo sapiens ribosomal protein S27 (RPS27):


(Seq ID No: 1341)



cgctcctttccggcggtgacgacctacgcacacgagaacatg



 


Homo sapiens ribosomal protein S28 (RPS28):


(Seq ID No: 1342)



actcctctccgcca



gaccgccgccgcgccgccatcatg


 


Homo sapiens ribosomal protein S29 (RPS29):


(Seq ID No: 1343)



gcttcttccttttac



ctcgttgcactgctgagagcaagatg


 


Homo sapiens ribosomal protein L15 (RPL15):


(Seq ID No: 1344)



agctctttcctttccgtctggcggcagccatcaggtaagccaagatg



 


Homo sapiens ribosomal protein S2 (RPS2):


(Seq ID No: 1345)



cgttcttcttttccgacaaaacaccaaatg



 


Homo sapiens ribosomal protein L14 (RPL14):


(Seq ID No: 1346)



gggtcttcttccttctcgcctaacgccgccaacatg



 


Homo sapiens ribosomal protein S14 (RPS14):


(Seq ID No: 1347)



ctctctttccggtgtggagtctggagacgacgtgcagaaatg



 


Homo sapiens ribosomal protein L10 (RPL10):


(Seq ID No: 1348)



gcgcctctttcccttcggtgtgccactgaagatcctggtgtcgccatg



 


Homo sapiens ribosomal protein L10a (RPL10A):


(Seq ID No: 1349)



tag



tctcttttccggttagcgcggcgtgagaagccatg


 


Homo sapiens ribosomal protein L35 (RPL35):


(Seq ID No: 1350)



tcctctttccctcg



gagcgggcggcggcgttggcggcttgtgcagcaatg


 


Homo sapiens ribosomal protein L13a (RPL13A):


(Seq ID No: 1351)



cctcctccttttccaagcggctgccgaagatg



 


Homo sapiens ribosomal protein L36 (RPL36):


(Seq ID No: 1352)



cagcccttccgccac



ggccgtctctggagagcagcagccatg


 


Homo sapiens ribosomal protein L36a (RPL36A):


(Seq ID No: 1353)



gtttctttctttccgcgccgatagcgctcacgcaagcatg



 


Homo sapiens ribosomal protein L41 (RPL41):


(Seq ID No: 1354)



tcgcc tttctctcggccttagcgccatttttttggaaacctctgcgccatg



 


Homo sapiens ribosomal protein S18 (RPS18):


(Seq ID No: 1355)



cgctctctcttcca



caggaggcctacacgccgccgcttgtgctgcagccatg


 


Homo sapiens ribosomal protein S24 (RPS24):


(Seq ID No: 1356)



ggttctcttttcctccttggctgtctgaagatagatcgccatcatg



 


Homo sapiens ribosomal protein L8 (RPL8):


(Seq ID No: 1357)



tttcctctttcggccgcgctggtgaacaggtaggtcatccttgcggccttgcggcatg



 


Homo sapiens ribosomal protein L34 (RPL34):


(Seq ID No: 1358)



cttcctcttccggg



gacgttgtctgcaggtatg


 


Homo sapiens ribosomal protein S17 (RPS17):


(Seq ID No: 1359)



gtttcctcttttac



caaggacccgccaacatg


 


Homo sapiens ribosomal protein SA (RPSA):


(Seq ID No: 1360)



ctgtcttttccgtgc



tacctgcagaggggtccatacggcgttgttctggattcccgtcg


taacttaaagggaaattttcacaatg


 


Homo


sapiens eukaryotic translation initiation factor 3, subunit


C (EIF3C):


(Seq ID No: 1361)



cttctctctcggcgtttccgctgtcagggccctgcggtgtgactcgcgggctcagctggt



ccggccgtagcacctccgcgccgtcgccatg


 


Homo sapiens poly(A) binding protein, cytoplasmic 1


(PABPC1):


(Seq ID No: 1362)



cgctctcctcctctcacggaaaggtcgcggcctgtggccctgcgggcag



ccgtgccgagatg


 


Homo sapiens tubulin, beta 1 class VI (TUBB1):


(Seq ID No: 1363)



cac



tcccttccaaaagcatgacaggcagaaagcagagaagggccag


gactggctgagggcggggagctgggcctctggggtggacacacccttggtcacatt


gtgagggtagcttggttggccagtcccaccactgcagtgaccacagttgtgtt


gggctcacaccagtgaaccgaagctctggattctgagagtctgaggattccgtgaa


gatctcagacttgggctcagagcaaggatg


 


PpLuc(GC)-ag-A64


(SEQ ID No: 1364)



GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTA



CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT


GGTGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGA


GTACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAA


CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGC


CCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCT


GAACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAA


GATCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAA


GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGG


CTTCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGAT


CATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGC


CTGCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACAC


CGCCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTA


CCTCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCG


GAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTT


CGCCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGG


GGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGG


CATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGG


GGACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGA


CCTGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCC


GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA


CGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGT


CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGA


GAGCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGA


CGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGA


GAAGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGG


CGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGAT


CCGCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATA


AGACTGACTAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTA


ATAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAA


 


RPL32-PpLuc(GC)-ag-A64-C30-histoneSL


(SEQ ID No: 1365)



GGGGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATCAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCC


TCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAATAGATCTAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCC


CCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


fragment of the 5′UTR of human ribosomal protein Large 32


(SEQ ID No: 1366)



ACGGAGGTGGCAGCCATCTCCTTCTCGGCATC



 


fragment of the 5′UTR of human ribosomal protein Large 32


(SEQ ID No: 1367)



GGCGCTGCCTACGGAGGTGGCAGCCATCTCCT



 


5′UTR of human ribosomal protein Large 32 lacking the 5′


terminal oligopyrimidine tract


(SEQ ID No. 1368)



GGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATC



 


Human albumin 3′UTR


(SEQ ID No: 1369)



CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA



TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC


CAACACCCTG TCTAAAAAAC ATAAATTTCT TTAATCATTT TGCCTCTTTT


CTCTGTGCTT CAATTAATAA AAAATGGAAA GAATCT


 


3′UTR of Homo sapiens hemoglobin, alpha 1 (HBA1)


(SEQ ID No: 1370)



gctggagcctcggtggccatgcttcttgcccctt



gggcctccccccagcccctcctccccttcctgcacccgtacccccgtggtctttgaa


taaagtctgagtgggcggc


 


3′UTR of Homo sapiens hemoglobin, alpha 2 (HBA2)


(SEQ ID No: 1371)



gctggagcctcggtagccgttcctcctgcccgctgggcctcccaac



gggccctcctcccctccttgcaccggcccttcctggtctttgaataaagtctgagtgggcag


 


3′UTR of Homo sapiens hemoglobin, beta (HBB)


(SEQ ID No: 1372)



Gctcgctttcttgctgtccaatttctattaaaggttcctttgttccctaagtccaactacta



aactgggggatattatgaagggccttgagcatctggattctgcctaa


taaaaaacatttattttcattgc


 


3′UTR of Homo sapiens tyrosine hydroxylase (TH)


(SEQ ID No: 1373)



gtgcacggcgtccctgagggcccttcccaacctcccctggtcctgcactgtcccg



gagctcaggccctggtgaggggctgggtcccgggtgccccccatgccctccctgctgcca


ggctcccactgcccctgcacctgcttctcagcg


caacagctgtgtgtgcccgtggtgaggtt


gtgctgcctgtggtgaggtcctgtcctggctcccagggtcctgggggctgctgcac


tgccctccgcccttccctgacactgtctgctgccccaatcaccgtcacaataaaa


gaaactgtggtctcta


 


3′UTR of Homo sapiens arachidonate 15-lipoxygenase (ALOX15)


(SEQ ID No: 1374)



gcgtcgccaccctttggttatttcagcccccatcacccaagccacaagctgaccccttcg



tggttatagccctgccctcccaagtcccaccctcttcccatgtcccaccctccctagagg


ggcaccttttcatggtctctgcacccagtgaacacattttactctagaggcatcacctgg


gaccttactcctctttccttccttcctcctttcctatcttccttcctctctctcttcctc


tttcttcattcagatctatatggcaaatagccacaattatataaatcatttcaagactag


aatagggggatataatacatattactccacaccttttatgaatcaaatatgatttttttg


ttgttgttaagacagagtctcactttgacacccaggctggagtgcagtggtgccatcacc


acggctcactgcagcctcagcgtcctgggctcaaatgatcctcccacctcagcctcctga


gtagctgggactacaggctcatgccatcatgcccagctaatatttttttattttcgtgga


gacggggcctcactatgttgcctaggctggaaataggattttgaacccaaattgagttta


acaataataaaaagttgttttacgctaaagatggaaaagaactaggactgaactatttta


aataaaatattggc


 


3′UTR of Homo sapiens collagen, type I, alpha 1 (COL1A1)


(SEQ ID No: 1375)



actccctccatcccaacctggctccctcccacccaaccaactttccccccaacccg



gaaacagacaagcaacccaaactgaaccccctcaaaagccaaaaaatgggaga


caatttcacatggactttggaaaatatttttttcctttgcattcatctctcaaacttag


tttttatctttgaccaaccgaacatgaccaaaaaccaaaagtgcattcaaccttac


caaaaaaaaaaaaaaaaaaagaataaataaataactttttaaaaaaggaagctt


ggtccacttgcttgaagacccatgcgggggtaagtccctttctgcccgtt


gggcttatgaaaccccaatgctgccctttctgctcctttctccacacccccctt


ggggcctcccctccactccttcccaaatctgtctccccagaagacacag


gaaacaatgtattgtctgcccag


caatcaaaggcaatgctcaaacacccaagtggcccccaccctcagcccgctcctgcccgc


ccagcacccccaggccctgggggacctggggttctcagactgccaaagaagcctt


gccatctggcgctcccatggctcttgcaacatctccccttcgttttt


gagggggtcatgccgggggagccaccagcccctcactgggttcggaggagagtcag


gaagggccacgacaaagcagaaacatcggatttggggaacgcgtgtcaatccctt


gtgccgcagggctgggcgggagagactgttctgttccttgtgtaactgtgttgctgaaa


gactacctcgttcttgtcttgatgtgtcaccggggcaactgcctgggggcggg


gatgggggcagggtggaagcggctccccattttataccaaaggtgc


tacatctatgtgatgggtggggtggggagggaatcactggtgctatagaaattga


gatgcccocccaggccagcaaatgttcctttttgttcaaagtctatttttattccttga


tatttttctttttttttttttttttttgtggatggggactt


gtgaatttttctaaaggtgctatttaacatgggagga


gagcgtgtgcggctccagcccagcccgctgctcactttccaccctctctccac


ctgcctctggcttctcaggcctctgctctccgac


ctctctcctctgaaaccctcctccacagctgcagcccatcctcccggctccctcctag


tctgtcctgcgtcctctgtccccgggtttcagagacaacttcccaaagcacaaagcag


tttttccccctaggggtgggaggaagcaaaagactctgtacctattttgtatgtg


tataataatttgagatgtttttaattattttgattgctggaataaagcatgtg


gaaatgacccaaacataa


 


albumin7 3'UTR


(SEQ ID No: 1376)



CATCACATTTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAA



GATCAATAGCTTATTCATCTCTTTTTCTTTTTCGTTGGTGTAAA


GCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTT


GCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCT


 


Human albumin 3'UTR + poly(A) sequence


(SEQ ID No: 1377)



CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAA



GATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC


CAACACCCTG TCTAAAAAAC ATAAATTTCT TTAATCATTT TGCCTCTTTT


CTCTGTGCTT CAATTAATAA AAAATGGAAA GAATCTAGAT CTAAAAAAAA


AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA


AAAAAA


 


Human albumin 3'UTR fragment 1


(SEQ ID No: 1378)



AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AA



GCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG


TCTAAAAAAC ATAAATTTCT TTAATCATTT TGCCTCTTTT CTCTGTGCTT CAATT


 


Human albumin 3'UTR fragment 2


(SEQ ID No: 1379)



CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA



TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC


CAACACCCTG


 


Human albumin 3'UTR fragment 3


(SEQ ID No: 1380)



AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA



AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG


TCTAAAAAAC


 


Human albumin 3'UTR fragment 4


(SEQ ID No: 1381)



CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC



ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC


ATAAATTTCT


 


Human albumin 3'UTR fragment 5


(SEQ ID No: 1382)



TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTTT



CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTTCT


TTAATCATTT


 


Human albumin 3'UTR fragment 6


(SEQ ID No: 1383)



AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT



GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTTCT TTAATCATTT


TGCCTCTTTT


 


Human albumin 3'UTR fragment 7


(SEQ ID No: 1384)



TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC



CAACACCCTG TCTAAAAAAC ATAAATTTCT TTAATCATTT TGCCTCTTTT


CTCTGTGCTT


 


Human albumin 3'UTR fragment 8


(SEQ ID No: 1385)



AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG



TCTAAAAAAC ATAAATTTCT TTAATCATTT TGCCTCTTTT CTCTGTGCTT


CAATTAATAA


 


Human albumin 3'UTR fragment 9


(SEQ ID No: 1386)



ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC



ATAAATTTCT TTAATCATTT TGCCTCTTTT CTCTGTGCTT CAATTAATAA


AAAATGGAAA


 


Human albumin 3'UTR fragment 10


(SEQ ID No: 1387)



CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC



ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC


ATAAATTTCT TTAATCATTT TGCCTCTTTT CTCTGTGCTT CAATTAATAA A


 


Human albumin 3'UTR fragment 11


(SEQ ID No: 1388)



TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC



CAACACCCTG TCTAAAAAAC ATAAATTTCT TTAATCATTT TGCCTCTTTT


CTCTGTGCTT CAATTAATAA A


 


Human albumin 3'UTR fragment 12


(SEQ ID No: 1389)



CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTTCT



TTAATCATTT TGCCTCTTTT CTCTGTGCTT CAATTAATAA A


 


Human albumin 3'UTR fragment 13


(SEQ ID No: 1390)



AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG



TCTAAAAAAC


 


Sequence according to formula (Ic)


(SEQ ID NO: 1391)



NGNNNNNNUNNNNNCN



 


Sequence according to formula (IIc):


(SEQ ID NO: 1392)



N*N*NNNNGNNNNNNUNNNNNCNNNN*N*N*



 


Sequence according to formula (Id):


(SEQ ID NO: 1393)



NCNNNNNNUNNNNNGN



 


Sequence according to formula (IId)


(SEQ ID NO: 1394)



N*N*NNNNCNNNNNNUNNNNNGNNNN*N*N*



 


Sequence according to formula (Ie)


(SEQ ID NO: 1395)



DGNNNNNNUNNNNNCH



 


Sequence according to formula (IIe)


(SEQ ID NO: 1396)



N*N*NNNDGNNNNNNUNNNNNCHNNN*N*N*



 


Sequence according to formula (If)


(SEQ ID NO: 1397)



NGNBYYNNUNVNDNCN



 


Sequence according to formula (IIf)


(SEQ ID NO: 1398)



N*N*NNNNGNBYYNNUNVNDNCNNNN*N*N*



 


Sequence according to formula (Ig)


(SEQ ID NO: 1399)



NGHYYYDNUHABRDCN



 


Sequence according to formula (IIg)


(SEQ ID NO: 1400)



N*N*HNNNGHYYYDNUHABRDCNNNN*N*H*



 


Sequence according to formula (Ih)


(SEQ ID NO: 1401)



DGHYCUDYUHASRRCC



 


Sequence according to formula (IIh)


(SEQ ID NO: 1402)



N*H*AAHDGHYCUDYUHASRRCCVHB*N*H*



 


Sequence according to formula (Ic)


(SEQ ID NO: 1403)



VGYYYYHHTHRVVRCB



 


Sequence according to formula (Ic)


(SEQ ID NO: 1404)



SGYYYTTYTMARRRCS



 


Sequence according to formula (Ic)


(SEQ ID NO: 1405)



SGYYCTTTTMAGRRCS



 


Sequence according to formula (Ie)


(SEQ ID NO: 1406)



DGNNNBNNTHVNNNCH



 


Sequence according to formula (Ie)


(SEQ ID NO: 1407)



RGNNNYHBTHRDNNCY



 


Sequence according to formula (Ie)


(SEQ ID NO: 1408)



RGNDBYHYTHRDHNCY



 


Sequence according to formula (If)


(SEQ ID NO: 1409)



VGYYYTYHTHRVRRCB



 


Sequence according to formula (If)


(SEQ ID NO: 1410)



SGYYCTTYTMAGRRCS



 


Sequence according to formula (If)


(SEQ ID NO: 1411)



SGYYCTTTTMAGRRCS



 


Sequence according to formula (Ig)


(SEQ ID NO: 1412)



GGYYCTTYTHAGRRCC



 


Sequence according to formula (Ig)


(SEQ ID NO: 1413)



GGCYCTTYTMAGRGCC



 


Sequence according to formula (Ig)


(SEQ ID NO: 1414)



GGCTCTTTTMAGRGCC



 


Sequence according to formula (Ih)


(SEQ ID NO: 1415)



DGHYCTDYTHASRRCC



 


Sequence according to formula (Ih)


(SEQ ID NO: 1416)



GGCYCTTTTHAGRGCC



 


Sequence according to formula (Ih)


(SEQ ID NO: 1417)



GGCYCTTTTMAGRGCC



 


Sequence according to formula (IIc)


(SEQ ID NO: 1418)



H*H*HHVVGYYYYHHTHRVVRCBVHH*N*N*



 


Sequence according to formula (IIc)


(SEQ ID NO: 1419)



M*H*MHMSGYYYTTYTMARRRCSMCH*H*H*



 


Sequence according to formula (IIc)


(SEQ ID NO: 1420)



M*M*MMMSGYYCTTTTMAGRRCSACH*M*H*



 


Sequence according to formula (IIe)


(SEQ ID NO: 1421)



N*N*NNNDGNNNBNNTHVNNNCHNHN*N*N*



 


Sequence according to formula (IIe)


(SEQ ID NO: 1422)



N*N*HHNRGNNNYHBTHRDNNCYDHH*N*N*



 


Sequence according to formula (IIe)


(SEQ ID NO: 1423)



N*H*HHVRGNDBYHYTHRDHNCYRHH*H*H*



 


Sequence according to formula (IIf)


(SEQ ID NO: 1424)



H*H*MHMVGYYYTYHTHRVRRCBVMH*H*N*



 


Sequence according to formula (IIf)


(SEQ ID NO: 1425)



M*M*MMMSGYYCTTYTMAGRRCSMCH*H*H*



 


Sequence according to formula (IIf)


(SEQ ID NO: 1426)



M*M*MMMSGYYCTTTTMAGRRCSACH*M*H*



 


Sequence according to formula (IIg)


(SEQ ID NO: 1427)



H*H*MAMGGYYCTTYTHAGRRCCVHN*N*M*



 


Sequence according to formula (IIg)


(SEQ ID NO: 1428)



H*H*AAMGGCYCTTYTMAGRGCCVCH*H*M*



 


Sequence according to formula (IIg)


(SEQ ID NO: 1429)



M*M*AAMGGCTCTTTTMAGRGCCMCY*M*M*



 


Sequence according to formula (IIh)


(SEQ ID NO: 1430)



N*H*AAHDGHYCTDYTHASRRCCVHB*N*H*



 


Sequence according to formula (IIh)


(SEQ ID NO: 1431)



H*H*AAMGGCYCTTTTHAGRGCCVMY*N*M*



 


Sequence according to formula (IIh)


(SEQ ID NO: 1432)



H*M*AAAGGCYCTTTTMAGRGCCRMY*H*M*



 


Specific histone stem-loop sequence


(SEQ ID NO: 1433)



CAAAGGCTCTTTTCAGAGCCACCA



 


Center, α-complex-binding portion of the 3'UTR of an α-globin


gene


(SEQ ID NO: 1434)



GCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCG



 


ATP synthase lipid-binding protein, mitochondrial (atp5g2)


(SEQ ID NO: 1435)



tagttt ctcctctcga acgccaggtg gagcaaccgg ccggataccg ccacagccct



ggcaggcggc gctgtgatg


 


RPL35-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1436)



GGGGAGCGGGCGGCGGCGTTGGCGGCTTGTGCAGCAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTGCATCACATTTAAAAGCATCTCAGCCTACCATGA


GAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTTCTTTTTCGTTGGT


GTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTC


TGTGCTTCAATTAATAAAAAATGGAAAGAACCTAGATCTAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCC


CCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


RPL21-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1437)



GGGGCCGGAACCGCCATCTTCCAGTAATTCGCCAAAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTGCATCACATTTAAAAGCATCTCAGCCTACCATGA


GAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTTCTTTTTCGTTGGT


GTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTC


TGTGCTTCAATTAATAAAAAATGGAAAGAACCTAGATCTAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCC


CCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


ATP5A1-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1438)



GGGCGGCTCGGCCATTTTGTCCCAGTCAGTCCGGAGGCTGCGGCTGCAGAAGTACCGCCT



GCGGAGTAACTGCAAAGAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCG


GCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAG


CGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATC


ACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGC


CTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCG


GTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAG


CGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAG


GGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATC


ATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCAC


CTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACC


ATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCG


CACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATC


ATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACG


ACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAG


CTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTG


TTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAG


ATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTC


CACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATC


ACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCC


AAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGC


GTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTC


ATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCAC


TTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCG


GCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGG


CTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAG


ACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAG


CTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGAC


GCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAA


GACTAGTGCATCACATTTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATG


AAGATCAATAGCTTATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTC


TAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAA


AATGGAAAGAACCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC


AAAGGCTCTTTTCAGAGCCACCAGAATT


 


HSD17B4-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1439)



GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGTGTGTCGTTGCAGGCCTT



ATTCAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACC


CGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGG


TGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGT


ACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACC


ACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCC


TCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGA


ACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGA


TCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGA


CCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCT


TCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCA


TGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCT


GCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCG


CCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACC


TCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGA


GCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCG


CCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGG


GCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCA


TCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGG


ACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACC


TGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGA


TGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACG


GCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCG


ACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGA


GCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACG


ACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGA


AGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCG


TGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCC


GCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCATCA


CATTTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCT


TATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAA


TTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACC


TAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAATGCATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTC


AGAGCCACCAGAATT


 


AIG1-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1440)



GGGCCGCCCAGCCGGTCCAGGCCTCTGGCGAACAAGCTTGAGGATGGAGGACGCCAAGAA



CATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCAGCT


CCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGCCCA


CATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGAGGC


CATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAGCCT


GCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAA


CGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGTGGT


GTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCATCAT


CCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTACAC


GTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAGCTT


CGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCGAA


GGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCCCAT


CTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCACGG


CTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGATGTA


CCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCGCT


GCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCT


GTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGC


CGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGACCAC


GAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGTGGT


CCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCA


GCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCCGGA


GGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTG


GGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAAGGG


CTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTTCGA


CGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGT


GCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCAGGT


GACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCT


GACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGGCGG


CAAGATCGCCGTGTAAGACTAGTGCATCACATTTAAAAGCATCTCAGCCTACCATGAGAA


TAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTTCTTTTTCGTTGGTGTA


AAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGT


GCTTCAATTAATAAAAAATGGAAAGAACCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCCCCC


CCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


COX6C-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1441)



GGAGTCAGGAAGGACGTTGGTGTTGAGGTTAGCATACGTATCAAGGACAGTAACTACCAA



GCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGG


AGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGG


GCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCG


AGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGA


TCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCA


TCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCA


TGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGA


ACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACT


ACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACG


AGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACA


GCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGC


GCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCC


TGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCT


GCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGC


AGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGA


GCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCC


CGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCC


AGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACA


AGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACA


CCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCA


TGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGC


TGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGC


TGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCC


TGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCG


GCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGA


TCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGT


TCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGA


TCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCATCACATTTA


AAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCA


TCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTT


TAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTAGATC


TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAATGCATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCC


ACCAGAATT


 


ASAH1-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1442)



GGGCCTCTGCTGGAGTCCGGGGAGTGGCGTTGGCTGCTAGAGCGAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCATCACATTTAAAAGCATCTCAGCC


TACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTTCTTTT


TCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCT


CTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTAGATCTAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCC


CCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


mRPL21-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1443)



GGGGCCGCCGCAGCCATCTTCCAGTAACTCGCCAAAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTGCATCACATTTAAAAGCATCTCAGCCTACCATGA


GAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTTCTTTTTCGTTGGT


GTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTC


TGTGCTTCAATTAATAAAAAATGGAAAGAACCTAGATCTAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCC


CCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


mRPL35A-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1444)



GGGCCATCTTGGCGCCTGTGGAGGCCTGCTGGGAACAGGACTTCTAACAGCAAGTAAGCT



TGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGG


ACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCA


CGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGA


TGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCG


TGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCG


GCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGG


GGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACG


TGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACC


AGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGT


ACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCA


GCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCT


TCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGA


GCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCG


GCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGG


ACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCA


CCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGC


TGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGG


GCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGC


CGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCG


GCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGA


GCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGC


ACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGA


AGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGC


TCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCG


AGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCG


TCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCG


TGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCC


TGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCATCACATTTAAAA


GCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCT


CTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAA


TCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTAGATCTAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AATGCATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACC


AGAATT


 


RPL35-PpLuc(GC)-A64-C30-histoneSL


(SEQ ID NO: 1445)



GGGGAGCGGGCGGCGGCGTTGGCGGCTTGTGCAGCAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCCCCCCCCC


CCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


RPL21-PpLuc(GC)-A64-C30-histoneSL


(SEQ ID NO: 1446)



GGGGCCGGAACCGCCATCTTCCAGTAATTCGCCAAAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCCCCCCCCC


CCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


ATP5A1-PpLuc(GC)-A64-C30-histoneSL


(SEQ ID NO: 1447)



GGGCGGCTCGGCCATTTTGTCCCAGTCAGTCCGGAGGCTGCGGCTGCAGAAGTACCGCCT



GCGGAGTAACTGCAAAGAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCG


GCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAG


CGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATC


ACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGC


CTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCG


GTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAG


CGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAG


GGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATC


ATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCAC


CTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACC


ATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCG


CACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATC


ATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACG


ACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAG


CTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTG


TTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAG


ATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTC


CACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATC


ACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCC


AAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGC


GTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTC


ATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCAC


TTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCG


GCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGG


CTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAG


ACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAG


CTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGAC


GCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAA


GACTAGTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCT


CTTTTCAGAGCCACCAGAATT


 


HSD17B4-PpLuc(GC)-A64-C30-histoneSL


(SEQ ID NO: 1448)



GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGTGTGTCGTTGCAGGCCTT



ATTCAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACC


CGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGG


TGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGT


ACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACC


ACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCC


TCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGA


ACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGA


TCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGA


CCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCT


TCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCA


TGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCT


GCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCG


CCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACC


TCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGA


GCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCG


CCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGG


GCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCA


TCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGG


ACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACC


TGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGA


TGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACG


GCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCG


ACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGA


GCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACG


ACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGA


AGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCG


TGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCC


GCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTAGATCT


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAATGCATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCA


CCAGAATT


 


AIG1-PpLuc(GC)-A64-C30-histoneSL


(SEQ ID NO: 1449)



GGGCCGCCCAGCCGGTCCAGGCCTCTGGCGAACAAGCTTGAGGATGGAGGACGCCAAGAA



CATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCAGCT


CCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGCCCA


CATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGAGGC


CATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAGCCT


GCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAA


CGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGTGGT


GTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCATCAT


CCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTACAC


GTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAGCTT


CGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCGAA


GGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCCCAT


CTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCACGG


CTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGATGTA


CCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCGCT


GCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCT


GTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGC


CGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGACCAC


GAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGTGGT


CCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCA


GCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCCGGA


GGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTG


GGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAAGGG


CTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTTCGA


CGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGT


GCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCAGGT


GACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCT


GACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGGCGG


CAAGATCGCCGTGTAAGACTAGTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCCCCCCCCCCCCC


CCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


COX6C-PpLuc(GC)-A64-C30-histoneSL


(SEQ ID NO: 1450)



GGAGTCAGGAAGGACGTTGGTGTTGAGGTTAGCATACGTATCAAGGACAGTAACTACCAA



GCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGG


AGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGG


GCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCG


AGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGA


TCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCA


TCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCA


TGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGA


ACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACT


ACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACG


AGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACA


GCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGC


GCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCC


TGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCT


GCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGC


AGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGA


GCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCC


CGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCC


AGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACA


AGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACA


CCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCA


TGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGC


TGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGC


TGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCC


TGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCG


GCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGA


TCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGT


TCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGA


TCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTAGATCTAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATG


CATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAA


TT


 


ASAH1-PpLuc(GC)-A64-C30-histoneSL


(SEQ ID NO: 1451)



GGGCCTCTGCTGGAGTCCGGGGAGTGGCGTTGGCTGCTAGAGCGAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTAGATCTAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCCCCCCCC


CCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


5′UTR of human ribosomal protein Large 35 (RPL35) lacking the 5′


terminal oligopyrimidine tract


(SEQ ID NO: 1452)



GGAGCGGGCGGCGGCGTTGGCGGCTTGTGCAGCA



 


5′UTR of human ribosomal protein Large 21 (RPL21) lacking the 5′


terminal oligopyrimidine tract


(SEQ ID NO: 1453)



GGCCGGAACCGCCATCTTCCAGTAATTCGCCAAA



 


5′UTR of human ATP synthase, H+ transporting, mitochondrial F1


complex, alpha subunit 1, cardiac muscle (ATP5A1) lacking the 5′


terminal oligopyrimidine tract


(SEQ ID NO: 1454)



GCGGCTCGGCCATTTTGTCCCAGTCAGTCCGGAGGCTGCGGCTGCAGAAGTACCGCCTGCG



GAGTAACTGCAAAG


 


5′UTR of human hydroxysteroid (17-beta) dehydrogenase 4 (HSD17B4)


lacking the 5′ terminal oligopyrimidine tract


(SEQ ID NO: 1455)



GTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGTGTGTCGTTGCAGGCCTTATTC



 


5′UTR of human androgen-induced 1 (AIG1) lacking the 5′ terminal


oligopyrimidine tract


(SEQ ID NO: 1456)



GCCGCCCAGCCGGTCCAGGCCTCTGGCGAAC



 


5′UTR of human cytochrome c oxidase subunit VIc (COX6C) lacking


the 5′ terminal oligopyrimidine tract


(SEQ ID NO: 1457)



AGTCAGGAAGGACGTTGGTGTTGAGGTTAGCATACGTATCAAGGACAGTAACTACC



 


5′UTR of human N-acylsphingosine amidohydrolase (acid ceramidase)


(ASAH1) lacking the 5′ terminal oligopyrimidine tract


(SEQ ID NO: 1458)



GCCTCTGCTGGAGTCCGGGGAGTGGCGTTGGCTGCTAGAGCG



 


5′UTR of mouse ribosomal protein Large 21 (mRPL21) lacking the 5′


terminal oligopyrimidine tract


(SEQ ID NO: 1459)



GGCCGCCGCAGCCATCTTCCAGTAACTCGCCAAA



 


5′UTR of mouse ribosomal protein large 35A (mRPL35A) lacking the


5′ terminal oligopyrimidine tract


(SEQ ID NO: 1460)



GCCATCTTGGCGCCTGTGGAGGCCTGCTGGGAACAGGACTTCTAACAGCAAGT



 


Mouse ribosomal protein Large 21 (mRPL21)


(SEQ ID NO: 1461)



TCCTCCTTTCGGCCGCCGCAGCCATCTTCCAGTAACTCGCCAAAATGCCATCTTCCAG



TAACTCGCCAAAATG


 


mouse ribosomal protein large 35A (mRPL35A)


(SEQ ID NO: 1462)



CTTCCTCTTTCCGCCATCTTGGCGCCTGTGGAGGCCTGCTGGGAACAGGACTTCTAACAG



CAAGTATG


 


RPL32-PpLuc(GC)-ag-A64


(SEQ ID NO: 1463)



GGGGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATCAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCC


TCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAATAGATCTAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1464)



GGGGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATCAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCC


TCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCAAAGGCTCTT


TTCAGAGCCACCA


 


PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1465)



GGGGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATCAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCATCACATTTAAAAGCATCTCAGCC


TACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTTCTTTT


TCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCT


CTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTAGATCTAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCC


CCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT


 


RPL35-PpLuc(GC)-ag-A64


(SEQ ID NO: 1466)



GGGGAGCGGGCGGCGGCGTTGGCGGCTTGTGCAGCAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACG


GGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


RPL21-PpLuc(GC)-ag-A64


(SEQ ID NO: 1467)



GGGGCCGGAACCGCCATCTTCCAGTAATTCGCCAAAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACG


GGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


atp5a1-PpLuc(GC)-ag-A64


(SEQ ID NO: 1468)



GGGCGGCTCGGCCATTTTGTCCCAGTCAGTCCGGAGGCTGCGGCTGCAGAAGTACCGCCT



GCGGAGTAACTGCAAAGAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCG


GCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAG


CGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATC


ACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGC


CTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCG


GTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAG


CGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAG


GGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATC


ATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCAC


CTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACC


ATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCG


CACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATC


ATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACG


ACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAG


CTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTG


TTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAG


ATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTC


CACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATC


ACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCC


AAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGC


GTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTC


ATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCAC


TTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCG


GCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGG


CTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAG


ACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAG


CTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGAC


GCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAA


GACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTG


CACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAA


 


HSD17B4-PpLuc(GC)-ag-A64


(SEQ ID NO: 1469)



GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGTGTGTCGTTGCAGGCCTT



ATTCAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACC


CGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGG


TGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGT


ACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACC


ACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCC


TCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGA


ACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGA


TCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGA


CCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCT


TCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCA


TGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCT


GCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCG


CCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACC


TCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGA


GCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCG


CCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGG


GCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCA


TCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGG


ACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACC


TGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGA


TGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACG


GCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCG


ACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGA


GCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACG


ACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGA


AGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCG


TGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCC


GCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAG


ACTGACTAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAAT


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAA


 


AIG1-PpLuc(GC)-ag-A64


(SEQ ID NO: 1470)



GGGCCGCCCAGCCGGTCCAGGCCTCTGGCGAACAAGCTTGAGGATGGAGGACGCCAAGAA



CATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCAGCT


CCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGCCCA


CATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGAGGC


CATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAGCCT


GCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAA


CGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGTGGT


GTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCATCAT


CCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTACAC


GTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAGCTT


CGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCGAA


GGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCCCAT


CTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCACGG


CTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGATGTA


CCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCGCT


GCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCT


GTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGC


CGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGACCAC


GAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGTGGT


CCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCA


GCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCCGGA


GGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTG


GGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAAGGG


CTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTTCGA


CGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGT


GCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCAGGT


GACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCT


GACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGGCGG


CAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACGGGC


CCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


COX6C-PpLuc(GC)-ag-A64


(SEQ ID NO: 1471)



GGAGTCAGGAAGGACGTTGGTGTTGAGGTTAGCATACGTATCAAGGACAGTAACTACCAA



GCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGG


AGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGG


GCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCG


AGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGA


TCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCA


TCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCA


TGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGA


ACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACT


ACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACG


AGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACA


GCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGC


GCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCC


TGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCT


GCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGC


AGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGA


GCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCC


CGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCC


AGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACA


AGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACA


CCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCA


TGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGC


TGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGC


TGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCC


TGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCG


GCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGA


TCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGT


TCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGA


TCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGAC


TAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


ASAH1-PpLuc(GC)-ag-A64


(SEQ ID NO: 1472)



GGGCCTCTGCTGGAGTCCGGGGAGTGGCGTTGGCTGCTAGAGCGAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCC


TCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


RPL35-PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1473)



GGGGAGCGGGCGGCGGCGTTGGCGGCTTGTGCAGCAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACG


GGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCAAAGGCTCTTTTCAGAGC


CACCA


 


RPL21-PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1474)



GGGGCCGGAACCGCCATCTTCCAGTAATTCGCCAAAAAGCTTGAGGATGGAGGACGCCAA



GAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCA


GCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGC


CCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGA


GGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAG


CCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGC


GAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGT


GGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCAT


CATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTA


CACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAG


CTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCC


GAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCC


CATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCA


CGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGAT


GTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGC


GCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGA


CCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGA


GGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGAC


CACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGT


GGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAA


CCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCC


GGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTA


CTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAA


GGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTT


CGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGT


GGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCA


GGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGG


CCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGG


CGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACG


GGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCAAAGGCTCTTTTCAGAGC


CACCA


 


atp5a1-PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1475)



GGGCGGCTCGGCCATTTTGTCCCAGTCAGTCCGGAGGCTGCGGCTGCAGAAGTACCGCCT



GCGGAGTAACTGCAAAGAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCG


GCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAG


CGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATC


ACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGC


CTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCG


GTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAG


CGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAG


GGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATC


ATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCAC


CTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACC


ATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCG


CACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATC


ATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACG


ACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAG


CTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTG


TTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAG


ATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTC


CACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATC


ACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCC


AAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGC


GTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTC


ATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCAC


TTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCG


GCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGG


CTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAG


ACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAG


CTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGAC


GCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAA


GACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTG


CACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAATGCATCAAAGGCTCTTTTCAGAGCCACCA


 


HSD17B4-PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1476)



GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGTGTGTCGTTGCAGGCCTT



ATTCAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACC


CGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGG


TGCCGGGCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGT


ACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACC


ACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCC


TCTTCATCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGA


ACAGCATGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGA


TCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGA


CCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCT


TCAACGAGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCA


TGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCT


GCGTGCGCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCG


CCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACC


TCATCTGCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGA


GCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCG


CCAAGAGCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGG


GCGCCCCGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCA


TCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGG


ACGACAAGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACC


TGGACACCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGA


TGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACG


GCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCG


ACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGA


GCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACG


ACGCCGGCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGA


AGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCG


TGGTGTTCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCC


GCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAG


ACTGACTAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAAT


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAATGCATCAAAGGCTCTTTTCAGAGCCACCA


 


AIG1-PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1477)



GGGCCGCCCAGCCGGTCCAGGCCTCTGGCGAACAAGCTTGAGGATGGAGGACGCCAAGAA



CATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCCGGCGAGCAGCT


CCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTCACCGACGCCCA


CATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGCCTGGCCGAGGC


CATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCGGAGAACAGCCT


GCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTCGCCCCGGCGAA


CGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAGCCGACCGTGGT


GTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAGCTGCCCATCAT


CCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAGTCGATGTACAC


GTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTCCCGGAGAGCTT


CGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCGAA


GGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCCCGGGACCCCAT


CTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCGTTCCACCACGG


CTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTGGTCCTGATGTA


CCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCGCT


GCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCT


GTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAGGTGGGCGAGGC


CGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTGACCGAGACCAC


GAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTGGGCAAGGTGGT


CCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCA


GCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTGAACAACCCGGA


GGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTG


GGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATCAAGTACAAGGG


CTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCCAACATCTTCGA


CGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCCGCGGTGGTGGT


GCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTGGCCAGCCAGGT


GACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTCCCGAAGGGCCT


GACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCCAAGAAGGGCGG


CAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACGGGC


CCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCAAAGGCTCTTTTCAGAGCCAC


CA


 


COX6C-PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1478)



GGAGTCAGGAAGGACGTTGGTGTTGAGGTTAGCATACGTATCAAGGACAGTAACTACCAA



GCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGG


AGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGG


GCACGATCGCCTTCACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCG


AGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGA


TCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCA


TCGGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCA


TGGGGATCAGCCAGCCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGA


ACGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACT


ACCAGGGCTTCCAGTCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACG


AGTACGACTTCGTCCCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACA


GCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGC


GCTTCTCGCACGCCCGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCC


TGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCT


GCGGCTTCCGGGTGGTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGC


AGGACTACAAGATCCAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGA


GCACCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCC


CGCTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCC


AGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACA


AGCCGGGCGCCGTGGGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACA


CCGGCAAGACCCTGGGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCA


TGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGC


TGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGC


TGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCC


TGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCG


GCGAGCTGCCGGCCGCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGA


TCGTCGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGT


TCGTGGACGAGGTCCCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGA


TCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGAC


TAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


TGCATCAAAGGCTCTTTTCAGAGCCACCA


 


ASAH1-PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1479)



GGGCCTCTGCTGGAGTCCGGGGAGTGGCGTTGGCTGCTAGAGCGAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCC


TCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCAAAGGCTCTT


TTCAGAGCCACCA


 


RPL32-PpLuc(GC)-ag-A64-histoneSL


(SEQ ID NO: 1480)



GGGGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATCAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTTATAAGACTGACTAGCCCGATGGGCC


TCCCAACGGGCCCTCCTCCCCTCCTTGCACCGAGATTAATAAAAAAAAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCAAAGGCTCTT


TTCAGAGCCACCA


 


RPL32-PpLuc(GC)-albumin7-A64-C30-histoneSL


(SEQ ID NO: 1481)



GGGGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATCAAGCTTGAGGATGGAG



GACGCCAAGAACATCAAGAAGGGCCCGGCGCCCTTCTACCCGCTGGAGGACGGGACCGCC


GGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCTGGTGCCGGGCACGATCGCCTTC


ACCGACGCCCACATCGAGGTCGACATCACCTACGCGGAGTACTTCGAGATGAGCGTGCGC


CTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCTCG


GAGAACAGCCTGCAGTTCTTCATGCCGGTGCTGGGCGCCCTCTTCATCGGCGTGGCCGTC


GCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCTGAACAGCATGGGGATCAGCCAG


CCGACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCTGAACGTGCAGAAGAAG


CTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGACTACCAGGGCTTCCAG


TCGATGTACACGTTCGTGACCAGCCACCTCCCGCCGGGCTTCAACGAGTACGACTTCGTC


CCGGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACC


GGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGCCTGCGTGCGCTTCTCGCACGCC


CGGGACCCCATCTTCGGCAACCAGATCATCCCGGACACCGCCATCCTGAGCGTGGTGCCG


TTCCACCACGGCTTCGGCATGTTCACGACCCTGGGCTACCTCATCTGCGGCTTCCGGGTG


GTCCTGATGTACCGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATC


CAGAGCGCGCTGCTCGTGCCGACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGAC


AAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGGGGGCGCCCCGCTGAGCAAGGAG


GTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGGCATCCGCCAGGGCTACGGCCTG


ACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGGGGACGACAAGCCGGGCGCCGTG


GGCAAGGTGGTCCCGTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAAGACCCTG


GGCGTGAACCAGCGGGGCGAGCTGTGCGTGCGGGGGCCGATGATCATGAGCGGCTACGTG


AACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGAC


ATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTCGACCGGCTGAAGTCGCTGATC


AAGTACAAGGGCTACCAGGTGGCGCCGGCCGAGCTGGAGAGCATCCTGCTCCAGCACCCC


AACATCTTCGACGCCGGCGTGGCCGGGCTGCCGGACGACGACGCCGGCGAGCTGCCGGCC


GCGGTGGTGGTGCTGGAGCACGGCAAGACCATGACGGAGAAGGAGATCGTCGACTACGTG


GCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGGCGGCGTGGTGTTCGTGGACGAGGTC


CCGAAGGGCCTGACCGGGAAGCTCGACGCCCGGAAGATCCGCGAGATCCTGATCAAGGCC


AAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCATCACATTTAAAAGCATCTCAGCC


TACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTTCTTTT


TCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCT


CTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTAGATCTAAAAAAAAAAAAA


AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCC


CCCCCCCCCCCCCCCCCCCCCCCCCCCAAAGGCTCTTTTCAGAGCCACCAGAATT

## Claims

1. An artificial nucleic acid molecule comprising, from 5′ to 3′:
(a) a 5′-untranslated region element (5′UTR element) of a TOP gene;
(b) at least one open reading frame (ORF); and
(c) at least one histone stem-loop sequence.

2. The artificial nucleic acid molecule according to claim 1, wherein the 5′UTR element is from a TOP gene encoding a ribosomal protein.

3. The artificial nucleic acid molecule according to claim 2, wherein the ribosomal protein is the ribosomal protein Large 32 (RPL32), the ribosomal protein Large 35 (RPL35), the ribosomal protein Large 35A (RPL35A), the ribosomal protein Large 31 (RPL31) or the ribosomal protein Large 21 (RPL21).

4. The artificial nucleic acid molecule according to claim 1, further comprising at least one 3′UTR element of a mammalian gene positioned 3′ relative to the ORF.

5. The artificial nucleic acid molecule according to claim 4, wherein the 3′ UTR element comprises a 3′ UTR element of a gene selected from the group consisting of an albumin gene, an α-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, and a collagen alpha gene.

6. The artificial nucleic acid molecule according to claim 4, wherein the 3′UTR element comprises a 3′UTR element of a human albumin gene.

7. The artificial nucleic acid molecule according to claim 4, further comprising a polyadenylation signal wherein the polyadenylation signal is located within the 3′UTR element.

8. The artificial nucleic acid molecule according to claim 1, further comprising a poly(A) sequence and/or a polyadenylation signal.

9. The artificial nucleic acid molecule according to claim 8, wherein the poly(A) sequence has a length of about 20 to about 300 adenine nucleotides.

10. The artificial nucleic acid molecule according to claim 1, wherein the ORF is heterologous relative to the 5′UTR element.

11. The artificial nucleic acid molecule according to claim 1, further comprising a poly(C) sequence position 3′ relative to the ORF.

12. The artificial nucleic acid molecule according to claim 1, wherein the molecule is a DNA and further comprises a promoter containing-sequence operably linked to the ORF.

13. The artificial nucleic acid molecule according to claim 1, wherein the molecule is a RNA.

14. The artificial nucleic acid molecule according to claim 13, wherein the RNA is a mRNA and comprises a 5′ cap.

15. The artificial nucleic acid molecule according to claim 13, wherein the RNA comprises at least one nucleotide position that is substituted with an analogue of the nucleotide selected from the group consisting of 2-amino-6-chloropurineriboside-5′triphosphate, 2-aminoadenosine-5′-triphosphate, 2-thiocytidine-5′-triphosphate, 2-thiouridine-5′-triphosphate, 4-thiouridine-5′-triphosphate, 5-aminoallylcytidine-5′triphosphate, 5-aminoallyluridine-5′-triphosphate, 5-bromocytidine-5′-triphosphate, 5-bromouridine-5′-triphosphate, 5-iodocytidine-5′-triphosphate, 5-iodouridine-5′triphosphate, 5-methylcytidine-5′-triphosphate, 5-methyluridine-5′-triphosphate, 6-azacytidine-5′-triphosphate, 6-azauridine-5′-triphosphate, 6-chloropurineriboside-5′-triphosphate, 7-deazaadenosine-5′-triphosphate, 7-deazaguanosine-5′-triphosphate, 8-azaadenosine-5′-triphosphate, 8-azidoadenosine-5′-triphosphate, benzimidazoleriboside-5′-triphosphate, N1-methyladenosine-5′-triphosphate, N1-methylguanosine-5′-triphosphate,triphosphate,N6-methyladenosine-5′-triphosphate, 06-methylguanosine-5′-pseudouridine-5′-triphosphate, puromycin-5′-triphosphate andxanthosine-5′-triphosphate.

16. The artificial nucleic acid molecule according to claim 1, wherein one or more codon of the open reading frame is modified to a codon encoding the same amino acid but having an increased G/C content compared to the wild-type codon, thereby increasing the G/C content of the open reading frame compared to the wild type version of the open reading frame.

17. The artificial nucleic acid molecule according to claim 1, wherein the ORF encodes a human polypeptide, a tumour antigen or an infectious disease antigen.

18. The artificial nucleic acid molecule according to claim 1, wherein the ORF encodes an antibody or a portion thereof.

19. The artificial nucleic acid molecule according to claim 1, wherein the 5′UTR element is from a TOP gene encoding a protein selected from the group consisting of: the ribosomal protein Large 32 (RPL32), hydroxysteroid (17-beta) dehydrogenase 4 (HSD17B4), H+transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1), androgen-induced 1 gene (AIG1), N-acylsphingosine amidohydrolase (acid ceramidase) 1 (ASAH1), cytochrome c oxidase subunit VIc (COX6C), ATP-binding cassette, sub-family B (MDR/TAP), the ribosomal protein Large 31 (RPL21) and the ribosomal protein Large 35A (RPL35A).

20. The artificial nucleic acid molecule according to claim 4, wherein the at least one 3′UTR element comprises an mRNA-stabilizing element.

21. A pharmaceutical composition comprising a RNA molecule in accordance with claim 13 in a pharmaceutically acceptable carrier.

22. A method of expressing a polypeptide in a subject comprising administering an artificial nucleic acid molecule according to claim 1 to the subject, wherein the polypeptide is encoded by the ORF of said artificial nucleic acid molecule.